diff --git a/apps/openchallenges/challenge-service/src/main/resources/db/challenges.csv b/apps/openchallenges/challenge-service/src/main/resources/db/challenges.csv new file mode 100644 index 0000000000..a9eeec9dd6 --- /dev/null +++ b/apps/openchallenges/challenge-service/src/main/resources/db/challenges.csv @@ -0,0 +1,280 @@ +"id","slug","name","headline","description","avatar_url","website_url","status","difficulty","platform","doi","start_date","end_date","createdAt","updatedAt" +"1","network-topology-and-parameter-inference","Network Topology and Parameter Inference","","Participants are asked to develop and/or apply optimization methods, including the selection of the most informative experiments, to accurately estimate parameters and predict outcomes of perturbations in Systems Biology models.","","https://www.synapse.org/#!Synapse:syn2821735","completed","intermediate","1","","2012-06-01","2012-10-01","2023-06-23 00:00:00","2023-09-29 09:45:30" +"2","breast-cancer-prognosis","Breast Cancer Prognosis","","The goal of the breast cancer prognosis Challenge is to assess the accuracy of computational models designed to predict breast cancer survival, based on clinical information about the patient's tumor as well as genome-wide molecular profiling data including gene expression and copy number profiles.","","https://www.synapse.org/#!Synapse:syn2813426","completed","intermediate","1","","2012-07-12","2012-10-15","2023-06-23 00:00:00","2023-09-28 18:31:42" +"3","phil-bowen-als-prediction-prize4life","Phil Bowen ALS Prediction Prize4Life","","Amyotrophic Lateral Sclerosis (ALS)–also known as Lou Gehrig's disease (in the US) or Motor Neurone disease (outside the US)–is a fatal neurological disease causing death of the nerve cells in the brain and spinal cord which control voluntary muscle movements. This leaves patients struggling with a progressive loss of motor function while leaving cognitive functions intact. Symptoms usually do not manifest until the age of 50 but can start earlier. At any given time, approximately five out of every 100,000 people worldwide suffer from ALS, though there would be a higher prevalence if the disease did not progress so rapidly, leading to the death of the patient. There are no known risk factors for developing ALS other than having a family member who has a hereditary form of the disease, which accounts for about 5-10% of ALS patients. There is also no known cure for ALS. The only FDA-approved drug for the disease is Riluzole, which has been shown to prolong the life span of someon...","","https://www.synapse.org/#!Synapse:syn2826267","completed","intermediate","1","","2012-06-01","2012-10-01","2023-06-23 00:00:00","2023-09-28 18:32:11" +"4","drug-sensitivity-and-drug-synergy-prediction","Drug Sensitivity and Drug Synergy Prediction","","Development of new cancer therapeutics currently requires a long and protracted process of experimentation and testing. Human cancer cell lines represent a good model to help identify associations between molecular subtypes, pathways, and drug response. In recent years there have been several efforts to generate genomic profiles of collections of cell lines and to determine their response to panels of candidate therapeutic compounds. These data provide the basis for the development of in silico models of sensitivity based either on the unperturbed genetic potential of a cancer cell, or by using perturbation data to incorporate knowledge of actual cell response. Making predictions from either of these data profiles will be beneficial in identifying single and combinatorial chemotherapeutic response in patients. To that end, the present challenge seeks computational methods, derived from the molecular profiling of cell lines both in a static state and in response to perturbation of ...","","https://www.synapse.org/#!Synapse:syn2785778","completed","intermediate","1","","2012-06-01","2012-10-01","2023-06-23 00:00:00","2023-09-28 20:57:05" +"5","niehs-ncats-unc-toxicogenetics","NIEHS-NCATS-UNC Toxicogenetics","","This challenge is designed to build predictive models of cytotoxicity as mediated by exposure to environmental toxicants and drugs. To approach this question, we will provide a dataset containing cytotoxicity estimates as measured in lymphoblastoid cell lines derived from 884 individuals following in vitro exposure to 156 chemical compounds. In subchallenge 1, participants will be asked to model interindividual variability in cytotoxicity based on genomic profiles in order to predict cytotoxicity in unknown individuals. In subchallenge 2, participants will be asked to predict population-level parameters of cytotoxicity across chemicals based on structural attributes of compounds in order to predict median cytotoxicity and mean variance in toxicity for unknown compounds.","","https://www.synapse.org/#!Synapse:syn1761567","completed","intermediate","1","","2013-06-10","2013-09-15","2023-06-23 00:00:00","2023-09-28 21:00:16" +"6","whole-cell-parameter-estimation","Whole-Cell Parameter Estimation","","The goal of this challenge is to explore and compare innovative approaches to parameter estimation of large, heterogeneous computational models. Participants are encouraged to develop and/or apply optimization methods, including the selection of the most informative experiments. The organizers encourage participants to form teams to collaboratively solve the challenge.","","https://www.synapse.org/#!Synapse:syn1876068","completed","intermediate","1","","2013-06-10","2013-09-23","2023-06-23 00:00:00","2023-09-28 21:03:49" +"7","hpn-dream-breast-cancer-network-inference","HPN-DREAM Breast Cancer Network Inference","","The overall goal of the Heritage-DREAM breast cancer network inference challenge is to quickly and effectively advance our ability to infer causal signaling networks and predict protein phosphorylation dynamics in cancer. We provide extensive training data from experiments on four breast cancer cell lines stimulated with various ligands. The data comprise protein abundance time-courses under inhibitor perturbations.","","https://www.synapse.org/#!Synapse:syn1720047","completed","intermediate","1","","2013-06-10","2013-09-16","2023-06-23 00:00:00","2023-09-28 21:06:20" +"8","rheumatoid-arthritis-responder","Rheumatoid Arthritis Responder","","The goal of this project is to use a crowd-based competition framework to develop a validated molecular predictor of anti-TNF response in RA. There is an increasing need for predictors of response to therapy in inflammatory disease driven by the observation that most clinically defined diseases show variable response and the growing availability of alternative therapies. Anti-TNF drugs in Rheumatoid Arthritis represent a prototypical example of this opportunity. A number of studies have tried, over the past decade, to develop a robust predictor of response. We believe the time is right to try a different approach to developing such a biomarker with a crowd-sourced collaborative competition. This is based on DREAM and Sage Bionetworks' experience with running competitions and the availability of new unpublished large-scale data relating to RA treatment response.THIS CHALLENGE RAN FROM FEBRUARY TO OCTOBER 2014 AND IS NOW CLOSED.","","https://www.synapse.org/#!Synapse:syn1734172","completed","intermediate","1","","2014-02-10","2014-06-04","2023-06-23 00:00:00","2023-09-28 21:07:55" +"9","icgc-tcga-dream-mutation-calling","ICGC-TCGA DREAM Mutation Calling","","The ICGC-TCGA DREAM Genomic Mutation Calling Challenge (herein, The Challenge) is an international effort to improve standard methods for identifying cancer-associated mutations and rearrangements in whole-genome sequencing (WGS) data. Leaders of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) cancer genomics projects are joining with Sage Bionetworks and IBM-DREAM to initiate this innovative open crowd-sourced Challenge [1-3].","","https://www.synapse.org/#!Synapse:syn312572","completed","intermediate","1","","2013-12-14","2016-04-22","2023-06-23 00:00:00","2023-09-28 21:09:46" +"10","acute-myeloid-leukemia-outcome-prediction","Acute Myeloid Leukemia Outcome Prediction","","The AML Outcome Prediction Challenge provides a unique opportunity to access and interpret a rich dataset for AML patients that includes clinical covariates, select gene mutation status and proteomic data. Capitalizing on a unique AML reverse phase protein array (RPPA) dataset obtained at M.D. Anderson Cancer Center that captures 271 measurements for each patient, participants of the DREAM 9 Challenge will help uncover what drives AML. Outcomes of this Challenge have the potential to be used immediately to tailor therapies for newly diagnosed leukemia patients and to accelerate the development of new drugs for leukemia.","","https://www.synapse.org/#!Synapse:syn2455683","completed","intermediate","1","","2014-06-02","2014-09-15","2023-06-23 00:00:00","2023-09-28 21:10:29" +"11","broad-dream-gene-essentiality-prediction","Broad-DREAM Gene Essentiality Prediction","","The goal of this project is to use a crowd-based competition to develop predictive models that can infer gene dependency scores in cancer cells (genes that are essential to cancer cell viability when suppressed) using features of those cell lines. An additional goal is to find a small set of biomarkers (gene expression, copy number, and mutation features) that can best predict a single gene or set of genes.","","https://www.synapse.org/#!Synapse:syn2384331","completed","intermediate","1","","2014-06-02","2014-09-29","2023-06-23 00:00:00","2023-09-28 21:10:55" +"12","alzheimers-disease-big-data","Alzheimer's Disease Big Data","","The goal of the Alzheimer's Disease Big Data DREAM Challenge #1 (AD#1) was to apply an open science approach to rapidly identify accurate predictive AD biomarkers that can be used by the scientific, industrial and regulatory communities to improve AD diagnosis and treatment. AD#1 will be the first in a series of AD Data Challenges to leverage genetics and brain imaging in combination with cognitive assessments, biomarkers and demographic information from cohorts ranging from cognitively normal to mild cognitively impaired to individuals with AD.","","https://www.synapse.org/#!Synapse:syn2290704","completed","intermediate","1","","2014-06-02","2014-10-17","2023-06-23 00:00:00","2023-09-28 21:11:46" +"13","olfaction-prediction","Olfaction Prediction","","The goal of the DREAM Olfaction Prediction Challenge is to find models that can predict how a molecule smells from its physical and chemical features. A model that allows us to predict a smell from a molecule will provide fundamental insights into how odor chemicals are transformed into a smell percept in the brain. Further, being able to predict how a chemical smells will greatly accelerate the design of new molecules to be used as fragrances. Currently, fragrance chemists synthesize many molecules to obtain a new ingredient, but most of these will not have the desired qualities.","","https://www.synapse.org/#!Synapse:syn2811262","completed","intermediate","1","","2015-01-15","2015-05-01","2023-06-23 00:00:00","2023-09-28 21:13:07" +"14","prostate-cancer","Prostate Cancer","","This challenge will attempt to improve the prediction of survival and toxicity of docetaxel treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary benefit of this Challenge will be to establish new quantitative benchmarks for prognostic modeling in mCRPC, with a potential impact for clinical decision making and ultimately understanding the mechanism of disease progression. Participating teams will be asked to submit predictive models based on clinical variables from the comparator arms of four phase III clinical trials with over 2,000 mCRPC patients treated with first-line docetaxel. The comparator arm of a clinical trial represents the patients that receive a treatment that is considered to be effective. This arm of the clinical trial is used to evaluate the effectiveness of the new therapy being tested.","","https://www.synapse.org/#!Synapse:syn2813558","completed","intermediate","1","","2015-03-16","2015-07-27","2023-06-23 00:00:00","2023-09-28 21:15:02" +"15","als-stratification-prize4life","ALS Stratification Prize4Life","","As illustrated by the overview figure below, (a) Challenge Data includes data from ALS clinical trials and ALS registries. ALS clinical trials consist of patients from clinical trials available open access on the PRO-ACT database and patients from 6 clinical trials not yet added into the database. Data from ALS registries was collected from patients in national ALS registries. (b) Data is divided into three subsets: training data provided to solvers in full, leaderboard, and validation data that is available only to the organizers and is reserved for the scoring of the challenge. (c) The goal of this challenge is then to predict the Clinical Targets, i.e. the disease progression as ALSFRS slope as well as survival. (d) For Building the Models, participants create two algorithms - one that selects features and one that predicts outcomes. To perform predictions, data from a given patient (1) is fed into the selector (2). The selector selects 6 features and a cluster/model ID (3), e....","","https://www.synapse.org/#!Synapse:syn2873386","completed","intermediate","1","","2015-06-22","2015-10-04","2023-06-23 00:00:00","2023-09-28 21:17:40" +"16","astrazeneca-sanger-drug-combination-prediction","AstraZeneca-Sanger Drug Combination Prediction","","To accelerate the understanding of drug synergy, AstraZeneca has partnered with the European Bioinformatic Institute, the Sanger Institute, Sage Bionetworks, and the distributed DREAM community to launch the AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge. This Challenge is designed to explore fundamental traits that underlie effective combination treatments and synergistic drug behavior using baseline genomic data, i.e. data collected pretreatment. As the basis of the Challenge, AstraZeneca is releasing ~11.5k experimentally tested drug combinations measuring cell viability over 118 drugs and 85 cancer cell lines (primarily colon, lung, and breast), and monotherapy drug response data for each drug and cell line. Moreover, in coordination with the Genomics of Drug Sensitivity in Cancer and COSMIC teams at the Sanger Institute, genomic data including gene expression, mutations (whole exome), copy-number alterations, and methylation data will be released into the publ...","","https://www.synapse.org/#!Synapse:syn4231880","completed","intermediate","1","","2015-09-03","2016-03-14","2023-06-23 00:00:00","2023-09-28 21:25:53" +"17","smc-dna-meta","SMC-DNA Meta","","The goal of this Challenge is to identify the most accurate meta-pipeline for somatic mutation detection, and establish the state-of-the-art. The algorithms in this Challenge must use as input mutations predicted by one or more variant callers and output mutation calls associated with cancer. An additional goal is to highlight the complementarity of the calling algorithms and help understand their individual advantages/deficiencies.","","https://www.synapse.org/#!Synapse:syn4588939","completed","intermediate","1","","2015-08-17","2016-04-10","2023-06-23 00:00:00","2023-09-28 21:27:11" +"18","smc-het","SMC-Het","","The ICGC-TCGA DREAM Somatic Mutation Calling - Tumour Heterogeneity Challenge (SMC-Het) is an international effort to improve standard methods for subclonal reconstruction: to quantify and genotype each individual cell population present within a tumor. Leaders of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) cancer genomics projects are joining with Sage Bionetworks and IBM-DREAM to initiate this innovative open crowd-sourced Challenge [1-3].","","https://www.synapse.org/#!Synapse:syn2813581","completed","intermediate","1","","2015-11-16","2016-06-30","2023-06-23 00:00:00","2023-09-28 21:27:27" +"19","respiratory-viral","Respiratory Viral","","Respiratory viruses are highly infectious and cause acute illness in millions of people every year. However, there is wide variation in the physiologic response to exposure at the individual level. Some people that are exposed to virus are able to completely avoid infection. Others contract virus but are able to fight it off without exhibiting any symptoms of illness such as coughing, sneezing, sore throat or fever. It is not well understood what characteristics may protect individuals from respiratory viral infection. These individual responses are likely influenced by multiple processes including both the basal state of the human host upon exposure and the dynamics of host immune response in the early hours immediately following exposure. Many of these processes play out in the peripheral blood through activation and recruitment of circulating immune cells. Global gene expression patterns measured in peripheral blood at the time of symptom onset - several days after viral exposu...","","https://www.synapse.org/#!Synapse:syn5647810","completed","intermediate","1","","2016-05-16","2016-09-28","2023-06-23 00:00:00","2023-09-28 21:28:17" +"20","disease-module-identification","Disease Module Identification","","The Disease Module Identification DREAM Challenge is an open community effort to systematically assess module identification methods on a panel of state-of-the-art genomic networks and leverage the “wisdom of crowds” to discover novel modules and pathways underlying complex diseases.","","https://www.synapse.org/#!Synapse:syn6156761","completed","intermediate","1","","2016-06-24","2016-10-01","2023-06-23 00:00:00","2023-09-28 21:29:53" +"21","encode","ENCODE","","Transcription factors (TFs) are regulatory proteins that bind specific DNA sequence patterns (motifs) in the genome and affect transcription rates of target genes. Binding sites of TFs differ across cell types and experimental conditions. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is an experimental method that is commonly used to obtain the genome-wide binding profile of a TF of interest in a specific cell type/condition. However, profiling the binding landscape of every TF in every cell type/condition is infeasible due to constraints on cost, material and effort. Hence, accurate computational prediction of in vivo TF binding sites is critical to complement experimental results.","","https://www.synapse.org/#!Synapse:syn6131484","completed","intermediate","1","","2016-07-07","2017-01-11","2023-06-23 00:00:00","2023-09-28 21:30:21" +"22","idea","Idea","","The DREAM Idea Challenge is designed to collaboratively shape and enable the solution of a question fundamental to improving human health. In the process, all proposals and their evaluation will be made publicly available for the explicit purpose of connecting modelers and experimentalists who want to address the same question. This Wall of Models will enable new collaborations, and help turn every good modeling idea into a success story. It will further serve as a basis for new DREAM challenges.","","https://www.synapse.org/#!Synapse:syn5659209","completed","advanced","1","","2016-06-15","2017-04-30","2023-06-23 00:00:00","2023-09-28 21:31:30" +"23","smc-rna","SMC-RNA","","The ICGC-TCGA DREAM Somatic Mutation Calling - RNA Challenge (SMC-RNA) is an international effort to improve standard methods for identifying cancer-associated rearrangements in RNA sequencing (RNA-seq) data. Leaders of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) cancer genomics projects are joining with Sage Bionetworks and IBM-DREAM to initiate this innovative open crowd-sourced Challenge [1-3].","","https://www.synapse.org/#!Synapse:syn2813589","completed","intermediate","1","","2016-06-29","2017-05-02","2023-06-23 00:00:00","2023-09-28 21:31:54" +"24","digital-mammography","Digital Mammography","","The Digital Mammography DREAM Challenge will attempt to improve the predictive accuracy of digital mammography for the early detection of breast cancer. The primary benefit of this Challenge will be to establish new quantitative tools - machine learning, deep learning or other - that can help decrease the recall rate of screening mammography, with a potential impact on shifting the balance of routine breast cancer screening towards more benefit and less harm. Participating teams will be asked to submit predictive models based on over 640,000 de-identified digital mammography images from over 86000 subjects, with corresponding clinical variables.","","https://www.synapse.org/#!Synapse:syn4224222","completed","advanced","1","10.1001/jamanetworkopen.2020.0265","2016-11-18","2017-05-16","2023-06-23 00:00:00","2023-09-28 21:32:18" +"25","multiple-myeloma","Multiple Myeloma","","Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, with about 25,000 newly diagnosed patients per year in the United States alone. The disease's clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells.1 Since risk-adapted therapy is becoming standard of care, there is an urgent need for a precise risk stratification model to assist in therapeutic decision-making and research. While progress has been made, there remains a significant opportunity to improve patient stratification to optimize treatment and to develop new therapies for high-risk patients. A DREAM Challenge represents a chance not only to integrate available data and analytical approaches to tackle this important problem, but also provides the ability to benchmark potential methods to identify those with the greatest potential to yield patient care benefits in the future.","","https://www.synapse.org/#!Synapse:syn6187098","completed","intermediate","1","","2017-06-30","2017-11-08","2023-06-23 00:00:00","2023-09-28 21:33:21" +"26","ga4gh-dream-workflow-execution","GA4GH-DREAM Workflow Execution","","The highly distributed and disparate nature of genomic and clinical data generated around the world presents an enormous challenge for those scientists who wish to integrate and analyze these data. The sheer volume of data often exceeds the capacity for storage at any one site and prohibits the efficient transfer between sites. To address this challenge, researchers must bring their computation to the data. Numerous groups are now developing technologies and best practice methodologies for running portable and reproducible genomic analysis pipelines as well as tools and APIs for discovering genomic analysis resources. Software development, deployment, and sharing efforts in these groups commonly rely on the use of modular workflow pipelines and virtualization based on Docker containers and related tools.","","https://www.synapse.org/#!Synapse:syn8507133","completed","intermediate","1","","2017-07-21","2017-12-31","2023-06-23 00:00:00","2023-09-28 21:34:08" +"27","parkinsons-disease-digital-biomarker","Parkinson's Disease Digital Biomarker","","The Parkinson's Disease Digital Biomarker DREAM Challenge is a first of it's kind challenge, designed to benchmark methods for the processing of sensor data for development of digital signatures reflective of Parkinson's Disease. Participants will be provided with raw sensor (accelerometer, gyroscope, and magnetometer) time series data recorded during the performance of pre-specified motor tasks, and will be asked to extract data features which are predictive of PD pathology. In contrast to traditional DREAM challenges, this one will focus on feature extraction rather than predictive modeling, and submissions will be evaluated based on their ability to predict disease phenotype using an array of standard machine learning algorithms.","","https://www.synapse.org/#!Synapse:syn8717496","completed","intermediate","1","","2017-07-06","2017-11-10","2023-06-23 00:00:00","2023-09-28 21:34:49" +"28","nci-cptac-proteogenomics","NCI-CPTAC Proteogenomics","","Cancer is driven by aberrations in the genome [1,2], and these alterations manifest themselves largely in the changes in the structure and abundance of proteins, the main functional gene products. Hence, characterization and analyses of alterations in the proteome has the promise to shed light into cancer development and may improve development of both biomarkers and therapeutics. Measuring the proteome is very challenging, but recent rapid technology developments in mass spectrometry are enabling deep proteomics analysis [3]. Multiple initiatives have been launched to take advantage of this development to characterize the proteome of tumours, such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC). These efforts hold the promise to revolutionize cancer research, but this will only be possible if the community develops computational tools powerful enough to extract the most information from the proteome, and to understand the association between genome, transcriptome and ...","","https://www.synapse.org/#!Synapse:syn8228304","completed","intermediate","1","","2017-06-26","2017-11-20","2023-06-23 00:00:00","2023-09-28 21:36:34" +"29","multi-targeting-drug","Multi-Targeting Drug","","The objective of this challenge is to incentivize development of methods for predicting compounds that bind to multiple targets. In particular, methods that are generalizable to multiple prediction problems are sought. To achieve this, participants will be asked to predict 2 separate compounds, each having specific targets to which they should bind, and a list of anti-targets to avoid. Participants should use the same methods to produce answers for questions 1 and 2.","","https://www.synapse.org/#!Synapse:syn8404040","completed","intermediate","1","","2017-10-05","2018-02-26","2023-06-23 00:00:00","2023-09-28 21:37:08" +"30","single-cell-transcriptomics","Single Cell Transcriptomics","","In this Challenge on Single-Cell Transcriptomics, participants will reconstruct the location of single cells in the Drosophila embryo using single-cell transcriptomic data. Data will be made available in late August and participating challenge teams can work on the data and submit their results previous to the DREAM Conference. The best performers will be announced at the DREAM conference on Dec 8.","","https://www.synapse.org/#!Synapse:syn15665609","completed","intermediate","1","","2018-09-04","2018-11-21","2023-06-23 00:00:00","2023-09-28 21:37:28" +"31","idg-drug-kinase-binding","IDG Drug-Kinase Binding","","This IDG-DREAM Drug-Kinase Binding Prediction Challenge seeks to evaluate the power of statistical and machine learning models as a systematic and cost-effective means for catalyzing compound-target interaction mapping efforts by prioritizing most potent interactions for further experimental evaluation. The Challenge will focus on kinase inhibitors, due to their clinical importance [2], and will be implemented in a screening-based, pre-competitive drug discovery project in collaboration with theIlluminating the Druggable Genome (IDG) Kinase-focused Data and Resource Generation Center, consortium, with the aim to establish kinome-wide target profiles of small-molecule agents, with the goal of extending the druggability of the human kinome space.","","https://www.synapse.org/#!Synapse:syn15667962","completed","intermediate","1","","2018-10-01","2019-04-18","2023-06-23 00:00:00","2023-09-28 21:37:39" +"32","malaria","Malaria","","The Malaria DREAM Challenge is open to anyone interested in contributing to the development of computational models that address important problems in advancing the fight against malaria. The overall goal of the first Malaria DREAM Challenge is to predict Artemisinin (Art) drug resistance level of a test set of malaria parasites using their in vitro transcription data and a training set consisting of published in vivo and unpublished in vitrotranscriptomes. The in vivodataset consists of ~1000 transcription samples from various geographic locations covering a wide range of life cycles and resistance levels, with other accompanying data such as patient age, geographic location, Art combination therapy used, etc [Mok et al (2015) Science]. The in vitro transcription dataset consists of 55 isolates, with transcription collected at two timepoints (6 and 24 hours post-invasion), in the absence or presence of an Art perturbation, for two biological replicates using a custom microarray a...","","https://www.synapse.org/#!Synapse:syn16924919","completed","intermediate","1","","2019-04-30","2019-08-15","2023-06-23 00:00:00","2023-09-28 21:38:10" +"33","preterm-birth-prediction-transcriptomics","Preterm Birth Prediction - Transcriptomics","","A basic need in pregnancy care is to establish gestational age, and inaccurate estimates may lead to unnecessary interventions and sub-optimal patient management. Current approaches to establish gestational age rely on patient's recollection of her last menstrual period and/or ultrasound, with the latter being not only costly but also less accurate if not performed during the first trimester of pregnancy. Therefore development of an inexpensive and accurate molecular clock of pregnancy would be of benefit to patients and health care systems. Participants in sub-challenge 1 (Prediction of gestational age) will be given whole blood gene topic_3170 collected from pregnant women to develop prediction models for the gestational age at blood draw. Another challenge in obstetrics, in both low and high-income countries, is identification and treatment of women at risk of developing the ‘great obstetrical syndromes‘. Of these, preterm birth (PTB), defined as giving birth prior to comple...","","https://www.synapse.org/#!Synapse:syn18380862","completed","good_for_beginners","1","","2019-05-04","2019-12-05","2023-06-23 00:00:00","2023-09-28 18:24:55" +"34","single-cell-signaling-in-breast-cancer","Single-Cell Signaling in Breast Cancer","","Signaling underlines nearly every cellular event. Individual cells, even if genetically identical, respond to perturbation in different ways. This underscores the relevance of cellular heterogeneity, in particular in how cells respond to drugs. This is of high relevance since the fact that a subset of cells do not respond (or only weakly) to drugs can render this drug an ineffective treatment. In spite of its relevance to many diseases, comprehensive studies on the heterogeneous signaling in single cells are still lacking. We have generated the, to our knowledge, currently largest single cell signaling dataset on a panel of 67 well-characterized breast cancer cell lines by mass cytometry (3'015 conditions, ~80 mio single cells, 38 markers; Bandura et al. 2009; Bendall et al., 2011; Bodenmiller et al., 2012; Lun et al., 2017; Lun et al., 2019). These cell lines are, among others, also characterized at the genomic, transcriptomic, and proteomic level (Marcotte et al., 2016). W...","","https://www.synapse.org/#!Synapse:syn20366914","completed","intermediate","1","","2018-08-20","2019-11-15","2023-06-23 00:00:00","2023-09-28 21:24:07" +"35","ehr-dream-challenge-patient-mortality-prediction","EHR DREAM Challenge: Patient Mortality Prediction","","The recent advent of new CRISPR-based molecular tools allows the reconstruction of cell lineages based on the phylogenetical analysis of DNA mutations induced by CRISPR during development and promises to solve the lineage of complex model organisms at single-cell resolution (see image from McKenna et al Science 2016). To date, however, no lineage reconstruction algorithms have been rigorously examined for their performance/robustness across diverse molecular tools, datasets, and number of cells/size of lineage trees. It also remains unclear whether new Machine-Learning algorithms that go beyond the classical ones developed for reconstructing phylogenetic trees, could consistently reconstruct cell lineages to a high degree of accuracy. The challenge - a partnership between The Allen Institute and DREAM - will comprise 3 subchallenges that consist of reconstructing cell lineage trees of different sizes and nature. In subchallenge 1, participants will be given experimental molecula...","","https://www.synapse.org/#!Synapse:syn18405991","completed","intermediate","1","https://doi.org/10.1093/jamia/ocad159","2019-09-09","2020-01-23","2023-06-23 00:00:00","2023-09-28 21:40:02" +"36","allen-institute-cell-lineage-reconstruction","Allen Institute Cell Lineage Reconstruction","","The recent advent of new CRISPR-based molecular tools allows the reconstruction of cell lineages based on the phylogenetical analysis of DNA mutations induced by CRISPR during development and promises to solve the lineage of complex model organisms at single-cell resolution. To date, however, no lineage reconstruction algorithms have been rigorously examined for their performance/robustness across diverse molecular tools, datasets, and number of cells/size of lineage trees. It also remains unclear whether new Machine-Learning algorithms that go beyond the classical ones developed for reconstructing phylogenetic trees, could consistently reconstruct cell lineages to a high degree of accuracy. The challenge - a partnership between The Allen Institute and DREAM - will comprise 3 subchallenges that consist of reconstructing cell lineage trees of different sizes and nature. In subchallenge 1, participants will be given experimental molecular data to reconstruct in vitro cell lineages ...","","https://www.synapse.org/#!Synapse:syn20692755","completed","intermediate","1","","2019-10-15","2020-02-06","2023-06-23 00:00:00","2023-09-28 21:40:13" +"37","tumor-deconvolution","Tumor Deconvolution","","The extent of stromal and immune cell infiltration within solid tumors has prognostic and predictive significance. Unfortunately, expression profiling of tumors has, until very recently, largely been undertaken using bulk techniques (e.g., microarray and RNA-seq). Unlike single-cell methods (e.g., single-cell RNA-seq, FACS, mass cytometry, or immunohistochemistry), bulk approaches average expression across all cells (cancer, stromal, and immune) within the sample and, hence, do not directly quantitate tumor infiltration. This information can be recovered by computational tumor deconvolution methods, which would thus allow interrogation of immune subpopulations across the large collection of public bulk topic_3170sets. The goal of this Challenge is to evaluate the ability of computational methods to deconvolve bulk topic_3170, reflecting a mixture of cell types, into individual immune components. Methods will be assessed based on in vitro and in silico admixtures specifically ge...","","https://www.synapse.org/#!Synapse:syn15589870","completed","intermediate","1","","2019-06-26","2020-04-30","2023-06-23 00:00:00","2023-09-28 21:41:19" +"38","ctd2-pancancer-drug-activity","CTD2 Pancancer Drug Activity","","NCI Genomic Data Commons,Harvard Chan School, Blue Collar Bioinformatics,ENCODE DCC, Stanford,CCHMC, Barski Lab,KnowEnG, UIUC,UCSC,OICR, ICGC,Broad Institute, GATK","","https://www.synapse.org/#!Synapse:syn20968331","completed","good_for_beginners","1","","2019-12-02","2020-02-13","2023-06-23 00:00:00","2023-09-28 21:41:36" +"39","ctd2-beataml","CTD2 BeatAML","","In the era of precision medicine, AML patients have few therapeutic options, with “7 + 3” induction chemotherapy having been the standard for decades (Bertoli et al. 2017). While several agents targeting the myeloid marker CD33 or alterations in FLT3 or IDH2 have demonstrated efficacy in patients (Wei and Tiong 2017), responses are uncertain in some populations (Castaigne et al. 2012) and relapse remains prevalent (Stone et al. 2017). These drugs highlight both the promise of targeted therapies in AML and the urgent need for additional treatment options that are tailored to more refined patient subpopulations in order to achieve durable responses. The BeatAML initiative was launched as a comprehensive study of the relationship between molecular alterations and ex-vivo drug sensitivity in patients with AML. One of the primary goals of this multi-center study was to develop a discovery cohort that could yield new drug target hypotheses and predictive biomarkers of therapeutic res...","","https://www.synapse.org/#!Synapse:syn20940518","completed","good_for_beginners","1","","2019-12-19","2020-04-28","2023-06-23 00:00:00","2023-09-28 21:41:59" +"40","metadata-automation","Metadata Automation","","The Cancer Research Data Commons (CRDC) will collate data across diverse groups of cancer researchers, each collecting biomedical data in different formats. This means the data must be retrospectively harmonized and transformed to enable this data to be submitted. In addition, to be findable by the broader scientific community, coherent information (metadata) is necessary about the data fields and values. Coherent metadata annotation of the data fields and their values can enable computational data transformation, query, and analysis. Creation of this type of descriptive metadata can require biomedical expertise to determine the best annotations and thus is a time-consuming and manual task which is both an obstacle and a bottleneck in data sharing and submissions. Goal: Using structured biomedical data files, challenge participants will develop tools to semi-automate annotation of metadata fields and values, using available research data annotations (e.g. caDSR CDEs) as well as...","","https://www.synapse.org/#!Synapse:syn18065891","completed","intermediate","1","","2020-01-14","2020-06-02","2023-06-23 00:00:00","2023-09-28 21:42:35" +"41","automated-scoring-of-radiographic-joint-damage","Automated Scoring of Radiographic Joint Damage","","The purpose of the RA2-DREAM Challenge is to develop an automated method to quickly and accurately quantify the degree of joint damage associated with rheumatoid arthritis (RA). Based on radiographs of the hands and feet, a novel, automated scoring method could be applied broadly for patient care and research. We challenge participants to develop algorithms to automatically assess joint space narrowing and erosions using a large set of existing radiographs with damage scores generated by visual assessment of images by trained readers using standard protocols. The end result will be a generalizable, publicly available, automated method to generate accurate, reproducible and unbiased RA damage scores to replace the current tedious, expensive, and non-scalable method of scoring by human visual inspection.","","https://www.synapse.org/#!Synapse:syn20545111","completed","intermediate","1","","2019-11-04","2020-05-21","2023-06-23 00:00:00","2023-09-28 21:42:55" +"42","beat-pd","BEAT-PD","","Recent advances in mobile health have demonstrated great potential to leverage sensor-based technologies for quantitative, remote monitoring of health and disease - particularly for diseases affecting motor function such as Parkinson's disease. Such approaches have been rolled out using research-grade wearable sensors and, increasingly, through the use of smartphones and consumer wearables, such as smart watches and fitness trackers. These devices not only provide the ability to measure much more detailed disease phenotypes but also provide the ability to follow patients longitudinally with much higher frequency than is possible through clinical exams. However, the conversion of sensor-based data streams into digital biomarkers is complex and no methodological standards have yet evolved to guide this process. Parkinson's disease (PD) is a neurodegenerative disease that primarily affects the motor system but also exhibits other symptoms. Typical motor symptoms of the disease inc...","","https://www.synapse.org/#!Synapse:syn20825169","completed","intermediate","1","","2020-01-13","2020-05-13","2023-06-23 00:00:00","2023-09-28 21:43:58" +"43","ctd2-pancancer-chemosensitivity","CTD2 Pancancer Chemosensitivity","","Over the last two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and molecular profiles representative of cellular responses to drug perturbations. PANACEA covers a broad spectrum of cellular contexts representative of poor outcome malignancies, including rare ones such as GIST sarcoma and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). PANACEA is uniquely suited to support DREAM Challenges related to the elucidation of drug mechanism of action (MOA), drug sensitivity, and drug synergy. The goal of this Challenge is to foster development and benchmarking of algorithms to predict the sensitivity, as measured by the area under the dose-response curve, of a cell line to a compound based on the baseline transcriptional profiles of the cell line. The drug perturbational RNAseq profiles of 11 cell lines for 30 chosen compounds will be provided to challenge participants,...","","https://www.synapse.org/#!Synapse:syn21763589","completed","good_for_beginners","1","","2020-04-28","2020-07-27","2023-06-23 00:00:00","2023-09-28 21:44:23" +"44","ehr-dream-challenge-covid-19","EHR DREAM Challenge: COVID-19","","The rapid rise of COVID-19 has challenged healthcare globally. The underlying risks and outcomes of infection are still incompletely characterized even as the world surpasses 4 million infections. Due to the importance and emergent need for better understanding of the condition and the development of patient specific clinical risk scores and early warning tools, we have developed a platform to support testing analytic and machine learning hypotheses on clinical data without data sharing as a platform to rapidly discover and implement approaches for care. We have previously applied this approach in the successful EHR DREAM Challenge focusing on Patient Mortality Prediction with UW Medicine. We have the goal of incorporating machine learning and predictive algorithms into clinical care and COVID-19 is an important and highly urgent challenge. In our first iteration, we will facilitate understanding risk factors that lead to a positive test utilizing electronic health recorded dat...","","https://www.synapse.org/#!Synapse:syn21849255","completed","intermediate","1","https://doi.org/10.1001/jamanetworkopen.2021.24946","2020-04-30","2021-07-01","2023-06-23 00:00:00","2023-09-28 21:44:46" +"45","anti-pd1-response-prediction","Anti-PD1 Response Prediction","","While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1 therapy, there remains a need to improve the ability to predict which patients are more likely to receive benefit from treatment with I-O. The goal of this challenge is to leverage clinical and biomarker data to develop predictive models of response to I-O therapy in lung cancer and ultimately gain insights that may facilitate potential novel monotherapies or combinations with I-O.","","https://www.synapse.org/#!Synapse:syn18404605","completed","intermediate","1","","2020-11-17","2021-02-25","2023-06-23 00:00:00","2023-09-28 21:46:36" +"46","brats-2021-challenge","BraTS 2021 Challenge","","Glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma (WHO Grade 4 astrocytoma), are the most common and aggressive malignant primary tumor of the central nervous system in adults, with extreme intrinsic heterogeneity in appearance, shape, and histology. Glioblastoma patients have very poor prognosis, and the current standard of care treatment comprises surgery, followed by radiotherapy and chemotherapy. The International Brain Tumor Segmentation (BraTS) Challenges —which have been running since 2012— assess state-of-the-art machine learning (ML) methods used for brain tumor image analysis in mpMRI scans.","","https://www.synapse.org/#!Synapse:syn25829067","completed","advanced","1","","2021-07-07","2021-10-15","2023-06-23 00:00:00","2023-09-28 21:45:07" +"47","cancer-data-registry-nlp","Cancer Data Registry NLP","","A critical bottleneck in translational and clinical research is access to large volumes of high-quality clinical data. While structured data exist in medical EHR systems, a large portion of patient information including patient status, treatments, and outcomes is contained in unstructured text fields. Research in Natural Language Processing (NLP) aims to unlock this hidden and often inaccessible information. However, numerous challenges exist in developing and evaluating NLP methods, much of it centered on having “gold-standard” metrics for evaluation, and access to data that may contain personal health information (PHI). This DREAM Challenge will focus on the development and evaluation of of NLP algorithms that can improve clinical trial matching and recruitment.","","https://www.synapse.org/#!Synapse:syn18361217","upcoming","intermediate","1","","\N","\N","2023-06-23 00:00:00","2023-09-28 21:46:04" +"48","barda-community-challenge-pediatric-covid-19-data-challenge","BARDA Community Challenge - Pediatric COVID-19 Data Challenge","","While most children with COVID-19 are asymptomatic or have mild symptoms, healthcare providers have difficulty determining which among their pediatric patients will progress to moderate or severe COVID-19 early in the progression. Some of these patients develop multisystem inflammatory syndrome in children (MIS-C), a life-threatening inflammation of organs and tissues. Methods to distinguish children at risk for severe COVID-19 complications, including conditions such as MIS-C, are needed for earlier interventions to improve pediatric patient outcomes. Multiple HHS divisions are coming together for a data challenge competition that will leverage de-identified electronic health record data to develop, train and validate computational models that can predict severe COVID-19 complications in children, equipping healthcare providers with the information and tools they need to identify pediatric patients at risk.","","https://www.synapse.org/#!Synapse:syn25875374/wiki/611225","completed","intermediate","1","","2021-08-19","2021-12-17","2023-06-23 00:00:00","2023-09-28 21:45:59" +"49","brats-continuous-evaluation","BraTS Continuous Evaluation","","Brain tumors are among the deadliest types of cancer. Specifically, glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma (WHO Grade 4 astrocytoma), are the most common and aggressive malignant primary tumor of the central nervous system in adults, with extreme intrinsic heterogeneity in appearance, shape, and histology, with a median survival of approximately 15 months. Brain tumors in general are challenging to diagnose, hard to treat and inherently resistant to conventional therapy because of the challenges in delivering drugs to the brain, as well as the inherent high heterogeneity of these tumors in their radiographic, morphologic, and molecular landscapes. Years of extensive research to improve diagnosis, characterization, and treatment have decreased mortality rates in the U.S by 7% over the past 30 years. Although modest, these research innovations have not translated to improvements in survival for adults and children in low- and middle-incom...","","https://www.synapse.org/brats_ce","completed","advanced","1","","2022-01-01","\N","2023-06-23 00:00:00","2023-09-28 21:47:08" +"50","fets-2022","FeTS 2022","","FeTS 2022 focuses on benchmarking methods for federated learning (FL), and particularly i) weight aggregation methods for federated training, and ii) algorithmic generalizability on out-of-sample data based on federated evaluation. In line with its last instance (FeTS 2021 - the 1st FL challenge ever organized), FeTS 2022 targets the task of brain tumor segmentation and builds upon i) the centralized dataset of >8,000 clinically-acquired multi-institutional MRI scans (from the RSNA-ASNR-MICCAI BraTS 2021 challenge) with their real-world partitioning, and ii) the collaborative network of remote independent institutions included in a real-world federation. Participants are welcome to compete in either of the two challenge tasks: Task 1 (“Federated Training”) seeks effective weight aggregation methods for the creation of a consensus model given a pre-defined segmentation algorithm for training, while also (optionally) accounting for network outages. Task 2 (“Federated Evaluation”) ...","","https://www.synapse.org/#!Synapse:syn28546456/wiki/617093","completed","advanced","1","","2022-04-08","2022-08-15","2023-06-23 00:00:00","2023-09-28 21:47:45" +"51","random-promotor","Random Promotor","","Decoding how gene expression is regulated is critical to understanding disease. Regulatory DNA is decoded by the cell in a process termed “cis-regulatory logic”, where proteins called Transcription Factors (TFs) bind to specific DNA sequences within the genome and work together to produce as output a level of gene expression for downstream adjacent genes. This process is exceedingly complex to model as a large number of parameters is needed to fully describe the process (see Rationale, de Boer et al. 2020; Zeitingler J. 2020). Understanding the cis-regulatory logic of the human genome is an important goal and would provide insight into the origins of many diseases. However, learning models from human data is challenging due to limitations in the diversity of sequences present within the human genome (e.g. extensive repetitive DNA), the vast number of cell types that differ in how they interpret regulatory DNA, limited reporter assay data, and substantial technical biases present ...","","https://www.synapse.org/#!Synapse:syn28469146/wiki/617075","completed","intermediate","1","","2022-05-02","2022-08-07","2023-06-23 00:00:00","2023-09-28 21:48:01" +"52","preterm-birth-prediction-microbiome","Preterm Birth Prediction - Microbiome","","Globally, about 11% of infants every year are born preterm, defined as birth prior to 37 weeks of gestation, totaling nearly 15 million births.(5) In addition to the emotional and financial toll on families, preterm births have higher rates of neonatal death, nearly 1 million deaths each year, and long-term health consequences for some children. Infants born preterm are at risk for a variety of adverse outcomes, such as respiratory illnesses, cerebral palsy, infections, and blindness, with infants born very preterm (i.e., before 32 weeks) at increased risk of these conditions.(6) The ability to accurately predict which women are at a higher risk for preterm birth would help healthcare providers to treat in a timely manner those at higher risk of delivering preterm. Currently available treatments for pregnant women at risk of preterm delivery include corticosteroids for fetal maturation and magnesium sulfate provided prior to 32 weeks to prevent cerebral palsy.(7) There are sever...","","https://www.synapse.org/#!Synapse:syn26133770/wiki/612541","completed","advanced","1","","2022-07-19","2022-09-16","2023-06-23 00:00:00","2023-09-28 21:49:33" +"53","finrisk","FINRISK - Heart Failure and Microbiome","","Cardiovascular diseases are the leading cause of death both in men and women worldwide. Heart failure (HF) is the most common form of heart disease, characterised by the heart's inability to pump a sufficient supply of blood to meet the needs of the body. The lifetime risk of developing HF is roughly 20%, yet, it remains difficult to diagnose due to its and a lack of agreement of diagnostic criteria. As the diagnosis of HF is dependent on ascertainment of clinical histories and appropriate screening of symptomatic individuals, identifying those at risk of HF is essential. This DREAM challenge focuses on the prediction of HF using a combination of gut microbiome and clinical variables. This challenge is designed to predict incident risk for heart failure in a large human population study of Finnish adults, FINRISK 2002 (Borodulin et al., 2018). The FINRISK study has been conducted in Finland to investigate the risk factors for cardiovascular disease every 5 years since 1972. A ran...","","https://www.synapse.org/#!Synapse:syn27130803/wiki/616705","completed","advanced","1","","2022-09-20","2023-01-30","2023-06-23 00:00:00","2023-09-28 21:49:51" +"54","scrna-seq-and-scatac-seq-data-analysis","scRNA-seq and scATAC-seq Data Analysis","","Understanding transcriptional regulation at individual cell resolution is fundamental to understanding complex biological systems such as tissues and organs. Emerging high-throughput sequencing technologies now allow for transcript quantification and chromatin accessibility at the single cell level. These technologies present unique challenges due to inherent data sparsity. Proper signal correction is key to accurate gene expression quantification via scRNA-seq, which propagates into downstream analyses such as differential gene expression analysis and cell-type identification. In the even more sparse scATAC-seq data, the correct identification of informative features is key to assessing cell heterogeneity at the chromatin level. The aims of this challenge will be two-fold: 1) To evaluate computational methods for signal correction and peak identification in scRNA-seq and scATAC-seq, respectively; 2) To assess the impact of these methods on downstream analysis","","https://www.synapse.org/#!Synapse:syn26720920/wiki/615338","completed","advanced","1","","2022-11-29","2023-02-08","2023-06-23 00:00:00","2023-09-28 21:50:07" +"55","cough-diagnostic-algorithm-for-tuberculosis","COugh Diagnostic Algorithm for Tuberculosis","","Tuberculosis (TB), a communicable disease caused by Mycobacterium tuberculosis, is a major cause of ill health and one of the leading causes of death worldwide. Until the COVID-19 pandemic, TB was the leading cause of death from a single infectious agent, ranking even above HIV/AIDS. In 2020, an estimated 9.9 million people fell ill with TB and 1.3 million died of TB worldwide. However, approximately 40% of people with TB were not diagnosed or reported to public health authorities because of challenges in accessing health facilities or failure to be tested or treated when they do. The development of low-cost, non-invasive digital screening tools may improve some of the gaps in diagnosis. As cough is a common symptom of TB, it has the potential to be used as a biomarker for diagnosis of disease. Several previous studies have demonstrated the potential for cough sounds to be used to screen for TB[1-3], though these were typically done in small samples or limited settings. Further ...","","https://www.synapse.org/#!Synapse:syn31472953/wiki/617828","completed","advanced","1","","2022-10-16","2023-02-13","2023-06-23 00:00:00","2023-09-28 21:51:27" +"56","nih-long-covid-computational-challenge","NIH Long COVID Computational Challenge","","The overall prevalence of post-acute sequelae of SARS-CoV-2 (PASC) is currently unknown, but there is growing evidence that more than half of COVID-19 survivors experience at least one symptom of PASC/Long COVID at six months after recovery of the acute illness. Reports also reflect an underlying heterogeneity of symptoms, multi-organ involvement, and persistence of PASC/Long COVID in some patients. Research is ongoing to understand prevalence, duration, and clinical outcomes of PASC/Long COVID. Symptoms of fatigue, cognitive impairment, shortness of breath, and cardiac damage, among others, have been observed in patients who had only mild initial disease. The breadth and complexity of data created in today's health care encounters require advanced analytics to extract meaning from longitudinal data on symptoms, laboratory results, images, functional tests, genomics, mobile health/wearable devices, written notes, electronic health records (EHR), and other relevant data types. Adva...","","https://www.synapse.org/#!Synapse:syn33576900/wiki/618451","completed","intermediate","1","","2022-08-25","2022-12-15","2023-06-23 00:00:00","2023-09-28 21:52:03" +"57","bridge2ai","Bridge2AI","What makes a good color palette?","What makes a good color palette?","","","upcoming","good_for_beginners","1","","\N","\N","2023-06-23 00:00:00","2023-09-28 21:53:15" +"58","rare-x-open-data-science","RARE-X Open Data Science","","The Xcelerate RARE: A Rare Disease Open Science Data Challenge is bringing together researchers and data scientists in a collaborative and competitive environment to make the best use of patient-provided data to solve big unknowns in healthcare. The Challenge will launch to researchers in late May 2023, focused on rare pediatric neurodevelopmental diseases.","","https://www.synapse.org/#!Synapse:syn51198355/wiki/621435","completed","intermediate","1","","2023-05-17","2023-08-16","2023-06-23 00:00:00","2023-09-28 21:53:17" +"59","cagi5-regulation-saturation","CAGI5: Regulation saturation","","17,500 single nucleotide variants (SNVs) in 5 human disease associated enhancers (including IRF4, IRF6, MYC, SORT1) and 9 promoters (including TERT, LDLR, F9, HBG1) were assessed in a saturation mutagenesis massively parallel reporter assay. Promoters were cloned into a plasmid upstream of a tagged reporter construct, and reporter expression was measured relative to the plasmid DNA to determine the impact of promoter variants. Enhancers were placed upstream of a minimal promoter and assayed similarly. The challenge is to predict the functional effects of these variants in the regulatory regions as measured from the reporter expression.","","https://genomeinterpretation.org/cagi5-regulation-saturation.html","completed","intermediate","2","","2018-01-04","2018-05-03","2023-06-23 00:00:00","2023-09-28 21:53:44" +"60","cagi5-calm1","CAGI5: CALM1","","Calmodulin is a calcium-sensing protein that modulates the activity of a large number of proteins in the cell. It is involved in many cellular processes, and is especially important for neuron and muscle cell function. Variants that affect calmodulin function have been found to be causally associated with cardiac arrhythmias. A large library of calmodulin missense variants was assessed with respect to their effects on protein function using a high-throughput yeast complementation assay. The challenge is to predict the functional effects of these calmodulin variants on competitive growth in a high-throughput yeast complementation assay.","","https://genomeinterpretation.org/cagi5-calm1.html","completed","intermediate","2","","2017-10-21","2017-12-20","2023-06-23 00:00:00","2023-09-28 21:53:50" +"61","cagi5-pcm1","CAGI5: PCM1","","The PCM1 (Pericentriolar Material 1) gene is a component of centriolar satellites occurring around centrosomes in vertebrate cells. Several studies have implicated PCM1 variants as a risk factor for schizophrenia. Ventricular enlargement is one of the most consistent abnormal structural brain findings in schizophrenia Therefore 38 transgenic human PCM1 missense mutations implicated in schizophrenia were assayed in a zebrafish model to determine their impact on the posterior ventricle area. The challenge is to predict whether variants implicated in schizophrenia impact zebrafish ventricular area.","","https://genomeinterpretation.org/cagi5-pcm1.html","completed","intermediate","2","","2017-11-09","2018-04-19","2023-06-23 00:00:00","2023-09-28 21:53:51" +"62","cagi5-frataxin","CAGI5: Frataxin","","Fraxatin is a highly-conserved protein found in prokaryotes and eukaryotes that is required for efficient regulation of cellular iron homeostasis. Humans with a frataxin deficiency have the cardio- and neurodegenerative disorder Friedreich's ataxia. A library of eight missense variants was assessed by near and far-UV circular dichroism and intrinsic fluorescence spectra to determine thermodynamic stability at different concentration of denaturant. These were used to calculate a ΔΔGH20 value, the difference in unfolding free energy (ΔGH20) between the mutant and wild-type proteins for each variant. The challenge is to predict ΔΔGH20 for each frataxin variant.","","https://genomeinterpretation.org/cagi5-frataxin.html","completed","intermediate","2","","2017-11-30","2018-04-18","2023-06-23 00:00:00","2023-09-28 21:54:19" +"63","cagi5-tpmt-and-p10","CAGI5: TPMT and p10","","The gene p10 encodes for PTEN (Phosphatase and TEnsin Homolog), an important secondary messenger molecule promoting cell growth and survival through signaling cascades including those controlled by AKT and mTOR. Thiopurine S-methyl transferase (TPMT) is a key enzyme involved in the metabolism of thiopurine drugs and functions by catalyzing the S-methylation of aromatic and heterocyclic sulfhydryl groups. A library of thousands of PTEN and TPMT mutations was assessed to measure the stability of the variant protein using a multiplexed variant stability profiling (VSP) assay, which detects the presence of EGFP fused to the mutated PTEN and TPMT protein respectively. The stability of the variant protein dictates the abundance of the fusion protein and thus the EGFP level of the cell. The challenge is to predict the effect of each variant on TPMT and/or PTEN protein stability.","","https://genomeinterpretation.org/cagi5-tpmt.html","completed","intermediate","2","","2017-11-30","2017-12-01","2023-06-23 00:00:00","2023-09-28 21:53:56" +"64","cagi5-annotate-all-nonsynonymous-variants","CAGI5: Annotate all nonsynonymous variants","","dbNSFP describes 810,848,49 possible protein-altering variants in the human genome. The challenge is to predict the functional effect of every such variant. For the vast majority of these missense variants, the functional impact is not currently known, but experimental and clinical evidence are accruing rapidly. Rather than drawing upon a single discrete dataset as typical with CAGI, predictions will be assessed by comparing with experimental or clinical annotations made available after the prediction submission date, on an ongoing basis. if predictors assent, predictions will also incorporated into dbNSFP.","","https://genomeinterpretation.org/cagi5-annotate-all-missense.html","completed","intermediate","2","","2017-11-30","2018-05-09","2023-06-23 00:00:00","2023-09-28 21:53:56" +"65","cagi5-gaa","CAGI5: GAA","","Acid alpha-glucosidase (GAA) is a lysosomal alpha-glucosidase. Some mutations in GAA cause a rare disorder, Pompe disease, (Glycogen Storage Disease II). Rare GAA missense variants found in a human population sample have been assayed for enzymatic activity in transfected cell lysates. The assessment of this challenge will include evaluations that recognize novelty of approach. The challenge is to predict the fractional enzyme activity of each mutant protein compared to the wild-type enzyme.","","https://genomeinterpretation.org/cagi5-gaa.html","completed","intermediate","2","","2017-11-09","2018-04-25","2023-06-23 00:00:00","2023-09-28 21:53:57" +"66","cagi5-chek2","CAGI5: CHEK2","","Variants in the CHEK2 gene are associated with breast cancer. This challenge includes CHEK2 gene variants from approximately 1200 Latino breast cancer cases and 1200 ethnically matched controls. This challenge is to estimate the probability of each gene variant occurring in an individual from the cancer affected cohort.","","https://genomeinterpretation.org/cagi5-chek2.html","completed","intermediate","2","","2017-12-20","2018-04-24","2023-06-23 00:00:00","2023-09-28 21:53:57" +"67","cagi5-enigma","CAGI5: ENIGMA","","Breast cancer is the most prevalent cancer among women worldwide. The association between germline mutations in the BRCA1 and BRCA2 genes and the development of cancer has been well established. The most common high-risk mutations associated with breast cancer are those in the autosomal dominant breast cancer genes 1 and 2 (BRCA1 and BRCA2). Mutations in these genes are found in 1-3% of breast cancer cases. The challenge is to predict which variants are associated with increased risk for breast cancer.","","https://genomeinterpretation.org/cagi5-enigma.html","completed","intermediate","2","","2017-12-20","2018-05-01","2023-06-23 00:00:00","2023-09-28 21:53:58" +"68","cagi5-mapsy","CAGI5: MaPSy","","The Massively Parallel Splicing Assay (MaPSy) approach was used to screen 797 reported exonic disease mutations using a mini-gene system, assaying both in vivo via transfection in tissue culture, and in vitro via incubation in cell nuclear extract. The challenge is to predict the degree to which a given variant causes changes in splicing.","","https://genomeinterpretation.org/cagi5-mapsy.html","completed","intermediate","2","","2017-11-29","2018-05-07","2023-06-23 00:00:00","2023-09-28 21:53:58" +"69","cagi5-vex-seq","CAGI5: Vex-seq","","A barcoding approach called Variant exon sequencing (Vex-seq) was applied to assess effect of 2,059 natural single nucleotide variants and short indels on splicing of a globin mini-gene construct transfected into HepG2 cells. This is reported as ΔΨ (delta PSI, or Percent Spliced In), between the variant Ψand the reference Ψ. The challenge is to predict ΔΨ for each variant.","","https://genomeinterpretation.org/cagi5-vex-seq.html","completed","intermediate","2","","2017-12-14","2018-05-02","2023-06-23 00:00:00","2023-09-28 21:53:58" +"70","cagi5-sickkids-clinical-genomes","CAGI5: SickKids clinical genomes","","This challenge involves 30 children with suspected genetic disorders who were referred for clinical genome sequencing. Predictors are given the 30 genome sequences, and are also provided with the phenotypic descriptions as shared with the diagnostic laboratory. The challenge is to predict what class of disease is associated with each genome, and which genome corresponds to which clinical description. Predictors may additionally identify the diagnostic variant(s) underlying the predictions, and identify predictive secondary variants conferring high risk of other diseases whose phenotypes are not reported in the clinical descriptions.","","https://genomeinterpretation.org/cagi5-sickkids5.html","completed","intermediate","2","","2017-12-22","2018-04-26","2023-06-23 00:00:00","2023-09-28 21:53:59" +"71","cagi5-id-panel","CAGI5: ID Panel","","The challenge presented here is to use computational methods to predict a patient's clinical phenotype and the causal variant(s) based on analysis of their gene panel sequence data. Sequence data for 74 genes associated with intellectual disability (ID) and/or Autism spectrum disorders (ASD) from a cohort of 150 patients with a range of neurodevelopmental presentations (ID, autism, epilepsy, etc..) have been made available for this challenge. For each patient, predictors must report the causative variants and which of seven phenotypes are present.","","https://genomeinterpretation.org/cagi5-intellectual-disability.html","completed","intermediate","2","","2017-12-22","2018-04-30","2023-06-23 00:00:00","2023-09-28 21:54:00" +"72","cagi5-clotting-disease-exomes","CAGI5: Clotting disease exomes","","African Americans have a higher incidence of developing venous thromboembolisms (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), than people of European ancestry. Participants are provided with exome data and clinical covariates for a cohort of African Americans who have been prescribed Warfarin either because they had experienced a VTE event or had been diagnosed with atrial fibrillation (which predisposes to clotting). The challenge is to distinguish between these conditions. At present, in contrast to European ancestry, there are no genetic methods for anticipating which African Americans are most at risk of a venous thromboembolism, and the results of this challenge may contribute to the development of such tools.","","https://genomeinterpretation.org/cagi5-clotting-disease.html","completed","intermediate","2","","2017-11-23","2018-04-28","2023-06-23 00:00:00","2023-09-28 21:54:01" +"73","cagi6-sickkids-clinical-genomes-and-transcriptomes","CAGI6: SickKids clinical genomes and transcriptomes","","This challenge involves data from 79 children who were referred to The Hospital for Sick Children's (SickKids) Genome Clinic for genome sequencing because of suspected but undiagnosed genetic disorders. Research subjects are consented for sharing of their sequence data and phenotype information with researchers working to understand the molecular causes of rare disease. When a candidate disease variant believed to be related to the phenotype is identified, the variant is adjudicated and confirmed in a clinical setting. In this challenge, transcriptomic and phenotype data from a subset of the “solved” (diagnosed) and “unsolved” SickKids patients will be provided, along with corresponding genomic sequence data. The challenge is to use a transcriptome-driven approach to identify the gene(s) and molecular mechanisms underlying the phenotypic descriptions in each case. For the unsolved cases, prioritized variants from the participating teams will be examined to see if additional diagno...","","https://genomeinterpretation.org/cagi6-sickkids.html","completed","intermediate","1","","2021-08-04","2021-12-31","2023-06-23 00:00:00","2023-08-09 08:43:37" +"74","cagi6-cam","CAGI6: CaM","","Calmodulin (CaM) is a ubiquitous calcium (Ca2+) sensor protein interacting with more than 200 molecular partners, thereby regulating a variety of biological processes. Missense point mutations in the genes encoding CaM have been associated with ventricular tachycardia and sudden cardiac death. A library encompassing up to 17 point mutations was assessed by far-UV circular dichroism (CD) by measuring melting temperature (Tm) and percentage of unfolding (%unfold) upon thermal denaturation at pH and salt concentration that mimic the physiological conditions. The challenge is to predict: (1) the Tm and %unfold values for isolated CaM variants under Ca2+-saturating conditions (Ca2+-CaM) and in the Ca2+-free (apo) state; (2) whether the point mutation stabilizes or destabilizes the protein (based on Tm and %unfold).","","https://genomeinterpretation.org/cagi6-cam.html","completed","intermediate","1","","2021-06-08","2021-10-11","2023-06-23 00:00:00","2023-09-28 21:54:01" +"75","cami-ii","CAMI II","","CAMI II offers several challenges: an assembly, a genome binning, a taxonomic binning and a taxonomic profiling challenge, on several multi-sample data sets from different environments, including long and short read data. This includes a marine data set and a high-strain diversity data set, with a third data set to follow later. A pathogen detection challenge on a clinical sample is also provided.","","https://www.microbiome-cosi.org/cami/cami/cami2","completed","intermediate","3","","2019-01-14","2021-01-31","2023-06-23 00:00:00","2023-09-28 21:54:01" +"76","camda18-metasub-forensics","CAMDA18: MetaSUB Forensics","","The MetaSUB International Consortium is building a longitudinal metagenomic map of mass-transit systems and other public spaces across the globe. The consortium maintains a strategic partnership with CAMDA and this year provides data from global City Sampling Days for the first-ever multi-city forensic analyses.","","http://camda2018.bioinf.jku.at/doku.php/contest_dataset#metasub_forensics_challenge","completed","intermediate","7","","\N","\N","2023-06-23 00:00:00","2023-09-28 21:54:01" +"77","camda18-cmap-drug-safety","CAMDA18: CMap Drug Safety","","Attrition in drug discovery and development due to safety / toxicity issues remains a significant concern, and there are strong efforts to identify and mitigate risk as early as possible. Drug-induced liver injury (DILI) is one of the primary problems in drug development and regulatory clearance due to the poor performance of existing preclinical models. There is a pressing need to evaluate alternative methods for predicting DILI, with great hopes being placed in modern approaches from statistics and machine learning applied to genome scale profiling data. A critical question thus is if we can better integrate, understand, and exploit information from cell-based screens like the Broad Institute Connectivity Map (CMap, Science 313, Nature Reviews Cancer 7). This CAMDA challenge focuses on understanding or predicting drug induced liver injury in humans from cell-based screens, specifically the CMap gene expression responses of two different cancer cell lines (MCF7 and PC3) to 276 d...","","http://camda2018.bioinf.jku.at/doku.php/contest_dataset#cmap_drug_safety_challenge","completed","intermediate","7","","\N","\N","2023-06-23 00:00:00","2023-09-28 21:54:02" +"78","camda18-cancer-data-integration","CAMDA18: Cancer Data Integration","","Examine the power of data integration in a real-world clinical settings. Many approaches work well on some data-sets yet not on others. We here challenge you to demonstrate a unified single approach to data-integration that matches or outperforms the current state of the art on two different diseases, breast cancer and neuroblastoma. Breast cancer affects about 3 million women every year (McGuire et al, Cancers 7), and this number is growing fast, especially in developed countries. Can you improve on the large Metabric study (Curtis et al., Nature 486, and Dream Challenge, Margolin et al, Sci Transl Med 5)? The cohort is biologically heterogeneous with all five distinct PAM50 breast cancer subtypes represented. Matched profiles for microarray and copy number data as well as clinical information (survival times, multiple prognostic markers, therapy data) are available for about 2,000 patients. Neuroblastoma is the most common extracranial solid tumor in children. The base study com...","","http://camda2018.bioinf.jku.at/doku.php/contest_dataset#cancer_data_integration_challenge","completed","intermediate","7","","\N","\N","2023-06-23 00:00:00","2023-09-28 21:54:03" +"79","cafa-4","CAFA 4","","The goal of the Critical Assessment of Functional Annotation(CAFA) challenge is to evaluate automated protein function prediction algorithms in the task of predicting Gene Ontology and Human Phenotype Ontology terms for a given set of protein sequences. For the GO-based predictions, the evaluation will be carried out for the Molecular Function Ontology, Biological Process Ontology and Cellular Component Ontology. Participants develop protein function prediction algorithms using training protein sequence data and submit their predictions on target protein sequence data.","","https://www.biofunctionprediction.org/cafa/","completed","intermediate","1","","2019-10-21","2020-02-12","2023-06-23 00:00:00","2023-09-28 21:54:04" +"80","casp13","CASP13","","CASP (Critical Assessment of Structure Prediction) is a community wide experiment to determine and advance the state of the art in modeling protein structure from amino acid sequence. Every two years, participants are invited to submit models for a set of proteins for which the experimental structures are not yet public. Independent assessors then compare the models with experiment. Assessments and results are published in a special issue of the journal PROTEINS. In the most recent CASP round, CASP12, nearly 100 groups from around the world submitted more than 50,000 models on 82 modeling targets","","https://predictioncenter.org/casp13/index.cgi","completed","intermediate","14","","2018-04-18","2018-08-20","2023-06-23 00:00:00","2023-09-28 21:54:45" +"81","casp14","CASP14","","CASP (Critical Assessment of Structure Prediction) is a community wide experiment to determine and advance the state of the art in modeling protein structure from amino acid sequence. Every two years, participants are invited to submit models for a set of proteins for which the experimental structures are not yet public. Independent assessors then compare the models with experiment. Assessments and results are published in a special issue of the journal PROTEINS. In the most recent CASP round, CASP14, nearly 100 groups from around the world submitted more than 67,000 models on 90 modeling targets.","","https://predictioncenter.org/casp14/index.cgi","completed","intermediate","14","","2020-05-04","2020-09-07","2023-06-23 00:00:00","2023-09-28 21:54:46" +"82","cfsan-pathogen-detection","CFSAN Pathogen Detection","","In the U.S. alone, one in six individuals, an estimated 48 million people, fall prey to foodborne illness, resulting in 128,000 hospitalizations and 3,000 deaths per year. Economic burdens are estimated cumulatively at $152 billion dollars annually, including $39 billion due to contamination of fresh and processed produce. One longstanding problem is the ability to rapidly identify the food-source associated with the outbreak being investigated. The faster an outbreak is identified and the increased certainty that a given source (e.g., papayas from Mexico) and patients are linked, the faster the outbreak can be stopped, limiting morbidity and mortality. In the last few years, the application of next-generation sequencing (NGS) technology for whole genome sequencing (WGS) of foodborne pathogens has revolutionized food pathogen outbreak surveillance. WGS of foodborne pathogens enables high-resolution identification of pathogens isolated from food or environmental samples. These p...","","https://precision.fda.gov/challenges/2","completed","intermediate","6","","2018-02-15","2018-04-26","2023-06-23 00:00:00","2023-09-28 21:55:07" +"83","cdrh-biothreat","CDRH Biothreat","","Many infectious diseases have similar signs and symptoms, making it challenging for healthcare providers to identify the disease-causing agent. Clinical samples are often tested by multiple test methods to help reveal the microbe that is causing the infectious disease. The results of these test methods can help healthcare professionals determine the best treatment for patients. Today, High-Throughput Sequencing (HTS) or Next Generation Sequencing (NGS) technology has the capability, as a single test, to accomplish what might have required several different tests in the past. NGS technology may allow the diagnosis of infections without prior knowledge of disease(s) cause. NGS technology can potentially reveal the presence of all microorganisms in a patient sample. Using infectious disease NGS (ID-NGS) technology, each microbial pathogen may be identified by its unique genomic fingerprint. The vision of ID-NGS technology is to further improve patient care by delivering diagnostic...","","https://precision.fda.gov/challenges/3","completed","intermediate","6","","2018-08-03","2018-10-18","2023-06-23 00:00:00","2023-09-28 21:55:18" +"84","multi-omics-enabled-sample-mislabeling-correction","Multi-omics Enabled Sample Mislabeling Correction","","In biomedical research, sample mislabeling (accidental swapping of patient samples) or data mislabeling (accidental swapping of patient omics data) has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies, in which multiple different omics experiments are carried out at different time periods and/or in different labs. Human errors could arise during sample transferring, sample tracking, large-scale data generation, and data sharing/management. Thus, there is a pressing need to identify and correct sample and data mislabeling events to ensure the right data for the right patient. Simultaneous use of multiple types of omics platforms to characterize a large set of biological samples, as utilized in The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) projects, has been demonstrated as a powerful approach to understanding the ...","","https://precision.fda.gov/challenges/4","completed","intermediate","6","https://doi.org/10.1038/s41591-018-0180-x","2018-09-24","2018-12-19","2023-06-23 00:00:00","2023-09-28 21:55:18" +"85","biocompute-object-app-a-thon","BioCompute Object App-a-thon","","Like scientific laboratory experiments, bioinformatics analysis results and interpretation are faced with reproducibility challenges due to the variability in multiple computational parameters, including input format, prerequisites, platform dependencies, and more. Even small changes in these computational parameters may have a large impact on the results and carry big implications for their scientific validity. Because there are currently no standardized schemas for reporting computational scientific workflows and parameters together with their results, the ways in which these workflows are communicated is highly variable, incomplete, and difficult or impossible to reproduce. The US Food and Drug Administration (FDA) High Performance Virtual Environment (HIVE) group and George Washington University (GW) have partnered to establish a framework for community-based standards development and harmonization of high-throughput sequencing (HTS) computations and data formats based arou...","","https://precision.fda.gov/challenges/7/","completed","intermediate","6","https://doi.org/10.1101/2020.11.02.365528","2019-05-14","2019-10-18","2023-06-23 00:00:00","2023-09-28 21:55:18" +"86","brain-cancer-predictive-modeling-and-biomarker-discovery","Brain Cancer Predictive Modeling and Biomarker Discovery","","An estimated 86,970 new cases of primary brain and other central nervous system tumors are expected to be diagnosed in the US in 2019. Brain tumors comprise a particularly deadly subset of all cancers due to limited treatment options and the high cost of care. Only a few prognostic and predictive markers have been successfully implemented in the clinic so far for gliomas, the most common malignant brain tumor type. These markers include MGMT promoter methylation in high-grade astrocytomas, co-deletion of 1p/19q in oligodendrogliomas, and mutations in IDH1 or IDH2 genes (Staedtke et al. 2016). There remains significant potential for identifying new clinical biomarkers in gliomas. Clinical investigators at Georgetown University are seeking to advance precision medicine techniques for the prognosis and treatment of brain tumors through the identification of novel multi-omics biomarkers. In support of this goal, precisionFDA and the Georgetown Lombardi Comprehensive Cancer Center a...","","https://precision.fda.gov/challenges/8/","completed","advanced","6","","2019-11-01","2020-02-14","2023-06-23 00:00:00","2023-09-28 21:55:20" +"87","gaining-new-insights-by-detecting-adverse-event-anomalies","Gaining New Insights by Detecting Adverse Event Anomalies","","The Food and Drug Administration (FDA) calls on the public to develop computational algorithms for automatic detection of adverse event anomalies using publicly available data.","","https://precision.fda.gov/challenges/9/","completed","intermediate","6","","2020-01-17","2020-05-18","2023-06-23 00:00:00","2023-09-28 21:55:21" +"88","calling-variants-in-difficult-to-map-regions","Calling Variants in Difficult-to-Map Regions","","This challenge calls on the public to assess variant calling pipeline performance on a common frame of reference, with a focus on benchmarking in difficult-to-map regions, segmental duplications, and the Major Histocompatibility Complex (MHC).","","https://precision.fda.gov/challenges/10/","completed","intermediate","6","https://doi.org/10.1016/j.xgen.2022.100129","2020-05-01","2020-06-15","2023-06-23 00:00:00","2023-09-28 21:55:22" +"89","vha-innovation-ecosystem-and-covid-19-risk-factor-modeling","VHA Innovation Ecosystem and COVID-19 Risk Factor Modeling","","The novel coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2,” or SARS-CoV-2. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a global pandemic. As of Monday, June 1, the Johns Hopkins University COVID-19 dashboard reports over 6.21 million total confirmed cases worldwide, including over 1.79 million cases in the United States. Although most people have mild to moderate symptoms, the disease can cause severe medical complications leading to death in some people. The Centers for Disease Control and Prevention (CDC) have identified several groups at elevated risk for severe illness, including people 65 years and older, individuals living in nursing homes or long term care facilities, and those with serious underlying medical conditions, such as severe obesity, diabetes, chronic lung disease or moderate to severe asthma, chronic kidney or liver dise...","","https://precision.fda.gov/challenges/11/","completed","intermediate","6","","2020-06-02","2020-07-03","2023-06-23 00:00:00","2023-09-28 21:55:24" +"90","covid-19-precision-immunology-app-a-thon","COVID-19 Precision Immunology App-a-thon","","The novel coronavirus disease 2019 (COVID-19), a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2” or SARS-CoV-2, was declared a global pandemic by the World Health Organization on March 11, 2020. To date, the Johns Hopkins University COVID-19 dashboard reports over 62 million confirmed cases worldwide, with a wide range of disease severity from asymptomatic to deaths (over 1.46 million). To effectively combat the widespread transmission of COVID-19 infection and save lives especially of those vulnerable individuals, it is imperative to better understand its pathophysiology to enable effective diagnosis, prognosis and treatment strategies using rapidly shared data.","","https://precision.fda.gov/challenges/12/","completed","intermediate","6","","2020-11-30","2021-01-29","2023-06-23 00:00:00","2023-09-28 21:55:24" +"91","smarter-food-safety-low-cost-tech-enabled-traceability","Smarter Food Safety Low Cost Tech-Enabled Traceability","","The motivation is tapping into new technologies and integrating data streams will help to advance the widespread, consistent implementation of traceability systems across the food industry. However, the affordability of such technologies, particularly for smaller companies, can be a barrier to implementing tech-enabled traceability systems. FDA's New Era of Smarter Food Safety initiative strives to work with stakeholders to explore low-cost or no-cost options so that our approaches are inclusive of and viable for human and animal food operations of all sizes. Democratizing the benefits of digitizing data will allow the entire food system to move more rapidly towards digital traceability systems. The primary goal is to encourage stakeholders, including technology providers, public health advocates, entrepreneurs, and innovators from all disciplines and around the world, to develop traceability hardware, software, or data analytics platforms that are low-cost or no-cost to the en...","","https://precision.fda.gov/challenges/13","completed","intermediate","6","","2021-06-01","2021-07-30","2023-06-23 00:00:00","2023-09-28 21:55:25" +"92","tumor-mutational-burden-tmb-challenge-phase-1","Tumor Mutational Burden (TMB) Challenge Phase 1","","Tumor mutational burden (TMB) is generally defined as the number of mutations detected in a patient's tumor sample per megabase of DNA sequenced. However different algorithms use different methods for calculating TMB. Mutations in genes in tumor cells may lead to the creation of neoantigens, which have the potential to activate an immune system response against the tumor, and the likelihood of an immune system response may increase with the number of mutations. Thus, TMB is a biomarker for some immunotherapy drugs, called immune checkpoint inhibitors, such as those that target the PD-1 and PD-L1 pathways (Chan et al., 2019). An outstanding problem is the lack of standardization for TMB calculation and reporting between different assays. To address this problem, the Friends of Cancer Research convened a working group of industry and regulatory stakeholders to develop guidance and tools for TMB harmonization. Results from the first phase of this effort were presented at AACR 2020...","","https://precision.fda.gov/challenges/17","completed","advanced","6","","2021-06-21","2021-09-13","2023-06-23 00:00:00","2023-09-28 21:55:27" +"93","kidney-and-kidney-tumor-segmentation","Kidney and Kidney Tumor Segmentation","","The 2021 Kidney and Kidney Tumor Segmentation challenge (abbreviated KiTS21) is a competition in which teams compete to develop the best system for automatic semantic segmentation of renal tumors and surrounding anatomy. Kidney cancer is one of the most common malignancies in adults around the world, and its incidence is thought to be increasing [1]. Fortunately, most kidney tumors are discovered early while they're still localized and operable. However, there are important questions concerning management of localized kidney tumors that remain unanswered [2], and metastatic renal cancer remains almost uniformly fatal [3]. Kidney tumors are notorious for their conspicuous appearance in computed tomography (CT) imaging, and this has enabled important work by radiologists and surgeons to study the relationship between tumor size, shape, and appearance and its prospects for treatment [4,5,6]. It's laborious work, however, and it relies on assessments that are often subjective and impr...","","https://kits21.kits-challenge.org/","completed","advanced","5","","2021-08-23","2021-09-17","2023-06-23 00:00:00","2023-09-28 21:56:07" +"94","cross-modality-da-for-medical-image-segmentation","Cross-Modality DA for Medical Image Segmentation","","Domain Adaptation (DA) has recently raised strong interests in the medical imaging community. By encouraging algorithms to be robust to unseen situations or different input data domains, Domain Adaptation improves the applicability of machine learning approaches to various clinical settings. While a large variety of DA techniques has been proposed for image segmentation, most of these techniques have been validated either on private datasets or on small publicly available datasets. Moreover, these datasets mostly address single-class problems. To tackle these limitations, the crossMoDA challenge introduces the first large and multi-class dataset for unsupervised cross-modality Domain Adaptation.","","https://crossmoda-challenge.ml/","completed","advanced","5","","2021-04-05","2021-09-27","2023-06-23 00:00:00","2023-09-28 22:02:11" +"95","real-noise-mri","Real Noise MRI","","In recent years, there is a growing focus on the application of fast magnetic resonance imaging (MRI) based on prior knowledge. In the 1980s and 2000s the community used either purely mathematical models such as the partial Fourier transform or solutions derived through advanced engineering such as parallel imaging to speed up MRI acquisition. Since the mid-2000's, compressed sensing and artificial intelligence have been employed to speed up MRI acquisition. These newer methods rely on under sampling the data acquired in Fourier (aka k-) space and then interpolating or augmenting k-space data based on training data content. One of the underlying problems for the development of fast imaging techniques, that just as in e.g. [1], it is common to use a fully sampled image as ground truth and then under sample it in k-space in order to simulate under sampled data. The problem with this approach is that in cases were the under sampled data is corrupted, through e.g. motion, this under s...","","https://realnoisemri.grand-challenge.org/Description/","completed","intermediate","5","","2021-09-21","2021-12-06","2023-06-23 00:00:00","2023-09-28 22:02:24" +"96","deep-generative-model-challenge-for-da-in-surgery","Deep Generative Model Challenge for DA in Surgery","","Mitral regurgitation (MR) is the second most frequent indication for valve surgery in Europe and may occur for organic or functional causes [1]. Mitral valve repair, although considerably more difficult, is prefered over mitral valve replacement, since the native tissue of the valve is preserved. It is a complex on-pump heart surgery, often conducted only by a handful of surgeons in high-volume centers. Minimally invasive procedures, which are performed with endoscopic video recordings, became more and more popular in recent years. However, data availability and data privacy concerns are still an issue for the development of automatic scene analysis algorithms. The AdaptOR challenge aims to address these issues by formulating a domain adaptation problem from simulation to surgery. We provide a smaller number of datasets from real surgeries, and a larger number of annotated recordings of training and planning sessions from a physical mitral valve simulator. The goal is to reduce th...","","https://adaptor2021.github.io/","completed","intermediate","1","","2021-04-01","2021-07-16","2023-06-23 00:00:00","2023-09-28 22:03:01" +"97","aimdatathon","AIM Datathon 2020","Join the AI in Medicine ( AIM ) Datathon 2020","Join the AI in Medicine ( AIM ) Datathon 2020","","https://www.kaggle.com/competitions/aimdatathon","completed","intermediate","8","","2020-11-09","2020-11-22","2023-06-23 00:00:00","2023-09-28 22:04:28" +"98","opc-recurrence","Oropharynx Cancer (OPC) Radiomics Challenge :: Local Recurrence Prediction","Determine from CT data whether a tumor will be controlled by definitive radi...","Determine from CT data whether a tumor will be controlled by definitive radiation therapy.","","https://www.kaggle.com/competitions/opc-recurrence","completed","intermediate","8","","2016-07-26","2016-09-12","2023-06-23 00:00:00","2023-09-28 22:04:27" +"99","oropharynx-radiomics-hpv","Oropharynx Cancer (OPC) Radiomics Challenge :: Human Papilloma Virus (HPV) Status Prediction","Predict from CT data the HPV phenotype of oropharynx tumors; compare to grou...","Predict from CT data the HPV phenotype of oropharynx tumors; compare to ground-truth results previously obtained by p16 or HPV testing.","","https://www.kaggle.com/competitions/oropharynx-radiomics-hpv","completed","intermediate","8","","2016-07-26","2016-09-12","2023-06-23 00:00:00","2023-09-28 22:04:46" +"100","data-science-bowl-2017","Data Science Bowl 2017","Can you improve lung cancer detection?","Can you improve lung cancer detection?","","https://www.kaggle.com/competitions/data-science-bowl-2017","completed","intermediate","8","","2017-01-12","2017-04-12","2023-06-23 00:00:00","2023-09-28 22:04:50" +"101","predict-impact-of-air-quality-on-death-rates","Predict impact of air quality on mortality rates","Predict CVD and cancer caused mortality rates in England using air quality d...","Predict CVD and cancer caused mortality rates in England using air quality data available from Copernicus Atmosphere Monitoring Service","","https://www.kaggle.com/competitions/predict-impact-of-air-quality-on-death-rates","completed","intermediate","8","","2017-02-13","2017-05-05","2023-06-23 00:00:00","2023-09-28 22:04:58" +"102","intel-mobileodt-cervical-cancer-screening","Intel & MobileODT Cervical Cancer Screening","Which cancer treatment will be most effective?","Which cancer treatment will be most effective?","","https://www.kaggle.com/competitions/intel-mobileodt-cervical-cancer-screening","completed","intermediate","8","","2017-03-15","2017-06-21","2023-06-23 00:00:00","2023-09-28 22:05:04" +"103","msk-redefining-cancer-treatment","Personalized Medicine: Redefining Cancer Treatment","Predict the effect of Genetic Variants to enable Personalized Medicine","Predict the effect of Genetic Variants to enable Personalized Medicine","","https://www.kaggle.com/competitions/msk-redefining-cancer-treatment","completed","intermediate","8","","2017-06-26","2017-10-02","2023-06-23 00:00:00","2023-09-28 22:05:28" +"104","mubravo","Predicting Cancer Diagnosis","Bravo's machine learning competition!","Bravo's machine learning competition!","","https://www.kaggle.com/competitions/mubravo","completed","intermediate","8","","2018-07-31","2018-08-13","2023-06-23 00:00:00","2023-09-28 22:05:55" +"105","histopathologic-cancer-detection","Histopathologic Cancer Detection","Identify metastatic tissue in histopathologic scans of lymph node sections","Identify metastatic tissue in histopathologic scans of lymph node sections","","https://www.kaggle.com/competitions/histopathologic-cancer-detection","completed","intermediate","8","","2018-11-16","2019-03-30","2023-06-23 00:00:00","2023-09-28 22:05:59" +"106","tjml1920-decision-trees","TJML 2019-20 Breast Cancer Detection Competition","Use a decision tree to identify malignant breast cancer tumors","Use a decision tree to identify malignant breast cancer tumors","","https://www.kaggle.com/competitions/tjml1920-decision-trees","completed","intermediate","8","","2019-09-22","2019-10-16","2023-06-23 00:00:00","2023-09-28 22:06:02" +"107","prostate-cancer-grade-assessment","Prostate cANcer graDe Assessment (PANDA) Challenge","Prostate cancer diagnosis using the Gleason grading system","Prostate cancer diagnosis using the Gleason grading system","","https://www.kaggle.com/competitions/prostate-cancer-grade-assessment","completed","intermediate","8","","2020-04-21","2020-07-22","2023-06-23 00:00:00","2023-09-28 22:06:03" +"108","breast-cancer","Breast Cancer","Use cell nuclei categories to predict breast cancer tumor.","Use cell nuclei categories to predict breast cancer tumor.","","https://www.kaggle.com/competitions/breast-cancer","completed","intermediate","8","","2020-08-12","2020-08-13","2023-06-23 00:00:00","2023-09-28 22:06:03" +"109","breast-cancer-detection","Breast Cancer Detection","breast cancer detection","breast cancer detection","","https://www.kaggle.com/competitions/breast-cancer-detection","completed","intermediate","8","","2020-09-25","2020-12-31","2023-06-23 00:00:00","2023-09-28 22:06:04" +"110","hrpred","Prediction of High Risk Patients","Classification of high and low risk cancer patients","Classification of high and low risk cancer patients","","https://www.kaggle.com/competitions/hrpred","completed","intermediate","8","","2020-11-25","2020-12-05","2023-06-23 00:00:00","2023-09-28 22:34:31" +"111","ml4moleng-cancer","MIT ML4MolEng: Predicting Cancer Progression","MIT 3.100, 10.402, 20.301 In class ML competition (Spring 2021)","MIT 3.100, 10.402, 20.301 In class ML competition (Spring 2021)","","https://www.kaggle.com/competitions/ml4moleng-cancer","completed","intermediate","8","","2021-05-06","2021-05-21","2023-06-23 00:00:00","2023-09-28 22:06:04" +"112","uw-madison-gi-tract-image-segmentation","UW-Madison GI Tract Image Segmentation","Track healthy organs in medical scans to improve cancer treatment","Track healthy organs in medical scans to improve cancer treatment","","https://www.kaggle.com/competitions/uw-madison-gi-tract-image-segmentation","completed","intermediate","8","","2022-04-14","2022-07-14","2023-06-23 00:00:00","2023-09-28 22:06:05" +"113","rsna-miccai-brain-tumor-radiogenomic-classification","RSNA-MICCAI Brain Tumor Radiogenomic Classification","Predict the status of a genetic biomarker important for brain cancer treatment","The Brain Tumor Segmentation (BraTS) challenge celebrates its 10th anniversary, and this year is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society. The RSNA-ASNR-MICCAI BraTS 2021 challenge utilizes multi-institutional pre-operative baseline multi-parametric magnetic resonance imaging (mpMRI) scans, and focuses on the evaluation of state-of-the-art methods for (Task 1) the segmentation of intrinsically heterogeneous brain glioblastoma sub-regions in mpMRI scans. Furthemore, this BraTS 2021 challenge also focuses on the evaluation of (Task 2) classification methods to predict the MGMT promoter methylation status. Participants are free to choose whether they want to focus only on one or both tasks.","","https://www.kaggle.com/competitions/rsna-miccai-brain-tumor-radiogenomic-classification","completed","advanced","8","","2021-07-13","2021-10-15","2023-06-23 00:00:00","2023-07-26 19:50:13" +"114","breastcancer","Breast Cancer - Beginners ML","Beginners hands-on experience with ML basics","Beginners hands-on experience with ML basics","","https://www.kaggle.com/competitions/breastcancer","completed","intermediate","8","","2021-12-21","2022-02-12","2023-06-23 00:00:00","2023-09-28 22:06:06" +"115","ml-olympiad-health-and-education","ML Olympiad - Let's Fight lung cancer","Use your ML expertise to help us step another step toward defeating cancer [...","Use your ML expertise to help us step another step toward defeating cancer [ Starts on the 14th February ]","","https://www.kaggle.com/competitions/ml-olympiad-health-and-education","completed","intermediate","8","","2022-01-31","2022-03-19","2023-06-23 00:00:00","2023-09-28 22:06:06" +"116","cs98-22-dl-task1","CS98X-22-DL-Task1","This competition is related to Task 1 in coursework - breast cancer classifi...","This competition is related to Task 1 in coursework - breast cancer classification","","https://www.kaggle.com/competitions/CS98-22-DL-Task1","completed","intermediate","8","","2022-02-28","2022-04-11","2023-06-23 00:00:00","2023-09-28 22:06:07" +"117","parasitedetection-iiitb2019","Parasite detection","detect if cell image has parasite or is uninfected","detect if cell image has parasite or is uninfected","","https://www.kaggle.com/competitions/parasitedetection-iiitb2019","completed","intermediate","8","","2019-10-13","2019-11-25","2023-06-23 00:00:00","2023-09-28 22:06:07" +"118","hpa-single-cell-image-classification","Human Protein Atlas - Single Cell Classification","Find individual human cell differences in microscope images","Find individual human cell differences in microscope images","","https://www.kaggle.com/competitions/hpa-single-cell-image-classification","completed","intermediate","8","","2021-01-26","2021-05-11","2023-06-23 00:00:00","2023-09-28 22:06:38" +"119","stem-cell-predcition","Stem Cell Predcition","Classify stem and non-stem cells using RNA-seq data","Classify stem and non-stem cells using RNA-seq data","","https://www.kaggle.com/competitions/stem-cell-predcition","completed","intermediate","8","","2021-04-01","2021-07-01","2023-06-23 00:00:00","2023-09-28 22:06:53" +"120","sartorius-cell-instance-segmentation","Sartorius - Cell Instance Segmentation","Detect single neuronal cells in microscopy images","In this competition, you’ll detect and delineate distinct objects of interest in biological images depicting neuronal cell types commonly used in the study of neurological disorders. More specifically, you'll use phase contrast microscopy images to train and test your model for instance segmentation of neuronal cells. Successful models will do this with a high level of accuracy. If successful, you'll help further research in neurobiology thanks to the collection of robust quantitative data. Researchers may be able to use this to more easily measure the effects of disease and treatment conditions on neuronal cells. As a result, new drugs could be discovered to treat the millions of people with these leading causes of death and disability.","","https://www.kaggle.com/competitions/sartorius-cell-instance-segmentation","completed","intermediate","8","","2021-10-14","2021-12-30","2023-06-23 00:00:00","2023-09-28 22:07:08" +"121","pvelad","Photovoltaic cell anomaly detection","Hosted by Hebei University of Technology (AIHebut research group) and Beihan...","Hosted by Hebei University of Technology (AIHebut research group) and Beihang University (NAVE research group)","","https://www.kaggle.com/competitions/pvelad","completed","intermediate","8","","2022-03-15","2022-07-30","2023-06-23 00:00:00","2023-09-28 22:07:37" +"122","blood-mnist","Blood-MNIST","Classifying blood cell types using Weights and Biases","Classifying blood cell types using Weights and Biases","","https://www.kaggle.com/competitions/blood-mnist","completed","intermediate","8","","2022-03-19","2022-03-19","2023-06-23 00:00:00","2023-09-28 22:08:38" +"123","insilicomolhack","MolHack","Apply deep learning to speedup drug validation","Apply deep learning to speedup drug validation","","https://www.kaggle.com/competitions/insilicomolhack","completed","intermediate","8","","2018-04-02","2018-05-25","2023-06-23 00:00:00","2023-09-28 22:09:52" +"124","codata2019challenge","Cell Response Classification","From recorded timeseries of many cells in a well, predict which drug treatme...","From recorded timeseries of many cells in a well, predict which drug treatment has been applied","","https://www.kaggle.com/competitions/codata2019challenge","completed","intermediate","8","","2019-04-08","2019-05-07","2023-06-23 00:00:00","2023-09-28 22:39:54" +"125","drug-solubility-challenge","Drug solubility challenge","Solubility is vital to achieve desired concentration of drug for anticipated...","Solubility is vital to achieve desired concentration of drug for anticipated pharmacological response.","","https://www.kaggle.com/competitions/drug-solubility-challenge","completed","intermediate","8","","2019-05-18","2019-10-18","2023-06-23 00:00:00","2023-09-28 22:41:56" +"126","kinase-inhibition-challenge","Kinase inhibition challenge","Protein kinases have become a major class of drug targets, accumulating a hu...","Protein kinases have become a major class of drug targets, accumulating a huge amount of data","","https://www.kaggle.com/competitions/kinase-inhibition-challenge","completed","intermediate","8","","2019-05-20","2019-12-28","2023-06-23 00:00:00","2023-09-28 22:42:13" +"127","ai-drug-discovery","AI Drug Discovery Workshop and Coding Challenge","Developing Fundamental AI Programming Skills for Drug Discovery","Developing Fundamental AI Programming Skills for Drug Discovery","","https://www.kaggle.com/competitions/ai-drug-discovery","completed","intermediate","8","","2021-11-12","2021-12-31","2023-06-23 00:00:00","2023-09-28 22:43:14" +"128","protein-compound-affinity","Structure-free protein-ligand affinity prediction - Task 1 Fitting","Developing new AI models for drug discovery, main portal (Task-1 fitting)","Developing new AI models for drug discovery, main portal (Task-1 fitting)","","https://www.kaggle.com/competitions/protein-compound-affinity","completed","intermediate","8","","2021-12-06","2021-12-31","2023-06-23 00:00:00","2023-09-28 22:43:19" +"129","cisc873-dm-f21-a5","CISC873-DM-F21-A5","Anti-Cancer Drug Activity Prediction","Anti-Cancer Drug Activity Prediction","","https://www.kaggle.com/competitions/cisc873-dm-f21-a5","completed","intermediate","8","","2021-11-26","2021-12-10","2023-06-23 00:00:00","2023-09-28 22:43:46" +"130","pro-lig-aff-task2-mse","Structure-free protein-ligand affinity prediction - Task 2 Fitting","Developing new AI models for drug discovery (Task-2 fitting)","Developing new AI models for drug discovery (Task-2 fitting)","","https://www.kaggle.com/competitions/pro-lig-aff-task2-mse","completed","intermediate","8","","2021-12-08","2021-12-31","2023-06-23 00:00:00","2023-09-28 22:44:19" +"131","pro-lig-aff-task1-pearsonr","Structure-free protein-ligand affinity prediction - Task 1 Ranking","Developing new AI models for drug discovery (Task-1 ranking)","Developing new AI models for drug discovery (Task-1 ranking)","","https://www.kaggle.com/competitions/pro-lig-aff-task1-pearsonr","completed","intermediate","8","","2021-12-08","2021-12-31","2023-06-23 00:00:00","2023-09-28 22:44:40" +"132","pro-lig-aff-task2-pearsonr","Structure-free protein-ligand affinity prediction - Task 2 Ranking","Developing new AI models for drug discovery (Task-2 ranking)","Developing new AI models for drug discovery (Task-2 ranking)","","https://www.kaggle.com/competitions/pro-lig-aff-task2-pearsonr","completed","intermediate","8","","2021-12-08","2021-12-31","2023-06-23 00:00:00","2023-09-28 22:44:40" +"133","pro-lig-aff-task3-spearmanr","Structure-free protein-ligand affinity prediction - Task 3 Ranking","Developing new AI models for drug discovery (Task-3 ranking)","Developing new AI models for drug discovery (Task-3 ranking)","","https://www.kaggle.com/competitions/pro-lig-aff-task3-spearmanr","completed","intermediate","8","","2021-12-08","2021-12-31","2023-06-23 00:00:00","2023-09-28 22:44:41" +"134","hhp","Heritage Health Prize","Identify patients who will be admitted to a hospital within the next year us...","Identify patients who will be admitted to a hospital within the next year using historical claims data. (Enter by 06:59:59 UTC Oct 4 2012)","","https://www.kaggle.com/competitions/hhp","completed","intermediate","8","","2011-04-04","2013-04-04","2023-06-23 00:00:00","2023-09-28 22:45:01" +"135","pf2012","Practice Fusion Analyze This! 2012 - Prediction Challenge","Start digging into electronic health records and submit your ideas for the m...","Start digging into electronic health records and submit your ideas for the most promising, impactful or interesting predictive modeling competitions","","https://www.kaggle.com/competitions/pf2012","completed","intermediate","8","","2012-06-07","2012-06-30","2023-06-23 00:00:00","2023-09-28 22:45:20" +"136","pf2012-at","Practice Fusion Analyze This! 2012 - Open Challenge","Start digging into electronic health records and submit your creative, insig...","Start digging into electronic health records and submit your creative, insightful, and visually striking analyses.","","https://www.kaggle.com/competitions/pf2012-at","completed","intermediate","8","","2012-06-07","2012-09-10","2023-06-23 00:00:00","2023-09-28 22:45:20" +"137","seizure-detection","UPenn and Mayo Clinic's Seizure Detection Challenge","Detect seizures in intracranial EEG recordings","Detect seizures in intracranial EEG recordings","","https://www.kaggle.com/competitions/seizure-detection","completed","intermediate","8","","2014-05-19","2014-08-19","2023-06-23 00:00:00","2023-09-28 22:45:29" +"138","seizure-prediction","American Epilepsy Society Seizure Prediction Challenge","Predict seizures in intracranial EEG recordings","Predict seizures in intracranial EEG recordings","","https://www.kaggle.com/competitions/seizure-prediction","completed","intermediate","8","","2014-08-25","2014-11-17","2023-06-23 00:00:00","2023-09-28 22:45:39" +"139","deephealth-1","Deep Health - alcohol","Find Correlations and patterns with Medical data","Find Correlations and patterns with Medical data","","https://www.kaggle.com/competitions/deephealth-1","completed","intermediate","8","","2017-02-13","2017-02-19","2023-06-23 00:00:00","2023-09-28 22:45:38" +"140","deep-health-3","Deep Health - Diabetes 2","This competition is for those attending the Deep Health Hackathon. Predic...","This competition is for those attending the Deep Health Hackathon. Predict the next occurrence of diabetes","","https://www.kaggle.com/competitions/deep-health-3","completed","intermediate","8","","2017-02-15","2017-02-19","2023-06-23 00:00:00","2023-09-28 22:45:50" +"141","d012554-2021","D012554 - 2021","Classify the health of a fetus using CTG data","Classify the health of a fetus using CTG data","","https://www.kaggle.com/competitions/d012554-2021","completed","intermediate","8","","2021-04-11","2021-05-09","2023-06-23 00:00:00","2023-09-28 22:46:10" +"142","idao-2022-bootcamp-insomnia","IDAO 2022. ML Bootcamp - Insomnia","Predict sleep disorder on given human health data","Predict sleep disorder on given human health data","","https://www.kaggle.com/competitions/idao-2022-bootcamp-insomnia","completed","intermediate","8","","2021-12-04","2021-12-05","2023-06-23 00:00:00","2023-09-28 22:46:21" +"143","tweet-mental-health-classification","Tweet Mental Health Classification","Build Models to classify tweets to determine mental health","Build Models to classify tweets to determine mental health","","https://www.kaggle.com/competitions/tweet-mental-health-classification","completed","intermediate","8","","2021-12-27","2022-01-31","2023-06-23 00:00:00","2023-09-28 22:46:52" +"144","ml-olympiad-good-health-and-well-being","ML Olympiad - GOOD HEALTH AND WELL BEING","Use your ML expertise to classify if a patient has heart disease or not","Use your ML expertise to classify if a patient has heart disease or not","","https://www.kaggle.com/competitions/ml-olympiad-good-health-and-well-being","completed","intermediate","8","","2022-02-03","2022-03-01","2023-06-23 00:00:00","2023-09-28 22:47:19" +"145","rsna-breast-cancer-detection","RSNA Screening Mammography Breast Cancer Detection","Find breast cancers in screening mammograms","Find breast cancers in screening mammograms","","https://www.kaggle.com/competitions/rsna-breast-cancer-detection","completed","intermediate","8","","2022-11-28","2023-02-27","2023-06-23 00:00:00","2023-09-28 22:48:07" +"146","biocreative-vii-text-mining-drug-and-chemical-protein-interactions-drugprot","BioCreative VII: Text mining drug and chemical-protein interactions (DrugProt)","","With the rapid accumulation of biomedical literature, it is getting increasingly challenging to exploit efficiently drug-related information described in the scientific literature. One of the most relevant aspects of drugs and chemical compounds are their relationships with certain biomedical entities, in particular genes and proteins. The aim of the DrugProt track (similar to the previous CHEMPROT task of BioCreative VI) is to promote the development and evaluation of systems that are able to automatically detect in relations between chemical compounds/drug and genes/proteins. There are a range of different types of drug-gene/protein interactions, and their systematic extraction and characterization is essential to analyze, predict and explore key biomedical properties underlying high impact biomedical applications. These application scenarios include use cases related to drug discovery, drug repurposing, drug design, metabolic engineering, modeling drug response, pharmacogenet...","","https://biocreative.bioinformatics.udel.edu/tasks/biocreative-vii/track-1/","completed","intermediate","7","","2021-06-15","2021-09-22","2023-06-23 00:00:00","2023-09-28 22:48:25" +"147","extended-literature-ai-for-drug-induced-liver-injury","Extended Literature AI for Drug Induced Liver Injury","","Unexpected Drug-Induced Liver Injury (DILI) still is one of the main killers of promising novel drug candidates. It is a clinically significant disease that can lead to severe outcomes such as acute liver failure and even death. It remains one of the primary liabilities in drug development and regulatory clearance due to the limited performance of mandated preclinical models even today. The free text of scientific publications is still the main medium carrying DILI results from clinical practice or experimental studies. The textual data still has to be analysed manually. This process, however, is tedious and prone to human mistakes or omissions, as results are very rarely available in a standardized form or organized form. There is thus great hope that modern techniques from machine learning or natural language processing could provide powerful tools to better process and derive the underlying knowledge within free form texts. The pressing need to faster process potential drug can...","","http://camda2022.bioinf.jku.at/contest_dataset#extended_literature_ai_for_drug_induced_liver_injury","completed","intermediate","7","","\N","2022-05-20","2023-06-23 00:00:00","2023-09-28 22:48:59" +"148","anti-microbial-resistance-forensics","Anti-Microbial Resistance Forensics","","Bacteriophages, being the re-occuring mystery in the history of science are believed to be they key for understanding of microbial evolution and the transfer of AMR genes. Recent studies show that there is a significant correlation between occurence of Phages and AMR genes, indicating that they are indeed taking part in the spread of them. While taking part in AMR dissemination the phages are also considered as the potential alternative to antibiotics. In such contradictory world there is a huge potential as well as urgent need for precise classification, description and analysis of capabilities. Due to pandemic of SARS-CoV-2, advance in phylogenetic algorithms and k-mer based methods have been extremely rapid and those improvements are witing to be adapted to different branches of life sciences.","","http://camda2022.bioinf.jku.at/contest_dataset#anti-microbial_resistance_forensics","completed","intermediate","7","","\N","2022-05-20","2023-06-23 00:00:00","2023-09-28 22:49:19" +"149","disease-maps-to-modelling-covid-19","Disease Maps to Modelling COVID-19","Use the COVID-19 disease map to suggest drugs candidate for repurposing, tha...","The Disease Maps to modeling COVID-19 Challenge provides highly detailed expert-curated molecular mechanistic maps for COVID-19. Combine them with available omic data to expand the current biological knowledge on COVID-19 mechanism of infection and downstream consequences. The main topic for this year's challenge is drug repurposing with the possibility of Real World Data based validation of the most promising candidates suggested.","","http://camda2022.bioinf.jku.at/contest_dataset#disease_maps_to_modelling_covid-19","completed","intermediate","7","","\N","2022-05-20","2023-06-23 00:00:00","2023-09-28 22:50:18" +"150","crowdsourced-evaluation-of-inchi-based-tautomer-identification","Crowdsourced Evaluation of InChI-based Tautomer Identification","Calling on scientists from industry, government, and academia dealing with c...","This challenge focuses on the International Chemical Identifier (InChI), which was developed and is maintained under the auspices of the International Union of Pure and Applied Chemistry (IUPAC) and the InChI Trust. The InChI Trust, the IUPAC Working Group on Tautomers, and the U.S. Food and Drug Administration (FDA) call on the scientific community dealing with chemical repositories/data sets and analytics of compounds to test the recently modified InChI algorithm, which was designed for advanced recognition of tautomers. Participants will evaluate this algorithm against real chemical samples in this Crowdsourced Evaluation of InChI-based Tautomer Identification.","","https://precision.fda.gov/challenges/29","completed","intermediate","6","","2022-11-01","2023-03-01","2023-06-23 00:00:00","2023-07-26 19:50:51" +"151","nctr-indel-calling-from-oncopanel-sequencing-challenge-phase-2","NCTR Indel Calling from Oncopanel Sequencing Challenge Phase 2","In Phase 2, participants who completed in Phase 1 of the challenge have the ...","The high value of clinically actionable information obtained by oncopanel sequencing makes it a crucial tool for precision oncology[1,2]. With the surge in availability of oncopanels, it is critical to ensure that they have been thoroughly tested and are properly used. FDA has initiated the Sequencing Quality Control phase II (SEQC2) project[3] to develop standard analysis protocols and quality control metrics for fit-for-purpose use of Next Generation Sequencing (NGS) data including oncopanel sequencing to inform regulatory science research and precision medicine. The Oncopanel Sequencing Working Group of FDA-led SEQC2 has developed a reference sample[4] suitable for benchmarking oncopanels and comprehensively assessed the analytical performance of several oncopanels[1,2]. The genomic deoxyribonucleic acid (gDNA) reference sample was derived from ten Universal Human Reference RNA (UHRR, Agilent Technologies, Inc) cell-lines and made publicly available by Agilent. Substantial gen...","","https://precision.fda.gov/challenges/22","completed","intermediate","6","","2022-07-11","2022-07-26","2023-06-23 00:00:00","2023-09-28 22:51:15" +"152","nctr-indel-calling-from-oncopanel-sequencing-data-challenge-phase-1","NCTR Indel Calling from Oncopanel Sequencing Data Challenge Phase 1","Genetic variation involving indels (insertions and deletions) in the cancer ...","The high value of clinically actionable information obtained by oncopanel sequencing makes it a crucial tool for precision oncology[1,2]. With the surge in availability of oncopanels, it is critical to ensure that they have been thoroughly tested and are properly used. FDA has initiated the Sequencing Quality Control phase II (SEQC2) project[3] to develop standard analysis protocols and quality control metrics for fit-for-purpose use of Next Generation Sequencing (NGS) data including oncopanel sequencing to inform regulatory science research and precision medicine. The Oncopanel Sequencing Working Group of FDA-led SEQC2 has developed a reference sample[4] suitable for benchmarking oncopanels and comprehensively assessed the analytical performance of several oncopanels[1,2]. The genomic deoxyribonucleic acid (gDNA) reference sample was derived from ten Universal Human Reference RNA (UHRR, Agilent Technologies, Inc) cell-lines and made publicly available by Agilent. Substantial gen...","","https://precision.fda.gov/challenges/21","completed","intermediate","6","","2022-05-02","2022-07-08","2023-06-23 00:00:00","2023-09-28 23:06:21" +"153","vha-innovation-ecosystem-and-precisionfda-covid-19-risk-factor-modeling-challenge-phase-2","VHA Innovation Ecosystem and precisionFDA COVID-19 Risk Factor Modeling Challenge Phase 2","The focus of Phase 2 was to validate the top performing models on two additi...","The novel coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2,” or SARS-CoV-2. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a global pandemic. As of January 22nd, 2022, the Johns Hopkins University COVID-19 dashboard reports over 338 million total confirmed cases worldwide. Although most people have mild to moderate symptoms, the disease can cause severe medical complications leading to death in some people. The Centers for Disease Control and Prevention (CDC) have identified several risk factors for severe COVID-19 illness, including people 65 years and older, individuals living in nursing homes or long-term care facilities, and those with serious underlying medical conditions. The Veteran population has a higher prevalence of several of the known risk factors for severe COVID-19 illness, such as advanced age, heart disease, and diabetes. Identi...","","https://precision.fda.gov/challenges/20","completed","intermediate","6","","2021-04-14","2022-01-28","2023-06-23 00:00:00","2023-09-28 23:07:02" +"154","tumor-mutational-burden-tmb-challenge-phase-2","Tumor Mutational Burden (TMB) Challenge Phase 2","The goal of the Friends of Cancer Research and precisionFDA Tumor Mutational...","Tumor mutational burden (TMB) is generally defined as the number of mutations detected in a patient's tumor sample per megabase of DNA sequenced. However different algorithms use different methods for calculating TMB. Mutations in genes in tumor cells may lead to the creation of neoantigens, which have the potential to activate an immune system response against the tumor, and the likelihood of an immune system response may increase with the number of mutations. Thus, TMB is a biomarker for some immunotherapy drugs, called immune checkpoint inhibitors, such as those that target the PD-1 and PD-L1 pathways (Chan et al., 2019). An outstanding problem is the lack of standardization for TMB calculation and reporting between different assays. To address this problem, the Friends of Cancer Research convened a working group of industry and regulatory stakeholders to develop guidance and tools for TMB harmonization. Results from the first phase of this effort were presented at AACR 2020 (...","","https://precision.fda.gov/challenges/18","completed","intermediate","6","","2021-07-19","2021-09-12","2023-06-23 00:00:00","2023-09-28 23:07:42" +"155","predicting-gene-expression-using-millions-of-random-promoter-sequences","Predicting Gene Expression Using Millions of Random Promoter Sequences","","Decoding how gene expression is regulated is critical to understanding disease. Regulatory DNA is decoded by the cell in a process termed “cis-regulatory logic”, where proteins called Transcription Factors (TFs) bind to specific DNA sequences within the genome and work together to produce as output a level of gene expression for downstream adjacent genes. This process is exceedingly complex to model as a large number of parameters is needed to fully describe the process (see Rationale, de Boer et al. 2020; Zeitingler J. 2020). Understanding the cis-regulatory logic of the human genome is an important goal and would provide insight into the origins of many diseases. However, learning models from human data is challenging due to limitations in the diversity of sequences present within the human genome (e.g. extensive repetitive DNA), the vast number of cell types that differ in how they interpret regulatory DNA, limited reporter assay data, and substantial technical biases present ...","","https://www.synapse.org/#!Synapse:syn28469146/wiki/617075","completed","intermediate","1","","2022-06-15","2022-08-07","2023-06-23 00:00:00","2023-09-28 23:09:31" +"156","brats-2023","BraTS 2023","","The International Brain Tumor Segmentation (BraTS) challenge. BraTS, since 2012, has focused on the generation of a benchmarking environment and dataset for the delineation of adult brain gliomas. The focus of this year’s challenge remains the generation of a common benchmarking environment, but its dataset is substantially expanded to ~4,500 cases towards addressing additional i) populations (e.g., sub-Saharan Africa patients), ii) tumors (e.g., meningioma), iii) clinical concerns (e.g., missing data), and iv) technical considerations (e.g., augmentations). Specifically, the focus of BraTS 2023 is to identify the current state-of-the-art algorithms for addressing (Task 1) the same adult glioma population as in the RSNA-ANSR-MICCAI BraTS challenge, as well as (Task 2) the underserved sub-Saharan African brain glioma patient population, (Task 3) intracranial meningioma, (Task 4) brain metastasis, (Task 5) pediatric brain tumor patients, (Task 6) global & local missing data, (Task 7...","","https://www.synapse.org/brats","active","advanced","1","","2023-06-01","2023-08-25","2023-06-23 00:00:00","2023-09-28 23:09:42" +"157","cagi7","CAGI7","The seventh round of CAGI","There have been six editions of CAGI experiments, held between 2010 and 2022. The seventh round of CAGI is planned to take place over the Summer of 2024.","","https://genomeinterpretation.org/challenges.html","upcoming","intermediate","1","","\N","\N","2023-08-04 21:47:38","2023-09-28 23:09:45" +"158","casp15","CASP15","Establish the state-of-art in modeling proteins and protein complexes","CASP14 (2020) saw an enormous jump in the accuracy of single protein and domain models such that many are competitive with experiment. That advance is largely the result of the successful application of deep learning methods, particularly by the AlphaFold and, since that CASP, RosettaFold. As a consequence, computed protein structures are becoming much more widely used in a broadening range of applications. CASP has responded to this new landscape with a revised set of modeling categories. Some old categories have been dropped (refinement, contact prediction, and aspects of model accuracy estimation) and new ones have been added (RNA structures, protein ligand complexes, protein ensembles, and accuracy estimation for protein complexes). We are also strengthening our interactions with our partners CAPRI and CAMEO. We hope that these changes will maximize the insight that CASP15 provides, particularly in new applications of deep learning.","","https://predictioncenter.org/casp15/index.cgi","completed","intermediate","14","","2022-04-18","\N","2023-08-04 21:52:12","2023-09-28 23:09:59" +"159","synthrad2023","SynthRAD2023","Synthesizing computed tomography for radiotherapy","This challenge aims to provide the first platform offering public data evaluation metrics to compare the latest developments in sCT generation methods. The accepted challenge design approved by MICCAI can be found at https://doi.org/10.5281/zenodo.7746019. A type 2 challenge will be run, where the participant needs to submit their algorithm packaged in a docker both for validation and test.","","https://synthrad2023.grand-challenge.org/","active","intermediate","5","","2023-04-01","2023-08-22","2023-08-04 21:54:31","2023-09-28 23:12:01" +"160","syn-iss","Synthetic Data for Instrument Segmentation in Surgery (Syn-ISS)","","A common limitation noted by the surgical data science community is the size of datasets and the resources needed to generate training data at scale for building reliable and high-performing machine learning models. Beyond unsupervised and self-supervised approaches another solution within the broader machine learning community has been a growing volume of literature in the use of synthetic data (simulation) for training algorithms than can be applied to real world data. Synthetic data has multiple benefits like free groundtruth at large scale, possibility to collect larger sample of rare events, include anatomical variations, etc. A first step towards proving the validity of using synthetic data for real world applications is to demonstrate the feasibility within the simulation world itself. Our proposed challenge is to train machine learning methods for instrument segmentation using synthetic datasets and test their performance on synthetic datasets. That is, the challenge part...","","https://www.synapse.org/#!Synapse:syn50908388/wiki/620516","active","intermediate","1","","2023-07-19","2023-09-07","2023-08-04 23:49:44","2023-09-28 23:12:03" +"161","pitvis","PitVis","Surgical workflow and instrument recognition in endonasal surgery","The pituitary gland, found just off the base of the brain, is commonly known as “the master gland”, performing essential functions required for sustaining human life. Clinically relevant tumours that have grown on the pituitary gland have an estimated prevalence of 1 in 1000 of the population, and if left untreated can be life-limiting. The “gold standard” treatment is endoscopic pituitary surgery, where the tumour is directly removed by entering through a nostril. This surgery is particularly challenging due to the small working space which limits both vision and instrument manoeuvrability and thus can lead to poor surgical technique causing adverse outcomes for the patient. Computer-assisted intervention can help overcome these challenges by providing guidance for senior surgeons and operative staff during surgery, and for junior surgeons during training.","","https://www.synapse.org/#!Synapse:syn51232283/wiki/","active","intermediate","1","","2023-06-29","2023-09-10","2023-08-04 23:58:01","2023-09-28 23:12:09" +"162","mvseg2023","MVSEG2023","Automatically segment mitral valve leaflets from single frame 3D trans-esoph...","Mitral valve (MV) disease is a common pathologic problem occurring in approximately 2 % of the general population but climbing to 10 % in those over the age of 75. The preferred intervention for mitral regurgitation is valve repair, due to superior patient outcomes compared to those following valve replacement. Mitral valve interventions are technically challenging due to the functional and anatomical complexity of mitral pathologies. Repair must be tailored to the patient-specific anatomy and pathology, which requires considerable expert training and experience. Automatic segmentation of the mitral valve leaflets from 3D transesophageal echocardiography (TEE) may play an important role in treatment planning, as well as physical and computational modelling of patient-specific valve pathologies and potential repair approaches. This may have important implications in the drive towards personalized care and has the potential to impact clinical outcomes for those undergoing mitral val...","","https://www.synapse.org/#!Synapse:syn51186045/wiki/621356","completed","intermediate","1","","2023-05-29","2023-08-07","2023-08-05 0:04:36","2023-09-28 23:12:19" +"163","crossmoda23","CrossMoDA23","This challenge proposes is the third edition of the first medical imaging be...","Domain Adaptation (DA) has recently raised strong interest in the medical imaging community. By encouraging algorithms to be robust to unseen situations or different input data domains, Domain Adaptation improves the applicability of machine learning approaches to various clinical settings. While a large variety of DA techniques has been proposed, most of these techniques have been validated either on private datasets or on small publicly available datasets. Moreover, these datasets mostly address single-class problems. To tackle these limitations, the crossMoDA challenge introduced the first large and multi-class dataset for unsupervised cross-modality Domain Adaptation. From an application perspective, crossMoDA focuses on MRI segmentation for Vestibular Schwannoma. Compared to the previous crossMoDA instance, which made use of multi-institutional data acquired in controlled conditions for radiosurgery planning and focused on a 2 class segmentation task (tumour and cochlea), the...","","https://www.synapse.org/#!Synapse:syn51236108/wiki/621615","completed","intermediate","1","","2023-04-15","2023-07-10","2023-08-05 0:13:23","2023-09-28 23:12:26" +"164","icr-identify-age-related-conditions","ICR - Identifying Age-Related Conditions","Use Machine Learning to detect conditions with measurements of anonymous cha...","The goal of this competition is to predict if a person has any of three medical conditions. You are being asked to predict if the person has one or more of any of the three medical conditions (Class 1), or none of the three medical conditions (Class 0). You will create a model trained on measurements of health characteristics. To determine if someone has these medical conditions requires a long and intrusive process to collect information from patients. With predictive models, we can shorten this process and keep patient details private by collecting key characteristics relative to the conditions, then encoding these characteristics.","","https://www.kaggle.com/competitions/icr-identify-age-related-conditions","completed","intermediate","8","","2023-05-11","2023-08-10","2023-08-05 0:32:01","2023-09-28 23:12:51" +"165","cafa-5-protein-function-prediction","CAFA 5 Protein Function Prediction","Predict the biological function of a protein","The goal of this competition is to predict the function of a set of proteins. You will develop a model trained on the amino-acid sequences of the proteins and on other data. Your work will help ​​researchers better understand the function of proteins, which is important for discovering how cells, tissues, and organs work. This may also aid in the development of new drugs and therapies for various diseases.","","https://www.kaggle.com/competitions/cafa-5-protein-function-prediction","completed","intermediate","8","","2023-04-18","2023-08-21","2023-08-05 5:18:40","2023-09-28 23:13:31" +"166","rsna-2023-abdominal-trauma-detection","RSNA 2023 Abdominal Trauma Detection","Detect and classify traumatic abdominal injuries","Traumatic injury is the most common cause of death in the first four decades of life and a major public health problem around the world. There are estimated to be more than 5 million annual deaths worldwide from traumatic injury. Prompt and accurate diagnosis of traumatic injuries is crucial for initiating appropriate and timely interventions, which can significantly improve patient outcomes and survival rates. Computed tomography (CT) has become an indispensable tool in evaluating patients with suspected abdominal injuries due to its ability to provide detailed cross-sectional images of the abdomen. Interpreting CT scans for abdominal trauma, however, can be a complex and time-consuming task, especially when multiple injuries or areas of subtle active bleeding are present. This challenge seeks to harness the power of artificial intelligence and machine learning to assist medical professionals in rapidly and precisely detecting injuries and grading their severity. The development...","","https://www.kaggle.com/competitions/rsna-2023-abdominal-trauma-detection","active","intermediate","8","","2023-07-26","2023-10-13","2023-08-05 5:24:09","2023-09-28 23:14:12" +"167","hubmap-hacking-the-human-vasculature","HuBMAP - Hacking the Human Vasculature","Segment instances of microvascular structures from healthy human kidney tiss...","The goal of this competition is to segment instances of microvascular structures, including capillaries, arterioles, and venules. You'll create a model trained on 2D PAS-stained histology images from healthy human kidney tissue slides. Your help in automating the segmentation of microvasculature structures will improve researchers' understanding of how the blood vessels are arranged in human tissues.","","https://www.kaggle.com/competitions/hubmap-hacking-the-human-vasculature","completed","intermediate","8","","2023-05-22","2023-07-31","2023-08-05 5:31:12","2023-09-28 23:14:14" +"168","amp-parkinsons-disease-progression-prediction","AMP(R)-Parkinson's Disease Progression Prediction","Use protein and peptide data measurements from Parkinson's Disease patients ...","The goal of this competition is to predict MDS-UPDR scores, which measure progression in patients with Parkinson's disease. The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a comprehensive assessment of both motor and non-motor symptoms associated with Parkinson's. You will develop a model trained on data of protein and peptide levels over time in subjects with Parkinson’s disease versus normal age-matched control subjects. Your work could help provide important breakthrough information about which molecules change as Parkinson’s disease progresses.","","https://www.kaggle.com/competitions/amp-parkinsons-disease-progression-prediction","completed","intermediate","8","","2023-02-16","2023-05-18","2023-08-05 5:37:12","2023-09-28 23:14:33" +"169","open-problems-multimodal","Open Problems - Multimodal Single-Cell Integration","Predict how DNA, RNA & protein measurements co-vary in single cells","The goal of this competition is to predict how DNA, RNA, and protein measurements co-vary in single cells as bone marrow stem cells develop into more mature blood cells. You will develop a model trained on a subset of 300,000-cell time course dataset of CD34+ hematopoietic stem and progenitor cells (HSPC) from four human donors at five time points generated for this competition by Cellarity, a cell-centric drug creation company. In the test set, taken from an unseen later time point in the dataset, competitors will be provided with one modality and be tasked with predicting a paired modality measured in the same cell. The added challenge of this competition is that the test data will be from a later time point than any time point in the training data. Your work will help accelerate innovation in methods of mapping genetic information across layers of cellular state. If we can predict one modality from another, we may expand our understanding of the rules governing these complex ...","","https://www.kaggle.com/competitions/open-problems-multimodal","completed","intermediate","8","","2022-08-15","2022-11-15","2023-08-05 5:43:25","2023-09-28 23:15:01" +"170","multi-atlas-labeling-beyond-the-cranial-vault","Multi-Atlas Labeling Beyond the Cranial Vault","","Multi-atlas labeling has proven to be an effective paradigm for creating segmentation algorithms from training data. These approaches have been extraordinarily successful for brain and cranial structures (e.g., our prior MICCAI workshops: MLSF’11, MAL’12, SATA’13). After the original challenges closed, the data continue to drive scientific innovation; 144 groups have registered for the 2012 challenge (brain only) and 115 groups for the 2013 challenge (brain/heart/canine leg). However, innovation in application outside of the head and to soft tissues has been more limited. This workshop will provide a snapshot of the current progress in the field through extended discussions and provide researchers an opportunity to characterize their methods on a newly created and released standardized dataset of abdominal anatomy on clinically acquired CT. The datasets will be freely available both during and after the challenge. We have two separate new challenges: abdomen and cervix on routine...","","https://www.synapse.org/#!Synapse:syn3193805/wiki/89480","active","intermediate","1","","2015-04-15","\N","2023-08-07 20:21:22","2023-09-28 23:15:18" +"171","hubmap-organ-segmentation","HuBMAP + HPA - Hacking the Human Body","Segment multi-organ functional tissue units","In this competition, you’ll identify and segment functional tissue units (FTUs) across five human organs. You'll build your model using a dataset of tissue section images, with the best submissions segmenting FTUs as accurately as possible. If successful, you'll help accelerate the world’s understanding of the relationships between cell and tissue organization. With a better idea of the relationship of cells, researchers will have more insight into the function of cells that impact human health. Further, the Human Reference Atlas constructed by HuBMAP will be freely available for use by researchers and pharmaceutical companies alike, potentially improving and prolonging human life.","","https://www.kaggle.com/competitions/hubmap-organ-segmentation","completed","intermediate","8","","2022-06-22","2022-09-22","2023-08-08 16:30:22","2023-09-28 23:16:12" +"172","hubmap-kidney-segmentation","HuBMAP - Hacking the Kidney","Identify glomeruli in human kidney tissue images","This competition, “Hacking the Kidney,"" starts by mapping the human kidney at single cell resolution. Your challenge is to detect functional tissue units (FTUs) across different tissue preparation pipelines. An FTU is defined as a “three-dimensional block of cells centered around a capillary, such that each cell in this block is within diffusion distance from any other cell in the same block” ([de Bono, 2013](https://www.ncbi.nlm.nih.gov/pubmed/24103658)). The goal of this competition is the implementation of a successful and robust glomeruli FTU detector. You will also have the opportunity to present your findings to a panel of judges for additional consideration. Successful submissions will construct the tools, resources, and cell atlases needed to determine how the relationships between cells can affect the health of an individual. Advancements in HuBMAP will accelerate the world’s understanding of the relationships between cell and tissue organization and function and human health.","","https://www.kaggle.com/competitions/hubmap-kidney-segmentation","completed","intermediate","8","","2020-11-16","2021-05-10","2023-08-08 17:31:46","2023-09-28 23:16:20" +"173","ventilator-pressure-prediction","Google Brain - Ventilator Pressure Prediction","Simulate a ventilator connected to a sedated patient's lung","In this competition, you’ll simulate a ventilator connected to a sedated patient's lung. The best submissions will take lung attributes compliance and resistance into account. If successful, you'll help overcome the cost barrier of developing new methods for controlling mechanical ventilators. This will pave the way for algorithms that adapt to patients and reduce the burden on clinicians during these novel times and beyond. As a result, ventilator treatments may become more widely available to help patients breathe.","","https://www.kaggle.com/competitions/ventilator-pressure-prediction","completed","intermediate","8","","2021-09-22","2021-11-03","2023-08-08 17:53:33","2023-09-28 23:16:31" +"174","stanford-covid-vaccine","OpenVaccine: COVID-19 mRNA Vaccine Degradation Prediction","Urgent need to bring the COVID-19 vaccine to mass production","In this competition, we are looking to leverage the data science expertise of the Kaggle community to develop models and design rules for RNA degradation. Your model will predict likely degradation rates at each base of an RNA molecule, trained on a subset of an Eterna dataset comprising over 3000 RNA molecules (which span a panoply of sequences and structures) and their degradation rates at each position. We will then score your models on a second generation of RNA sequences that have just been devised by Eterna players for COVID-19 mRNA vaccines. These final test sequences are currently being synthesized and experimentally characterized at Stanford University in parallel to your modeling efforts -- Nature will score your models!","","https://www.kaggle.com/competitions/stanford-covid-vaccine","completed","intermediate","8","","2020-09-10","2020-10-06","2023-08-08 18:06:17","2023-09-28 23:16:54" +"175","openvaccine","OpenVaccine","To develop mRNA vaccines stable enough to be deployed to everyone in the wor...","mRNA vaccines are a relatively new technology that have come into the limelight with the onset of COVID-19. They were the first COVID-19 vaccines to start clinical trials (initially formulated in a matter of days) and the first to be approved and distributed. mRNA vaccines have the potential to transform immunization, being significantly faster to formulate and produce, cheaper, and more effective - including against mutant strains. However, there is one key bottleneck to their widespread viability and our ability to immunize the entire world: poor refrigerator stability in prefilled syringes. The OpenVaccine challenge aims to allow a worldwide community of game players to create an enhanced vaccine to be injected into millions of people. The challenge: design an mRNA that codes for the same amino acid sequence of the spike protein, but is 2x-10x+ more stable. Through a number of academic partnerships and the launch of a Kaggle machine learning challenge to create best-in-class al...","","https://eternagame.org/challenges/10845741","completed","intermediate","13","https://doi.org/10.1038/s41467-022-28776-w","\N","2021-12-12","2023-08-08 18:22:49","2023-09-28 23:17:02" +"176","opentb","OpenTB","What if we could use RNA to detect a gene sequence found to be present only ...","OpenTB used a recently reported gene signature for active tuberculosis based on three RNAs in the blood. This signature could form the basis for a fast, color-based test for TB, similar to an over-the-counter pregnancy test. What was needed was a sensor that could detect the concentrations of three RNAs, carry out the needed calculation, and report the result by binding another molecule. Over four rounds, players designed RNA sensors that can do the math on these 3 genes. Through experimental feedback, they honed their skills and techniques, which resulted in the creation of multiple designs that have been shown to be successful. These findings are being prepared to be published, and future work will be done to develop diagnostic devices integrating these designs","","https://eternagame.org/challenges/10845742","completed","intermediate","13","","2016-05-04","2018-04-15","2023-08-08 18:43:09","2023-09-28 23:17:09" +"177","opencrispr","OpenCRISPR","A project to discover design patterns for guide RNAs to make gene editing mo...","CRISPR gene editing is a RNA-based method that can target essentially any gene in a living organism for genetic changes. Since its first demonstration, CRISPR has been revolutionizing biology and promises to change how we tackle numerous human diseases from malaria to cancer. Stanford's Center for Personal Dynamic Regulomes and UC Berkeley's Innovative Genomics Institute have challenged Eterna players to solve a remaining hurdle in making this technology safe for use. Scientists want the power to turn on and off CRISPR on demand with small molecules. This is almost a perfect match to the small-molecule switches that the Eterna community has worked on. In fact, the MS2 RNA hairpin often used in Eterna is routinely used to recruit new functionality to CRISPR complexes through other molecules tethered to the MS2 protein. The puzzles began with OpenCRISPR Controls, looking for solutions to lock in or lock out the MS2 RNA hairpin within a special loop in the CRISPR RNA. We hope the res...","","https://eternagame.org/challenges/10845743","completed","intermediate","13","https://doi.org/10.1021/acssynbio.9b00142","2017-08-26","\N","2023-08-08 18:43:14","2023-09-28 23:17:13" +"178","openknot","OpenKnot","Many important biological processes depend on RNAs that form pseudoknots, an...","RNA pseudoknots have significant biological importance in various processes. They participate in gene regulation by influencing translation initiation or termination in mRNA molecules. Pseudoknots also play a role in programmed ribosomal frameshifting, leading to the production of different protein products from a single mRNA. RNA viruses, including SARS-CoV-2 and Dengue virus, utilize pseudoknots to regulate their replication and control the synthesis of viral proteins. Additionally, certain RNA molecules with pseudoknot structures exhibit enzymatic activity, acting as ribozymes and catalyzing biochemical reactions. These functions highlight the crucial role of RNA pseudoknots in gene expression, proteomic diversity, viral replication, and enzymatic processes. Several unanswered scientific questions surround RNA pseudoknots. One key area of inquiry is understanding the folding pathways of pseudoknots and how they form from linear RNA sequences. Elucidating the structural dynamic...","","https://eternagame.org/challenges/11843006","active","intermediate","13","","2022-06-17","\N","2023-08-08 18:43:22","2023-09-28 23:17:12" +"179","openaso","OpenASO","A research initiative aimed at developing innovative design principles for R...","The DNA genome is the blueprint for building and operating cells, but this information must be decoded into RNA molecules to be useful. Transcription is the process of decoding DNA genomic information into RNA, resulting in RNA transcripts. Genes are specific sequences of DNA that contain information to produce a specific RNA transcript. The fate of most mRNA molecules in the cell is to be translated by ribosomes into protein molecules. However, mRNA splicing is a crucial step that occurs between the formation of an RNA transcript and protein translation. This step is essential because genes contain non-protein coding introns and protein-coding exons. Splicing removes introns and joins exons to produce a mature mRNA molecule that can be decoded into the correct protein molecule. When the splicing process is corrupted due to genetic mutations, the resulting RNA can become toxic, leading to the synthesis of non-functional proteins or no protein at all, causing various human disease...","","https://eternagame.org/challenges/11546273","active","intermediate","13","","2023-02-20","\N","2023-08-08 18:43:25","2023-09-28 23:17:27" +"180","openribosome","OpenRibosome","We aim to 1) gain fundamental insights into the ribosome's RNA sequence-fold...","Our modern world has many challenges - challenges like climate change, increasing waste production, and human health. Imagine: we could replace petrochemistry with biology, single-use plastics with selectively degradable polymers, broad chemotherapeutics with targeted medicines for fighting specific cancer cells, and complex health equipment with point-of-care diagnostics. These innovations and many more can empower us to confront the challenges affecting humanity, our world, and beyond. But how do we actually create these smart materials and medicines? Is it possible to do so by repurposing one of Nature's molecular machines? We think we can. The answer? Customized ribosomes. In Nature, ribosomes are the catalysts for protein assembly. And proteins are more or less similar, chemically, to the smart materials and medicines we want to synthesize. If we could modify ribosomes to build polymers with diverse components - beyond the canonical amino acids us","","https://eternagame.org/challenges/11043833","active","intermediate","13","https://doi.org/10.1038/s41467-023-35827-3","2019-01-31","\N","2023-08-08 18:43:27","2023-09-28 23:17:30" +"181","lish-moa","Mechanisms of Action (MoA) Prediction","Can you improve the algorithm that classifies drugs based on their biologica...","Can you improve the algorithm that classifies drugs based on their biological activity?","","https://www.kaggle.com/competitions/lish-moa","completed","intermediate","8","","2020-09-03","2020-11-30","2023-08-08 19:09:31","2023-09-28 23:18:04" +"182","recursion-cellular-image-classification","Recursion Cellular Image Classification","CellSignal: Disentangling biological signal from experimental noise in cellu...","This competition will have you disentangling experimental noise from real biological signals. Your entry will classify images of cells under one of 1,108 different genetic perturbations. You can help eliminate the noise introduced by technical execution and environmental variation between experiments. If successful, you could dramatically improve the industry’s ability to model cellular images according to their relevant biology. In turn, applying AI could greatly decrease the cost of treatments, and ensure these treatments get to patients faster.","","https://www.kaggle.com/competitions/recursion-cellular-image-classification","completed","intermediate","8","","2019-06-27","2019-09-26","2023-08-08 19:38:42","2023-09-28 23:18:30" +"183","tlvmc-parkinsons-freezing-gait-prediction","Parkinson's Freezing of Gait Prediction","Event detection from wearable sensor data","The goal of this competition is to detect freezing of gait (FOG), a debilitating symptom that afflicts many people with Parkinson’s disease. You will develop a machine learning model trained on data collected from a wearable 3D lower back sensor. Your work will help researchers better understand when and why FOG episodes occur. This will improve the ability of medical professionals to optimally evaluate, monitor, and ultimately, prevent FOG events.","","https://www.kaggle.com/competitions/tlvmc-parkinsons-freezing-gait-prediction","completed","intermediate","8","","2023-03-09","2023-06-08","2023-08-08 19:47:54","2023-09-28 23:18:53" +"184","chaimeleon","CHAIMELEON Open Challenges","","The CHAIMELEON Open Challenges is a competition designed to train and refine AI models to answer clinical questions about five types of cancer: prostate, lung, breast, colon, and rectal. Participants are challenged to collaborate and develop innovative AI-powered solutions that can significantly impact cancer diagnosis, management, and treatment. They will be evaluated considering a balance between the performance of their AI algorithms to predict different clinical endpoints such as disease staging, treatment response or progression free survival and their trustworthiness. The challenges are open to the whole scientific and tech community interested in AI. They are a unique opportunity to showcase how AI can be used to advance medical research and improve patient outcomes within the CHAIMELEON project.","","https://chaimeleon.grand-challenge.org/","upcoming","intermediate","5","","\N","2023-12-31","2023-08-09 17:13:09","2023-09-28 23:24:23" +"185","topcow23","Topology-Aware Anatomical Segmentation of the Circle of Willis for CTA and MRA","","The aim of the challenge is to extract the CoW angio-architecture from 3D angiographic imaging by segmentation of the vessel components. There are two sub-tasks: binary segmentation of CoW vessels, and multi-class CoW anatomical segmentation. We release a new dataset of joint-modalities, CTA and MRA of the same patient cohort, both with annotations of the anatomy of CoW. Our challenge has two tracks for the same segmentation task, namely CTA track and MRA track. We made use of the clinical information from both modalities during our annotation. And participants can pick whichever modality they want, both CTA and MRA, and choose to tackle the task for either modality.","","https://topcow23.grand-challenge.org/","completed","intermediate","5","","2023-08-20","2023-09-25","2023-08-09 17:16:22","2023-09-28 23:24:41" +"186","crown2023","Circle of Willis Intracranial Artery Classification and Quantification Challenge 2023","","The purpose of this challenge is to compare automatic methods for classification of the circle of Willis (CoW) configuration and quantification of the CoW major artery diameters and bifurcation angles.","","https://crown.isi.uu.nl/","completed","intermediate","14","","2023-05-01","2023-08-15","2023-08-09 22:13:24","2023-09-28 23:24:54" +"187","making-sense-of-electronic-health-record-ehr-race-and-ethnicity-data","Making Sense of Electronic Health Record (EHR) Race and Ethnicity Data","The US Food and Drug Administration (FDA) calls on stakeholders, including t...","The urgency of the coronavirus disease 2019 (COVID-19) pandemic has heightened interest in the use of real-world data (RWD) to obtain timely information about patients and populations and has focused attention on EHRs. The pandemic has also heightened awareness of long-standing racial and ethnic health disparities along a continuum from underlying social determinants of health, exposure to risk, access to insurance and care, quality of care, and responses to treatments. This highlighted the potential that EHRs can be used to describe and contribute to our understanding of racial and ethnic health disparities and their solutions. The OMB Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity provides minimum standards for maintaining, collecting, and presenting data on race and ethnicity for all Federal reporting purposes, and defines the two separate constructs of race and ethnicity.","","https://precision.fda.gov/challenges/30","completed","intermediate","6","","2023-05-31","2023-06-23","2023-08-10 18:28:06","2023-09-28 23:25:10" +"188","v-champs","The Veterans Cardiac Health and AI Model Predictions (V-CHAMPS)","The Veterans Health Administration Innovation Ecosystem, the Digital Health ...","To better understand the risk and protective factors in the Veteran population, the VHA IE and its collaborating partners are calling upon the public to develop AI/ML models to predict cardiovascular health outcomes, including readmission and mortality, using synthetically generated Veteran health records. The Challenge consists of two Phases: Phase 1 is focused on synthetic data. In this Phase of the Challenge, AI/ML models will be developed by Challenge participants and trained and tested on the synthetic data sets provided to them, with a view towards predicting outcome variables for Veterans who have been diagnosed with chronic heart failure (please note that in Phase 1, the data is synthetic Veteran health records). Phase 2 will focus on validating and further exploring the limits of the AI/ML models. During this Phase, high-performing AI/ML models from Phase 1 will be brought into the VA system and validated on the real-world Veterans health data within the VHA. These model...","","https://precision.fda.gov/challenges/31","completed","intermediate","6","","2023-05-25","2023-08-02","2023-08-10 21:41:10","2023-09-28 23:25:45" +"189","predicting-high-risk-breast-cancer-phase-1","Predicting High Risk Breast Cancer - Phase 1","Predicting High Risk Breast Cancer: a Nightingale OS & AHLI data challenge","Every year, 40 million women get a mammogram; some go on to have an invasive biopsy to better examine a concerning area. Underneath these routine tests lies a deep—and disturbing—mystery. Since the 1990s, we have found far more ‘cancers’, which has in turn prompted vastly more surgical procedures and chemotherapy. But death rates from metastatic breast cancer have hardly changed. When a pathologist looks at a biopsy slide, she is looking for known signs of cancer: tubules, cells with atypical looking nuclei, evidence of rapid cell division. These features, first identified in 1928, still underlie critical decisions today: which women must receive urgent treatment with surgery and chemotherapy? And which can be prescribed “watchful waiting”, sparing them invasive procedures for cancers that would not harm them? There is already evidence that algorithms can predict which cancers will metastasize and harm patients on the basis of the biopsy image. Fascinatingly, these algorithms al...","","https://app.nightingalescience.org/contests/3jmp2y128nxd","completed","intermediate","15","","2022-06-01","2023-01-12","2023-08-22 17:07:00","2023-09-28 23:26:19" +"190","predicting-high-risk-breast-cancer-phase-2","Predicting High Risk Breast Cancer - Phase 2","Predicting High Risk Breast Cancer: a Nightingale OS & AHLI data challenge","Every year, 40 million women get a mammogram; some go on to have an invasive biopsy to better examine a concerning area. Underneath these routine tests lies a deep—and disturbing—mystery. Since the 1990s, we have found far more ‘cancers’, which has in turn prompted vastly more surgical procedures and chemotherapy. But death rates from metastatic breast cancer have hardly changed. When a pathologist looks at a biopsy slide, she is looking for known signs of cancer: tubules, cells with atypical looking nuclei, evidence of rapid cell division. These features, first identified in 1928, still underlie critical decisions today: which women must receive urgent treatment with surgery and chemotherapy? And which can be prescribed “watchful waiting”, sparing them invasive procedures for cancers that would not harm them? There is already evidence that algorithms can predict which cancers will metastasize and harm patients on the basis of the biopsy image. Fascinatingly, these algorithms al...","","https://app.nightingalescience.org/contests/vd8g98zv9w0p","completed","intermediate","15","","2023-02-03","2023-05-13","2023-08-22 17:07:01","2023-09-28 23:26:20" +"191","dream-2-in-silico-network-inference","DREAM 2 - In Silico Network Inference","Predicting the connectivity and properties of in-silico networks.","Three in-silico networks were created and endowed with a dynamics that simulate biological interactions. The challenge consists of predicting the connectivity and some of the properties of one or more of these three networks.","","https://www.synapse.org/#!Synapse:syn2825394/wiki/71150","completed","intermediate","1","","2007-03-25","\N","2023-08-24 18:54:05","2023-09-28 23:27:16" +"192","dream-3-in-silico-network-challenge","DREAM 3 - In Silico Network Challenge","The goal of the in silico challenges is the reverse engineering of gene netw...","The goal of the in silico challenges is the reverse engineering of gene networks from steady state and time series data. Participants are challenged to predict the directed unsigned network topology from the given in silico generated gene topic_3170sets.","","https://www.synapse.org/#!Synapse:syn2853594/wiki/71567","completed","intermediate","1","https://doi.org/10.1089/cmb.2008.09TT","2008-06-09","\N","2023-08-25 16:43:41","2023-09-28 23:27:25" +"193","dream-4-in-silico-network-challenge","DREAM 4 - In Silico Network Challenge","The goal of the in silico network challenge is to reverse engineer gene regu...","The goal of the in silico network challenge is to reverse engineer gene regulation networks from simulated steady-state and time-series data. Participants are challenged to infer the network structure from the given in silico gene topic_3170sets. Optionally, participants may also predict the response of the networks to a set of novel perturbations that were not included in the provided datasets.","","https://www.synapse.org/#!Synapse:syn3049712/wiki/74628","completed","intermediate","1","https://doi.org/10.1073/pnas.0913357107","2009-06-09","\N","2023-08-25 16:43:42","2023-09-28 23:27:25" +"194","dream-5-network-inference-challenge","DREAM 5 - Network Inference Challenge","The goal of this Network Inference Challenge is to reverse engineer gene reg...","The goal of this Network Inference Challenge is to reverse engineer gene regulatory networks from gene topic_3170sets. Participants are given four microarray compendia and are challenged to infer the structure of the underlying transcriptional regulatory networks. Three of the four compendia were obtained from microorganisms, some of which are pathogens of clinical relevance. The fourth compendium is based on an in-silico (i.e., simulated) network. Each compendium consists of hundreds of microarray experiments, which include a wide range of genetic, drug, and environmental perturbations (or in the in-silico network case, simulations thereof). Network predictions will be evaluated on a subset of known interactions for each organism, or on the known network for the in-silico case.","","https://www.synapse.org/#!Synapse:syn2787209/wiki/70349","completed","intermediate","1","https://doi.org/10.1038/nmeth.2016","2010-06-09","2010-10-31","2023-08-25 16:43:43","2023-09-28 23:27:29" +"195","nlp-sandbox-date-annotation","NLP Sandbox Date Annotation","Identify dates in clinical notes.","An NLP Sandbox Date Annotator takes as input a clinical note and outputs a list of predicted date annotations found in the clinical note.","","https://www.synapse.org/#!Synapse:syn22277123/wiki/609134","completed","intermediate","1","https://doi.org/10.7303/syn22277123","2021-06-04","2023-09-01","2023-08-25 16:45:22","2023-09-28 23:59:02" +"196","nlp-sandbox-person-name-annotation","NLP Sandbox Person Name Annotation","Identify person names in clinical notes.","An NLP Sandbox Person Name Annotator takes as input a clinical note and outputs a list of predicted person name annotations found in the clinical note.","","https://www.synapse.org/#!Synapse:syn22277123/wiki/609134","completed","intermediate","1","https://doi.org/10.7303/syn22277123","2021-06-04","2023-09-01","2023-09-08 16:44:20","2023-09-28 23:59:20" +"197","nlp-sandbox-location-annotation","NLP Sandbox Location Annotation","Identify location information in clinical notes.","An NLP Sandbox Location Annotator takes as input a clinical note and outputs a list of predicted location annotations found in the clinical note.","","https://www.synapse.org/#!Synapse:syn22277123/wiki/609134","completed","intermediate","1","https://doi.org/10.7303/syn22277123","2021-06-04","2023-09-01","2023-09-08 16:44:21","2023-09-28 23:59:21" +"198","nlp-sandbox-contact-annotation","NLP Sandbox Contact Annotation","Identify contact information in clinical notes.","An NLP Sandbox contact annotator takes as input a clinical note and outputs a list of predicted contact annotations found in the clinical note.","","https://www.synapse.org/#!Synapse:syn22277123/wiki/609134","completed","intermediate","1","https://doi.org/10.7303/syn22277123","2021-06-04","2023-09-01","2023-09-08 16:44:22","2023-09-28 23:59:21" +"199","nlp-sandbox-id-annotation","NLP Sandbox ID Annotation","Identify identifiers in clinical notes.","An NLP Sandbox ID annotator takes as input a clinical note and outputs a list of predicted ID annotations found in the clinical note.","","https://www.synapse.org/#!Synapse:syn22277123/wiki/609134","completed","intermediate","1","https://doi.org/10.7303/syn22277123","2021-06-04","2023-09-01","2023-09-08 16:44:22","2023-09-28 23:59:22" +"200","dream-2-bcl6-transcriptomic-target-prediction","DREAM 2 – BCL6 Transcriptomic Target Prediction","","A number of potential transcriptional targets of BCL6, a gene that encodes for a transcription factor active in B cells, have been identified with ChIP-on-chip data and functionally validated by perturbing the BCL6 pathway with CD40 and anti-IgM, and by over-expressing exogenous BCL6 in Ramos cell. We subselected a number of targets found in this way (the ""gold standard positive"" set), and added a number decoys (genes that have no evidence of being BCL6 targets, named the ""gold standard negative"" set), compiling a list of 200 genes in total. Given this list of 200 genes, the challenge consists of identifying which ones are the true targets and which ones are the decoys, using an independent panel of gene topic_3170.","","https://www.synapse.org/#!Synapse:syn3034857/wiki/","completed","intermediate","1","https://doi.org/10.1073/pnas.0437996100","2007-04-19","\N","2023-09-12 21:26:22","2023-09-28 23:59:34" +"201","dream-2-protein-protein-interaction-network-inference","DREAM 2 – Protein-Protein Interaction Network Inference","Predict a PPI network of 47 proteins","For many pairs of bait and prey genes, yeast protein-protein interactions were tested in an unbiased fashion using a high saturation, high-stringency variant of the yeast two-hybrid (Y2H) method. A high confidence subset of gene pairs that were found to interact in at least three repetitions of the experiment but that hadn’t been reported in the literature was extracted. There were 47 yeast genes involved in these pairs. Including self interactions, there are a total of 47*48/2 possible pairs of genes that can be formed with these 47 genes. As mentioned above some of these gene pairs were seen to consistently interact in at least three repetitions of the Y2H experiments: these gene pairs form the ""gold standard positive"" set. A second set among these gene pairs were seen never to interact in repeated experiments and were not reported as interacting in the literature; we call this the ""gold standard negative"" set. Finally in a third set of gene pairs, which we shall call the ""undec...","","https://www.synapse.org/#!Synapse:syn2825374/wiki/","completed","intermediate","1","https://doi.org/10.1126/science.1158684","2007-05-24","\N","2023-09-12 21:26:28","2023-09-28 23:59:55" +"202","dream-2-genome-scale-network-inference","DREAM 2 – Genome-Scale Network Inference","","A panel of single-channel microarrays was collected for a particular microorganism, including some already published and some in-print data. The data was appropriately normalized (to the logarithmic scale). The challenge consists of reconstructing a genome-scale transcriptional network for this organism. The accuracy of network inference will be judged using chromatin precipitation and otherwise experimentally verified Transcription Factor (TF)-target interactions.","","https://www.synapse.org/#!Synapse:syn3034894/wiki/74418","completed","intermediate","1","https://doi.org/10.1371/journal.pbio.0050008","2007-06-05","2007-10-31","2023-09-12 21:26:34","2023-09-29 0:00:23" +"203","dream-2-synthetic-five-gene-network-inference","DREAM 2 – Synthetic Five-Gene Network Inference","","A synthetic-biology network consisting of 5 interacting genes was created and transfected to an in-vivo model organism. The challenge consists of predicting the connectivity of the five-gene network from in-vivo measurements.","","https://www.synapse.org/#!Synapse:syn3034869/wiki/74411","completed","intermediate","1","https://doi.org/10.1016/j.cell.2009.01.055","2007-06-20","2007-10-31","2023-09-12 21:26:56","2023-09-29 0:00:55" +"204","dream-3-signaling-cascade-identification","DREAM 3 – Signaling Cascade Identification","","The concentration of four intracellular proteins or phospho-proteins (X1, X2, X3 and X4) participating in a signaling cascade were measured in about 104 cells by antibody staining and flow cytometry. The idea of this challenge is to explore what key aspects of the dynamics and topology of interactions of a signaling cascade can be inferred from incomplete flow cytometry data.","","https://www.synapse.org/#!Synapse:syn3033068/wiki/74362","completed","intermediate","1","","2008-06-01","2008-10-31","2023-09-12 21:27:04","2023-09-29 0:03:05" +"205","dream-3-gene-expression-prediction","DREAM 3 – Gene Expression Prediction","","Gene expression time course data is provided for four different strains of yeast (S. Cerevisiae), after perturbation of the cells. The challenge is to predict the rank order of induction/repression of a small subset of genes (the ""prediction targets"") in one of the four strains, given complete data for three of the strains, and data for all genes except the prediction targets in the other strain. You are also allowed to use any information that is in the public domain and are expected to be forthcoming about what information was used.","","https://www.synapse.org/#!Synapse:syn3033083/wiki/74369","completed","intermediate","1","","2008-06-01","2008-10-31","2023-09-12 21:27:12","2023-09-29 0:03:19" +"206","dream-4-predictive-signaling-network-modelling","DREAM 4 – Predictive Signaling Network Modelling","Cell-type specific high-throughput experimental data","This challenge explores the extent to which our current knowledge of signaling pathways, collected from a variety of cell types, agrees with cell-type specific high-throughput experimental data. Specifically, we ask the challenge participants to create a cell-type specific model of signal transduction using the measured activity levels of signaling proteins in HepG2 cell lines. The model, which can leverage prior information encoded in a generic signaling pathway provided in the challenge, should be biologically interpretable as a network, and capable of predicting the outcome of new experiments.","","https://www.synapse.org/#!Synapse:syn2825304/wiki/71129","completed","intermediate","1","","2009-03-09","\N","2023-09-12 21:27:14","2023-09-29 0:03:40" +"207","dream-3-signaling-response-prediction","DREAM 3 – Signaling Response Prediction","Predict missing protein concentrations from a large corpus of measurements","Approximately 10,000 intracellular measurements (fluorescence signals proportional to the concentrations of phosphorylated proteins) and extracellular measurements (concentrations of cytokines released in response to cell stimulation) were acquired in human normal hepatocytes and the hepatocellular carcinoma cell line HepG2 cells. The datasets consist of measurements of 17 phospho-proteins (at 0 min, 30 min, and 3 hrs) and 20 cytokines (at 0 min, 3 hrs, and 24 hrs) in two cell types (normal and cancer) after perturbations to the pathway induced by the combinatorial treatment of 7 stimuli and 7 selective inhibitors.","","https://www.synapse.org/#!Synapse:syn2825325/wiki/","completed","intermediate","1","https://doi.org/10.1126%2Fscisignal.2002212","2009-03-09","\N","2023-09-12 21:27:20","2023-09-29 0:04:55" +"208","dream-4-peptide-recognition-domain-prd-specificity-prediction","DREAM 4 – Peptide Recognition Domain (PRD) Specificity Prediction","","Many important protein-protein interactions are mediated by peptide recognition domains (PRD), which bind short linear sequence motifs in other proteins. For example, SH3 domains typically recognize proline-rich motifs, PDZ domains recognize hydrophobic C-terminal tails, and kinases recognize short sequence regions around a phosphorylatable residue (Pawson, 2003). Given the sequence of the domains, the challenge consists of predicting a position weight matrix (PWM) that describes the specificity profile of each of the given domains to their target peptides. Any publicly accessible peptide specificity information available for the domain may be used.","","https://www.synapse.org/#!Synapse:syn2925957/wiki/72976","completed","intermediate","1","","2009-06-01","2009-10-31","2023-09-12 21:27:35","2023-09-29 0:04:53" +"209","dream-5-transcription-factor-dna-motif-recognition-challenge","DREAM 5 – Transcription-Factor, DNA-Motif Recognition Challenge","","Transcription factors (TFs) control the expression of genes through sequence-specific interactions with genomic DNA. Different TFs bind preferentially to different sequences, with the majority recognizing short (6-12 base), degenerate ‘motifs’. Modeling the sequence specificities of TFs is a central problem in understanding the function and evolution of the genome, because many types of genomic analyses involve scanning for potential TF binding sites. Models of TF binding specificity are also important for understanding the function and evolution of the TFs themselves. The challenge consists of predicting the signal intensities for the remaining TFs.","","https://www.synapse.org/#!Synapse:syn2887863/wiki/72185","completed","intermediate","1","https://doi.org/10.1038/nbt.2486","2011-06-01","2011-09-30","2023-09-12 21:27:41","2023-09-29 0:05:35" +"210","dream-5-epitope-antibody-recognition-ear-challenge","DREAM 5 – Epitope-Antibody Recognition (EAR) Challenge","Predict the binding specificity of peptide-antibody interactions.","Humoral immune responses are mediated through antibodies. About 1010 to 1012 different antigen binding sites called paratopes are generated by genomic recombination. These antibodies are capable to bind to a variety of structures ranging from small molecules to protein complexes, including any posttranslational modification thereof. When studying protein-antibody interactions, two types of epitopes (the region paratopes interact with) are to be distinguished from each other: i) conformational and ii) linear epitopes. All potential linear epitopes of a protein can be represented by short peptides derived from the primary amino acid sequence. These peptides can be synthesized and arrayed on solid supports, e.g. glass slides (see Lorenz et al., 2009 [1]). By incubating these peptide arrays with antibody mixtures such as human serum or plasma, peptides can be determined that interact with antibodies in a specific fashion.","","https://www.synapse.org/#!Synapse:syn2820433/wiki/71017","completed","intermediate","1","","2010-06-09","\N","2023-09-12 21:27:44","2023-09-29 0:08:30" +"211","dream-gene-expression-prediction-challenge","DREAM Gene Expression Prediction Challenge","Predict gene expression levels from promoter sequences in eukaryotes","The level by which genes are transcribed is determined in large part by the DNA sequence upstream to the gene, known as the promoter region. Although widely studied, we are still far from a quantitative and predictive understanding of how transcriptional regulation is encoded in gene promoters. One obstacle in the field is obtaining accurate measurements of transcription derived by different promoters. To address this, an experimental system was designed to measure the transcription derived by different promoters, all of which are inserted into the same genomic location upstream to a reporter gene – a yellow florescence protein gene (YFP). The challenge consists of the prediction of the promoter activity given a promoter sequence and a specific experimental condition. To study a set of promoters that share many elements of the regulatory program, and thus are suitable for computational learning, the data pertains to promoters of most of the ribosomal protein genes (RP) of yeast (S...","","https://www.synapse.org/#!Synapse:syn2820426/wiki/71010","completed","intermediate","1","","2010-07-09","\N","2023-09-12 21:28:00","2023-09-29 0:08:46" +"212","dream-5-systems-genetics-challenge","DREAM 5 – Systems Genetics Challenge","Predict disease phenotypes and infer Gene Networks from Systems Genetics data","The central goal of systems biology is to gain a predictive, system-level understanding of biological networks. This can be done, for example, by inferring causal networks from observations on a perturbed biological system. An ideal experimental design for causal inference is randomized, multifactorial perturbation. The recognition that the genetic variation in a segregating population represents randomized, multifactorial perturbations (Jansen and Nap (2001), Jansen (2003)) gave rise to Systems Genetics (SG), where a segregating or genetically randomized population is genotyped for many DNA variants, and profiled for phenotypes of interest (e.g. disease phenotypes), gene expression, and potentially other ‘omics’ variables (protein expression, metabolomics, DNA methylation, etc.; Figure 1. Figure 1 was taken from Jansen and Nap (2001)). In this challenge we explore the use of Systems Genetics data for elucidating causal network models among genes, i.e. Gene Networks (DREAM5 SYSGEN...","","https://www.synapse.org/#!Synapse:syn2820440/wiki/","completed","intermediate","1","","2010-07-09","\N","2023-09-12 21:28:10","2023-09-29 0:09:02" +"213","dream-6-estimation-of-model-parameters-challenge","DREAM 6 – Estimation of Model Parameters Challenge","","Given the complete model structures (including expressions for the kinetic rate laws) for three gene regulatory networks, participants are asked to develop and/or apply optimization methods, including the selection of the most informative experiments, to accurately estimate parameters and predict outcomes of perturbations in Systems Biology models.","","https://www.synapse.org/#!Synapse:syn2841366/wiki/71372","completed","intermediate","1","","2011-06-01","2011-10-31","2023-09-12 21:28:12","2023-09-29 0:09:39" +"214","dream-6-flowcap2-molecular-classification-of-acute-myeloid-leukemia-challenge","DREAM 6 – FlowCAP2 Molecular Classification of Acute Myeloid Leukemia Challenge","The goal of this challenge is to diagnose Acute Myeloid Leukaemia from patie...","Flow cytometry (FCM) has been widely used by immunologists and cancer biologists for more than 30 years as a biomedical research tool to distinguish different cell types in mixed populations, based on the expression of cellular markers. It has also become a widely used diagnostic tool for clinicians to identify abnormal cell populations associated with disease. In the last decade, advances in instrumentation and reagent technologies have enabled simultaneous single-cell measurement of tens of surface and intracellular markers, as well as tens of signaling molecules, positioning FCM to play an even bigger role in medicine and systems biology [1,2]. However, the rapid expansion of FCM applications has outpaced the functionality of traditional analysis tools used to interpret FCM data such that scientists are faced with the daunting prospect of manually identifying interesting cell populations in 20 dimensional data from a collection of millions of cells. For these reasons a reliable...","","https://www.synapse.org/#!Synapse:syn2887788/wiki/72178","completed","intermediate","1","https://doi.org/10.1038/nmeth.2365","2011-06-01","2011-09-30","2023-09-12 21:28:19","2023-09-29 0:11:17" +"215","dream-6-alternative-splicing-challenge","DREAM 6 – Alternative Splicing Challenge","","The goal of the mRNA-seq alternative splicing challenge is to assess the accuracy of the reconstruction of alternatively spliced mRNA transcripts from Illumina short-read mRNA-seq. Reconstructed transcripts will be scored against Pacific Biosciences long-read mRNA-seq. The ensuing analysis of the transcriptomes from mandrill and rhinoceros fibroblasts and their derived induced pluripotent stem cells (iPSC), as well as the transcriptome for human Embrionic Stem Cells (hESC) is an opportunity to discover novel biology as well as investigate species-bias of different methods.","","https://www.synapse.org/#!Synapse:syn2817724/wiki/","completed","intermediate","1","","2011-08-09","\N","2023-09-12 21:28:25","2023-09-29 0:11:35" +"216","causalbench-challenge","CausalBench Challenge","A machine learning contest for gene network inference from single-cell pertu...","Mapping gene–gene interactions in cellular systems is a fundamental step in early-stage drug discovery that helps generate hypotheses on what molecular mechanisms may effectively be targeted by potential future medicines. In the CausalBench Challenge, we invite the machine-learning community to advance the state-of-the-art in deriving gene–gene networks from large-scale real-world perturbational single-cell datasets to improve our ability to glean causal insights into disease-relevant biology.","","https://www.gsk.ai/causalbench-challenge/","completed","intermediate","16","https://doi.org/10.48550/arXiv.2308.15395","2023-03-01","2023-04-21","2023-09-13 0:41:58","2023-09-29 0:12:18" +"217","iclr-computational-geometry-and-topology-challenge-2022","ICLR Computational Geometry & Topology Challenge 2022","","The purpose of this challenge is to foster reproducible research in geometric (deep) learning, by crowdsourcing the open-source implementation of learning algorithms on manifolds. Participants are asked to contribute code for a published/unpublished algorithm, following Scikit-Learn/Geomstats' or pytorch's APIs and computational primitives, benchmark it, and demonstrate its use in real-world scenarios.","","https://github.com/geomstats/challenge-iclr-2022","completed","intermediate","14","","\N","2022-04-04","2023-09-13 16:54:06","2023-09-29 0:14:04" +"218","iclr-computational-geometry-and-topology-challenge-2021","ICLR Computational Geometry & Topology Challenge 2021","","The purpose of this challenge is to push forward the fields of computational differential geometry and topology, by creating the best data analysis, computational method, or numerical experiment relying on state-of-the-art geometric and topological Python packages.","","https://github.com/geomstats/challenge-iclr-2021","completed","intermediate","14","https://doi.org/10.48550/arXiv.2108.09810","\N","2021-05-02","2023-09-13 17:02:12","2023-09-29 0:14:06" +"219","genedisco-challenge","GeneDisco Challenge","","The GeneDisco challenge is a machine learning community challenge for evaluating batch active learning algorithms for exploring the vast experimental design space in genetic perturbation experiments. Genetic perturbation experiments, using for example CRISPR technologies to perturb the genome, are a vital component of early-stage drug discovery, including target discovery and target validation. The GeneDisco challenge is organized in conjunction with the Machine Learning for Drug Discovery workshop at ICLR-22.","","https://www.gsk.ai/genedisco-challenge/","completed","intermediate","16","https://doi.org/10.48550/arXiv.2110.11875","2022-01-31","2022-03-31","2023-09-13 17:20:30","2023-09-29 0:16:54" +"220","hidden-treasures-warm-up","Hidden Treasures - Warm Up","","In the context of human genome sequencing, software pipelines typically involve a wide range of processing elements, including aligning sequencing reads to a reference genome and subsequently identifying variants (differences). One way of assessing the performance of such pipelines is by using well-characterized datasets such as Genome in a Bottle’s NA12878. However, because the existing NGS reference datasets are very limited and have been widely used to train/develop software pipelines, benchmarking of pipeline performance would ideally be done on samples with unknown variants. This challenge will provide a unique opportunity for participants to investigate the accuracy of their pipelines by testing the ability to find in silico injected variants in FASTQ files from exome sequencing of reference cell lines. It will be a warm up for the community ahead of a more difficult in silico challenge to come in the fall. This challenge will provide users with a FASTQ file of a NA12878 se...","","https://precision.fda.gov/challenges/1","completed","intermediate","6","","2017-07-17","2017-09-13","2023-09-13 23:31:39","2023-09-29 0:17:12" +"221","cmu-dnanexus-2023","Data management and graph extraction for large models in the biomedical space","Collaborative hackathon on the topic of data management and graph extraction...","This fall, CMU Libraries is hosting a hackathon in partnership with DNAnexus on the topic of data management and graph extraction for large models in the biomedical space. The hackathon will be held in person at CMU, October 19-21, 2023. The hackathon is a collaborative, rather than competitive, event, with each team working on a dedicated part of the problem. The teams will be focused on the following topics: 1) Knowledge graph-based validation for variant (genomic) assertions; 2) Continuous monitoring for RLHF and flexible infrastructure for layering assertions with rollback; 3) Flexible tokenization of complex data types; 4) Assertion tracking in large models; 5) Column headers for data harmonization. The outputs are often published as preprints or on the F1000 hackathon channel. Contact Ben Busby (bbusby@dnanexus.com) with any questions about the hackathon or serving as a team lead.","","https://library.cmu.edu/about/news/2023-08/hackathon-2023","upcoming","intermediate","14","","2023-10-19","2023-10-21","2023-09-13 23:32:59","2023-09-27 21:08:26" +"222","cagi2-asthma-discordant-monozygotic-twins","CAGI2: Asthma discordant monozygotic twins","With the provided whole genome and RNA sequencing data, identify which two i...","The dataset includes whole genomes of 8 pairs of discordant monozygotic twins (randomly numbered from 1 to 16) that is, in each pair identical twins one has asthma and one does not. In addition, RNA sequencing data for each individual is provided. One of the twins in each pair suffers from asthma while the other twin is healthy.","","https://genomeinterpretation.org/cagi2-asthma-twins.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-29 3:55:34" +"223","cagi4-bipolar-disorder","CAGI4: Bipolar disorder","With the provided exome data, identify which individuals have BD and which i...","Bipolar disorder (BD) is a serious mental illness characterized by recurrent episodes of manias and depression, which are syndromes of abnormal mood, thinking and behavior. It affects 1.0-4.5% of the population [1], and it is among the major causes of disability worldwide. This challenge involved the prediction of which of a set of individuals have been diagnosed with bipolar disorder, given exome data. 500 of the 1000 exome samples were provided for training.","","https://genomeinterpretation.org/cagi4-bipolar.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-28 18:25:17" +"224","cagi3-brca1-and-brca2","CAGI3: BRCA1 & BRCA2","For each variant, provide the probability that Myriad Genetics has classifie...","In normal cells, the BRCA1 and BRCA2 genes are involved in homologous recombination for double strand break repair and ensure the stability of a cell's genetic material. Mutations in these genes have been linked to development of breast and ovarian cancer. Myriad Genetics created the BRACAnalysis test in order to assess a woman’s risk of developing hereditary breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes. This test has become the standard of care in identification of individuals with hereditary breast and ovarian cancer (HBOC) syndrome. It is based on proprietary methods.","","https://genomeinterpretation.org/cagi3-brca.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-29 3:58:34" +"225","cagi2-breast-cancer pharmacogenomics","CAGI2: Breast cancer pharmacogenomics","Cancer tissues are specifically responsive to different drugs. For this expe...","Cell-cycle-checkpoint kinase 2 (CHEK2; OMIM #604373) is a protein that plays an important role in the maintenance of genome integrity and in the regulation of the G2/M cell cycle checkpoint. CHEK2 has been shown to interact with other proteins involved in DNA repair processes such as BRCA1 and TP53. These findings render CHEK2 an 23 attractive candidate susceptibility gene for a variety of cancers.","","https://genomeinterpretation.org/cagi2-breast-cancer-pkg.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-27 18:55:45" +"226","cagi4-eqtl-causal-snps","CAGI4: eQTL causal SNPs","Participants are asked to submit predictions of the regulatory sequences tha...","Identifying the causal alleles responsible for variation in expression of human genes has been particularly difficult. This is an important problem, as genome-wide association studies (GWAS) suggest that much of the variation underlying common traits and diseases maps within regions of the genome that do not encode protein. A massively parallel reporter assay (MPRA) has been applied to thousands of single nucleotide polymorphisms (SNPs) and small insertion/deletion polymorphisms in linkage disequilibrium (LD) with cis-expression quantitative trait loci (eQTLs). The results identify variants showing differential expression between alleles. The challenge is to identify the regulatory sequences and the expression-modulating variants (emVars) underlying each eQTL and estimate their effects in the assay.","","https://genomeinterpretation.org/cagi4-2eqtl.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-29 3:58:33" +"227","cagi1-cbs","CAGI1: CBS","Participants were asked to submit predictions for the effect of the variant...","CBS is a vitamin-dependent enzyme involved in cysteine biosynthesis. The human CBS requires two cofactors for function, vitamin B6 and heme. Homocystinuria due to CBS deficiency (OMIM #236200) is a recessive inborn error of sulfur amino acid metabolism.","","https://genomeinterpretation.org/cagi1-cbs.html","completed","intermediate","2","","\N","2010-12-10","2023-09-28 18:19:48","2023-09-29 3:58:32" +"228","cagi2-cbs","CAGI2: CBS","Participants were asked to submit predictions for the effect of the variant...","CBS is a vitamin-dependent enzyme involved in cysteine biosynthesis. The human CBS requires two cofactors for function, vitamin B6 and heme. Homocystinuria due to CBS deficiency (OMIM #236200) is a recessive inborn error of sulfur amino acid metabolism.","","https://genomeinterpretation.org/cagi2-cbs.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-29 3:58:32" +"229","cagi1-chek2","CAGI1: CHEK2","Variants in the ATM & CHEK2 genes are associated with breast cancer.","Predictors will be provided with 41 rare missense, nonsense, splicing, and indel variants in CHEK2.","","https://genomeinterpretation.org/cagi1-chek2.html","completed","intermediate","2","","\N","2010-12-10","2023-09-28 18:19:48","2023-09-29 3:58:32" +"230","cagi3-fch","CAGI3: FCH","The challenge involved exome sequencing data for 5 subjects in an FCH family...","Familial combined hyperlipidemia (FCH; OMIM 14380) the most prevalent hyperlipidemia, is a complex metabolic disorder characterized by variable occurrence of elevated low-density lipoprotein cholesterol (LDL-C) level and high triglycerides (TG)—a condition that is commonly associated with coronary artery disease (CAD).","","https://genomeinterpretation.org/cagi3-fch.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-28 18:25:19" +"231","cagi3-ha","CAGI3: HA","The dataset for this challenge comprises of exome sequencing data for 4 sub...","Hypoalphalipoproteinemia (HA; OMIM #604091) is characterized by severely decreased serum high-density lipoprotein cholesterol (HDL-C) levels and low apolipoprotein A1 (APOA1). Low HDL-C is a risk factor for coronary artery disease.","","https://genomeinterpretation.org/cagi3-ha.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-27 21:09:03" +"232","cagi2crohns-disease","CAGI2:Crohn's disease","With the provided exome data, identify which individuals have Crohn's diseas...","Crohn's disease (CD [MIM 266600]) a form of inflammatory bowel disease (IBD) is a complex genetic disorder characterized by chronic relapsing inflammation that can involve any part of the gastrointestinal tract.","","https://genomeinterpretation.org/cagi2-croshn-s.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-27 21:09:04" +"233","cagi3crohns-disease","CAGI3:Crohn's disease","With the provided exome data, identify which individuals have Crohn's diseas...","Crohn's disease (CD [MIM 266600]) a form of inflammatory bowel disease (IBD) is a complex genetic disorder characterized by chronic relapsing inflammation that can involve any part of the gastrointestinal tract.","","https://genomeinterpretation.org/cagi3-crohn-s.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-28 18:25:20" +"234","cagi4crohns-disease","CAGI4:Crohn's disease","With the provided exome data, identify which individuals have Crohn's diseas...","Crohn's disease (CD [MIM 266600]) a form of inflammatory bowel disease (IBD) is a complex genetic disorder characterized by chronic relapsing inflammation that can involve any part of the gastrointestinal tract.","","https://genomeinterpretation.org/challenges.html#:~:text=exomes%2C%20(2)-,Crohn%27s%20exomes%2C,-(3)%20eQTL","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-28 18:25:21" +"235","cagi4-hopkins-clinical-panel","CAGI4: Hopkins clinical panel","Participants were tasked with identifying the disease class for each of 106 ...","The Johns Hopkins challenge, provided by the Johns Hopkins DNA Diagnostic Laboratory (http://www.hopkinsmedicine.org/dnadiagnostic), comprised of exonic sequence for 83 genes associated with one of 14 disease classes, including 5 decoys","","https://genomeinterpretation.org/cagi4-hopkins.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-28 18:19:48" +"236","cagi2-mouse-exomes","CAGI2: Mouse exomes","The challenge involved identifying the causative variants leading to one of ...","Predictors were given SNVs and indels found from exome sequencing. Causative variants had been identified for the L11Jus74 and Sofa phenotypes by the use of traditional breeding crosses,47 and the predictions were compared to these results, which were unpublished at the time of the CAGI submissions. The L11Jus74 phenotype is caused by two SNVs (chr11:102258914A>T and chr11:77984176A>T), whereas a 15-nucleotide deletion in the Pfas gene is responsible for the Sofa phenotype. 9 The predictions for Frg and Stn phenotypes could not be compared to experimental data, as the causative variants could not successfully be mapped by linkage","","https://genomeinterpretation.org/cagi2-mouse-exomes.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-29 3:55:38" +"237","cagi3-mre11","CAGI3: MRE11","Genomes are subject to constant threat by damaging agents that generate DNA ...","Predict probability of pathogenicity (a number between 0 and 1) for individual rare variants of MRE11 and NBS1.","","https://genomeinterpretation.org/cagi3-mrn.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-29 3:55:51" +"238","cagi4-naglu","CAGI4: NAGLU","Participants are asked to submit predictions on the effect of the variants o...","NAGLU is a lysosomal glycohydrolyase. Deficiency of NAGLU causes the rare disorder Mucopolysaccharidosis IIIB or Sanfilippo B disease. Naturally occurring NAGLU mutants have been assayed for enzymatic activity in transfected cell lysates. The challenge is to predict the fractional activity of each mutant protein compared to the wild-type enzyme.","","https://genomeinterpretation.org/cagi4-naglu.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-29 3:55:52" +"239","cagi4-npm-alk","CAGI4: NPM-ALK","Participants are asked to submit predictions of both the kinase activity and...","NPM-ALK is a fusion protein in which the ALK tyrosine kinase is constitutively activated, contributing to cancer. NPM-ALK constructs with mutations in the kinase domain have been assayed in extracts of transfected cells. The challenge is to predict the kinase activity and the Hsp90 binding affinity of the mutant proteins relative to the reference NPM-ALK fusion protein.","","https://genomeinterpretation.org/cagi4-npm-alk.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-29 3:55:53" +"240","cagi3-nbs1","CAGI3: NBS1","Genomes are subject to constant threat by damaging agents that generate DNA ...","Predict probability of pathogenicity (a number between 0 and 1) for individual rare variants of MRE11 and NBS1.","","https://genomeinterpretation.org/cagi3-mrn.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-29 3:55:53" +"241","cagi3-p16","CAGI3: p16","CDKN2A is the most common, high penetrance, susceptibility gene identified t...","Evaluate how different variants of p16 protein impact its ability to block cell proliferation.","","https://genomeinterpretation.org/cagi3-p16.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-29 3:55:38" +"242","cagi2-p53-reactivation","CAGI2: p53 reactivation","Predictors are asked to submit predictions on the effect of the cancer rescu...","The transcription factor p53 is a central tumor suppressor protein that controls DNA repair, cell cycle arrest, and apoptosis (programmed cell death). About half of human cancers have p53 mutations that inactivate p53. Over 250,000 US deaths yearly are due to tumors that express full-length p53 that has been inactivated by a single point mutation. For the past several years, the group of Rick Lathrop at University of California, Irvine, has been engaged in a complete functional census of p53 second-site suppressor (“cancer rescue”) mutations. These cancer rescue mutations are additional amino acids changes (to otherwise cancerous p53 mutations), which have been found to rescue p53 tumor suppressor function, reactivating otherwise inactive p53. These intragenic rescue mutations reactivate cancer mutant p53 in yeast and human cell assays by providing structural changes that compensate for the cancer mutation.","","https://genomeinterpretation.org/cagi2-p53.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-29 3:55:53" +"243","cagi1-pgp","CAGI1: PGP","PGP challenge requires matching of full genome sequences to extensive phenot...","Participants in the project make their full sequence and phenotypic profile data publicly available. The four CAGI challenges were based on prerelease samples from this resource.","","https://genomeinterpretation.org/cagi1-pgp.html","completed","intermediate","2","","\N","2010-12-10","2023-09-28 18:19:48","2023-09-27 21:05:22" +"244","cagi2-pgp","CAGI2: PGP","PGP challenge requires matching of full genome sequences to extensive phenot...","Participants in the project make their full sequence and phenotypic profile data publicly available. The four CAGI challenges were based on prerelease samples from this resource.","","https://genomeinterpretation.org/cagi2-pgp.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-27 21:05:23" +"245","cagi3-pgp","CAGI3: PGP","PGP challenge requires matching of full genome sequences to extensive phenot...","Participants in the project make their full sequence and phenotypic profile data publicly available. The four CAGI challenges were based on prerelease samples from this resource.","","https://genomeinterpretation.org/cagi3-pgp.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-27 21:05:23" +"246","cagi4-pgp","CAGI4: PGP","PGP challenge requires matching of full genome sequences to extensive phenot...","Participants in the project make their full sequence and phenotypic profile data publicly available. The four CAGI challenges were based on prerelease samples from this resource.","","https://genomeinterpretation.org/cagi4-pgp.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-27 21:05:24" +"247","cagi4-pyruvate-kinase","CAGI4: Pyruvate kinase","Participants are asked to submit predictions on the effect of the mutations ...","Pyruvate kinase catalyzes the last step in glycolysis and is regulated by allosteric effectors. Variants in the gene encoding the isozymes expressed in red blood cells and liver, including missense variants mapping near the effector binding sites, cause PK deficiency. A large set of single amino acid mutations in the liver enzyme has been assayed in E. coli extracts for the effect on allosteric regulation of enzyme activity. The challenge is to predict the impacts of mutations on enzyme activity and allosteric regulation.","","https://genomeinterpretation.org/cagi4-pyruvate-kinase.html","completed","intermediate","2","","\N","2015-01-11","2023-09-28 18:19:48","2023-09-29 22:06:22" +"248","cagi2-rad50","CAGI2: RAD50","Predict the probability of the variant occurring in a case individual.","RAD50 is a candidate intermediate-risk breast cancer susceptibility gene. The RAD50 data provided for CAGI challenge include a list of potentially interesting sequence variants observed from sequencing RAD50 gene in about 1,400 breast cancer cases and 1,200 ethnically matched controls. Variants in the list were observed between 1 and 20 times.","","https://genomeinterpretation.org/cagi2-rad50.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-29 3:55:55" +"249","cagi2-risksnps","CAGI2: riskSNPs","The goal of these challenges is to investigate the community’s ability to id...","The goal of this experiment is to explore current understanding of the molecular level mechanisms underlying associations between SNPs and disease risk, incorporating expertise in each of the known mechanism areas, and as far as possible assigning possible mechanisms for each association locus. The correct mechanisms are unknown, so there can be no ranking of accuracy - that is not the point of the experiment. Rather, the goal is to ascertain which mechanisms appear most relevant, how confidently they can be assigned, and what fraction of loci can currently be assigned plausible mechanisms.","","https://genomeinterpretation.org/cagi2-risksnps.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-29 3:55:57" +"250","cagi3risksnps","CAGI3:riskSNPs","The goal of these challenges is to investigate the community’s ability to id...","The goal of this experiment is to explore current understanding of the molecular level mechanisms underlying associations between SNPs and disease risk, incorporating expertise in each of the known mechanism areas, and as far as possible assigning possible mechanisms for each association locus. The correct mechanisms are unknown, so there can be no ranking of accuracy - that is not the point of the experiment. Rather, the goal is to ascertain which mechanisms appear most relevant, how confidently they can be assigned, and what fraction of loci can currently be assigned plausible mechanisms.","","https://genomeinterpretation.org/cagi3-risksnps.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-29 3:55:57" +"251","cagi2scn5a","CAGI2:SCN5A","Predictors are asked to submit predictions on the effect of the mutants on t...","The cardiac action potential (AP) is the sum of a number of distinct ionic currents. It can be divided into five phases (phase 0‐4). From pacemaker cells of the SA node the initial depolarizing wave front will spread throughout the cardiomyocytes via gap junctions. If the depolarization is sufficient voltage‐dependent sodium channels (Nav1.5) are activated and allow Na+ influx. This results in a further depolarization of the membrane which will lead to opening of even more Nav channels. This positive feedback mechanism is seen as the rapid upstroke in the initial phase (phase 0) of the action potential. Nav1.5 is encoded by SCN5A and mutations in this gene have been associated with various diseases such as Atrial fibrillation, Long QT syndrome, Cardiac Conduction Defect, Sick Sinus Disease, and Brugada Syndrome (BrS).","","https://genomeinterpretation.org/cagi2-nav1.5.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-29 3:55:56" +"252","cagi2-shewanella-oneidensis-strain-mr-1","CAGI2: Shewanella oneidensis strain MR-1","Shewanella oneidensis strain MR-1 (formerly known as S. putrefaciens) is a m...","Predictors are asked to submit predictions on how insertions in the given gene of MR-1 affect the fitness of that gene in a given condition (stressor).","","https://genomeinterpretation.org/cagi2-mr-1.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:55","2023-09-29 3:55:38" +"253","cagi3-shewanella-oneidensis-strain-mr-1","CAGI3: Shewanella oneidensis strain MR-1","Shewanella oneidensis strain MR-1 (formerly known as S. putrefaciens) is a m...","Predictors are asked to submit predictions on how insertions in the given gene of MR-1 affect the fitness of that gene in a given condition (stressor).","","https://genomeinterpretation.org/cagi3-mr-1.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:20:01","2023-09-28 18:20:01" +"254","cagi4-sickkids","CAGI4: SickKids","The challenge presented here is to use computational methods to match each g...","Realizing the promise of precision medicine will require developing methods for interpreting genome sequence data to infer individuals’ phenotypic traits and predispositions to disease. This challenge involves 25 children with suspected genetic disorders who were referred for clinical genome sequencing. Predictors are given their genome sequences and their clinical phenotypic descriptions, as provided to the diagnostic laboratory, and asked to predict which genome corresponds to which clinical description. Additionally, identify the diagnostic variants underlying the predictions. Optionally, identify predictive secondary variants conferring high risk of other diseases whose phenotypes are not reported in the clinical descriptions.","","https://genomeinterpretation.org/cagi4-sickkids.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-29 3:55:41" +"255","cagi4-sumo-ligase","CAGI4: SUMO ligase","Participants are asked to submit predictions of the effect of the variants o...","SUMO ligase identifies target proteins and covalently attaches SUMO to them, thereby modulating the functions of hundreds of proteins including proteins implicated in cancer, neurodegeneration, and other diseases. A large library of missense mutations in human SUMO ligase has been assessed for competitive growth in a high-throughput yeast-based complementation assay. The challenge is to predict the effect of mutations on function, as measured by the change in fractional representation of each mutant SUMO ligase clone, relative to wild-type clones, in a competitive yeast growth assay.","","https://genomeinterpretation.org/cagi4-sumo-ligase.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-29 3:55:59" +"256","cagi3-tp53-splicing","CAGI3: TP53 splicing","With the provided data determine which disease-causing mutations in the T...","The function of exonic splicing regulatory elements can be undermined by DNA sequence variation and in some cases can contribute to pathogenesis. Thousands of disease-causing mutations disrupt exonic splicing regulatory elements. These data suggest that >25 percent of missense mutations may impact pre-mRNA splicing rather than mRNA translation. Using minigene constructs derived from a fragment of the TP53 gene, we have experimentally determined if each mutation influences splicing fidelity in HEK293T cells. We hope that CAGI participants will be able to predict the outcome of our experiments. A long-term goal will be the computational prioritization of disease-causing mutations prior to experimental validation. This contribution is expected to have major impacts in understanding the pathogenic basis of disease-causing mutations.","","https://genomeinterpretation.org/cagi3-splicing.html","completed","intermediate","2","","\N","2013-04-25","2023-09-28 18:19:48","2023-09-29 3:55:59" +"257","cagi4-warfarin-exomes","CAGI4: Warfarin exomes","With the provided exome data and clinical covariates, predict the therapeuti...","With over 33 million prescriptions in 2011, warfarin is the most commonly used anticoagulant for preventing thromboembolic events. Warfarin has a twenty-fold inter-individual dose variability and a narrow therapeutic index, and it is responsible for a third of adverse drug event hospitalizations in older Americans [2]. Alternatives to warfarin, such as direct thrombin inhibitors and factor Xa inhibitors, are now available. However, these are more expensive, irreversible, and may cause a higher rate of acute coronary events compared to warfarin [3,4]. Thus, warfarin remains a mainstay of anticoagulant therapy, and better methods of dosing warfarin will lead to fewer adverse events due to overcoagulation.","","https://genomeinterpretation.org/cagi4-warfarin.html","completed","intermediate","2","","\N","2016-04-04","2023-09-28 18:19:48","2023-09-28 21:19:03" +"258","cagi6-calmodulin","CAGI6: Calmodulin","participants were asked to submit predictions for the competitive growth sco...","Calmodulin (CaM) is a ubiquitous calcium (Ca2+) sensor protein interacting with more than 200 molecular partners, thereby regulating a variety of biological processes. Missense point mutations in the genes encoding CaM have been associated with ventricular tachycardia and sudden cardiac death. A library encompassing up to 17 point mutations was assessed by far-UV circular dichroism (CD) by measuring melting temperature (Tm) and percentage of unfolding (%unfold) upon thermal denaturation at pH and salt concentration that mimic the physiological conditions. The challenge is to predict: (1) the Tm and %unfold values for isolated CaM variants under Ca2+-saturating conditions (Ca2+-CaM) and in the Ca2+-free (apo) state; (2) whether the point mutation stabilizes or destabilizes the protein (based on Tm and %unfold).","","https://genomeinterpretation.org/cagi6-cam.html","completed","intermediate","1","","\N","2021-12-31","2023-09-28 18:19:48","2023-09-29 3:56:03" +"259","cagi6-sickkids6","CAGI6: SickKids6","The SickKids Genome Clinic is providing clinical phenotypic information in t...","This challenge involves data from 79 children who were referred to The Hospital for Sick Children’s (SickKids) Genome Clinic for genome sequencing because of suspected but undiagnosed genetic disorders. Research subjects are consented for sharing of their sequence data and phenotype information with researchers working to understand the molecular causes of rare disease. When a candidate disease variant believed to be related to the phenotype is identified, the variant is adjudicated and confirmed in a clinical setting. In this challenge, transcriptomic and phenotype data from a subset of the “solved” (diagnosed) and “unsolved” SickKids patients will be provided, along with corresponding genomic sequence data. The challenge is to use a transcriptome-driven approach to identify the gene(s) and molecular mechanisms underlying the phenotypic descriptions in each case. For the unsolved cases, prioritized variants from the participating teams will be examined to see if additional diagno...","","https://genomeinterpretation.org/cagi6-sickkids.html","completed","intermediate","1","","\N","2021-12-31","2023-09-28 18:19:48","2023-09-27 21:05:30" +"260","cagi2-splicing","CAGI2: splicing","Predictors are asked to compare exons from wild type and disease-associated ...","Accurate precursor mRNA (pre-mRNA) splicing is required for the expression of protein coding genes from the human genome. In this process, intervening sequences (introns) are removed from pre-mRNA and coding/regulatory sequences (exons) are ligated together generating a mature mRNA. A large ribonucleoprotein machine called the spliceosome assembles de novo upon every nascent intron and catalyzes the chemical steps of splicing.","","https://genomeinterpretation.org/cagi2-splicing.html","completed","intermediate","2","","\N","2011-10-06","2023-09-28 18:19:48","2023-09-29 3:56:03" +"261","cagi6-arsa","CAGI6: ARSA","Predicting the effect of naturally occurring missense mutations on enzymatic...","Metachromatic Leukodystrophy (MLD) is an autosomal recessive, lysosomal-storage disease caused by mutations in Arylsulfatase A (ARSA) and toxic accumulation of sulfatide substrate. Genome sequencing has revealed hundreds of protein-altering, ARSA missense variants, but the functional effect of most variants remains unknown. ARSA enzyme activity using a high-throughput cellular assay was measured for a large set of variants of known significance and variants of unknown significance. The challenge is to predict the fractional enzyme activity of each mutant protein compared to the wildtype protein.","","https://genomeinterpretation.org/cagi6-lc-arsa.html","completed","intermediate","1","","\N","2022-11-16","2023-09-28 18:20:23","2023-09-28 18:20:23" +"262","cache1predict-hits-for-the-wdr-domain-of-lrrk2","CACHE1:PREDICT HITS FOR THE WDR DOMAIN OF LRRK2","Finding ligands targeting the central cavity of the WD-40 repeat (WDR) domai...","The first CACHE Challenge target is LRRK2, the most commonly mutated gene in familial Parkinson's Disease. Participants are asked to find hits for the WD40 repeat (WDR) domain of LRRK2. Read more under Details below.","","https://cache-challenge.org/challenges/predict-hits-for-the-wdr-domain-of-lrrk2","completed","intermediate","14","","2021-12-01","2022-01-31","2023-09-27 19:01:55","2023-09-29 22:43:03" +"263","cache2finding-ligands-targeting-the-conserved-rna-binding-site-of-sars-cov-2-nsp13","CACHE2:FINDING LIGANDS TARGETING THE CONSERVED RNA BINDING SITE OF SARS-CoV-2 NSP13","Finding ligands targeting the conserved RNA binding site of SARS-CoV-2 NSP13.","Predicted compounds will be procured and tested at CACHE using both enzymatic and binding assays.","","https://cache-challenge.org/challenges/finding-ligands-targeting-the-conserved-rna-binding-site-of-sars-cov-2-nsp13","completed","intermediate","14","","2022-06-22","2022-09-04","2023-09-27 19:02:43","2023-09-29 22:43:09" +"264","cache3finding-ligands-targeting-the-macrodomain-of-sars-cov-2-nsp3","CACHE3:Finding ligands targeting the macrodomain of SARS-CoV-2 Nsp3","Severe acute respiratory syndrome coronavirus 2","To predict ligands that bind to the ADPr site of SARS-CoV-2 Nsp3 macrodomain (Mac1).","","https://cache-challenge.org/challenges/finding-ligands-targeting-the-macrodomain-of-sars-cov-2-nsp3","completed","intermediate","14","","2022-11-02","2023-01-01","2023-09-27 19:03:13","2023-09-29 22:43:12" +"265","cache4finding-ligands-targeting-the-tkb-domain-of-cblb","CACHE4:Finding ligands targeting the TKB domain of CBLB","Several cancers (PMID: 33306199), potential immunotherapy (PMID: 24875217), ...","Predict compounds that bind to the closed conformation of the CBLB TKB domain with novel chemical templates and KD below 30 micromolar.","","https://cache-challenge.org/challenges/finding-ligands-targeting-the-tkb-domain-of-cblb","completed","intermediate","14","","2023-03-09","2023-05-09","2023-09-27 19:03:14","2023-09-29 22:43:15" +"266","jan2024-rare-disease-ai-hackathon","Jan2024: Rare Disease AI Hackathon","Researchers and medical experts are invited to collaborate on our patient ca...","Bring AI and medical experts together to build open source models for rare diseases. Create zero-barrier access to rare disease expertise for patients, researchers and physicians. Use AI to Uncover novel links between rare diseases. Establish validation methods for medical AI models. Jumpstart an open source community for rare disease AI models. Launch models for Beta testing on Hypophosphatasia.ai and EhlersDanlos.ai.","","https://www.rarediseaseaihackathon.org/","upcoming","intermediate","14","","2023-09-30","2024-01-15","2023-09-27 19:10:40","2023-09-29 22:43:17" +"267","cometh-benchmark","COMETH Benchmark","Quantify tumor heterogeneity: how many cell types are present and in which p...","Successful treatment of cancer is still a challenge and this is partly due to a wide heterogeneity of cancer composition across patient population. Unfortunately, accounting for such heterogeneity is very difficult. Clinical evaluation of tumor heterogeneity often requires the expertise of anatomical pathologists and radiologists. This benchmark is dedicated to the quantification of intra-tumor heterogeneity using appropriate statistical methods on cancer omics data. In particular, it focuses on estimating cell types and proportion in biological samples based on methylation and methylome data sets. The goal is to explore various statistical methods for source separation/deconvolution analysis (Non-negative Matrix Factorization, Surrogate Variable Analysis, Principal component Analysis, Latent Factor Models, ...) using both RNA-seq and methylome data.","","https://www.codabench.org/competitions/218/","completed","intermediate","10","","2020-06-14","2020-12-29","2023-09-28 23:25:52","2023-09-29 2:26:38" +"268","the-miccai-2014-machine-learning-challenge","The MICCAI 2014 Machine Learning Challenge","Predicting Binary and Continuous Phenotypes from Structural Brain MRI Data","Machine learning tools have been increasingly applied to structural brain magnetic resonance imaging (MRI) scans, largely for developing models to predict clinical phenotypes at the individual level. Despite significant methodological developments and novel application domains, there has been little effort to conduct benchmark studies with standardized datasets, which researchers can use to validate new tools, and more importantly conduct an objective comparison with state-of-the-art algorithms. The MICCAI 2014 Machine Learning Challenge (MLC) will take a significant step in this direction, where we will employ four separate, carefully compiled, and curated large-scale (each N > 70) structural brain MRI datasets with accompanying clinically relevant phenotypes. Our goal is to provide a snapshot of the current state of the art in the field of neuroimage-based prediction, and attract machine-learning practitioners to the MICCAI community and the field of medical image computing in g...","","https://competitions.codalab.org/competitions/1471","completed","intermediate","9","","2014-04-16","2014-06-14","2023-09-28 23:36:12","2023-09-29 3:55:21" +"269","cagi6-annotate-all-missense","CAGI6: Annotate All Missense","Predictors are asked to predict the functional effect predict each coding SNV.","dbNSFP currently describes 81,782,923 possible protein-altering variants in the human genome. The challenge is to predict the functional effect of every such variant. For the vast majority of these missense and nonsense variants, the functional impact is not currently known, but experimental and clinical evidence is accruing rapidly. Rather than drawing upon a single discrete dataset as typical with CAGI, predictions will be assessed by comparing with experimental or clinical annotations made available after the prediction submission date, on an ongoing basis. If predictors assent, predictions will also be incorporated into dbNSFP.","","https://genomeinterpretation.org/cagi6-annotate-all-missense.html","completed","intermediate","1","","2021-06-01","2021-10-11","2023-06-23 00:00:00","2023-09-28 19:28:25" +"270","cagi6-hmbs","CAGI6: HMBS","Participants are asked to submit predictions of the fitness score for each o...","Hydroxymethylbilane synthase (HMBS), also known as porphobilinogen deaminase (PBGD) or uroporphyrinogen I synthase, is an enzyme involved in heme production. In humans, variants that affect HMBS function result in acute intermittent porphyria (AIP), an autosomal dominant genetic disorder caused by a build-up of porphobilinogen in the cytoplasm. A large library of HMBS missense variants was assessed with respect to their effects on protein function using a high-throughput yeast complementation assay. The challenge is to predict the functional effects of these variants.","","https://genomeinterpretation.org/cagi6-hmbs.html","completed","intermediate","1","","2021-06-08","2021-10-11","2023-06-23 00:00:00","2023-09-27 18:56:50" +"271","cagi6-intellectual-disability-panel","CAGI6: Intellectual Disability Panel","In this challenge predictors are asked to analyze the sequence data for the ...","The objective in this challenge is to predict a patient's clinical phenotype and the causal variant(s) based on their gene panel sequences. Sequence data for 74 genes from a cohort of 500 patients with a range of neurodevelopmental presentations (intellectual disability, autistic spectrum disorder, epilepsy, microcephaly, macrocephaly, hypotonia, ataxia) has been made available for this challenge. Additional data from 150 patients from the same clinical study is available for training and validation.","","https://genomeinterpretation.org/cagi6-id-panel.html","completed","intermediate","1","","2021-06-08","2021-10-11","2023-06-23 00:00:00","2023-09-28 18:24:00" +"272","cagi6-mapk1","CAGI6: MAPK1","For each variant, participants are asked to predict the ΔΔGH20 value for the...","MAPK1 (ERK2) is active as serine/threonine kinase in the Ras-Raf-MEK-ERK signal transduction cascade that regulates cell proliferation, transcription, differentiation, and cell cycle progression. MAPK1 is activated by phosphorylation which occurs with strict specificity by MEK1/2 on Thr185 and Tyr187, and may also act as a transcriptional repressor independent of its kinase activity. A library of eleven missense variants selected from the COSMIC database was assessed by near and far-UV circular dichroism and intrinsic fluorescence spectra to determine thermodynamic stability at different concentrations of denaturant. These data were used to calculate a ΔΔGH20 value; i.e., the difference in unfolding free energy ΔGH20 between each variant and the wildtype protein, both in phosphorylated and unphosphorylated forms. The challenge is to predict these two ΔΔGH20 values and the catalytic efficiency (kcat/km)mut/(kcat/km)wt, as determined by a fluorescence assay, of the phosphorylated fo...","","https://genomeinterpretation.org/cagi6-mapk1.html","completed","intermediate","1","","2021-07-08","2021-10-11","2023-06-23 00:00:00","2023-09-27 18:56:17" +"273","cagi6-mapk3","CAGI6: MAPK3","For each variant, participants are asked to predict the ΔΔGH20 value for the...","MAPK3 (ERK1) is active as serine/threonine kinase in the Ras-Raf-MEK-ERK signal transduction cascade that regulates cell proliferation, transcription, differentiation, and cell cycle progression. MAPK3 is activated by phosphorylation which occurs with strict specificity by MEK1/2 on Thr202 and Tyr204, and may also act as a transcriptional repressor independent of its kinase activity. A library of twelve missense variants selected from the COSMIC database was assessed by near and far-UV circular dichroism and intrinsic fluorescence spectra to determine thermodynamic stability at different concentrations of denaturant. These data were used to calculate a ΔΔGH20 value; i.e., the difference in unfolding free energy ΔGH20 between each variant and the wildtype protein, both in phosphorylated and unphosphorylated forms. The challenge is to predict these two ΔΔGH20 values and the catalytic efficiency (kcat/km)mut/(kcat/km)wt, as determined by a fluorescence assay, of the phosphorylated fo...","","https://genomeinterpretation.org/cagi6-mapk3.html","completed","intermediate","1","","2021-08-04","2021-10-11","2023-06-23 00:00:00","2023-09-27 18:56:19" +"274","cagi6-mthfr","CAGI6: MTHFR","Participants are asked to submit predictions of the fitness score for each m...","Methylenetetrahydrofolate reductase (MTHFR) catalyzes the production of 5-methyltetrahydrofolate, which is needed for conversion of homocysteine to methionine. Humans with variants affecting MTHFR function present with a wide range of phenotypes, including homocystinuria, homocysteinemia, developmental delay, severe mental retardation, psychiatric disturbances, and late-onset neurodegenerative disorders. A further complication to interpretation of variants in this gene is a common variant, Ala222Val, carried by a large fraction of the human population. A large library of MTHFR missense variants was assessed with respect to their effects on protein function using a high-throughput yeast complementation assay. The challenge is to predict the functional effects of these variants in two different settings: (1) for the wildtype protein, and (2) for the protein with the common Ala222Val variant.","","https://genomeinterpretation.org/cagi6-mthfr.html","completed","intermediate","1","","2021-05-03","2021-06-30","2023-06-23 00:00:00","2023-09-27 18:56:19" +"275","cagi6-polygenic-risk-scores","CAGI6: Polygenic Risk Scores","Participants will be expected to provide a fully trained prediction model th...","Polygenic risk scores (PRS) have potential clinical utility for risk surveillance, prevention and personalized medicine. Participants will be provided with datasets of four real phenotypes (Type 2 Diabetes, Breast Cancer, Inflammatory Bowel Disease and Coronary Artery Disease) and of thirty simulated phenotypes representing a range of genetic architectures of common polygenic diseases. The challenge is to predict the disease outcomes of individuals in held-out validation cohorts.","","https://genomeinterpretation.org/cagi6-prs.html","completed","intermediate","1","","2021-06-08","2021-10-11","2023-06-23 00:00:00","2023-09-27 18:57:59" +"276","cagi6-rare-genomes-project","CAGI6: Rare Genomes Project","The prediction challenge involves approximately 30 families.The prediction s...","The Rare Genomes Project (RGP) is a direct-to-participant research study on the utility of genome sequencing for rare disease diagnosis and gene discovery. The study is led by genomics experts and clinicians at the Broad Institute of MIT and Harvard. Research subjects are consented for genomic sequencing and the sharing of their sequence and phenotype information with researchers working to understand the molecular causes of rare disease. When a candidate disease variant believed to be related to the phenotype is identified, the variant is confirmed with Sanger sequencing in a clinical setting and returned to the participant via his or her local physician. In this challenge, whole genome sequence data and phenotype data from a subset of the solved and unsolved RGP families will be provided. Participants in the challenge will try to identify the causative variant(s) in each case. For the unsolved cases, prioritized variants from the participating teams will be examined to see if ad...","","https://genomeinterpretation.org/cagi6-rgp.html","completed","intermediate","1","","2021-06-08","2021-10-11","2023-06-23 00:00:00","2023-09-29 10:30:26" +"277","cagi6-sherloc-clinical-classification","CAGI6: Sherloc clinical classification","Over 122,000 coding (missense, silent, frameshift, stop gained, in-frame cod...","Invitae is a genetic testing company that publishes their variant interpretations to ClinVar. In this challenge, over 122,000 previously uncharacterized variants are provided, spanning the range of effects seen in the clinic. Following the close of this challenge, Invitae will submit their interpretations for these variants to ClinVar. Predictors are asked to interpret the pathogenicity of these variants, and the clinical utility of predictions will be assessed across multiple categories by Invitae.","","https://genomeinterpretation.org/cagi6-invitae.html","completed","intermediate","1","","2021-07-08","2021-12-01","2023-06-23 00:00:00","2023-09-27 18:56:22" +"278","cagi6-splicing-vus","CAGI6: Splicing VUS","Predict whether the experimentally validated variants of unknown significanc...","Variants causing aberrant splicing have been implicated in a range of common and rare disorders, including retinitis pigmentosa, autism spectrum disorder, amyotrophic lateral sclerosis, and a variety of cancers. However, such variants are frequently overlooked by diagnostic sequencing pipelines, leading to missed diagnoses for patients. Clinically ascertained variants of unknown significance underwent whole-blood based RT-PCR to test for impact on splicing. The challenge is to predict which of the tested variants disrupt splicing.","","https://genomeinterpretation.org/cagi6-splicing-vus.html","completed","intermediate","1","","2021-06-08","2021-10-11","2023-06-23 00:00:00","2023-09-27 18:58:18" +"279","cagi6-stk11","CAGI6: STK11","Participants are asked to submit predictions on the impact of the variants l...","Serine/Threonine Kinase 11 (STK11) is considered a master kinase that functions as a tumor suppressor and nutrient sensor within a heterotrimeric complex with pseudo-kinase STRAD-alpha and structural protein MO25. Germline variants resulting in loss of STK11 define Peutz-Jaghers Syndrome, an autosomal dominant cancer predisposition syndrome marked by gastrointestinal hamartomas and freckling of the oral mucosa. Somatic loss of function variants, both nonsense and missense, occur in 15-30% of non-small cell lung adenocarcinomas, where they correlate clinically with insensitivity to anti-PD1 monoclonal antibody therapy. The challenge is to predict the impact on STK11 function for each missense variant in relation to wildtype STK11.","","https://genomeinterpretation.org/cagi6-stk11.html","completed","intermediate","1","","2021-06-08","2021-09-01","2023-06-23 00:00:00","2023-09-29 10:14:41" diff --git a/apps/openchallenges/challenge-service/src/main/resources/db/contribution_roles.csv b/apps/openchallenges/challenge-service/src/main/resources/db/contribution_roles.csv new file mode 100644 index 0000000000..ae36f3d9b6 --- /dev/null +++ b/apps/openchallenges/challenge-service/src/main/resources/db/contribution_roles.csv @@ -0,0 +1,950 @@ +"id","challenge_id","organization_id","role" +"1","1","75","sponsor" +"2","2","28","data_contributor" +"3","2","45","data_contributor" +"4","2","151","data_contributor" +"5","2","52","sponsor" +"6","3","154","data_contributor" +"7","3","118","data_contributor" +"8","3","17","data_contributor" +"9","3","142","data_contributor" +"10","4","150","data_contributor" +"11","4","52","data_contributor" +"12","4","131","sponsor" +"13","5","134","challenge_organizer" +"14","5","132","challenge_organizer" +"15","5","211","challenge_organizer" +"16","5","101","data_contributor" +"17","6","54","challenge_organizer" +"18","6","146","challenge_organizer" +"19","6","171","challenge_organizer" +"20","6","227","challenge_organizer" +"21","6","27","challenge_organizer" +"22","6","128","challenge_organizer" +"23","6","93","challenge_organizer" +"24","6","179","challenge_organizer" +"25","6","89","challenge_organizer" +"26","6","73","challenge_organizer" +"27","6","170","challenge_organizer" +"28","6","119","challenge_organizer" +"29","6","171","sponsor" +"30","6","93","sponsor" +"31","6","57","sponsor" +"32","6","146","sponsor" +"33","6","120","sponsor" +"34","7","171","challenge_organizer" +"35","7","128","challenge_organizer" +"36","7","93","challenge_organizer" +"37","7","71","challenge_organizer" +"38","7","89","challenge_organizer" +"39","7","73","challenge_organizer" +"40","7","170","challenge_organizer" +"41","7","150","challenge_organizer" +"42","7","130","challenge_organizer" +"43","8","171","challenge_organizer" +"44","8","206","challenge_organizer" +"45","8","128","challenge_organizer" +"46","8","93","challenge_organizer" +"47","8","56","challenge_organizer" +"48","8","37","challenge_organizer" +"49","8","25","challenge_organizer" +"50","8","78","challenge_organizer" +"51","8","125","challenge_organizer" +"52","8","23","challenge_organizer" +"53","8","55","data_contributor" +"54","8","24","sponsor" +"55","8","125","sponsor" +"56","8","145","sponsor" +"57","8","181","sponsor" +"58","8","93","sponsor" +"59","9","171","challenge_organizer" +"60","9","150","challenge_organizer" +"61","9","128","challenge_organizer" +"62","9","93","challenge_organizer" +"63","9","197","challenge_organizer" +"64","9","149","challenge_organizer" +"65","9","23","challenge_organizer" +"66","9","99","data_contributor" +"67","10","165","challenge_organizer" +"68","10","171","challenge_organizer" +"69","10","128","challenge_organizer" +"70","10","93","challenge_organizer" +"71","10","23","challenge_organizer" +"72","10","122","challenge_organizer" +"73","10","122","data_contributor" +"74","10","122","sponsor" +"75","10","93","sponsor" +"76","10","171","sponsor" +"77","10","165","sponsor" +"78","11","171","challenge_organizer" +"79","11","150","challenge_organizer" +"80","11","128","challenge_organizer" +"81","11","41","challenge_organizer" +"82","11","58","challenge_organizer" +"83","11","205","challenge_organizer" +"84","11","93","challenge_organizer" +"85","11","23","challenge_organizer" +"86","11","41","data_contributor" +"87","11","58","data_contributor" +"88","11","46","sponsor" +"89","11","109","sponsor" +"90","12","107","challenge_organizer" +"91","12","171","challenge_organizer" +"92","12","204","challenge_organizer" +"93","12","128","challenge_organizer" +"94","12","93","challenge_organizer" +"95","12","38","challenge_organizer" +"96","12","223","challenge_organizer" +"97","12","119","challenge_organizer" +"98","12","23","challenge_organizer" +"99","12","82","challenge_organizer" +"100","12","169","data_contributor" +"101","12","18","data_contributor" +"102","12","94","data_contributor" +"103","12","19","sponsor" +"104","12","39","sponsor" +"105","12","74","sponsor" +"106","12","153","sponsor" +"107","12","164","sponsor" +"108","12","168","sponsor" +"109","12","172","sponsor" +"110","12","181","sponsor" +"111","13","206","challenge_organizer" +"112","13","167","challenge_organizer" +"113","13","171","challenge_organizer" +"114","13","93","challenge_organizer" +"115","13","128","challenge_organizer" +"116","13","23","challenge_organizer" +"117","13","167","data_contributor" +"118","13","100","sponsor" +"119","13","93","sponsor" +"120","13","171","sponsor" +"121","13","1","sponsor" +"122","14","58","challenge_organizer" +"123","14","93","challenge_organizer" +"124","14","124","challenge_organizer" +"125","14","155","challenge_organizer" +"126","14","157","challenge_organizer" +"127","14","171","challenge_organizer" +"128","14","188","challenge_organizer" +"129","14","196","challenge_organizer" +"130","14","199","challenge_organizer" +"131","14","219","challenge_organizer" +"132","14","26","data_contributor" +"133","14","47","data_contributor" +"134","14","172","data_contributor" +"135","14","124","data_contributor" +"136","14","157","sponsor" +"137","14","131","sponsor" +"138","14","21","sponsor" +"139","15","128","challenge_organizer" +"140","15","93","challenge_organizer" +"141","15","171","challenge_organizer" +"142","15","118","challenge_organizer" +"143","15","154","challenge_organizer" +"144","15","187","challenge_organizer" +"145","15","115","challenge_organizer" +"146","15","23","challenge_organizer" +"147","15","154","data_contributor" +"148","15","140","data_contributor" +"149","15","142","data_contributor" +"150","15","154","sponsor" +"151","15","93","sponsor" +"152","15","171","sponsor" +"153","15","1","sponsor" +"154","15","32","sponsor" +"155","15","67","sponsor" +"156","16","128","challenge_organizer" +"157","16","93","challenge_organizer" +"158","16","26","challenge_organizer" +"159","16","89","challenge_organizer" +"160","16","73","challenge_organizer" +"161","16","170","challenge_organizer" +"162","16","171","challenge_organizer" +"163","16","23","challenge_organizer" +"164","16","26","data_contributor" +"165","16","235","data_contributor" +"166","16","29","data_contributor" +"167","16","26","sponsor" +"168","17","128","challenge_organizer" +"169","17","93","challenge_organizer" +"170","17","197","challenge_organizer" +"171","17","149","challenge_organizer" +"172","17","171","challenge_organizer" +"173","17","23","challenge_organizer" +"174","17","99","data_contributor" +"175","17","149","sponsor" +"176","17","81","sponsor" +"177","17","138","sponsor" +"178","17","171","sponsor" +"179","17","197","sponsor" +"180","17","150","sponsor" +"181","18","235","challenge_organizer" +"182","18","128","challenge_organizer" +"183","18","93","challenge_organizer" +"184","18","197","challenge_organizer" +"185","18","150","challenge_organizer" +"186","18","149","challenge_organizer" +"187","18","79","challenge_organizer" +"188","18","220","challenge_organizer" +"189","18","171","challenge_organizer" +"190","18","23","challenge_organizer" +"191","18","149","data_contributor" +"192","18","99","data_contributor" +"193","18","149","data_contributor" +"194","18","156","sponsor" +"195","18","81","sponsor" +"196","18","138","sponsor" +"197","19","171","challenge_organizer" +"198","19","64","challenge_organizer" +"199","19","229","challenge_organizer" +"200","19","59","challenge_organizer" +"201","19","59","sponsor" +"202","20","171","challenge_organizer" +"203","20","205","challenge_organizer" +"204","20","128","challenge_organizer" +"205","20","93","challenge_organizer" +"206","20","89","challenge_organizer" +"207","20","73","challenge_organizer" +"208","20","170","challenge_organizer" +"209","20","118","challenge_organizer" +"210","20","23","challenge_organizer" +"211","20","111","challenge_organizer" +"212","20","205","data_contributor" +"213","20","180","sponsor" +"214","21","179","challenge_organizer" +"215","21","171","challenge_organizer" +"216","21","128","challenge_organizer" +"217","21","93","challenge_organizer" +"218","21","199","challenge_organizer" +"219","21","150","challenge_organizer" +"220","21","115","challenge_organizer" +"221","21","23","challenge_organizer" +"222","21","69","data_contributor" +"223","22","220","challenge_organizer" +"224","22","91","challenge_organizer" +"225","22","127","challenge_organizer" +"226","22","95","challenge_organizer" +"227","22","128","challenge_organizer" +"228","22","93","challenge_organizer" +"229","22","171","challenge_organizer" +"230","22","23","challenge_organizer" +"231","22","64","data_contributor" +"232","22","229","data_contributor" +"233","23","232","challenge_organizer" +"234","23","128","challenge_organizer" +"235","23","93","challenge_organizer" +"236","23","197","challenge_organizer" +"237","23","150","challenge_organizer" +"238","23","149","challenge_organizer" +"239","23","171","challenge_organizer" +"240","23","23","challenge_organizer" +"241","23","99","data_contributor" +"242","23","131","data_contributor" +"243","23","149","data_contributor" +"244","23","138","sponsor" +"245","23","81","sponsor" +"246","23","156","sponsor" +"247","23","131","sponsor" +"248","24","171","challenge_organizer" +"249","24","93","challenge_organizer" +"250","24","106","challenge_organizer" +"251","24","128","challenge_organizer" +"252","24","175","challenge_organizer" +"253","24","189","challenge_organizer" +"254","24","36","data_contributor" +"255","24","128","data_contributor" +"256","24","110","sponsor" +"257","24","80","sponsor" +"258","24","236","sponsor" +"259","24","93","sponsor" +"260","24","20","sponsor" +"261","25","47","challenge_organizer" +"262","25","129","challenge_organizer" +"263","25","171","challenge_organizer" +"264","25","193","data_contributor" +"265","25","58","data_contributor" +"266","25","86","data_contributor" +"267","25","89","data_contributor" +"268","25","129","data_contributor" +"269","25","47","sponsor" +"270","26","85","challenge_organizer" +"271","26","197","challenge_organizer" +"272","26","63","challenge_organizer" +"273","26","149","challenge_organizer" +"274","26","171","challenge_organizer" +"275","26","131","data_contributor" +"276","26","88","data_contributor" +"277","26","179","data_contributor" +"278","26","49","data_contributor" +"279","26","108","data_contributor" +"280","26","202","data_contributor" +"281","26","197","data_contributor" +"282","26","149","data_contributor" +"283","26","99","data_contributor" +"284","26","41","data_contributor" +"285","27","126","challenge_organizer" +"286","27","65","challenge_organizer" +"287","27","230","challenge_organizer" +"288","27","88","challenge_organizer" +"289","27","171","challenge_organizer" +"290","27","224","challenge_organizer" +"291","27","208","challenge_organizer" +"292","27","216","challenge_organizer" +"293","27","126","data_contributor" +"294","27","171","data_contributor" +"295","27","126","sponsor" +"296","27","166","sponsor" +"297","28","141","challenge_organizer" +"298","28","128","challenge_organizer" +"299","28","93","challenge_organizer" +"300","28","131","challenge_organizer" +"301","28","89","challenge_organizer" +"302","28","73","challenge_organizer" +"303","28","170","challenge_organizer" +"304","28","149","challenge_organizer" +"305","28","59","challenge_organizer" +"306","28","152","challenge_organizer" +"307","28","171","challenge_organizer" +"308","28","51","data_contributor" +"309","28","51","sponsor" +"310","28","59","sponsor" +"311","28","147","sponsor" +"312","29","211","challenge_organizer" +"313","29","128","challenge_organizer" +"314","29","210","challenge_organizer" +"315","29","171","challenge_organizer" +"316","29","195","challenge_organizer" +"317","29","128","data_contributor" +"318","29","128","sponsor" +"319","30","89","challenge_organizer" +"320","30","128","challenge_organizer" +"321","30","93","challenge_organizer" +"322","30","73","challenge_organizer" +"323","30","170","challenge_organizer" +"324","30","121","challenge_organizer" +"325","30","171","challenge_organizer" +"326","30","121","data_contributor" +"327","31","171","challenge_organizer" +"328","31","96","challenge_organizer" +"329","31","128","challenge_organizer" +"330","31","93","challenge_organizer" +"331","31","190","data_contributor" +"332","31","15","sponsor" +"333","32","87","challenge_organizer" +"334","32","48","challenge_organizer" +"335","32","66","challenge_organizer" +"336","32","128","challenge_organizer" +"337","32","93","challenge_organizer" +"338","32","171","challenge_organizer" +"339","32","182","data_contributor" +"340","32","116","data_contributor" +"341","32","15","data_contributor" +"342","32","31","sponsor" +"343","33","233","challenge_organizer" +"344","33","196","challenge_organizer" +"345","33","128","challenge_organizer" +"346","33","93","challenge_organizer" +"347","33","199","challenge_organizer" +"348","33","179","challenge_organizer" +"349","33","72","challenge_organizer" +"350","33","72","data_contributor" +"351","33","233","data_contributor" +"352","33","117","data_contributor" +"353","34","89","challenge_organizer" +"354","34","226","challenge_organizer" +"355","34","171","challenge_organizer" +"356","34","73","challenge_organizer" +"357","34","170","challenge_organizer" +"358","34","71","challenge_organizer" +"359","34","226","data_contributor" +"360","34","71","data_contributor" +"361","35","171","challenge_organizer" +"362","35","224","challenge_organizer" +"363","35","224","data_contributor" +"364","35","133","sponsor" +"365","35","97","sponsor" +"366","35","224","sponsor" +"367","36","43","challenge_organizer" +"368","36","171","challenge_organizer" +"369","36","234","challenge_organizer" +"370","36","114","challenge_organizer" +"371","36","224","challenge_organizer" +"372","36","16","challenge_organizer" +"373","36","93","challenge_organizer" +"374","36","43","data_contributor" +"375","36","114","data_contributor" +"376","36","234","data_contributor" +"377","37","95","challenge_organizer" +"378","37","113","challenge_organizer" +"379","37","150","challenge_organizer" +"380","37","171","challenge_organizer" +"381","37","179","challenge_organizer" +"382","37","16","data_contributor" +"383","37","234","data_contributor" +"384","37","114","data_contributor" +"385","37","43","data_contributor" +"386","37","171","data_contributor" +"387","37","131","sponsor" +"388","38","171","challenge_organizer" +"389","38","52","challenge_organizer" +"390","38","176","challenge_organizer" +"391","38","15","challenge_organizer" +"392","38","131","challenge_organizer" +"393","38","46","challenge_organizer" +"394","38","128","challenge_organizer" +"395","38","93","challenge_organizer" +"396","38","89","challenge_organizer" +"397","38","73","challenge_organizer" +"398","38","170","challenge_organizer" +"399","38","52","data_contributor" +"400","39","171","challenge_organizer" +"401","39","150","challenge_organizer" +"402","39","128","challenge_organizer" +"403","39","15","challenge_organizer" +"404","39","131","challenge_organizer" +"405","39","46","challenge_organizer" +"406","39","112","data_contributor" +"407","39","150","data_contributor" +"408","40","131","challenge_organizer" +"409","40","171","challenge_organizer" +"410","40","150","challenge_organizer" +"411","40","22","data_contributor" +"412","40","44","data_contributor" +"413","40","131","sponsor" +"414","41","192","challenge_organizer" +"415","41","128","challenge_organizer" +"416","41","93","challenge_organizer" +"417","41","199","challenge_organizer" +"418","41","171","challenge_organizer" +"419","41","192","data_contributor" +"420","41","133","sponsor" +"421","41","40","sponsor" +"422","42","171","challenge_organizer" +"423","42","144","challenge_organizer" +"424","42","126","challenge_organizer" +"425","42","76","challenge_organizer" +"426","42","126","data_contributor" +"427","42","144","data_contributor" +"428","42","216","data_contributor" +"429","42","191","data_contributor" +"430","42","198","data_contributor" +"431","42","161","data_contributor" +"432","43","171","challenge_organizer" +"433","43","52","challenge_organizer" +"434","43","176","challenge_organizer" +"435","43","15","challenge_organizer" +"436","43","46","challenge_organizer" +"437","43","128","challenge_organizer" +"438","43","89","challenge_organizer" +"439","43","52","data_contributor" +"440","43","46","sponsor" +"441","44","171","challenge_organizer" +"442","44","224","challenge_organizer" +"443","44","224","data_contributor" +"444","45","211","challenge_organizer" +"445","45","40","challenge_organizer" +"446","45","148","challenge_organizer" +"447","45","171","challenge_organizer" +"448","45","40","data_contributor" +"449","46","215","challenge_organizer" +"450","46","131","challenge_organizer" +"451","46","196","data_contributor" +"452","46","220","data_contributor" +"453","46","171","challenge_organizer" +"454","46","185","data_contributor" +"455","46","61","data_contributor" +"456","46","226","challenge_organizer" +"457","46","148","data_contributor" +"458","47","47","challenge_organizer" +"459","47","171","challenge_organizer" +"460","47","158","challenge_organizer" +"461","47","124","challenge_organizer" +"462","47","58","challenge_organizer" +"463","47","160","challenge_organizer" +"464","47","47","sponsor" +"465","59","30","data_contributor" +"466","59","224","data_contributor" +"467","59","196","data_contributor" +"468","61","64","data_contributor" +"469","62","173","data_contributor" +"470","63","224","data_contributor" +"471","64","184","data_contributor" +"472","65","33","data_contributor" +"473","66","196","data_contributor" +"474","67","159","data_contributor" +"475","67","70","data_contributor" +"476","68","42","data_contributor" +"477","69","200","data_contributor" +"478","70","91","data_contributor" +"479","71","214","data_contributor" +"480","72","179","data_contributor" +"481","276","41","data_contributor" +"482","271","213","data_contributor" +"483","73","91","data_contributor" +"484","275","88","data_contributor" +"485","270","220","data_contributor" +"486","74","222","data_contributor" +"487","269","217","data_contributor" +"488","279","221","data_contributor" +"489","272","173","data_contributor" +"490","273","173","data_contributor" +"491","274","220","data_contributor" +"492","278","218","data_contributor" +"493","277","41","data_contributor" +"494","79","104","challenge_organizer" +"495","79","3","challenge_organizer" +"496","79","102","challenge_organizer" +"497","79","215","challenge_organizer" +"498","79","143","challenge_organizer" +"499","79","224","challenge_organizer" +"500","79","203","challenge_organizer" +"501","79","219","challenge_organizer" +"502","79","137","sponsor" +"503","79","15","sponsor" +"504","79","60","sponsor" +"505","79","68","sponsor" +"506","80","209","challenge_organizer" +"507","80","183","challenge_organizer" +"508","80","194","challenge_organizer" +"509","80","207","challenge_organizer" +"510","80","135","sponsor" +"511","81","209","challenge_organizer" +"512","81","183","challenge_organizer" +"513","81","194","challenge_organizer" +"514","81","207","challenge_organizer" +"515","81","135","sponsor" +"516","82","189","sponsor" +"517","83","13","challenge_organizer" +"518","83","189","challenge_organizer" +"519","83","34","challenge_organizer" +"520","83","62","challenge_organizer" +"521","83","228","challenge_organizer" +"522","83","136","challenge_organizer" +"523","83","189","sponsor" +"524","84","13","challenge_organizer" +"525","84","189","challenge_organizer" +"526","84","152","challenge_organizer" +"527","84","201","challenge_organizer" +"528","84","128","challenge_organizer" +"529","84","93","challenge_organizer" +"530","84","62","challenge_organizer" +"531","84","34","challenge_organizer" +"532","84","189","sponsor" +"533","85","13","challenge_organizer" +"534","85","189","challenge_organizer" +"535","85","82","challenge_organizer" +"536","85","62","challenge_organizer" +"537","85","34","challenge_organizer" +"538","85","189","sponsor" +"539","86","13","challenge_organizer" +"540","86","189","challenge_organizer" +"541","86","83","challenge_organizer" +"542","86","34","challenge_organizer" +"543","86","189","sponsor" +"544","87","13","challenge_organizer" +"545","87","189","challenge_organizer" +"546","87","62","challenge_organizer" +"547","87","53","challenge_organizer" +"548","87","34","challenge_organizer" +"549","87","189","sponsor" +"550","88","136","challenge_organizer" +"551","88","13","challenge_organizer" +"552","88","189","challenge_organizer" +"553","88","62","challenge_organizer" +"554","88","34","challenge_organizer" +"555","88","189","sponsor" +"556","89","13","challenge_organizer" +"557","89","189","challenge_organizer" +"558","89","231","challenge_organizer" +"559","89","34","challenge_organizer" +"560","89","62","challenge_organizer" +"561","89","189","sponsor" +"562","90","13","challenge_organizer" +"563","90","189","challenge_organizer" +"564","90","34","challenge_organizer" +"565","90","62","challenge_organizer" +"566","90","189","sponsor" +"567","91","13","challenge_organizer" +"568","91","189","challenge_organizer" +"569","91","34","challenge_organizer" +"570","91","62","challenge_organizer" +"571","91","189","sponsor" +"572","92","13","challenge_organizer" +"573","92","189","challenge_organizer" +"574","92","34","challenge_organizer" +"575","92","62","challenge_organizer" +"576","92","131","challenge_organizer" +"577","92","177","challenge_organizer" +"578","92","189","sponsor" +"579","93","12","challenge_organizer" +"580","93","215","challenge_organizer" +"581","93","84","challenge_organizer" +"582","93","7","challenge_organizer" +"583","93","15","sponsor" +"584","93","90","sponsor" +"585","93","103","sponsor" +"586","93","50","sponsor" +"587","94","12","challenge_organizer" +"588","94","147","sponsor" +"589","94","35","sponsor" +"590","95","12","challenge_organizer" +"591","95","186","sponsor" +"592","95","178","sponsor" +"593","96","12","challenge_organizer" +"594","96","77","sponsor" +"595","113","12","sponsor" +"596","113","215","challenge_organizer" +"597","113","84","challenge_organizer" +"598","113","7","challenge_organizer" +"599","113","98","sponsor" +"600","113","139","sponsor" +"601","113","162","sponsor" +"602","150","13","challenge_organizer" +"603","150","237","challenge_organizer" +"604","151","13","challenge_organizer" +"605","151","238","challenge_organizer" +"606","152","13","challenge_organizer" +"607","152","238","challenge_organizer" +"608","153","13","challenge_organizer" +"609","153","231","challenge_organizer" +"610","154","13","challenge_organizer" +"611","55","1","sponsor" +"612","53","1","sponsor" +"613","52","1","sponsor" +"614","54","1","sponsor" +"615","155","1","sponsor" +"616","45","1","sponsor" +"617","44","1","sponsor" +"618","43","1","sponsor" +"619","40","1","sponsor" +"620","42","1","sponsor" +"621","39","1","sponsor" +"622","41","1","sponsor" +"623","35","1","sponsor" +"624","36","1","sponsor" +"625","34","1","sponsor" +"626","37","1","sponsor" +"627","33","1","sponsor" +"628","32","1","sponsor" +"629","31","1","sponsor" +"630","30","1","sponsor" +"631","29","1","sponsor" +"632","21","1","sponsor" +"633","27","1","sponsor" +"634","26","1","sponsor" +"635","28","1","sponsor" +"636","24","1","sponsor" +"637","25","1","sponsor" +"638","23","1","sponsor" +"639","20","1","sponsor" +"640","19","1","sponsor" +"641","18","1","sponsor" +"642","17","1","sponsor" +"643","16","1","sponsor" +"644","14","1","sponsor" +"645","8","1","sponsor" +"646","7","1","sponsor" +"647","11","1","sponsor" +"648","12","1","sponsor" +"649","10","1","sponsor" +"650","9","1","sponsor" +"651","6","1","sponsor" +"652","5","1","sponsor" +"653","4","1","sponsor" +"654","1","1","sponsor" +"655","3","1","sponsor" +"656","156","215","challenge_organizer" +"657","156","171","challenge_organizer" +"658","156","239","challenge_organizer" +"659","156","240","challenge_organizer" +"660","156","195","challenge_organizer" +"661","156","226","challenge_organizer" +"662","156","241","challenge_organizer" +"663","156","242","challenge_organizer" +"664","156","185","challenge_organizer" +"665","156","196","challenge_organizer" +"666","156","243","challenge_organizer" +"667","156","244","challenge_organizer" +"668","156","245","challenge_organizer" +"669","156","246","challenge_organizer" +"670","156","247","challenge_organizer" +"671","156","248","challenge_organizer" +"672","156","13","challenge_organizer" +"673","156","249","challenge_organizer" +"674","156","34","challenge_organizer" +"675","156","62","challenge_organizer" +"676","156","215","data_contributor" +"677","156","240","data_contributor" +"678","156","250","data_contributor" +"679","156","251","data_contributor" +"680","156","241","data_contributor" +"681","156","185","data_contributor" +"682","156","243","data_contributor" +"683","156","245","data_contributor" +"684","156","49","data_contributor" +"685","156","252","data_contributor" +"686","156","253","data_contributor" +"687","156","98","sponsor" +"688","156","139","sponsor" +"689","156","254","sponsor" +"690","156","255","sponsor" +"691","158","209","challenge_organizer" +"692","158","195","challenge_organizer" +"693","158","194","challenge_organizer" +"694","158","257","challenge_organizer" +"695","158","135","sponsor" +"696","159","258","challenge_organizer" +"697","159","258","data_contributor" +"698","159","161","challenge_organizer" +"699","159","161","data_contributor" +"700","159","259","challenge_organizer" +"701","159","260","challenge_organizer" +"702","159","261","challenge_organizer" +"703","159","261","data_contributor" +"704","159","262","challenge_organizer" +"705","159","263","challenge_organizer" +"706","159","264","challenge_organizer" +"707","159","265","sponsor" +"708","159","260","sponsor" +"709","159","266","sponsor" +"710","159","261","sponsor" +"711","160","267","challenge_organizer" +"712","160","267","sponsor" +"713","160","267","data_contributor" +"714","161","269","sponsor" +"715","161","268","challenge_organizer" +"716","162","272","challenge_organizer" +"717","162","271","challenge_organizer" +"718","162","270","challenge_organizer" +"719","163","273","sponsor" +"720","163","107","challenge_organizer" +"721","163","256","challenge_organizer" +"722","163","270","challenge_organizer" +"723","163","147","challenge_organizer" +"724","163","215","challenge_organizer" +"725","163","270","data_contributor" +"726","165","104","challenge_organizer" +"727","165","143","challenge_organizer" +"728","165","213","challenge_organizer" +"729","165","275","challenge_organizer" +"730","165","102","challenge_organizer" +"731","163","274","data_contributor" +"732","163","276","data_contributor" +"733","163","277","data_contributor" +"734","166","162","challenge_organizer" +"735","165","3","challenge_organizer" +"736","164","278","challenge_organizer" +"737","168","279","challenge_organizer" +"738","163","12","sponsor" +"739","161","12","sponsor" +"740","162","12","sponsor" +"741","160","12","sponsor" +"742","156","12","sponsor" +"743","170","12","sponsor" +"744","170","280","challenge_organizer" +"745","170","281","challenge_organizer" +"746","170","211","challenge_organizer" +"747","170","282","challenge_organizer" +"748","170","171","challenge_organizer" +"749","171","283","challenge_organizer" +"750","171","284","challenge_organizer" +"751","171","285","challenge_organizer" +"752","171","67","challenge_organizer" +"753","171","286","challenge_organizer" +"754","171","12","sponsor" +"755","171","15","sponsor" +"756","172","283","challenge_organizer" +"757","172","67","challenge_organizer" +"758","172","287","challenge_organizer" +"759","172","286","challenge_organizer" +"760","172","288","challenge_organizer" +"761","172","289","challenge_organizer" +"762","172","12","sponsor" +"763","172","15","sponsor" +"764","173","290","challenge_organizer" +"765","173","291","challenge_organizer" +"766","174","179","challenge_organizer" +"767","175","179","challenge_organizer" +"768","175","292","challenge_organizer" +"769","176","179","challenge_organizer" +"770","176","119","challenge_organizer" +"771","177","179","challenge_organizer" +"772","177","293","challenge_organizer" +"773","178","179","challenge_organizer" +"774","179","197","challenge_organizer" +"775","180","179","challenge_organizer" +"776","180","294","challenge_organizer" +"777","180","144","challenge_organizer" +"778","180","295","challenge_organizer" +"779","181","41","challenge_organizer" +"780","181","296","challenge_organizer" +"781","181","297","challenge_organizer" +"782","182","298","challenge_organizer" +"783","182","299","sponsor" +"784","182","300","sponsor" +"785","182","147","sponsor" +"786","182","301","sponsor" +"787","183","302","challenge_organizer" +"788","183","302","data_contributor" +"789","183","303","data_contributor" +"790","183","304","data_contributor" +"791","183","126","sponsor" +"792","184","75","sponsor" +"793","184","312","challenge_organizer" +"794","185","12","sponsor" +"795","185","226","challenge_organizer" +"796","185","306","challenge_organizer" +"797","185","307","challenge_organizer" +"798","185","308","challenge_organizer" +"799","185","248","challenge_organizer" +"800","185","305","challenge_organizer" +"801","185","309","challenge_organizer" +"802","185","310","challenge_organizer" +"803","185","220","challenge_organizer" +"804","185","261","data_contributor" +"805","185","311","data_contributor" +"806","186","261","challenge_organizer" +"807","186","261","data_contributor" +"808","186","12","sponsor" +"809","185","305","data_contributor" +"810","187","13","challenge_organizer" +"811","187","313","challenge_organizer" +"812","187","314","challenge_organizer" +"813","187","315","challenge_organizer" +"814","188","231","challenge_organizer" +"815","188","249","challenge_organizer" +"816","188","313","challenge_organizer" +"817","188","315","challenge_organizer" +"818","188","136","challenge_organizer" +"819","188","316","challenge_organizer" +"820","188","34","challenge_organizer" +"821","188","317","challenge_organizer" +"822","188","318","challenge_organizer" +"823","195","171","challenge_organizer" +"824","196","171","challenge_organizer" +"825","197","171","challenge_organizer" +"826","198","171","challenge_organizer" +"827","199","171","challenge_organizer" +"828","195","319","data_contributor" +"829","196","319","data_contributor" +"830","197","319","data_contributor" +"831","198","319","data_contributor" +"832","199","319","data_contributor" +"833","195","247","data_contributor" +"834","196","247","data_contributor" +"835","197","247","data_contributor" +"836","198","247","data_contributor" +"837","199","247","data_contributor" +"838","200","1","sponsor" +"839","201","1","sponsor" +"840","202","1","sponsor" +"841","203","1","sponsor" +"842","204","1","sponsor" +"843","205","1","sponsor" +"844","206","1","sponsor" +"845","207","1","sponsor" +"846","208","1","sponsor" +"847","209","1","sponsor" +"848","210","1","sponsor" +"849","211","1","sponsor" +"850","212","1","sponsor" +"851","213","1","sponsor" +"852","214","1","sponsor" +"853","215","1","sponsor" +"854","191","1","sponsor" +"855","192","1","sponsor" +"856","193","1","sponsor" +"857","194","1","sponsor" +"858","200","52","data_contributor" +"859","201","58","data_contributor" +"860","202","320","data_contributor" +"861","203","321","data_contributor" +"862","204","124","data_contributor" +"863","205","322","data_contributor" +"864","206","256","data_contributor" +"865","206","119","data_contributor" +"866","206","93","challenge_organizer" +"867","207","256","data_contributor" +"868","207","119","data_contributor" +"869","207","93","challenge_organizer" +"870","207","256","challenge_organizer" +"871","207","119","challenge_organizer" +"872","208","220","data_contributor" +"873","208","242","data_contributor" +"874","208","93","challenge_organizer" +"875","209","220","data_contributor" +"876","209","93","challenge_organizer" +"877","209","256","challenge_organizer" +"878","209","119","challenge_organizer" +"879","210","93","challenge_organizer" +"880","210","256","challenge_organizer" +"881","210","119","challenge_organizer" +"882","210","323","challenge_organizer" +"883","210","323","data_contributor" +"884","211","234","data_contributor" +"885","211","93","challenge_organizer" +"886","212","93","challenge_organizer" +"887","212","256","challenge_organizer" +"888","212","119","challenge_organizer" +"889","213","93","challenge_organizer" +"890","214","324","challenge_organizer" +"891","214","93","challenge_organizer" +"892","215","93","challenge_organizer" +"893","215","242","challenge_organizer" +"894","215","93","data_contributor" +"895","215","242","data_contributor" +"896","217","325","challenge_organizer" +"897","218","325","challenge_organizer" +"898","216","326","challenge_organizer" +"899","219","326","challenge_organizer" +"900","2","1","sponsor" +"901","38","1","sponsor" +"902","49","1","sponsor" +"903","58","1","sponsor" +"904","220","13","challenge_organizer" +"905","221","327","challenge_organizer" +"906","221","62","challenge_organizer" +"907","100","34","challenge_organizer" +"908","102","98","challenge_organizer" +"909","103","105","challenge_organizer" +"910","105","105","challenge_organizer" +"911","107","12","sponsor" +"912","107","328","sponsor" +"913","107","286","sponsor" +"914","107","161","challenge_organizer" +"915","107","329","challenge_organizer" +"916","112","225","challenge_organizer" +"917","113","162","challenge_organizer" +"918","118","92","challenge_organizer" +"919","120","174","challenge_organizer" +"920","145","162","challenge_organizer" +"921","167","15","sponsor" +"922","59","4","challenge_organizer" +"923","61","4","challenge_organizer" +"924","62","4","challenge_organizer" +"925","63","4","challenge_organizer" +"926","64","4","challenge_organizer" +"927","65","4","challenge_organizer" +"928","66","4","challenge_organizer" +"929","67","4","challenge_organizer" +"930","68","4","challenge_organizer" +"931","69","4","challenge_organizer" +"932","70","4","challenge_organizer" +"933","71","4","challenge_organizer" +"934","72","4","challenge_organizer" +"935","276","4","challenge_organizer" +"936","271","4","challenge_organizer" +"937","73","4","challenge_organizer" +"938","275","4","challenge_organizer" +"939","270","4","challenge_organizer" +"940","74","4","challenge_organizer" +"941","269","4","challenge_organizer" +"942","279","4","challenge_organizer" +"943","272","4","challenge_organizer" +"944","273","4","challenge_organizer" +"945","274","4","challenge_organizer" +"946","278","4","challenge_organizer" +"947","277","4","challenge_organizer" +"948","266","330","challenge_organizer" +"949","266","179","challenge_organizer" diff --git a/apps/openchallenges/challenge-service/src/main/resources/db/incentives.csv b/apps/openchallenges/challenge-service/src/main/resources/db/incentives.csv new file mode 100644 index 0000000000..3e85748de3 --- /dev/null +++ b/apps/openchallenges/challenge-service/src/main/resources/db/incentives.csv @@ -0,0 +1,274 @@ +"","incentives","challenge_id" +"1","publication","1" +"2","publication","2" +"3","speaking_engagement","2" +"4","monetary","3" +"5","publication","5" +"6","speaking_engagement","5" +"7","publication","6" +"8","speaking_engagement","6" +"9","monetary","7" +"10","publication","7" +"11","publication","8" +"12","speaking_engagement","8" +"13","publication","9" +"14","publication","10" +"15","speaking_engagement","10" +"16","publication","11" +"17","speaking_engagement","11" +"18","publication","12" +"19","speaking_engagement","12" +"20","monetary","14" +"21","publication","14" +"22","speaking_engagement","14" +"23","monetary","15" +"24","publication","15" +"25","speaking_engagement","15" +"26","publication","16" +"27","speaking_engagement","16" +"28","publication","17" +"29","speaking_engagement","17" +"30","monetary","24" +"31","publication","24" +"32","speaking_engagement","24" +"33","monetary","25" +"34","publication","25" +"35","speaking_engagement","25" +"36","publication","26" +"37","monetary","27" +"38","publication","27" +"39","publication","28" +"40","publication","29" +"41","publication","30" +"42","publication","31" +"43","speaking_engagement","31" +"44","publication","33" +"45","speaking_engagement","33" +"46","publication","34" +"47","speaking_engagement","34" +"48","publication","37" +"49","speaking_engagement","37" +"50","publication","38" +"51","speaking_engagement","38" +"52","monetary","46" +"53","publication","84" +"54","publication","88" +"55","other","88" +"56","publication","89" +"57","speaking_engagement","89" +"58","publication","90" +"59","speaking_engagement","90" +"60","other","91" +"61","monetary","100" +"62","monetary","102" +"63","monetary","103" +"64","monetary","107" +"65","monetary","112" +"66","monetary","113" +"67","monetary","118" +"68","monetary","120" +"69","monetary","134" +"70","monetary","135" +"71","monetary","136" +"72","monetary","137" +"73","monetary","138" +"74","monetary","145" +"75","publication","146" +"76","other","146" +"77","publication","147" +"78","speaking_engagement","147" +"79","publication","148" +"80","speaking_engagement","148" +"81","publication","149" +"82","speaking_engagement","149" +"83","publication","150" +"84","other","150" +"85","publication","151" +"86","speaking_engagement","151" +"87","publication","152" +"88","speaking_engagement","152" +"89","publication","154" +"90","speaking_engagement","155" +"91","other","155" +"92","publication","157" +"93","publication","158" +"94","speaking_engagement","158" +"95","monetary","160" +"96","speaking_engagement","160" +"97","publication","162" +"98","monetary","164" +"99","monetary","165" +"100","monetary","166" +"101","speaking_engagement","166" +"102","monetary","167" +"103","monetary","168" +"104","monetary","169" +"105","speaking_engagement","169" +"106","monetary","171" +"107","speaking_engagement","171" +"108","monetary","172" +"109","monetary","173" +"110","monetary","174" +"111","publication","175" +"112","publication","176" +"113","publication","177" +"114","publication","178" +"115","publication","179" +"116","publication","180" +"117","monetary","181" +"118","monetary","182" +"119","speaking_engagement","182" +"120","other","182" +"121","monetary","183" +"122","speaking_engagement","183" +"123","monetary","184" +"124","publication","184" +"125","publication","185" +"126","speaking_engagement","185" +"127","other","185" +"128","publication","186" +"129","speaking_engagement","186" +"130","other","187" +"131","publication","188" +"132","speaking_engagement","188" +"133","monetary","189" +"134","publication","189" +"135","speaking_engagement","189" +"136","monetary","190" +"137","publication","190" +"138","speaking_engagement","190" +"139","publication","191" +"140","speaking_engagement","191" +"141","publication","192" +"142","speaking_engagement","192" +"143","publication","193" +"144","speaking_engagement","193" +"145","publication","194" +"146","speaking_engagement","194" +"147","publication","195" +"148","publication","196" +"149","publication","197" +"150","publication","198" +"151","publication","199" +"152","monetary","216" +"153","publication","216" +"154","monetary","217" +"155","publication","217" +"156","monetary","218" +"157","publication","218" +"158","monetary","219" +"159","publication","219" +"160","other","220" +"161","publication","221" +"162","publication","222" +"163","speaking_engagement","222" +"164","publication","223" +"165","speaking_engagement","223" +"166","publication","224" +"167","speaking_engagement","224" +"168","publication","225" +"169","speaking_engagement","225" +"170","publication","226" +"171","speaking_engagement","226" +"172","publication","227" +"173","speaking_engagement","227" +"174","publication","228" +"175","speaking_engagement","228" +"176","publication","229" +"177","speaking_engagement","229" +"178","publication","230" +"179","speaking_engagement","230" +"180","publication","231" +"181","speaking_engagement","231" +"182","publication","232" +"183","speaking_engagement","232" +"184","publication","233" +"185","speaking_engagement","233" +"186","publication","234" +"187","speaking_engagement","234" +"188","publication","235" +"189","speaking_engagement","235" +"190","publication","236" +"191","speaking_engagement","236" +"192","publication","237" +"193","speaking_engagement","237" +"194","publication","238" +"195","speaking_engagement","238" +"196","publication","239" +"197","speaking_engagement","239" +"198","publication","240" +"199","speaking_engagement","240" +"200","publication","241" +"201","speaking_engagement","241" +"202","publication","242" +"203","speaking_engagement","242" +"204","publication","243" +"205","speaking_engagement","243" +"206","publication","244" +"207","speaking_engagement","244" +"208","publication","245" +"209","speaking_engagement","245" +"210","publication","246" +"211","speaking_engagement","246" +"212","publication","247" +"213","speaking_engagement","247" +"214","publication","248" +"215","speaking_engagement","248" +"216","publication","249" +"217","speaking_engagement","249" +"218","publication","250" +"219","speaking_engagement","250" +"220","publication","251" +"221","speaking_engagement","251" +"222","publication","252" +"223","speaking_engagement","252" +"224","publication","253" +"225","speaking_engagement","253" +"226","publication","254" +"227","speaking_engagement","254" +"228","publication","255" +"229","speaking_engagement","255" +"230","publication","256" +"231","speaking_engagement","256" +"232","publication","257" +"233","speaking_engagement","257" +"234","publication","258" +"235","speaking_engagement","258" +"236","publication","259" +"237","speaking_engagement","259" +"238","publication","260" +"239","speaking_engagement","260" +"240","publication","261" +"241","speaking_engagement","261" +"242","publication","262" +"243","speaking_engagement","262" +"244","publication","263" +"245","speaking_engagement","263" +"246","publication","264" +"247","speaking_engagement","264" +"248","publication","265" +"249","speaking_engagement","265" +"250","publication","266" +"251","speaking_engagement","266" +"252","publication","269" +"253","speaking_engagement","269" +"254","publication","270" +"255","speaking_engagement","270" +"256","publication","271" +"257","speaking_engagement","271" +"258","publication","272" +"259","speaking_engagement","272" +"260","publication","273" +"261","speaking_engagement","273" +"262","publication","274" +"263","speaking_engagement","274" +"264","publication","275" +"265","speaking_engagement","275" +"266","publication","276" +"267","speaking_engagement","276" +"268","publication","277" +"269","speaking_engagement","277" +"270","publication","278" +"271","speaking_engagement","278" +"272","publication","279" +"273","speaking_engagement","279" diff --git a/apps/openchallenges/challenge-service/src/main/resources/db/migration/V1.0.1__insert_temp_data.sql b/apps/openchallenges/challenge-service/src/main/resources/db/migration/V1.0.1__insert_temp_data.sql index e43eda3a8f..527cc4d0c7 100644 --- a/apps/openchallenges/challenge-service/src/main/resources/db/migration/V1.0.1__insert_temp_data.sql +++ b/apps/openchallenges/challenge-service/src/main/resources/db/migration/V1.0.1__insert_temp_data.sql @@ -1,5212 +1,61 @@ -- challenge_platform data - -INSERT INTO challenge_platform (id, slug, name, avatar_key, website_url) -VALUES ( - 1, - 'synapse', - 'Synapse', - 'logo/synapse.png', - 'https://synapse.org/' - ), - ( - 2, - 'cagi', - 'CAGI', - 'logo/cagi.png', - 'https://genomeinterpretation.org/challenges.html' - ), - ( - 3, - 'cami', - 'CAMI', - 'logo/cami.png', - 'https://data.cami-challenge.org/' - ), - ( - 4, - 'casp', - 'CASP', - 'logo/casp.png', - 'https://predictioncenter.org/' - ), - ( - 5, - 'grand-challenge', - 'Grand Challenge', - 'logo/grand-challenge.png', - 'https://grand-challenge.org/' - ), - ( - 6, - 'precision-fda', - 'precisionFDA', - 'logo/precisionfda.png', - 'https://precision.fda.gov/challenges' - ), - ( - 7, - 'easychair', - 'EasyChair', - 'logo/easy-chair.jpg', - 'https://easychair.org/' - ), - ( - 8, - 'kaggle', - 'Kaggle', - 'logo/kaggle.png', - 'https://www.kaggle.com/' - ), - ( - 9, - 'codalab', - 'CodaLab', - 'logo/codalab.jpg', - 'https://codalab.lisn.upsaclay.fr/' - ), - ( - 10, - 'codabench', - 'CodaBench', - 'logo/codalab.jpg', - 'https://www.codabench.org/' - ), - ( - 11, - 'openml', - 'OpenML', - 'logo/openml.jpg', - 'https://www.openml.org/' - ), - ( - 12, - 'papers-with-code', - 'PapersWithCode', - 'logo/papers-with-code.jpg', - 'https://paperswithcode.com/' - ), - ( - 13, - 'eterna', - 'Eterna', - 'logo/eterna.svg', - 'https://eternagame.org/' - ), - ( - 14, - 'other', - 'Other', - '', - '' - ), - ( - 15, - 'nightingale-os', - 'Nightingale OS', - 'logo/nightingale-os.png', - 'https://app.nightingalescience.org/' - ), - ( - 16, - 'evalai', - 'EvalAI', - 'logo/evalai.png', - 'https://eval.ai/' - ); - --- challenge_input_data_type - -INSERT INTO challenge_input_data_type (id, slug, name) -VALUES (1, 'genomic', 'genomic'), - (2, 'proteomic', 'proteomic'), - (3, 'gene-expression', 'gene expression'), - (4, 'metabolomic', 'metabolomic'); +LOAD DATA LOCAL INFILE '/workspace/BOOT-INF/classes/db/platforms.csv' INTO TABLE challenge_platform + FIELDS TERMINATED BY ',' OPTIONALLY ENCLOSED BY '"' + LINES TERMINATED BY '\n' + IGNORE 1 LINES; -- challenge data +LOAD DATA LOCAL INFILE '/workspace/BOOT-INF/classes/db/challenges.csv' INTO TABLE challenge + FIELDS TERMINATED BY ',' OPTIONALLY ENCLOSED BY '"' + LINES TERMINATED BY '\n' + IGNORE 1 LINES; -INSERT INTO challenge ( - id, - slug, - name, - headline, - description, - website_url, - status, - difficulty, - platform_id, - doi, - start_date, - end_date, - created_at, - updated_at - ) -VALUES ( - 1, - 'network-topology-and-parameter-inference', - 'Network Topology and Parameter Inference', - '', - 'Participants are asked to develop and/or apply optimization methods, including the selection of the most informative experiments, to accurately estimate parameters and - predict outcomes of perturbations in Systems Biology models.', - 'https://www.synapse.org/#!Synapse:syn2821735', - 'completed', - 'intermediate', - '1', - '', - '2012-06-01', - '2012-10-01', - '2023-06-23 00:00:00', - '2023-08-09 08:42:17' - ), - ( - 2, - 'breast-cancer-prognosis', - 'Breast Cancer Prognosis', - '', - 'The goal of the breast cancer prognosis Challenge is to assess the accuracy of computational models designed to predict breast cancer survival, based on clinical information about the patient''s tumor as well as genome-wide molecular profiling data including gene expression and copy number profiles.', - 'https://www.synapse.org/#!Synapse:syn2813426', - 'completed', - 'intermediate', - '1', - '', - '2012-07-12', - '2012-10-15', - '2023-06-23 00:00:00', - '2023-07-26 19:47:13' - ), - ( - 3, - 'phil-bowen-als-prediction-prize4life', - 'Phil Bowen ALS Prediction Prize4Life', - '', - 'Amyotrophic Lateral Sclerosis (ALS)–also known as Lou Gehrig''s disease (in the US) or Motor Neurone disease (outside the US)–is a fatal neurological disease causing death of the nerve cells in the brain and spinal cord which control voluntary muscle movements. This leaves patients struggling with a progressive loss of motor function while leaving cognitive functions intact. Symptoms usually do not manifest until the age of 50 but can start earlier. At any given time, approximately five out of every 100,000 people worldwide suffer from ALS, though there would be a higher prevalence if the disease did not progress so rapidly, leading to the death of the patient. There are no known risk factors for developing ALS other than having a family member who has a hereditary form of the disease, which accounts for about 5-10% of ALS patients. There is also no known cure for ALS. The only FDA-approved drug for the disease is Riluzole, which has been shown to prolong the life span of someone...', - 'https://www.synapse.org/#!Synapse:syn2826267', - 'completed', - 'intermediate', - '1', - '', - '2012-06-01', - '2012-10-01', - '2023-06-23 00:00:00', - '2023-07-26 19:47:15' - ), - ( - 4, - 'drug-sensitivity-and-drug-synergy-prediction', - 'Drug Sensitivity and Drug Synergy Prediction', - '', - 'Development of new cancer therapeutics currently requires a long and protracted process of experimentation and testing. Human cancer cell lines represent a good model to help identify associations between molecular subtypes, pathways, and drug response. In recent years there have been several efforts to generate genomic profiles of collections of cell lines and to determine their response to panels of candidate therapeutic compounds. These data provide the basis for the development of in silico models of sensitivity based either on the unperturbed genetic potential of a cancer cell, or by using perturbation data to incorporate knowledge of actual cell response. Making predictions from either of these data profiles will be beneficial in identifying single and combinatorial chemotherapeutic response in patients. To that end, the present challenge seeks computational methods, derived from the molecular profiling of cell lines both in a static state and in response to perturbation of ...', - 'https://www.synapse.org/#!Synapse:syn2785778', - 'completed', - 'intermediate', - '1', - '', - '2012-06-01', - '2012-10-01', - '2023-06-23 00:00:00', - '2023-08-09 08:42:24' - ), - ( - 5, - 'niehs-ncats-unc-toxicogenetics', - 'NIEHS-NCATS-UNC Toxicogenetics', - '', - 'This challenge is designed to build predictive models of cytotoxicity as mediated by exposure to environmental toxicants and drugs. To approach this question, we will provide a dataset containing cytotoxicity estimates as measured in lymphoblastoid cell lines derived from 884 individuals following in vitro exposure to 156 chemical compounds. In subchallenge 1, participants will be asked to model interindividual variability in cytotoxicity based on genomic profiles in order to predict cytotoxicity in unknown individuals. In subchallenge 2, participants will be asked to predict population-level parameters of cytotoxicity across chemicals based on structural attributes of compounds in order to predict median cytotoxicity and mean variance in toxicity for unknown compounds.', - 'https://www.synapse.org/#!Synapse:syn1761567', - 'completed', - 'intermediate', - '1', - '', - '2013-06-10', - '2013-09-15', - '2023-06-23 00:00:00', - '2023-08-09 08:42:24' - ), - ( - 6, - 'whole-cell-parameter-estimation', - 'Whole-Cell Parameter Estimation', - '', - 'The goal of this challenge is to explore and compare innovative approaches to parameter estimation of large, heterogeneous computational models. Participants are encouraged to develop and/or apply optimization methods, including the selection of the most informative experiments. The organizers encourage participants to form teams to collaboratively solve the challenge.', - 'https://www.synapse.org/#!Synapse:syn1876068', - 'completed', - 'intermediate', - '1', - '', - '2013-06-10', - '2013-09-23', - '2023-06-23 00:00:00', - '2023-07-26 19:47:21' - ), - ( - 7, - 'hpn-dream-breast-cancer-network-inference', - 'HPN-DREAM Breast Cancer Network Inference', - '', - 'The overall goal of the Heritage-DREAM breast cancer network inference challenge is to quickly and effectively advance our ability to infer causal signaling networks and predict protein phosphorylation dynamics in cancer. We provide extensive training data from experiments on four breast cancer cell lines stimulated with various ligands. The data comprise protein abundance time-courses under inhibitor perturbations.', - 'https://www.synapse.org/#!Synapse:syn1720047', - 'completed', - 'intermediate', - '1', - '', - '2013-06-10', - '2013-09-16', - '2023-06-23 00:00:00', - '2023-07-26 19:47:22' - ), - ( - 8, - 'rheumatoid-arthritis-responder', - 'Rheumatoid Arthritis Responder', - '', - 'The goal of this project is to use a crowd-based competition framework to develop a validated molecular predictor of anti-TNF response in RA. There is an increasing need for predictors of response to therapy in inflammatory disease driven by the observation that most clinically defined diseases show variable response and the growing availability of alternative therapies. Anti-TNF drugs in Rheumatoid Arthritis represent a prototypical example of this opportunity. A number of studies have tried, over the past decade, to develop a robust predictor of response. We believe the time is right to try a different approach to developing such a biomarker with a crowd-sourced collaborative competition. This is based on DREAM and Sage Bionetworks'' experience with running competitions and the availability of new unpublished large-scale data relating to RA treatment response.THIS CHALLENGE RAN FROM FEBRUARY TO OCTOBER 2014 AND IS NOW CLOSED.', - 'https://www.synapse.org/#!Synapse:syn1734172', - 'completed', - 'intermediate', - '1', - '', - '2014-02-10', - '2014-06-04', - '2023-06-23 00:00:00', - '2023-07-26 19:47:24' - ), - ( - 9, - 'icgc-tcga-dream-mutation-calling', - 'ICGC-TCGA DREAM Mutation Calling', - '', - 'The ICGC-TCGA DREAM Genomic Mutation Calling Challenge (herein, The Challenge) is an international effort to improve standard methods for identifying cancer-associated mutations and rearrangements in whole-genome sequencing (WGS) data. Leaders of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) cancer genomics projects are joining with Sage Bionetworks and IBM-DREAM to initiate this innovative open crowd-sourced Challenge [1-3].', - 'https://www.synapse.org/#!Synapse:syn312572', - 'completed', - 'intermediate', - '1', - '', - '2013-12-14', - '2016-04-22', - '2023-06-23 00:00:00', - '2023-09-13 21:11:42' - ), - ( - 10, - 'acute-myeloid-leukemia-outcome-prediction', - 'Acute Myeloid Leukemia Outcome Prediction', - '', - 'The AML Outcome Prediction Challenge provides a unique opportunity to access and interpret a rich dataset for AML patients that includes clinical covariates, select gene mutation status and proteomic data. Capitalizing on a unique AML reverse phase protein array (RPPA) dataset obtained at M.D. Anderson Cancer Center that captures 271 measurements for each patient, participants of the DREAM 9 Challenge will help uncover what drives AML. Outcomes of this Challenge have the potential to be used immediately to tailor therapies for newly diagnosed leukemia patients and to accelerate the development of new drugs for leukemia.', - 'https://www.synapse.org/#!Synapse:syn2455683', - 'completed', - 'intermediate', - '1', - '', - '2014-06-02', - '2014-09-15', - '2023-06-23 00:00:00', - '2023-07-26 19:47:28' - ), - ( - 11, - 'broad-dream-gene-essentiality-prediction', - 'Broad-DREAM Gene Essentiality Prediction', - '', - 'The goal of this project is to use a crowd-based competition to develop predictive models that can infer gene dependency scores in cancer cells (genes that are essential to cancer cell viability when suppressed) using features of those cell lines. An additional goal is to find a small set of biomarkers (gene expression, copy number, and mutation features) that can best predict a single gene or set of genes.', - 'https://www.synapse.org/#!Synapse:syn2384331', - 'completed', - 'intermediate', - '1', - '', - '2014-06-02', - '2014-09-29', - '2023-06-23 00:00:00', - '2023-07-26 19:47:33' - ), - ( - 12, - 'alzheimers-disease-big-data', - 'Alzheimer''s Disease Big Data', - '', - 'The goal of the Alzheimer''s Disease Big Data DREAM Challenge #1 (AD#1) was to apply an open science approach to rapidly identify accurate predictive AD biomarkers that can be used by the scientific, industrial and regulatory communities to improve AD diagnosis and treatment. AD#1 will be the first in a series of AD Data Challenges to leverage genetics and brain imaging in combination with cognitive assessments, biomarkers and demographic information from cohorts ranging from cognitively normal to mild cognitively impaired to individuals with AD.', - 'https://www.synapse.org/#!Synapse:syn2290704', - 'completed', - 'intermediate', - '1', - '', - '2014-06-02', - '2014-10-17', - '2023-06-23 00:00:00', - '2023-07-26 19:47:34' - ), - ( - 13, - 'olfaction-prediction', - 'Olfaction Prediction', - '', - 'The goal of the DREAM Olfaction Prediction Challenge is to find models that can predict how a molecule smells from its physical and chemical features. A model that allows us to predict a smell from a molecule will provide fundamental insights into how odor chemicals are transformed into a smell percept in the brain. Further, being able to predict how a chemical smells will greatly accelerate the design of new molecules to be used as fragrances. Currently, fragrance chemists synthesize many molecules to obtain a new ingredient, but most of these will not have the desired qualities.', - 'https://www.synapse.org/#!Synapse:syn2811262', - 'completed', - 'intermediate', - '1', - '', - '2015-01-15', - '2015-05-01', - '2023-06-23 00:00:00', - '2023-07-26 19:47:36' - ), - ( - 14, - 'prostate-cancer', - 'Prostate Cancer', - '', - 'This challenge will attempt to improve the prediction of survival and toxicity of docetaxel treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary benefit of this Challenge will be to establish new quantitative benchmarks for prognostic modeling in mCRPC, with a potential impact for clinical decision making and ultimately understanding the mechanism of disease progression. Participating teams will be asked to submit predictive models based on clinical variables from the comparator arms of four phase III clinical trials with over 2,000 mCRPC patients treated with first-line docetaxel. The comparator arm of a clinical trial represents the patients that receive a treatment that is considered to be effective. This arm of the clinical trial is used to evaluate the effectiveness of the new therapy being tested.', - 'https://www.synapse.org/#!Synapse:syn2813558', - 'completed', - 'intermediate', - '1', - '', - '2015-03-16', - '2015-07-27', - '2023-06-23 00:00:00', - '2023-07-26 19:47:38' - ), - ( - 15, - 'als-stratification-prize4life', - 'ALS Stratification Prize4Life', - '', - 'As illustrated by the overview figure below, (a) Challenge Data includes data from ALS clinical trials and ALS registries. ALS clinical trials consist of patients from clinical trials available open access on the PRO-ACT database and patients from 6 clinical trials not yet added into the database. Data from ALS registries was collected from patients in national ALS registries. (b) Data is divided into three subsets: training data provided to solvers in full, leaderboard, and validation data that is available only to the organizers and is reserved for the scoring of the challenge. (c) The goal of this challenge is then to predict the Clinical Targets, i.e. the disease progression as ALSFRS slope as well as survival. (d) For Building the Models, participants create two algorithms - one that selects features and one that predicts outcomes. To perform predictions, data from a given patient (1) is fed into the selector (2). The selector selects 6 features and a cluster/model ID (3), e....', - 'https://www.synapse.org/#!Synapse:syn2873386', - 'completed', - 'intermediate', - '1', - '', - '2015-06-22', - '2015-10-04', - '2023-06-23 00:00:00', - '2023-07-26 19:47:40' - ), - ( - 16, - 'astrazeneca-sanger-drug-combination-prediction', - 'AstraZeneca-Sanger Drug Combination Prediction', - '', - 'To accelerate the understanding of drug synergy, AstraZeneca has partnered with the European Bioinformatic Institute, the Sanger Institute, Sage Bionetworks, and the distributed DREAM community to launch the AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge. This Challenge is designed to explore fundamental traits that underlie effective combination treatments and synergistic drug behavior using baseline genomic data, i.e. data collected pretreatment. As the basis of the Challenge, AstraZeneca is releasing ~11.5k experimentally tested drug combinations measuring cell viability over 118 drugs and 85 cancer cell lines (primarily colon, lung, and breast), and monotherapy drug response data for each drug and cell line. Moreover, in coordination with the Genomics of Drug Sensitivity in Cancer and COSMIC teams at the Sanger Institute, genomic data including gene expression, mutations (whole exome), copy-number alterations, and methylation data will be released into the publ...', - 'https://www.synapse.org/#!Synapse:syn4231880', - 'completed', - 'intermediate', - '1', - '', - '2015-09-03', - '2016-03-14', - '2023-06-23 00:00:00', - '2023-07-26 19:47:41' - ), - ( - 17, - 'smc-dna-meta', - 'SMC-DNA Meta', - '', - 'The goal of this Challenge is to identify the most accurate meta-pipeline for somatic mutation detection, and establish the state-of-the-art. The algorithms in this Challenge must use as input mutations predicted by one or more variant callers and output mutation calls associated with cancer. An additional goal is to highlight the complementarity of the calling algorithms and help understand their individual advantages/deficiencies.', - 'https://www.synapse.org/#!Synapse:syn4588939', - 'completed', - 'intermediate', - '1', - '', - '2015-08-17', - '2016-04-10', - '2023-06-23 00:00:00', - '2023-07-26 19:47:43' - ), - ( - 18, - 'smc-het', - 'SMC-Het', - '', - 'The ICGC-TCGA DREAM Somatic Mutation Calling - Tumour Heterogeneity Challenge (SMC-Het) is an international effort to improve standard methods for subclonal reconstruction: to quantify and genotype each individual cell population present within a tumor. Leaders of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) cancer genomics projects are joining with Sage Bionetworks and IBM-DREAM to initiate this innovative open crowd-sourced Challenge [1-3].', - 'https://www.synapse.org/#!Synapse:syn2813581', - 'completed', - 'intermediate', - '1', - '', - '2015-11-16', - '2016-06-30', - '2023-06-23 00:00:00', - '2023-07-26 20:40:13' - ), - ( - 19, - 'respiratory-viral', - 'Respiratory Viral', - '', - 'Respiratory viruses are highly infectious and cause acute illness in millions of people every year. However, there is wide variation in the physiologic response to exposure at the individual level. Some people that are exposed to virus are able to completely avoid infection. Others contract virus but are able to fight it off without exhibiting any symptoms of illness such as coughing, sneezing, sore throat or fever. It is not well understood what characteristics may protect individuals from respiratory viral infection. These individual responses are likely influenced by multiple processes including both the basal state of the human host upon exposure and the dynamics of host immune response in the early hours immediately following exposure. Many of these processes play out in the peripheral blood through activation and recruitment of circulating immune cells. Global gene expression patterns measured in peripheral blood at the time of symptom onset - several days after viral exposu...', - 'https://www.synapse.org/#!Synapse:syn5647810', - 'completed', - 'intermediate', - '1', - '', - '2016-05-16', - '2016-09-28', - '2023-06-23 00:00:00', - '2023-07-26 19:47:46' - ), - ( - 20, - 'disease-module-identification', - 'Disease Module Identification', - '', - 'The Disease Module Identification DREAM Challenge is an open community effort to systematically assess module identification methods on a panel of state-of-the-art genomic networks and leverage the “wisdom of crowds” to discover novel modules and pathways underlying complex diseases.', - 'https://www.synapse.org/#!Synapse:syn6156761', - 'completed', - 'intermediate', - '1', - '', - '2016-06-24', - '2016-10-01', - '2023-06-23 00:00:00', - '2023-07-26 19:48:43' - ), - ( - 21, - 'encode', - 'ENCODE', - '', - 'Transcription factors (TFs) are regulatory proteins that bind specific DNA sequence patterns (motifs) in the genome and affect transcription rates of target genes. Binding sites of TFs differ across cell types and experimental conditions. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is an experimental method that is commonly used to obtain the genome-wide binding profile of a TF of interest in a specific cell type/condition. However, profiling the binding landscape of every TF in every cell type/condition is infeasible due to constraints on cost, material and effort. Hence, accurate computational prediction of in vivo TF binding sites is critical to complement experimental results.', - 'https://www.synapse.org/#!Synapse:syn6131484', - 'completed', - 'intermediate', - '1', - '', - '2016-07-07', - '2017-01-11', - '2023-06-23 00:00:00', - '2023-07-26 19:48:44' - ), - ( - 22, - 'idea', - 'Idea', - '', - 'The DREAM Idea Challenge is designed to collaboratively shape and enable the solution of a question fundamental to improving human health. In the process, all proposals and their evaluation will be made publicly available for the explicit purpose of connecting modelers and experimentalists who want to address the same question. This Wall of Models will enable new collaborations, and help turn every good modeling idea into a success story. It will further serve as a basis for new DREAM challenges.', - 'https://www.synapse.org/#!Synapse:syn5659209', - 'completed', - 'advanced', - '1', - '', - '2016-06-15', - '2017-04-30', - '2023-06-23 00:00:00', - '2023-07-26 19:48:45' - ), - ( - 23, - 'smc-rna', - 'SMC-RNA', - '', - 'The ICGC-TCGA DREAM Somatic Mutation Calling - RNA Challenge (SMC-RNA) is an international effort to improve standard methods for identifying cancer-associated rearrangements in RNA sequencing (RNA-seq) data. Leaders of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) cancer genomics projects are joining with Sage Bionetworks and IBM-DREAM to initiate this innovative open crowd-sourced Challenge [1-3].', - 'https://www.synapse.org/#!Synapse:syn2813589', - 'completed', - 'intermediate', - '1', - '', - '2016-06-29', - '2017-05-02', - '2023-06-23 00:00:00', - '2023-07-26 19:48:46' - ), - ( - 24, - 'digital-mammography', - 'Digital Mammography', - '', - 'The Digital Mammography DREAM Challenge will attempt to improve the predictive accuracy of digital mammography for the early detection of breast cancer. The primary benefit of this Challenge will be to establish new quantitative tools - machine learning, deep learning or other - that can help decrease the recall rate of screening mammography, with a potential impact on shifting the balance of routine breast cancer screening towards more benefit and less harm. Participating teams will be asked to submit predictive models based on over 640,000 de-identified digital mammography images from over 86000 subjects, with corresponding clinical variables.', - 'https://www.synapse.org/#!Synapse:syn4224222', - 'completed', - 'advanced', - '1', - '10.1001/jamanetworkopen.2020.0265', - '2016-11-18', - '2017-05-16', - '2023-06-23 00:00:00', - '2023-07-26 19:48:48' - ), - ( - 25, - 'multiple-myeloma', - 'Multiple Myeloma', - '', - 'Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, with about 25,000 newly diagnosed patients per year in the United States alone. The disease''s clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells.1 Since risk-adapted therapy is becoming standard of care, there is an urgent need for a precise risk stratification model to assist in therapeutic decision-making and research. While progress has been made, there remains a significant opportunity to improve patient stratification to optimize treatment and to develop new therapies for high-risk patients. A DREAM Challenge represents a chance not only to integrate available data and analytical approaches to tackle this important problem, but also provides the ability to benchmark potential methods to identify those with the greatest potential to yield patient care benefits in the future.', - 'https://www.synapse.org/#!Synapse:syn6187098', - 'completed', - 'intermediate', - '1', - '', - '2017-06-30', - '2017-11-08', - '2023-06-23 00:00:00', - '2023-07-26 19:48:48' - ), - ( - 26, - 'ga4gh-dream-workflow-execution', - 'GA4GH-DREAM Workflow Execution', - '', - 'The highly distributed and disparate nature of genomic and clinical data generated around the world presents an enormous challenge for those scientists who wish to integrate and analyze these data. The sheer volume of data often exceeds the capacity for storage at any one site and prohibits the efficient transfer between sites. To address this challenge, researchers must bring their computation to the data. Numerous groups are now developing technologies and best practice methodologies for running portable and reproducible genomic analysis pipelines as well as tools and APIs for discovering genomic analysis resources. Software development, deployment, and sharing efforts in these groups commonly rely on the use of modular workflow pipelines and virtualization based on Docker containers and related tools.', - 'https://www.synapse.org/#!Synapse:syn8507133', - 'completed', - 'intermediate', - '1', - '', - '2017-07-21', - '2017-12-31', - '2023-06-23 00:00:00', - '2023-07-26 19:48:51' - ), - ( - 27, - 'parkinsons-disease-digital-biomarker', - 'Parkinson''s Disease Digital Biomarker', - '', - 'The Parkinson''s Disease Digital Biomarker DREAM Challenge is a first of it''s kind challenge, designed to benchmark methods for the processing of sensor data for development of digital signatures reflective of Parkinson''s Disease. Participants will be provided with raw sensor (accelerometer, gyroscope, and magnetometer) time series data recorded during the performance of pre-specified motor tasks, and will be asked to extract data features which are predictive of PD pathology. In contrast to traditional DREAM challenges, this one will focus on feature extraction rather than predictive modeling, and submissions will be evaluated based on their ability to predict disease phenotype using an array of standard machine learning algorithms.', - 'https://www.synapse.org/#!Synapse:syn8717496', - 'completed', - 'intermediate', - '1', - '', - '2017-07-06', - '2017-11-10', - '2023-06-23 00:00:00', - '2023-07-26 19:48:52' - ), - ( - 28, - 'nci-cptac-proteogenomics', - 'NCI-CPTAC Proteogenomics', - '', - 'Cancer is driven by aberrations in the genome [1,2], and these alterations manifest themselves largely in the changes in the structure and abundance of proteins, the main functional gene products. Hence, characterization and analyses of alterations in the proteome has the promise to shed light into cancer development and may improve development of both biomarkers and therapeutics. Measuring the proteome is very challenging, but recent rapid technology developments in mass spectrometry are enabling deep proteomics analysis [3]. Multiple initiatives have been launched to take advantage of this development to characterize the proteome of tumours, such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC). These efforts hold the promise to revolutionize cancer research, but this will only be possible if the community develops computational tools powerful enough to extract the most information from the proteome, and to understand the association between genome, transcriptome and ...', - 'https://www.synapse.org/#!Synapse:syn8228304', - 'completed', - 'intermediate', - '1', - '', - '2017-06-26', - '2017-11-20', - '2023-06-23 00:00:00', - '2023-07-26 19:48:52' - ), - ( - 29, - 'multi-targeting-drug', - 'Multi-Targeting Drug', - '', - 'The objective of this challenge is to incentivize development of methods for predicting compounds that bind to multiple targets. In particular, methods that are generalizable to multiple prediction problems are sought. To achieve this, participants will be asked to predict 2 separate compounds, each having specific targets to which they should bind, and a list of anti-targets to avoid. Participants should use the same methods to produce answers for questions 1 and 2.', - 'https://www.synapse.org/#!Synapse:syn8404040', - 'completed', - 'intermediate', - '1', - '', - '2017-10-05', - '2018-02-26', - '2023-06-23 00:00:00', - '2023-07-26 19:48:53' - ), - ( - 30, - 'single-cell-transcriptomics', - 'Single Cell Transcriptomics', - '', - 'In this Challenge on Single-Cell Transcriptomics, participants will reconstruct the location of single cells in the Drosophila embryo using single-cell transcriptomic data. Data will be made available in late August and participating challenge teams can work on the data and submit their results previous to the DREAM Conference. The best performers will be announced at the DREAM conference on Dec 8.', - 'https://www.synapse.org/#!Synapse:syn15665609', - 'completed', - 'intermediate', - '1', - '', - '2018-09-04', - '2018-11-21', - '2023-06-23 00:00:00', - '2023-07-26 19:48:54' - ), - ( - 31, - 'idg-drug-kinase-binding', - 'IDG Drug-Kinase Binding', - '', - 'This IDG-DREAM Drug-Kinase Binding Prediction Challenge seeks to evaluate the power of statistical and machine learning models as a systematic and cost-effective means for catalyzing compound-target interaction mapping efforts by prioritizing most potent interactions for further experimental evaluation. The Challenge will focus on kinase inhibitors, due to their clinical importance [2], and will be implemented in a screening-based, pre-competitive drug discovery project in collaboration with theIlluminating the Druggable Genome (IDG) Kinase-focused Data and Resource Generation Center, consortium, with the aim to establish kinome-wide target profiles of small-molecule agents, with the goal of extending the druggability of the human kinome space.', - 'https://www.synapse.org/#!Synapse:syn15667962', - 'completed', - 'intermediate', - '1', - '', - '2018-10-01', - '2019-04-18', - '2023-06-23 00:00:00', - '2023-07-26 19:48:57' - ), - ( - 32, - 'malaria', - 'Malaria', - '', - 'The Malaria DREAM Challenge is open to anyone interested in contributing to the development of computational models that address important problems in advancing the fight against malaria. The overall goal of the first Malaria DREAM Challenge is to predict Artemisinin (Art) drug resistance level of a test set of malaria parasites using their in vitro transcription data and a training set consisting of published in vivo and unpublished in vitrotranscriptomes. The in vivodataset consists of ~1000 transcription samples from various geographic locations covering a wide range of life cycles and resistance levels, with other accompanying data such as patient age, geographic location, Art combination therapy used, etc [Mok et al (2015) Science]. The in vitro transcription dataset consists of 55 isolates, with transcription collected at two timepoints (6 and 24 hours post-invasion), in the absence or presence of an Art perturbation, for two biological replicates using a custom microarray a...', - 'https://www.synapse.org/#!Synapse:syn16924919', - 'completed', - 'intermediate', - '1', - '', - '2019-04-30', - '2019-08-15', - '2023-06-23 00:00:00', - '2023-07-26 19:48:58' - ), - ( - 33, - 'preterm-birth-prediction-transcriptomics', - 'Preterm Birth Prediction - Transcriptomics', - '', - 'A basic need in pregnancy care is to establish gestational age, and inaccurate estimates may lead to unnecessary interventions and sub-optimal patient management. Current approaches to establish gestational age rely on patient''s recollection of her last menstrual period and/or ultrasound, with the latter being not only costly but also less accurate if not performed during the first trimester of pregnancy. Therefore development of an inexpensive and accurate molecular clock of pregnancy would be of benefit to patients and health care systems. Participants in sub-challenge 1 (Prediction of gestational age) will be given whole blood gene expression data collected from pregnant women to develop prediction models for the gestational age at blood draw. Another challenge in obstetrics, in both low and high-income countries, is identification and treatment of women at risk of developing the ‘great obstetrical syndromes‘. Of these, preterm birth (PTB), defined as giving birth prior to co...', - 'https://www.synapse.org/#!Synapse:syn18380862', - 'completed', - 'good_for_beginners', - '1', - '', - '2019-05-04', - '2019-12-05', - '2023-06-23 00:00:00', - '2023-07-26 19:48:58' - ), - ( - 34, - 'single-cell-signaling-in-breast-cancer', - 'Single-Cell Signaling in Breast Cancer', - '', - 'Signaling underlines nearly every cellular event. Individual cells, even if genetically identical, respond to perturbation in different ways. This underscores the relevance of cellular heterogeneity, in particular in how cells respond to drugs. This is of high relevance since the fact that a subset of cells do not respond (or only weakly) to drugs can render this drug an ineffective treatment. In spite of its relevance to many diseases, comprehensive studies on the heterogeneous signaling in single cells are still lacking. We have generated the, to our knowledge, currently largest single cell signaling dataset on a panel of 67 well-characterized breast cancer cell lines by mass cytometry (3''015 conditions, ~80 mio single cells, 38 markers; Bandura et al. 2009; Bendall et al., 2011; Bodenmiller et al., 2012; Lun et al., 2017; Lun et al., 2019). These cell lines are, among others, also characterized at the genomic, transcriptomic, and proteomic level (Marcotte et al., 2016). We a...', - 'https://www.synapse.org/#!Synapse:syn20366914', - 'completed', - 'intermediate', - '1', - '', - '2018-08-20', - '2019-11-15', - '2023-06-23 00:00:00', - '2023-07-26 19:48:59' - ), - ( - 35, - 'ehr-dream-challenge-patient-mortality-prediction', - 'EHR DREAM Challenge: Patient Mortality Prediction', - '', - 'The recent advent of new CRISPR-based molecular tools allows the reconstruction of cell lineages based on the phylogenetical analysis of DNA mutations induced by CRISPR during development and promises to solve the lineage of complex model organisms at single-cell resolution (see image from McKenna et al Science 2016). To date, however, no lineage reconstruction algorithms have been rigorously examined for their performance/robustness across diverse molecular tools, datasets, and number of cells/size of lineage trees. It also remains unclear whether new Machine-Learning algorithms that go beyond the classical ones developed for reconstructing phylogenetic trees, could consistently reconstruct cell lineages to a high degree of accuracy. The challenge - a partnership between The Allen Institute and DREAM - will comprise 3 subchallenges that consist of reconstructing cell lineage trees of different sizes and nature. In subchallenge 1, participants will be given experimental molecular ...', - 'https://www.synapse.org/#!Synapse:syn18405991', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1093/jamia/ocad159', - '2019-09-09', - '2020-01-23', - '2023-06-23 00:00:00', - '2023-07-26 19:49:00' - ), - ( - 36, - 'allen-institute-cell-lineage-reconstruction', - 'Allen Institute Cell Lineage Reconstruction', - '', - 'The recent advent of new CRISPR-based molecular tools allows the reconstruction of cell lineages based on the phylogenetical analysis of DNA mutations induced by CRISPR during development and promises to solve the lineage of complex model organisms at single-cell resolution. To date, however, no lineage reconstruction algorithms have been rigorously examined for their performance/robustness across diverse molecular tools, datasets, and number of cells/size of lineage trees. It also remains unclear whether new Machine-Learning algorithms that go beyond the classical ones developed for reconstructing phylogenetic trees, could consistently reconstruct cell lineages to a high degree of accuracy. The challenge - a partnership between The Allen Institute and DREAM - will comprise 3 subchallenges that consist of reconstructing cell lineage trees of different sizes and nature. In subchallenge 1, participants will be given experimental molecular data to reconstruct in vitro cell lineages ...', - 'https://www.synapse.org/#!Synapse:syn20692755', - 'completed', - 'intermediate', - '1', - '', - '2019-10-15', - '2020-02-06', - '2023-06-23 00:00:00', - '2023-08-09 08:39:22' - ), - ( - 37, - 'tumor-deconvolution', - 'Tumor Deconvolution', - '', - 'The extent of stromal and immune cell infiltration within solid tumors has prognostic and predictive significance. Unfortunately, expression profiling of tumors has, until very recently, largely been undertaken using bulk techniques (e.g., microarray and RNA-seq). Unlike single-cell methods (e.g., single-cell RNA-seq, FACS, mass cytometry, or immunohistochemistry), bulk approaches average expression across all cells (cancer, stromal, and immune) within the sample and, hence, do not directly quantitate tumor infiltration. This information can be recovered by computational tumor deconvolution methods, which would thus allow interrogation of immune subpopulations across the large collection of public bulk expression datasets. The goal of this Challenge is to evaluate the ability of computational methods to deconvolve bulk expression data, reflecting a mixture of cell types, into individual immune components. Methods will be assessed based on in vitro and in silico admixtures specifi...', - 'https://www.synapse.org/#!Synapse:syn15589870', - 'completed', - 'intermediate', - '1', - '', - '2019-06-26', - '2020-04-30', - '2023-06-23 00:00:00', - '2023-07-26 19:49:01' - ), - ( - 38, - 'ctd2-pancancer-drug-activity', - 'CTD2 Pancancer Drug Activity', - '', - 'NCI Genomic Data Commons,Harvard Chan School, Blue Collar Bioinformatics,ENCODE DCC, Stanford,CCHMC, Barski Lab,KnowEnG, UIUC,UCSC,OICR, ICGC,Broad Institute, GATK', - 'https://www.synapse.org/#!Synapse:syn20968331', - 'completed', - 'good_for_beginners', - '1', - '', - '2019-12-02', - '2020-02-13', - '2023-06-23 00:00:00', - '2023-07-26 19:49:04' - ), - ( - 39, - 'ctd2-beataml', - 'CTD2 BeatAML', - '', - 'In the era of precision medicine, AML patients have few therapeutic options, with “7 + 3” induction chemotherapy having been the standard for decades (Bertoli et al. 2017). While several agents targeting the myeloid marker CD33 or alterations in FLT3 or IDH2 have demonstrated efficacy in patients (Wei and Tiong 2017), responses are uncertain in some populations (Castaigne et al. 2012) and relapse remains prevalent (Stone et al. 2017). These drugs highlight both the promise of targeted therapies in AML and the urgent need for additional treatment options that are tailored to more refined patient subpopulations in order to achieve durable responses. The BeatAML initiative was launched as a comprehensive study of the relationship between molecular alterations and ex-vivo drug sensitivity in patients with AML. One of the primary goals of this multi-center study was to develop a discovery cohort that could yield new drug target hypotheses and predictive biomarkers of therapeutic respo...', - 'https://www.synapse.org/#!Synapse:syn20940518', - 'completed', - 'good_for_beginners', - '1', - '', - '2019-12-19', - '2020-04-28', - '2023-06-23 00:00:00', - '2023-07-26 19:49:04' - ), - ( - 40, - 'metadata-automation', - 'Metadata Automation', - '', - 'The Cancer Research Data Commons (CRDC) will collate data across diverse groups of cancer researchers, each collecting biomedical data in different formats. This means the data must be retrospectively harmonized and transformed to enable this data to be submitted. In addition, to be findable by the broader scientific community, coherent information (metadata) is necessary about the data fields and values. Coherent metadata annotation of the data fields and their values can enable computational data transformation, query, and analysis. Creation of this type of descriptive metadata can require biomedical expertise to determine the best annotations and thus is a time-consuming and manual task which is both an obstacle and a bottleneck in data sharing and submissions. Goal: Using structured biomedical data files, challenge participants will develop tools to semi-automate annotation of metadata fields and values, using available research data annotations (e.g. caDSR CDEs) as well as e...', - 'https://www.synapse.org/#!Synapse:syn18065891', - 'completed', - 'intermediate', - '1', - '', - '2020-01-14', - '2020-06-02', - '2023-06-23 00:00:00', - '2023-07-26 19:49:05' - ), - ( - 41, - 'automated-scoring-of-radiographic-joint-damage', - 'Automated Scoring of Radiographic Joint Damage', - '', - 'The purpose of the RA2-DREAM Challenge is to develop an automated method to quickly and accurately quantify the degree of joint damage associated with rheumatoid arthritis (RA). Based on radiographs of the hands and feet, a novel, automated scoring method could be applied broadly for patient care and research. We challenge participants to develop algorithms to automatically assess joint space narrowing and erosions using a large set of existing radiographs with damage scores generated by visual assessment of images by trained readers using standard protocols. The end result will be a generalizable, publicly available, automated method to generate accurate, reproducible and unbiased RA damage scores to replace the current tedious, expensive, and non-scalable method of scoring by human visual inspection.', - 'https://www.synapse.org/#!Synapse:syn20545111', - 'completed', - 'intermediate', - '1', - '', - '2019-11-04', - '2020-05-21', - '2023-06-23 00:00:00', - '2023-07-26 19:49:08' - ), - ( - 42, - 'beat-pd', - 'BEAT-PD', - '', - 'Recent advances in mobile health have demonstrated great potential to leverage sensor-based technologies for quantitative, remote monitoring of health and disease - particularly for diseases affecting motor function such as Parkinson''s disease. Such approaches have been rolled out using research-grade wearable sensors and, increasingly, through the use of smartphones and consumer wearables, such as smart watches and fitness trackers. These devices not only provide the ability to measure much more detailed disease phenotypes but also provide the ability to follow patients longitudinally with much higher frequency than is possible through clinical exams. However, the conversion of sensor-based data streams into digital biomarkers is complex and no methodological standards have yet evolved to guide this process. Parkinson''s disease (PD) is a neurodegenerative disease that primarily affects the motor system but also exhibits other symptoms. Typical motor symptoms of the disease inc...', - 'https://www.synapse.org/#!Synapse:syn20825169', - 'completed', - 'intermediate', - '1', - '', - '2020-01-13', - '2020-05-13', - '2023-06-23 00:00:00', - '2023-07-26 19:49:09' - ), - ( - 43, - 'ctd2-pancancer-chemosensitivity', - 'CTD2 Pancancer Chemosensitivity', - '', - 'Over the last two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and molecular profiles representative of cellular responses to drug perturbations. PANACEA covers a broad spectrum of cellular contexts representative of poor outcome malignancies, including rare ones such as GIST sarcoma and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). PANACEA is uniquely suited to support DREAM Challenges related to the elucidation of drug mechanism of action (MOA), drug sensitivity, and drug synergy. The goal of this Challenge is to foster development and benchmarking of algorithms to predict the sensitivity, as measured by the area under the dose-response curve, of a cell line to a compound based on the baseline transcriptional profiles of the cell line. The drug perturbational RNAseq profiles of 11 cell lines for 30 chosen compounds will be provided to challenge participants, wit...', - 'https://www.synapse.org/#!Synapse:syn21763589', - 'completed', - 'good_for_beginners', - '1', - '', - '2020-04-28', - '2020-07-27', - '2023-06-23 00:00:00', - '2023-07-26 19:49:10' - ), - ( - 44, - 'ehr-dream-challenge-covid-19', - 'EHR DREAM Challenge: COVID-19', - '', - 'The rapid rise of COVID-19 has challenged healthcare globally. The underlying risks and outcomes of infection are still incompletely characterized even as the world surpasses 4 million infections. Due to the importance and emergent need for better understanding of the condition and the development of patient specific clinical risk scores and early warning tools, we have developed a platform to support testing analytic and machine learning hypotheses on clinical data without data sharing as a platform to rapidly discover and implement approaches for care. We have previously applied this approach in the successful EHR DREAM Challenge focusing on Patient Mortality Prediction with UW Medicine. We have the goal of incorporating machine learning and predictive algorithms into clinical care and COVID-19 is an important and highly urgent challenge. In our first iteration, we will facilitate understanding risk factors that lead to a positive test utilizing electronic health recorded data ...', - 'https://www.synapse.org/#!Synapse:syn21849255', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1001/jamanetworkopen.2021.24946', - '2020-04-30', - '2021-07-01', - '2023-06-23 00:00:00', - '2023-07-27 19:18:50' - ), - ( - 45, - 'anti-pd1-response-prediction', - 'Anti-PD1 Response Prediction', - '', - 'While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1 therapy, there remains a need to improve the ability to predict which patients are more likely to receive benefit from treatment with I-O. The goal of this challenge is to leverage clinical and biomarker data to develop predictive models of response to I-O therapy in lung cancer and ultimately gain insights that may facilitate potential novel monotherapies or combinations with I-O.', - 'https://www.synapse.org/#!Synapse:syn18404605', - 'completed', - 'intermediate', - '1', - '', - '2020-11-17', - '2021-02-25', - '2023-06-23 00:00:00', - '2023-07-26 19:49:12' - ), - ( - 46, - 'brats-2021-challenge', - 'BraTS 2021 Challenge', - '', - 'Glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma (WHO Grade 4 astrocytoma), are the most common and aggressive malignant primary tumor of the central nervous system in adults, with extreme intrinsic heterogeneity in appearance, shape, and histology. Glioblastoma patients have very poor prognosis, and the current standard of care treatment comprises surgery, followed by radiotherapy and chemotherapy. The International Brain Tumor Segmentation (BraTS) Challenges —which have been running since 2012— assess state-of-the-art machine learning (ML) methods used for brain tumor image analysis in mpMRI scans.', - 'https://www.synapse.org/#!Synapse:syn25829067', - 'completed', - 'advanced', - '1', - '', - '2021-07-07', - '2021-10-15', - '2023-06-23 00:00:00', - '2023-07-26 19:49:17' - ), - ( - 47, - 'cancer-data-registry-nlp', - 'Cancer Data Registry NLP', - '', - 'A critical bottleneck in translational and clinical research is access to large volumes of high-quality clinical data. While structured data exist in medical EHR systems, a large portion of patient information including patient status, treatments, and outcomes is contained in unstructured text fields. Research in Natural Language Processing (NLP) aims to unlock this hidden and often inaccessible information. However, numerous challenges exist in developing and evaluating NLP methods, much of it centered on having “gold-standard” metrics for evaluation, and access to data that may contain personal health information (PHI). This DREAM Challenge will focus on the development and evaluation of of NLP algorithms that can improve clinical trial matching and recruitment.', - 'https://www.synapse.org/#!Synapse:syn18361217', - 'upcoming', - 'intermediate', - '1', - '', - NULL, - NULL, - '2023-06-23 00:00:00', - '2023-07-26 19:49:19' - ), - ( - 48, - 'barda-community-challenge-pediatric-covid-19-data-challenge', - 'BARDA Community Challenge - Pediatric COVID-19 Data Challenge', - '', - 'While most children with COVID-19 are asymptomatic or have mild symptoms, healthcare providers have difficulty determining which among their pediatric patients will progress to moderate or severe COVID-19 early in the progression. Some of these patients develop multisystem inflammatory syndrome in children (MIS-C), a life-threatening inflammation of organs and tissues. Methods to distinguish children at risk for severe COVID-19 complications, including conditions such as MIS-C, are needed for earlier interventions to improve pediatric patient outcomes. Multiple HHS divisions are coming together for a data challenge competition that will leverage de-identified electronic health record data to develop, train and validate computational models that can predict severe COVID-19 complications in children, equipping healthcare providers with the information and tools they need to identify pediatric patients at risk.', - 'https://www.synapse.org/#!Synapse:syn25875374/wiki/611225', - 'completed', - 'intermediate', - '1', - '', - '2021-08-19', - '2021-12-17', - '2023-06-23 00:00:00', - '2023-07-26 19:49:20' - ), - ( - 49, - 'brats-continuous-evaluation', - 'BraTS Continuous Evaluation', - '', - 'Brain tumors are among the deadliest types of cancer. Specifically, glioblastoma, and diffuse astrocytic glioma with molecular features of glioblastoma (WHO Grade 4 astrocytoma), are the most common and aggressive malignant primary tumor of the central nervous system in adults, with extreme intrinsic heterogeneity in appearance, shape, and histology, with a median survival of approximately 15 months. Brain tumors in general are challenging to diagnose, hard to treat and inherently resistant to conventional therapy because of the challenges in delivering drugs to the brain, as well as the inherent high heterogeneity of these tumors in their radiographic, morphologic, and molecular landscapes. Years of extensive research to improve diagnosis, characterization, and treatment have decreased mortality rates in the U.S by 7% over the past 30 years. Although modest, these research innovations have not translated to improvements in survival for adults and children in low- and middle-incom...', - 'https://www.synapse.org/brats_ce', - 'completed', - 'advanced', - '1', - '', - '2022-01-01', - NULL, - '2023-06-23 00:00:00', - '2023-08-09 08:42:59' - ), - ( - 50, - 'fets-2022', - 'FeTS 2022', - '', - 'FeTS 2022 focuses on benchmarking methods for federated learning (FL), and particularly i) weight aggregation methods for federated training, and ii) algorithmic generalizability on out-of-sample data based on federated evaluation. In line with its last instance (FeTS 2021 - the 1st FL challenge ever organized), FeTS 2022 targets the task of brain tumor segmentation and builds upon i) the centralized dataset of >8,000 clinically-acquired multi-institutional MRI scans (from the RSNA-ASNR-MICCAI BraTS 2021 challenge) with their real-world partitioning, and ii) the collaborative network of remote independent institutions included in a real-world federation. Participants are welcome to compete in either of the two challenge tasks: Task 1 (“Federated Training”) seeks effective weight aggregation methods for the creation of a consensus model given a pre-defined segmentation algorithm for training, while also (optionally) accounting for network outages. Task 2 (“Federated Evaluation”) ...', - 'https://www.synapse.org/#!Synapse:syn28546456/wiki/617093', - 'completed', - 'advanced', - '1', - '', - '2022-04-08', - '2022-08-15', - '2023-06-23 00:00:00', - '2023-08-09 08:40:15' - ), - ( - 51, - 'random-promotor', - 'Random Promotor', - '', - 'Decoding how gene expression is regulated is critical to understanding disease. Regulatory DNA is decoded by the cell in a process termed “cis-regulatory logic”, where proteins called Transcription Factors (TFs) bind to specific DNA sequences within the genome and work together to produce as output a level of gene expression for downstream adjacent genes. This process is exceedingly complex to model as a large number of parameters is needed to fully describe the process (see Rationale, de Boer et al. 2020; Zeitingler J. 2020). Understanding the cis-regulatory logic of the human genome is an important goal and would provide insight into the origins of many diseases. However, learning models from human data is challenging due to limitations in the diversity of sequences present within the human genome (e.g. extensive repetitive DNA), the vast number of cell types that differ in how they interpret regulatory DNA, limited reporter assay data, and substantial technical biases present i...', - 'https://www.synapse.org/#!Synapse:syn28469146/wiki/617075', - 'completed', - 'intermediate', - '1', - '', - '2022-05-02', - '2022-08-07', - '2023-06-23 00:00:00', - '2023-07-26 19:49:22' - ), - ( - 52, - 'preterm-birth-prediction-microbiome', - 'Preterm Birth Prediction - Microbiome', - '', - 'Globally, about 11% of infants every year are born preterm, defined as birth prior to 37 weeks of gestation, totaling nearly 15 million births.(5) In addition to the emotional and financial toll on families, preterm births have higher rates of neonatal death, nearly 1 million deaths each year, and long-term health consequences for some children. Infants born preterm are at risk for a variety of adverse outcomes, such as respiratory illnesses, cerebral palsy, infections, and blindness, with infants born very preterm (i.e., before 32 weeks) at increased risk of these conditions.(6) The ability to accurately predict which women are at a higher risk for preterm birth would help healthcare providers to treat in a timely manner those at higher risk of delivering preterm. Currently available treatments for pregnant women at risk of preterm delivery include corticosteroids for fetal maturation and magnesium sulfate provided prior to 32 weeks to prevent cerebral palsy.(7) There are several...', - 'https://www.synapse.org/#!Synapse:syn26133770/wiki/612541', - 'completed', - 'advanced', - '1', - '', - '2022-07-19', - '2022-09-16', - '2023-06-23 00:00:00', - '2023-07-26 19:49:23' - ), - ( - 53, - 'finrisk', - 'FINRISK - Heart Failure and Microbiome', - '', - 'Cardiovascular diseases are the leading cause of death both in men and women worldwide. Heart failure (HF) is the most common form of heart disease, characterised by the heart''s inability to pump a sufficient supply of blood to meet the needs of the body. The lifetime risk of developing HF is roughly 20%, yet, it remains difficult to diagnose due to its and a lack of agreement of diagnostic criteria. As the diagnosis of HF is dependent on ascertainment of clinical histories and appropriate screening of symptomatic individuals, identifying those at risk of HF is essential. This DREAM challenge focuses on the prediction of HF using a combination of gut microbiome and clinical variables. This challenge is designed to predict incident risk for heart failure in a large human population study of Finnish adults, FINRISK 2002 (Borodulin et al., 2018). The FINRISK study has been conducted in Finland to investigate the risk factors for cardiovascular disease every 5 years since 1972. A ran...', - 'https://www.synapse.org/#!Synapse:syn27130803/wiki/616705', - 'completed', - 'advanced', - '1', - '', - '2022-09-20', - '2023-01-30', - '2023-06-23 00:00:00', - '2023-07-26 19:51:19' - ), - ( - 54, - 'scrna-seq-and-scatac-seq-data-analysis', - 'scRNA-seq and scATAC-seq Data Analysis', - '', - 'Understanding transcriptional regulation at individual cell resolution is fundamental to understanding complex biological systems such as tissues and organs. Emerging high-throughput sequencing technologies now allow for transcript quantification and chromatin accessibility at the single cell level. These technologies present unique challenges due to inherent data sparsity. Proper signal correction is key to accurate gene expression quantification via scRNA-seq, which propagates into downstream analyses such as differential gene expression analysis and cell-type identification. In the even more sparse scATAC-seq data, the correct identification of informative features is key to assessing cell heterogeneity at the chromatin level. The aims of this challenge will be two-fold: 1) To evaluate computational methods for signal correction and peak identification in scRNA-seq and scATAC-seq, respectively; 2) To assess the impact of these methods on downstream analysis', - 'https://www.synapse.org/#!Synapse:syn26720920/wiki/615338', - 'completed', - 'advanced', - '1', - '', - '2022-11-29', - '2023-02-08', - '2023-06-23 00:00:00', - '2023-08-09 08:40:41' - ), - ( - 55, - 'cough-diagnostic-algorithm-for-tuberculosis', - 'COugh Diagnostic Algorithm for Tuberculosis', - '', - 'Tuberculosis (TB), a communicable disease caused by Mycobacterium tuberculosis, is a major cause of ill health and one of the leading causes of death worldwide. Until the COVID-19 pandemic, TB was the leading cause of death from a single infectious agent, ranking even above HIV/AIDS. In 2020, an estimated 9.9 million people fell ill with TB and 1.3 million died of TB worldwide. However, approximately 40% of people with TB were not diagnosed or reported to public health authorities because of challenges in accessing health facilities or failure to be tested or treated when they do. The development of low-cost, non-invasive digital screening tools may improve some of the gaps in diagnosis. As cough is a common symptom of TB, it has the potential to be used as a biomarker for diagnosis of disease. Several previous studies have demonstrated the potential for cough sounds to be used to screen for TB[1-3], though these were typically done in small samples or limited settings. Further de...', - 'https://www.synapse.org/#!Synapse:syn31472953/wiki/617828', - 'completed', - 'advanced', - '1', - '', - '2022-10-16', - '2023-02-13', - '2023-06-23 00:00:00', - '2023-07-26 19:49:25' - ), - ( - 56, - 'nih-long-covid-computational-challenge', - 'NIH Long COVID Computational Challenge', - '', - 'The overall prevalence of post-acute sequelae of SARS-CoV-2 (PASC) is currently unknown, but there is growing evidence that more than half of COVID-19 survivors experience at least one symptom of PASC/Long COVID at six months after recovery of the acute illness. Reports also reflect an underlying heterogeneity of symptoms, multi-organ involvement, and persistence of PASC/Long COVID in some patients. Research is ongoing to understand prevalence, duration, and clinical outcomes of PASC/Long COVID. Symptoms of fatigue, cognitive impairment, shortness of breath, and cardiac damage, among others, have been observed in patients who had only mild initial disease. The breadth and complexity of data created in today''s health care encounters require advanced analytics to extract meaning from longitudinal data on symptoms, laboratory results, images, functional tests, genomics, mobile health/wearable devices, written notes, electronic health records (EHR), and other relevant data types. Adv...', - 'https://www.synapse.org/#!Synapse:syn33576900/wiki/618451', - 'completed', - 'intermediate', - '1', - '', - '2022-08-25', - '2022-12-15', - '2023-06-23 00:00:00', - '2023-07-26 19:49:26' - ), - ( - 57, - 'bridge2ai', - 'Bridge2AI', - 'What makes a good color palette?', - 'What makes a good color palette?', - '', - 'upcoming', - 'good_for_beginners', - '1', - '', - NULL, - NULL, - '2023-06-23 00:00:00', - '2023-07-26 19:49:28' - ), - ( - 58, - 'rare-x-open-data-science', - 'RARE-X Open Data Science', - '', - 'The Xcelerate RARE: A Rare Disease Open Science Data Challenge is bringing together researchers and data scientists in a collaborative and competitive environment to make the best use of patient-provided data to solve big unknowns in healthcare. The Challenge will launch to researchers in late May 2023, focused on rare pediatric neurodevelopmental diseases. ', - 'https://www.synapse.org/#!Synapse:syn51198355/wiki/621435', - 'completed', - 'intermediate', - '1', - '', - '2023-05-17', - '2023-08-16', - '2023-06-23 00:00:00', - '2023-08-07 20:19:38' - ), - ( - 59, - 'cagi5-regulation-saturation', - 'CAGI5: Regulation saturation', - '', - '17,500 single nucleotide variants (SNVs) in 5 human disease associated enhancers (including IRF4, IRF6, MYC, SORT1) and 9 promoters (including TERT, LDLR, F9, HBG1) were assessed in a saturation mutagenesis massively parallel reporter assay. Promoters were cloned into a plasmid upstream of a tagged reporter construct, and reporter expression was measured relative to the plasmid DNA to determine the impact of promoter variants. Enhancers were placed upstream of a minimal promoter and assayed similarly. The challenge is to predict the functional effects of these variants in the regulatory regions as measured from the reporter expression.', - 'https://genomeinterpretation.org/cagi5-regulation-saturation.html', - 'completed', - 'intermediate', - '2', - '', - '2018-01-04', - '2018-05-03', - '2023-06-23 00:00:00', - '2023-07-26 19:49:31' - ), - ( - 60, - 'cagi5-calm1', - 'CAGI5: CALM1', - '', - 'Calmodulin is a calcium-sensing protein that modulates the activity of a large number of proteins in the cell. It is involved in many cellular processes, and is especially important for neuron and muscle cell function. Variants that affect calmodulin function have been found to be causally associated with cardiac arrhythmias. A large library of calmodulin missense variants was assessed with respect to their effects on protein function using a high-throughput yeast complementation assay. The challenge is to predict the functional effects of these calmodulin variants on competitive growth in a high-throughput yeast complementation assay.', - 'https://genomeinterpretation.org/cagi5-calm1.html', - 'completed', - 'intermediate', - '2', - '', - '2017-10-21', - '2017-12-20', - '2023-06-23 00:00:00', - '2023-07-26 19:49:33' - ), - ( - 61, - 'cagi5-pcm1', - 'CAGI5: PCM1', - '', - 'The PCM1 (Pericentriolar Material 1) gene is a component of centriolar satellites occurring around centrosomes in vertebrate cells. Several studies have implicated PCM1 variants as a risk factor for schizophrenia. Ventricular enlargement is one of the most consistent abnormal structural brain findings in schizophrenia Therefore 38 transgenic human PCM1 missense mutations implicated in schizophrenia were assayed in a zebrafish model to determine their impact on the posterior ventricle area. The challenge is to predict whether variants implicated in schizophrenia impact zebrafish ventricular area.', - 'https://genomeinterpretation.org/cagi5-pcm1.html', - 'completed', - 'intermediate', - '2', - '', - '2017-11-09', - '2018-04-19', - '2023-06-23 00:00:00', - '2023-07-26 19:49:36' - ), - ( - 62, - 'cagi5-frataxin', - 'CAGI5: Frataxin', - '', - 'Fraxatin is a highly-conserved protein found in prokaryotes and eukaryotes that is required for efficient regulation of cellular iron homeostasis. Humans with a frataxin deficiency have the cardio- and neurodegenerative disorder Friedreich''s ataxia. A library of eight missense variants was assessed by near and far-UV circular dichroism and intrinsic fluorescence spectra to determine thermodynamic stability at different concentration of denaturant. These were used to calculate a ΔΔGH20 value, the difference in unfolding free energy (ΔGH20) between the mutant and wild-type proteins for each variant. The challenge is to predict ΔΔGH20 for each frataxin variant.', - 'https://genomeinterpretation.org/cagi5-frataxin.html', - 'completed', - 'intermediate', - '2', - '', - '2017-11-30', - '2018-04-18', - '2023-06-23 00:00:00', - '2023-07-26 19:49:36' - ), - ( - 63, - 'cagi5-tpmt-and-p10', - 'CAGI5: TPMT and p10', - '', - 'The gene p10 encodes for PTEN (Phosphatase and TEnsin Homolog), an important secondary messenger molecule promoting cell growth and survival through signaling cascades including those controlled by AKT and mTOR. Thiopurine S-methyl transferase (TPMT) is a key enzyme involved in the metabolism of thiopurine drugs and functions by catalyzing the S-methylation of aromatic and heterocyclic sulfhydryl groups. A library of thousands of PTEN and TPMT mutations was assessed to measure the stability of the variant protein using a multiplexed variant stability profiling (VSP) assay, which detects the presence of EGFP fused to the mutated PTEN and TPMT protein respectively. The stability of the variant protein dictates the abundance of the fusion protein and thus the EGFP level of the cell. The challenge is to predict the effect of each variant on TPMT and/or PTEN protein stability.', - 'https://genomeinterpretation.org/cagi5-tpmt.html', - 'completed', - 'intermediate', - '2', - '', - '2017-11-30', - '2017-12-01', - '2023-06-23 00:00:00', - '2023-07-26 19:49:37' - ), - ( - 64, - 'cagi5-annotate-all-nonsynonymous-variants', - 'CAGI5: Annotate all nonsynonymous variants', - '', - 'dbNSFP describes 810,848,49 possible protein-altering variants in the human genome. The challenge is to predict the functional effect of every such variant. For the vast majority of these missense variants, the functional impact is not currently known, but experimental and clinical evidence are accruing rapidly. Rather than drawing upon a single discrete dataset as typical with CAGI, predictions will be assessed by comparing with experimental or clinical annotations made available after the prediction submission date, on an ongoing basis. if predictors assent, predictions will also incorporated into dbNSFP.', - 'https://genomeinterpretation.org/cagi5-annotate-all-missense.html', - 'completed', - 'intermediate', - '2', - '', - '2017-11-30', - '2018-05-09', - '2023-06-23 00:00:00', - '2023-07-26 19:49:38' - ), - ( - 65, - 'cagi5-gaa', - 'CAGI5: GAA', - '', - 'Acid alpha-glucosidase (GAA) is a lysosomal alpha-glucosidase. Some mutations in GAA cause a rare disorder, Pompe disease, (Glycogen Storage Disease II). Rare GAA missense variants found in a human population sample have been assayed for enzymatic activity in transfected cell lysates. The assessment of this challenge will include evaluations that recognize novelty of approach. The challenge is to predict the fractional enzyme activity of each mutant protein compared to the wild-type enzyme.', - 'https://genomeinterpretation.org/cagi5-gaa.html', - 'completed', - 'intermediate', - '2', - '', - '2017-11-09', - '2018-04-25', - '2023-06-23 00:00:00', - '2023-07-26 19:49:39' - ), - ( - 66, - 'cagi5-chek2', - 'CAGI5: CHEK2', - '', - 'Variants in the CHEK2 gene are associated with breast cancer. This challenge includes CHEK2 gene variants from approximately 1200 Latino breast cancer cases and 1200 ethnically matched controls. This challenge is to estimate the probability of each gene variant occurring in an individual from the cancer affected cohort.', - 'https://genomeinterpretation.org/cagi5-chek2.html', - 'completed', - 'intermediate', - '2', - '', - '2017-12-20', - '2018-04-24', - '2023-06-23 00:00:00', - '2023-07-26 19:49:40' - ), - ( - 67, - 'cagi5-enigma', - 'CAGI5: ENIGMA', - '', - 'Breast cancer is the most prevalent cancer among women worldwide. The association between germline mutations in the BRCA1 and BRCA2 genes and the development of cancer has been well established. The most common high-risk mutations associated with breast cancer are those in the autosomal dominant breast cancer genes 1 and 2 (BRCA1 and BRCA2). Mutations in these genes are found in 1-3% of breast cancer cases. The challenge is to predict which variants are associated with increased risk for breast cancer.', - 'https://genomeinterpretation.org/cagi5-enigma.html', - 'completed', - 'intermediate', - '2', - '', - '2017-12-20', - '2018-05-01', - '2023-06-23 00:00:00', - '2023-07-26 19:49:42' - ), - ( - 68, - 'cagi5-mapsy', - 'CAGI5: MaPSy', - '', - 'The Massively Parallel Splicing Assay (MaPSy) approach was used to screen 797 reported exonic disease mutations using a mini-gene system, assaying both in vivo via transfection in tissue culture, and in vitro via incubation in cell nuclear extract. The challenge is to predict the degree to which a given variant causes changes in splicing.', - 'https://genomeinterpretation.org/cagi5-mapsy.html', - 'completed', - 'intermediate', - '2', - '', - '2017-11-29', - '2018-05-07', - '2023-06-23 00:00:00', - '2023-07-26 19:49:42' - ), - ( - 69, - 'cagi5-vex-seq', - 'CAGI5: Vex-seq', - '', - 'A barcoding approach called Variant exon sequencing (Vex-seq) was applied to assess effect of 2,059 natural single nucleotide variants and short indels on splicing of a globin mini-gene construct transfected into HepG2 cells. This is reported as ΔΨ (delta PSI, or Percent Spliced In), between the variant Ψand the reference Ψ. The challenge is to predict ΔΨ for each variant.', - 'https://genomeinterpretation.org/cagi5-vex-seq.html', - 'completed', - 'intermediate', - '2', - '', - '2017-12-14', - '2018-05-02', - '2023-06-23 00:00:00', - '2023-07-26 19:49:43' - ), - ( - 70, - 'cagi5-sickkids-clinical-genomes', - 'CAGI5: SickKids clinical genomes', - '', - 'This challenge involves 30 children with suspected genetic disorders who were referred for clinical genome sequencing. Predictors are given the 30 genome sequences, and are also provided with the phenotypic descriptions as shared with the diagnostic laboratory. The challenge is to predict what class of disease is associated with each genome, and which genome corresponds to which clinical description. Predictors may additionally identify the diagnostic variant(s) underlying the predictions, and identify predictive secondary variants conferring high risk of other diseases whose phenotypes are not reported in the clinical descriptions.', - 'https://genomeinterpretation.org/cagi5-sickkids5.html', - 'completed', - 'intermediate', - '2', - '', - '2017-12-22', - '2018-04-26', - '2023-06-23 00:00:00', - '2023-07-26 19:49:43' - ), - ( - 71, - 'cagi5-id-panel', - 'CAGI5: ID Panel', - '', - 'The challenge presented here is to use computational methods to predict a patient''s clinical phenotype and the causal variant(s) based on analysis of their gene panel sequence data. Sequence data for 74 genes associated with intellectual disability (ID) and/or Autism spectrum disorders (ASD) from a cohort of 150 patients with a range of neurodevelopmental presentations (ID, autism, epilepsy, etc..) have been made available for this challenge. For each patient, predictors must report the causative variants and which of seven phenotypes are present.', - 'https://genomeinterpretation.org/cagi5-intellectual-disability.html', - 'completed', - 'intermediate', - '2', - '', - '2017-12-22', - '2018-04-30', - '2023-06-23 00:00:00', - '2023-07-26 19:49:44' - ), - ( - 72, - 'cagi5-clotting-disease-exomes', - 'CAGI5: Clotting disease exomes', - '', - 'African Americans have a higher incidence of developing venous thromboembolisms (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), than people of European ancestry. Participants are provided with exome data and clinical covariates for a cohort of African Americans who have been prescribed Warfarin either because they had experienced a VTE event or had been diagnosed with atrial fibrillation (which predisposes to clotting). The challenge is to distinguish between these conditions. At present, in contrast to European ancestry, there are no genetic methods for anticipating which African Americans are most at risk of a venous thromboembolism, and the results of this challenge may contribute to the development of such tools.', - 'https://genomeinterpretation.org/cagi5-clotting-disease.html', - 'completed', - 'intermediate', - '2', - '', - '2017-11-23', - '2018-04-28', - '2023-06-23 00:00:00', - '2023-08-09 08:43:32' - ), - ( - 73, - 'cagi6-rare-genomes-project', - 'CAGI6: Rare Genomes Project', - '', - 'The Rare Genomes Project (RGP) is a direct-to-participant research study on the utility of genome sequencing for rare disease diagnosis and gene discovery. The study is led by genomics experts and clinicians at the Broad Institute of MIT and Harvard. Research subjects are consented for genomic sequencing and the sharing of their sequence and phenotype information with researchers working to understand the molecular causes of rare disease. When a candidate disease variant believed to be related to the phenotype is identified, the variant is confirmed with Sanger sequencing in a clinical setting and returned to the participant via his or her local physician. In this challenge, whole genome sequence data and phenotype data from a subset of the solved and unsolved RGP families will be provided. Participants in the challenge will try to identify the causative variant(s) in each case. For the unsolved cases, prioritized variants from the participating teams will be examined to see if ad...', - 'https://genomeinterpretation.org/cagi6-rgp.html', - 'completed', - 'intermediate', - '1', - '', - '2021-06-08', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:32' - ), - ( - 74, - 'cagi6-intellectual-disability-panel', - 'CAGI6: Intellectual Disability Panel', - '', - 'The objective in this challenge is to predict a patient''s clinical phenotype and the causal variant(s) based on their gene panel sequences. Sequence data for 74 genes from a cohort of 500 patients with a range of neurodevelopmental presentations (intellectual disability, autistic spectrum disorder, epilepsy, microcephaly, macrocephaly, hypotonia, ataxia) has been made available for this challenge. Additional data from 150 patients from the same clinical study is available for training and validation.', - 'https://genomeinterpretation.org/cagi6-id-panel.html', - 'completed', - 'intermediate', - '1', - '', - '2021-06-08', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:34' - ), - ( - 75, - 'cagi6-sickkids-clinical-genomes-and-transcriptomes', - 'CAGI6: SickKids clinical genomes and transcriptomes', - '', - 'This challenge involves data from 79 children who were referred to The Hospital for Sick Children''s (SickKids) Genome Clinic for genome sequencing because of suspected but undiagnosed genetic disorders. Research subjects are consented for sharing of their sequence data and phenotype information with researchers working to understand the molecular causes of rare disease. When a candidate disease variant believed to be related to the phenotype is identified, the variant is adjudicated and confirmed in a clinical setting. In this challenge, transcriptomic and phenotype data from a subset of the “solved” (diagnosed) and “unsolved” SickKids patients will be provided, along with corresponding genomic sequence data. The challenge is to use a transcriptome-driven approach to identify the gene(s) and molecular mechanisms underlying the phenotypic descriptions in each case. For the unsolved cases, prioritized variants from the participating teams will be examined to see if additional diagn...', - 'https://genomeinterpretation.org/cagi6-sickkids.html', - 'completed', - 'intermediate', - '1', - '', - '2021-08-04', - '2021-12-31', - '2023-06-23 00:00:00', - '2023-08-09 08:43:37' - ), - ( - 76, - 'cagi6-polygenic-risk-scores', - 'CAGI6: Polygenic Risk Scores', - '', - 'Polygenic risk scores (PRS) have potential clinical utility for risk surveillance, prevention and personalized medicine. Participants will be provided with datasets of four real phenotypes (Type 2 Diabetes, Breast Cancer, Inflammatory Bowel Disease and Coronary Artery Disease) and of thirty simulated phenotypes representing a range of genetic architectures of common polygenic diseases. The challenge is to predict the disease outcomes of individuals in held-out validation cohorts.', - 'https://genomeinterpretation.org/cagi6-prs.html', - 'completed', - 'intermediate', - '1', - '', - '2021-06-08', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:39' - ), - ( - 77, - 'cagi6-hmbs', - 'CAGI6: HMBS', - '', - 'Hydroxymethylbilane synthase (HMBS), also known as porphobilinogen deaminase (PBGD) or uroporphyrinogen I synthase, is an enzyme involved in heme production. In humans, variants that affect HMBS function result in acute intermittent porphyria (AIP), an autosomal dominant genetic disorder caused by a build-up of porphobilinogen in the cytoplasm. A large library of HMBS missense variants was assessed with respect to their effects on protein function using a high-throughput yeast complementation assay. The challenge is to predict the functional effects of these variants.', - 'https://genomeinterpretation.org/cagi6-hmbs.html', - 'completed', - 'intermediate', - '1', - '', - '2021-06-08', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:40' - ), - ( - 78, - 'cagi6-cam', - 'CAGI6: CaM', - '', - 'Calmodulin (CaM) is a ubiquitous calcium (Ca2+) sensor protein interacting with more than 200 molecular partners, thereby regulating a variety of biological processes. Missense point mutations in the genes encoding CaM have been associated with ventricular tachycardia and sudden cardiac death. A library encompassing up to 17 point mutations was assessed by far-UV circular dichroism (CD) by measuring melting temperature (Tm) and percentage of unfolding (%unfold) upon thermal denaturation at pH and salt concentration that mimic the physiological conditions. The challenge is to predict: (1) the Tm and %unfold values for isolated CaM variants under Ca2+-saturating conditions (Ca2+-CaM) and in the Ca2+-free (apo) state; (2) whether the point mutation stabilizes or destabilizes the protein (based on Tm and %unfold).', - 'https://genomeinterpretation.org/cagi6-cam.html', - 'completed', - 'intermediate', - '1', - '', - '2021-06-08', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:41' - ), - ( - 79, - 'cagi6-annotate-all-missense', - 'CAGI6: Annotate All Missense', - '', - 'dbNSFP currently describes 81,782,923 possible protein-altering variants in the human genome. The challenge is to predict the functional effect of every such variant. For the vast majority of these missense and nonsense variants, the functional impact is not currently known, but experimental and clinical evidence is accruing rapidly. Rather than drawing upon a single discrete dataset as typical with CAGI, predictions will be assessed by comparing with experimental or clinical annotations made available after the prediction submission date, on an ongoing basis. If predictors assent, predictions will also be incorporated into dbNSFP.', - 'https://genomeinterpretation.org/cagi6-annotate-all-missense.html', - 'completed', - 'intermediate', - '1', - '', - '2021-06-01', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:42' - ), - ( - 80, - 'cagi6-stk11', - 'CAGI6: STK11', - '', - 'Serine/Threonine Kinase 11 (STK11) is considered a master kinase that functions as a tumor suppressor and nutrient sensor within a heterotrimeric complex with pseudo-kinase STRAD-alpha and structural protein MO25. Germline variants resulting in loss of STK11 define Peutz-Jaghers Syndrome, an autosomal dominant cancer predisposition syndrome marked by gastrointestinal hamartomas and freckling of the oral mucosa. Somatic loss of function variants, both nonsense and missense, occur in 15-30% of non-small cell lung adenocarcinomas, where they correlate clinically with insensitivity to anti-PD1 monoclonal antibody therapy. The challenge is to predict the impact on STK11 function for each missense variant in relation to wildtype STK11.', - 'https://genomeinterpretation.org/cagi6-stk11.html', - 'completed', - 'intermediate', - '1', - '', - '2021-06-08', - '2021-09-01', - '2023-06-23 00:00:00', - '2023-08-09 08:43:43' - ), - ( - 81, - 'cagi6-mapk1', - 'CAGI6: MAPK1', - '', - 'MAPK1 (ERK2) is active as serine/threonine kinase in the Ras-Raf-MEK-ERK signal transduction cascade that regulates cell proliferation, transcription, differentiation, and cell cycle progression. MAPK1 is activated by phosphorylation which occurs with strict specificity by MEK1/2 on Thr185 and Tyr187, and may also act as a transcriptional repressor independent of its kinase activity. A library of eleven missense variants selected from the COSMIC database was assessed by near and far-UV circular dichroism and intrinsic fluorescence spectra to determine thermodynamic stability at different concentrations of denaturant. These data were used to calculate a ΔΔGH20 value; i.e., the difference in unfolding free energy ΔGH20 between each variant and the wildtype protein, both in phosphorylated and unphosphorylated forms. The challenge is to predict these two ΔΔGH20 values and the catalytic efficiency (kcat/km)mut/(kcat/km)wt, as determined by a fluorescence assay, of the phosphorylated fo...', - 'https://genomeinterpretation.org/cagi6-mapk1.html', - 'completed', - 'intermediate', - '1', - '', - '2021-07-08', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:44' - ), - ( - 82, - 'cagi6-mapk3', - 'CAGI6: MAPK3', - '', - 'MAPK3 (ERK1) is active as serine/threonine kinase in the Ras-Raf-MEK-ERK signal transduction cascade that regulates cell proliferation, transcription, differentiation, and cell cycle progression. MAPK3 is activated by phosphorylation which occurs with strict specificity by MEK1/2 on Thr202 and Tyr204, and may also act as a transcriptional repressor independent of its kinase activity. A library of twelve missense variants selected from the COSMIC database was assessed by near and far-UV circular dichroism and intrinsic fluorescence spectra to determine thermodynamic stability at different concentrations of denaturant. These data were used to calculate a ΔΔGH20 value; i.e., the difference in unfolding free energy ΔGH20 between each variant and the wildtype protein, both in phosphorylated and unphosphorylated forms. The challenge is to predict these two ΔΔGH20 values and the catalytic efficiency (kcat/km)mut/(kcat/km)wt, as determined by a fluorescence assay, of the phosphorylated fo...', - 'https://genomeinterpretation.org/cagi6-mapk3.html', - 'completed', - 'intermediate', - '1', - '', - '2021-08-04', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:45' - ), - ( - 83, - 'cagi6-mthfr', - 'CAGI6: MTHFR', - '', - 'Methylenetetrahydrofolate reductase (MTHFR) catalyzes the production of 5-methyltetrahydrofolate, which is needed for conversion of homocysteine to methionine. Humans with variants affecting MTHFR function present with a wide range of phenotypes, including homocystinuria, homocysteinemia, developmental delay, severe mental retardation, psychiatric disturbances, and late-onset neurodegenerative disorders. A further complication to interpretation of variants in this gene is a common variant, Ala222Val, carried by a large fraction of the human population. A large library of MTHFR missense variants was assessed with respect to their effects on protein function using a high-throughput yeast complementation assay. The challenge is to predict the functional effects of these variants in two different settings: (1) for the wildtype protein, and (2) for the protein with the common Ala222Val variant.', - 'https://genomeinterpretation.org/cagi6-mthfr.html', - 'completed', - 'intermediate', - '1', - '', - '2021-05-03', - '2021-06-30', - '2023-06-23 00:00:00', - '2023-08-09 08:43:45' - ), - ( - 84, - 'cagi6-splicing-vus', - 'CAGI6: Splicing VUS', - '', - 'Variants causing aberrant splicing have been implicated in a range of common and rare disorders, including retinitis pigmentosa, autism spectrum disorder, amyotrophic lateral sclerosis, and a variety of cancers. However, such variants are frequently overlooked by diagnostic sequencing pipelines, leading to missed diagnoses for patients. Clinically ascertained variants of unknown significance underwent whole-blood based RT-PCR to test for impact on splicing. The challenge is to predict which of the tested variants disrupt splicing.', - 'https://genomeinterpretation.org/cagi6-splicing-vus.html', - 'completed', - 'intermediate', - '1', - '', - '2021-06-08', - '2021-10-11', - '2023-06-23 00:00:00', - '2023-08-09 08:43:47' - ), - ( - 85, - 'cagi6-sherloc-clinical-classification', - 'CAGI6: Sherloc clinical classification', - '', - 'Invitae is a genetic testing company that publishes their variant interpretations to ClinVar. In this challenge, over 122,000 previously uncharacterized variants are provided, spanning the range of effects seen in the clinic. Following the close of this challenge, Invitae will submit their interpretations for these variants to ClinVar. Predictors are asked to interpret the pathogenicity of these variants, and the clinical utility of predictions will be assessed across multiple categories by Invitae.', - 'https://genomeinterpretation.org/cagi6-invitae.html', - 'completed', - 'intermediate', - '1', - '', - '2021-07-08', - '2021-12-01', - '2023-06-23 00:00:00', - '2023-08-09 08:43:48' - ), - ( - 86, - 'cami-ii', - 'CAMI II', - '', - 'CAMI II offers several challenges: an assembly, a genome binning, a taxonomic binning and a taxonomic profiling challenge, on several multi-sample data sets from different environments, including long and short read data. This includes a marine data set and a high-strain diversity data set, with a third data set to follow later. A pathogen detection challenge on a clinical sample is also provided.', - 'https://www.microbiome-cosi.org/cami/cami/cami2', - 'completed', - 'intermediate', - '3', - '', - '2019-01-14', - '2021-01-31', - '2023-06-23 00:00:00', - '2023-07-26 19:49:45' - ), - ( - 87, - 'camda18-metasub-forensics', - 'CAMDA18: MetaSUB Forensics', - '', - 'The MetaSUB International Consortium is building a longitudinal metagenomic map of mass-transit systems and other public spaces across the globe. The consortium maintains a strategic partnership with CAMDA and this year provides data from global City Sampling Days for the first-ever multi-city forensic analyses.', - 'http://camda2018.bioinf.jku.at/doku.php/contest_dataset#metasub_forensics_challenge', - 'completed', - 'intermediate', - '7', - '', - NULL, - NULL, - '2023-06-23 00:00:00', - '2023-07-26 19:49:46' - ), - ( - 88, - 'camda18-cmap-drug-safety', - 'CAMDA18: CMap Drug Safety', - '', - 'Attrition in drug discovery and development due to safety / toxicity issues remains a significant concern, and there are strong efforts to identify and mitigate risk as early as possible. Drug-induced liver injury (DILI) is one of the primary problems in drug development and regulatory clearance due to the poor performance of existing preclinical models. There is a pressing need to evaluate alternative methods for predicting DILI, with great hopes being placed in modern approaches from statistics and machine learning applied to genome scale profiling data. A critical question thus is if we can better integrate, understand, and exploit information from cell-based screens like the Broad Institute Connectivity Map (CMap, Science 313, Nature Reviews Cancer 7). - This CAMDA challenge focuses on understanding or predicting drug induced liver injury in humans from cell-based screens, specifically the CMap gene expression responses of two different cancer cell lines (MCF7 and PC3) to 276 d...', - 'http://camda2018.bioinf.jku.at/doku.php/contest_dataset#cmap_drug_safety_challenge', - 'completed', - 'intermediate', - '7', - '', - NULL, - NULL, - '2023-06-23 00:00:00', - '2023-07-26 19:49:46' - ), - ( - 89, - 'camda18-cancer-data-integration', - 'CAMDA18: Cancer Data Integration', - '', - 'Examine the power of data integration in a real-world clinical settings. Many approaches work well on some data-sets yet not on others. We here challenge you to demonstrate a unified single approach to data-integration that matches or outperforms the current state of the art on two different diseases, breast cancer and neuroblastoma. Breast cancer affects about 3 million women every year (McGuire et al, Cancers 7), and this number is growing fast, especially in developed countries. Can you improve on the large Metabric study (Curtis et al., Nature 486, and Dream Challenge, Margolin et al, Sci Transl Med 5)? The cohort is biologically heterogeneous with all five distinct PAM50 breast cancer subtypes represented. Matched profiles for microarray and copy number data as well as clinical information (survival times, multiple prognostic markers, therapy data) are available for about 2,000 patients. Neuroblastoma is the most common extracranial solid tumor in children. The base study com...', - 'http://camda2018.bioinf.jku.at/doku.php/contest_dataset#cancer_data_integration_challenge', - 'completed', - 'intermediate', - '7', - '', - NULL, - NULL, - '2023-06-23 00:00:00', - '2023-07-26 19:49:47' - ), - ( - 90, - 'cafa-4', - 'CAFA 4', - '', - 'The goal of the Critical Assessment of Functional Annotation(CAFA) challenge is to evaluate automated protein function prediction algorithms in the task of predicting Gene Ontology and Human Phenotype Ontology terms for a given set of protein sequences. For the GO-based predictions, the evaluation will be carried out for the Molecular Function Ontology, Biological Process Ontology and Cellular Component Ontology. Participants develop protein function prediction algorithms using training protein sequence data and submit their predictions on target protein sequence data.', - 'https://www.biofunctionprediction.org/cafa/', - 'completed', - 'intermediate', - '1', - '', - '2019-10-21', - '2020-02-12', - '2023-06-23 00:00:00', - '2023-08-05 00:32:49' - ), - ( - 91, - 'casp13', - 'CASP13', - '', - 'CASP (Critical Assessment of Structure Prediction) is a community wide experiment to determine and advance the state of the art in modeling protein structure from amino acid sequence. Every two years, participants are invited to submit models for a set of proteins for which the experimental structures are not yet public. Independent assessors then compare the models with experiment. Assessments and results are published in a special issue of the journal PROTEINS. In the most recent CASP round, CASP12, nearly 100 groups from around the world submitted more than 50,000 models on 82 modeling targets', - 'https://predictioncenter.org/casp13/index.cgi', - 'completed', - 'intermediate', - '4', - '', - '2018-04-18', - '2018-08-20', - '2023-06-23 00:00:00', - '2023-07-26 19:49:48' - ), - ( - 92, - 'casp14', - 'CASP14', - '', - 'CASP (Critical Assessment of Structure Prediction) is a community wide experiment to determine and advance the state of the art in modeling protein structure from amino acid sequence. Every two years, participants are invited to submit models for a set of proteins for which the experimental structures are not yet public. Independent assessors then compare the models with experiment. Assessments and results are published in a special issue of the journal PROTEINS. In the most recent CASP round, CASP14, nearly 100 groups from around the world submitted more than 67,000 models on 90 modeling targets.', - 'https://predictioncenter.org/casp14/index.cgi', - 'completed', - 'intermediate', - '4', - '', - '2020-05-04', - '2020-09-07', - '2023-06-23 00:00:00', - '2023-07-26 19:49:51' - ), - ( - 93, - 'cfsan-pathogen-detection', - 'CFSAN Pathogen Detection', - '', - 'In the U.S. alone, one in six individuals, an estimated 48 million people, fall prey to foodborne illness, resulting in 128,000 hospitalizations and 3,000 deaths per year. Economic burdens are estimated cumulatively at $152 billion dollars annually, including $39 billion due to contamination of fresh and processed produce. One longstanding problem is the ability to rapidly identify the food-source associated with the outbreak being investigated. The faster an outbreak is identified and the increased certainty that a given source (e.g., papayas from Mexico) and patients are linked, the faster the outbreak can be stopped, limiting morbidity and mortality. In the last few years, the application of next-generation sequencing (NGS) technology for whole genome sequencing (WGS) of foodborne pathogens has revolutionized food pathogen outbreak surveillance. WGS of foodborne pathogens enables high-resolution identification of pathogens isolated from food or environmental samples. These pat...', - 'https://precision.fda.gov/challenges/2', - 'completed', - 'intermediate', - '6', - '', - '2018-02-15', - '2018-04-26', - '2023-06-23 00:00:00', - '2023-07-26 19:49:51' - ), - ( - 94, - 'cdrh-biothreat', - 'CDRH Biothreat', - '', - 'Many infectious diseases have similar signs and symptoms, making it challenging for healthcare providers to identify the disease-causing agent. Clinical samples are often tested by multiple test methods to help reveal the microbe that is causing the infectious disease. The results of these test methods can help healthcare professionals determine the best treatment for patients. Today, High-Throughput Sequencing (HTS) or Next Generation Sequencing (NGS) technology has the capability, as a single test, to accomplish what might have required several different tests in the past. NGS technology may allow the diagnosis of infections without prior knowledge of disease(s) cause. NGS technology can potentially reveal the presence of all microorganisms in a patient sample. Using infectious disease NGS (ID-NGS) technology, each microbial pathogen may be identified by its unique genomic fingerprint. The vision of ID-NGS technology is to further improve patient care by delivering diagnostics ...', - 'https://precision.fda.gov/challenges/3', - 'completed', - 'intermediate', - '6', - '', - '2018-08-03', - '2018-10-18', - '2023-06-23 00:00:00', - '2023-07-26 19:49:52' - ), - ( - 95, - 'multi-omics-enabled-sample-mislabeling-correction', - 'Multi-omics Enabled Sample Mislabeling Correction', - '', - 'In biomedical research, sample mislabeling (accidental swapping of patient samples) or data mislabeling (accidental swapping of patient omics data) has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies, in which multiple different omics experiments are carried out at different time periods and/or in different labs. Human errors could arise during sample transferring, sample tracking, large-scale data generation, and data sharing/management. Thus, there is a pressing need to identify and correct sample and data mislabeling events to ensure the right data for the right patient. Simultaneous use of multiple types of omics platforms to characterize a large set of biological samples, as utilized in The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) projects, has been demonstrated as a powerful approach to understanding the ...', - 'https://precision.fda.gov/challenges/4', - 'completed', - 'intermediate', - '6', - 'https://doi.org/10.1038/s41591-018-0180-x', - '2018-09-24', - '2018-12-19', - '2023-06-23 00:00:00', - '2023-09-13 23:40:44' - ), - ( - 96, - 'biocompute-object-app-a-thon', - 'BioCompute Object App-a-thon', - '', - 'Like scientific laboratory experiments, bioinformatics analysis results and interpretation are faced with reproducibility challenges due to the variability in multiple computational parameters, including input format, prerequisites, platform dependencies, and more. Even small changes in these computational parameters may have a large impact on the results and carry big implications for their scientific validity. Because there are currently no standardized schemas for reporting computational scientific workflows and parameters together with their results, the ways in which these workflows are communicated is highly variable, incomplete, and difficult or impossible to reproduce. The US Food and Drug Administration (FDA) High Performance Virtual Environment (HIVE) group and George Washington University (GW) have partnered to establish a framework for community-based standards development and harmonization of high-throughput sequencing (HTS) computations and data formats based around...', - 'https://precision.fda.gov/challenges/7/', - 'completed', - 'intermediate', - '6', - 'https://doi.org/10.1101/2020.11.02.365528', - '2019-05-14', - '2019-10-18', - '2023-06-23 00:00:00', - '2023-09-13 23:42:22' - ), - ( - 97, - 'brain-cancer-predictive-modeling-and-biomarker-discovery', - 'Brain Cancer Predictive Modeling and Biomarker Discovery', - '', - 'An estimated 86,970 new cases of primary brain and other central nervous system tumors are expected to be diagnosed in the US in 2019. Brain tumors comprise a particularly deadly subset of all cancers due to limited treatment options and the high cost of care. Only a few prognostic and predictive markers have been successfully implemented in the clinic so far for gliomas, the most common malignant brain tumor type. These markers include MGMT promoter methylation in high-grade astrocytomas, co-deletion of 1p/19q in oligodendrogliomas, and mutations in IDH1 or IDH2 genes (Staedtke et al. 2016). There remains significant potential for identifying new clinical biomarkers in gliomas. Clinical investigators at Georgetown University are seeking to advance precision medicine techniques for the prognosis and treatment of brain tumors through the identification of novel multi-omics biomarkers. In support of this goal, precisionFDA and the Georgetown Lombardi Comprehensive Cancer Center and...', - 'https://precision.fda.gov/challenges/8/', - 'completed', - 'advanced', - '6', - '', - '2019-11-01', - '2020-02-14', - '2023-06-23 00:00:00', - '2023-07-26 19:49:53' - ), - ( - 98, - 'gaining-new-insights-by-detecting-adverse-event-anomalies', - 'Gaining New Insights by Detecting Adverse Event Anomalies', - '', - 'The Food and Drug Administration (FDA) calls on the public to develop computational algorithms for automatic detection of adverse event anomalies using publicly available data.', - 'https://precision.fda.gov/challenges/9/', - 'completed', - 'intermediate', - '6', - '', - '2020-01-17', - '2020-05-18', - '2023-06-23 00:00:00', - '2023-07-26 19:49:54' - ), - ( - 99, - 'calling-variants-in-difficult-to-map-regions', - 'Calling Variants in Difficult-to-Map Regions', - '', - 'This challenge calls on the public to assess variant calling pipeline performance on a common frame of reference, with a focus on benchmarking in difficult-to-map regions, segmental duplications, and the Major Histocompatibility Complex (MHC).', - 'https://precision.fda.gov/challenges/10/', - 'completed', - 'intermediate', - '6', - 'https://doi.org/10.1016/j.xgen.2022.100129', - '2020-05-01', - '2020-06-15', - '2023-06-23 00:00:00', - '2023-09-13 23:41:29' - ), - ( - 100, - 'vha-innovation-ecosystem-and-covid-19-risk-factor-modeling', - 'VHA Innovation Ecosystem and COVID-19 Risk Factor Modeling', - '', - 'The novel coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2,” or SARS-CoV-2. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a global pandemic. As of Monday, June 1, the Johns Hopkins University COVID-19 dashboard reports over 6.21 million total confirmed cases worldwide, including over 1.79 million cases in the United States. Although most people have mild to moderate symptoms, the disease can cause severe medical complications leading to death in some people. The Centers for Disease Control and Prevention (CDC) have identified several groups at elevated risk for severe illness, including people 65 years and older, individuals living in nursing homes or long term care facilities, and those with serious underlying medical conditions, such as severe obesity, diabetes, chronic lung disease or moderate to severe asthma, chronic kidney or liver diseas...', - 'https://precision.fda.gov/challenges/11/', - 'completed', - 'intermediate', - '6', - '', - '2020-06-02', - '2020-07-03', - '2023-06-23 00:00:00', - '2023-07-26 19:49:56' - ), - ( - 101, - 'covid-19-precision-immunology-app-a-thon', - 'COVID-19 Precision Immunology App-a-thon', - '', - 'The novel coronavirus disease 2019 (COVID-19), a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2” or SARS-CoV-2, was declared a global pandemic by the World Health Organization on March 11, 2020. To date, the Johns Hopkins University COVID-19 dashboard reports over 62 million confirmed cases worldwide, with a wide range of disease severity from asymptomatic to deaths (over 1.46 million). To effectively combat the widespread transmission of COVID-19 infection and save lives especially of those vulnerable individuals, it is imperative to better understand its pathophysiology to enable effective diagnosis, prognosis and treatment strategies using rapidly shared data.', - 'https://precision.fda.gov/challenges/12/', - 'completed', - 'intermediate', - '6', - '', - '2020-11-30', - '2021-01-29', - '2023-06-23 00:00:00', - '2023-07-26 19:49:57' - ), - ( - 102, - 'smarter-food-safety-low-cost-tech-enabled-traceability', - 'Smarter Food Safety Low Cost Tech-Enabled Traceability', - '', - 'The motivation is tapping into new technologies and integrating data streams will help to advance the widespread, consistent implementation of traceability systems across the food industry. However, the affordability of such technologies, particularly for smaller companies, can be a barrier to implementing tech-enabled traceability systems. FDA''s New Era of Smarter Food Safety initiative strives to work with stakeholders to explore low-cost or no-cost options so that our approaches are inclusive of and viable for human and animal food operations of all sizes. Democratizing the benefits of digitizing data will allow the entire food system to move more rapidly towards digital traceability systems. The primary goal is to encourage stakeholders, including technology providers, public health advocates, entrepreneurs, and innovators from all disciplines and around the world, to develop traceability hardware, software, or data analytics platforms that are low-cost or no-cost to the end...', - 'https://precision.fda.gov/challenges/13', - 'completed', - 'intermediate', - '6', - '', - '2021-06-01', - '2021-07-30', - '2023-06-23 00:00:00', - '2023-09-13 23:42:00' - ), - ( - 103, - 'tumor-mutational-burden-tmb-challenge-phase-1', - 'Tumor Mutational Burden (TMB) Challenge Phase 1', - '', - 'Tumor mutational burden (TMB) is generally defined as the number of mutations detected in a patient''s tumor sample per megabase of DNA sequenced. However different algorithms use different methods for calculating TMB. Mutations in genes in tumor cells may lead to the creation of neoantigens, which have the potential to activate an immune system response against the tumor, and the likelihood of an immune system response may increase with the number of mutations. Thus, TMB is a biomarker for some immunotherapy drugs, called immune checkpoint inhibitors, such as those that target the PD-1 and PD-L1 pathways (Chan et al., 2019). An outstanding problem is the lack of standardization for TMB calculation and reporting between different assays. To address this problem, the Friends of Cancer Research convened a working group of industry and regulatory stakeholders to develop guidance and tools for TMB harmonization. Results from the first phase of this effort were presented at AACR 2020 ...', - 'https://precision.fda.gov/challenges/17', - 'completed', - 'advanced', - '6', - '', - '2021-06-21', - '2021-09-13', - '2023-06-23 00:00:00', - '2023-07-26 19:49:57' - ), - ( - 104, - 'kidney-and-kidney-tumor-segmentation', - 'Kidney and Kidney Tumor Segmentation', - '', - 'The 2021 Kidney and Kidney Tumor Segmentation challenge (abbreviated KiTS21) is a competition in which teams compete to develop the best system for automatic semantic segmentation of renal tumors and surrounding anatomy. Kidney cancer is one of the most common malignancies in adults around the world, and its incidence is thought to be increasing [1]. Fortunately, most kidney tumors are discovered early while they''re still localized and operable. However, there are important questions concerning management of localized kidney tumors that remain unanswered [2], and metastatic renal cancer remains almost uniformly fatal [3]. Kidney tumors are notorious for their conspicuous appearance in computed tomography (CT) imaging, and this has enabled important work by radiologists and surgeons to study the relationship between tumor size, shape, and appearance and its prospects for treatment [4,5,6]. It''s laborious work, however, and it relies on assessments that are often subjective and im...', - 'https://kits21.kits-challenge.org/', - 'completed', - 'advanced', - '5', - '', - '2021-08-23', - '2021-09-17', - '2023-06-23 00:00:00', - '2023-07-26 19:49:58' - ), - ( - 105, - 'cross-modality-da-for-medical-image-segmentation', - 'Cross-Modality DA for Medical Image Segmentation', - '', - 'Domain Adaptation (DA) has recently raised strong interests in the medical imaging community. By encouraging algorithms to be robust to unseen situations or different input data domains, Domain Adaptation improves the applicability of machine learning approaches to various clinical settings. While a large variety of DA techniques has been proposed for image segmentation, most of these techniques have been validated either on private datasets or on small publicly available datasets. Moreover, these datasets mostly address single-class problems. To tackle these limitations, the crossMoDA challenge introduces the first large and multi-class dataset for unsupervised cross-modality Domain Adaptation.', - 'https://crossmoda-challenge.ml/', - 'completed', - 'advanced', - '5', - '', - '2021-04-05', - '2021-09-27', - '2023-06-23 00:00:00', - '2023-07-26 19:49:59' - ), - ( - 106, - 'real-noise-mri', - 'Real Noise MRI', - '', - 'In recent years, there is a growing focus on the application of fast magnetic resonance imaging (MRI) based on prior knowledge. In the 1980s and 2000s the community used either purely mathematical models such as the partial Fourier transform or solutions derived through advanced engineering such as parallel imaging to speed up MRI acquisition. Since the mid-2000''s, compressed sensing and artificial intelligence have been employed to speed up MRI acquisition. These newer methods rely on under sampling the data acquired in Fourier (aka k-) space and then interpolating or augmenting k-space data based on training data content. One of the underlying problems for the development of fast imaging techniques, that just as in e.g. [1], it is common to use a fully sampled image as ground truth and then under sample it in k-space in order to simulate under sampled data. The problem with this approach is that in cases were the under sampled data is corrupted, through e.g. motion, this under ...', - 'https://realnoisemri.grand-challenge.org/Description/', - 'completed', - 'intermediate', - '5', - '', - '2021-09-21', - '2021-12-06', - '2023-06-23 00:00:00', - '2023-07-26 19:49:59' - ), - ( - 107, - 'deep-generative-model-challenge-for-da-in-surgery', - 'Deep Generative Model Challenge for DA in Surgery', - '', - 'Mitral regurgitation (MR) is the second most frequent indication for valve surgery in Europe and may occur for organic or functional causes [1]. Mitral valve repair, although considerably more difficult, is prefered over mitral valve replacement, since the native tissue of the valve is preserved. It is a complex on-pump heart surgery, often conducted only by a handful of surgeons in high-volume centers. Minimally invasive procedures, which are performed with endoscopic video recordings, became more and more popular in recent years. However, data availability and data privacy concerns are still an issue for the development of automatic scene analysis algorithms. The AdaptOR challenge aims to address these issues by formulating a domain adaptation problem from simulation to surgery. We provide a smaller number of datasets from real surgeries, and a larger number of annotated recordings of training and planning sessions from a physical mitral valve simulator. The goal is to reduce th...', - 'https://adaptor2021.github.io/', - 'completed', - 'intermediate', - '1', - '', - '2021-04-01', - '2021-07-16', - '2023-06-23 00:00:00', - '2023-07-26 19:50:00' - ), - ( - 108, - 'aimdatathon', - 'AIM Datathon 2020', - 'Join the AI in Medicine ( AIM ) Datathon 2020', - 'Join the AI in Medicine ( AIM ) Datathon 2020', - 'https://www.kaggle.com/competitions/aimdatathon', - 'completed', - 'intermediate', - '8', - '', - '2020-11-09', - '2020-11-22', - '2023-06-23 00:00:00', - '2023-07-26 19:50:02' - ), - ( - 109, - 'opc-recurrence', - 'Oropharynx Cancer (OPC) Radiomics Challenge :: Local Recurrence Prediction', - 'Determine from CT data whether a tumor will be controlled by definitive radi...', - 'Determine from CT data whether a tumor will be controlled by definitive radiation therapy.', - 'https://www.kaggle.com/competitions/opc-recurrence', - 'completed', - 'intermediate', - '8', - '', - '2016-07-26', - '2016-09-12', - '2023-06-23 00:00:00', - '2023-07-26 19:50:03' - ), - ( - 110, - 'oropharynx-radiomics-hpv', - 'Oropharynx Cancer (OPC) Radiomics Challenge :: Human Papilloma Virus (HPV) Status Prediction', - 'Predict from CT data the HPV phenotype of oropharynx tumors; compare to grou...', - 'Predict from CT data the HPV phenotype of oropharynx tumors; compare to ground-truth results previously obtained by p16 or HPV testing.', - 'https://www.kaggle.com/competitions/oropharynx-radiomics-hpv', - 'completed', - 'intermediate', - '8', - '', - '2016-07-26', - '2016-09-12', - '2023-06-23 00:00:00', - '2023-07-26 19:50:03' - ), - ( - 111, - 'data-science-bowl-2017', - 'Data Science Bowl 2017', - 'Can you improve lung cancer detection?', - 'Can you improve lung cancer detection?', - 'https://www.kaggle.com/competitions/data-science-bowl-2017', - 'completed', - 'intermediate', - '8', - '', - '2017-01-12', - '2017-04-12', - '2023-06-23 00:00:00', - '2023-07-26 19:50:04' - ), - ( - 112, - 'predict-impact-of-air-quality-on-death-rates', - 'Predict impact of air quality on mortality rates', - 'Predict CVD and cancer caused mortality rates in England using air quality d...', - 'Predict CVD and cancer caused mortality rates in England using air quality data available from Copernicus Atmosphere Monitoring Service', - 'https://www.kaggle.com/competitions/predict-impact-of-air-quality-on-death-rates', - 'completed', - 'intermediate', - '8', - '', - '2017-02-13', - '2017-05-05', - '2023-06-23 00:00:00', - '2023-07-26 19:50:04' - ), - ( - 113, - 'intel-mobileodt-cervical-cancer-screening', - 'Intel & MobileODT Cervical Cancer Screening', - 'Which cancer treatment will be most effective?', - 'Which cancer treatment will be most effective?', - 'https://www.kaggle.com/competitions/intel-mobileodt-cervical-cancer-screening', - 'completed', - 'intermediate', - '8', - '', - '2017-03-15', - '2017-06-21', - '2023-06-23 00:00:00', - '2023-07-26 19:50:05' - ), - ( - 114, - 'msk-redefining-cancer-treatment', - 'Personalized Medicine: Redefining Cancer Treatment', - 'Predict the effect of Genetic Variants to enable Personalized Medicine', - 'Predict the effect of Genetic Variants to enable Personalized Medicine', - 'https://www.kaggle.com/competitions/msk-redefining-cancer-treatment', - 'completed', - 'intermediate', - '8', - '', - '2017-06-26', - '2017-10-02', - '2023-06-23 00:00:00', - '2023-07-26 19:50:05' - ), - ( - 115, - 'mubravo', - 'Predicting Cancer Diagnosis', - 'Bravo''s machine learning competition!', - 'Bravo''s machine learning competition!', - 'https://www.kaggle.com/competitions/mubravo', - 'completed', - 'intermediate', - '8', - '', - '2018-07-31', - '2018-08-13', - '2023-06-23 00:00:00', - '2023-07-26 19:50:08' - ), - ( - 116, - 'histopathologic-cancer-detection', - 'Histopathologic Cancer Detection', - 'Identify metastatic tissue in histopathologic scans of lymph node sections', - 'Identify metastatic tissue in histopathologic scans of lymph node sections', - 'https://www.kaggle.com/competitions/histopathologic-cancer-detection', - 'completed', - 'intermediate', - '8', - '', - '2018-11-16', - '2019-03-30', - '2023-06-23 00:00:00', - '2023-07-26 19:50:10' - ), - ( - 117, - 'tjml1920-decision-trees', - 'TJML 2019-20 Breast Cancer Detection Competition', - 'Use a decision tree to identify malignant breast cancer tumors', - 'Use a decision tree to identify malignant breast cancer tumors', - 'https://www.kaggle.com/competitions/tjml1920-decision-trees', - 'completed', - 'intermediate', - '8', - '', - '2019-09-22', - '2019-10-16', - '2023-06-23 00:00:00', - '2023-07-26 19:50:09' - ), - ( - 118, - 'prostate-cancer-grade-assessment', - 'Prostate cANcer graDe Assessment (PANDA) Challenge', - 'Prostate cancer diagnosis using the Gleason grading system', - 'Prostate cancer diagnosis using the Gleason grading system', - 'https://www.kaggle.com/competitions/prostate-cancer-grade-assessment', - 'completed', - 'intermediate', - '8', - '', - '2020-04-21', - '2020-07-22', - '2023-06-23 00:00:00', - '2023-07-26 19:50:10' - ), - ( - 119, - 'breast-cancer', - 'Breast Cancer', - 'Use cell nuclei categories to predict breast cancer tumor.', - 'Use cell nuclei categories to predict breast cancer tumor.', - 'https://www.kaggle.com/competitions/breast-cancer', - 'completed', - 'intermediate', - '8', - '', - '2020-08-12', - '2020-08-13', - '2023-06-23 00:00:00', - '2023-07-26 19:50:10' - ), - ( - 120, - 'breast-cancer-detection', - 'Breast Cancer Detection', - 'breast cancer detection', - 'breast cancer detection', - 'https://www.kaggle.com/competitions/breast-cancer-detection', - 'completed', - 'intermediate', - '8', - '', - '2020-09-25', - '2020-12-31', - '2023-06-23 00:00:00', - '2023-07-26 19:50:11' - ), - ( - 121, - 'hrpred', - 'Prediction of High Risk Patients', - 'Classification of high and low risk cancer patients', - 'Classification of high and low risk cancer patients', - 'https://www.kaggle.com/competitions/hrpred', - 'completed', - 'intermediate', - '8', - '', - '2020-11-25', - '2020-12-05', - '2023-06-23 00:00:00', - '2023-07-26 19:50:11' - ), - ( - 122, - 'ml4moleng-cancer', - 'MIT ML4MolEng: Predicting Cancer Progression', - 'MIT 3.100, 10.402, 20.301 In class ML competition (Spring 2021)', - 'MIT 3.100, 10.402, 20.301 In class ML competition (Spring 2021)', - 'https://www.kaggle.com/competitions/ml4moleng-cancer', - 'completed', - 'intermediate', - '8', - '', - '2021-05-06', - '2021-05-21', - '2023-06-23 00:00:00', - '2023-07-26 19:50:12' - ), - ( - 123, - 'uw-madison-gi-tract-image-segmentation', - 'UW-Madison GI Tract Image Segmentation', - 'Track healthy organs in medical scans to improve cancer treatment', - 'Track healthy organs in medical scans to improve cancer treatment', - 'https://www.kaggle.com/competitions/uw-madison-gi-tract-image-segmentation', - 'completed', - 'intermediate', - '8', - '', - '2022-04-14', - '2022-07-14', - '2023-06-23 00:00:00', - '2023-07-26 19:50:13' - ), - ( - 124, - 'rsna-miccai-brain-tumor-radiogenomic-classification', - 'RSNA-MICCAI Brain Tumor Radiogenomic Classification', - 'Predict the status of a genetic biomarker important for brain cancer treatment', - 'The Brain Tumor Segmentation (BraTS) challenge celebrates its 10th anniversary, and this year is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society. The RSNA-ASNR-MICCAI BraTS 2021 challenge utilizes multi-institutional pre-operative baseline multi-parametric magnetic resonance imaging (mpMRI) scans, and focuses on the evaluation of state-of-the-art methods for (Task 1) the segmentation of intrinsically heterogeneous brain glioblastoma sub-regions in mpMRI scans. Furthemore, this BraTS 2021 challenge also focuses on the evaluation of (Task 2) classification methods to predict the MGMT promoter methylation status. Participants are free to choose whether they want to focus only on one or both tasks.', - 'https://www.kaggle.com/competitions/rsna-miccai-brain-tumor-radiogenomic-classification', - 'completed', - 'advanced', - '8', - '', - '2021-07-13', - '2021-10-15', - '2023-06-23 00:00:00', - '2023-07-26 19:50:13' - ), - ( - 125, - 'breastcancer', - 'Breast Cancer - Beginners ML', - 'Beginners hands-on experience with ML basics', - 'Beginners hands-on experience with ML basics', - 'https://www.kaggle.com/competitions/breastcancer', - 'completed', - 'intermediate', - '8', - '', - '2021-12-21', - '2022-02-12', - '2023-06-23 00:00:00', - '2023-07-26 19:50:13' - ), - ( - 126, - 'ml-olympiad-health-and-education', - 'ML Olympiad - Let''s Fight lung cancer', - 'Use your ML expertise to help us step another step toward defeating cancer [...', - 'Use your ML expertise to help us step another step toward defeating cancer [ Starts on the 14th February ]', - 'https://www.kaggle.com/competitions/ml-olympiad-health-and-education', - 'completed', - 'intermediate', - '8', - '', - '2022-01-31', - '2022-03-19', - '2023-06-23 00:00:00', - '2023-07-26 19:50:14' - ), - ( - 127, - 'cs98-22-dl-task1', - 'CS98X-22-DL-Task1', - 'This competition is related to Task 1 in coursework - breast cancer classifi...', - 'This competition is related to Task 1 in coursework - breast cancer classification', - 'https://www.kaggle.com/competitions/CS98-22-DL-Task1', - 'completed', - 'intermediate', - '8', - '', - '2022-02-28', - '2022-04-11', - '2023-06-23 00:00:00', - '2023-07-26 19:50:16' - ), - ( - 128, - 'parasitedetection-iiitb2019', - 'Parasite detection', - 'detect if cell image has parasite or is uninfected', - 'detect if cell image has parasite or is uninfected', - 'https://www.kaggle.com/competitions/parasitedetection-iiitb2019', - 'completed', - 'intermediate', - '8', - '', - '2019-10-13', - '2019-11-25', - '2023-06-23 00:00:00', - '2023-07-26 19:50:16' - ), - ( - 129, - 'hpa-single-cell-image-classification', - 'Human Protein Atlas - Single Cell Classification', - 'Find individual human cell differences in microscope images', - 'Find individual human cell differences in microscope images', - 'https://www.kaggle.com/competitions/hpa-single-cell-image-classification', - 'completed', - 'intermediate', - '8', - '', - '2021-01-26', - '2021-05-11', - '2023-06-23 00:00:00', - '2023-07-26 19:50:17' - ), - ( - 130, - 'stem-cell-predcition', - 'Stem Cell Predcition', - 'Classify stem and non-stem cells using RNA-seq data', - 'Classify stem and non-stem cells using RNA-seq data', - 'https://www.kaggle.com/competitions/stem-cell-predcition', - 'completed', - 'intermediate', - '8', - '', - '2021-04-01', - '2021-07-01', - '2023-06-23 00:00:00', - '2023-07-26 19:50:18' - ), - ( - 131, - 'sartorius-cell-instance-segmentation', - 'Sartorius - Cell Instance Segmentation', - 'Detect single neuronal cells in microscopy images', - 'In this competition, you’ll detect and delineate distinct objects of interest in biological images depicting neuronal cell types commonly used in the study of neurological disorders. More specifically, you''ll use phase contrast microscopy images to train and test your model for instance segmentation of neuronal cells. Successful models will do this with a high level of accuracy. If successful, you''ll help further research in neurobiology thanks to the collection of robust quantitative data. Researchers may be able to use this to more easily measure the effects of disease and treatment conditions on neuronal cells. As a result, new drugs could be discovered to treat the millions of people with these leading causes of death and disability.', - 'https://www.kaggle.com/competitions/sartorius-cell-instance-segmentation', - 'completed', - 'intermediate', - '8', - '', - '2021-10-14', - '2021-12-30', - '2023-06-23 00:00:00', - '2023-08-08 17:53:06' - ), - ( - 132, - 'pvelad', - 'Photovoltaic cell anomaly detection', - 'Hosted by Hebei University of Technology (AIHebut research group) and Beihan...', - 'Hosted by Hebei University of Technology (AIHebut research group) and Beihang University (NAVE research group)', - 'https://www.kaggle.com/competitions/pvelad', - 'completed', - 'intermediate', - '8', - '', - '2022-03-15', - '2022-07-30', - '2023-06-23 00:00:00', - '2023-07-26 19:50:19' - ), - ( - 133, - 'blood-mnist', - 'Blood-MNIST', - 'Classifying blood cell types using Weights and Biases', - 'Classifying blood cell types using Weights and Biases', - 'https://www.kaggle.com/competitions/blood-mnist', - 'completed', - 'intermediate', - '8', - '', - '2022-03-19', - '2022-03-19', - '2023-06-23 00:00:00', - '2023-07-26 19:50:19' - ), - ( - 134, - 'insilicomolhack', - 'MolHack', - 'Apply deep learning to speedup drug validation', - 'Apply deep learning to speedup drug validation', - 'https://www.kaggle.com/competitions/insilicomolhack', - 'completed', - 'intermediate', - '8', - '', - '2018-04-02', - '2018-05-25', - '2023-06-23 00:00:00', - '2023-07-26 19:50:20' - ), - ( - 135, - 'codata2019challenge', - 'Cell Response Classification', - 'From recorded timeseries of many cells in a well, predict which drug treatme...', - 'From recorded timeseries of many cells in a well, predict which drug treatment has been applied', - 'https://www.kaggle.com/competitions/codata2019challenge', - 'completed', - 'intermediate', - '8', - '', - '2019-04-08', - '2019-05-07', - '2023-06-23 00:00:00', - '2023-07-26 19:50:21' - ), - ( - 136, - 'drug-solubility-challenge', - 'Drug solubility challenge', - 'Solubility is vital to achieve desired concentration of drug for anticipated...', - 'Solubility is vital to achieve desired concentration of drug for anticipated pharmacological response.', - 'https://www.kaggle.com/competitions/drug-solubility-challenge', - 'completed', - 'intermediate', - '8', - '', - '2019-05-18', - '2019-10-18', - '2023-06-23 00:00:00', - '2023-07-26 19:50:22' - ), - ( - 137, - 'kinase-inhibition-challenge', - 'Kinase inhibition challenge', - 'Protein kinases have become a major class of drug targets, accumulating a hu...', - 'Protein kinases have become a major class of drug targets, accumulating a huge amount of data', - 'https://www.kaggle.com/competitions/kinase-inhibition-challenge', - 'completed', - 'intermediate', - '8', - '', - '2019-05-20', - '2019-12-28', - '2023-06-23 00:00:00', - '2023-07-26 19:50:22' - ), - ( - 138, - 'ai-drug-discovery', - 'AI Drug Discovery Workshop and Coding Challenge', - 'Developing Fundamental AI Programming Skills for Drug Discovery', - 'Developing Fundamental AI Programming Skills for Drug Discovery', - 'https://www.kaggle.com/competitions/ai-drug-discovery', - 'completed', - 'intermediate', - '8', - '', - '2021-11-12', - '2021-12-31', - '2023-06-23 00:00:00', - '2023-07-26 19:50:23' - ), - ( - 139, - 'protein-compound-affinity', - 'Structure-free protein-ligand affinity prediction - Task 1 Fitting', - 'Developing new AI models for drug discovery, main portal (Task-1 fitting)', - 'Developing new AI models for drug discovery, main portal (Task-1 fitting)', - 'https://www.kaggle.com/competitions/protein-compound-affinity', - 'completed', - 'intermediate', - '8', - '', - '2021-12-06', - '2021-12-31', - '2023-06-23 00:00:00', - '2023-07-26 19:50:24' - ), - ( - 140, - 'cisc873-dm-f21-a5', - 'CISC873-DM-F21-A5', - 'Anti-Cancer Drug Activity Prediction', - 'Anti-Cancer Drug Activity Prediction', - 'https://www.kaggle.com/competitions/cisc873-dm-f21-a5', - 'completed', - 'intermediate', - '8', - '', - '2021-11-26', - '2021-12-10', - '2023-06-23 00:00:00', - '2023-07-26 19:50:24' - ), - ( - 141, - 'pro-lig-aff-task2-mse', - 'Structure-free protein-ligand affinity prediction - Task 2 Fitting', - 'Developing new AI models for drug discovery (Task-2 fitting)', - 'Developing new AI models for drug discovery (Task-2 fitting)', - 'https://www.kaggle.com/competitions/pro-lig-aff-task2-mse', - 'completed', - 'intermediate', - '8', - '', - '2021-12-08', - '2021-12-31', - '2023-06-23 00:00:00', - '2023-07-26 19:50:25' - ), - ( - 142, - 'pro-lig-aff-task1-pearsonr', - 'Structure-free protein-ligand affinity prediction - Task 1 Ranking', - 'Developing new AI models for drug discovery (Task-1 ranking)', - 'Developing new AI models for drug discovery (Task-1 ranking)', - 'https://www.kaggle.com/competitions/pro-lig-aff-task1-pearsonr', - 'completed', - 'intermediate', - '8', - '', - '2021-12-08', - '2021-12-31', - '2023-06-23 00:00:00', - '2023-07-26 19:50:25' - ), - ( - 143, - 'pro-lig-aff-task2-pearsonr', - 'Structure-free protein-ligand affinity prediction - Task 2 Ranking', - 'Developing new AI models for drug discovery (Task-2 ranking)', - 'Developing new AI models for drug discovery (Task-2 ranking)', - 'https://www.kaggle.com/competitions/pro-lig-aff-task2-pearsonr', - 'completed', - 'intermediate', - '8', - '', - '2021-12-08', - '2021-12-31', - '2023-06-23 00:00:00', - '2023-07-26 19:50:38' - ), - ( - 144, - 'pro-lig-aff-task3-spearmanr', - 'Structure-free protein-ligand affinity prediction - Task 3 Ranking', - 'Developing new AI models for drug discovery (Task-3 ranking)', - 'Developing new AI models for drug discovery (Task-3 ranking)', - 'https://www.kaggle.com/competitions/pro-lig-aff-task3-spearmanr', - 'completed', - 'intermediate', - '8', - '', - '2021-12-08', - '2021-12-31', - '2023-06-23 00:00:00', - '2023-07-26 19:50:39' - ), - ( - 145, - 'hhp', - 'Heritage Health Prize', - 'Identify patients who will be admitted to a hospital within the next year us...', - 'Identify patients who will be admitted to a hospital within the next year using historical claims data. (Enter by 06:59:59 UTC Oct 4 2012)', - 'https://www.kaggle.com/competitions/hhp', - 'completed', - 'intermediate', - '8', - '', - '2011-04-04', - '2013-04-04', - '2023-06-23 00:00:00', - '2023-07-26 19:50:39' - ), - ( - 146, - 'pf2012', - 'Practice Fusion Analyze This! 2012 - Prediction Challenge', - 'Start digging into electronic health records and submit your ideas for the m...', - 'Start digging into electronic health records and submit your ideas for the most promising, impactful or interesting predictive modeling competitions', - 'https://www.kaggle.com/competitions/pf2012', - 'completed', - 'intermediate', - '8', - '', - '2012-06-07', - '2012-06-30', - '2023-06-23 00:00:00', - '2023-07-26 19:50:40' - ), - ( - 147, - 'pf2012-at', - 'Practice Fusion Analyze This! 2012 - Open Challenge', - 'Start digging into electronic health records and submit your creative, insig...', - 'Start digging into electronic health records and submit your creative, insightful, and visually striking analyses.', - 'https://www.kaggle.com/competitions/pf2012-at', - 'completed', - 'intermediate', - '8', - '', - '2012-06-07', - '2012-09-10', - '2023-06-23 00:00:00', - '2023-07-26 19:50:41' - ), - ( - 148, - 'seizure-detection', - 'UPenn and Mayo Clinic''s Seizure Detection Challenge', - 'Detect seizures in intracranial EEG recordings', - 'Detect seizures in intracranial EEG recordings', - 'https://www.kaggle.com/competitions/seizure-detection', - 'completed', - 'intermediate', - '8', - '', - '2014-05-19', - '2014-08-19', - '2023-06-23 00:00:00', - '2023-07-26 19:50:41' - ), - ( - 149, - 'seizure-prediction', - 'American Epilepsy Society Seizure Prediction Challenge', - 'Predict seizures in intracranial EEG recordings', - 'Predict seizures in intracranial EEG recordings', - 'https://www.kaggle.com/competitions/seizure-prediction', - 'completed', - 'intermediate', - '8', - '', - '2014-08-25', - '2014-11-17', - '2023-06-23 00:00:00', - '2023-07-26 19:50:42' - ), - ( - 150, - 'deephealth-1', - 'Deep Health - alcohol', - 'Find Correlations and patterns with Medical data', - 'Find Correlations and patterns with Medical data', - 'https://www.kaggle.com/competitions/deephealth-1', - 'completed', - 'intermediate', - '8', - '', - '2017-02-13', - '2017-02-19', - '2023-06-23 00:00:00', - '2023-07-26 19:50:44' - ), - ( - 151, - 'deep-health-3', - 'Deep Health - Diabetes 2', - 'This competition is for those attending the Deep Health Hackathon. Predict ...', - 'This competition is for those attending the Deep Health Hackathon. Predict the next occurrence of diabetes', - 'https://www.kaggle.com/competitions/deep-health-3', - 'completed', - 'intermediate', - '8', - '', - '2017-02-15', - '2017-02-19', - '2023-06-23 00:00:00', - '2023-07-26 19:50:44' - ), - ( - 152, - 'd012554-2021', - 'D012554 - 2021', - 'Classify the health of a fetus using CTG data', - 'Classify the health of a fetus using CTG data', - 'https://www.kaggle.com/competitions/d012554-2021', - 'completed', - 'intermediate', - '8', - '', - '2021-04-11', - '2021-05-09', - '2023-06-23 00:00:00', - '2023-07-26 19:50:45' - ), - ( - 153, - 'idao-2022-bootcamp-insomnia', - 'IDAO 2022. ML Bootcamp - Insomnia', - 'Predict sleep disorder on given human health data', - 'Predict sleep disorder on given human health data', - 'https://www.kaggle.com/competitions/idao-2022-bootcamp-insomnia', - 'completed', - 'intermediate', - '8', - '', - '2021-12-04', - '2021-12-05', - '2023-06-23 00:00:00', - '2023-07-26 19:50:46' - ), - ( - 154, - 'tweet-mental-health-classification', - 'Tweet Mental Health Classification', - 'Build Models to classify tweets to determine mental health', - 'Build Models to classify tweets to determine mental health', - 'https://www.kaggle.com/competitions/tweet-mental-health-classification', - 'completed', - 'intermediate', - '8', - '', - '2021-12-27', - '2022-01-31', - '2023-06-23 00:00:00', - '2023-07-26 19:50:46' - ), - ( - 155, - 'ml-olympiad-good-health-and-well-being', - 'ML Olympiad - GOOD HEALTH AND WELL BEING', - 'Use your ML expertise to classify if a patient has heart disease or not', - 'Use your ML expertise to classify if a patient has heart disease or not', - 'https://www.kaggle.com/competitions/ml-olympiad-good-health-and-well-being', - 'completed', - 'intermediate', - '8', - '', - '2022-02-03', - '2022-03-01', - '2023-06-23 00:00:00', - '2023-07-26 19:50:47' - ), - ( - 156, - 'rsna-breast-cancer-detection', - 'RSNA Screening Mammography Breast Cancer Detection', - 'Find breast cancers in screening mammograms', - 'Find breast cancers in screening mammograms', - 'https://www.kaggle.com/competitions/rsna-breast-cancer-detection', - 'completed', - 'intermediate', - '8', - '', - '2022-11-28', - '2023-02-27', - '2023-06-23 00:00:00', - '2023-08-09 08:47:37' - ), - ( - 157, - 'biocreative-vii-text-mining-drug-and-chemical-protein-interactions-drugprot', - 'BioCreative VII: Text mining drug and chemical-protein interactions (DrugProt)', - '', - 'With the rapid accumulation of biomedical literature, it is getting increasingly challenging to exploit efficiently drug-related information described in the scientific literature. One of the most relevant aspects of drugs and chemical compounds are their relationships with certain biomedical entities, in particular genes and proteins. - The aim of the DrugProt track (similar to the previous CHEMPROT task of BioCreative VI) is to promote the development and evaluation of systems that are able to automatically detect in relations between chemical compounds/drug and genes/proteins. - There are a range of different types of drug-gene/protein interactions, and their systematic extraction and characterization is essential to analyze, predict and explore key biomedical properties underlying high impact biomedical applications. These application scenarios include use cases related to drug discovery, drug repurposing, drug design, metabolic engineering, modeling drug response, pharmacogenet...', - 'https://biocreative.bioinformatics.udel.edu/tasks/biocreative-vii/track-1/', - 'completed', - 'intermediate', - '7', - '', - '2021-06-15', - '2021-09-22', - '2023-06-23 00:00:00', - '2023-07-26 19:50:48' - ), - ( - 158, - 'extended-literature-ai-for-drug-induced-liver-injury', - 'Extended Literature AI for Drug Induced Liver Injury', - '', - 'Unexpected Drug-Induced Liver Injury (DILI) still is one of the main killers of promising novel drug candidates. It is a clinically significant disease that can lead to severe outcomes such as acute liver failure and even death. It remains one of the primary liabilities in drug development and regulatory clearance due to the limited performance of mandated preclinical models even today. The free text of scientific publications is still the main medium carrying DILI results from clinical practice or experimental studies. The textual data still has to be analysed manually. This process, however, is tedious and prone to human mistakes or omissions, as results are very rarely available in a standardized form or organized form. There is thus great hope that modern techniques from machine learning or natural language processing could provide powerful tools to better process and derive the underlying knowledge within free form texts. The pressing need to faster process potential drug can...', - 'http://camda2022.bioinf.jku.at/contest_dataset#extended_literature_ai_for_drug_induced_liver_injury', - 'completed', - 'intermediate', - '7', - '', - NULL, - '2022-05-20', - '2023-06-23 00:00:00', - '2023-07-26 19:50:49' - ), - ( - 159, - 'anti-microbial-resistance-forensics', - 'Anti-Microbial Resistance Forensics', - '', - 'Bacteriophages, being the re-occuring mystery in the history of science are believed to be they key for understanding of microbial evolution and the transfer of AMR genes. Recent studies show that there is a significant correlation between occurence of Phages and AMR genes, indicating that they are indeed taking part in the spread of them. While taking part in AMR dissemination the phages are also considered as the potential alternative to antibiotics. In such contradictory world there is a huge potential as well as urgent need for precise classification, description and analysis of capabilities. Due to pandemic of SARS-CoV-2, advance in phylogenetic algorithms and k-mer based methods have been extremely rapid and those improvements are witing to be adapted to different branches of life sciences.', - 'http://camda2022.bioinf.jku.at/contest_dataset#anti-microbial_resistance_forensics', - 'completed', - 'intermediate', - '7', - '', - NULL, - '2022-05-20', - '2023-06-23 00:00:00', - '2023-07-26 19:50:49' - ), - ( - 160, - 'disease-maps-to-modelling-covid-19', - 'Disease Maps to Modelling COVID-19', - 'Use the COVID-19 disease map to suggest drugs candidate for repurposing, tha...', - 'The Disease Maps to modeling COVID-19 Challenge provides highly detailed expert-curated molecular mechanistic maps for COVID-19. Combine them with available omic data to expand the current biological knowledge on COVID-19 mechanism of infection and downstream consequences. The main topic for this year''s challenge is drug repurposing with the possibility of Real World Data based validation of the most promising candidates suggested.', - 'http://camda2022.bioinf.jku.at/contest_dataset#disease_maps_to_modelling_covid-19', - 'completed', - 'intermediate', - '7', - '', - NULL, - '2022-05-20', - '2023-06-23 00:00:00', - '2023-07-26 19:50:50' - ), - ( - 161, - 'crowdsourced-evaluation-of-inchi-based-tautomer-identification', - 'Crowdsourced Evaluation of InChI-based Tautomer Identification', - 'Calling on scientists from industry, government, and academia dealing with c...', - 'This challenge focuses on the International Chemical Identifier (InChI), which was developed and is maintained under the auspices of the International Union of Pure and Applied Chemistry (IUPAC) and the InChI Trust. The InChI Trust, the IUPAC Working Group on Tautomers, and the U.S. Food and Drug Administration (FDA) call on the scientific community dealing with chemical repositories/data sets and analytics of compounds to test the recently modified InChI algorithm, which was designed for advanced recognition of tautomers. Participants will evaluate this algorithm against real chemical samples in this Crowdsourced Evaluation of InChI-based Tautomer Identification.', - 'https://precision.fda.gov/challenges/29', - 'completed', - 'intermediate', - '6', - '', - '2022-11-01', - '2023-03-01', - '2023-06-23 00:00:00', - '2023-07-26 19:50:51' - ), - ( - 162, - 'nctr-indel-calling-from-oncopanel-sequencing-challenge-phase-2', - 'NCTR Indel Calling from Oncopanel Sequencing Challenge Phase 2', - 'In Phase 2, participants who completed in Phase 1 of the challenge have the ...', - 'The high value of clinically actionable information obtained by oncopanel sequencing makes it a crucial tool for precision oncology[1,2]. With the surge in availability of oncopanels, it is critical to ensure that they have been thoroughly tested and are properly used. FDA has initiated the Sequencing Quality Control phase II (SEQC2) project[3] to develop standard analysis protocols and quality control metrics for fit-for-purpose use of Next Generation Sequencing (NGS) data including oncopanel sequencing to inform regulatory science research and precision medicine. The Oncopanel Sequencing Working Group of FDA-led SEQC2 has developed a reference sample[4] suitable for benchmarking oncopanels and comprehensively assessed the analytical performance of several oncopanels[1,2]. The genomic deoxyribonucleic acid (gDNA) reference sample was derived from ten Universal Human Reference RNA (UHRR, Agilent Technologies, Inc) cell-lines and made publicly available by Agilent. Substantial gene...', - 'https://precision.fda.gov/challenges/22', - 'completed', - 'intermediate', - '6', - '', - '2022-07-11', - '2022-07-26', - '2023-06-23 00:00:00', - '2023-07-26 19:50:51' - ), - ( - 163, - 'nctr-indel-calling-from-oncopanel-sequencing-data-challenge-phase-1', - 'NCTR Indel Calling from Oncopanel Sequencing Data Challenge Phase 1', - 'Genetic variation involving indels (insertions and deletions) in the cancer ...', - 'The high value of clinically actionable information obtained by oncopanel sequencing makes it a crucial tool for precision oncology[1,2]. With the surge in availability of oncopanels, it is critical to ensure that they have been thoroughly tested and are properly used. FDA has initiated the Sequencing Quality Control phase II (SEQC2) project[3] to develop standard analysis protocols and quality control metrics for fit-for-purpose use of Next Generation Sequencing (NGS) data including oncopanel sequencing to inform regulatory science research and precision medicine. The Oncopanel Sequencing Working Group of FDA-led SEQC2 has developed a reference sample[4] suitable for benchmarking oncopanels and comprehensively assessed the analytical performance of several oncopanels[1,2]. The genomic deoxyribonucleic acid (gDNA) reference sample was derived from ten Universal Human Reference RNA (UHRR, Agilent Technologies, Inc) cell-lines and made publicly available by Agilent. Substantial gene...', - 'https://precision.fda.gov/challenges/21', - 'completed', - 'intermediate', - '6', - '', - '2022-05-02', - '2022-07-08', - '2023-06-23 00:00:00', - '2023-07-26 19:50:54' - ), - ( - 164, - 'vha-innovation-ecosystem-and-precisionfda-covid-19-risk-factor-modeling-challenge-phase-2', - 'VHA Innovation Ecosystem and precisionFDA COVID-19 Risk Factor Modeling Challenge Phase 2', - 'The focus of Phase 2 was to validate the top performing models on two additi...', - 'The novel coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a new type of coronavirus, known as “severe acute respiratory syndrome coronavirus 2,” or SARS-CoV-2. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a global pandemic. As of January 22nd, 2022, the Johns Hopkins University COVID-19 dashboard reports over 338 million total confirmed cases worldwide. Although most people have mild to moderate symptoms, the disease can cause severe medical complications leading to death in some people. The Centers for Disease Control and Prevention (CDC) have identified several risk factors for severe COVID-19 illness, including people 65 years and older, individuals living in nursing homes or long-term care facilities, and those with serious underlying medical conditions. The Veteran population has a higher prevalence of several of the known risk factors for severe COVID-19 illness, such as advanced age, heart disease, and diabetes. Identif...', - 'https://precision.fda.gov/challenges/20', - 'completed', - 'intermediate', - '6', - '', - '2021-04-14', - '2022-01-28', - '2023-06-23 00:00:00', - '2023-07-26 19:50:54' - ), - ( - 165, - 'tumor-mutational-burden-tmb-challenge-phase-2', - 'Tumor Mutational Burden (TMB) Challenge Phase 2', - 'The goal of the Friends of Cancer Research and precisionFDA Tumor Mutational...', - 'Tumor mutational burden (TMB) is generally defined as the number of mutations detected in a patient''s tumor sample per megabase of DNA sequenced. However different algorithms use different methods for calculating TMB. Mutations in genes in tumor cells may lead to the creation of neoantigens, which have the potential to activate an immune system response against the tumor, and the likelihood of an immune system response may increase with the number of mutations. Thus, TMB is a biomarker for some immunotherapy drugs, called immune checkpoint inhibitors, such as those that target the PD-1 and PD-L1 pathways (Chan et al., 2019). An outstanding problem is the lack of standardization for TMB calculation and reporting between different assays. To address this problem, the Friends of Cancer Research convened a working group of industry and regulatory stakeholders to develop guidance and tools for TMB harmonization. Results from the first phase of this effort were presented at AACR 2020 (...', - 'https://precision.fda.gov/challenges/18', - 'completed', - 'intermediate', - '6', - '', - '2021-07-19', - '2021-09-12', - '2023-06-23 00:00:00', - '2023-07-26 19:50:55' - ), - ( - 166, - 'predicting-gene-expression-using-millions-of-random-promoter-sequences', - 'Predicting Gene Expression Using Millions of Random Promoter Sequences', - '', - 'Decoding how gene expression is regulated is critical to understanding disease. Regulatory DNA is decoded by the cell in a process termed “cis-regulatory logic”, where proteins called Transcription Factors (TFs) bind to specific DNA sequences within the genome and work together to produce as output a level of gene expression for downstream adjacent genes. This process is exceedingly complex to model as a large number of parameters is needed to fully describe the process (see Rationale, de Boer et al. 2020; Zeitingler J. 2020). Understanding the cis-regulatory logic of the human genome is an important goal and would provide insight into the origins of many diseases. However, learning models from human data is challenging due to limitations in the diversity of sequences present within the human genome (e.g. extensive repetitive DNA), the vast number of cell types that differ in how they interpret regulatory DNA, limited reporter assay data, and substantial technical biases present i...', - 'https://www.synapse.org/#!Synapse:syn28469146/wiki/617075', - 'completed', - 'intermediate', - '1', - '', - '2022-06-15', - '2022-08-07', - '2023-06-23 00:00:00', - '2023-08-07 20:20:45' - ), - ( - 167, - 'brats-2023', - 'BraTS 2023', - '', - 'The International Brain Tumor Segmentation (BraTS) challenge. BraTS, since 2012, has focused on the generation of a benchmarking environment and dataset for the delineation of adult brain gliomas. The focus of this year’s challenge remains the generation of a common benchmarking environment, but its dataset is substantially expanded to ~4,500 cases towards addressing additional i) populations (e.g., sub-Saharan Africa patients), ii) tumors (e.g., meningioma), iii) clinical concerns (e.g., missing data), and iv) technical considerations (e.g., augmentations). Specifically, the focus of BraTS 2023 is to identify the current state-of-the-art algorithms for addressing (Task 1) the same adult glioma population as in the RSNA-ANSR-MICCAI BraTS challenge, as well as (Task 2) the underserved sub-Saharan African brain glioma patient population, (Task 3) intracranial meningioma, (Task 4) brain metastasis, (Task 5) pediatric brain tumor patients, (Task 6) global & local missing data, (Task 7...', - 'https://www.synapse.org/brats', - 'active', - 'advanced', - '1', - '', - '2023-06-01', - '2023-08-25', - '2023-06-23 00:00:00', - '2023-08-04 21:51:07' - ), - ( - 168, - 'cagi7', - 'CAGI7', - 'The seventh round of CAGI', - 'There have been six editions of CAGI experiments, held between 2010 and 2022. The seventh round of CAGI is planned to take place over the Summer of 2024.', - 'https://genomeinterpretation.org/challenges.html', - 'upcoming', - 'intermediate', - '2', - '', - NULL, - NULL, - '2023-08-04 21:47:38', - '2023-08-08 18:52:54' - ), - ( - 169, - 'casp15', - 'CASP15', - 'Establish the state-of-art in modeling proteins and protein complexes', - 'CASP14 (2020) saw an enormous jump in the accuracy of single protein and domain models such that many are competitive with experiment. That advance is largely the result of the successful application of deep learning methods, particularly by the AlphaFold and, since that CASP, RosettaFold. As a consequence, computed protein structures are becoming much more widely used in a broadening range of applications. CASP has responded to this new landscape with a revised set of modeling categories. Some old categories have been dropped (refinement, contact prediction, and aspects of model accuracy estimation) and new ones have been added (RNA structures, protein ligand complexes, protein ensembles, and accuracy estimation for protein complexes). We are also strengthening our interactions with our partners CAPRI and CAMEO. We hope that these changes will maximize the insight that CASP15 provides, particularly in new applications of deep learning. ', - 'https://predictioncenter.org/casp15/index.cgi', - 'completed', - 'intermediate', - '4', - '', - '2022-04-18', - NULL, - '2023-08-04 21:52:12', - '2023-08-08 18:52:57' - ), - ( - 170, - 'synthrad2023', - 'SynthRAD2023', - 'Synthesizing computed tomography for radiotherapy', - 'This challenge aims to provide the first platform offering public data evaluation metrics to compare the latest developments in sCT generation methods. The accepted challenge design approved by MICCAI can be found at https://doi.org/10.5281/zenodo.7746019. A type 2 challenge will be run, where the participant needs to submit their algorithm packaged in a docker both for validation and test.', - 'https://synthrad2023.grand-challenge.org/', - 'active', - 'intermediate', - '5', - '', - '2023-04-01', - '2023-08-22', - '2023-08-04 21:54:31', - '2023-08-07 20:20:05' - ), - ( - 171, - 'syn-iss', - 'Synthetic Data for Instrument Segmentation in Surgery (Syn-ISS)', - '', - 'A common limitation noted by the surgical data science community is the size of datasets and the resources needed to generate training data at scale for building reliable and high-performing machine learning models. Beyond unsupervised and self-supervised approaches another solution within the broader machine learning community has been a growing volume of literature in the use of synthetic data (simulation) for training algorithms than can be applied to real world data. Synthetic data has multiple benefits like free groundtruth at large scale, possibility to collect larger sample of rare events, include anatomical variations, etc. A first step towards proving the validity of using synthetic data for real world applications is to demonstrate the feasibility within the simulation world itself. Our proposed challenge is to train machine learning methods for instrument segmentation using synthetic datasets and test their performance on synthetic datasets. That is, the challenge parti...', - 'https://www.synapse.org/#!Synapse:syn50908388/wiki/620516', - 'active', - 'intermediate', - '1', - '', - '2023-07-19', - '2023-09-07', - '2023-08-04 23:49:44', - '2023-08-07 20:20:07' - ), - ( - 172, - 'pitvis', - 'PitVis', - 'Surgical workflow and instrument recognition in endonasal surgery', - 'The pituitary gland, found just off the base of the brain, is commonly known as “the master gland”, performing essential functions required for sustaining human life. Clinically relevant tumours that have grown on the pituitary gland have an estimated prevalence of 1 in 1000 of the population, and if left untreated can be life-limiting. The “gold standard” treatment is endoscopic pituitary surgery, where the tumour is directly removed by entering through a nostril. This surgery is particularly challenging due to the small working space which limits both vision and instrument manoeuvrability and thus can lead to poor surgical technique causing adverse outcomes for the patient. Computer-assisted intervention can help overcome these challenges by providing guidance for senior surgeons and operative staff during surgery, and for junior surgeons during training.', - 'https://www.synapse.org/#!Synapse:syn51232283/wiki/', - 'active', - 'intermediate', - '1', - '', - '2023-06-29', - '2023-09-10', - '2023-08-04 23:58:01', - '2023-08-07 20:20:08' - ), - ( - 173, - 'mvseg2023', - 'MVSEG2023', - 'Automatically segment mitral valve leaflets from single frame 3D trans-esoph...', - 'Mitral valve (MV) disease is a common pathologic problem occurring in approximately 2 % of the general population but climbing to 10 % in those over the age of 75. The preferred intervention for mitral regurgitation is valve repair, due to superior patient outcomes compared to those following valve replacement. Mitral valve interventions are technically challenging due to the functional and anatomical complexity of mitral pathologies. Repair must be tailored to the patient-specific anatomy and pathology, which requires considerable expert training and experience. Automatic segmentation of the mitral valve leaflets from 3D transesophageal echocardiography (TEE) may play an important role in treatment planning, as well as physical and computational modelling of patient-specific valve pathologies and potential repair approaches. This may have important implications in the drive towards personalized care and has the potential to impact clinical outcomes for those undergoing mitral val...', - 'https://www.synapse.org/#!Synapse:syn51186045/wiki/621356', - 'completed', - 'intermediate', - '1', - '', - '2023-05-29', - '2023-08-07', - '2023-08-05 0:04:36', - '2023-08-05 0:06:32' - ), - ( - 174, - 'crossmoda23', - 'CrossMoDA23', - 'This challenge proposes is the third edition of the first medical imaging be...', - 'Domain Adaptation (DA) has recently raised strong interest in the medical imaging community. By encouraging algorithms to be robust to unseen situations or different input data domains, Domain Adaptation improves the applicability of machine learning approaches to various clinical settings. While a large variety of DA techniques has been proposed, most of these techniques have been validated either on private datasets or on small publicly available datasets. Moreover, these datasets mostly address single-class problems. To tackle these limitations, the crossMoDA challenge introduced the first large and multi-class dataset for unsupervised cross-modality Domain Adaptation. From an application perspective, crossMoDA focuses on MRI segmentation for Vestibular Schwannoma. Compared to the previous crossMoDA instance, which made use of multi-institutional data acquired in controlled conditions for radiosurgery planning and focused on a 2 class segmentation task (tumour and cochlea), the...', - 'https://www.synapse.org/#!Synapse:syn51236108/wiki/621615', - 'completed', - 'intermediate', - '1', - '', - '2023-04-15', - '2023-07-10', - '2023-08-05 0:13:23', - '2023-08-05 0:22:59' - ), - ( - 175, - 'icr-identify-age-related-conditions', - 'ICR - Identifying Age-Related Conditions', - 'Use Machine Learning to detect conditions with measurements of anonymous cha...', - 'The goal of this competition is to predict if a person has any of three medical conditions. You are being asked to predict if the person has one or more of any of the three medical conditions (Class 1), or none of the three medical conditions (Class 0). You will create a model trained on measurements of health characteristics. To determine if someone has these medical conditions requires a long and intrusive process to collect information from patients. With predictive models, we can shorten this process and keep patient details private by collecting key characteristics relative to the conditions, then encoding these characteristics.', - 'https://www.kaggle.com/competitions/icr-identify-age-related-conditions', - 'completed', - 'intermediate', - '8', - '', - '2023-05-11', - '2023-08-10', - '2023-08-05 0:32:01', - '2023-08-08 21:59:15' - ), - ( - 176, - 'cafa-5-protein-function-prediction', - 'CAFA 5 Protein Function Prediction', - 'Predict the biological function of a protein', - 'The goal of this competition is to predict the function of a set of proteins. You will develop a model trained on the amino-acid sequences of the proteins and on other data. Your work will help ​​researchers better understand the function of proteins, which is important for discovering how cells, tissues, and organs work. This may also aid in the development of new drugs and therapies for various diseases.', - 'https://www.kaggle.com/competitions/cafa-5-protein-function-prediction', - 'completed', - 'intermediate', - '8', - '', - '2023-04-18', - '2023-08-21', - '2023-08-05 5:18:40', - '2023-08-07 20:20:11' - ), - ( - 177, - 'rsna-2023-abdominal-trauma-detection', - 'RSNA 2023 Abdominal Trauma Detection', - 'Detect and classify traumatic abdominal injuries', - 'Traumatic injury is the most common cause of death in the first four decades of life and a major public health problem around the world. There are estimated to be more than 5 million annual deaths worldwide from traumatic injury. Prompt and accurate diagnosis of traumatic injuries is crucial for initiating appropriate and timely interventions, which can significantly improve patient outcomes and survival rates. Computed tomography (CT) has become an indispensable tool in evaluating patients with suspected abdominal injuries due to its ability to provide detailed cross-sectional images of the abdomen. Interpreting CT scans for abdominal trauma, however, can be a complex and time-consuming task, especially when multiple injuries or areas of subtle active bleeding are present. This challenge seeks to harness the power of artificial intelligence and machine learning to assist medical professionals in rapidly and precisely detecting injuries and grading their severity. The development ...', - 'https://www.kaggle.com/competitions/rsna-2023-abdominal-trauma-detection', - 'active', - 'intermediate', - '8', - '', - '2023-07-26', - '2023-10-13', - '2023-08-05 5:24:09', - '2023-08-07 20:20:12' - ), - ( - 178, - 'hubmap-hacking-the-human-vasculature', - 'HuBMAP - Hacking the Human Vasculature', - 'Segment instances of microvascular structures from healthy human kidney tiss...', - 'The goal of this competition is to segment instances of microvascular structures, including capillaries, arterioles, and venules. You''ll create a model trained on 2D PAS-stained histology images from healthy human kidney tissue slides. Your help in automating the segmentation of microvasculature structures will improve researchers'' understanding of how the blood vessels are arranged in human tissues.', - 'https://www.kaggle.com/competitions/hubmap-hacking-the-human-vasculature', - 'completed', - 'intermediate', - '8', - '', - '2023-05-22', - '2023-07-31', - '2023-08-05 5:31:12', - '2023-08-05 5:36:41' - ), - ( - 179, - 'amp-parkinsons-disease-progression-prediction', - 'AMP(R)-Parkinson''s Disease Progression Prediction', - 'Use protein and peptide data measurements from Parkinson''s Disease patients...', - 'The goal of this competition is to predict MDS-UPDR scores, which measure progression in patients with Parkinson''s disease. The Movement Disorder Society-Sponsored Revision of the Unified Parkinson''s Disease Rating Scale (MDS-UPDRS) is a comprehensive assessment of both motor and non-motor symptoms associated with Parkinson''s. You will develop a model trained on data of protein and peptide levels over time in subjects with Parkinson’s disease versus normal age-matched control subjects. Your work could help provide important breakthrough information about which molecules change as Parkinson’s disease progresses.', - 'https://www.kaggle.com/competitions/amp-parkinsons-disease-progression-prediction', - 'completed', - 'intermediate', - '8', - '', - '2023-02-16', - '2023-05-18', - '2023-08-05 5:37:12', - '2023-08-05 5:39:03' - ), - ( - 180, - 'open-problems-multimodal', - 'Open Problems - Multimodal Single-Cell Integration', - 'Predict how DNA, RNA & protein measurements co-vary in single cells', - 'The goal of this competition is to predict how DNA, RNA, and protein measurements co-vary in single cells as bone marrow stem cells develop into more mature blood cells. You will develop a model trained on a subset of 300,000-cell time course dataset of CD34+ hematopoietic stem and progenitor cells (HSPC) from four human donors at five time points generated for this competition by Cellarity, a cell-centric drug creation company. In the test set, taken from an unseen later time point in the dataset, competitors will be provided with one modality and be tasked with predicting a paired modality measured in the same cell. The added challenge of this competition is that the test data will be from a later time point than any time point in the training data. Your work will help accelerate innovation in methods of mapping genetic information across layers of cellular state. If we can predict one modality from another, we may expand our understanding of the rules governing these complex re...', - 'https://www.kaggle.com/competitions/open-problems-multimodal', - 'completed', - 'intermediate', - '8', - '', - '2022-08-15', - '2022-11-15', - '2023-08-05 5:43:25', - '2023-08-05 5:44:44' - ), - ( - 181, - 'multi-atlas-labeling-beyond-the-cranial-vault', - 'Multi-Atlas Labeling Beyond the Cranial Vault', - '', - 'Multi-atlas labeling has proven to be an effective paradigm for creating segmentation algorithms from training data. These approaches have been extraordinarily successful for brain and cranial structures (e.g., our prior MICCAI workshops: MLSF’11, MAL’12, SATA’13). After the original challenges closed, the data continue to drive scientific innovation; 144 groups have registered for the 2012 challenge (brain only) and 115 groups for the 2013 challenge (brain/heart/canine leg). However, innovation in application outside of the head and to soft tissues has been more limited. This workshop will provide a snapshot of the current progress in the field through extended discussions and provide researchers an opportunity to characterize their methods on a newly created and released standardized dataset of abdominal anatomy on clinically acquired CT. The datasets will be freely available both during and after the challenge. We have two separate new challenges: abdomen and cervix on routinel...', - 'https://www.synapse.org/#!Synapse:syn3193805/wiki/89480', - 'active', - 'intermediate', - '1', - '', - '2015-04-15', - NULL, - '2023-08-07 20:21:22', - '2023-08-10 5:38:08' - ), - ( - 182, - 'hubmap-organ-segmentation', - 'HuBMAP + HPA - Hacking the Human Body', - 'Segment multi-organ functional tissue units', - 'In this competition, you’ll identify and segment functional tissue units (FTUs) across five human organs. You''ll build your model using a dataset of tissue section images, with the best submissions segmenting FTUs as accurately as possible. If successful, you''ll help accelerate the world’s understanding of the relationships between cell and tissue organization. With a better idea of the relationship of cells, researchers will have more insight into the function of cells that impact human health. Further, the Human Reference Atlas constructed by HuBMAP will be freely available for use by researchers and pharmaceutical companies alike, potentially improving and prolonging human life.', - 'https://www.kaggle.com/competitions/hubmap-organ-segmentation', - 'completed', - 'intermediate', - '8', - '', - '2022-06-22', - '2022-09-22', - '2023-08-08 16:30:22', - '2023-08-08 21:47:25' - ), - ( - 183, - 'hubmap-kidney-segmentation', - 'HuBMAP - Hacking the Kidney', - 'Identify glomeruli in human kidney tissue images', - 'This competition, “Hacking the Kidney," starts by mapping the human kidney at single cell resolution. Your challenge is to detect functional tissue units (FTUs) across different tissue preparation pipelines. An FTU is defined as a “three-dimensional block of cells centered around a capillary, such that each cell in this block is within diffusion distance from any other cell in the same block” ([de Bono, 2013](https://www.ncbi.nlm.nih.gov/pubmed/24103658)). The goal of this competition is the implementation of a successful and robust glomeruli FTU detector. You will also have the opportunity to present your findings to a panel of judges for additional consideration. Successful submissions will construct the tools, resources, and cell atlases needed to determine how the relationships between cells can affect the health of an individual. Advancements in HuBMAP will accelerate the world’s understanding of the relationships between cell and tissue organization and function and human health.', - 'https://www.kaggle.com/competitions/hubmap-kidney-segmentation', - 'completed', - 'intermediate', - '8', - '', - '2020-11-16', - '2021-05-10', - '2023-08-08 17:31:46', - '2023-08-08 21:47:21' - ), - ( - 184, - 'ventilator-pressure-prediction', - 'Google Brain - Ventilator Pressure Prediction', - 'Simulate a ventilator connected to a sedated patient''s lung', - 'In this competition, you’ll simulate a ventilator connected to a sedated patient''s lung. The best submissions will take lung attributes compliance and resistance into account. If successful, you''ll help overcome the cost barrier of developing new methods for controlling mechanical ventilators. This will pave the way for algorithms that adapt to patients and reduce the burden on clinicians during these novel times and beyond. As a result, ventilator treatments may become more widely available to help patients breathe.', - 'https://www.kaggle.com/competitions/ventilator-pressure-prediction', - 'completed', - 'intermediate', - '8', - '', - '2021-09-22', - '2021-11-03', - '2023-08-08 17:53:33', - '2023-08-08 17:54:50' - ), - ( - 185, - 'stanford-covid-vaccine', - 'OpenVaccine: COVID-19 mRNA Vaccine Degradation Prediction', - 'Urgent need to bring the COVID-19 vaccine to mass production', - 'In this competition, we are looking to leverage the data science expertise of the Kaggle community to develop models and design rules for RNA degradation. Your model will predict likely degradation rates at each base of an RNA molecule, trained on a subset of an Eterna dataset comprising over 3000 RNA molecules (which span a panoply of sequences and structures) and their degradation rates at each position. We will then score your models on a second generation of RNA sequences that have just been devised by Eterna players for COVID-19 mRNA vaccines. These final test sequences are currently being synthesized and experimentally characterized at Stanford University in parallel to your modeling efforts -- Nature will score your models!', - 'https://www.kaggle.com/competitions/stanford-covid-vaccine', - 'completed', - 'intermediate', - '8', - '', - '2020-09-10', - '2020-10-06', - '2023-08-08 18:06:17', - '2023-08-08 18:07:30' - ), - ( - 186, - 'openvaccine', - 'OpenVaccine', - 'To develop mRNA vaccines stable enough to be deployed to everyone in the wor...', - 'mRNA vaccines are a relatively new technology that have come into the limelight with the onset of COVID-19. They were the first COVID-19 vaccines to start clinical trials (initially formulated in a matter of days) and the first to be approved and distributed. mRNA vaccines have the potential to transform immunization, being significantly faster to formulate and produce, cheaper, and more effective - including against mutant strains. However, there is one key bottleneck to their widespread viability and our ability to immunize the entire world: poor refrigerator stability in prefilled syringes. The OpenVaccine challenge aims to allow a worldwide community of game players to create an enhanced vaccine to be injected into millions of people. The challenge: design an mRNA that codes for the same amino acid sequence of the spike protein, but is 2x-10x+ more stable. Through a number of academic partnerships and the launch of a Kaggle machine learning challenge to create best-in-class al...', - 'https://eternagame.org/challenges/10845741', - 'completed', - 'intermediate', - '13', - 'https://doi.org/10.1038/s41467-022-28776-w', - NULL, - '2021-12-12', - '2023-08-08 18:22:49', - '2023-08-08 19:08:57' - ), - ( - 187, - 'opentb', - 'OpenTB', - 'What if we could use RNA to detect a gene sequence found to be present only ...', - 'OpenTB used a recently reported gene signature for active tuberculosis based on three RNAs in the blood. This signature could form the basis for a fast, color-based test for TB, similar to an over-the-counter pregnancy test. What was needed was a sensor that could detect the concentrations of three RNAs, carry out the needed calculation, and report the result by binding another molecule. Over four rounds, players designed RNA sensors that can do the math on these 3 genes. Through experimental feedback, they honed their skills and techniques, which resulted in the creation of multiple designs that have been shown to be successful. These findings are being prepared to be published, and future work will be done to develop diagnostic devices integrating these designs', - 'https://eternagame.org/challenges/10845742', - 'completed', - 'intermediate', - '13', - '', - '2016-05-04', - '2018-04-15', - '2023-08-08 18:43:09', - '2023-08-08 19:04:00' - ), - ( - 188, - 'opencrispr', - 'OpenCRISPR', - 'A project to discover design patterns for guide RNAs to make gene editing mo...', - 'CRISPR gene editing is a RNA-based method that can target essentially any gene in a living organism for genetic changes. Since its first demonstration, CRISPR has been revolutionizing biology and promises to change how we tackle numerous human diseases from malaria to cancer. Stanford''s Center for Personal Dynamic Regulomes and UC Berkeley''s Innovative Genomics Institute have challenged Eterna players to solve a remaining hurdle in making this technology safe for use. Scientists want the power to turn on and off CRISPR on demand with small molecules. This is almost a perfect match to the small-molecule switches that the Eterna community has worked on. In fact, the MS2 RNA hairpin often used in Eterna is routinely used to recruit new functionality to CRISPR complexes through other molecules tethered to the MS2 protein. The puzzles began with OpenCRISPR Controls, looking for solutions to lock in or lock out the MS2 RNA hairpin within a special loop in the CRISPR RNA. We hope the r...', - 'https://eternagame.org/challenges/10845743', - 'completed', - 'intermediate', - '13', - 'https://doi.org/10.1021/acssynbio.9b00142', - '2017-08-26', - NULL, - '2023-08-08 18:43:14', - '2023-08-10 5:38:26' - ), - ( - 189, - 'openknot', - 'OpenKnot', - 'Many important biological processes depend on RNAs that form pseudoknots, an...', - 'RNA pseudoknots have significant biological importance in various processes. They participate in gene regulation by influencing translation initiation or termination in mRNA molecules. Pseudoknots also play a role in programmed ribosomal frameshifting, leading to the production of different protein products from a single mRNA. RNA viruses, including SARS-CoV-2 and Dengue virus, utilize pseudoknots to regulate their replication and control the synthesis of viral proteins. Additionally, certain RNA molecules with pseudoknot structures exhibit enzymatic activity, acting as ribozymes and catalyzing biochemical reactions. These functions highlight the crucial role of RNA pseudoknots in gene expression, proteomic diversity, viral replication, and enzymatic processes. Several unanswered scientific questions surround RNA pseudoknots. One key area of inquiry is understanding the folding pathways of pseudoknots and how they form from linear RNA sequences. Elucidating the structural dynamics...', - 'https://eternagame.org/challenges/11843006', - 'active', - 'intermediate', - '13', - '', - '2022-06-17', - NULL, - '2023-08-08 18:43:22', - '2023-08-10 5:38:35' - ), - ( - 190, - 'openaso', - 'OpenASO', - 'A research initiative aimed at developing innovative design principles for R...', - 'The DNA genome is the blueprint for building and operating cells, but this information must be decoded into RNA molecules to be useful. Transcription is the process of decoding DNA genomic information into RNA, resulting in RNA transcripts. Genes are specific sequences of DNA that contain information to produce a specific RNA transcript. The fate of most mRNA molecules in the cell is to be translated by ribosomes into protein molecules. However, mRNA splicing is a crucial step that occurs between the formation of an RNA transcript and protein translation. This step is essential because genes contain non-protein coding introns and protein-coding exons. Splicing removes introns and joins exons to produce a mature mRNA molecule that can be decoded into the correct protein molecule. When the splicing process is corrupted due to genetic mutations, the resulting RNA can become toxic, leading to the synthesis of non-functional proteins or no protein at all, causing various human diseases...', - 'https://eternagame.org/challenges/11546273', - 'active', - 'intermediate', - '13', - '', - '2023-02-20', - NULL, - '2023-08-08 18:43:25', - '2023-08-10 5:38:36' - ), - ( - 191, - 'openribosome', - 'OpenRibosome', - 'We aim to 1) gain fundamental insights into the ribosome''s RNA sequence-fol...', - 'Our modern world has many challenges - challenges like climate change, increasing waste production, and human health. Imagine: we could replace petrochemistry with biology, single-use plastics with selectively degradable polymers, broad chemotherapeutics with targeted medicines for fighting specific cancer cells, and complex health equipment with point-of-care diagnostics. These innovations and many more can empower us to confront the challenges affecting humanity, our world, and beyond. But how do we actually create these smart materials and medicines? Is it possible to do so by repurposing one of Nature''s molecular machines? We think we can. The answer? Customized ribosomes. In Nature, ribosomes are the catalysts for protein assembly. And proteins are more or less similar, chemically, to the smart materials and medicines we want to synthesize. If we could modify ribosomes to build polymers with diverse components - beyond the canonical amino acids us', - 'https://eternagame.org/challenges/11043833', - 'active', - 'intermediate', - '13', - 'https://doi.org/10.1038/s41467-023-35827-3', - '2019-01-31', - NULL, - '2023-08-08 18:43:27', - '2023-08-10 5:42:45' - ), - ( - 192, - 'lish-moa', - 'Mechanisms of Action (MoA) Prediction', - 'Can you improve the algorithm that classifies drugs based on their biologica...', - 'Can you improve the algorithm that classifies drugs based on their biological activity?', - 'https://www.kaggle.com/competitions/lish-moa', - 'completed', - 'intermediate', - '8', - '', - '2020-09-03', - '2020-11-30', - '2023-08-08 19:09:31', - '2023-08-08 19:10:54' - ), - ( - 193, - 'recursion-cellular-image-classification', - 'Recursion Cellular Image Classification', - 'CellSignal: Disentangling biological signal from experimental noise in cellu...', - 'This competition will have you disentangling experimental noise from real biological signals. Your entry will classify images of cells under one of 1,108 different genetic perturbations. You can help eliminate the noise introduced by technical execution and environmental variation between experiments. If successful, you could dramatically improve the industry’s ability to model cellular images according to their relevant biology. In turn, applying AI could greatly decrease the cost of treatments, and ensure these treatments get to patients faster.', - 'https://www.kaggle.com/competitions/recursion-cellular-image-classification', - 'completed', - 'intermediate', - '8', - '', - '2019-06-27', - '2019-09-26', - '2023-08-08 19:38:42', - '2023-08-08 19:40:06' - ), - ( - 194, - 'tlvmc-parkinsons-freezing-gait-prediction', - 'Parkinson''s Freezing of Gait Prediction', - 'Event detection from wearable sensor data', - 'The goal of this competition is to detect freezing of gait (FOG), a debilitating symptom that afflicts many people with Parkinson’s disease. You will develop a machine learning model trained on data collected from a wearable 3D lower back sensor. Your work will help researchers better understand when and why FOG episodes occur. This will improve the ability of medical professionals to optimally evaluate, monitor, and ultimately, prevent FOG events.', - 'https://www.kaggle.com/competitions/tlvmc-parkinsons-freezing-gait-prediction', - 'completed', - 'intermediate', - '8', - '', - '2023-03-09', - '2023-06-08', - '2023-08-08 19:47:54', - '2023-08-08 21:47:57' - ), - ( - 195, - 'chaimeleon', - 'CHAIMELEON Open Challenges', - '', - 'The CHAIMELEON Open Challenges is a competition designed to train and refine AI models to answer clinical questions about five types of cancer: prostate, lung, breast, colon, and rectal. Participants are challenged to collaborate and develop innovative AI-powered solutions that can significantly impact cancer diagnosis, management, and treatment. They will be evaluated considering a balance between the performance of their AI algorithms to predict different clinical endpoints such as disease staging, treatment response or progression free survival and their trustworthiness. The challenges are open to the whole scientific and tech community interested in AI. They are a unique opportunity to showcase how AI can be used to advance medical research and improve patient outcomes within the CHAIMELEON project.', - 'https://chaimeleon.grand-challenge.org/', - 'upcoming', - 'intermediate', - '5', - '', - NULL, - '2023-12-31', - '2023-08-09 17:13:09', - '2023-08-09 22:40:12' - ), - ( - 196, - 'topcow23', - 'Topology-Aware Anatomical Segmentation of the Circle of Willis for CTA and MRA', - '', - 'The aim of the challenge is to extract the CoW angio-architecture from 3D angiographic imaging by segmentation of the vessel components. There are two sub-tasks: binary segmentation of CoW vessels, and multi-class CoW anatomical segmentation. We release a new dataset of joint-modalities, CTA and MRA of the same patient cohort, both with annotations of the anatomy of CoW. Our challenge has two tracks for the same segmentation task, namely CTA track and MRA track. We made use of the clinical information from both modalities during our annotation. And participants can pick whichever modality they want, both CTA and MRA, and choose to tackle the task for either modality.', - 'https://topcow23.grand-challenge.org/', - 'active', - 'intermediate', - '5', - '', - '2023-08-20', - '2023-09-25', - '2023-08-09 17:16:22', - '2023-08-09 22:41:03' - ), - ( - 197, - 'crown2023', - 'Circle of Willis Intracranial Artery Classification and Quantification Challenge 2023', - '', - 'The purpose of this challenge is to compare automatic methods for classification of the circle of Willis (CoW) configuration and quantification of the CoW major artery diameters and bifurcation angles.', - 'https://crown.isi.uu.nl/', - 'completed', - 'intermediate', - '14', - '', - '2023-05-01', - '2023-08-15', - '2023-08-09 22:13:24', - '2023-08-10 5:44:38' - ), - ( - 198, - 'making-sense-of-electronic-health-record-ehr-race-and-ethnicity-data', - 'Making Sense of Electronic Health Record (EHR) Race and Ethnicity Data', - 'The US Food and Drug Administration (FDA) calls on stakeholders, including t...', - 'The urgency of the coronavirus disease 2019 (COVID-19) pandemic has heightened interest in the use of real-world data (RWD) to obtain timely information about patients and populations and has focused attention on EHRs. The pandemic has also heightened awareness of long-standing racial and ethnic health disparities along a continuum from underlying social determinants of health, exposure to risk, access to insurance and care, quality of care, and responses to treatments. This highlighted the potential that EHRs can be used to describe and contribute to our understanding of racial and ethnic health disparities and their solutions. The OMB Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity provides minimum standards for maintaining, collecting, and presenting data on race and ethnicity for all Federal reporting purposes, and defines the two separate constructs of race and ethnicity.', - 'https://precision.fda.gov/challenges/30', - 'completed', - 'intermediate', - '6', - '', - '2023-05-31', - '2023-06-23', - '2023-08-10 18:28:06', - '2023-08-10 21:18:15' - ), - ( - 199, - 'v-champs', - 'The Veterans Cardiac Health and AI Model Predictions (V-CHAMPS)', - 'The Veterans Health Administration Innovation Ecosystem, the Digital Health ...', - 'To better understand the risk and protective factors in the Veteran population, the VHA IE and its collaborating partners are calling upon the public to develop AI/ML models to predict cardiovascular health outcomes, including readmission and mortality, using synthetically generated Veteran health records. The Challenge consists of two Phases: Phase 1 is focused on synthetic data. In this Phase of the Challenge, AI/ML models will be developed by Challenge participants and trained and tested on the synthetic data sets provided to them, with a view towards predicting outcome variables for Veterans who have been diagnosed with chronic heart failure (please note that in Phase 1, the data is synthetic Veteran health records). Phase 2 will focus on validating and further exploring the limits of the AI/ML models. During this Phase, high-performing AI/ML models from Phase 1 will be brought into the VA system and validated on the real-world Veterans health data within the VHA. These model...', - 'https://precision.fda.gov/challenges/31', - 'completed', - 'intermediate', - '6', - '', - '2023-05-25', - '2023-08-02', - '2023-08-10 21:41:10', - '2023-08-10 22:08:01' - ), - ( - 200, - 'predicting-high-risk-breast-cancer-phase-1', - 'Predicting High Risk Breast Cancer - Phase 1', - 'Predicting High Risk Breast Cancer: a Nightingale OS & AHLI data challenge', - ' Every year, 40 million women get a mammogram; some go on to have an invasive biopsy to better examine a concerning area. Underneath these routine tests lies a deep—and disturbing—mystery. Since the 1990s, we have found far more ‘cancers’, which has in turn prompted vastly more surgical procedures and chemotherapy. But death rates from metastatic breast cancer have hardly changed. When a pathologist looks at a biopsy slide, she is looking for known signs of cancer: tubules, cells with atypical looking nuclei, evidence of rapid cell division. These features, first identified in 1928, still underlie critical decisions today: which women must receive urgent treatment with surgery and chemotherapy? And which can be prescribed “watchful waiting”, sparing them invasive procedures for cancers that would not harm them? There is already evidence that algorithms can predict which cancers will metastasize and harm patients on the basis of the biopsy image. Fascinatingly, these algorithms als...', - 'https://app.nightingalescience.org/contests/3jmp2y128nxd', - 'completed', - 'intermediate', - '15', - '', - '2022-06-01', - '2023-01-12', - '2023-08-22 17:07:00', - '2023-09-12 23:52:21' - ), - ( - 201, - 'predicting-high-risk-breast-cancer-phase-2', - 'Predicting High Risk Breast Cancer - Phase 2', - 'Predicting High Risk Breast Cancer: a Nightingale OS & AHLI data challenge', - ' Every year, 40 million women get a mammogram; some go on to have an invasive biopsy to better examine a concerning area. Underneath these routine tests lies a deep—and disturbing—mystery. Since the 1990s, we have found far more ‘cancers’, which has in turn prompted vastly more surgical procedures and chemotherapy. But death rates from metastatic breast cancer have hardly changed. When a pathologist looks at a biopsy slide, she is looking for known signs of cancer: tubules, cells with atypical looking nuclei, evidence of rapid cell division. These features, first identified in 1928, still underlie critical decisions today: which women must receive urgent treatment with surgery and chemotherapy? And which can be prescribed “watchful waiting”, sparing them invasive procedures for cancers that would not harm them? There is already evidence that algorithms can predict which cancers will metastasize and harm patients on the basis of the biopsy image. Fascinatingly, these algorithms als...', - 'https://app.nightingalescience.org/contests/vd8g98zv9w0p', - 'completed', - 'intermediate', - '15', - '', - '2023-02-03', - '2023-05-13', - '2023-08-22 17:07:01', - '2023-09-12 23:52:25' - ), - ( - 202, - 'dream-2-in-silico-network-inference', - 'DREAM 2 - In Silico Network Inference', - 'Predicting the connectivity and properties of in-silico networks.', - 'Three in-silico networks were created and endowed with a dynamics that simulate biological interactions. The challenge consists of predicting the connectivity and some of the properties of one or more of these three networks.', - 'https://www.synapse.org/#!Synapse:syn2825394/wiki/71150', - 'completed', - 'intermediate', - '1', - '', - '2007-03-25', - NULL, - '2023-08-24 18:54:05', - '2023-09-12 23:52:36' - ), - ( - 203, - 'dream-3-in-silico-network-challenge', - 'DREAM 3 - In Silico Network Challenge', - 'The goal of the in silico challenges is the reverse engineering of gene netw...', - 'The goal of the in silico challenges is the reverse engineering of gene networks from steady state and time series data. Participants are challenged to predict the directed unsigned network topology from the given in silico generated gene expression datasets.', - 'https://www.synapse.org/#!Synapse:syn2853594/wiki/71567', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1089/cmb.2008.09TT', - '2008-06-09', - NULL, - '2023-08-25 16:43:41', - '2023-09-12 23:52:32' - ), - ( - 204, - 'dream-4-in-silico-network-challenge', - 'DREAM 4 - In Silico Network Challenge', - 'The goal of the in silico network challenge is to reverse engineer gene regu...', - 'The goal of the in silico network challenge is to reverse engineer gene regulation networks from simulated steady-state and time-series data. Participants are challenged to infer the network structure from the given in silico gene expression datasets. Optionally, participants may also predict the response of the networks to a set of novel perturbations that were not included in the provided datasets.', - 'https://www.synapse.org/#!Synapse:syn3049712/wiki/74628', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1073/pnas.0913357107', - '2009-06-09', - NULL, - '2023-08-25 16:43:42', - '2023-09-12 23:52:35' - ), - ( - 205, - 'dream-5-network-inference-challenge', - 'DREAM 5 - Network Inference Challenge', - 'The goal of this Network Inference Challenge is to reverse engineer gene reg...', - 'The goal of this Network Inference Challenge is to reverse engineer gene regulatory networks from gene expression datasets. Participants are given four microarray compendia and are challenged to infer the structure of the underlying transcriptional regulatory networks. Three of the four compendia were obtained from microorganisms, some of which are pathogens of clinical relevance. The fourth compendium is based on an in-silico (i.e., simulated) network. Each compendium consists of hundreds of microarray experiments, which include a wide range of genetic, drug, and environmental perturbations (or in the in-silico network case, simulations thereof). Network predictions will be evaluated on a subset of known interactions for each organism, or on the known network for the in-silico case.', - 'https://www.synapse.org/#!Synapse:syn2787209/wiki/70349', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1038/nmeth.2016', - '2010-06-09', - '2010-10-31', - '2023-08-25 16:43:43', - '2023-09-12 23:52:37' - ), - ( - 206, - 'nlp-sandbox-date-annotation', - 'NLP Sandbox Date Annotation', - 'Identify dates in clinical notes.', - 'An NLP Sandbox Date Annotator takes as input a clinical note and outputs a list of predicted date annotations found in the clinical note.', - 'https://www.synapse.org/#!Synapse:syn22277123/wiki/609134', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.7303/syn22277123', - '2021-06-04', - '2023-09-01', - '2023-08-25 16:45:22', - '2023-09-08 16:44:46' - ), - ( - 207, - 'nlp-sandbox-person-name-annotation', - 'NLP Sandbox Person Name Annotation', - 'Identify person names in clinical notes.', - 'An NLP Sandbox Person Name Annotator takes as input a clinical note and outputs a list of predicted person name annotations found in the clinical note.', - 'https://www.synapse.org/#!Synapse:syn22277123/wiki/609134', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.7303/syn22277123', - '2021-06-04', - '2023-09-01', - '2023-09-08 16:44:20', - '2023-09-08 16:44:20' - ), - ( - 208, - 'nlp-sandbox-location-annotation', - 'NLP Sandbox Location Annotation', - 'Identify location information in clinical notes.', - 'An NLP Sandbox Location Annotator takes as input a clinical note and outputs a list of predicted location annotations found in the clinical note.', - 'https://www.synapse.org/#!Synapse:syn22277123/wiki/609134', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.7303/syn22277123', - '2021-06-04', - '2023-09-01', - '2023-09-08 16:44:21', - '2023-09-08 16:44:21' - ), - ( - 209, - 'nlp-sandbox-contact-annotation', - 'NLP Sandbox Contact Annotation', - 'Identify contact information in clinical notes.', - 'An NLP Sandbox contact annotator takes as input a clinical note and outputs a list of predicted contact annotations found in the clinical note.', - 'https://www.synapse.org/#!Synapse:syn22277123/wiki/609134', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.7303/syn22277123', - '2021-06-04', - '2023-09-01', - '2023-09-08 16:44:22', - '2023-09-08 16:44:22' - ), - ( - 210, - 'nlp-sandbox-id-annotation', - 'NLP Sandbox ID Annotation', - 'Identify identifiers in clinical notes.', - 'An NLP Sandbox ID annotator takes as input a clinical note and outputs a list of predicted ID annotations found in the clinical note.', - 'https://www.synapse.org/#!Synapse:syn22277123/wiki/609134', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.7303/syn22277123', - '2021-06-04', - '2023-09-01', - '2023-09-08 16:44:22', - '2023-09-09 2:50:13' - ), - ( - 211, - 'dream-2-bcl6-transcriptomic-target-prediction', - 'DREAM 2 – BCL6 Transcriptomic Target Prediction', - '', - 'A number of potential transcriptional targets of BCL6, a gene that encodes for a transcription factor active in B cells, have been identified with ChIP-on-chip data and functionally validated by perturbing the BCL6 pathway with CD40 and anti-IgM, and by over-expressing exogenous BCL6 in Ramos cell. We subselected a number of targets found in this way (the "gold standard positive" set), and added a number decoys (genes that have no evidence of being BCL6 targets, named the "gold standard negative" set), compiling a list of 200 genes in total. Given this list of 200 genes, the challenge consists of identifying which ones are the true targets and which ones are the decoys, using an independent panel of gene expression data.', - 'https://www.synapse.org/#!Synapse:syn3034857/wiki/', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1073/pnas.0437996100', - '2007-04-19', - NULL, - '2023-09-12 21:26:22', - '2023-09-12 23:53:56' - ), - ( - 212, - 'dream-2-protein-protein-interaction-network-inference', - 'DREAM 2 – Protein-Protein Interaction Network Inference', - 'Predict a PPI network of 47 proteins', - 'For many pairs of bait and prey genes, yeast protein-protein interactions were tested in an unbiased fashion using a high saturation, high-stringency variant of the yeast two-hybrid (Y2H) method. A high confidence subset of gene pairs that were found to interact in at least three repetitions of the experiment but that hadn’t been reported in the literature was extracted. There were 47 yeast genes involved in these pairs. Including self interactions, there are a total of 47*48/2 possible pairs of genes that can be formed with these 47 genes. As mentioned above some of these gene pairs were seen to consistently interact in at least three repetitions of the Y2H experiments: these gene pairs form the "gold standard positive" set. A second set among these gene pairs were seen never to interact in repeated experiments and were not reported as interacting in the literature; we call this the "gold standard negative" set. Finally in a third set of gene pairs, which we shall call the "undec...', - 'https://www.synapse.org/#!Synapse:syn2825374/wiki/', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1126/science.1158684', - '2007-05-24', - NULL, - '2023-09-12 21:26:28', - '2023-09-12 23:56:04' - ), - ( - 213, - 'dream-2-genome-scale-network-inference', - 'DREAM 2 – Genome-Scale Network Inference', - '', - 'A panel of single-channel microarrays was collected for a particular microorganism, including some already published and some in-print data. The data was appropriately normalized (to the logarithmic scale). The challenge consists of reconstructing a genome-scale transcriptional network for this organism. The accuracy of network inference will be judged using chromatin precipitation and otherwise experimentally verified Transcription Factor (TF)-target interactions.', - 'https://www.synapse.org/#!Synapse:syn3034894/wiki/74418', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1371/journal.pbio.0050008', - '2007-06-05', - '2007-10-31', - '2023-09-12 21:26:34', - '2023-09-13 0:02:45' - ), - ( - 214, - 'dream-2-synthetic-five-gene-network-inference', - 'DREAM 2 – Synthetic Five-Gene Network Inference', - '', - 'A synthetic-biology network consisting of 5 interacting genes was created and transfected to an in-vivo model organism. The challenge consists of predicting the connectivity of the five-gene network from in-vivo measurements.', - 'https://www.synapse.org/#!Synapse:syn3034869/wiki/74411', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1016/j.cell.2009.01.055', - '2007-06-20', - '2007-10-31', - '2023-09-12 21:26:56', - '2023-09-13 0:02:34' - ), - ( - 215, - 'dream-3-signaling-cascade-identification', - 'DREAM 3 – Signaling Cascade Identification', - '', - 'The concentration of four intracellular proteins or phospho-proteins (X1, X2, X3 and X4) participating in a signaling cascade were measured in about 104 cells by antibody staining and flow cytometry. The idea of this challenge is to explore what key aspects of the dynamics and topology of interactions of a signaling cascade can be inferred from incomplete flow cytometry data.', - 'https://www.synapse.org/#!Synapse:syn3033068/wiki/74362', - 'completed', - 'intermediate', - '1', - '', - '2008-06-01', - '2008-10-31', - '2023-09-12 21:27:04', - '2023-09-13 0:03:50' - ), - ( - 216, - 'dream-3-gene-expression-prediction', - 'DREAM 3 – Gene Expression Prediction', - '', - 'Gene expression time course data is provided for four different strains of yeast (S. Cerevisiae), after perturbation of the cells. The challenge is to predict the rank order of induction/repression of a small subset of genes (the "prediction targets") in one of the four strains, given complete data for three of the strains, and data for all genes except the prediction targets in the other strain. You are also allowed to use any information that is in the public domain and are expected to be forthcoming about what information was used.', - 'https://www.synapse.org/#!Synapse:syn3033083/wiki/74369', - 'completed', - 'intermediate', - '1', - '', - '2008-06-01', - '2008-10-31', - '2023-09-12 21:27:12', - '2023-09-13 0:05:21' - ), - ( - 217, - 'dream-4-predictive-signaling-network-modelling', - 'DREAM 4 – Predictive Signaling Network Modelling', - 'Cell-type specific high-throughput experimental data', - 'This challenge explores the extent to which our current knowledge of signaling pathways, collected from a variety of cell types, agrees with cell-type specific high-throughput experimental data. Specifically, we ask the challenge participants to create a cell-type specific model of signal transduction using the measured activity levels of signaling proteins in HepG2 cell lines. The model, which can leverage prior information encoded in a generic signaling pathway provided in the challenge, should be biologically interpretable as a network, and capable of predicting the outcome of new experiments.', - 'https://www.synapse.org/#!Synapse:syn2825304/wiki/71129', - 'completed', - 'intermediate', - '1', - '', - '2009-03-09', - NULL, - '2023-09-12 21:27:14', - '2023-09-13 0:07:43' - ), - ( - 218, - 'dream-3-signaling-response-prediction', - 'DREAM 3 – Signaling Response Prediction', - 'Predict missing protein concentrations from a large corpus of measurements', - 'Approximately 10,000 intracellular measurements (fluorescence signals proportional to the concentrations of phosphorylated proteins) and extracellular measurements (concentrations of cytokines released in response to cell stimulation) were acquired in human normal hepatocytes and the hepatocellular carcinoma cell line HepG2 cells. The datasets consist of measurements of 17 phospho-proteins (at 0 min, 30 min, and 3 hrs) and 20 cytokines (at 0 min, 3 hrs, and 24 hrs) in two cell types (normal and cancer) after perturbations to the pathway induced by the combinatorial treatment of 7 stimuli and 7 selective inhibitors.', - 'https://www.synapse.org/#!Synapse:syn2825325/wiki/', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1126%2Fscisignal.2002212', - '2009-03-09', - NULL, - '2023-09-12 21:27:20', - '2023-09-13 0:12:14' - ), - ( - 219, - 'dream-4-peptide-recognition-domain-prd-specificity-prediction', - 'DREAM 4 – Peptide Recognition Domain (PRD) Specificity Prediction', - '', - 'Many important protein-protein interactions are mediated by peptide recognition domains (PRD), which bind short linear sequence motifs in other proteins. For example, SH3 domains typically recognize proline-rich motifs, PDZ domains recognize hydrophobic C-terminal tails, and kinases recognize short sequence regions around a phosphorylatable residue (Pawson, 2003). Given the sequence of the domains, the challenge consists of predicting a position weight matrix (PWM) that describes the specificity profile of each of the given domains to their target peptides. Any publicly accessible peptide specificity information available for the domain may be used.', - 'https://www.synapse.org/#!Synapse:syn2925957/wiki/72976', - 'completed', - 'intermediate', - '1', - '', - '2009-06-01', - '2009-10-31', - '2023-09-12 21:27:35', - '2023-09-13 0:15:42' - ), - ( - 220, - 'dream-5-transcription-factor-dna-motif-recognition-challenge', - 'DREAM 5 – Transcription-Factor, DNA-Motif Recognition Challenge', - '', - 'Transcription factors (TFs) control the expression of genes through sequence-specific interactions with genomic DNA. Different TFs bind preferentially to different sequences, with the majority recognizing short (6-12 base), degenerate ‘motifs’. Modeling the sequence specificities of TFs is a central problem in understanding the function and evolution of the genome, because many types of genomic analyses involve scanning for potential TF binding sites. Models of TF binding specificity are also important for understanding the function and evolution of the TFs themselves. The challenge consists of predicting the signal intensities for the remaining TFs.', - 'https://www.synapse.org/#!Synapse:syn2887863/wiki/72185', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1038/nbt.2486', - '2011-06-01', - '2011-09-30', - '2023-09-12 21:27:41', - '2023-09-13 0:20:22' - ), - ( - 221, - 'dream-5-epitope-antibody-recognition-ear-challenge', - 'DREAM 5 – Epitope-Antibody Recognition (EAR) Challenge', - 'Predict the binding specificity of peptide-antibody interactions.', - 'Humoral immune responses are mediated through antibodies. About 1010 to 1012 different antigen binding sites called paratopes are generated by genomic recombination. These antibodies are capable to bind to a variety of structures ranging from small molecules to protein complexes, including any posttranslational modification thereof. When studying protein-antibody interactions, two types of epitopes (the region paratopes interact with) are to be distinguished from each other: i) conformational and ii) linear epitopes. All potential linear epitopes of a protein can be represented by short peptides derived from the primary amino acid sequence. These peptides can be synthesized and arrayed on solid supports, e.g. glass slides (see Lorenz et al., 2009 [1]). By incubating these peptide arrays with antibody mixtures such as human serum or plasma, peptides can be determined that interact with antibodies in a specific fashion.', - 'https://www.synapse.org/#!Synapse:syn2820433/wiki/71017', - 'completed', - 'intermediate', - '1', - '', - '2010-06-09', - NULL, - '2023-09-12 21:27:44', - '2023-09-13 0:25:03' - ), - ( - 222, - 'dream-gene-expression-prediction-challenge', - 'DREAM Gene Expression Prediction Challenge', - 'Predict gene expression levels from promoter sequences in eukaryotes', - 'The level by which genes are transcribed is determined in large part by the DNA sequence upstream to the gene, known as the promoter region. Although widely studied, we are still far from a quantitative and predictive understanding of how transcriptional regulation is encoded in gene promoters. One obstacle in the field is obtaining accurate measurements of transcription derived by different promoters. To address this, an experimental system was designed to measure the transcription derived by different promoters, all of which are inserted into the same genomic location upstream to a reporter gene – a yellow florescence protein gene (YFP). The challenge consists of the prediction of the promoter activity given a promoter sequence and a specific experimental condition. To study a set of promoters that share many elements of the regulatory program, and thus are suitable for computational learning, the data pertains to promoters of most of the ribosomal protein genes (RP) of yeast (S...', - 'https://www.synapse.org/#!Synapse:syn2820426/wiki/71010', - 'completed', - 'intermediate', - '1', - '', - '2010-07-09', - NULL, - '2023-09-12 21:28:00', - '2023-09-13 0:31:58' - ), - ( - 223, - 'dream-5-systems-genetics-challenge', - 'DREAM 5 – Systems Genetics Challenge', - 'Predict disease phenotypes and infer Gene Networks from Systems Genetics data', - 'The central goal of systems biology is to gain a predictive, system-level understanding of biological networks. This can be done, for example, by inferring causal networks from observations on a perturbed biological system. An ideal experimental design for causal inference is randomized, multifactorial perturbation. The recognition that the genetic variation in a segregating population represents randomized, multifactorial perturbations (Jansen and Nap (2001), Jansen (2003)) gave rise to Systems Genetics (SG), where a segregating or genetically randomized population is genotyped for many DNA variants, and profiled for phenotypes of interest (e.g. disease phenotypes), gene expression, and potentially other ‘omics’ variables (protein expression, metabolomics, DNA methylation, etc.; Figure 1. Figure 1 was taken from Jansen and Nap (2001)). In this challenge we explore the use of Systems Genetics data for elucidating causal network models among genes, i.e. Gene Networks (DREAM5 SYSGEN...', - 'https://www.synapse.org/#!Synapse:syn2820440/wiki/', - 'completed', - 'intermediate', - '1', - '', - '2010-07-09', - NULL, - '2023-09-12 21:28:10', - '2023-09-13 0:32:10' - ), - ( - 224, - 'dream-6-estimation-of-model-parameters-challenge', - 'DREAM 6 – Estimation of Model Parameters Challenge', - '', - 'Given the complete model structures (including expressions for the kinetic rate laws) for three gene regulatory networks, participants are asked to develop and/or apply optimization methods, including the selection of the most informative experiments, to accurately estimate parameters and predict outcomes of perturbations in Systems Biology models.', - 'https://www.synapse.org/#!Synapse:syn2841366/wiki/71372', - 'completed', - 'intermediate', - '1', - '', - '2011-06-01', - '2011-10-31', - '2023-09-12 21:28:12', - '2023-09-13 0:32:54' - ), - ( - 225, - 'dream-6-flowcap2-molecular-classification-of-acute-myeloid-leukemia-challenge', - 'DREAM 6 – FlowCAP2 Molecular Classification of Acute Myeloid Leukemia Challenge', - 'The goal of this challenge is to diagnose Acute Myeloid Leukaemia from patie...', - 'Flow cytometry (FCM) has been widely used by immunologists and cancer biologists for more than 30 years as a biomedical research tool to distinguish different cell types in mixed populations, based on the expression of cellular markers. It has also become a widely used diagnostic tool for clinicians to identify abnormal cell populations associated with disease. In the last decade, advances in instrumentation and reagent technologies have enabled simultaneous single-cell measurement of tens of surface and intracellular markers, as well as tens of signaling molecules, positioning FCM to play an even bigger role in medicine and systems biology [1,2]. However, the rapid expansion of FCM applications has outpaced the functionality of traditional analysis tools used to interpret FCM data such that scientists are faced with the daunting prospect of manually identifying interesting cell populations in 20 dimensional data from a collection of millions of cells. For these reasons a reliable...', - 'https://www.synapse.org/#!Synapse:syn2887788/wiki/72178', - 'completed', - 'intermediate', - '1', - 'https://doi.org/10.1038/nmeth.2365', - '2011-06-01', - '2011-09-30', - '2023-09-12 21:28:19', - '2023-09-13 0:37:41' - ), - ( - 226, - 'dream-6-alternative-splicing-challenge', - 'DREAM 6 – Alternative Splicing Challenge', - '', - 'The goal of the mRNA-seq alternative splicing challenge is to assess the accuracy of the reconstruction of alternatively spliced mRNA transcripts from Illumina short-read mRNA-seq. Reconstructed transcripts will be scored against Pacific Biosciences long-read mRNA-seq. The ensuing analysis of the transcriptomes from mandrill and rhinoceros fibroblasts and their derived induced pluripotent stem cells (iPSC), as well as the transcriptome for human Embrionic Stem Cells (hESC) is an opportunity to discover novel biology as well as investigate species-bias of different methods.', - 'https://www.synapse.org/#!Synapse:syn2817724/wiki/', - 'completed', - 'intermediate', - '1', - '', - '2011-08-09', - NULL, - '2023-09-12 21:28:25', - '2023-09-13 0:40:05' - ), - ( - 227, - 'causalbench-challenge', - 'CausalBench Challenge', - 'A machine learning contest for gene network inference from single-cell pertu...', - 'Mapping gene–gene interactions in cellular systems is a fundamental step in early-stage drug discovery that helps generate hypotheses on what molecular mechanisms may effectively be targeted by potential future medicines. In the CausalBench Challenge, we invite the machine-learning community to advance the state-of-the-art in deriving gene–gene networks from large-scale real-world perturbational single-cell datasets to improve our ability to glean causal insights into disease-relevant biology.', - 'https://www.gsk.ai/causalbench-challenge/', - 'completed', - 'intermediate', - '16', - 'https://doi.org/10.48550/arXiv.2308.15395', - '2023-03-01', - '2023-04-21', - '2023-09-13 0:41:58', - '2023-09-15 16:01:07' - ), - ( - 228, - 'iclr-computational-geometry-and-topology-challenge-2022', - 'ICLR Computational Geometry & Topology Challenge 2022', - '', - 'The purpose of this challenge is to foster reproducible research in geometric (deep) learning, by crowdsourcing the open-source implementation of learning algorithms on manifolds. Participants are asked to contribute code for a published/unpublished algorithm, following Scikit-Learn/Geomstats'' or pytorch''s APIs and computational primitives, benchmark it, and demonstrate its use in real-world scenarios.', - 'https://github.com/geomstats/challenge-iclr-2022', - 'completed', - 'intermediate', - '14', - '', - NULL, - '2022-04-04', - '2023-09-13 16:54:06', - '2023-09-13 17:26:29' - ), - ( - 229, - 'iclr-computational-geometry-and-topology-challenge-2021', - 'ICLR Computational Geometry & Topology Challenge 2021', - '', - 'The purpose of this challenge is to push forward the fields of computational differential geometry and topology, by creating the best data analysis, computational method, or numerical experiment relying on state-of-the-art geometric and topological Python packages.', - 'https://github.com/geomstats/challenge-iclr-2021', - 'completed', - 'intermediate', - '14', - 'https://doi.org/10.48550/arXiv.2108.09810', - NULL, - '2021-05-02', - '2023-09-13 17:02:12', - '2023-09-13 17:26:31' - ), - ( - 230, - 'genedisco-challenge', - 'GeneDisco Challenge', - '', - 'The GeneDisco challenge is a machine learning community challenge for evaluating batch active learning algorithms for exploring the vast experimental design space in genetic perturbation experiments. Genetic perturbation experiments, using for example CRISPR technologies to perturb the genome, are a vital component of early-stage drug discovery, including target discovery and target validation. The GeneDisco challenge is organized in conjunction with the Machine Learning for Drug Discovery workshop at ICLR-22.', - 'https://www.gsk.ai/genedisco-challenge/', - 'completed', - 'intermediate', - '16', - 'https://doi.org/10.48550/arXiv.2110.11875', - '2022-01-31', - '2022-03-31', - '2023-09-13 17:20:30', - '2023-09-15 16:03:06' - ), - ( - 231, - 'hidden-treasures-warm-up', - 'Hidden Treasures - Warm Up', - '', - 'In the context of human genome sequencing, software pipelines typically involve a wide range of processing elements, including aligning sequencing reads to a reference genome and subsequently identifying variants (differences). One way of assessing the performance of such pipelines is by using well-characterized datasets such as Genome in a Bottle’s NA12878. However, because the existing NGS reference datasets are very limited and have been widely used to train/develop software pipelines, benchmarking of pipeline performance would ideally be done on samples with unknown variants. This challenge will provide a unique opportunity for participants to investigate the accuracy of their pipelines by testing the ability to find in silico injected variants in FASTQ files from exome sequencing of reference cell lines. It will be a warm up for the community ahead of a more difficult in silico challenge to come in the fall. This challenge will provide users with a FASTQ file of a NA12878 se...', - 'https://precision.fda.gov/challenges/1', - 'completed', - 'intermediate', - '6', - '', - '2017-07-17', - '2017-09-13', - '2023-09-13 23:31:39', - '2023-09-15 16:45:51' - ), - ( - 232, - 'cmu-dnanexus-2023', - 'Data management and graph extraction for large models in the biomedical space', - 'Collaborative hackathon on the topic of data management and graph extraction...', - 'This fall, CMU Libraries is hosting a hackathon in partnership with DNAnexus on the topic of data management and graph extraction for large models in the biomedical space. The hackathon will be held in person at CMU, October 19-21, 2023. The hackathon is a collaborative, rather than competitive, event, with each team working on a dedicated part of the problem. The teams will be focused on the following topics: 1) Knowledge graph-based validation for variant (genomic) assertions; 2) Continuous monitoring for RLHF and flexible infrastructure for layering assertions with rollback; 3) Flexible tokenization of complex data types; 4) Assertion tracking in large models; 5) Column headers for data harmonization. The outputs are often published as preprints or on the F1000 hackathon channel. Contact Ben Busby (bbusby@dnanexus.com) with any questions about the hackathon or serving as a team lead.', - 'https://library.cmu.edu/about/news/2023-08/hackathon-2023', - 'upcoming', - 'intermediate', - '14', - '', - '2023-10-19', - '2023-10-21', - '2023-09-13 23:32:59', - '2023-09-13 23:35:17' - ); - -- challenge_organization_role data +-- challenge_organization_role data +LOAD DATA LOCAL INFILE '/workspace/BOOT-INF/classes/db/contribution_roles.csv' INTO TABLE challenge_contribution + FIELDS TERMINATED BY ',' OPTIONALLY ENCLOSED BY '"' + LINES TERMINATED BY '\n' + IGNORE 1 LINES; -INSERT INTO challenge_contribution (id, challenge_id, organization_id, role) -VALUES (1, 1, 75, 'sponsor'), - (2, 2, 28, 'data_contributor'), - (3, 2, 45, 'data_contributor'), - (4, 2, 151, 'data_contributor'), - (5, 2, 52, 'sponsor'), - (6, 3, 154, 'data_contributor'), - (7, 3, 118, 'data_contributor'), - (8, 3, 17, 'data_contributor'), - (9, 3, 142, 'data_contributor'), - (10, 4, 150, 'data_contributor'), - (11, 4, 52, 'data_contributor'), - (12, 4, 131, 'sponsor'), - (13, 5, 134, 'challenge_organizer'), - (14, 5, 132, 'challenge_organizer'), - (15, 5, 211, 'challenge_organizer'), - (16, 5, 101, 'data_contributor'), - (17, 6, 54, 'challenge_organizer'), - (18, 6, 146, 'challenge_organizer'), - (19, 6, 171, 'challenge_organizer'), - (20, 6, 227, 'challenge_organizer'), - (21, 6, 27, 'challenge_organizer'), - (22, 6, 128, 'challenge_organizer'), - (23, 6, 93, 'challenge_organizer'), - (24, 6, 179, 'challenge_organizer'), - (25, 6, 89, 'challenge_organizer'), - (26, 6, 73, 'challenge_organizer'), - (27, 6, 170, 'challenge_organizer'), - (28, 6, 119, 'challenge_organizer'), - (29, 6, 171, 'sponsor'), - (30, 6, 93, 'sponsor'), - (31, 6, 57, 'sponsor'), - (32, 6, 146, 'sponsor'), - (33, 6, 120, 'sponsor'), - (34, 7, 171, 'challenge_organizer'), - (35, 7, 128, 'challenge_organizer'), - (36, 7, 93, 'challenge_organizer'), - (37, 7, 71, 'challenge_organizer'), - (38, 7, 89, 'challenge_organizer'), - (39, 7, 73, 'challenge_organizer'), - (40, 7, 170, 'challenge_organizer'), - (41, 7, 150, 'challenge_organizer'), - (42, 7, 130, 'challenge_organizer'), - (43, 8, 171, 'challenge_organizer'), - (44, 8, 206, 'challenge_organizer'), - (45, 8, 128, 'challenge_organizer'), - (46, 8, 93, 'challenge_organizer'), - (47, 8, 56, 'challenge_organizer'), - (48, 8, 37, 'challenge_organizer'), - (49, 8, 25, 'challenge_organizer'), - (50, 8, 78, 'challenge_organizer'), - (51, 8, 125, 'challenge_organizer'), - (52, 8, 23, 'challenge_organizer'), - (53, 8, 55, 'data_contributor'), - (54, 8, 24, 'sponsor'), - (55, 8, 125, 'sponsor'), - (56, 8, 145, 'sponsor'), - (57, 8, 181, 'sponsor'), - (58, 8, 93, 'sponsor'), - (59, 9, 171, 'challenge_organizer'), - (60, 9, 150, 'challenge_organizer'), - (61, 9, 128, 'challenge_organizer'), - (62, 9, 93, 'challenge_organizer'), - (63, 9, 197, 'challenge_organizer'), - (64, 9, 149, 'challenge_organizer'), - (65, 9, 23, 'challenge_organizer'), - (66, 9, 99, 'data_contributor'), - (67, 10, 165, 'challenge_organizer'), - (68, 10, 171, 'challenge_organizer'), - (69, 10, 128, 'challenge_organizer'), - (70, 10, 93, 'challenge_organizer'), - (71, 10, 23, 'challenge_organizer'), - (72, 10, 122, 'challenge_organizer'), - (73, 10, 122, 'data_contributor'), - (74, 10, 122, 'sponsor'), - (75, 10, 93, 'sponsor'), - (76, 10, 171, 'sponsor'), - (77, 10, 165, 'sponsor'), - (78, 11, 171, 'challenge_organizer'), - (79, 11, 150, 'challenge_organizer'), - (80, 11, 128, 'challenge_organizer'), - (81, 11, 41, 'challenge_organizer'), - (82, 11, 58, 'challenge_organizer'), - (83, 11, 205, 'challenge_organizer'), - (84, 11, 93, 'challenge_organizer'), - (85, 11, 23, 'challenge_organizer'), - (86, 11, 41, 'data_contributor'), - (87, 11, 58, 'data_contributor'), - (88, 11, 46, 'sponsor'), - (89, 11, 109, 'sponsor'), - (90, 12, 107, 'challenge_organizer'), - (91, 12, 171, 'challenge_organizer'), - (92, 12, 204, 'challenge_organizer'), - (93, 12, 128, 'challenge_organizer'), - (94, 12, 93, 'challenge_organizer'), - (95, 12, 38, 'challenge_organizer'), - (96, 12, 223, 'challenge_organizer'), - (97, 12, 119, 'challenge_organizer'), - (98, 12, 23, 'challenge_organizer'), - (99, 12, 82, 'challenge_organizer'), - (100, 12, 169, 'data_contributor'), - (101, 12, 18, 'data_contributor'), - (102, 12, 94, 'data_contributor'), - (103, 12, 19, 'sponsor'), - (104, 12, 39, 'sponsor'), - (105, 12, 74, 'sponsor'), - (106, 12, 153, 'sponsor'), - (107, 12, 164, 'sponsor'), - (108, 12, 168, 'sponsor'), - (109, 12, 172, 'sponsor'), - (110, 12, 181, 'sponsor'), - (111, 13, 206, 'challenge_organizer'), - (112, 13, 167, 'challenge_organizer'), - (113, 13, 171, 'challenge_organizer'), - (114, 13, 93, 'challenge_organizer'), - (115, 13, 128, 'challenge_organizer'), - (116, 13, 23, 'challenge_organizer'), - (117, 13, 167, 'data_contributor'), - (118, 13, 100, 'sponsor'), - (119, 13, 93, 'sponsor'), - (120, 13, 171, 'sponsor'), - (121, 13, 1, 'sponsor'), - (122, 14, 58, 'challenge_organizer'), - (123, 14, 93, 'challenge_organizer'), - (124, 14, 124, 'challenge_organizer'), - (125, 14, 155, 'challenge_organizer'), - (126, 14, 157, 'challenge_organizer'), - (127, 14, 171, 'challenge_organizer'), - (128, 14, 188, 'challenge_organizer'), - (129, 14, 196, 'challenge_organizer'), - (130, 14, 199, 'challenge_organizer'), - (131, 14, 219, 'challenge_organizer'), - (132, 14, 26, 'data_contributor'), - (133, 14, 47, 'data_contributor'), - (134, 14, 172, 'data_contributor'), - (135, 14, 124, 'data_contributor'), - (136, 14, 157, 'sponsor'), - (137, 14, 131, 'sponsor'), - (138, 14, 21, 'sponsor'), - (139, 15, 128, 'challenge_organizer'), - (140, 15, 93, 'challenge_organizer'), - (141, 15, 171, 'challenge_organizer'), - (142, 15, 118, 'challenge_organizer'), - (143, 15, 154, 'challenge_organizer'), - (144, 15, 187, 'challenge_organizer'), - (145, 15, 115, 'challenge_organizer'), - (146, 15, 23, 'challenge_organizer'), - (147, 15, 154, 'data_contributor'), - (148, 15, 140, 'data_contributor'), - (149, 15, 142, 'data_contributor'), - (150, 15, 154, 'sponsor'), - (151, 15, 93, 'sponsor'), - (152, 15, 171, 'sponsor'), - (153, 15, 1, 'sponsor'), - (154, 15, 32, 'sponsor'), - (155, 15, 67, 'sponsor'), - (156, 16, 128, 'challenge_organizer'), - (157, 16, 93, 'challenge_organizer'), - (158, 16, 26, 'challenge_organizer'), - (159, 16, 89, 'challenge_organizer'), - (160, 16, 73, 'challenge_organizer'), - (161, 16, 170, 'challenge_organizer'), - (162, 16, 171, 'challenge_organizer'), - (163, 16, 23, 'challenge_organizer'), - (164, 16, 26, 'data_contributor'), - (165, 16, 235, 'data_contributor'), - (166, 16, 29, 'data_contributor'), - (167, 16, 26, 'sponsor'), - (168, 17, 128, 'challenge_organizer'), - (169, 17, 93, 'challenge_organizer'), - (170, 17, 197, 'challenge_organizer'), - (171, 17, 149, 'challenge_organizer'), - (172, 17, 171, 'challenge_organizer'), - (173, 17, 23, 'challenge_organizer'), - (174, 17, 99, 'data_contributor'), - (175, 17, 149, 'sponsor'), - (176, 17, 81, 'sponsor'), - (177, 17, 138, 'sponsor'), - (178, 17, 171, 'sponsor'), - (179, 17, 197, 'sponsor'), - (180, 17, 150, 'sponsor'), - (181, 18, 235, 'challenge_organizer'), - (182, 18, 128, 'challenge_organizer'), - (183, 18, 93, 'challenge_organizer'), - (184, 18, 197, 'challenge_organizer'), - (185, 18, 150, 'challenge_organizer'), - (186, 18, 149, 'challenge_organizer'), - (187, 18, 79, 'challenge_organizer'), - (188, 18, 220, 'challenge_organizer'), - (189, 18, 171, 'challenge_organizer'), - (190, 18, 23, 'challenge_organizer'), - (191, 18, 149, 'data_contributor'), - (192, 18, 99, 'data_contributor'), - (193, 18, 149, 'data_contributor'), - (194, 18, 156, 'sponsor'), - (195, 18, 81, 'sponsor'), - (196, 18, 138, 'sponsor'), - (197, 19, 171, 'challenge_organizer'), - (198, 19, 64, 'challenge_organizer'), - (199, 19, 229, 'challenge_organizer'), - (200, 19, 59, 'challenge_organizer'), - (201, 19, 59, 'sponsor'), - (202, 20, 171, 'challenge_organizer'), - (203, 20, 205, 'challenge_organizer'), - (204, 20, 128, 'challenge_organizer'), - (205, 20, 93, 'challenge_organizer'), - (206, 20, 89, 'challenge_organizer'), - (207, 20, 73, 'challenge_organizer'), - (208, 20, 170, 'challenge_organizer'), - (209, 20, 118, 'challenge_organizer'), - (210, 20, 23, 'challenge_organizer'), - (211, 20, 111, 'challenge_organizer'), - (212, 20, 205, 'data_contributor'), - (213, 20, 180, 'sponsor'), - (214, 21, 179, 'challenge_organizer'), - (215, 21, 171, 'challenge_organizer'), - (216, 21, 128, 'challenge_organizer'), - (217, 21, 93, 'challenge_organizer'), - (218, 21, 199, 'challenge_organizer'), - (219, 21, 150, 'challenge_organizer'), - (220, 21, 115, 'challenge_organizer'), - (221, 21, 23, 'challenge_organizer'), - (222, 21, 69, 'data_contributor'), - (223, 22, 220, 'challenge_organizer'), - (224, 22, 91, 'challenge_organizer'), - (225, 22, 127, 'challenge_organizer'), - (226, 22, 95, 'challenge_organizer'), - (227, 22, 128, 'challenge_organizer'), - (228, 22, 93, 'challenge_organizer'), - (229, 22, 171, 'challenge_organizer'), - (230, 22, 23, 'challenge_organizer'), - (231, 22, 64, 'data_contributor'), - (232, 22, 229, 'data_contributor'), - (233, 23, 232, 'challenge_organizer'), - (234, 23, 128, 'challenge_organizer'), - (235, 23, 93, 'challenge_organizer'), - (236, 23, 197, 'challenge_organizer'), - (237, 23, 150, 'challenge_organizer'), - (238, 23, 149, 'challenge_organizer'), - (239, 23, 171, 'challenge_organizer'), - (240, 23, 23, 'challenge_organizer'), - (241, 23, 99, 'data_contributor'), - (242, 23, 131, 'data_contributor'), - (243, 23, 149, 'data_contributor'), - (244, 23, 138, 'sponsor'), - (245, 23, 81, 'sponsor'), - (246, 23, 156, 'sponsor'), - (247, 23, 131, 'sponsor'), - (248, 24, 171, 'challenge_organizer'), - (249, 24, 93, 'challenge_organizer'), - (250, 24, 106, 'challenge_organizer'), - (251, 24, 128, 'challenge_organizer'), - (252, 24, 175, 'challenge_organizer'), - (253, 24, 189, 'challenge_organizer'), - (254, 24, 36, 'data_contributor'), - (255, 24, 128, 'data_contributor'), - (256, 24, 110, 'sponsor'), - (257, 24, 80, 'sponsor'), - (258, 24, 236, 'sponsor'), - (259, 24, 93, 'sponsor'), - (260, 24, 20, 'sponsor'), - (261, 25, 47, 'challenge_organizer'), - (262, 25, 129, 'challenge_organizer'), - (263, 25, 171, 'challenge_organizer'), - (264, 25, 193, 'data_contributor'), - (265, 25, 58, 'data_contributor'), - (266, 25, 86, 'data_contributor'), - (267, 25, 89, 'data_contributor'), - (268, 25, 129, 'data_contributor'), - (269, 25, 47, 'sponsor'), - (270, 26, 85, 'challenge_organizer'), - (271, 26, 197, 'challenge_organizer'), - (272, 26, 63, 'challenge_organizer'), - (273, 26, 149, 'challenge_organizer'), - (274, 26, 171, 'challenge_organizer'), - (275, 26, 131, 'data_contributor'), - (276, 26, 88, 'data_contributor'), - (277, 26, 179, 'data_contributor'), - (278, 26, 49, 'data_contributor'), - (279, 26, 108, 'data_contributor'), - (280, 26, 202, 'data_contributor'), - (281, 26, 197, 'data_contributor'), - (282, 26, 149, 'data_contributor'), - (283, 26, 99, 'data_contributor'), - (284, 26, 41, 'data_contributor'), - (285, 27, 126, 'challenge_organizer'), - (286, 27, 65, 'challenge_organizer'), - (287, 27, 230, 'challenge_organizer'), - (288, 27, 88, 'challenge_organizer'), - (289, 27, 171, 'challenge_organizer'), - (290, 27, 224, 'challenge_organizer'), - (291, 27, 208, 'challenge_organizer'), - (292, 27, 216, 'challenge_organizer'), - (293, 27, 126, 'data_contributor'), - (294, 27, 171, 'data_contributor'), - (295, 27, 126, 'sponsor'), - (296, 27, 166, 'sponsor'), - (297, 28, 141, 'challenge_organizer'), - (298, 28, 128, 'challenge_organizer'), - (299, 28, 93, 'challenge_organizer'), - (300, 28, 131, 'challenge_organizer'), - (301, 28, 89, 'challenge_organizer'), - (302, 28, 73, 'challenge_organizer'), - (303, 28, 170, 'challenge_organizer'), - (304, 28, 149, 'challenge_organizer'), - (305, 28, 59, 'challenge_organizer'), - (306, 28, 152, 'challenge_organizer'), - (307, 28, 171, 'challenge_organizer'), - (308, 28, 51, 'data_contributor'), - (309, 28, 51, 'sponsor'), - (310, 28, 59, 'sponsor'), - (311, 28, 147, 'sponsor'), - (312, 29, 211, 'challenge_organizer'), - (313, 29, 128, 'challenge_organizer'), - (314, 29, 210, 'challenge_organizer'), - (315, 29, 171, 'challenge_organizer'), - (316, 29, 195, 'challenge_organizer'), - (317, 29, 128, 'data_contributor'), - (318, 29, 128, 'sponsor'), - (319, 30, 89, 'challenge_organizer'), - (320, 30, 128, 'challenge_organizer'), - (321, 30, 93, 'challenge_organizer'), - (322, 30, 73, 'challenge_organizer'), - (323, 30, 170, 'challenge_organizer'), - (324, 30, 121, 'challenge_organizer'), - (325, 30, 171, 'challenge_organizer'), - (326, 30, 121, 'data_contributor'), - (327, 31, 171, 'challenge_organizer'), - (328, 31, 96, 'challenge_organizer'), - (329, 31, 128, 'challenge_organizer'), - (330, 31, 93, 'challenge_organizer'), - (331, 31, 190, 'data_contributor'), - (332, 31, 15, 'sponsor'), - (333, 32, 87, 'challenge_organizer'), - (334, 32, 48, 'challenge_organizer'), - (335, 32, 66, 'challenge_organizer'), - (336, 32, 128, 'challenge_organizer'), - (337, 32, 93, 'challenge_organizer'), - (338, 32, 171, 'challenge_organizer'), - (339, 32, 182, 'data_contributor'), - (340, 32, 116, 'data_contributor'), - (341, 32, 15, 'data_contributor'), - (342, 32, 31, 'sponsor'), - (343, 33, 233, 'challenge_organizer'), - (344, 33, 196, 'challenge_organizer'), - (345, 33, 128, 'challenge_organizer'), - (346, 33, 93, 'challenge_organizer'), - (347, 33, 199, 'challenge_organizer'), - (348, 33, 179, 'challenge_organizer'), - (349, 33, 72, 'challenge_organizer'), - (350, 33, 72, 'data_contributor'), - (351, 33, 233, 'data_contributor'), - (352, 33, 117, 'data_contributor'), - (353, 34, 89, 'challenge_organizer'), - (354, 34, 226, 'challenge_organizer'), - (355, 34, 171, 'challenge_organizer'), - (356, 34, 73, 'challenge_organizer'), - (357, 34, 170, 'challenge_organizer'), - (358, 34, 71, 'challenge_organizer'), - (359, 34, 226, 'data_contributor'), - (360, 34, 71, 'data_contributor'), - (361, 35, 171, 'challenge_organizer'), - (362, 35, 224, 'challenge_organizer'), - (363, 35, 224, 'data_contributor'), - (364, 35, 133, 'sponsor'), - (365, 35, 97, 'sponsor'), - (366, 35, 224, 'sponsor'), - (367, 36, 43, 'challenge_organizer'), - (368, 36, 171, 'challenge_organizer'), - (369, 36, 234, 'challenge_organizer'), - (370, 36, 114, 'challenge_organizer'), - (371, 36, 224, 'challenge_organizer'), - (372, 36, 16, 'challenge_organizer'), - (373, 36, 93, 'challenge_organizer'), - (374, 36, 43, 'data_contributor'), - (375, 36, 114, 'data_contributor'), - (376, 36, 234, 'data_contributor'), - (377, 37, 95, 'challenge_organizer'), - (378, 37, 113, 'challenge_organizer'), - (379, 37, 150, 'challenge_organizer'), - (380, 37, 171, 'challenge_organizer'), - (381, 37, 179, 'challenge_organizer'), - (382, 37, 16, 'data_contributor'), - (383, 37, 234, 'data_contributor'), - (384, 37, 114, 'data_contributor'), - (385, 37, 43, 'data_contributor'), - (386, 37, 171, 'data_contributor'), - (387, 37, 131, 'sponsor'), - (388, 38, 171, 'challenge_organizer'), - (389, 38, 52, 'challenge_organizer'), - (390, 38, 176, 'challenge_organizer'), - (391, 38, 15, 'challenge_organizer'), - (392, 38, 131, 'challenge_organizer'), - (393, 38, 46, 'challenge_organizer'), - (394, 38, 128, 'challenge_organizer'), - (395, 38, 93, 'challenge_organizer'), - (396, 38, 89, 'challenge_organizer'), - (397, 38, 73, 'challenge_organizer'), - (398, 38, 170, 'challenge_organizer'), - (399, 38, 52, 'data_contributor'), - (400, 39, 171, 'challenge_organizer'), - (401, 39, 150, 'challenge_organizer'), - (402, 39, 128, 'challenge_organizer'), - (403, 39, 15, 'challenge_organizer'), - (404, 39, 131, 'challenge_organizer'), - (405, 39, 46, 'challenge_organizer'), - (406, 39, 112, 'data_contributor'), - (407, 39, 150, 'data_contributor'), - (408, 40, 131, 'challenge_organizer'), - (409, 40, 171, 'challenge_organizer'), - (410, 40, 150, 'challenge_organizer'), - (411, 40, 22, 'data_contributor'), - (412, 40, 44, 'data_contributor'), - (413, 40, 131, 'sponsor'), - (414, 41, 192, 'challenge_organizer'), - (415, 41, 128, 'challenge_organizer'), - (416, 41, 93, 'challenge_organizer'), - (417, 41, 199, 'challenge_organizer'), - (418, 41, 171, 'challenge_organizer'), - (419, 41, 192, 'data_contributor'), - (420, 41, 133, 'sponsor'), - (421, 41, 40, 'sponsor'), - (422, 42, 171, 'challenge_organizer'), - (423, 42, 144, 'challenge_organizer'), - (424, 42, 126, 'challenge_organizer'), - (425, 42, 76, 'challenge_organizer'), - (426, 42, 126, 'data_contributor'), - (427, 42, 144, 'data_contributor'), - (428, 42, 216, 'data_contributor'), - (429, 42, 191, 'data_contributor'), - (430, 42, 198, 'data_contributor'), - (431, 42, 161, 'data_contributor'), - (432, 43, 171, 'challenge_organizer'), - (433, 43, 52, 'challenge_organizer'), - (434, 43, 176, 'challenge_organizer'), - (435, 43, 15, 'challenge_organizer'), - (436, 43, 46, 'challenge_organizer'), - (437, 43, 128, 'challenge_organizer'), - (438, 43, 89, 'challenge_organizer'), - (439, 43, 52, 'data_contributor'), - (440, 43, 46, 'sponsor'), - (441, 44, 171, 'challenge_organizer'), - (442, 44, 224, 'challenge_organizer'), - (443, 44, 224, 'data_contributor'), - (444, 45, 211, 'challenge_organizer'), - (445, 45, 40, 'challenge_organizer'), - (446, 45, 148, 'challenge_organizer'), - (447, 45, 171, 'challenge_organizer'), - (448, 45, 40, 'data_contributor'), - (449, 46, 215, 'challenge_organizer'), - (450, 46, 131, 'challenge_organizer'), - (451, 46, 196, 'data_contributor'), - (452, 46, 220, 'data_contributor'), - (453, 46, 171, 'challenge_organizer'), - (454, 46, 185, 'data_contributor'), - (455, 46, 61, 'data_contributor'), - (456, 46, 226, 'challenge_organizer'), - (457, 46, 148, 'data_contributor'), - (458, 47, 47, 'challenge_organizer'), - (459, 47, 171, 'challenge_organizer'), - (460, 47, 158, 'challenge_organizer'), - (461, 47, 124, 'challenge_organizer'), - (462, 47, 58, 'challenge_organizer'), - (463, 47, 160, 'challenge_organizer'), - (464, 47, 47, 'sponsor'), - (465, 59, 30, 'data_contributor'), - (466, 59, 224, 'data_contributor'), - (467, 59, 196, 'data_contributor'), - (468, 61, 64, 'data_contributor'), - (469, 62, 173, 'data_contributor'), - (470, 63, 224, 'data_contributor'), - (471, 64, 184, 'data_contributor'), - (472, 65, 33, 'data_contributor'), - (473, 66, 196, 'data_contributor'), - (474, 67, 159, 'data_contributor'), - (475, 67, 70, 'data_contributor'), - (476, 68, 42, 'data_contributor'), - (477, 69, 200, 'data_contributor'), - (478, 70, 91, 'data_contributor'), - (479, 71, 214, 'data_contributor'), - (480, 72, 179, 'data_contributor'), - (481, 73, 41, 'data_contributor'), - (482, 74, 213, 'data_contributor'), - (483, 75, 91, 'data_contributor'), - (484, 76, 88, 'data_contributor'), - (485, 77, 220, 'data_contributor'), - (486, 78, 222, 'data_contributor'), - (487, 79, 217, 'data_contributor'), - (488, 80, 221, 'data_contributor'), - (489, 81, 173, 'data_contributor'), - (490, 82, 173, 'data_contributor'), - (491, 83, 220, 'data_contributor'), - (492, 84, 218, 'data_contributor'), - (493, 85, 41, 'data_contributor'), - (494, 90, 104, 'challenge_organizer'), - (495, 90, 3, 'challenge_organizer'), - (496, 90, 102, 'challenge_organizer'), - (497, 90, 215, 'challenge_organizer'), - (498, 90, 143, 'challenge_organizer'), - (499, 90, 224, 'challenge_organizer'), - (500, 90, 203, 'challenge_organizer'), - (501, 90, 219, 'challenge_organizer'), - (502, 90, 137, 'sponsor'), - (503, 90, 15, 'sponsor'), - (504, 90, 60, 'sponsor'), - (505, 90, 68, 'sponsor'), - (506, 91, 209, 'challenge_organizer'), - (507, 91, 183, 'challenge_organizer'), - (508, 91, 194, 'challenge_organizer'), - (509, 91, 207, 'challenge_organizer'), - (510, 91, 135, 'sponsor'), - (511, 92, 209, 'challenge_organizer'), - (512, 92, 183, 'challenge_organizer'), - (513, 92, 194, 'challenge_organizer'), - (514, 92, 207, 'challenge_organizer'), - (515, 92, 135, 'sponsor'), - (516, 93, 189, 'sponsor'), - (517, 94, 13, 'challenge_organizer'), - (518, 94, 189, 'challenge_organizer'), - (519, 94, 34, 'challenge_organizer'), - (520, 94, 62, 'challenge_organizer'), - (521, 94, 228, 'challenge_organizer'), - (522, 94, 136, 'challenge_organizer'), - (523, 94, 189, 'sponsor'), - (524, 95, 13, 'challenge_organizer'), - (525, 95, 189, 'challenge_organizer'), - (526, 95, 152, 'challenge_organizer'), - (527, 95, 201, 'challenge_organizer'), - (528, 95, 128, 'challenge_organizer'), - (529, 95, 93, 'challenge_organizer'), - (530, 95, 62, 'challenge_organizer'), - (531, 95, 34, 'challenge_organizer'), - (532, 95, 189, 'sponsor'), - (533, 96, 13, 'challenge_organizer'), - (534, 96, 189, 'challenge_organizer'), - (535, 96, 82, 'challenge_organizer'), - (536, 96, 62, 'challenge_organizer'), - (537, 96, 34, 'challenge_organizer'), - (538, 96, 189, 'sponsor'), - (539, 97, 13, 'challenge_organizer'), - (540, 97, 189, 'challenge_organizer'), - (541, 97, 83, 'challenge_organizer'), - (542, 97, 34, 'challenge_organizer'), - (543, 97, 189, 'sponsor'), - (544, 98, 13, 'challenge_organizer'), - (545, 98, 189, 'challenge_organizer'), - (546, 98, 62, 'challenge_organizer'), - (547, 98, 53, 'challenge_organizer'), - (548, 98, 34, 'challenge_organizer'), - (549, 98, 189, 'sponsor'), - (550, 99, 136, 'challenge_organizer'), - (551, 99, 13, 'challenge_organizer'), - (552, 99, 189, 'challenge_organizer'), - (553, 99, 62, 'challenge_organizer'), - (554, 99, 34, 'challenge_organizer'), - (555, 99, 189, 'sponsor'), - (556, 100, 13, 'challenge_organizer'), - (557, 100, 189, 'challenge_organizer'), - (558, 100, 231, 'challenge_organizer'), - (559, 100, 34, 'challenge_organizer'), - (560, 100, 62, 'challenge_organizer'), - (561, 100, 189, 'sponsor'), - (562, 101, 13, 'challenge_organizer'), - (563, 101, 189, 'challenge_organizer'), - (564, 101, 34, 'challenge_organizer'), - (565, 101, 62, 'challenge_organizer'), - (566, 101, 189, 'sponsor'), - (567, 102, 13, 'challenge_organizer'), - (568, 102, 189, 'challenge_organizer'), - (569, 102, 34, 'challenge_organizer'), - (570, 102, 62, 'challenge_organizer'), - (571, 102, 189, 'sponsor'), - (572, 103, 13, 'challenge_organizer'), - (573, 103, 189, 'challenge_organizer'), - (574, 103, 34, 'challenge_organizer'), - (575, 103, 62, 'challenge_organizer'), - (576, 103, 131, 'challenge_organizer'), - (577, 103, 177, 'challenge_organizer'), - (578, 103, 189, 'sponsor'), - (579, 104, 12, 'challenge_organizer'), - (580, 104, 215, 'challenge_organizer'), - (581, 104, 84, 'challenge_organizer'), - (582, 104, 7, 'challenge_organizer'), - (583, 104, 15, 'sponsor'), - (584, 104, 90, 'sponsor'), - (585, 104, 103, 'sponsor'), - (586, 104, 50, 'sponsor'), - (587, 105, 12, 'challenge_organizer'), - (588, 105, 147, 'sponsor'), - (589, 105, 35, 'sponsor'), - (590, 106, 12, 'challenge_organizer'), - (591, 106, 186, 'sponsor'), - (592, 106, 178, 'sponsor'), - (593, 107, 12, 'challenge_organizer'), - (594, 107, 77, 'sponsor'), - (595, 124, 12, 'sponsor'), - (596, 124, 215, 'challenge_organizer'), - (597, 124, 84, 'challenge_organizer'), - (598, 124, 7, 'challenge_organizer'), - (599, 124, 98, 'sponsor'), - (600, 124, 139, 'sponsor'), - (601, 124, 162, 'sponsor'), - (602, 161, 13, 'challenge_organizer'), - (603, 161, 237, 'challenge_organizer'), - (604, 162, 13, 'challenge_organizer'), - (605, 162, 238, 'challenge_organizer'), - (606, 163, 13, 'challenge_organizer'), - (607, 163, 238, 'challenge_organizer'), - (608, 164, 13, 'challenge_organizer'), - (609, 164, 231, 'challenge_organizer'), - (610, 165, 13, 'challenge_organizer'), - (611, 55, 1, 'sponsor'), - (612, 53, 1, 'sponsor'), - (613, 52, 1, 'sponsor'), - (614, 54, 1, 'sponsor'), - (615, 166, 1, 'sponsor'), - (616, 45, 1, 'sponsor'), - (617, 44, 1, 'sponsor'), - (618, 43, 1, 'sponsor'), - (619, 40, 1, 'sponsor'), - (620, 42, 1, 'sponsor'), - (621, 39, 1, 'sponsor'), - (622, 41, 1, 'sponsor'), - (623, 35, 1, 'sponsor'), - (624, 36, 1, 'sponsor'), - (625, 34, 1, 'sponsor'), - (626, 37, 1, 'sponsor'), - (627, 33, 1, 'sponsor'), - (628, 32, 1, 'sponsor'), - (629, 31, 1, 'sponsor'), - (630, 30, 1, 'sponsor'), - (631, 29, 1, 'sponsor'), - (632, 21, 1, 'sponsor'), - (633, 27, 1, 'sponsor'), - (634, 26, 1, 'sponsor'), - (635, 28, 1, 'sponsor'), - (636, 24, 1, 'sponsor'), - (637, 25, 1, 'sponsor'), - (638, 23, 1, 'sponsor'), - (639, 20, 1, 'sponsor'), - (640, 19, 1, 'sponsor'), - (641, 18, 1, 'sponsor'), - (642, 17, 1, 'sponsor'), - (643, 16, 1, 'sponsor'), - (644, 14, 1, 'sponsor'), - (645, 8, 1, 'sponsor'), - (646, 7, 1, 'sponsor'), - (647, 11, 1, 'sponsor'), - (648, 12, 1, 'sponsor'), - (649, 10, 1, 'sponsor'), - (650, 9, 1, 'sponsor'), - (651, 6, 1, 'sponsor'), - (652, 5, 1, 'sponsor'), - (653, 4, 1, 'sponsor'), - (654, 1, 1, 'sponsor'), - (655, 3, 1, 'sponsor'), - (656, 167, 215, 'challenge_organizer'), - (657, 167, 171, 'challenge_organizer'), - (658, 167, 239, 'challenge_organizer'), - (659, 167, 240, 'challenge_organizer'), - (660, 167, 195, 'challenge_organizer'), - (661, 167, 226, 'challenge_organizer'), - (662, 167, 241, 'challenge_organizer'), - (663, 167, 242, 'challenge_organizer'), - (664, 167, 185, 'challenge_organizer'), - (665, 167, 196, 'challenge_organizer'), - (666, 167, 243, 'challenge_organizer'), - (667, 167, 244, 'challenge_organizer'), - (668, 167, 245, 'challenge_organizer'), - (669, 167, 246, 'challenge_organizer'), - (670, 167, 247, 'challenge_organizer'), - (671, 167, 248, 'challenge_organizer'), - (672, 167, 13, 'challenge_organizer'), - (673, 167, 249, 'challenge_organizer'), - (674, 167, 34, 'challenge_organizer'), - (675, 167, 62, 'challenge_organizer'), - (676, 167, 215, 'data_contributor'), - (677, 167, 240, 'data_contributor'), - (678, 167, 250, 'data_contributor'), - (679, 167, 251, 'data_contributor'), - (680, 167, 241, 'data_contributor'), - (681, 167, 185, 'data_contributor'), - (682, 167, 243, 'data_contributor'), - (683, 167, 245, 'data_contributor'), - (684, 167, 49, 'data_contributor'), - (685, 167, 252, 'data_contributor'), - (686, 167, 253, 'data_contributor'), - (687, 167, 98, 'sponsor'), - (688, 167, 139, 'sponsor'), - (689, 167, 254, 'sponsor'), - (690, 167, 255, 'sponsor'), - (691, 169, 209, 'challenge_organizer'), - (692, 169, 195, 'challenge_organizer'), - (693, 169, 194, 'challenge_organizer'), - (694, 169, 257, 'challenge_organizer'), - (695, 169, 135, 'sponsor'), - (696, 170, 258, 'challenge_organizer'), - (697, 170, 258, 'data_contributor'), - (698, 170, 161, 'challenge_organizer'), - (699, 170, 161, 'data_contributor'), - (700, 170, 259, 'challenge_organizer'), - (701, 170, 260, 'challenge_organizer'), - (702, 170, 261, 'challenge_organizer'), - (703, 170, 261, 'data_contributor'), - (704, 170, 262, 'challenge_organizer'), - (705, 170, 263, 'challenge_organizer'), - (706, 170, 264, 'challenge_organizer'), - (707, 170, 265, 'sponsor'), - (708, 170, 260, 'sponsor'), - (709, 170, 266, 'sponsor'), - (710, 170, 261, 'sponsor'), - (711, 171, 267, 'challenge_organizer'), - (712, 171, 267, 'sponsor'), - (713, 171, 267, 'data_contributor'), - (714, 172, 269, 'sponsor'), - (715, 172, 268, 'challenge_organizer'), - (716, 173, 272, 'challenge_organizer'), - (717, 173, 271, 'challenge_organizer'), - (718, 173, 270, 'challenge_organizer'), - (719, 174, 273, 'sponsor'), - (720, 174, 107, 'challenge_organizer'), - (721, 174, 256, 'challenge_organizer'), - (722, 174, 270, 'challenge_organizer'), - (723, 174, 147, 'challenge_organizer'), - (724, 174, 215, 'challenge_organizer'), - (725, 174, 270, 'data_contributor'), - (726, 176, 104, 'challenge_organizer'), - (727, 176, 143, 'challenge_organizer'), - (728, 176, 213, 'challenge_organizer'), - (729, 176, 275, 'challenge_organizer'), - (730, 176, 102, 'challenge_organizer'), - (731, 174, 274, 'data_contributor'), - (732, 174, 276, 'data_contributor'), - (733, 174, 277, 'data_contributor'), - (734, 177, 162, 'challenge_organizer'), - (735, 176, 3, 'challenge_organizer'), - (736, 175, 278, 'challenge_organizer'), - (737, 179, 279, 'challenge_organizer'), - (738, 174, 12, 'sponsor'), - (739, 172, 12, 'sponsor'), - (740, 173, 12, 'sponsor'), - (741, 171, 12, 'sponsor'), - (742, 167, 12, 'sponsor'), - (743, 181, 12, 'sponsor'), - (744, 181, 280, 'challenge_organizer'), - (745, 181, 281, 'challenge_organizer'), - (746, 181, 211, 'challenge_organizer'), - (747, 181, 282, 'challenge_organizer'), - (748, 181, 171, 'challenge_organizer'), - (749, 182, 283, 'challenge_organizer'), - (750, 182, 284, 'challenge_organizer'), - (751, 182, 285, 'challenge_organizer'), - (752, 182, 67, 'challenge_organizer'), - (753, 182, 286, 'challenge_organizer'), - (754, 182, 12, 'sponsor'), - (755, 182, 15, 'sponsor'), - (756, 183, 283, 'challenge_organizer'), - (757, 183, 67, 'challenge_organizer'), - (758, 183, 287, 'challenge_organizer'), - (759, 183, 286, 'challenge_organizer'), - (760, 183, 288, 'challenge_organizer'), - (761, 183, 289, 'challenge_organizer'), - (762, 183, 12, 'sponsor'), - (763, 183, 15, 'sponsor'), - (764, 184, 290, 'challenge_organizer'), - (765, 184, 291, 'challenge_organizer'), - (766, 185, 179, 'challenge_organizer'), - (767, 186, 179, 'challenge_organizer'), - (768, 186, 292, 'challenge_organizer'), - (769, 187, 179, 'challenge_organizer'), - (770, 187, 119, 'challenge_organizer'), - (771, 188, 179, 'challenge_organizer'), - (772, 188, 293, 'challenge_organizer'), - (773, 189, 179, 'challenge_organizer'), - (774, 190, 197, 'challenge_organizer'), - (775, 191, 179, 'challenge_organizer'), - (776, 191, 294, 'challenge_organizer'), - (777, 191, 144, 'challenge_organizer'), - (778, 191, 295, 'challenge_organizer'), - (779, 192, 41, 'challenge_organizer'), - (780, 192, 296, 'challenge_organizer'), - (781, 192, 297, 'challenge_organizer'), - (782, 193, 298, 'challenge_organizer'), - (783, 193, 299, 'sponsor'), - (784, 193, 300, 'sponsor'), - (785, 193, 147, 'sponsor'), - (786, 193, 301, 'sponsor'), - (787, 194, 302, 'challenge_organizer'), - (788, 194, 302, 'data_contributor'), - (789, 194, 303, 'data_contributor'), - (790, 194, 304, 'data_contributor'), - (791, 194, 126, 'sponsor'), - (792, 195, 75, 'sponsor'), - (793, 195, 312, 'challenge_organizer'), - (794, 196, 12, 'sponsor'), - (795, 196, 226, 'challenge_organizer'), - (796, 196, 306, 'challenge_organizer'), - (797, 196, 307, 'challenge_organizer'), - (798, 196, 308, 'challenge_organizer'), - (799, 196, 248, 'challenge_organizer'), - (800, 196, 305, 'challenge_organizer'), - (801, 196, 309, 'challenge_organizer'), - (802, 196, 310, 'challenge_organizer'), - (803, 196, 220, 'challenge_organizer'), - (804, 196, 261, 'data_contributor'), - (805, 196, 311, 'data_contributor'), - (806, 197, 261, 'challenge_organizer'), - (807, 197, 261, 'data_contributor'), - (808, 197, 12, 'sponsor'), - (809, 196, 305, 'data_contributor'), - (810, 198, 13, 'challenge_organizer'), - (811, 198, 313, 'challenge_organizer'), - (812, 198, 314, 'challenge_organizer'), - (813, 198, 315, 'challenge_organizer'), - (814, 199, 231, 'challenge_organizer'), - (815, 199, 249, 'challenge_organizer'), - (816, 199, 313, 'challenge_organizer'), - (817, 199, 315, 'challenge_organizer'), - (818, 199, 136, 'challenge_organizer'), - (819, 199, 316, 'challenge_organizer'), - (820, 199, 34, 'challenge_organizer'), - (821, 199, 317, 'challenge_organizer'), - (822, 199, 318, 'challenge_organizer'), - (823, 206, 171, 'challenge_organizer'), - (824, 207, 171, 'challenge_organizer'), - (825, 208, 171, 'challenge_organizer'), - (826, 209, 171, 'challenge_organizer'), - (827, 210, 171, 'challenge_organizer'), - (828, 206, 319, 'data_contributor'), - (829, 207, 319, 'data_contributor'), - (830, 208, 319, 'data_contributor'), - (831, 209, 319, 'data_contributor'), - (832, 210, 319, 'data_contributor'), - (833, 206, 247, 'data_contributor'), - (834, 207, 247, 'data_contributor'), - (835, 208, 247, 'data_contributor'), - (836, 209, 247, 'data_contributor'), - (837, 210, 247, 'data_contributor'), - (838, 211, 1, 'sponsor'), - (839, 212, 1, 'sponsor'), - (840, 213, 1, 'sponsor'), - (841, 214, 1, 'sponsor'), - (842, 215, 1, 'sponsor'), - (843, 216, 1, 'sponsor'), - (844, 217, 1, 'sponsor'), - (845, 218, 1, 'sponsor'), - (846, 219, 1, 'sponsor'), - (847, 220, 1, 'sponsor'), - (848, 221, 1, 'sponsor'), - (849, 222, 1, 'sponsor'), - (850, 223, 1, 'sponsor'), - (851, 224, 1, 'sponsor'), - (852, 225, 1, 'sponsor'), - (853, 226, 1, 'sponsor'), - (854, 202, 1, 'sponsor'), - (855, 203, 1, 'sponsor'), - (856, 204, 1, 'sponsor'), - (857, 205, 1, 'sponsor'), - (858, 211, 52, 'data_contributor'), - (859, 212, 58, 'data_contributor'), - (860, 213, 320, 'data_contributor'), - (861, 214, 321, 'data_contributor'), - (862, 215, 124, 'data_contributor'), - (863, 216, 322, 'data_contributor'), - (864, 217, 256, 'data_contributor'), - (865, 217, 119, 'data_contributor'), - (866, 217, 93, 'challenge_organizer'), - (867, 218, 256, 'data_contributor'), - (868, 218, 119, 'data_contributor'), - (869, 218, 93, 'challenge_organizer'), - (870, 218, 256, 'challenge_organizer'), - (871, 218, 119, 'challenge_organizer'), - (872, 219, 220, 'data_contributor'), - (873, 219, 242, 'data_contributor'), - (874, 219, 93, 'challenge_organizer'), - (875, 220, 220, 'data_contributor'), - (876, 220, 93, 'challenge_organizer'), - (877, 220, 256, 'challenge_organizer'), - (878, 220, 119, 'challenge_organizer'), - (879, 221, 93, 'challenge_organizer'), - (880, 221, 256, 'challenge_organizer'), - (881, 221, 119, 'challenge_organizer'), - (882, 221, 323, 'challenge_organizer'), - (883, 221, 323, 'data_contributor'), - (884, 222, 234, 'data_contributor'), - (885, 222, 93, 'challenge_organizer'), - (886, 223, 93, 'challenge_organizer'), - (887, 223, 256, 'challenge_organizer'), - (888, 223, 119, 'challenge_organizer'), - (889, 224, 93, 'challenge_organizer'), - (890, 225, 324, 'challenge_organizer'), - (891, 225, 93, 'challenge_organizer'), - (892, 226, 93, 'challenge_organizer'), - (893, 226, 242, 'challenge_organizer'), - (894, 226, 93, 'data_contributor'), - (895, 226, 242, 'data_contributor'), - (896, 228, 325, 'challenge_organizer'), - (897, 229, 325, 'challenge_organizer'), - (898, 227, 326, 'challenge_organizer'), - (899, 230, 326, 'challenge_organizer'), - (900, 2, 1, 'sponsor'), - (901, 38, 1, 'sponsor'), - (902, 49, 1, 'sponsor'), - (903, 58, 1, 'sponsor'), - (904, 231, 13, 'challenge_organizer'), - (905, 232, 327, 'challenge_organizer'), - (906, 232, 62, 'challenge_organizer'), - (907, 111, 34, 'challenge_organizer'), - (908, 113, 98, 'challenge_organizer'), - (909, 114, 105, 'challenge_organizer'), - (910, 116, 105, 'challenge_organizer'), - (911, 118, 12, 'sponsor'), - (912, 118, 328, 'sponsor'), - (913, 118, 286, 'sponsor'), - (914, 118, 161, 'challenge_organizer'), - (915, 118, 329, 'challenge_organizer'), - (916, 123, 225, 'challenge_organizer'), - (917, 124, 162, 'challenge_organizer'), - (918, 129, 92, 'challenge_organizer'), - (919, 131, 174, 'challenge_organizer'), - (920, 156, 162, 'challenge_organizer'), - (921, 178, 15, 'sponsor'); -- challenge_incentive data +LOAD DATA LOCAL INFILE '/workspace/BOOT-INF/classes/db/incentives.csv' INTO TABLE challenge_incentive + FIELDS TERMINATED BY ',' OPTIONALLY ENCLOSED BY '"' + LINES TERMINATED BY '\n' + IGNORE 1 LINES; -INSERT INTO challenge_incentive (id, name, challenge_id) -VALUES (1, 'publication', 1), - (2, 'publication', 2), - (3, 'speaking_engagement', 2), - (4, 'monetary', 3), - (5, 'publication', 5), - (6, 'speaking_engagement', 5), - (7, 'publication', 6), - (8, 'speaking_engagement', 6), - (9, 'monetary', 7), - (10, 'publication', 7), - (11, 'publication', 8), - (12, 'speaking_engagement', 8), - (13, 'publication', 9), - (14, 'publication', 10), - (15, 'speaking_engagement', 10), - (16, 'publication', 11), - (17, 'speaking_engagement', 11), - (18, 'publication', 12), - (19, 'speaking_engagement', 12), - (20, 'monetary', 14), - (21, 'publication', 14), - (22, 'speaking_engagement', 14), - (23, 'monetary', 15), - (24, 'publication', 15), - (25, 'speaking_engagement', 15), - (26, 'publication', 16), - (27, 'speaking_engagement', 16), - (28, 'publication', 17), - (29, 'speaking_engagement', 17), - (30, 'monetary', 24), - (31, 'publication', 24), - (32, 'speaking_engagement', 24), - (33, 'monetary', 25), - (34, 'publication', 25), - (35, 'speaking_engagement', 25), - (36, 'publication', 26), - (37, 'monetary', 27), - (38, 'publication', 27), - (39, 'publication', 28), - (40, 'publication', 29), - (41, 'publication', 30), - (42, 'publication', 31), - (43, 'speaking_engagement', 31), - (44, 'publication', 34), - (45, 'speaking_engagement', 34), - (46, 'publication', 37), - (47, 'speaking_engagement', 37), - (48, 'publication', 38), - (49, 'speaking_engagement', 38), - (50, 'monetary', 46), - (51, 'publication', 95), - (52, 'publication', 99), - (53, 'other', 99), - (54, 'publication', 100), - (55, 'speaking_engagement', 100), - (56, 'publication', 101), - (57, 'speaking_engagement', 101), - (58, 'other', 102), - (59, 'monetary', 111), - (60, 'monetary', 113), - (61, 'monetary', 114), - (62, 'monetary', 118), - (63, 'monetary', 123), - (64, 'monetary', 124), - (65, 'monetary', 129), - (66, 'monetary', 131), - (67, 'monetary', 145), - (68, 'monetary', 146), - (69, 'monetary', 147), - (70, 'monetary', 148), - (71, 'monetary', 149), - (72, 'monetary', 156), - (73, 'publication', 157), - (74, 'other', 157), - (75, 'publication', 158), - (76, 'speaking_engagement', 158), - (77, 'publication', 159), - (78, 'speaking_engagement', 159), - (79, 'publication', 160), - (80, 'speaking_engagement', 160), - (81, 'publication', 161), - (82, 'other', 161), - (83, 'publication', 162), - (84, 'speaking_engagement', 162), - (85, 'publication', 163), - (86, 'speaking_engagement', 163), - (87, 'publication', 165), - (88, 'speaking_engagement', 166), - (89, 'other', 166), - (90, 'publication', 168), - (91, 'publication', 169), - (92, 'speaking_engagement', 169), - (93, 'monetary', 171), - (94, 'speaking_engagement', 171), - (95, 'publication', 173), - (96, 'monetary', 175), - (97, 'monetary', 176), - (98, 'monetary', 177), - (99, 'speaking_engagement', 177), - (100, 'monetary', 178), - (101, 'monetary', 179), - (102, 'monetary', 180), - (103, 'speaking_engagement', 180), - (104, 'monetary', 182), - (105, 'speaking_engagement', 182), - (106, 'monetary', 183), - (107, 'monetary', 184), - (108, 'monetary', 185), - (109, 'publication', 186), - (110, 'publication', 187), - (111, 'publication', 188), - (112, 'publication', 189), - (113, 'publication', 190), - (114, 'publication', 191), - (115, 'monetary', 192), - (116, 'monetary', 193), - (117, 'speaking_engagement', 193), - (118, 'other', 193), - (119, 'monetary', 194), - (120, 'speaking_engagement', 194), - (121, 'monetary', 195), - (122, 'publication', 195), - (123, 'publication', 196), - (124, 'speaking_engagement', 196), - (125, 'other', 196), - (126, 'publication', 197), - (127, 'speaking_engagement', 197), - (128, 'other', 198), - (129, 'publication', 199), - (130, 'speaking_engagement', 199), - (131, 'monetary', 200), - (132, 'publication', 200), - (133, 'speaking_engagement', 200), - (134, 'monetary', 201), - (135, 'publication', 201), - (136, 'speaking_engagement', 201), - (137, 'publication', 202), - (138, 'speaking_engagement', 202), - (139, 'publication', 203), - (140, 'speaking_engagement', 203), - (141, 'publication', 204), - (142, 'speaking_engagement', 204), - (143, 'publication', 205), - (144, 'speaking_engagement', 205), - (145, 'publication', 206), - (146, 'publication', 207), - (147, 'publication', 208), - (148, 'publication', 209), - (149, 'publication', 210), - (150, 'monetary', 227), - (151, 'publication', 227), - (152, 'monetary', 228), - (153, 'publication', 228), - (154, 'monetary', 229), - (155, 'publication', 229), - (156, 'monetary', 230), - (157, 'publication', 230), - (158, 'other', 231), - (159, 'publication', 232); -- challenge_submission_type data +LOAD DATA LOCAL INFILE '/workspace/BOOT-INF/classes/db/submission_types.csv' INTO TABLE challenge_submission_type + FIELDS TERMINATED BY ',' OPTIONALLY ENCLOSED BY '"' + LINES TERMINATED BY '\n' + IGNORE 1 LINES; -INSERT INTO challenge_submission_type (id, name, challenge_id) -VALUES (1, 'prediction_file', 1), - (2, 'prediction_file', 2), - (3, 'prediction_file', 3), - (4, 'prediction_file', 4), - (5, 'prediction_file', 5), - (6, 'prediction_file', 6), - (7, 'prediction_file', 7), - (8, 'prediction_file', 8), - (9, 'prediction_file', 9), - (10, 'prediction_file', 10), - (11, 'prediction_file', 11), - (12, 'prediction_file', 12), - (13, 'prediction_file', 13), - (14, 'prediction_file', 14), - (15, 'prediction_file', 15), - (16, 'prediction_file', 16), - (17, 'prediction_file', 17), - (18, 'prediction_file', 18), - (19, 'prediction_file', 19), - (20, 'prediction_file', 20), - (21, 'prediction_file', 21), - (22, 'other', 22), - (23, 'prediction_file', 23), - (24, 'container_image', 24), - (25, 'container_image', 25), - (26, 'prediction_file', 26), - (27, 'prediction_file', 27), - (28, 'container_image', 28), - (29, 'prediction_file', 29), - (30, 'prediction_file', 30), - (31, 'prediction_file', 31), - (32, 'prediction_file', 32), - (33, 'prediction_file', 33), - (34, 'prediction_file', 34), - (35, 'container_image', 35), - (36, 'prediction_file', 36), - (37, 'container_image', 37), - (38, 'prediction_file', 38), - (39, 'container_image', 39), - (40, 'container_image', 40), - (41, 'container_image', 41), - (42, 'prediction_file', 42), - (43, 'prediction_file', 43), - (44, 'container_image', 44), - (45, 'container_image', 45), - (46, 'prediction_file', 46), - (47, 'container_image', 46), - (48, 'container_image', 47), - (49, 'other', 48), - (50, 'prediction_file', 49), - (51, 'container_image', 49), - (52, 'prediction_file', 50), - (53, 'container_image', 50), - (54, 'prediction_file', 51), - (55, 'container_image', 52), - (56, 'container_image', 53), - (57, 'container_image', 54), - (58, 'container_image', 55), - (59, 'other', 56), - (60, 'prediction_file', 57), - (61, 'container_image', 58), - (62, 'prediction_file', 59), - (63, 'prediction_file', 60), - (64, 'prediction_file', 61), - (65, 'prediction_file', 62), - (66, 'prediction_file', 63), - (67, 'prediction_file', 64), - (68, 'prediction_file', 65), - (69, 'prediction_file', 66), - (70, 'prediction_file', 67), - (71, 'prediction_file', 68), - (72, 'prediction_file', 69), - (73, 'prediction_file', 70), - (74, 'prediction_file', 71), - (75, 'prediction_file', 72), - (76, 'prediction_file', 73), - (77, 'prediction_file', 74), - (78, 'prediction_file', 75), - (79, 'prediction_file', 76), - (80, 'prediction_file', 77), - (81, 'prediction_file', 78), - (82, 'prediction_file', 79), - (83, 'prediction_file', 80), - (84, 'prediction_file', 81), - (85, 'prediction_file', 82), - (86, 'prediction_file', 83), - (87, 'prediction_file', 84), - (88, 'prediction_file', 85), - (89, 'prediction_file', 86), - (90, 'container_image', 86), - (91, 'other', 87), - (92, 'other', 88), - (93, 'other', 89), - (94, 'prediction_file', 90), - (95, 'prediction_file', 91), - (96, 'prediction_file', 92), - (97, 'prediction_file', 93), - (98, 'prediction_file', 94), - (99, 'prediction_file', 95), - (100, 'other', 95), - (101, 'prediction_file', 96), - (102, 'prediction_file', 97), - (103, 'prediction_file', 98), - (104, 'prediction_file', 99), - (105, 'prediction_file', 100), - (106, 'prediction_file', 101), - (107, 'prediction_file', 102), - (108, 'prediction_file', 103), - (109, 'container_image', 104), - (110, 'prediction_file', 105), - (111, 'container_image', 105), - (112, 'prediction_file', 106), - (113, 'container_image', 107), - (114, 'notebook', 108), - (115, 'notebook', 109), - (116, 'notebook', 110), - (117, 'notebook', 111), - (118, 'notebook', 112), - (119, 'notebook', 113), - (120, 'notebook', 114), - (121, 'notebook', 115), - (122, 'notebook', 116), - (123, 'notebook', 117), - (124, 'notebook', 118), - (125, 'notebook', 119), - (126, 'notebook', 120), - (127, 'notebook', 121), - (128, 'notebook', 122), - (129, 'notebook', 123), - (130, 'notebook', 124), - (131, 'notebook', 125), - (132, 'notebook', 126), - (133, 'notebook', 127), - (134, 'notebook', 128), - (135, 'notebook', 129), - (136, 'notebook', 130), - (137, 'notebook', 131), - (138, 'notebook', 132), - (139, 'notebook', 133), - (140, 'notebook', 134), - (141, 'notebook', 135), - (142, 'notebook', 136), - (143, 'notebook', 137), - (144, 'notebook', 138), - (145, 'notebook', 139), - (146, 'notebook', 140), - (147, 'notebook', 141), - (148, 'notebook', 142), - (149, 'notebook', 143), - (150, 'notebook', 144), - (151, 'notebook', 145), - (152, 'notebook', 146), - (153, 'notebook', 147), - (154, 'notebook', 148), - (155, 'notebook', 149), - (156, 'notebook', 150), - (157, 'notebook', 151), - (158, 'notebook', 152), - (159, 'notebook', 153), - (160, 'notebook', 154), - (161, 'notebook', 155), - (162, 'notebook', 156), - (163, 'prediction_file', 157), - (164, 'other', 158), - (165, 'other', 159), - (166, 'other', 160), - (167, 'prediction_file', 161), - (168, 'prediction_file', 162), - (169, 'other', 162), - (170, 'prediction_file', 163), - (171, 'other', 163), - (172, 'prediction_file', 164), - (173, 'prediction_file', 165), - (174, 'prediction_file', 166), - (175, 'other', 166), - (176, 'prediction_file', 167), - (177, 'container_image', 167), - (178, 'prediction_file', 169), - (179, 'container_image', 170), - (180, 'prediction_file', 174), - (181, 'container_image', 174), - (182, 'notebook', 175), - (183, 'notebook', 176), - (184, 'notebook', 177), - (185, 'notebook', 178), - (186, 'notebook', 179), - (187, 'notebook', 180), - (188, 'prediction_file', 181), - (189, 'notebook', 182), - (190, 'notebook', 183), - (191, 'notebook', 184), - (192, 'notebook', 185), - (193, 'other', 186), - (194, 'other', 187), - (195, 'other', 188), - (196, 'other', 189), - (197, 'other', 190), - (198, 'other', 191), - (199, 'notebook', 192), - (200, 'container_image', 192), - (201, 'notebook', 193), - (202, 'notebook', 194), - (203, 'container_image', 195), - (204, 'container_image', 196), - (205, 'container_image', 197), - (206, 'notebook', 198), - (207, 'prediction_file', 199), - (208, 'other', 199), - (209, 'prediction_file', 200), - (210, 'prediction_file', 201), - (211, 'prediction_file', 202), - (212, 'prediction_file', 203), - (213, 'prediction_file', 204), - (214, 'prediction_file', 205), - (215, 'container_image', 206), - (216, 'container_image', 207), - (217, 'container_image', 208), - (218, 'container_image', 209), - (219, 'container_image', 210), - (220, 'prediction_file', 211), - (221, 'prediction_file', 212), - (222, 'prediction_file', 213), - (223, 'prediction_file', 214), - (224, 'prediction_file', 215), - (225, 'prediction_file', 216), - (226, 'prediction_file', 217), - (227, 'prediction_file', 218), - (228, 'prediction_file', 219), - (229, 'prediction_file', 220), - (230, 'prediction_file', 221), - (231, 'prediction_file', 222), - (232, 'prediction_file', 223), - (233, 'prediction_file', 224), - (234, 'prediction_file', 225), - (235, 'prediction_file', 226), - (236, 'container_image', 227), - (237, 'notebook', 228), - (238, 'notebook', 229), - (239, 'container_image', 230), - (240, 'prediction_file', 231), - (241, 'other', 232); -- challenge_star data - INSERT INTO challenge_star (id, challenge_id, user_id) VALUES (1, 1, 1), (2, 2, 1), (3, 1, 2); --- challenge_x_challenge_input_data_type definition +-- challenge_input_data_type +INSERT INTO challenge_input_data_type (id, slug, name) +VALUES (1, 'genomic', 'genomic'), + (2, 'proteomic', 'proteomic'), + (3, 'gene-expression', 'gene expression'), + (4, 'metabolomic', 'metabolomic'); + + +-- challenge_x_challenge_input_data_type definition INSERT INTO challenge_x_challenge_input_data_type (id, challenge_id, challenge_input_data_type_id) VALUES ('1', 1, 1), ('2', 2, 1), ('3', 1, 2), ('4', 4, 4); --- challenge_category data +-- challenge_category data INSERT INTO challenge_category (id, challenge_id, category) VALUES (1, 161, 'featured'), (2, 156, 'featured'), diff --git a/apps/openchallenges/challenge-service/src/main/resources/db/platforms.csv b/apps/openchallenges/challenge-service/src/main/resources/db/platforms.csv new file mode 100644 index 0000000000..8e1086e383 --- /dev/null +++ b/apps/openchallenges/challenge-service/src/main/resources/db/platforms.csv @@ -0,0 +1,17 @@ +"id","slug","name","avatar_url","website_url","createdAt","updatedAt" +"1","synapse","Synapse","logo/synapse.png","https://synapse.org/","2023-08-09 23:01:32","2023-08-10 5:24:20" +"2","cagi","CAGI","logo/cagi.png","https://genomeinterpretation.org/challenges.html","2023-08-09 23:01:32","2023-08-09 23:02:49" +"3","cami","CAMI","logo/cami.png","https://data.cami-challenge.org/","2023-08-09 23:01:32","2023-08-09 23:02:05" +"4","casp","CASP","logo/casp.png","https://predictioncenter.org/","2023-08-09 23:01:32","2023-08-09 23:02:05" +"5","grand-challenge","Grand Challenge","logo/grand-challenge.png","https://grand-challenge.org/","2023-08-09 23:01:32","2023-08-09 23:02:06" +"6","precision-fda","precisionFDA","logo/precisionfda.png","https://precision.fda.gov/challenges","2023-08-09 23:01:32","2023-08-09 23:02:06" +"7","easychair","EasyChair","logo/easy-chair.jpg","https://easychair.org/","2023-08-09 23:01:32","2023-08-09 23:02:07" +"8","kaggle","Kaggle","logo/kaggle.png","https://www.kaggle.com/","2023-08-09 23:01:32","2023-08-09 23:02:07" +"9","codalab","CodaLab","logo/codalab.jpg","https://codalab.lisn.upsaclay.fr/","2023-08-09 23:01:32","2023-08-09 23:02:08" +"10","codabench","CodaBench","logo/codalab.jpg","https://www.codabench.org/","2023-08-09 23:01:32","2023-08-09 23:02:08" +"11","openml","OpenML","logo/openml.jpg","https://www.openml.org/","2023-08-09 23:01:32","2023-08-09 23:02:09" +"12","papers-with-code","PapersWithCode","logo/papers-with-code.jpg","https://paperswithcode.com/","2023-08-09 23:01:32","2023-08-09 23:02:09" +"13","eterna","Eterna","logo/eterna.svg","https://eternagame.org/","2023-08-09 23:01:32","2023-08-14 16:39:27" +"14","other","Other","","","2023-08-09 23:01:32","2023-08-10 6:25:36" +"15","nightingale-os","Nightingale OS","logo/nightingale-os.png","https://app.nightingalescience.org/","2023-08-22 15:58:49","2023-09-13 18:00:43" +"16","evalai","EvalAI","logo/evalai.png","https://eval.ai/","2023-09-15 16:00:34","2023-09-15 16:05:29" diff --git a/apps/openchallenges/challenge-service/src/main/resources/db/submission_types.csv b/apps/openchallenges/challenge-service/src/main/resources/db/submission_types.csv new file mode 100644 index 0000000000..5c8ef9997f --- /dev/null +++ b/apps/openchallenges/challenge-service/src/main/resources/db/submission_types.csv @@ -0,0 +1,294 @@ +"","submission_types","challenge_id" +"1","prediction_file","1" +"2","prediction_file","2" +"3","prediction_file","3" +"4","prediction_file","4" +"5","prediction_file","5" +"6","prediction_file","6" +"7","prediction_file","7" +"8","prediction_file","8" +"9","prediction_file","9" +"10","prediction_file","10" +"11","prediction_file","11" +"12","prediction_file","12" +"13","prediction_file","13" +"14","prediction_file","14" +"15","prediction_file","15" +"16","prediction_file","16" +"17","prediction_file","17" +"18","prediction_file","18" +"19","prediction_file","19" +"20","prediction_file","20" +"21","prediction_file","21" +"22","other","22" +"23","prediction_file","23" +"24","container_image","24" +"25","container_image","25" +"26","prediction_file","26" +"27","prediction_file","27" +"28","container_image","28" +"29","prediction_file","29" +"30","prediction_file","30" +"31","prediction_file","31" +"32","prediction_file","32" +"33","prediction_file","33" +"34","prediction_file","34" +"35","container_image","35" +"36","prediction_file","36" +"37","container_image","37" +"38","prediction_file","38" +"39","container_image","39" +"40","container_image","40" +"41","container_image","41" +"42","prediction_file","42" +"43","prediction_file","43" +"44","container_image","44" +"45","container_image","45" +"46","prediction_file","46" +"47","container_image","46" +"48","container_image","47" +"49","other","48" +"50","prediction_file","49" +"51","container_image","49" +"52","prediction_file","50" +"53","container_image","50" +"54","prediction_file","51" +"55","container_image","52" +"56","container_image","53" +"57","container_image","54" +"58","container_image","55" +"59","other","56" +"60","prediction_file","57" +"61","container_image","58" +"62","prediction_file","59" +"63","prediction_file","60" +"64","prediction_file","61" +"65","prediction_file","62" +"66","prediction_file","63" +"67","prediction_file","64" +"68","prediction_file","65" +"69","prediction_file","66" +"70","prediction_file","67" +"71","prediction_file","68" +"72","prediction_file","69" +"73","prediction_file","70" +"74","prediction_file","71" +"75","prediction_file","72" +"76","prediction_file","73" +"77","prediction_file","74" +"78","prediction_file","75" +"79","container_image","75" +"80","other","76" +"81","other","77" +"82","other","78" +"83","prediction_file","79" +"84","prediction_file","80" +"85","prediction_file","81" +"86","prediction_file","82" +"87","prediction_file","83" +"88","prediction_file","84" +"89","other","84" +"90","prediction_file","85" +"91","prediction_file","86" +"92","prediction_file","87" +"93","prediction_file","88" +"94","prediction_file","89" +"95","prediction_file","90" +"96","prediction_file","91" +"97","prediction_file","92" +"98","container_image","93" +"99","prediction_file","94" +"100","container_image","94" +"101","prediction_file","95" +"102","container_image","96" +"103","notebook","97" +"104","notebook","98" +"105","notebook","99" +"106","notebook","100" +"107","notebook","101" +"108","notebook","102" +"109","notebook","103" +"110","notebook","104" +"111","notebook","105" +"112","notebook","106" +"113","notebook","107" +"114","notebook","108" +"115","notebook","109" +"116","notebook","110" +"117","notebook","111" +"118","notebook","112" +"119","notebook","113" +"120","notebook","114" +"121","notebook","115" +"122","notebook","116" +"123","notebook","117" +"124","notebook","118" +"125","notebook","119" +"126","notebook","120" +"127","notebook","121" +"128","notebook","122" +"129","notebook","123" +"130","notebook","124" +"131","notebook","125" +"132","notebook","126" +"133","notebook","127" +"134","notebook","128" +"135","notebook","129" +"136","notebook","130" +"137","notebook","131" +"138","notebook","132" +"139","notebook","133" +"140","notebook","134" +"141","notebook","135" +"142","notebook","136" +"143","notebook","137" +"144","notebook","138" +"145","notebook","139" +"146","notebook","140" +"147","notebook","141" +"148","notebook","142" +"149","notebook","143" +"150","notebook","144" +"151","notebook","145" +"152","prediction_file","146" +"153","other","147" +"154","other","148" +"155","other","149" +"156","prediction_file","150" +"157","prediction_file","151" +"158","other","151" +"159","prediction_file","152" +"160","other","152" +"161","prediction_file","153" +"162","prediction_file","154" +"163","prediction_file","155" +"164","other","155" +"165","prediction_file","156" +"166","container_image","156" +"167","prediction_file","158" +"168","container_image","159" +"169","prediction_file","163" +"170","container_image","163" +"171","notebook","164" +"172","notebook","165" +"173","notebook","166" +"174","notebook","167" +"175","notebook","168" +"176","notebook","169" +"177","prediction_file","170" +"178","notebook","171" +"179","notebook","172" +"180","notebook","173" +"181","notebook","174" +"182","other","175" +"183","other","176" +"184","other","177" +"185","other","178" +"186","other","179" +"187","other","180" +"188","notebook","181" +"189","container_image","181" +"190","notebook","182" +"191","notebook","183" +"192","container_image","184" +"193","container_image","185" +"194","container_image","186" +"195","notebook","187" +"196","prediction_file","188" +"197","other","188" +"198","prediction_file","189" +"199","prediction_file","190" +"200","prediction_file","191" +"201","prediction_file","192" +"202","prediction_file","193" +"203","prediction_file","194" +"204","container_image","195" +"205","container_image","196" +"206","container_image","197" +"207","container_image","198" +"208","container_image","199" +"209","prediction_file","200" +"210","prediction_file","201" +"211","prediction_file","202" +"212","prediction_file","203" +"213","prediction_file","204" +"214","prediction_file","205" +"215","prediction_file","206" +"216","prediction_file","207" +"217","prediction_file","208" +"218","prediction_file","209" +"219","prediction_file","210" +"220","prediction_file","211" +"221","prediction_file","212" +"222","prediction_file","213" +"223","prediction_file","214" +"224","prediction_file","215" +"225","container_image","216" +"226","notebook","217" +"227","notebook","218" +"228","container_image","219" +"229","prediction_file","220" +"230","other","221" +"231","prediction_file","222" +"232","prediction_file","223" +"233","prediction_file","224" +"234","prediction_file","225" +"235","prediction_file","226" +"236","prediction_file","227" +"237","prediction_file","228" +"238","prediction_file","229" +"239","prediction_file","230" +"240","prediction_file","231" +"241","prediction_file","232" +"242","prediction_file","233" +"243","prediction_file","234" +"244","prediction_file","235" +"245","prediction_file","236" +"246","prediction_file","237" +"247","prediction_file","238" +"248","prediction_file","239" +"249","prediction_file","240" +"250","prediction_file","241" +"251","prediction_file","242" +"252","prediction_file","243" +"253","prediction_file","244" +"254","prediction_file","245" +"255","prediction_file","246" +"256","prediction_file","247" +"257","prediction_file","248" +"258","prediction_file","249" +"259","prediction_file","250" +"260","prediction_file","251" +"261","prediction_file","252" +"262","prediction_file","253" +"263","prediction_file","254" +"264","prediction_file","255" +"265","prediction_file","256" +"266","prediction_file","257" +"267","prediction_file","258" +"268","prediction_file","259" +"269","prediction_file","260" +"270","prediction_file","261" +"271","prediction_file","262" +"272","container_image","262" +"273","prediction_file","263" +"274","container_image","263" +"275","prediction_file","264" +"276","container_image","264" +"277","prediction_file","265" +"278","container_image","265" +"279","prediction_file","266" +"280","container_image","266" +"281","other","267" +"282","prediction_file","268" +"283","prediction_file","269" +"284","prediction_file","270" +"285","prediction_file","271" +"286","prediction_file","272" +"287","prediction_file","273" +"288","prediction_file","274" +"289","prediction_file","275" +"290","prediction_file","276" +"291","prediction_file","277" +"292","prediction_file","278" +"293","prediction_file","279" diff --git a/apps/openchallenges/mariadb/docker-entrypoint-initdb.d/init-db.sql b/apps/openchallenges/mariadb/docker-entrypoint-initdb.d/init-db.sql index 1531de3ec7..66dd52c213 100644 --- a/apps/openchallenges/mariadb/docker-entrypoint-initdb.d/init-db.sql +++ b/apps/openchallenges/mariadb/docker-entrypoint-initdb.d/init-db.sql @@ -1,3 +1,5 @@ +SET GLOBAL local_infile = 'ON'; + create database challenge_service; create database organization_service; create database user_service; diff --git a/apps/openchallenges/organization-service/src/main/resources/db/contribution_roles.csv b/apps/openchallenges/organization-service/src/main/resources/db/contribution_roles.csv new file mode 100644 index 0000000000..ae36f3d9b6 --- /dev/null +++ b/apps/openchallenges/organization-service/src/main/resources/db/contribution_roles.csv @@ -0,0 +1,950 @@ +"id","challenge_id","organization_id","role" +"1","1","75","sponsor" +"2","2","28","data_contributor" +"3","2","45","data_contributor" +"4","2","151","data_contributor" +"5","2","52","sponsor" +"6","3","154","data_contributor" +"7","3","118","data_contributor" +"8","3","17","data_contributor" +"9","3","142","data_contributor" +"10","4","150","data_contributor" +"11","4","52","data_contributor" +"12","4","131","sponsor" +"13","5","134","challenge_organizer" +"14","5","132","challenge_organizer" +"15","5","211","challenge_organizer" +"16","5","101","data_contributor" +"17","6","54","challenge_organizer" +"18","6","146","challenge_organizer" +"19","6","171","challenge_organizer" +"20","6","227","challenge_organizer" +"21","6","27","challenge_organizer" +"22","6","128","challenge_organizer" +"23","6","93","challenge_organizer" +"24","6","179","challenge_organizer" +"25","6","89","challenge_organizer" +"26","6","73","challenge_organizer" +"27","6","170","challenge_organizer" +"28","6","119","challenge_organizer" +"29","6","171","sponsor" +"30","6","93","sponsor" +"31","6","57","sponsor" +"32","6","146","sponsor" +"33","6","120","sponsor" +"34","7","171","challenge_organizer" +"35","7","128","challenge_organizer" +"36","7","93","challenge_organizer" +"37","7","71","challenge_organizer" +"38","7","89","challenge_organizer" +"39","7","73","challenge_organizer" +"40","7","170","challenge_organizer" +"41","7","150","challenge_organizer" +"42","7","130","challenge_organizer" +"43","8","171","challenge_organizer" +"44","8","206","challenge_organizer" +"45","8","128","challenge_organizer" +"46","8","93","challenge_organizer" +"47","8","56","challenge_organizer" +"48","8","37","challenge_organizer" +"49","8","25","challenge_organizer" +"50","8","78","challenge_organizer" +"51","8","125","challenge_organizer" +"52","8","23","challenge_organizer" +"53","8","55","data_contributor" +"54","8","24","sponsor" +"55","8","125","sponsor" +"56","8","145","sponsor" +"57","8","181","sponsor" +"58","8","93","sponsor" +"59","9","171","challenge_organizer" +"60","9","150","challenge_organizer" +"61","9","128","challenge_organizer" +"62","9","93","challenge_organizer" +"63","9","197","challenge_organizer" +"64","9","149","challenge_organizer" +"65","9","23","challenge_organizer" +"66","9","99","data_contributor" +"67","10","165","challenge_organizer" +"68","10","171","challenge_organizer" +"69","10","128","challenge_organizer" +"70","10","93","challenge_organizer" +"71","10","23","challenge_organizer" +"72","10","122","challenge_organizer" +"73","10","122","data_contributor" +"74","10","122","sponsor" +"75","10","93","sponsor" +"76","10","171","sponsor" +"77","10","165","sponsor" +"78","11","171","challenge_organizer" +"79","11","150","challenge_organizer" +"80","11","128","challenge_organizer" +"81","11","41","challenge_organizer" +"82","11","58","challenge_organizer" +"83","11","205","challenge_organizer" +"84","11","93","challenge_organizer" +"85","11","23","challenge_organizer" +"86","11","41","data_contributor" +"87","11","58","data_contributor" +"88","11","46","sponsor" +"89","11","109","sponsor" +"90","12","107","challenge_organizer" +"91","12","171","challenge_organizer" +"92","12","204","challenge_organizer" +"93","12","128","challenge_organizer" +"94","12","93","challenge_organizer" +"95","12","38","challenge_organizer" +"96","12","223","challenge_organizer" +"97","12","119","challenge_organizer" +"98","12","23","challenge_organizer" +"99","12","82","challenge_organizer" +"100","12","169","data_contributor" +"101","12","18","data_contributor" +"102","12","94","data_contributor" +"103","12","19","sponsor" +"104","12","39","sponsor" +"105","12","74","sponsor" +"106","12","153","sponsor" +"107","12","164","sponsor" +"108","12","168","sponsor" +"109","12","172","sponsor" +"110","12","181","sponsor" +"111","13","206","challenge_organizer" +"112","13","167","challenge_organizer" +"113","13","171","challenge_organizer" +"114","13","93","challenge_organizer" +"115","13","128","challenge_organizer" +"116","13","23","challenge_organizer" +"117","13","167","data_contributor" +"118","13","100","sponsor" +"119","13","93","sponsor" +"120","13","171","sponsor" +"121","13","1","sponsor" +"122","14","58","challenge_organizer" +"123","14","93","challenge_organizer" +"124","14","124","challenge_organizer" +"125","14","155","challenge_organizer" +"126","14","157","challenge_organizer" +"127","14","171","challenge_organizer" +"128","14","188","challenge_organizer" +"129","14","196","challenge_organizer" +"130","14","199","challenge_organizer" +"131","14","219","challenge_organizer" +"132","14","26","data_contributor" +"133","14","47","data_contributor" +"134","14","172","data_contributor" +"135","14","124","data_contributor" +"136","14","157","sponsor" +"137","14","131","sponsor" +"138","14","21","sponsor" +"139","15","128","challenge_organizer" +"140","15","93","challenge_organizer" +"141","15","171","challenge_organizer" +"142","15","118","challenge_organizer" +"143","15","154","challenge_organizer" +"144","15","187","challenge_organizer" +"145","15","115","challenge_organizer" +"146","15","23","challenge_organizer" +"147","15","154","data_contributor" +"148","15","140","data_contributor" +"149","15","142","data_contributor" +"150","15","154","sponsor" +"151","15","93","sponsor" +"152","15","171","sponsor" +"153","15","1","sponsor" +"154","15","32","sponsor" +"155","15","67","sponsor" +"156","16","128","challenge_organizer" +"157","16","93","challenge_organizer" +"158","16","26","challenge_organizer" +"159","16","89","challenge_organizer" +"160","16","73","challenge_organizer" +"161","16","170","challenge_organizer" +"162","16","171","challenge_organizer" +"163","16","23","challenge_organizer" +"164","16","26","data_contributor" +"165","16","235","data_contributor" +"166","16","29","data_contributor" +"167","16","26","sponsor" +"168","17","128","challenge_organizer" +"169","17","93","challenge_organizer" +"170","17","197","challenge_organizer" +"171","17","149","challenge_organizer" +"172","17","171","challenge_organizer" +"173","17","23","challenge_organizer" +"174","17","99","data_contributor" +"175","17","149","sponsor" +"176","17","81","sponsor" +"177","17","138","sponsor" +"178","17","171","sponsor" +"179","17","197","sponsor" +"180","17","150","sponsor" +"181","18","235","challenge_organizer" +"182","18","128","challenge_organizer" +"183","18","93","challenge_organizer" +"184","18","197","challenge_organizer" +"185","18","150","challenge_organizer" +"186","18","149","challenge_organizer" +"187","18","79","challenge_organizer" +"188","18","220","challenge_organizer" +"189","18","171","challenge_organizer" +"190","18","23","challenge_organizer" +"191","18","149","data_contributor" +"192","18","99","data_contributor" +"193","18","149","data_contributor" +"194","18","156","sponsor" +"195","18","81","sponsor" +"196","18","138","sponsor" +"197","19","171","challenge_organizer" +"198","19","64","challenge_organizer" +"199","19","229","challenge_organizer" +"200","19","59","challenge_organizer" +"201","19","59","sponsor" +"202","20","171","challenge_organizer" +"203","20","205","challenge_organizer" +"204","20","128","challenge_organizer" +"205","20","93","challenge_organizer" +"206","20","89","challenge_organizer" +"207","20","73","challenge_organizer" +"208","20","170","challenge_organizer" +"209","20","118","challenge_organizer" +"210","20","23","challenge_organizer" +"211","20","111","challenge_organizer" +"212","20","205","data_contributor" +"213","20","180","sponsor" +"214","21","179","challenge_organizer" +"215","21","171","challenge_organizer" +"216","21","128","challenge_organizer" +"217","21","93","challenge_organizer" +"218","21","199","challenge_organizer" +"219","21","150","challenge_organizer" +"220","21","115","challenge_organizer" +"221","21","23","challenge_organizer" +"222","21","69","data_contributor" +"223","22","220","challenge_organizer" +"224","22","91","challenge_organizer" +"225","22","127","challenge_organizer" +"226","22","95","challenge_organizer" +"227","22","128","challenge_organizer" +"228","22","93","challenge_organizer" +"229","22","171","challenge_organizer" +"230","22","23","challenge_organizer" +"231","22","64","data_contributor" +"232","22","229","data_contributor" +"233","23","232","challenge_organizer" +"234","23","128","challenge_organizer" +"235","23","93","challenge_organizer" +"236","23","197","challenge_organizer" +"237","23","150","challenge_organizer" +"238","23","149","challenge_organizer" +"239","23","171","challenge_organizer" +"240","23","23","challenge_organizer" +"241","23","99","data_contributor" +"242","23","131","data_contributor" +"243","23","149","data_contributor" +"244","23","138","sponsor" +"245","23","81","sponsor" +"246","23","156","sponsor" +"247","23","131","sponsor" +"248","24","171","challenge_organizer" +"249","24","93","challenge_organizer" +"250","24","106","challenge_organizer" +"251","24","128","challenge_organizer" +"252","24","175","challenge_organizer" +"253","24","189","challenge_organizer" +"254","24","36","data_contributor" +"255","24","128","data_contributor" +"256","24","110","sponsor" +"257","24","80","sponsor" +"258","24","236","sponsor" +"259","24","93","sponsor" +"260","24","20","sponsor" +"261","25","47","challenge_organizer" +"262","25","129","challenge_organizer" +"263","25","171","challenge_organizer" +"264","25","193","data_contributor" +"265","25","58","data_contributor" +"266","25","86","data_contributor" +"267","25","89","data_contributor" +"268","25","129","data_contributor" +"269","25","47","sponsor" +"270","26","85","challenge_organizer" +"271","26","197","challenge_organizer" +"272","26","63","challenge_organizer" +"273","26","149","challenge_organizer" +"274","26","171","challenge_organizer" +"275","26","131","data_contributor" +"276","26","88","data_contributor" +"277","26","179","data_contributor" +"278","26","49","data_contributor" +"279","26","108","data_contributor" +"280","26","202","data_contributor" +"281","26","197","data_contributor" +"282","26","149","data_contributor" +"283","26","99","data_contributor" +"284","26","41","data_contributor" +"285","27","126","challenge_organizer" +"286","27","65","challenge_organizer" +"287","27","230","challenge_organizer" +"288","27","88","challenge_organizer" +"289","27","171","challenge_organizer" +"290","27","224","challenge_organizer" +"291","27","208","challenge_organizer" +"292","27","216","challenge_organizer" +"293","27","126","data_contributor" +"294","27","171","data_contributor" +"295","27","126","sponsor" +"296","27","166","sponsor" +"297","28","141","challenge_organizer" +"298","28","128","challenge_organizer" +"299","28","93","challenge_organizer" +"300","28","131","challenge_organizer" +"301","28","89","challenge_organizer" +"302","28","73","challenge_organizer" +"303","28","170","challenge_organizer" +"304","28","149","challenge_organizer" +"305","28","59","challenge_organizer" +"306","28","152","challenge_organizer" +"307","28","171","challenge_organizer" +"308","28","51","data_contributor" +"309","28","51","sponsor" +"310","28","59","sponsor" +"311","28","147","sponsor" +"312","29","211","challenge_organizer" +"313","29","128","challenge_organizer" +"314","29","210","challenge_organizer" +"315","29","171","challenge_organizer" +"316","29","195","challenge_organizer" +"317","29","128","data_contributor" +"318","29","128","sponsor" +"319","30","89","challenge_organizer" +"320","30","128","challenge_organizer" +"321","30","93","challenge_organizer" +"322","30","73","challenge_organizer" +"323","30","170","challenge_organizer" +"324","30","121","challenge_organizer" +"325","30","171","challenge_organizer" +"326","30","121","data_contributor" +"327","31","171","challenge_organizer" +"328","31","96","challenge_organizer" +"329","31","128","challenge_organizer" +"330","31","93","challenge_organizer" +"331","31","190","data_contributor" +"332","31","15","sponsor" +"333","32","87","challenge_organizer" +"334","32","48","challenge_organizer" +"335","32","66","challenge_organizer" +"336","32","128","challenge_organizer" +"337","32","93","challenge_organizer" +"338","32","171","challenge_organizer" +"339","32","182","data_contributor" +"340","32","116","data_contributor" +"341","32","15","data_contributor" +"342","32","31","sponsor" +"343","33","233","challenge_organizer" +"344","33","196","challenge_organizer" +"345","33","128","challenge_organizer" +"346","33","93","challenge_organizer" +"347","33","199","challenge_organizer" +"348","33","179","challenge_organizer" +"349","33","72","challenge_organizer" +"350","33","72","data_contributor" +"351","33","233","data_contributor" +"352","33","117","data_contributor" +"353","34","89","challenge_organizer" +"354","34","226","challenge_organizer" +"355","34","171","challenge_organizer" +"356","34","73","challenge_organizer" +"357","34","170","challenge_organizer" +"358","34","71","challenge_organizer" +"359","34","226","data_contributor" +"360","34","71","data_contributor" +"361","35","171","challenge_organizer" +"362","35","224","challenge_organizer" +"363","35","224","data_contributor" +"364","35","133","sponsor" +"365","35","97","sponsor" +"366","35","224","sponsor" +"367","36","43","challenge_organizer" +"368","36","171","challenge_organizer" +"369","36","234","challenge_organizer" +"370","36","114","challenge_organizer" +"371","36","224","challenge_organizer" +"372","36","16","challenge_organizer" +"373","36","93","challenge_organizer" +"374","36","43","data_contributor" +"375","36","114","data_contributor" +"376","36","234","data_contributor" +"377","37","95","challenge_organizer" +"378","37","113","challenge_organizer" +"379","37","150","challenge_organizer" +"380","37","171","challenge_organizer" +"381","37","179","challenge_organizer" +"382","37","16","data_contributor" +"383","37","234","data_contributor" +"384","37","114","data_contributor" +"385","37","43","data_contributor" +"386","37","171","data_contributor" +"387","37","131","sponsor" +"388","38","171","challenge_organizer" +"389","38","52","challenge_organizer" +"390","38","176","challenge_organizer" +"391","38","15","challenge_organizer" +"392","38","131","challenge_organizer" +"393","38","46","challenge_organizer" +"394","38","128","challenge_organizer" +"395","38","93","challenge_organizer" +"396","38","89","challenge_organizer" +"397","38","73","challenge_organizer" +"398","38","170","challenge_organizer" +"399","38","52","data_contributor" +"400","39","171","challenge_organizer" +"401","39","150","challenge_organizer" +"402","39","128","challenge_organizer" +"403","39","15","challenge_organizer" +"404","39","131","challenge_organizer" +"405","39","46","challenge_organizer" +"406","39","112","data_contributor" +"407","39","150","data_contributor" +"408","40","131","challenge_organizer" +"409","40","171","challenge_organizer" +"410","40","150","challenge_organizer" +"411","40","22","data_contributor" +"412","40","44","data_contributor" +"413","40","131","sponsor" +"414","41","192","challenge_organizer" +"415","41","128","challenge_organizer" +"416","41","93","challenge_organizer" +"417","41","199","challenge_organizer" +"418","41","171","challenge_organizer" +"419","41","192","data_contributor" +"420","41","133","sponsor" +"421","41","40","sponsor" +"422","42","171","challenge_organizer" +"423","42","144","challenge_organizer" +"424","42","126","challenge_organizer" +"425","42","76","challenge_organizer" +"426","42","126","data_contributor" +"427","42","144","data_contributor" +"428","42","216","data_contributor" +"429","42","191","data_contributor" +"430","42","198","data_contributor" +"431","42","161","data_contributor" +"432","43","171","challenge_organizer" +"433","43","52","challenge_organizer" +"434","43","176","challenge_organizer" +"435","43","15","challenge_organizer" +"436","43","46","challenge_organizer" +"437","43","128","challenge_organizer" +"438","43","89","challenge_organizer" +"439","43","52","data_contributor" +"440","43","46","sponsor" +"441","44","171","challenge_organizer" +"442","44","224","challenge_organizer" +"443","44","224","data_contributor" +"444","45","211","challenge_organizer" +"445","45","40","challenge_organizer" +"446","45","148","challenge_organizer" +"447","45","171","challenge_organizer" +"448","45","40","data_contributor" +"449","46","215","challenge_organizer" +"450","46","131","challenge_organizer" +"451","46","196","data_contributor" +"452","46","220","data_contributor" +"453","46","171","challenge_organizer" +"454","46","185","data_contributor" +"455","46","61","data_contributor" +"456","46","226","challenge_organizer" +"457","46","148","data_contributor" +"458","47","47","challenge_organizer" +"459","47","171","challenge_organizer" +"460","47","158","challenge_organizer" +"461","47","124","challenge_organizer" +"462","47","58","challenge_organizer" +"463","47","160","challenge_organizer" +"464","47","47","sponsor" +"465","59","30","data_contributor" +"466","59","224","data_contributor" +"467","59","196","data_contributor" +"468","61","64","data_contributor" +"469","62","173","data_contributor" +"470","63","224","data_contributor" +"471","64","184","data_contributor" +"472","65","33","data_contributor" +"473","66","196","data_contributor" +"474","67","159","data_contributor" +"475","67","70","data_contributor" +"476","68","42","data_contributor" +"477","69","200","data_contributor" +"478","70","91","data_contributor" +"479","71","214","data_contributor" +"480","72","179","data_contributor" +"481","276","41","data_contributor" +"482","271","213","data_contributor" +"483","73","91","data_contributor" +"484","275","88","data_contributor" +"485","270","220","data_contributor" +"486","74","222","data_contributor" +"487","269","217","data_contributor" +"488","279","221","data_contributor" +"489","272","173","data_contributor" +"490","273","173","data_contributor" +"491","274","220","data_contributor" +"492","278","218","data_contributor" +"493","277","41","data_contributor" +"494","79","104","challenge_organizer" +"495","79","3","challenge_organizer" +"496","79","102","challenge_organizer" +"497","79","215","challenge_organizer" +"498","79","143","challenge_organizer" +"499","79","224","challenge_organizer" +"500","79","203","challenge_organizer" +"501","79","219","challenge_organizer" +"502","79","137","sponsor" +"503","79","15","sponsor" +"504","79","60","sponsor" +"505","79","68","sponsor" +"506","80","209","challenge_organizer" +"507","80","183","challenge_organizer" +"508","80","194","challenge_organizer" +"509","80","207","challenge_organizer" +"510","80","135","sponsor" +"511","81","209","challenge_organizer" +"512","81","183","challenge_organizer" +"513","81","194","challenge_organizer" +"514","81","207","challenge_organizer" +"515","81","135","sponsor" +"516","82","189","sponsor" +"517","83","13","challenge_organizer" +"518","83","189","challenge_organizer" +"519","83","34","challenge_organizer" +"520","83","62","challenge_organizer" +"521","83","228","challenge_organizer" +"522","83","136","challenge_organizer" +"523","83","189","sponsor" +"524","84","13","challenge_organizer" +"525","84","189","challenge_organizer" +"526","84","152","challenge_organizer" +"527","84","201","challenge_organizer" +"528","84","128","challenge_organizer" +"529","84","93","challenge_organizer" +"530","84","62","challenge_organizer" +"531","84","34","challenge_organizer" +"532","84","189","sponsor" +"533","85","13","challenge_organizer" +"534","85","189","challenge_organizer" +"535","85","82","challenge_organizer" +"536","85","62","challenge_organizer" +"537","85","34","challenge_organizer" +"538","85","189","sponsor" +"539","86","13","challenge_organizer" +"540","86","189","challenge_organizer" +"541","86","83","challenge_organizer" +"542","86","34","challenge_organizer" +"543","86","189","sponsor" +"544","87","13","challenge_organizer" +"545","87","189","challenge_organizer" +"546","87","62","challenge_organizer" +"547","87","53","challenge_organizer" +"548","87","34","challenge_organizer" +"549","87","189","sponsor" +"550","88","136","challenge_organizer" +"551","88","13","challenge_organizer" +"552","88","189","challenge_organizer" +"553","88","62","challenge_organizer" +"554","88","34","challenge_organizer" +"555","88","189","sponsor" +"556","89","13","challenge_organizer" +"557","89","189","challenge_organizer" +"558","89","231","challenge_organizer" +"559","89","34","challenge_organizer" +"560","89","62","challenge_organizer" +"561","89","189","sponsor" +"562","90","13","challenge_organizer" +"563","90","189","challenge_organizer" +"564","90","34","challenge_organizer" +"565","90","62","challenge_organizer" +"566","90","189","sponsor" +"567","91","13","challenge_organizer" +"568","91","189","challenge_organizer" +"569","91","34","challenge_organizer" +"570","91","62","challenge_organizer" +"571","91","189","sponsor" +"572","92","13","challenge_organizer" +"573","92","189","challenge_organizer" +"574","92","34","challenge_organizer" +"575","92","62","challenge_organizer" +"576","92","131","challenge_organizer" +"577","92","177","challenge_organizer" +"578","92","189","sponsor" +"579","93","12","challenge_organizer" +"580","93","215","challenge_organizer" +"581","93","84","challenge_organizer" +"582","93","7","challenge_organizer" +"583","93","15","sponsor" +"584","93","90","sponsor" +"585","93","103","sponsor" +"586","93","50","sponsor" +"587","94","12","challenge_organizer" +"588","94","147","sponsor" +"589","94","35","sponsor" +"590","95","12","challenge_organizer" +"591","95","186","sponsor" +"592","95","178","sponsor" +"593","96","12","challenge_organizer" +"594","96","77","sponsor" +"595","113","12","sponsor" +"596","113","215","challenge_organizer" +"597","113","84","challenge_organizer" +"598","113","7","challenge_organizer" +"599","113","98","sponsor" +"600","113","139","sponsor" +"601","113","162","sponsor" +"602","150","13","challenge_organizer" +"603","150","237","challenge_organizer" +"604","151","13","challenge_organizer" +"605","151","238","challenge_organizer" +"606","152","13","challenge_organizer" +"607","152","238","challenge_organizer" +"608","153","13","challenge_organizer" +"609","153","231","challenge_organizer" +"610","154","13","challenge_organizer" +"611","55","1","sponsor" +"612","53","1","sponsor" +"613","52","1","sponsor" +"614","54","1","sponsor" +"615","155","1","sponsor" +"616","45","1","sponsor" +"617","44","1","sponsor" +"618","43","1","sponsor" +"619","40","1","sponsor" +"620","42","1","sponsor" +"621","39","1","sponsor" +"622","41","1","sponsor" +"623","35","1","sponsor" +"624","36","1","sponsor" +"625","34","1","sponsor" +"626","37","1","sponsor" +"627","33","1","sponsor" +"628","32","1","sponsor" +"629","31","1","sponsor" +"630","30","1","sponsor" +"631","29","1","sponsor" +"632","21","1","sponsor" +"633","27","1","sponsor" +"634","26","1","sponsor" +"635","28","1","sponsor" +"636","24","1","sponsor" +"637","25","1","sponsor" +"638","23","1","sponsor" +"639","20","1","sponsor" +"640","19","1","sponsor" +"641","18","1","sponsor" +"642","17","1","sponsor" +"643","16","1","sponsor" +"644","14","1","sponsor" +"645","8","1","sponsor" +"646","7","1","sponsor" +"647","11","1","sponsor" +"648","12","1","sponsor" +"649","10","1","sponsor" +"650","9","1","sponsor" +"651","6","1","sponsor" +"652","5","1","sponsor" +"653","4","1","sponsor" +"654","1","1","sponsor" +"655","3","1","sponsor" +"656","156","215","challenge_organizer" +"657","156","171","challenge_organizer" +"658","156","239","challenge_organizer" +"659","156","240","challenge_organizer" +"660","156","195","challenge_organizer" +"661","156","226","challenge_organizer" +"662","156","241","challenge_organizer" +"663","156","242","challenge_organizer" +"664","156","185","challenge_organizer" +"665","156","196","challenge_organizer" +"666","156","243","challenge_organizer" +"667","156","244","challenge_organizer" +"668","156","245","challenge_organizer" +"669","156","246","challenge_organizer" +"670","156","247","challenge_organizer" +"671","156","248","challenge_organizer" +"672","156","13","challenge_organizer" +"673","156","249","challenge_organizer" +"674","156","34","challenge_organizer" +"675","156","62","challenge_organizer" +"676","156","215","data_contributor" +"677","156","240","data_contributor" +"678","156","250","data_contributor" +"679","156","251","data_contributor" +"680","156","241","data_contributor" +"681","156","185","data_contributor" +"682","156","243","data_contributor" +"683","156","245","data_contributor" +"684","156","49","data_contributor" +"685","156","252","data_contributor" +"686","156","253","data_contributor" +"687","156","98","sponsor" +"688","156","139","sponsor" +"689","156","254","sponsor" +"690","156","255","sponsor" +"691","158","209","challenge_organizer" +"692","158","195","challenge_organizer" +"693","158","194","challenge_organizer" +"694","158","257","challenge_organizer" +"695","158","135","sponsor" +"696","159","258","challenge_organizer" +"697","159","258","data_contributor" +"698","159","161","challenge_organizer" +"699","159","161","data_contributor" +"700","159","259","challenge_organizer" +"701","159","260","challenge_organizer" +"702","159","261","challenge_organizer" +"703","159","261","data_contributor" +"704","159","262","challenge_organizer" +"705","159","263","challenge_organizer" +"706","159","264","challenge_organizer" +"707","159","265","sponsor" +"708","159","260","sponsor" +"709","159","266","sponsor" +"710","159","261","sponsor" +"711","160","267","challenge_organizer" +"712","160","267","sponsor" +"713","160","267","data_contributor" +"714","161","269","sponsor" +"715","161","268","challenge_organizer" +"716","162","272","challenge_organizer" +"717","162","271","challenge_organizer" +"718","162","270","challenge_organizer" +"719","163","273","sponsor" +"720","163","107","challenge_organizer" +"721","163","256","challenge_organizer" +"722","163","270","challenge_organizer" +"723","163","147","challenge_organizer" +"724","163","215","challenge_organizer" +"725","163","270","data_contributor" +"726","165","104","challenge_organizer" +"727","165","143","challenge_organizer" +"728","165","213","challenge_organizer" +"729","165","275","challenge_organizer" +"730","165","102","challenge_organizer" +"731","163","274","data_contributor" +"732","163","276","data_contributor" +"733","163","277","data_contributor" +"734","166","162","challenge_organizer" +"735","165","3","challenge_organizer" +"736","164","278","challenge_organizer" +"737","168","279","challenge_organizer" +"738","163","12","sponsor" +"739","161","12","sponsor" +"740","162","12","sponsor" +"741","160","12","sponsor" +"742","156","12","sponsor" +"743","170","12","sponsor" +"744","170","280","challenge_organizer" +"745","170","281","challenge_organizer" +"746","170","211","challenge_organizer" +"747","170","282","challenge_organizer" +"748","170","171","challenge_organizer" +"749","171","283","challenge_organizer" +"750","171","284","challenge_organizer" +"751","171","285","challenge_organizer" +"752","171","67","challenge_organizer" +"753","171","286","challenge_organizer" +"754","171","12","sponsor" +"755","171","15","sponsor" +"756","172","283","challenge_organizer" +"757","172","67","challenge_organizer" +"758","172","287","challenge_organizer" +"759","172","286","challenge_organizer" +"760","172","288","challenge_organizer" +"761","172","289","challenge_organizer" +"762","172","12","sponsor" +"763","172","15","sponsor" +"764","173","290","challenge_organizer" +"765","173","291","challenge_organizer" +"766","174","179","challenge_organizer" +"767","175","179","challenge_organizer" +"768","175","292","challenge_organizer" +"769","176","179","challenge_organizer" +"770","176","119","challenge_organizer" +"771","177","179","challenge_organizer" +"772","177","293","challenge_organizer" +"773","178","179","challenge_organizer" +"774","179","197","challenge_organizer" +"775","180","179","challenge_organizer" +"776","180","294","challenge_organizer" +"777","180","144","challenge_organizer" +"778","180","295","challenge_organizer" +"779","181","41","challenge_organizer" +"780","181","296","challenge_organizer" +"781","181","297","challenge_organizer" +"782","182","298","challenge_organizer" +"783","182","299","sponsor" +"784","182","300","sponsor" +"785","182","147","sponsor" +"786","182","301","sponsor" +"787","183","302","challenge_organizer" +"788","183","302","data_contributor" +"789","183","303","data_contributor" +"790","183","304","data_contributor" +"791","183","126","sponsor" +"792","184","75","sponsor" +"793","184","312","challenge_organizer" +"794","185","12","sponsor" +"795","185","226","challenge_organizer" +"796","185","306","challenge_organizer" +"797","185","307","challenge_organizer" +"798","185","308","challenge_organizer" +"799","185","248","challenge_organizer" +"800","185","305","challenge_organizer" +"801","185","309","challenge_organizer" +"802","185","310","challenge_organizer" +"803","185","220","challenge_organizer" +"804","185","261","data_contributor" +"805","185","311","data_contributor" +"806","186","261","challenge_organizer" +"807","186","261","data_contributor" +"808","186","12","sponsor" +"809","185","305","data_contributor" +"810","187","13","challenge_organizer" +"811","187","313","challenge_organizer" +"812","187","314","challenge_organizer" +"813","187","315","challenge_organizer" +"814","188","231","challenge_organizer" +"815","188","249","challenge_organizer" +"816","188","313","challenge_organizer" +"817","188","315","challenge_organizer" +"818","188","136","challenge_organizer" +"819","188","316","challenge_organizer" +"820","188","34","challenge_organizer" +"821","188","317","challenge_organizer" +"822","188","318","challenge_organizer" +"823","195","171","challenge_organizer" +"824","196","171","challenge_organizer" +"825","197","171","challenge_organizer" +"826","198","171","challenge_organizer" +"827","199","171","challenge_organizer" +"828","195","319","data_contributor" +"829","196","319","data_contributor" +"830","197","319","data_contributor" +"831","198","319","data_contributor" +"832","199","319","data_contributor" +"833","195","247","data_contributor" +"834","196","247","data_contributor" +"835","197","247","data_contributor" +"836","198","247","data_contributor" +"837","199","247","data_contributor" +"838","200","1","sponsor" +"839","201","1","sponsor" +"840","202","1","sponsor" +"841","203","1","sponsor" +"842","204","1","sponsor" +"843","205","1","sponsor" +"844","206","1","sponsor" +"845","207","1","sponsor" +"846","208","1","sponsor" +"847","209","1","sponsor" +"848","210","1","sponsor" +"849","211","1","sponsor" +"850","212","1","sponsor" +"851","213","1","sponsor" +"852","214","1","sponsor" +"853","215","1","sponsor" +"854","191","1","sponsor" +"855","192","1","sponsor" +"856","193","1","sponsor" +"857","194","1","sponsor" +"858","200","52","data_contributor" +"859","201","58","data_contributor" +"860","202","320","data_contributor" +"861","203","321","data_contributor" +"862","204","124","data_contributor" +"863","205","322","data_contributor" +"864","206","256","data_contributor" +"865","206","119","data_contributor" +"866","206","93","challenge_organizer" +"867","207","256","data_contributor" +"868","207","119","data_contributor" +"869","207","93","challenge_organizer" +"870","207","256","challenge_organizer" +"871","207","119","challenge_organizer" +"872","208","220","data_contributor" +"873","208","242","data_contributor" +"874","208","93","challenge_organizer" +"875","209","220","data_contributor" +"876","209","93","challenge_organizer" +"877","209","256","challenge_organizer" +"878","209","119","challenge_organizer" +"879","210","93","challenge_organizer" +"880","210","256","challenge_organizer" +"881","210","119","challenge_organizer" +"882","210","323","challenge_organizer" +"883","210","323","data_contributor" +"884","211","234","data_contributor" +"885","211","93","challenge_organizer" +"886","212","93","challenge_organizer" +"887","212","256","challenge_organizer" +"888","212","119","challenge_organizer" +"889","213","93","challenge_organizer" +"890","214","324","challenge_organizer" +"891","214","93","challenge_organizer" +"892","215","93","challenge_organizer" +"893","215","242","challenge_organizer" +"894","215","93","data_contributor" +"895","215","242","data_contributor" +"896","217","325","challenge_organizer" +"897","218","325","challenge_organizer" +"898","216","326","challenge_organizer" +"899","219","326","challenge_organizer" +"900","2","1","sponsor" +"901","38","1","sponsor" +"902","49","1","sponsor" +"903","58","1","sponsor" +"904","220","13","challenge_organizer" +"905","221","327","challenge_organizer" +"906","221","62","challenge_organizer" +"907","100","34","challenge_organizer" +"908","102","98","challenge_organizer" +"909","103","105","challenge_organizer" +"910","105","105","challenge_organizer" +"911","107","12","sponsor" +"912","107","328","sponsor" +"913","107","286","sponsor" +"914","107","161","challenge_organizer" +"915","107","329","challenge_organizer" +"916","112","225","challenge_organizer" +"917","113","162","challenge_organizer" +"918","118","92","challenge_organizer" +"919","120","174","challenge_organizer" +"920","145","162","challenge_organizer" +"921","167","15","sponsor" +"922","59","4","challenge_organizer" +"923","61","4","challenge_organizer" +"924","62","4","challenge_organizer" +"925","63","4","challenge_organizer" +"926","64","4","challenge_organizer" +"927","65","4","challenge_organizer" +"928","66","4","challenge_organizer" +"929","67","4","challenge_organizer" +"930","68","4","challenge_organizer" +"931","69","4","challenge_organizer" +"932","70","4","challenge_organizer" +"933","71","4","challenge_organizer" +"934","72","4","challenge_organizer" +"935","276","4","challenge_organizer" +"936","271","4","challenge_organizer" +"937","73","4","challenge_organizer" +"938","275","4","challenge_organizer" +"939","270","4","challenge_organizer" +"940","74","4","challenge_organizer" +"941","269","4","challenge_organizer" +"942","279","4","challenge_organizer" +"943","272","4","challenge_organizer" +"944","273","4","challenge_organizer" +"945","274","4","challenge_organizer" +"946","278","4","challenge_organizer" +"947","277","4","challenge_organizer" +"948","266","330","challenge_organizer" +"949","266","179","challenge_organizer" diff --git a/apps/openchallenges/organization-service/src/main/resources/db/migration/V1.0.1__insert_temp_data.sql b/apps/openchallenges/organization-service/src/main/resources/db/migration/V1.0.1__insert_temp_data.sql index 957f0e37d0..f089bf76b5 100644 --- a/apps/openchallenges/organization-service/src/main/resources/db/migration/V1.0.1__insert_temp_data.sql +++ b/apps/openchallenges/organization-service/src/main/resources/db/migration/V1.0.1__insert_temp_data.sql @@ -1,5097 +1,19 @@ -- organization data +LOAD DATA LOCAL INFILE '/workspace/BOOT-INF/classes/db/organizations.csv' INTO TABLE organization + FIELDS TERMINATED BY ',' OPTIONALLY ENCLOSED BY '"' + LINES TERMINATED BY '\n' + IGNORE 1 LINES; -INSERT INTO organization ( - id, - name, - acronym, - email, - login, - avatar_key, - website_url, - description, - created_at, - updated_at, - challenge_count - ) -VALUES ( - 1, - 'DREAM', - 'DREAM', - 'dream@sagebionetworks.org', - 'dream', - 'logo/dream.png', - 'https://dreamchallenges.org', - 'Together, we share a vision to enable individuals and groups to collaborate openly so that the “wisdom of the crowd” provides the greatest impact on science and human health.', - '2023-08-04 07:33:09', - '2023-08-05 06:10:02', - 71 - ), - ( - 3, - 'CAFA', - 'CAFA', - '', - 'cafa', - 'logo/cafa.png', - 'https://www.biofunctionprediction.org/cafa/', - 'The Critical Assessment of protein Function Annotation algorithms (CAFA) is an experiment designed to assess the performance of computational methods dedicated to predicting protein function, often using a time challenge. Briefly, CAFA organizers provide a large number of unannotated or incompletely annotated protein sequences. The predictors then predict the function of these proteins by associating them with Gene Ontology terms or Human Phenoytpe Ontology terms. Following the prediction deadline, there is a wait period of several months during which some proteins whose functions were unknown will receive experimental verification. Those proteins constitute the benchmark set, against which the methods are tested. Other data sources include experiments by wet lab collaborators and biocuration dedicated to CAFA.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:18', - 2 - ), - ( - 7, - 'CAMI', - 'CAMI', - '', - 'cami', - 'logo/cami.png', - 'https://data.cami-challenge.org/', - 'CAMI, the initiative for the “Critical Assessment of Metagenome Interpretation” aims to evaluate methods in metagenomics independently, comprehensively and without bias. The initiative supplies users with exhaustive quantitative data about the performance of methods in all relevant scenarios. It therefore guides users in the selection and application of methods and in their proper interpretation. Furthermore it provides valuable information to developers, allowing them to identify promising directions for their future work. CAMI organized in 2015 the first community driven benchmarking challenge in metagenomics. For the second CAMI challenge (starting on January 16th, 2019) visit https://data.cami-challenge.org', - '2023-06-23 00:00:00', - '2023-07-26 20:13:21', - 2 - ), - ( - 12, - 'MICCAI', - 'MICCAI', - '', - 'miccai', - 'logo/miccai.png', - 'http://www.miccai.org/special-interest-groups/challenges/miccai-registered-challenges/', - 'The Medical Image Computing and Computer Assisted Intervention Society (the MICCAI Society) is dedicated to the promotion, preservation and facilitation of research, education and practice in the field of medical image computing and computer assisted medical interventions including biomedical imaging and medical robotics. The Society achieves this aim through the organization and operation of annual high quality international conferences, workshops, tutorials and publications that promote and foster the exchange and dissemination of advanced knowledge, expertise and experience in the field produced by leading institutions and outstanding scientists, physicians and educators around the world. The MICCAI Society is committed to maintaining high academic standards and independence from any personal, political or commercial interests.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:24', - 16 - ), - ( - 13, - 'precisionFDA', - 'pFDA', - 'PrecisionFDA@fda.hhs.gov', - 'pfda', - 'logo/precisionfda.png', - 'https://precision.fda.gov/challenges', - 'A secure, collaborative, high-performance computing platform that builds a community of experts around the analysis of biological datasets in order to advance precision medicine.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:25', - 18 - ), - ( - 15, - 'National Institutes of Health', - 'NIH', - '', - 'nih', - 'logo/nih.png', - 'https://www.nih.gov/', - 'The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation''s medical research agency — making important discoveries that improve health and save lives.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:26', - 10 - ), - ( - 16, - 'Allen Institute', - '', - '', - 'allen-institute', - 'logo/allen-institute.svg', - 'https://alleninstitute.org/', - 'The Allen Institute is an independent nonprofit bioscience research institute aimed at unlocking the mysteries of human biology through foundational science that fuels the discovery of new treatments and cures.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:27', - 2 - ), - ( - 17, - 'ALS Therapy Alliance', - 'ATA', - 'Staff@lstherapyalliance.org', - 'ata', - 'logo/als-therapy-alliance.png', - 'https://alstherapyalliance.org/', - 'For over a decade, researchers and scientists have been relying on the ALS Therapy Alliance''s expertise and funding to advance their studies of amyotrophic lateral sclerosis (ALS), or Lou Gehrig''s disease. 2015 marks the 14th year of our annual Breakthrough ALS fundraising campaign (formerly known as Researching a Cure). The ALS Therapy Alliance''s ongoing grant award process is overseen by the organization''s board of award-winning researchers and scientists, as well as corporate executives and individuals who strive to learn more about the neurodegenerative disease, its cause and possible cure.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:28', - 1 - ), - ( - 18, - 'Alzheimer''s Disease Neuroimaging Initiative', - 'ADNI', - '', - 'adni', - 'logo/adni.jpg', - 'http://adni.loni.usc.edu/', - 'The Alzheimer''s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer''s disease (AD). ADNI researchers collect, validate and utilize data, including MRI and PET images, genetics, cognitive tests, CSF and blood biomarkers as predictors of the disease. Study resources and data from the North American ADNI study are available through this website, including Alzheimer''s disease patients, mild cognitive impairment subjects, and elderly controls.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:29', - 1 - ), - ( - 19, - 'Alzheimer''s Research UK', - '', - '', - 'alzheimers-research-uk', - 'logo/alzheimers-research-uk.jpg', - 'https://www.alzheimersresearchuk.org/', - 'Without effective treatments, one in three children born today will die with dementia. Today, there are no dementia survivors but research can change this. Alzheimer''s Research UK is the UK''s leading dementia research charity, dedicated to causes, diagnosis, prevention, treatment and cure. Backed by our passionate scientists and supporters, we''re challenging the way people think about dementia, uniting the big thinkers in the field and funding the innovative science that will deliver a cure.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:31', - 1 - ), - ( - 20, - 'Amazon Web Services', - 'AWS', - '', - 'aws', - 'logo/aws.svg', - 'https://aws.amazon.com/', - 'Whether you''re looking for compute power, database storage, content delivery, or other functionality, AWS has the services to help you build sophisticated applications with increased flexibility, scalability and reliability', - '2023-06-23 00:00:00', - '2023-07-26 20:13:31', - 1 - ), - ( - 21, - 'American Joint Committee on Cancer', - 'AJCC', - '', - 'ajcc', - '', - 'https://www.facs.org/quality-programs/cancer/ajcc', - 'Validating science, improving patient care.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:32', - 1 - ), - ( - 22, - 'APOLLO network', - '', - 'cancer.proteomics@mail.nih.gov', - 'apollo', - 'logo/apollo.png', - 'https://proteomics.cancer.gov/programs/apollo-network', - 'The Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) network is a collaboration between NCI, the Department of Defense (DoD), and the Department of Veterans Affairs (VA) to incorporate proteogenomics into patient care as a way of looking beyond the genome, to the activity and expression of the proteins that the genome encodes. The emerging field of proteogenomics aims to better predict how patients will respond to therapy by screening their tumors for both genetic abnormalities and protein information, an approach that has been made possible in recent years due to advances in proteomic technology.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:33', - 1 - ), - ( - 23, - 'Apple Health', - '', - '', - 'apple-health', - 'logo/wa-healthcare-authority.jpg', - 'https://www.hca.wa.gov/', - 'HCA is the largest purchaser of health care in the state. We lead the effort on transforming health care through programs and initiatives that range from the administration of Apple Health (Medicaid) and behavioral health activities to developing models for value-based purchasing and health technology assessments. We use data to inform our decisions and work in collaboration with local communities to ensure that Washington residents have access to better health care at a lower cost.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:33', - 14 - ), - ( - 24, - 'Arthritis Foundation', - '', - '', - 'arthritis-foundation', - 'logo/arthritis-foundation.png', - 'https://www.arthritis.org/', - 'Live your best life with the help of a compassionate and caring community. Get empowering information and make meaningful connections. Online and in person, we are all working together to promote life-changing resources and research, push for change and create community connections that welcome, inform and uplift. This is what makes our community of millions thrive — and why we are all Champions of Yes.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:35', - 1 - ), - ( - 25, - 'Arthritis Internet Registry', - '', - '', - 'arthritis-internet-registry', - '', - '', - 'This organization may no longer exist or has been merged under another organization.', - '2023-06-23 00:00:00', - '2023-08-08 17:59:48', - 1 - ), - ( - 26, - 'AstraZeneca', - '', - '', - 'astrazeneca', - 'logo/astrazeneca.png', - 'https://www.astrazeneca.com/', - 'We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:36', - 2 - ), - ( - 27, - 'Autodesk Research', - '', - 'autodesk.research@autodesk.com', - 'autodesk', - 'logo/autodesk-research.png', - 'https://www.research.autodesk.com/', - 'Autodesk is changing how the world is designed and made. At Autodesk Research, we advance this mission by exploring new possibilities where others see roadblocks. With a diverse team of scientists and industry experts, we conduct industrial research that helps customers design and make a better world for all.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:36', - 1 - ), - ( - 28, - 'BC Cancer Research Centre', - 'BCCRC', - '', - 'bccrc', - 'logo/bccrc.jpg', - 'https://www.bccrc.ca/', - 'BC Cancer Research strives to improve the lives of patients through the integration of basic biomedical research, genomics, clinical trials, health services research, cancer surveillance, population health, and the development of innovative new technology, programs, and interventions. Organized through departments and programs with various themes, BC Cancer supports groundbreaking cancer research and personalized care approaches through world-class facilities and platforms including genomics, bioinformatics, imaging, drug development and tissue banking.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:36', - 1 - ), - ( - 29, - 'Bellvitge Institute for Biomedical Research', - 'IDIBELL', - 'info@idibell.cat', - 'idibell', - 'logo/idibell.jpg', - 'https://idibell.cat/en/the-institute/', - 'The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and the Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L''Hospitalet de Llobregat city council. In 2017, the Center for Regenerative Medicine of Barcelona (CMR[B]), now part of IDIBELL, launched the Program for Advancing the Clinical Translation of Regenerative Medicine of Catalonia (P-CMR[C]) together with IDIBELL.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:37', - 1 - ), - ( - 30, - 'Berlin Institute of Health', - 'BIH', - 'info@bih-charite.de', - 'bih', - 'logo/bih.jpg', - 'https://www.bihealth.org/en/', - 'The mission of the BIH is medical translation: The BIH aims to translate findings from biomedical research into new approaches for personalised prediction, prevention and therapy and, conversely, to develop new research approaches from clinical observations.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:38', - 1 - ), - ( - 31, - 'Bill and Melinda Gates Foundation', - '', - '', - 'gates-foundation', - 'logo/gates-foundation.jpg', - 'https://www.gatesfoundation.org/', - 'Our mission is to create a world where every person has the opportunity to live a healthy, productive life.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:40', - 1 - ), - ( - 32, - 'Biogen', - '', - '', - 'biogen', - 'logo/biogen.png', - 'https://www.biogen.com/en_us/home.html', - 'Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world. Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer''s disease.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:42', - 1 - ), - ( - 33, - 'BioMarin Pharmaceutical Inc.', - '', - '', - 'biomarin', - 'logo/biomarin.jpg', - 'https://www.biomarin.com/', - 'Over two decades ago when we first opened our doors, we focused on giving much-needed attention to the underserved communities of those with rare diseases. These rare disease communities mostly affected children and were often ignored. At the time, BioMarin developed the only treatments for these life-altering conditions, giving hope to patients and families. Throughout our history, we''ve worked tirelessly to make a difference by pursuing bold science while respecting, educating, and connecting with patients. Through our expertise in genetics and molecular biology, we have been able to develop targeted therapies that address the root cause of the exact conditions we seek to treat. Our discoveries have led us to countless breakthroughs, best-in-class treatments and many ‘firsts'' in the category. We are grateful to able to better the lives of those struggling with genetic diseases.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:44', - 1 - ), - ( - 34, - 'Booz Allen Hamilton', - '', - '', - 'booz-allen', - 'logo/booz-allen.jpg', - 'https://www.boozallen.com/', - 'Booz Allen Hamilton has been at the forefront of strategy and technology for more than 100 years. Today, the firm provides management and technology consulting and engineering services to leading Fortune 500 corporations, governments, and not-for-profits across the globe. Booz Allen partners with public and private sector clients to solve their most difficult challenges through a combination of consulting, analytics, mission operations, technology, systems delivery, cybersecurity, engineering, and innovation expertise. \n\nWith international headquarters in McLean, Virginia, the firm employs more than 22,600 people globally and had revenue of $5.41 billion for the 12 months ended March 31, 2016.\n\nBooz Allen brings its pioneering work in advanced analytics—and the industry-leading expertise of its more than 600-member data science team—to transform our clients'' data into actions that keep them competitive in today''s data-driven economy. To learn about Booz Allen''s data science ...', - '2023-06-23 00:00:00', - '2023-07-26 20:13:45', - 13 - ), - ( - 35, - 'Braille Authority of North America', - 'BANA', - 'chair@brailleauthority.org', - 'bana', - 'logo/bana.jpeg', - 'http://www.brailleauthority.org/', - 'The purpose of BANA is to promote and to facilitate the uses, teaching, and production of braille. Pursuant to this purpose, BANA will promulgate rules, make interpretations, and render opinions pertaining to braille codes and guidelines for the provisions of literary and technical materials and related forms and formats of embossed materials now in existence or to be developed in the future for the use of blind persons in North America. When appropriate, BANA shall accomplish these activities in international collaboration with countries using English braille. In exercising its function and authority, BANA shall consider the effects of its decisions on other existing braille codes and guidelines, forms and formats; ease of production by various methods; and acceptability to readers.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:46', - 1 - ), - ( - 36, - 'Breast Cancer Surveillance Consortium', - 'BCSC', - 'KPWA.scc@kp.org', - 'bcsc', - 'logo/bcsc.jpeg', - 'https://www.bcsc-research.org/', - 'The Breast Cancer Surveillance Consortium (BCSC) is a collaborative network of six active breast imaging registries and two historic registries focused on research to assess and improve the delivery and quality of breast cancer screening and related outcomes in the United States. The registries perform annual linkages to tumor and pathology registries in their geographic region and are supported by a central Statistical Coordinating Center.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:47', - 1 - ), - ( - 37, - 'Brigham and Women''s Hospital', - 'BWH', - '', - 'bwh', - 'logo/bwh.png', - 'https://www.brighamandwomens.org/', - 'Brigham and Women''s Hospital is a world-class academic medical center based in Boston, Massachusetts. The Brigham serves patients from New England, across the United States and from 120 countries around the world. A major teaching hospital of Harvard Medical School, Brigham and Women''s Hospital has a legacy of clinical excellence that continues to grow year after year.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:47', - 1 - ), - ( - 38, - 'Brigham Young University', - 'BYU', - 'byu-info@byu.edu', - 'byu', - 'logo/byu.jpg', - 'https://www.byu.edu/', - 'At BYU, helping students to develop their full divine potential is central to both our teaching and our scholarship. As the flagship higher education institution of The Church of Jesus Christ of Latter-day Saints, BYU strives to emit a unique light for the benefit of the world—a light that will enable BYU to be counted among the exceptional universities in the world and an essential example for the world.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:48', - 1 - ), - ( - 39, - 'BrightFocus Foundation', - '', - 'info@brightfocus.org', - 'brightfocus-foundation', - 'logo/bright-focus.jpg', - 'https://www.brightfocus.org/', - 'BrightFocus funds exceptional scientific research worldwide to defeat Alzheimer''s disease, macular degeneration, and glaucoma and provides expert information on these heartbreaking diseases.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:49', - 1 - ), - ( - 40, - 'Bristol Myers Squibb', - 'BMS', - '', - 'bms', - 'logo/bms.jpg', - 'https://www.bms.com/', - 'At Bristol Myers Squibb, we work every day to transform patients'' lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. We have the brightest people in the industry and believe that their diverse experiences and perspectives help to bring out our best ideas, drive innovation and achieve transformative business results.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:50', - 2 - ), - ( - 41, - 'Broad Institute', - '', - '', - 'broad', - 'logo/broad.jpg', - 'https://www.broadinstitute.org/', - 'We seek to better understand the roots of disease and narrow the gap between new biological insights and impact for patients.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:51', - 5 - ), - ( - 42, - 'Brown University', - '', - '', - 'brown', - 'logo/brown.jpg', - 'https://www.brown.edu/', - 'Founded in 1764, Brown is a nonprofit leading research university, home to world-renowned faculty, and also an innovative educational institution where the curiosity, creativity and intellectual joy of students drives academic excellence. The spirit of the undergraduate Open Curriculum infuses every aspect of the University. Brown is a place where rigorous scholarship, complex problem-solving and service to the public good are defined by intense collaboration, intellectual discovery and working in ways that transcend traditional boundaries. As a private, nonprofit institution, the University advances its mission through support from a community invested in Brown''s commitment to advance knowledge and make a positive difference locally and globally.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:52', - 1 - ), - ( - 43, - 'California Institute of Technology', - '', - '', - 'caltech', - 'logo/caltech.jpg', - 'https://www.caltech.edu/', - 'Caltech is a world-renowned science and engineering institute that marshals some of the world''s brightest minds and most innovative tools to address fundamental scientific questions and pressing societal challenges.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:52', - 2 - ), - ( - 44, - 'Cancer Imaging Archive', - 'TCIA', - '', - 'tcia', - 'logo/tcia.jpeg', - 'https://www.cancerimagingarchive.net/', - 'The Cancer Imaging Archive (TCIA) is a service which de-identifies and hosts a large publicly available archive of medical images of cancer. TCIA is funded by the Cancer Imaging Program (CIP), a part of the United States National Cancer Institute (NCI), and is managed by the Frederick National Laboratory for Cancer Research (FNLCR).', - '2023-06-23 00:00:00', - '2023-07-26 20:13:53', - 1 - ), - ( - 45, - 'Cancer Research UK', - '', - '', - 'cancer-research-uk', - 'logo/cancer-research-uk.jpg', - 'https://www.cancerresearchuk.org/', - 'Cancer Research UK was formed 20 years ago, in 2002. However, our history goes back much further, to 1902, with the founding of the Imperial Cancer Research Fund. Thanks to supporters like you, our pioneering work into how to prevent, diagnose and treat cancer has benefitted millions of lives over the past 120 years. Find out more about how our research has already made a difference to patients and what we are funding right now.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:54', - 1 - ), - ( - 46, - 'Cancer Target Discovery and Development', - 'CTD2', - '', - 'ctd2', - 'logo/ctd2.png', - 'https://ocg.cancer.gov/programs/ctd2', - 'The Cancer Target Discovery and Development (CTD2) Network, also known as C-T-D-Squared, is a functional genomics initiative that bridges the gap between genomics and development of effective therapeutics. The Network aims to understand tumor development, heterogeneity, drug resistance, and metastasis to develop optimal combinations of chemotherapy with immunotherapy.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:55', - 4 - ), - ( - 47, - 'Celgene', - '', - '', - 'celgene', - 'logo/celgene.jpg', - 'https://www.celgene.com', - 'This organization may no longer exist or has been merged under another organization.', - '2023-06-23 00:00:00', - '2023-08-08 17:58:26', - 3 - ), - ( - 48, - 'Center for Research Computing', - 'CRC', - 'CRCSupport@nd.edu', - 'crc', - 'logo/crc.jpeg', - 'https://crc.nd.edu/', - 'The Center for Research Computing (CRC) at University of Notre Dame is an innovative and multidisciplinary research environment that supports collaboration to facilitate multidisciplinary discoveries through advanced computation, software engineering, artificial intelligence, and other digital research tools. The Center enhances the University''s innovative applications of cyberinfrastructure, provides support for interdisciplinary research and education, and conducts computational research.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:57', - 1 - ), - ( - 49, - 'Cincinnati Children''s', - 'CCHMC', - '', - 'cchmc', - 'logo/cchmc.jpg', - 'https://www.cincinnatichildrens.org/', - 'Cincinnati Children''s, a nonprofit academic medical center established in 1883, is one of the oldest and most distinguished pediatric hospitals in the United States.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:57', - 2 - ), - ( - 50, - 'Climb 4 Kidney Cancer', - 'C4KC', - '', - 'c4kc', - 'logo/c4kc.jpg', - 'https://climb4kc.org/', - 'Climb 4 Kidney Cancer is a nonprofit organization that aims to raise money for kidney cancer research while bringing people together through climbing. We are physicians, scientists, survivors, and loved ones who share a passion for climbing and a passion for improving the lives of those affected by kidney cancer.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:58', - 1 - ), - ( - 51, - 'Clinical Proteomic Tumor Analysis Consortium', - 'CPTAC', - '', - 'cptac', - 'logo/cptac.png', - 'https://proteomics.cancer.gov/programs/cptac', - 'The National Cancer Institute''s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:58', - 1 - ), - ( - 52, - 'Columbia University', - '', - 'askcuit@columbia.edu', - 'columbia', - 'logo/columbia.jpg', - 'https://www.columbia.edu/', - 'Columbia University is one of the world''s most important centers of research and at the same time a distinctive and distinguished learning environment for undergraduates and graduate students in many scholarly and professional fields. The University recognizes the importance of its location in New York City and seeks to link its research and teaching to the vast resources of a great metropolis. It seeks to attract a diverse and international faculty, staff, and student body, to support research and teaching on global issues, and to create academic relationships with many countries and regions. It expects all areas of the University to advance knowledge and learning at the highest level and to convey the products of its efforts to the world.', - '2023-06-23 00:00:00', - '2023-07-26 20:13:59', - 5 - ), - ( - 53, - 'Conceptant', - '', - 'connect@conceptant.com', - 'conceptant', - 'logo/conceptant.webp', - 'https://www.conceptant.com/', - 'We want to improve humanity and the world through technology, plain and simple. Tech has so much promise to improve lives, but we felt it was constantly overshadowed by stuffy boardrooms and corporate red tape. Which is why Conceptant takes a different path, one we created. We go against the grain using creative techniques to develop cutting edge solutions while avoiding the pot holes of slow stuffy suits. ', - '2023-06-23 00:00:00', - '2023-07-26 20:14:00', - 1 - ), - ( - 54, - 'Consejo Superior de Investigaciones Cientificas', - 'CSIC', - '', - 'csic', - 'logo/csic.jpg', - 'https://www.csic.es/', - 'The Higher Council for Scientific Research (CSIC) is a State Agency for scientific research and technological development, with differentiated legal personality, its own assets and treasury, functional and management autonomy, full legal capacity to act and of indefinite duration (art. 1 Statute).', - '2023-06-23 00:00:00', - '2023-07-26 20:14:00', - 1 - ), - ( - 55, - 'CorEvitas', - '', - 'info@corevitas.com', - 'corevitas', - 'logo/corevitas.jpeg', - 'https://www.corevitas.com/', - 'CorEvitas is a science-led, data intelligence company that provides the life sciences industry with the objective data and clinical insights needed to demonstrate the real-world safety, effectiveness, and patient experience of therapeutics in the post-approval setting', - '2023-06-23 00:00:00', - '2023-07-26 20:14:02', - 1 - ), - ( - 56, - 'Corrona', - '', - '', - 'corrona', - 'logo/corrona.jpeg', - 'https://www.corrona.org', - 'This organization may no longer exist or has been merged under another organization.', - '2023-06-23 00:00:00', - '2023-08-08 17:58:48', - 1 - ), - ( - 57, - 'Covert Lab', - '', - 'covert.lab@gmail.com', - 'covert-lab', - '', - 'https://www.covert.stanford.edu/', - 'We''re a scrappy bunch of scientists who like to do cutting-edge research with the latest technology (often home-made)! Our primary biological focus is in host-pathogen interactions, most particularly in terms of the innate immune system, and our technological foci are whole-cell modeling and live-cell imaging, as shown above. We''re always looking for top talent - if you''re a budding, intellectually ambidextrous scientist with a creative streak and an aptitude for team play, this could be the place for you!', - '2023-06-23 00:00:00', - '2023-07-26 20:14:04', - 1 - ), - ( - 58, - 'Dana-Farber Cancer Institute', - 'DFCI', - '', - 'dfci', - 'logo/dfci.png', - 'https://www.dana-farber.org/', - 'Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow''s cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:04', - 5 - ), - ( - 59, - 'Defense Advanced Research Projects Agency', - 'DARPA', - '', - 'darpa', - 'logo/darpa.jpg', - 'https://www.darpa.mil/', - 'For sixty years, DARPA has held to a singular and enduring mission: to make pivotal investments in breakthrough technologies for national security. The genesis of that mission and of DARPA itself dates to the launch of Sputnik in 1957, and a commitment by the United States that, from that time forward, it would be the initiator and not the victim of strategic technological surprises. Working with innovators inside and outside of government, DARPA has repeatedly delivered on that mission, transforming revolutionary concepts and even seeming impossibilities into practical capabilities. The ultimate results have included not only game-changing military capabilities such as precision weapons and stealth technology, but also such icons of modern civilian society such as the Internet, automated voice recognition and language translation, and Global Positioning System receivers small enough to embed in myriad consumer devices.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:05', - 2 - ), - ( - 60, - 'Department of Energy', - 'DOE', - '', - 'doe', - 'logo/doe.jpg', - 'https://www.energy.gov/', - 'The mission of the Energy Department is to ensure America''s security and prosperity by addressing its energy, environmental and nuclear challenges through transformative science and technology solutions.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:06', - 1 - ), - ( - 61, - 'Diagnosticos da America SA', - 'DASA', - '', - 'dasa', - 'logo/dasa.jpeg', - 'https://dasa.com.br/', - 'We are Dasa. A new model that expands and integrates health care throughout life. We have brought together the largest diagnostic medicine network, a robust hospital group and the best care management company, so that nothing is missing and full care is provided. We connect spaces, technologies, knowledge, multiply specialties and become a complete company, alive and moving, always evolving. We develop the most innovative technology and health with new digital solutions that we seek in the market, via open innovation and in Dasa startups. Today we are more than 40,000 professionals ready to meet‌ ‌all‌ ‌‌‌your‌ health needs. We are for you. A comprehensive health network with a ‌grand purpose, which is to make sure you experience the best of your health every day.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:06', - 1 - ), - ( - 62, - 'DNAnexus', - '', - '', - 'dnanexus', - 'logo/dnanexus.png', - 'https://www.dnanexus.com/', - 'DNAnexus(R) has built the world''s most secure cloud platform and global network for scientific collaboration and accelerated discovery. We embrace challenges and partnership to tackle the world''s most exciting opportunities in human health.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:08', - 11 - ), - ( - 63, - 'Dockstore', - '', - '', - 'dockstore', - 'logo/dockstore.jpg', - 'https://dockstore.org/', - 'Dockstore is a free and open source platform for sharing reusable and scalable analytical tools and workflows. It''s developed by the Cancer Genome Collaboratory and used by the GA4GH.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:08', - 1 - ), - ( - 64, - 'Duke University', - '', - '', - 'duke', - 'logo/duke.jpg', - 'https://duke.edu/', - 'The mission of Duke University is to provide a superior liberal education to undergraduate students, attending not only to their intellectual growth but also to their development as adults committed to high ethical standards and full participation as leaders in their communities; to prepare future members of the learned professions for lives of skilled and ethical service by providing excellent graduate and professional education; to advance the frontiers of knowledge and contribute boldly to the international community of scholarship; to promote an intellectual environment built on a commitment to free and open inquiry; to help those who suffer, cure disease, and promote health, through sophisticated medical research and thoughtful patient care; to provide wide ranging educational opportunities, on and beyond our campuses, for traditional students, active professionals and life-long learners using the power of information technologies; and to promote a deep appreciation for the ra...', - '2023-06-23 00:00:00', - '2023-07-26 20:14:09', - 3 - ), - ( - 65, - 'Early Signal Foundation', - '', - '', - 'early-signal', - '', - 'http://www.earlysignal.org', - 'This organization may no longer exist or has been merged under another organization.', - '2023-06-23 00:00:00', - '2023-08-08 17:58:54', - 1 - ), - ( - 66, - 'Eck Institute for Global Health', - 'EIGH', - '', - 'eigh', - 'logo/eigh.jpg', - 'https://globalhealth.nd.edu/', - 'The University of Notre Dame''s Eck Institute for Global Health (EIGH) serves as a university-wide enterprise that recognizes health as a fundamental human right and works to promote research, training, and service to advance health standards and reduce health disparities for all. The EIGH brings together multidisciplinary teams to understand and address health challenges that disproportionately affect the poor and to train the next generation of global health leaders.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:10', - 1 - ), - ( - 67, - 'Eli Lilly and Company', - '', - '', - 'lilly', - 'logo/lilly.png', - 'https://www.lilly.com/', - 'Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: "Take what you find here and make it better and better." More than 145 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live. ', - '2023-06-23 00:00:00', - '2023-07-26 20:14:11', - 3 - ), - ( - 68, - 'Elixir', - '', - '', - 'elixir', - 'logo/elixir.jpg', - 'https://www.elixirsolutions.com/', - 'Elixir is a pharmacy benefits and services company with the scale, flexibility and expertise to help our clients achieve their unique business goals. We have been purposely built and own all the assets needed to optimize the full pharmacy care experience, including: a) An industry leading adjudication platform, offering flexibility, efficiency and data privacy protection; b) Accredited mail and specialty pharmacies, creating an exceptional member experience, waste reduction and cost savings; c) Population health services through our sister company, Health Dialog; and d) Prescription discount programs for uninsured and under-insured and Medicare Part D plans for individuals, associations and groups.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:12', - 1 - ), - ( - 69, - 'Encyclopedia of DNA Elements Data Coordinating Center', - 'ENCODE', - 'encode-help@lists.stanford.edu', - 'encode', - 'logo/encode.png', - 'https://www.encodeproject.org/', - 'The ENCODE Data Coordination Center (DCC)''s primary task is to curate, uniformly process and validate the data generated and submitted by ENCODE Consortium members in preparation for release to the scientific community.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:13', - 1 - ), - ( - 70, - 'ENIGMA Consortium', - 'ENIGMA', - 'enigma@ini.usc.edu', - 'enigma', - 'logo/enigma.jpg', - 'http://enigma.ini.usc.edu/', - 'The ENIGMA Consortium brings together researchers in imaging genomics to understand brain structure, function, and disease, based on brain imaging and genetic data. We welcome brain researchers, imagers, geneticists, methods developers, and others interested in cracking the neuro-genetic code!', - '2023-06-23 00:00:00', - '2023-07-26 20:14:13', - 1 - ), - ( - 71, - 'ETH Zurich', - 'ETH', - '', - 'eth', - 'logo/eth.jpg', - 'https://ethz.ch/en.html', - 'Freedom and individual responsibility, entrepreneurial spirit and open-​​mindedness: ETH Zurich stands on a bedrock of true Swiss values.  ', - '2023-06-23 00:00:00', - '2023-07-26 20:14:14', - 2 - ), - ( - 72, - 'Eunice Kennedy Shriver National Institute', - 'NICHD', - 'NICHDInformationResourceCenter@mail.nih.gov', - 'nichd', - 'logo/nichd.jpg', - 'https://www.nichd.nih.gov/', - 'NICHD was founded in 1962 to investigate human development throughout the entire life process, with a focus on understanding disabilities and important events that occur during pregnancy. Since then, research conducted and funded by NICHD has helped save lives, improve wellbeing, and reduce societal costs associated with illness and disability. NICHD''s mission is to lead research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:15', - 1 - ), - ( - 73, - 'European Bioinformatics Institute', - 'EMBL-EBI', - '', - 'embl-ebi', - 'logo/embl-ebi.jpg', - 'https://www.ebi.ac.uk/', - 'At EMBL''s European Bioinformatics Institute (EMBL-EBI), we help scientists realise the potential of big data in biology, exploiting complex information to make discoveries that benefit humankind.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:15', - 8 - ), - ( - 74, - 'European Medicines Agency', - 'EMA', - '', - 'ema', - 'logo/ema.jpg', - 'https://www.ema.europa.eu/en', - 'The mission of the European Medicines Agency (EMA) is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health in the European Union (EU).', - '2023-06-23 00:00:00', - '2023-07-26 20:14:16', - 1 - ), - ( - 75, - 'European Union', - 'EU', - '', - 'eu', - 'logo/eu.png', - 'https://europa.eu/european-union/index_en', - 'The common principles and values that underlie life in the EU: freedom, democracy, equality and the rule of law, promoting peace and stability.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:16', - 2 - ), - ( - 76, - 'Evidation Health', - '', - '', - 'evidation', - 'logo/evidation.png', - 'https://evidation.com/', - 'We believe everyday health data is the most compelling force in medicine—because under rigorous study, it''s proving to be a new and exceptionally powerful lens on health. These novel discoveries—emanating from data generated and controlled by individuals—can be turned into tools they use to take control of their health. By connecting our member community to research and innovation partners across the health ecosystem, we''re creating a new platform for medical advancements and innovation.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:17', - 1 - ), - ( - 77, - 'Fehling Instruments', - '', - '', - 'fehling-instruments', - 'logo/fehling-instruments.jpeg', - 'https://www.fehling-instruments.de/en/', - 'Fehling Instruments is a traditional family owned and family run company with more than thirty years of experience in the medical business. Fehling Instruments is constantly striving for excellence in function and economy of products. This objective is achieved by continuous innovation in materials, mechanics and design. Customer satisfaction is the prevailing goal of our business. Therefore, Fehling Instruments provides outstanding service in addition to quality products. Fehling Instruments develops, manufactures, and distributes surgical instruments, implants and single use products for use mainly in the OR. FI also provides all corresponding repair service. The most important target markets for Fehling Instruments are neuro surgery (spine and brain) and thoracic, cardiac and vascular surgery.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:18', - 1 - ), - ( - 78, - 'Feinstein Institutes for Medical Research', - '', - '', - 'feinstein-institute', - 'logo/feinstein-institute.png', - 'https://feinstein.northwell.edu/', - 'The Feinstein Institutes for Medical Research is the home of research at Northwell Health. In conjunction with our partners in government, academia, industry and philanthropy, we strive to advance knowledge and make innovative therapies a reality. Our researchers work to transform the treatment of conditions like lupus, arthritis, sepsis, cancer, psychiatric illness and Alzheimer''s disease. As the global headquarters of bioelectronic medicine, we''re exploring ways to raise the standard of medical innovation and are using electronic medical devices to signal the body to heal itself.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:19', - 1 - ), - ( - 79, - 'Francis Crick Institute', - '', - 'info@crick.ac.uk', - 'francis-crick-institute', - 'logo/francis-crick-institute.jpeg', - 'https://www.crick.ac.uk/', - 'The Francis Crick Institute is a biomedical research institute working with organisations across academia, medicine and industry to make discoveries about how life works.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:20', - 1 - ), - ( - 80, - 'Fred Hutchinson Cancer Research Center', - '', - '', - 'fred-hutch', - 'logo/fred-hutch.jpg', - 'https://www.fredhutch.org/', - 'Fred Hutchinson Cancer Center unites innovative research and compassionate care to prevent and eliminate cancer and infectious disease. We''re driven by the urgency of our patients, the hope of our community and our passion for discovery to pursue scientific breakthroughs and healthier lives for every person in every community. ', - '2023-06-23 00:00:00', - '2023-07-26 20:14:21', - 1 - ), - ( - 81, - 'Genome Canada', - '', - 'info@genomecanada.ca', - 'genome-canada', - 'logo/genome-canada.png', - 'https://www.genomecanada.ca/', - 'Genome Canada is an independent, federally funded not-for-profit organization and a national leader for Canada''s genomics ecosystem. Working in partnership, and across sectors, we invest in, and coordinate, genomics research, innovation, data and talent to generate solutions to today''s biggest challenges.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:21', - 3 - ), - ( - 82, - 'George Washington University', - 'GWU', - '', - 'gwu', - 'logo/gwu.jpg', - 'https://www.gwu.edu/', - 'Since our capital city''s first days, people have traveled here for many reasons. They come to explore the past and to chart new futures. They come to ask questions and to seek expert answers. They come to start discourse and to remember in silence. They come to demand change and to be that change. They come to grow. They come to learn. They come to make history and join the ranks alongside many monumental GW alumni.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:23', - 2 - ), - ( - 83, - 'Georgetown University', - '', - '', - 'georgetown', - 'logo/georgetown.png', - 'https://www.georgetown.edu/', - 'We''re a leading research university with a heart. Founded in the decade that the U.S. Constitution was signed, we''re the nation''s oldest Catholic and Jesuit university. Today we''re a forward-looking, diverse community devoted to social justice, restless inquiry and respect for each person''s individual needs and talents.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:23', - 1 - ), - ( - 84, - 'German Cancer Research Center', - 'DKFZ', - '', - 'dkfz', - 'logo/dkfz.jpg', - 'https://www.dkfz.de/en/index.html', - 'More than 450,000 people are diagnosed with cancer each year in Germany. Cancer is a disease that poses enormous challenges to research, because every cancer is different and its course can vary immensely even from one patient to the next. To perform research into cancer is the task of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) according to its statutes. DKFZ is the largest biomedical research institute in Germany and a member of the Helmholtz Association of National Research Centers. In more than 100 divisions and research groups, our more than 3,000 employees, of which more than 1,200 are scientists, are investigating the mechanisms of cancer, are identifying cancer risk factors and are trying to find strategies to prevent people from getting cancer.They are developing novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:24', - 2 - ), - ( - 85, - 'Global Alliance for Genomics and Health', - 'GA4GH', - 'info@ga4gh.org', - 'ga4gh', - 'logo/ga4gh.png', - 'https://www.ga4gh.org/', - 'The Global Alliance for Genomics and Health (GA4GH) is an international, nonprofit alliance formed in 2013 to accelerate the potential of research and medicine to advance human health. Bringing together 600+ leading organizations working in healthcare, research, patient advocacy, life science, and information technology, the GA4GH community is working together to create frameworks and standards to enable the responsible, voluntary, and secure sharing of genomic and health-related data. All of our work builds upon the Framework for Responsible Sharing of Genomic and Health-Related Data.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:24', - 1 - ), - ( - 86, - 'H. Lee Moffitt Cancer Center and Research Institute', - '', - '', - 'moffitt', - 'logo/moffitt.png', - 'https://moffitt.org/', - 'At Moffitt Cancer Center, we are working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease. We are committed to the health and safety of our patients and dedicated to providing expert cancer care.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:25', - 1 - ), - ( - 87, - 'H3ABioNet', - '', - 'info@h3abionet.org', - 'h3abionet', - 'logo/h3abionet.png', - 'https://h3abionet.org/', - 'H3ABioNet is a Pan African Bioinformatics network comprising 28 Nodes distributed amongst 17 countries, 16 of which are African. H3ABioNet was developed to support H3Africa research projects through the development of bioinformatics capacity on the continent. Specifically H3ABioNet aims to: a) Implement a Pan African informatics infrastructure; b) Develop an H3Africa data coordinating center; c) Provide high quality informatics support to H3Africa; d) Enable and enhance innovative translational research; and e) Address outreach, development and sustainability.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:26', - 1 - ), - ( - 88, - 'Harvard University', - '', - '', - 'harvard', - 'logo/harvard.jpg', - 'https://www.harvard.edu/', - 'As a research university and nonprofit institution, Harvard is focused on creating educational opportunities for people from many lived experiences.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:26', - 3 - ), - ( - 89, - 'Heidelberg University', - '', - '', - 'heidelberg-university', - 'logo/heidelberg-university.jpg', - 'https://www.heidelberg.edu/', - 'A day at Heidelberg University is filled with connection. Whether it''s walking to class, receiving one-on-one instruction from excellent faculty, or perfecting new skills at practice, students are uplifted every moment. Each time a Student Prince makes their own success, they know they have a dedicated community standing behind them.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:27', - 10 - ), - ( - 90, - 'HistoSonics Inc.', - '', - '', - 'histosonics', - 'logo/histosonics.jpg', - 'https://histosonics.com/', - 'Minimally invasive isn''t minimal enough. HistoSonics(R) is developing a non-invasive, sonic beam therapy platform capable of destroying tissue at a sub-cellular level.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:28', - 1 - ), - ( - 91, - 'Hospital for Sick Children', - '', - '', - 'sickkids', - 'logo/sickkids.jpg', - 'https://www.sickkids.ca/Research/', - 'SickKids Research Institute (RI) is where over 2,000 researchers, trainees, and staff are working together to take on the toughest challenges in child health. As Canada''s largest, hospital-based child health research institute, we conduct and translate groundbreaking research to improve child health outcomes, policy, and clinical care, train the next generation of researchers, and support global scientific communities with knowledge and state-of-the-art facilities. Innovation and collaboration across our seven distinct research programs have led to a number of incredible discoveries at SickKids, uncovering the mechanisms and outcomes of childhood disease. And with every research question in the lab, we are driving clinical changes.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:28', - 3 - ), - ( - 92, - 'Human Protein Atlas', - 'HPA', - '', - 'hpa', - 'logo/hpa.png', - 'www.proteinatlas.org', - 'The Human Protein Atlas is a Swedish-based program initiated in 2003 with the aim to map the expression and spatial distribution of all human proteins in cells and tissues using an integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics and systems biology. The data is freely available in the Protein Atlas database (www.proteinatlas.org) to allow scientists both in academia and industry to freely access the data for exploration of the human proteome with the mission to accelerate life science research and drug discovery.The database is used by over 200,000 users per month and nearly 10 publications per day use data from the Protein Atlas.\n\nThe image data in the challenge comes from the HPA Cell Atlas, led by Dr. Emma Lundberg.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:29', - 1 - ), - ( - 93, - 'IBM', - 'IBM', - '', - 'ibm', - 'logo/ibm.svg', - 'https://www.research.ibm.com/', - 'At IBM Research we live by the scientific method. It''s at the core of everything we do. We choose impact over market cycles, vision over vanity. We deeply believe that creative freedom, excellence, and integrity are essential to any breakthrough. We operate with a backbone. We don''t cut corners. We take responsibility for technology and its role in society. We make decisions with a conscience — for a future that we believe is worth living in. We recognize the immense power and potential of computing — not as a commodity, but as an agent of progress and connection. This is the future, built right.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:30', - 37 - ), - ( - 94, - 'Innovative Medicines Initiative', - 'IMI', - '', - 'imi', - 'logo/imi.png', - 'http://www.imi.europa.eu/', - 'At the Innovative Medicines Initiative (IMI), we are working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. We do this by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world''s biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through the IMI2 programme, we have a €3.3 billion budget for the period 2014-2020.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:30', - 1 - ), - ( - 95, - 'Institut Curie', - '', - '', - 'institut-curie', - 'logo/institut-curie.jpg', - 'https://institut-curie.org/', - 'Institut Curie is the leading cancer research and treatment centre in France and has been a recognised public utility foundation since 1921. Since its creation by Marie Curie, Institut Curie has worked on three missions: Care, Reserach, Transmission.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:31', - 2 - ), - ( - 96, - 'Institute for Molecular Medicine Finland', - 'FIMM', - '', - 'fimm', - 'logo/fimm.png', - 'https://www.helsinki.fi/en/hilife-helsinki-institute-life-science/units/fimm', - 'FIMM – Institute for Molecular Medicine Finland is a translational research institute focusing on human genomics and precision medicine as part of the Helsinki Institute of Life Science HiLIFE at the University of Helsinki. FIMM has a driving mission to perform innovative research on patients and populations targeted towards understanding drivers of health and disease. We aim at delivering improvements to the safety, efficacy, and efficiency of healthcare in Finland and beyond. ', - '2023-06-23 00:00:00', - '2023-07-26 20:14:33', - 1 - ), - ( - 97, - 'Institute of Translational Health Sciences', - 'ITHS', - '', - 'iths', - 'logo/iths.jpg', - 'https://www.iths.org/', - 'The Institute of Translational Health Sciences is dedicated to speeding science to the clinic for the benefit of patients and communities throughout Washington, Wyoming, Alaska, Montana, and Idaho.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:34', - 1 - ), - ( - 98, - 'Intel Corporation', - '', - '', - 'intel', - 'logo/intel.svg', - 'https://www.intel.com/content/www/us/en/homepage.html', - 'Intel(R) Software sits at the intersection of hardware, interoperability, and amazing customer experiences. We partner with the global technology ecosystem to make development EASY, OPEN, and SCALABLE so developers can do what they do best: deliver groundbreaking applications and end-to-end solutions on Intel technologies. Visit the Intel(r) Nervana(TM) AI Academy to gain access to tools, Intel optimized frameworks, libraries, technical experts and training, getting started guides, and more.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:37', - 3 - ), - ( - 99, - 'International Cancer Genome Consortium', - 'ICGC', - '', - 'icgc', - 'logo/icgc.jpg', - 'https://dcc.icgc.org/', - 'The ICGC Data Portal provides many tools for visualizing, querying, and downloading cancer data, which is released on a quarterly schedule.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:38', - 5 - ), - ( - 100, - 'International Flavors and Fragrances Inc.', - 'IFF', - '', - 'iff', - 'logo/iff.png', - 'https://www.iff.com/', - 'We apply science and creativity for a better world. With the beauty of art and the precision of science, we are an international collective of thinkers who partner with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. As a global leader in food, beverage, health, biosciences and sensorial experiences, we do a lot and continually innovate to do it better. For more than 130 years we''ve been focused on finding the most innovative solutions to help bring “better for you” products to market. While we have grown over the years, we remain agile in our approach and put our customers'' needs at the forefront of our thinking. We offer end-to-end service that few can deliver on. Our unparalleled product portfolio is the most robust in the industry and we have leadership positions across key taste, texture, scent, nutrition, enzymes, cultures, soy proteins and probiotics categories.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:38', - 1 - ), - ( - 101, - 'International Genome Sample Resource', - 'IGSR', - '', - 'igsr', - 'logo/igsr.jpg', - 'https://www.internationalgenome.org/home', - 'The 1000 Genomes Project created a catalogue of common human genetic variation, using openly consented samples from people who declared themselves to be healthy. The reference data resources generated by the project remain heavily used by the biomedical science community. The International Genome Sample Resource (IGSR) maintains and shares the human genetic variation resources built by the 1000 Genomes Project. We also update the resources to the current reference assembly, add new data sets generated from the 1000 Genomes Project samples and add data from projects working with other openly consented samples.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:39', - 1 - ), - ( - 102, - 'International Society for Computational Biology', - 'ISCB', - '', - 'iscb', - 'logo/iscb.png', - 'https://www.iscb.org/cms_addon/conferences/ismbeccb2021/tracks/function', - 'Society membership reflects commitment toward the advancement of computational biology. The ISCB is an international non-profit organization whose members come from the global bioinformatics and computational biology communities. The ISCB serves its global membership by providing high-quality meetings, publications, and reports on methods and tools; by disseminating key information about bioinformatics resources and relevant news from related fields; and by actively facilitating training, education, employment, career development, and networking. We advocate and provide leadership for resources and policies in support of scientific endeavors and to benefit society at large.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:40', - 2 - ), - ( - 103, - 'Intuitive Surgical Inc.', - '', - '', - 'intuitive', - 'logo/intuitive.jpg', - 'https://www.intuitive.com/en-us', - 'Intuitive advances minimally invasive care by innovating at the point of possibility. For nearly three decades we''ve created products and services born of inspiration and intelligence—from robotic-assisted surgical systems to data generation that unlocks the potential to benefit care systems worldwide. We work closely and collaboratively with our customers to help achieve better outcomes, better care team experiences, better patient experiences, and lower cost of care. Together, we envision a future of care that''s less invasive, profoundly better, and where diseases are identified early and treated quickly so patients can get back to what matters most.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:41', - 1 - ), - ( - 104, - 'Iowa State University', - '', - 'contact@iastate.edu', - 'iowa-state-university', - 'logo/iowa-state-university.png', - 'https://www.iastate.edu/', - 'Iowa State is a large university with a small feel. Forge lifelong friendships and earn a degree that will take you anywhere.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:42', - 2 - ), - ( - 105, - 'Kaggle', - '', - '', - 'kaggle', - 'logo/kaggle.png', - 'https://www.kaggle.com/', - 'Kaggle is a community of data scientists and data enthusiasts. Our platform enables you to learn from and mentor each other on your personal, academic, and professional data science journeys. \n\nTo get involved, you can [enter a machine learning competition](https://www.kaggle.com/competitions), [publish an open dataset](https://www.kaggle.com/datasets), or [share code in our reproducible data science environment](https://www.kaggle.com/kernels). \n\nKaggle''s headquarters is located in San Francisco, but we have team members working from across the US and Australia. [Join our team](https://www.kaggle.com/careers) from wherever you call home.', - '2023-06-23 00:00:00', - '2023-09-15 16:54:08', - 2 - ), - ( - 106, - 'Kaiser Permanente Washington Health Research Institute', - 'KPWHRI', - '', - 'kpwhri', - 'logo/kpwhri.jpg', - 'https://www.kpwashingtonresearch.org/', - 'Kaiser Permanente Washington Health Research Institute (KPWHRI) is the non-proprietary, public-interest research center within Kaiser Permanente Washington, a nonprofit health system based in Seattle. Kaiser Permanente Washington provides coverage and care for more than 710,170 people in Washington. Our research produces timely, relevant findings that help people everywhere stay healthy and get the care they need. From testing new vaccines to helping people quit smoking to finding ways to delay or prevent Alzheimer''s disease, our discoveries have helped millions of people worldwide lead healthier, happier lives.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:44', - 1 - ), - ( - 107, - 'King''s College London', - 'KCL', - '', - 'kcl', - 'logo/kcl.jpg', - 'https://www.kcl.ac.uk/', - 'King''s College London is an internationally renowned university delivering exceptional education and world-leading research. We are dedicated to driving positive and sustainable change in society and realising our vision of making the world a better place. ', - '2023-06-23 00:00:00', - '2023-07-26 20:14:44', - 2 - ), - ( - 108, - 'Knowledge Engine for Genomics', - '', - 'knoweng@illinois.edu', - 'knoweng', - 'logo/knoweng.png', - 'https://knoweng.org/', - 'KnowEnG, The Knowledge Engine for Genomics, will transform the way biomedical researchers analyze their genome-wide data by integrating multiple analytical methods derived from the most advanced data mining and machine learning research. Embedded with the breadth of existing knowledge of genes, and an intuitive and professionally designed user interface, the Knowledge Engine platform provides advanced capabilities in data analytics. The KnowEnG environment is deployed in a cloud infrastructure and will be fully available to the research community, as will be the software developed by the Center.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:45', - 1 - ), - ( - 109, - 'Koch Institute', - '', - 'cancer@mit.edu', - 'koch-institute', - 'logo/koch-institute.jpg', - 'https://ki.mit.edu/', - 'At the Koch Institute for Integrative Cancer Research, we take a uniquely MIT approach to solving some of the most difficult problems in cancer. Our research combines MIT''s rich traditions of interdisciplinary inquiry and technological innovation with the most advanced investigation into the fundamental biology of cancer. With an unprecedented commitment to cross-disciplinary collaboration, we are accelerating the discovery and application of new ways to detect, monitor, treat, and prevent the disease.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:46', - 1 - ), - ( - 110, - 'Laura and John Arnold Foundation', - '', - '', - 'arnold-ventures', - 'logo/arnold-ventures.jpg', - 'https://www.arnoldventures.org/people/laura-arnold-john-arnold/', - 'Arnold Ventures is a philanthropy working to improve the lives of all Americans by pursuing evidence-based solutions to our nation''s most pressing problems. We fund research to better understand the root causes of broken systems that limit opportunity and create injustice. Our focus areas include Criminal Justice, Higher Education, Health, and Public Finance. In each area, we advocate for policy reforms that will lead to lasting, scalable change.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:46', - 1 - ), - ( - 111, - 'Lausanne University Hospital', - 'CHUV', - '', - 'chuv', - 'logo/chuv.jpg', - 'https://www.lausanneuniversityhospital.com/home', - 'Lausanne University Hospital is one of the five university hospitals in Switzerland, with Geneva, Bern, Basel and Zurich. With its 16 clinical and medico-technical departments and their numerous services, the CHUV is renowned for its academic achievements in health care, research, and teaching. The CHUV is also a well-known center of medical education and research thanks to its collaboration with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). Together, these institutions form a vast campus in the Lake Geneva region.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:47', - 1 - ), - ( - 112, - 'Leukemia and Lymphoma Society', - 'LLS', - '', - 'lls', - 'logo/lls.jpg', - 'https://www.lls.org/', - 'The Leukemia & Lymphoma Society (LLS) is at the forefront of the fight to cure blood cancer. We are the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, we''ve invested more than $1.6 billion in groundbreaking research, pioneering many of today''s most innovative approaches. LLS is a global leader in the fight against blood cancer.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:48', - 1 - ), - ( - 113, - 'Ligue Nationale Contre le Cancer', - '', - '', - 'ligue-cancer', - 'logo/ligue-cancer.jpg', - 'https://www.ligue-cancer.net/', - 'Since 1918, the League has been fighting against cancer by being the first independent funder of research', - '2023-06-23 00:00:00', - '2023-07-26 20:14:48', - 1 - ), - ( - 114, - 'London''s Global University', - 'UCL', - '', - 'ucl', - 'logo/ucl.jpg', - 'https://www.ucl.ac.uk/', - 'Founded in 1826 in the heart of London, UCL is London''s leading multidisciplinary university, with more than 16,000 staff and 50,000 students from over 150 different countries. We are a diverse community with the freedom and courage to challenge, to question and to think differently.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:49', - 2 - ), - ( - 115, - 'Ludwig Maximilian University of Munich', - 'LMU', - '', - 'lmu', - 'logo/lmu.jpg', - 'https://www.lmu.de/en/index.html', - 'Ludwig-Maximilians-Universitat Munchen is a leading research university in Europe. Since its founding in 1472 it has been committed to the highest international standards of excellence in research and teaching.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:51', - 2 - ), - ( - 116, - 'Mahidol Oxford Tropical Medicine Research Unit', - 'MORU', - '', - 'moru', - 'logo/moru.jpeg', - 'https://www.tropmedres.ac/', - 'The MORU Tropical Health Network, which hosts the ‘Thailand Wellcome Africa and Asia Programme'', conducts targeted clinical and public health research that aims to discover and develop appropriate, practical, affordable interventions that measurably improve the health of people living in resource-limited parts of the world.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:51', - 1 - ), - ( - 117, - 'March of Dimes', - '', - '', - 'march-of-dimes', - 'logo/march-of-dimes.jpg', - 'https://www.marchofdimes.org/', - 'March of Dimes is a nonprofit organization committed to ending preventable maternal health risks and death, ending preventable preterm birth and infant death and closing the health equity gap for all families.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:51', - 1 - ), - ( - 118, - 'Massachusetts General Hospital', - '', - '', - 'mass-general', - 'logo/mass-general.png', - 'https://www.massgeneral.org/', - 'In the delivery of our care, through our research and within our communities, Mass General is committed to the well-being of our patients locally and globally.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:54', - 3 - ), - ( - 119, - 'Massachusetts Institute of Technology', - 'MIT', - '', - 'mit', - 'logo/mit.jpg', - 'https://www.mit.edu/', - 'The MIT community is driven by a shared purpose: to make a better world through education, research, and innovation. We are fun and quirky, elite but not elitist, inventive and artistic, obsessed with numbers, and welcoming to talented people regardless of where they come from.', - '2023-06-23 00:00:00', - '2023-08-08 18:47:20', - 8 - ), - ( - 120, - 'MathWorks', - '', - '', - 'mathworks', - 'logo/mathworks.jpg', - 'https://www.mathworks.com/', - 'We at MathWorks believe in the importance of engineers and scientists. They increase human knowledge and profoundly improve our standard of living. We created MATLAB and Simulink to help them do their best work.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:56', - 1 - ), - ( - 121, - 'Max Delbruck Center for Molecular Medicine', - 'MDC', - '', - 'mdc', - 'logo/mdc.jpg', - 'https://www.mdc-berlin.de/', - 'The Max Delbruck Center is an internationally renowned biomedical research center in Berlin. It is named after Max Delbrück, one of the founders of modern genetics and molecular biology.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:56', - 1 - ), - ( - 122, - 'MD Anderson Cancer Center', - '', - '', - 'md-anderson', - 'logo/md-anderson.jpg', - 'https://www.mdanderson.org/', - 'At MD Anderson, we understand how hard it can be to choose a hospital for cancer treatment. You''ve just received life-changing news, and now you have to decide how to handle it. Here are some of the reasons why MD Anderson is your best hope for cancer care.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:57', - 1 - ), - ( - 123, - 'Medical Research Council', - 'MRC', - '', - 'mrc', - '', - 'https://www.ukri.org/councils/mrc/', - 'The Medical Research Council (MRC) improves the health of people in the UK – and around the world – by supporting excellent science, and training the very best scientists.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:58', - 0 - ), - ( - 124, - 'Memorial Sloan Kettering Cancer Center', - 'MSK', - '', - 'msk', - 'logo/msk.jpg', - 'https://www.mskcc.org/', - 'The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world''s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years. ', - '2023-06-23 00:00:00', - '2023-07-26 20:14:58', - 3 - ), - ( - 125, - 'Merck Co.', - '', - '', - 'merck', - 'logo/merck.jpg', - 'https://www.merck.com/', - 'Our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.', - '2023-06-23 00:00:00', - '2023-07-26 20:14:59', - 1 - ), - ( - 126, - 'Michael J. Fox Foundation', - 'MJFF', - 'info@michaeljfox.org', - 'mjff', - 'logo/mjff.jpg', - 'https://www.michaeljfox.org/', - 'The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson''s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson''s today.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:00', - 3 - ), - ( - 127, - 'MINES ParisTech', - '', - 'contact@mines-paristech.fr', - 'mines-paristech', - '', - 'http://www.mines-paristech.eu/', - '250 years of history for the Graduate School. 1 500 students. 17 research centres, 230 talented research professors, 1st school for collaborative research, a unique link with companies. Values built over the years, which we are proud to display, to maintain, to share.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:00', - 1 - ), - ( - 128, - 'Mount Sinai', - '', - '', - 'mt-sinai', - 'logo/mt-sinai.jpg', - 'https://www.mountsinai.org/', - 'The Mount Sinai Health System is an integrated health care system providing exceptional medical care to our local and global communities. Encompassing the Icahn School of Medicine at Mount Sinai and eight hospital campuses in the New York metropolitan area, as well as a large, regional ambulatory footprint, Mount Sinai is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties. The Mount Sinai Health System was created from the combination of the Mount Sinai Medical Center and Continuum Health Partners, which both agreed unanimously to combine the two entities in July 2013.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:01', - 28 - ), - ( - 129, - 'Multiple Myeloma Research Foundation', - 'MMRF', - '', - 'mmrf', - 'logo/mmrf.jpg', - 'https://themmrf.org/', - 'The MMRF is the largest nonprofit in the world focused on accelerating the cure for multiple myeloma. Our work is not done until each and every multiple myeloma patient has the answers they need. With our exceptional leadership, strategic collaboration and uniquely innovative approach, we are on the path to finding a cure for multiple myeloma.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:03', - 1 - ), - ( - 130, - 'Nathan S. Kline Institute for Psychiatric Research', - 'NKI', - 'Webmaster@nki.rfmh.org', - 'nki', - 'logo/nki.png', - 'https://www.nki.rfmh.org/', - 'As one of the nation''s most respected research centers focused on mental health, investigators at the Nathan S. Kline Institute for Psychiatric Research (NKI) study the causes, treatment, prevention, and rehabilitation of severe and persistent mental illnesses. As a facility of the New York State Office of Mental Health, founded in 1952, NKI has earned a reputation for its landmark contributions in psychiatric research, especially in the areas of psychopharmacological treatments for schizophrenia and major mood disorders, dementia research, clinical trials methodology, neuroimaging, therapeutic drug monitoring, and the application of computer technology to mental health services.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:03', - 1 - ), - ( - 131, - 'National Cancer Institute', - 'NCI', - 'NCIinfo@nih.gov', - 'nci', - 'logo/nci.jpg', - 'https://www.cancer.gov/', - 'The National Cancer Institute (NCI) is the federal government''s principal agency for cancer research and training. NCI leads, conducts, and supports cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:04', - 11 - ), - ( - 132, - 'National Center for Advancing Translational Sciences', - 'NCATS', - 'info@ncats.nih.gov', - 'ncats', - 'logo/ncats.jpg', - 'https://ncats.nih.gov/', - 'The National Center for Advancing Translational Sciences (NCATS) — one of 27 Institutes and Centers at the National Institutes of Health (NIH) — was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:05', - 1 - ), - ( - 133, - 'National Center for Data to Health', - 'CD2H', - '', - 'cd2h', - '', - 'https://cd2h.org/', - 'The National Center for Data to Health (CD2H) accelerates advancements in informatics by using findable, accessible, interoperable, and reusable (FAIR) principles to promote collaboration across the Clinical and Translational Science Awards (CTSA) Program community. CD2H tools and resources make it simple and valuable for CTSA Program members to get engaged, connect with peers, and contribute. By promoting collaboration, CD2H fosters a robust translational science informatics ecosystem that collectively develops solutions to solve clinical problems faster, more efficiently, and more effectively. CTSA Program members are poised to lead this charge by harnessing collective expertise and strengths to solve key informatics challenges. With this team science approach, advancements in translational research can ultimately improve patient care.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:05', - 2 - ), - ( - 134, - 'National Institute of Environmental Health Sciences', - 'NIEHS', - '', - 'niehs', - 'logo/niehs.png', - 'https://www.niehs.nih.gov/', - 'The National Institute of Environmental Health Sciences (NIEHS) is expanding and accelerating its contributions to scientific knowledge of human health and the environment, and to the health and well-being of people everywhere.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:06', - 1 - ), - ( - 135, - 'National Institute of General Medical Sciences', - 'NIGMS', - '', - 'nigms', - 'logo/nigms.jpg', - 'https://www.nigms.nih.gov/', - 'The National Institute of General Medical Sciences (NIGMS) supports basic research that increases our understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS-funded scientists investigate how living systems work at a range of levels—from molecules and cells to tissues and organs—in research organisms, humans, and populations. Additionally, to ensure the vitality and continued productivity of the research enterprise, NIGMS provides leadership in training the next generation of scientists, enhancing the diversity of the scientific workforce, and developing research capacity throughout the country.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:07', - 3 - ), - ( - 136, - 'National Institute of Standards and Technology', - 'NIST', - 'do-webmaster@nist.gov', - 'nist', - 'logo/nist.png', - 'https://www.nist.gov/', - 'The National Institute of Standards and Technology (NIST) was founded in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation''s oldest physical science laboratories. Congress established the agency to remove a major challenge to U.S. industrial competitiveness at the time — a second-rate measurement infrastructure that lagged behind the capabilities of the United Kingdom, Germany and other economic rivals. From the smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials and computer chips, innumerable products and services rely in some way on technology, measurement and standards provided by the National Institute of Standards and Technology.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:08', - 3 - ), - ( - 137, - 'National Science Foundation', - 'NSF', - '', - 'nsf', - 'logo/nsf.jpg', - 'https://www.nsf.gov/', - 'The U.S. National Science Foundation is an independent federal agency that supports science and engineering in all 50 states and U.S. territories. NSF was established in 1950 by Congress to: a) Promote the progress of science. b) Advance the national health, prosperity and welfare. c) Secure the national defense.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:09', - 1 - ), - ( - 138, - 'Natural Sciences and Engineering Research Council', - 'NSERC', - '', - 'nserc', - 'logo/nserc.jpg', - 'https://www.nserc-crsng.gc.ca/index_eng.asp', - 'The Natural Sciences and Engineering Research Council of Canada funds visionaries, explorers and innovators who are searching for the scientific and technical breakthroughs that will benefit our country. We are Canada''s largest supporter of discovery and innovation. We work with universities, colleges, businesses and not-for-profits to remove barriers, develop opportunities and attract new expertise to make Canada''s research community thrive. We give Canadian scientists and engineers the means to go further because we believe in research without borders and beyond frontiers.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:09', - 3 - ), - ( - 139, - 'Neosoma Inc.', - '', - '', - 'neosoma', - 'logo/neosoma.jpg', - 'https://www.neosomainc.com/', - 'Every brain cancer patient is unique, and so is every brain tumor. Neuro-oncology teams need new tools and insights to advance the state of care. At Neosoma, our mission is to help clinicians improve outcomes by providing novel disease insights to physicians and clinical trials through innovative AI technology.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:10', - 2 - ), - ( - 140, - 'Neurological Clinical Research Institute', - 'NCRI', - 'NCRI-info@mgh.harvard.edu', - 'ncri', - '', - 'https://www.massgeneral.org/ncri', - 'The Neurological Clinical Research Institute (NCRI) at Mass General is an academic research organization composed of innovative researchers experienced and passionate about designing, developing, facilitating, and conducting multicenter clinical trials in neurological diseases. Our goal is to develop new treatments for the patients we care for and for patients around the globe. We have particular expertise in ALS, Parkinson''s disease and other neurodegenerative diseases. ', - '2023-06-23 00:00:00', - '2023-07-26 20:15:11', - 1 - ), - ( - 141, - 'New York University', - 'NYC', - '', - 'nyc', - 'logo/nyu.png', - 'https://www.nyu.edu/', - 'Since its founding in 1831, NYU has been an innovator in higher education, reaching out to an emerging middle class, embracing an urban identity and professional focus, and promoting a global vision that informs its 20 schools and colleges. Today, that trailblazing spirit makes NYU one of the most prominent and respected research universities in the world, featuring top-ranked academic programs and accepting fewer than one in eight undergraduates. Anchored in New York City and with degree-granting campuses in Abu Dhabi and Shanghai as well as 12 study away sites throughout the world, NYU is a leader in global education, with more international students and more students studying abroad than any other US university.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:12', - 1 - ), - ( - 142, - 'Northeast ALS Consortium', - 'NEALS', - 'alstrials@neals.org', - 'neals', - 'logo/neals.jpg', - 'https://www.neals.org/', - 'The mission of the Northeast Amyotrophic Lateral Sclerosis Consortium(R) (NEALS) is to rapidly translate scientific advances into clinical research and new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and motor neuron disease.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:12', - 2 - ), - ( - 143, - 'Northeastern University', - 'NEU', - '', - 'neu', - 'logo/neu.jpg', - 'https://www.northeastern.edu/', - 'At Northeastern, experience is our essence and ethos. It''s what you gain when you make the world your classroom, your laboratory, and your platform to create change or grow your enterprise. Throughout our university network, experience draws you into society and compels you to solve its complex challenges. It makes you agile and able to reinvent yourself. To find ways of doing things differently, and better. And to seize opportunities as they unfold—anytime, anywhere.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:13', - 2 - ), - ( - 144, - 'Northwestern University', - 'NU', - '', - 'nu', - 'logo/nu.jpg', - 'https://www.northwestern.edu/', - 'Northwestern is committed to excellent teaching, innovative research and the personal and intellectual growth of its students in a diverse academic community.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:14', - 2 - ), - ( - 145, - 'Novo Nordisk', - '', - '', - 'novo-nordisk', - 'logo/novo-nordisk.jpg', - 'https://www.novonordisk-us.com/', - 'For more than 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems. Our treatments today are helping millions of people living with diabetes, obesity, rare bleeding disorders and growth hormone-related disorders. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:15', - 1 - ), - ( - 146, - 'Numerate', - '', - '', - 'numerate', - '', - '', - 'This organization may no longer exist or has been merged under another organization.', - '2023-06-23 00:00:00', - '2023-08-08 17:59:10', - 1 - ), - ( - 147, - 'NVIDIA', - '', - '', - 'nvidia', - 'logo/nvidia.png', - 'https://www.nvidia.com/en-us/', - 'NVIDIA pioneered accelerated computing to tackle challenges no one else can solve. Our work in AI and the metaverse is transforming the world''s largest industries and profoundly impacting society.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:16', - 4 - ), - ( - 148, - 'Ohio State University', - 'OSU', - 'webmaster@osu.edu', - 'osu', - 'logo/osu.png', - 'https://www.osu.edu/', - 'Discover the Ohio State difference. We create unrivaled experiences that bring together expertise, ideas and resources that improve communities locally and globally.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:17', - 2 - ), - ( - 149, - 'Ontario Institute for Cancer Research', - 'OICR', - 'info@oicr.on.ca', - 'oicr', - 'logo/oicr.svg', - 'https://oicr.on.ca/', - 'The Ontario Institute for Cancer Research helps close the gap between groundbreaking cancer discoveries and life-changing patient outcomes. OICR is a research institute that collaborates with partners across Ontario and around the world to accelerate the development of new cancer research discoveries and propel them from the lab to the clinic, bringing health and economic benefits to the people of Ontario.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:18', - 6 - ), - ( - 150, - 'Oregon Health and Science University', - 'OHSU', - '', - 'ohsu', - 'logo/ohsu.jpg', - 'https://www.ohsu.edu/', - 'OHSU is Oregon''s only public academic health center. We are a system of hospitals and clinics across Oregon and southwest Washington. We are an institution of higher learning, with schools of medicine, nursing, pharmacy, dentistry and public health – and with a network of campuses and partners throughout Oregon. We are a national research hub, with thousands of scientists developing lifesaving therapies and deeper understanding. We are a statewide economic engine and Portland''s largest employer. And as a public organization, we provide services for the most vulnerable Oregonians, and outreach to improve health in communities across the state.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:19', - 11 - ), - ( - 151, - 'Oslo University Hospital', - 'OUS', - '', - 'ous', - 'logo/ous.png', - 'https://oslo-universitetssykehus.no/oslo-university-hospital', - '​Oslo University Hospital (OUS) ​is a highly specialised hospital in charge of extensive regional and local hospital assignments and the provision of high quality services for the citizens of Oslo. The hospital also has a nationwide responsibility for a number of national and multi-regional assignments and has several national centres of competence.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:21', - 1 - ), - ( - 152, - 'Pacific Northwest National Laboratory', - 'PNNL', - '', - 'pnnl', - 'logo/pnnl.png', - 'https://www.pnnl.gov/', - 'Pacific Northwest National Laboratory is a different kind of national lab. PNNL advances the frontiers of knowledge, taking on some of the world''s greatest science and technology challenges. Distinctive strengths in chemistry, Earth sciences, biology, and data science are central to our scientific discovery mission. Our research lays a foundation for innovations that advance sustainable energy through decarbonization and energy storage and enhance national security through nuclear materials and threat analyses. PNNL collaborates with academia in fundamental research and with industry to transition technologies to market.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:22', - 2 - ), - ( - 153, - 'Pfizer Inc.', - '', - '', - 'pfizer', - 'logo/pfizer.jpg', - 'https://www.pfizer.com/', - 'We''re in relentless pursuit of breakthroughs that change patients'' lives. We innovate every day to make the world a healthier place. It was Charles Pfizer''s vision at the beginning and it holds true today.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:22', - 1 - ), - ( - 154, - 'Prize4Life', - '', - '', - 'prize4life', - 'logo/prize4life.jpeg', - 'http://www.prize4life.org', - 'This organization may no longer exist or has been merged under another organization. -======== -Prize4Life seeks to create breakthroughs in effective treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig''s Disease) using the leverage of large inducement prizes. Instead of recognizing historical accomplishments, Prize4Life has a simple formula for transformational change. We design and launch prizes that we believe are achievable in a 2-3 year timeframe and then recruit teams to compete for the prize purse. The first team to find and demonstrate the required breakthrough wins the prize.', - '2023-06-23 00:00:00', - '2023-08-08 17:45:38', - 2 - ), - ( - 155, - 'Project Data Sphere', - '', - '', - 'project-data-sphere', - 'logo/project-data-sphere.jpg', - 'https://www.projectdatasphere.org/', - 'At Project Data Sphere®, we believe in breaking down barriers to cancer clinical trial data sharing — barriers that historically have kept valuable trial data from ultimately benefitting the patients who so selflessly participate in them. By aggregating trial data from biopharmaceutical companies, academic medical centers, and government organizations and making it freely available on our open-access platform, we have established ourselves as a premier resource for the global oncology research community. Our deep relationships with renowned oncology experts allow us to convene research collaborations that leverage the power of pooled clinical trial data and which ultimately position PDS to be a catalyst for the discovery of urgently needed new treatments while helping to make cancer trials faster, more effective, and less expensive.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:26', - 1 - ), - ( - 156, - 'Prostate Cancer Canada', - '', - '', - 'prostate-cancer-canada', - 'logo/prostate-cancer-canada.png', - 'https://cancer.ca/en/', - 'At the Canadian Cancer Society, we are committed to improving and saving lives. That''s why we are always looking for new ways to prevent cancer, find it early and treat it more successfully. It''s why we''re always ready to give people with cancer the help and support they need to lead more fulfilling lives. ', - '2023-06-23 00:00:00', - '2023-07-26 20:15:27', - 2 - ), - ( - 157, - 'Prostate Cancer Foundation', - 'PCF', - '', - 'pcf', - 'logo/pcf.jpg', - 'https://www.pcf.org/', - 'The Prostate Cancer Foundation (PCF) funds the world''s most promising research to improve the prevention, detection, and treatment of prostate cancer and ultimately cure it for good.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:28', - 1 - ), - ( - 158, - 'Providence Health and Services', - '', - '', - 'providence', - 'logo/providence.jpg', - 'https://www.providence.org/en', - 'At Providence we see more than patients, we see the life that pulses through us all. That''s why we''re dedicated to a holistic approach to medicine that employs not only the most advanced treatments to improve outcomes, but also puts compassion and humanity at the heart of every interaction.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:29', - 1 - ), - ( - 159, - 'QIMR Berghofer Medical Research Institute', - '', - '', - 'qimr-berghofer', - 'logo/qimr-berghofer.jpg', - 'https://www.qimrberghofer.edu.au/', - 'From humble beginnings in 1945, the Queensland Institute of Medical Research, now known as QIMR Berghofer, is one of Australia''s most successful medical research institutes, translating discoveries from bench to bedside for a better future of health.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:30', - 1 - ), - ( - 160, - 'Queen''s University', - '', - '', - 'queensu', - 'logo/queensu.jpg', - 'https://www.queensu.ca/', - 'We stand on a strong history of scholarship, discovery, and innovation. nOur education transforms Queen''s students. Our diversity enriches the community. Our research changes the world. Together, we are tackling humanity''s greatest challenges.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:31', - 1 - ), - ( - 161, - 'Radboud University Medical Center', - '', - '', - 'radboud-umc', - 'logo/radboud-umc.jpeg', - 'https://www.radboudumc.nl/en/research', - 'Radboud university medical center specializes in patient care, scientific research, teaching and training. Our mission is to have a significant impact on health care. We aim to be pioneers in shaping the health care of the future. We do this in a person-centered and innovative way.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:31', - 3 - ), - ( - 162, - 'Radiological Society of North America', - 'RSNA', - '', - 'rsna', - 'logo/rsna.png', - 'https://www.rsna.org/', - 'The Radiological Society of North America (RSNA(R)) is an international society of radiologists, medical physicists and other medical professionals with more than 53,400 members from 136 countries across the globe. RSNA hosts the world''s premier radiology forum, drawing approximately 55,000 attendees annually to McCormick Place in Chicago, and publishes two top peer-reviewed journals: *Radiology*, the highest-impact scientific journal in the field, and *RadioGraphics*, the only journal dedicated to continuing education in radiology. The Society is based in Oak Brook, Ill.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:33', - 3 - ), - ( - 164, - 'Ray and Dagmar Dolby Family Fund', - '', - 'info@dolbyventures.com', - 'dolby-family-ventures', - 'logo/dolby-family-ventures.jpg', - 'http://www.dolbyventures.com/', - 'Dolby Family Ventures is an early stage venture firm focused on building great technology companies. We partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company''s development. The fund honors the legacy of Ray Dolby and his commitment to engineers and their vision to solve the world''s toughest problems. Dolby Family Ventures formalizes the Dolby family''s ongoing multi-generational commitment to supporting talented entrepreneurs. We work actively with entrepreneurs to implement best practices in operational finance, strategy, and board development processes.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:34', - 1 - ), - ( - 165, - 'Rice University', - '', - '', - 'rice', - 'logo/rice.jpg', - 'https://www.rice.edu/', - 'Located in an urban environment on a 300-acre tree-lined campus, Rice University seizes its advantageous position to pursue pathbreaking research and create innovative collaboration opportunities that contribute to the betterment of our world.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:35', - 1 - ), - ( - 166, - 'Robert Wood Johnson Foundation', - 'RWJF', - '', - 'rwjf', - 'logo/rwjf.jpg', - 'https://www.rwjf.org/', - 'RWJF works in collaboration with policymakers, business leaders, community groups and many others. Together, we share a common interest in addressing the many harmful obstacles to wellbeing, including poverty, powerlessness, and discrimination, and advancing health equity for all. We focus on identifying, illuminating, and addressing barriers to health, particularly those caused by structural racism and its intersection with other forms of discrimination, including sexism, ableism, and prejudice based on sexual orientation. We lean on evidence to advance health equity. We cultivate leaders who work individually and collectively across sectors to address health equity. We promote policies, practices, and systems change to dismantle the structural barriers to wellbeing created by racism. And we work to amplify voices to shift national conversations and attitudes about health and health equity.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:35', - 1 - ), - ( - 167, - 'Rockefeller University', - '', - '', - 'rockefeller', - 'logo/rockefeller.jpg', - 'https://www.rockefeller.edu/', - 'The world''s leading biomedical research university, Rockefeller draws top scientists and graduate students from around the world in pursuit of one mission: to conduct science for the benefit of humanity.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:36', - 1 - ), - ( - 168, - 'Rosenberg Alzheimer''s Project', - '', - '', - 'rosenberg-alzheimers-project', - '', - '', - 'This organization may no longer exist or has been merged under another organization.', - '2023-06-23 00:00:00', - '2023-08-08 17:59:30', - 1 - ), - ( - 169, - 'Rush University Medical Center', - 'RUSH', - '', - 'rush', - 'logo/rush.jpg', - 'https://www.rush.edu/', - 'Rush University System for Health is consistently recognized for our outstanding patient care, education, research and community partnerships. Learn more about our mission, history, policies and leadership.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:38', - 1 - ), - ( - 170, - 'RWTH Aachen University', - '', - '', - 'rwth-aachen', - 'logo/rwth-aachen.png', - 'https://www.rwth-aachen.de/go/id/a/?lidx=1', - 'RWTH Aachen University is a place where the future of our industrialised world is thought out. The University is proving to be a hotspot with increasing international recognition where innovative answers to global challenges are developed.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:39', - 8 - ), - ( - 171, - 'Sage Bionetworks', - '', - 'info@sagebase.org', - 'sage', - 'logo/sage-bionetworks.png', - 'https://sagebionetworks.org/', - 'Sage Bionetworks is a nonprofit health research organization that is speeding the translation of science into medicine. We believe that high-quality, well-annotated data acts as the foundation of modern biomedical innovation. We dream of a world where people work together across institutional boundaries to meaningfully address major medical research problems. We incubate new ways for diverse groups of people to practice research together. We advance our practices using an integrated and iterative design cycle that plays out between our scientific teams and our core service teams. As our innovations become norms, we develop them into robust core capabilities that can be put into practice across our portfolio of research programs. This portfolio includes publicly funded programs that create data resources and knowledge bases, pre-competitive collaborations across industry partners, and federated networks of healthcare data providers. In turn, these projects provide an active pl...', - '2023-06-23 00:00:00', - '2023-07-26 20:15:40', - 48 - ), - ( - 172, - 'Sanofi', - '', - '', - 'sanofi', - 'logo/sanofi.jpg', - 'https://www.sanofi.com/', - 'We are Sanofi. We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people''s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world''s poorest countries.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:41', - 2 - ), - ( - 173, - 'Sapienza University of Rome', - '', - '', - 'sapienza', - 'logo/sapienza.png', - 'https://www.uniroma1.it/en/pagina-strutturale/home', - 'Founded in 1303, Sapienza is the oldest university in Rome and the largest in Europe. Its mission is to contribute to the development of a knowledge society through research, excellence, quality education and international cooperation.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:43', - 3 - ), - ( - 174, - 'Sartorius AG', - '', - '', - 'sartorius', - 'logo/sartorius.jpg', - 'https://www.sartorius.com/en', - 'Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:42', - 1 - ), - ( - 175, - 'Seattle Cancer Care Alliance', - 'SCCA', - '', - 'scca', - 'logo/fred-hutch.jpg', - 'https://www.seattlecca.org/', - 'SCCA is now Fred Hutchinson Cancer Center, an independent, nonprofit cancer care and research center that also serves as the cancer program for UW Medicine. The superior care you have come to expect will continue uninterrupted.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:43', - 1 - ), - ( - 176, - 'Semmelweis University', - '', - '', - 'semmelweis-university', - 'logo/semmelweis-university.png', - 'https://semmelweis.hu/english/', - 'Semmelweis University is a leading institution of higher education in Hungary and the Central European region within the area of medicine and health sciences. Its main commitment is based on the integrity of education, research and healing, which make Semmelweis University an internationally renowned centre of knowledge.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:43', - 2 - ), - ( - 177, - 'Sentieon', - '', - '​info@sentieon.com', - 'sentieon', - 'logo/sentieon.jpg', - 'https://www.sentieon.com/', - 'Sentieon(R), incorporated in July 2014, develops highly-optimized algorithms for bioinformatics applications, using the team''s expertise in algorithm, software, and system optimization. Sentieon(R) is a team of professionals experienced in image processing, telecom, computational lithography, large-scale data mining, and bioinformatics. Using our accumulated expertise in modeling, optimization, machine learning, and high-performance computing, we strive to enable precision data for precision medicine.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:44', - 1 - ), - ( - 178, - 'Siemens Healthineers', - '', - '', - 'siemens-healthineers', - 'logo/siemens-healthineers.jpg', - 'https://www.siemens-healthineers.com/', - 'We pioneer breakthroughs in healthcare. For everyone. Everywhere.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:45', - 1 - ), - ( - 179, - 'Stanford University', - '', - '', - 'stanford', - 'logo/stanford.jpg', - 'https://www.stanford.edu/', - 'Stanford was founded almost 150 years ago on a bedrock of societal purpose. Our mission is to contribute to the world by educating students for lives of leadership and purposeful contribution; advancing fundamental knowledge and cultivating creativity; and accelerating solutions and amplifying their impact.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:46', - 12 - ), - ( - 180, - 'Swiss Initiative in Systems Biology', - '', - 'admin@systemsx.ch', - 'systemsx', - 'logo/systemsx.jpg', - 'http://www.systemsx.ch/', - 'SystemsX.ch is the largest ever public research initiative in Switzerland and focuses specifically on a broad topical area of basic research. The initiative advances systems biology in our country with the claim of belonging to the best in the world in this area of research.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:47', - 1 - ), - ( - 181, - 'Takeda', - '', - '', - 'takeda', - 'logo/takeda.jpg', - 'https://www.takeda.com/en-us/', - 'Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:48', - 2 - ), - ( - 182, - 'Texas Biomedical Research Institute', - '', - '', - 'texas-biomedical-research-institute', - 'logo/texas_biomed.png', - 'https://www.txbiomed.org/', - 'Texas Biomedical Research Institute is pioneering and sharing scientific breakthroughs to protect you, your families and our global community from the threat of infectious diseases. The Institute has an 80-year history of success that includes work on the first COVID-19 vaccine and therapies, the first Ebola treatment, the first Hepatitis-C therapy, and thousands of developmental discoveries. Texas Biomed helps create healthier communities with science that inspires new generations through STEM education programs, delivers jobs and economic impact in our community and heals through innovative research. Learn more about how you can #Stand4Science.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:50', - 1 - ), - ( - 183, - 'The University of California-Davis', - '', - '', - 'uc-davis', - 'logo/uc_davis.png', - 'https://www.ucdavis.edu/', - 'We grow California. UC Davis was founded in 1908 to serve the state of California. We do and we always will. And today, the seed that was planted those years ago has grown into one of the world''s top universities.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:51', - 2 - ), - ( - 184, - 'The University of Texas at Austin', - 'UT', - '', - 'ut', - 'logo/ut-austin.svg', - 'https://www.utexas.edu/', - 'Like the state it calls home, The University of Texas at Austin is a bold, ambitious leader supporting some 52,000 diverse students, 3,000 teaching faculty, and top national programs across 18 colleges and schools. As Texas'' leading research university, UT attracts more than $650 million annually for discovery. Amid the backdrop of Austin, Texas, a city recognized for its creative and entrepreneurial spirit, the university provides a place to explore countless opportunities for tomorrow''s artists, scientists, athletes, doctors, entrepreneurs and engineers.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:52', - 1 - ), - ( - 185, - 'Thomas Jefferson University Hospital', - '', - '', - 'jefferson-health', - 'logo/jefferson.jpeg', - 'https://hospitals.jefferson.edu/', - 'We are Jefferson. At Jefferson Health, we are reimagining health care through our service-minded and diverse community of providers and specialists. Our mission is to improve lives. We strive to be bold and innovative, while putting your health and safety first. Each day, we are focused on you.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:52', - 2 - ), - ( - 186, - 'TracInnovations', - '', - 'info@tracinno.dk', - 'tracinnovations', - 'logo/tracinnovations.webp', - 'https://tracinnovations.com/', - 'TracInnovations is a Danish company established in 2015 focusing on innovative solutions for image based diagnosis and treatment. TracInnovations has developed the Tracoline system, which is a MRI Markerless Motion Tracker and Monitor System that unnoticed records patient''s head movements during brain scans.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:53', - 1 - ), - ( - 187, - 'Trinity College Institute of Neuroscience', - '', - 'neuroscience@tcd.ie', - 'tcd---neuroscience', - 'logo/tcd.png', - 'https://www.tcd.ie/Neuroscience/', - 'The Trinity College Institute of Neuroscience (TCIN) is a Trinity Research Institute (TRI) with 50 Principal Investigators and 250 researchers from a wide range of disciplines including Psychology, Psychiatry, Physiology, Pharmacology, Medicine, Biochemistry, Engineering, and Genetics, among others. These diverse disciplinary origins contribute to its core activities: promoting and supporting interdisciplinary basic and translational research, as well as teaching, public engagement, and national leadership in Neuroscience.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:53', - 1 - ), - ( - 188, - 'Tulane University', - '', - '', - 'tulane', - 'logo/tu_new_shield.svg', - 'https://tulane.edu/', - 'Tulane''s motto — non sibi, sed suis — embodies who we are and what we stand for. We are entrepreneurs on the front lines of life-changing technologies, as well as hometown heroes. Tulanians see challenges as opportunities, and strive to improve the lives of others in our own community and around the globe.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:54', - 1 - ), - ( - 189, - 'U.S. Food and Drug Administration', - 'FDA', - '', - 'fda', - 'logo/fda.svg', - 'https://www.fda.gov/home', - 'The Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation''s food supply, cosmetics, and products that emit radiation. FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. FDA also plays a significant role in the Nation''s counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to ...', - '2023-06-23 00:00:00', - '2023-07-26 20:15:55', - 12 - ), - ( - 190, - 'UNC Eshelman School of Pharmacy', - '', - '', - 'unc-eshelman-school-of-pharmacy', - 'logo/unc.png', - 'https://pharmacy.unc.edu/', - 'Everything we do begins and ends with a patient in mind. Developing leaders in pharmacy education, pharmacy practice and pharmaceutical sciences who make a difference in human health worldwide.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:56', - 1 - ), - ( - 191, - 'University of Alabama', - 'UA', - '', - 'ua', - 'logo/ua.png', - 'https://www.ua.edu/', - 'We are dedicated to excellence in teaching, research and service. We provide a robust campus environment where our students can reach their greatest potential while learning from the best and brightest faculty and making a positive difference in the community, the state and the world.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:57', - 1 - ), - ( - 192, - 'University of Alabama at Birmingham', - 'UAB', - '', - 'uab', - 'logo/uab.jpg', - 'https://www.uab.edu/home/', - 'At UAB, we have never settled on merely finding what''s next—we have helped build the future through new ideas and initiatives in the classroom, the laboratory, the studio and the clinic.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:58', - 1 - ), - ( - 193, - 'University of Arkansas for Medical Sciences', - 'UAMS', - '', - 'uams', - 'logo/uams.jpg', - 'https://www.uams.edu/', - 'By 2029, the University of Arkansas for Medical Sciences (UAMS) will lead Arkansas to be the healthiest state in the region through its synergies of education, clinical care, research and purposeful leadership. With this bold statement, UAMS resolved that in the coming decade its status as Arkansas'' only academic health system will allow it to deliver dramatic and lasting health and health care improvements to its home state. Aiding in this vision will be its statewide network of campuses for public education and clinical outreach, along with cores of expertise in medical specialties, population health, digital health, health informatics and translational research.', - '2023-06-23 00:00:00', - '2023-07-26 20:15:59', - 1 - ), - ( - 194, - 'University of Basel', - '', - '', - 'university-of-basel', - 'logo/uni_basel.svg', - 'https://www.unibas.ch/en.html', - 'As a comprehensive university offering a wide range of high-quality educational opportunities, the University of Basel attracts students from Switzerland and the entire world, offering them outstanding studying conditions as they work towards their bachelor''s, master''s or PhD degrees. Today, the University of Basel has around 13,000 students from over a hundred nations, including 2,900 PhD students. The University of Basel has seven faculties covering a wide spectrum of academic disciplines. At the same time, the university has positioned itself amidst the international competition in the form of five strategic focal areas: Life Sciences, Visual Studies, Nanosciences, Sustainability and Energy Research and European and Global Studies. In international rankings, the University of Basel is regularly placed among the 100 top universities in the world thanks to its research achievements. The University of Basel has deep roots in the economically powerful and culturally rich Basel r...', - '2023-06-23 00:00:00', - '2023-07-26 20:15:59', - 3 - ), - ( - 195, - 'University of California, San Diego', - 'UCSD', - '', - 'ucsd', - 'logo/ucsd.png', - 'https://ucsd.edu/', - 'We make changemakers. Recognized as one of the top 15 research universities worldwide, our culture of collaboration sparks discoveries that advance society and drive economic impact. Everything we do is dedicated to ensuring our students have the opportunity to become changemakers, equipped with the multidisciplinary tools needed to accelerate answers to our world''s most pressing issues.', - '2023-06-23 00:00:00', - '2023-08-08 18:48:47', - 3 - ), - ( - 196, - 'University of California, San Francisco', - 'UCSF', - '', - 'ucsf', - 'logo/ucsf.svg', - 'https://www.ucsf.edu/', - 'At UC San Francisco, we are driven by the idea that when the best research, the best teaching and the best patient care converge, we can deliver breakthroughs that help heal the world. Excellence is in our DNA. From genomics and immunology to specialty care for women and children, UCSF brings together the world''s leading experts in nearly every area of health. We are home to five Nobel laureates who have advanced the understanding of cancer, neurodegenerative diseases, aging and stem cells. Our hospitals and educational programs consistently rank among the best in the country, according to the latest surveys by U.S. News & World Report. We are the leading university dedicated exclusively to the health sciences.', - '2023-06-23 00:00:00', - '2023-08-08 18:48:39', - 6 - ), - ( - 197, - 'University of California, Santa Cruz', - 'UCSC', - '', - 'ucsc', - 'logo/uc-santa-cruz-2021.svg', - 'https://www.ucsc.edu/', - 'An inspired, global, public research university leading at the intersection of innovation and justice.', - '2023-06-23 00:00:00', - '2023-08-08 18:48:44', - 6 - ), - ( - 198, - 'University of Cincinnati', - 'UC', - '', - 'uc', - 'logo/uc.png', - 'https://www.uc.edu/', - 'The University of Cincinnati offers students a balance of educational excellence and real-world experience. UC is a public research university with an enrollment of nearly 48,000 students and is ranked No. 4 in the nation for co-ops and internships by U.S. News & World Report (No. 1 among public institutions). Today, more than 315,000 living alumni count themselves as Bearcats — united not just by their loyalty to our nationally known sports teams, but by their common love of the place, the people and the ideas that make up the University of Cincinnati.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:03', - 1 - ), - ( - 199, - 'University of Colorado Anschutz Medical Campus', - '', - '', - 'cu-anschutz', - 'logo/cu_anschutz.svg', - 'https://www.cuanschutz.edu/', - 'The ​University of Colorado Anschutz Medical Campus is the largest academic health center in the Rocky Mountain region at the forefront of transformative education, science, medicine and healthcare. The campus includes the University of Colorado health professional schools, multiple centers and institutes and two nationally ranked hospitals, UCHealth University of Colorado Hospital and Children''s Hospital Colorado, which treat nearly 2 million patients each year. All interconnected, these organizations collaboratively improve the quality of patient care they deliver, research they conduct and health professionals they train.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:03', - 4 - ), - ( - 200, - 'University of Connecticut', - 'UCONN', - '', - 'uconn', - 'logo/uconn.png', - 'https://uconn.edu/', - 'Learning and academics are about exploring the things that interest you, growing with that knowledge, and finding the path on which you''ll be most successful. With 14 schools and colleges and more than 115+ undergraduate majors, you''ll find what you''re looking for at UConn. And what if you come up with something unique to study? You can create your own major. Whether you want to learn from the past by studying history or you want to set the course for the future with groundbreaking scientific research, learning opportunities here abound. Challenge yourself to reach new academic heights in rigorous courses taught by our expert faculty. Take advantage of undergraduate research awards including the Summer Undergraduate Research Fund or UConn IDEA Grants; study in a lab; or pursue a creative endeavor. Push yourself further, supplementing traditional coursework with enrichment such as Education Abroad or our acclaimed Honors Program. Whatever you choose, we''re here to help you fin...', - '2023-06-23 00:00:00', - '2023-07-26 20:16:05', - 1 - ), - ( - 201, - 'University of Houston', - 'UH', - '', - 'uh', - 'logo/uh-primary.svg', - 'https://www.uh.edu/', - 'At the University of Houston, we spur innovation by encouraging the very spark of an idea to the transfer of knowledge and technology. The UH innovation ecosystem has a rich history of advancing Houston''s innovation economy.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:06', - 1 - ), - ( - 202, - 'University of Illinois Urbana-Champaign', - 'UIUC', - '', - 'uiuc', - 'logo/wordmark_horizontal.png', - 'https://illinois.edu/', - 'Illinois students, scholars, and alumni are a community with the power to change the world. With our land-grant heritage as a foundation, we pioneer innovative research that tackles global problems and expands the human experience. Our transformative learning experiences, in and out of the classroom, are designed to produce alumni who desire to make a significant, societal impact.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:07', - 1 - ), - ( - 203, - 'University of Kent', - '', - '', - 'kent', - 'logo/ukent.jpeg', - 'https://www.kent.ac.uk/', - 'Welcome to the university of ambition where desire meets determination. We stand for ambition, with our diverse community of staff and students committed to making a difference at regional, national and global level. It''s something we''re very proud of.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:07', - 1 - ), - ( - 204, - 'University of Kentucky', - 'UK', - '', - 'uk', - 'logo/uky.png', - 'http://www.uky.edu/', - 'The University of Kentucky has a broad range of resources centered on a single campus in the heart of the Bluegrass. Our wide array of programs allows us to excel in multidisciplinary studies and fosters an environment of cooperative engagement across all colleges, programs, and research endeavors. Because of the lives we touch and teach, we remain anchored in our mission to Kentucky– to educate, innovate, heal, and serve. To be sure, our complex, multi-faceted mission looks different today in many ways than it did in 1865. However, our sense of responsibility to our communities on campus and across the region is resolute. The mission has evolved and grown. The vision of service to our Commonwealth and the world beyond remains the same. They remain our compass – the soul of the University of Kentucky.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:19', - 1 - ), - ( - 205, - 'University of Lausanne', - 'UNIL', - '', - 'unil', - 'logo/unil-logo.svg', - 'https://www.unil.ch/central/en/home.html', - 'The University of Lausanne is a higher teaching and research institution composed of seven faculties with approximately 17,100 students and about 4,400 research, teaching and technical staff. Its research activities focus on three main themes: human and social sciences, life sciences and medicine, and environmental sciences. UNIL lays great store by the quality and innovation of its teaching. This is characterised by a highly interdisciplinary approach which is even reflected in the organisation of its faculties.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:09', - 2 - ), - ( - 206, - 'University of Lisbon', - '', - '', - 'ulisboa', - 'logo/ulisboa.png', - 'https://www.ulisboa.pt/en', - 'Universidade de Lisboa (ULisboa) is the largest and most prestigious university in Portugal and is one of Europe''s leading universities. Heir to a university tradition that spans over seven centuries, ULisboa acquired its current status in July 2013, following the merger of the former Universidade Técnica de Lisboa and Universidade de Lisboa. ULisboa brings together various areas of knowledge and has a privileged position for facilitating the contemporary evolution of science, technology, arts and humanities. The quality of teaching, research, innovation and culture of ULisboa is attracting an ever increasing amount of talent from around the world.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:10', - 2 - ), - ( - 207, - 'University of London', - 'UoL', - '', - 'uol', - 'logo/uol.jpg', - 'https://london.ac.uk/', - 'The University of London is the UK''s leading provider of digital and blended distance education internationally, offering programmes to 45,000 students in 190 countries around the world. Although proudly rooted in London, our community and impact are global. We are a national leader in the humanities, and we promote their value to society and the economy through knowledge creation and exchange. We are also a federation of 17 esteemed higher education institutions, with collaboration at the heart of our ethos. The University of London federation is a collective community of more than 240,000 learners and 50,000 staff, delivering world-leading research across all disciplines. Our passion for increasing access to education and mobilising the collective power and expertise of the federation is central to our ability to transform lives around the world and address the global challenges of the future.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:10', - 2 - ), - ( - 208, - 'University of Luxembourg', - '', - '', - 'university-of-luxembourg', - 'logo/university-of-luxembourg.png', - 'https://wwwen.uni.lu/', - 'Founded in 2003, the University of Luxembourg is the only public university of the Grand Duchy of Luxembourg. Multilingual, international and research-oriented, it is also a modern institution with a personal atmosphere.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:11', - 1 - ), - ( - 209, - 'University of Maryland', - 'UMD', - '', - 'umd', - 'logo/umd.png', - 'https://www.umd.edu/', - 'The University of Maryland, College Park is the state''s flagship university and one of the nation''s preeminent public research universities. A global leader in research, entrepreneurship and innovation, the university is home to more than 40,700 students, 14,000 faculty and staff, and nearly 400,000 alumni all dedicated to the pursuit of Fearless Ideas. Located just outside Washington, D.C., we discover and share new knowledge every day through our renowned research enterprise and programs in academics, the arts and athletics. And we are committed to social entrepreneurship as the nation''s first “Do Good” campus.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:12', - 3 - ), - ( - 210, - 'University of Michigan', - '', - '', - 'umich', - 'logo/block-m-maize.png', - 'https://umich.edu/', - 'Welcome to the University of Michigan, a place with deep traditions focused on creating brighter futures. We invite you to explore the diverse and vibrant community that makes us the home of Leaders & Best. More than any other university, we have the potential to be so much more than the sum of our many excellent parts. It''s this potential to have a positive impact on the society we serve that represents our greatest value as a university.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:14', - 1 - ), - ( - 211, - 'University of North Carolina at Chapel Hill', - 'UNC', - '', - 'unc', - 'logo/univ-unc.png', - 'https://www.unc.edu/', - 'The nation''s first public university is at the heart of what''s next, preparing a diverse student body to become creators, explorers, innovators and leaders in North Carolina and throughout the world. Carolina''s nationally recognized, innovative teaching, campus-wide spirit of inquiry and dedication to public service continue the legacy that began in 1795 when the University first opened its doors to students. In Chapel Hill, students develop a voice for critical thought and the courage to guide change. They connect to the future they''re already shaping. Carolina is committed to access for all, providing life-changing opportunities such as the Carolina Covenant, which promises a debt-free education to low-income students. In its third century – an era of groundbreaking study and research – UNC-Chapel Hill is harnessing the very best of our fast-changing world. We''re proud to advance knowledge for this and each generation to come.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:15', - 4 - ), - ( - 212, - 'University of Notre Dame', - '', - '', - 'notre-dame', - 'logo/notre_dame.png', - 'https://www.nd.edu/', - 'The University of Notre Dame was founded in November 1842 by Rev. Edward F. Sorin, C.S.C., a priest of the Congregation of Holy Cross, a French missionary order. It is located adjacent to South Bend, Indiana, the center of a metropolitan area with a population of more than 315,000. Chartered by the state of Indiana in 1844, the University was governed by the Holy Cross priests until 1967, when governance was transferred to a two-tiered, mixed board of lay and religious trustees and fellows. Notre Dame has grown from the vision of Father Sorin, who sought to establish a great Catholic university in America, and has remained faithful to both its religious and intellectual traditions. Today, we seek to be an enlightening force for a world deeply in need. Our departments of theology and philosophy are regarded as among the finest in the world while faculty in all departments participate in our mission to ensure that Notre Dame''s Catholic character informs all of our endeavors. From l...', - '2023-06-23 00:00:00', - '2023-07-26 20:16:15', - 0 - ), - ( - 213, - 'University of Padova', - '', - '', - 'university-of-padova', - 'logo/university-of-padua.jpg', - 'https://www.unipd.it/en/', - 'The University of Padua is one of Europe''s oldest and most prestigious seats of learning. As a multi-disciplinary institute of higher education, the University aims to provide its students with professional training and a solid cultural background. The qualification received from the University of Padua act as a symbol of the ambitious objectives respected and coveted by both students and employers alike. Founded in 1222, Padua''s Studium Patavinum was a place of study that readily welcomed Italian students and scholars, as well as those from various European countries searching for cultural freedom and expression. This freedom continues to define and express the essence of the University through its motto as Universa universis patavina libertas.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:16', - 2 - ), - ( - 214, - 'University of Padua', - '', - '', - 'university-of-padua', - 'logo/university-of-padua.jpg', - 'https://www.unipd.it/en/', - 'The University of Padua is one of Europe''s oldest and most prestigious seats of learning. As a multi-disciplinary institute of higher education, the University aims to provide its students with professional training and a solid cultural background. The qualification received from the University of Padua act as a symbol of the ambitious objectives respected and coveted by both students and employers alike. Founded in 1222, Padua''s Studium Patavinum was a place of study that readily welcomed Italian students and scholars, as well as those from various European countries searching for cultural freedom and expression. This freedom continues to define and express the essence of the University through its motto as Universa universis patavina libertas.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:17', - 1 - ), - ( - 215, - 'University of Pennsylvania', - '', - '', - 'upenn', - 'logo/upenn.png', - 'https://www.upenn.edu/', - 'Penn''s academics are boosted by its inherent culture and ecosystem of innovation. You name it, if it''s cutting-edge, the University''s faculty—and students—have their hands in it. Grounded in the liberal arts and sciences and enriched by the integrated resources of four undergraduate and 12 graduate schools, Penn offers students an unparalleled education informed by inclusivity, intellectual rigor, research, and the impetus to create new knowledge to the benefit of individuals and communities around the world.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:17', - 6 - ), - ( - 216, - 'University of Rochester', - '', - '', - 'rochester', - 'logo/rochester.jpeg', - 'https://www.rochester.edu/', - 'One of the world''s leading research universities, Rochester has a long tradition of breaking boundaries—always pushing and questioning, learning and unlearning. We transform ideas into enterprises that create value and make the world ever better.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:18', - 2 - ), - ( - 217, - 'University of South Florida', - 'USF', - '', - 'usf', - 'logo/usf.png', - 'https://www.usf.edu/', - 'Welcome to the University of South Florida. Though a relatively young university, founded in 1956, we have rich traditions – traditions of access and opportunity for students, of academic excellence, of groundbreaking research, of serving our communities.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:19', - 1 - ), - ( - 218, - 'University of Southampton', - '', - '', - 'university-of-southampton', - 'logo/university-of-southampton.png', - 'https://www.southampton.ac.uk/', - 'As a global top 100 university, our expert academics and wide range of study options will help you achieve your goals.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:21', - 1 - ), - ( - 219, - 'University of Texas Southwestern Medical Center', - '', - '', - 'ut-southwestern', - 'logo/ut-swestern.gif', - 'https://www.utsouthwestern.edu/', - 'UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution''s faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. The faculty of more than 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:21', - 2 - ), - ( - 220, - 'University of Toronto', - 'U of T', - '', - 'utoronto', - 'logo/utoronto.png', - 'https://www.utoronto.ca/', - 'We are proud to be one of the world''s top research-intensive universities, bringing together top minds from every conceivable background and discipline to collaborate on the world''s most pressing challenges. Our community is a catalyst for discovery, innovation and progress, creating knowledge and solutions that make a tangible difference around the globe. And we prepare our students for success through an outstanding global education rooted in excellence, inclusion and close-knit learning communities. The ideas, innovations and contributions of more than 660,000 graduates advance U of T''s impact on communities across the globe. Together, we continue to defy gravity by taking on what might seem unattainable today and generating the ideas and talent needed to build a more equitable, sustainable and prosperous future.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:21', - 8 - ), - ( - 221, - 'University of Vermont', - 'UVM', - '', - 'uvm', - 'logo/the-university-of-vermont.png', - 'https://www.uvm.edu/', - 'UVM is a top research university of ideal size, large enough to offer a breadth of ideas, resources, and opportunities, yet scaled to enable close faculty-student mentorship across all levels of study, from bachelor''s to doctoral programs.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:22', - 1 - ), - ( - 222, - 'University of Verona', - '', - 'relazioni.internazionali@ateneo.univr.it', - 'university-of-verona', - 'logo/university-of-verona.png', - 'https://www.univr.it/en/international', - '', - '2023-06-23 00:00:00', - '2023-07-26 20:16:22', - 1 - ), - ( - 223, - 'University of Virginia', - 'UVA', - '', - 'uva', - 'logo/uva_primary_logo.jpg', - 'https://www.virginia.edu/', - 'The University is an iconic public institution of higher education, boasting nationally ranked schools and programs, diverse and distinguished faculty, a major academic medical center and proud history as a renowned research university. The community and culture of the University are enriched by active student self-governance, sustained commitment to the arts and a robust NCAA Division I Athletics program.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:24', - 1 - ), - ( - 224, - 'University of Washington', - 'UW', - '', - 'uw', - 'logo/uw.svg', - 'https://www.washington.edu/', - 'Since our founding in 1861, the University of Washington has been a hub for learning, innovation, problem solving and community building. Driven by a mission to serve the greater good, our students, faculty and staff tackle today''s most pressing challenges with courage and creativity, making a difference across Washington state — and around the world.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:25', - 7 - ), - ( - 225, - 'University of Wisconsin-Madison', - '', - '', - 'uw-madison', - 'logo/uw-logo.png', - 'https://www.wisc.edu/', - 'Since its founding in 1848, this campus has been a catalyst for the extraordinary. As a public land-grant university and major research institution, our students, staff, and faculty engage in a world-class education while solving real-world problems. With public service — or as we call it, the Wisconsin Idea — as our guiding principle, Badgers are creating a better future for everyone.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:26', - 1 - ), - ( - 226, - 'University of Zurich', - 'UZH', - '', - 'uzh', - 'logo/uzh.png', - 'https://www.uzh.ch/en.html', - 'With its 28,000 enrolled students, the University of Zurich is Switzerland''s largest university. Founded in the year 1833, UZH was Europe''s first university to be established by a democratic political system. Made up of seven faculties covering some 100 different subject areas, the University offers a wide variety of Bachelor''s, Master''s and PhD programs.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:26', - 4 - ), - ( - 227, - 'Urban Green Energy', - 'UGE', - '', - 'uge', - 'logo/ugei-logo.svg', - 'https://www.ugei.com/', - 'Since 2008 when our journey began, we''ve been focused on expanding utilization of renewable energy. In our early days, we worked on finding use cases for clean energy technologies before they were widely adopted, building projects ranging from wind and solar microgrids in remote locations, to lighting the Eiffel Tower with 100% renewable energy in 2014. Over time we turned our focus entirely to solar and battery storage in the U.S. where we''re building a growing portfolio of distributed energy assets, Leaning on more than a decade of experience across 700 projects totaling more than 500 megawatts, we''re proud to be making a significant impact on the world''s transition to clean energy, and we''re just getting started. ', - '2023-06-23 00:00:00', - '2023-07-26 20:16:28', - 1 - ), - ( - 228, - 'US Army Medical Research Institute of Infectious Diseases', - 'USAMRIID', - '', - 'usamriid', - 'logo/usarmy.png', - 'https://www.usamriid.army.mil/', - '', - '2023-06-23 00:00:00', - '2023-07-26 20:16:28', - 1 - ), - ( - 229, - 'VA Durham Health Care', - '', - '', - 'va-durham-health-care', - 'logo/va-logo-white.png', - 'https://www.durham.va.gov/', - 'Since 1953, Durham Veterans Affairs Medical Center has been improving the health of the men and women who have so proudly served our nation. We consider it our privilege to serve your healthcare needs in any way we can. Services are available to more than 200,000 Veterans living in a 27-county area of central and eastern North Carolina. The VA Durham Healthcare System provides you with outstanding health care, trains America''s future health care providers, and conducts important medical research. ', - '2023-06-23 00:00:00', - '2023-07-26 20:16:29', - 2 - ), - ( - 230, - 'Verily', - '', - 'info@verily.com', - 'verily', - 'logo/verily.jpeg', - 'https://verily.com/', - 'True, comprehensive health is expanding exponentially. Massive increases in health information & computing power are coinciding with health challenges of a scale & magnitude we''ve never seen—creating urgency for value-based care and improved outcomes for all. Precision health represents a fundamental shift to health and to care that is more individualized, accessible, and affordable.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:29', - 1 - ), - ( - 231, - 'VHA Innovation Ecosystem', - 'VHA IE', - '', - 'vha-ie', - 'logo/vaInnovation.jpeg', - 'https://www.innovation.va.gov/ecosystem/views/home.html', - 'VHA Innovation Ecosystem (VHA IE) is the catalyst for enabling the discovery and spread of mission-driven health care innovation that exceeds expectations, restores hope, and builds trust within the Veteran community. VHA IE leverages the collective power of innovation champions from across VA, academia, non-profit and industry to operationalize innovation in the Nation''s largest integrated health care system.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:31', - 3 - ), - ( - 232, - 'Washington University in St. Louis', - 'WUStL', - '', - 'wustl', - 'logo/wustl.png', - 'https://wustl.edu/', - 'At WashU, we generate, disseminate, and apply knowledge. We foster freedom of inquiry and expression of ideas in our research, teaching and learning. We aim to create an environment that encourages and supports wide-ranging exploration at the frontier of discovery by embracing diverse perspectives from individuals of all identities and backgrounds. We promote higher education and rigorous research as a fundamental component of an open, vibrant society. We strive to enhance the lives and livelihoods not only of our students, patients, and employees but also of the people of the greater St. Louis community and beyond. We do so by addressing scientific, social, economic, medical, and other challenges in the local, national, and international realms.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:32', - 1 - ), - ( - 233, - 'Wayne State University', - '', - '', - 'wayne-state-university', - 'logo/wayne-state-university.png', - 'https://wayne.edu/', - 'Our mission is to create and advance knowledge, prepare a diverse student body to thrive, and positively impact local and global communities. Our guiding values cut across organizational boundaries, bind us culturally, and permeate our strategic and tactical initiatives. They are the defining traits of the WSU community.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:32', - 1 - ), - ( - 234, - 'Weizmann Institute of Science', - '', - 'contact-us@weizmann.ac.il', - 'weizmann-institute-of-science', - 'logo/wiz.jpeg', - 'https://www.weizmann.ac.il/pages/', - 'The Weizmann Institute of Science is one of the world''s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:33', - 3 - ), - ( - 235, - 'Wellcome Sanger Institute', - '', - '', - 'sanger', - 'logo/sanger.jpeg', - 'https://www.sanger.ac.uk/', - 'We tackle some of the most difficult challenges in genomic research. This demands science at scale; a visionary and creative approach to research that pushes the boundaries of our understanding in ever new and exciting ways.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:34', - 2 - ), - ( - 236, - 'White House Office of Science and Technology Policy', - 'OSTP', - '', - 'ostp', - 'logo/ostp.png', - 'https://www.whitehouse.gov/ostp/', - 'President Biden often says, ''America is the only nation that can be defined by a single word: possibilities.'' The White House Office of Science and Technology (OSTP) works to bring that idea to life by harnessing the power of science, technology, and innovation to achieve America''s greatest aspirations. OSTP''s mission includes: a) Providing advice to the President and the Executive Office of the President on matters related to science and technology; b) Strengthening and advancing American science and technology; c) Working with federal departments and agencies and with Congress to create bold visions, unified strategies, clear plans, wise policies, and effective, equitable programs for science and technology; d) Engaging with external partners, including industry, academia, philanthropic organizations, and civil society; state, local, Tribal and territorial governments; and other nations; and, e) Ensuring equity, inclusion, and integrity in all aspects of science and technology.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:34', - 1 - ), - ( - 237, - 'InChI Trust', - '', - '', - 'inchi', - 'logo/inchi.png', - 'https://www.inchi-trust.org/', - 'InChI: open-source chemical structure representation algorithm. InChI is a structure-based chemical identifier, originally developed by IUPAC. As a standard identifier for chemical databases, InChI is essential for enabling effective information management across chemistry. InChI with InChIKey are non-proprietary open standards. InChI turns chemical structures into unique machine readable strings, used for describing, storing and searching chemical structures. All associated algorithms and software are open source.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:35', - 1 - ), - ( - 238, - 'National Center for Toxicological Research', - 'NCTR', - '', - 'nctr', - '', - 'https://www.fda.gov/about-fda/office-chief-scientist/national-center-toxicological-research', - 'The National Center for Toxicological Research (NCTR), is the only FDA Center located outside the Washington D.C. metropolitan area. The one-million square foot research campus in Jefferson, Arkansas plays a critical role in the missions of FDA and the Department of Health and Human Services to promote and protect public health. Regulatory science researchers, academia, and other regulatory science research organizations and groups from around the world investigate, learn, and train at the Federal facility. NCTR, FDA''s internationally recognized research center, plays a critical role in FDA''s mission. The unique scientific expertise of NCTR is critical in supporting FDA product centers and their regulatory roles. ', - '2023-06-23 00:00:00', - '2023-07-26 20:16:36', - 2 - ), - ( - 239, - 'McGill University', - '', - '', - 'mcgill', - 'logo/mcgill.jpg', - 'https://www.mcgill.ca/', - 'McGill University is one of Canada''s best-known institutions of higher learning and one of the leading universities in the world. International students from more than 150 countries make up nearly 30% of McGill''s student body ‒ the highest proportion of any Canadian research university.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:36', - 1 - ), - ( - 240, - 'Medical Artificial Intelligence Lab', - '', - 'spark@mailab.io', - 'mai-lab', - 'logo/mai-lab.jpg', - 'https://mailab.io/', - 'We are a leading ecosystem for data science and artificial intelligence (AI) innovations in medical diagnostic imaging. Our lab is dedicated to creating AI solutions and data science applications to transform the healthcare landscape of countries in Africa. We are a team of scientists from around the world working locally to disrupt healthcare challenges in resourced limited settings by implementing AI innovations in Africa where it has the most potential.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:37', - 1 - ), - ( - 241, - 'Duke University Medical Center', - '', - '', - 'duke-health', - 'logo/duke-health.jpg', - 'https://www.dukehealth.org/locations/duke-university-medical-center', - 'Duke University Medical Center is the name given to the group of patient care, education and medical research facilities on the medical campus of Duke University in Durham, North Carolina.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:37', - 1 - ), - ( - 242, - 'Yale University', - '', - '', - 'yale', - 'logo/yale.jpg', - 'https://www.yale.edu/', - 'Since its founding in 1701, Yale has been dedicated to expanding and sharing knowledge, inspiring innovation, and preserving cultural and scientific information for future generations. Yale’s reach is both local and international. It partners with its hometown of New Haven, Connecticut to strengthen the city’s community and economy. And it engages with people and institutions across the globe in the quest to promote cultural understanding, improve the human condition, delve more deeply into the secrets of the universe, and train the next generation of world leaders.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:40', - 3 - ), - ( - 243, - 'Missouri University', - '', - '', - 'mizzou', - 'logo/mizzou.jpg', - 'https://missouri.edu/', - '', - '2023-06-23 00:00:00', - '2023-07-26 20:16:40', - 1 - ), - ( - 244, - 'Yale School of Medicine', - 'YSM', - '', - 'ysm', - 'logo/ysm.png', - 'https://medicine.yale.edu/', - 'Yale School of Medicine educates and nurtures creative leaders in medicine and science, promoting curiosity and critical inquiry in an inclusive environment enriched by diversity. We advance discovery and innovation fostered by partnerships across the university, our local community, and the world. We care for patients with compassion, and commit to improving the health of all people.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:42', - 1 - ), - ( - 245, - 'Children''s National Hospital', - '', - '', - 'childrens-national', - 'logo/childrens-national.jpg', - 'https://childrensnational.org/', - 'Children''s National Hospital is ranked #5 in the nation by U.S. News & World Report. We''re ranked #1 for newborns and we''re the best pediatric hospital for neurology and neurosurgery in the Mid-Atlantic. What''s more, we ranked in all 10 specialties, with top 10 honors in neurology and neurosurgery, cancer, nephrology, orthopedics, pulmonology and lung surgery, and diabetes and endocrinology. This recognition of our commitment to bringing health and well-being to all children continues to inspire our teams.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:42', - 1 - ), - ( - 246, - 'Helmholtz AI', - '', - '', - 'helmholtz-ai', - 'logo/helmholtz-ai.jpg', - 'https://www.helmholtz.ai/', - 'We are a research-driven hub for applied artificial intelligence (AI) that: a) fosters cross-field creativity by stimulating collaborative research projects; b) identifies and leverages similarities between applications to advance generalised AI / machine learning (ML) methods; c) integrates field-specific excellence and AI/ML prowess; d) improves the quality, scalability and timely availability of emerging methods and tools; and e) empowers and trains the current and next generation of scientists, to enable the efficient and agile development and implementation of AI/ML assets across the whole Helmholtz Association.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:43', - 1 - ), - ( - 247, - 'Mayo Clinic', - '', - '', - 'mayo-clinic', - 'logo/mayo-clinic.png', - 'https://www.mayoclinic.org/', - 'Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:43', - 6 - ), - ( - 248, - 'Technical University of Munich', - 'TUM', - '', - 'tum', - 'logo/tum.jpg', - 'https://www.tum.de/en/', - 'TUM has once again been named a University of Excellence and is thus the only technical university to continuously retain this status since 2006. The title is awarded as a part of the Excellence Strategy of the German federal and state governments, in strategic international support of German cutting-edge research. We are using this funding to realize the future concept TUM Agenda 2030. We are expanding technically-oriented humanities and social sciences and are reorganizing previous internal structures to be more innovation-oriented: The constraining, discipline-based Faculty structure is being replaced by seven Schools which are linked to one another by integrative research institutes. In the sense of an "open marketplace of knowledge", we support talented individuals in all their diversity, at all levels and across substantive subject boundaries. We work in alliances with international partners to re-orient towards Europe as well as to the southern global hemisphere in order to...', - '2023-06-23 00:00:00', - '2023-07-26 20:16:44', - 2 - ), - ( - 249, - 'FDA Center for Devices and Radiological Health', - 'CDRH', - '', - 'cdrh', - 'logo/fda.svg', - 'https://www.fda.gov/about-fda/fda-organization/center-devices-and-radiological-health', - 'In keeping with our mission, the Center for Devices and Radiological Health (CDRH) is responsible for protecting and promoting the public health. We assure that patients and providers have timely and continued access to safe, effective, and high-quality medical devices and safe radiation-emitting products. We provide consumers, patients, their caregivers, and providers with understandable and accessible science-based information about the products we oversee. We facilitate medical device innovation by advancing regulatory science, providing industry with predictable, consistent, transparent, and efficient regulatory pathways, and assuring consumer confidence in devices marketed in the U.S. We seek to continually improve our effectiveness in fulfilling our mission by planning strategically and regularly monitoring our progress.', - '2023-06-23 00:00:00', - '2023-08-10 21:36:27', - 2 - ), - ( - 250, - 'Lagos State University Teaching Hospital', - 'LASUTH', - '', - 'lasuth', - 'logo/lasuth.jpg', - 'https://www.lasuth.org.ng/', - 'To provide high quality Healthcare Services in a friendly Environment where patients'' satisfaction is the ultimate. Guided by the needs of our patients and their families, we aim to deliver the very best health care in a safe and compassionate environment; to advance care through innovative research and education; and to improve the health and well-being of the diverse communities we serve.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:45', - 1 - ), - ( - 251, - 'NSIA-Kano Diagnostic Center', - 'NKDC', - 'enquiries@nkdc.ng', - 'nkdc', - 'logo/nkdc.jpeg', - 'https://www.nhdic.ng/facility/nkdc/', - 'The NKDC medical diagnostics facility opened its doors to the public on the 16th of March, 2020, in Kano - Northern Nigeria’s commercial centre. This state-of-the-art facility is home to a group of enthusiastic, passionate and patient-centric medical professionals who continuously aim to improve patient experiences. We offer 24/7 radiology and medical laboratory services all year round.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:45', - 1 - ), - ( - 252, - 'Nationwide Children''s', - '', - '', - 'nationwide-childrens', - 'logo/nationwide-childrens.jpg', - 'https://www.nationwidechildrens.org/', - 'At Nationwide Children’s Hospital, our vision remains unchanged. We aspire to create the best outcomes for children everywhere. This means families come to Nationwide Children’s from around the globe knowing they will get the highest quality care. It means we will reach to cure rare diseases. It means we will sequence a child’s tumor to select the best care pathway. It means we will strive to make an entire population healthier, not just through their physical health, but also in their mental health. It means we will redefine the role of the children’s hospital in the achievement of optimal health.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:46', - 1 - ), - ( - 253, - 'Dana-Farber Brigham Cancer Center', - '', - '', - 'dana-farber-brigham-cancer-center', - 'logo/bwh.png', - 'https://www.brighamandwomens.org/cancer', - 'At Dana-Farber Brigham Cancer Center, all we do is cancer. Because no two people are the same, our approach to treatment and care is personalized – with a deep understanding of your cancer and how to get you well. Through our 12 specialized disease treatment centers, experts from our two organizations, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, work together as one team to offer the most advanced treatments with compassion and care that makes all the difference.', - '2023-06-23 00:00:00', - '2023-07-26 20:16:46', - 1 - ), - ( - 254, - 'Lacunda Fund', - '', - 'secretariat@lacunafund.org', - 'lacunda-fund', - 'logo/lacuna-fund.jpg', - 'https://lacunafund.org/', - 'Lacuna Fund is the world’s first collaborative effort to provide data scientists, researchers, and social entrepreneurs in low- and middle-income contexts globally with the resources they need to produce labeled datasets that address urgent problems in their communities.', - '2023-06-23 00:00:00', - '2023-08-04 22:03:25', - 1 - ), - ( - 255, - 'MLCommons', - '', - '', - 'mlcommons', - 'logo/mlc.jpg', - 'https://mlcommons.org/en/', - 'The mission of MLCommons(R) is to accelerate machine learning innovation and increase its positive impact on society. Together with its 50+ founding Members and Affiliates, including startups, leading companies, academics, and non-profits from around the globe, MLCommons will help grow machine learning from a research field into a mature industry through benchmarks, public datasets and best practices. Every major technological advance follows a similar trajectory towards universal adoption and impact. The arc from research to broad accessibility generally takes from 30-40 years: from early automobiles to the family car, from development of ARPANET to the mainstream World Wide Web, from the first cellular phones to an smartphone in every pocket. Each of these examples started with technological breakthroughs, but for decades was limited by expertise, access, and expense. Machine learning is no different. ML and artificial intelligence have been around for decades, but even today t...', - '2023-06-23 00:00:00', - '2023-08-04 23:38:22', - 1 - ), - ( - 256, - 'Harvard Medical School', - 'HMS', - '', - 'hms', - 'logo/hms.jpg', - 'https://hms.harvard.edu/', - 'Since the School was established in 1782, faculty members have improved human health by innovating in their roles as physicians, mentors and scholars. They’ve piloted educational models, developed new curricula to address emerging needs in health care, and produced thousands of leaders and compassionate caregivers who are shaping the fields of science and medicine throughout the world with their expertise and passion.', - '2023-08-04 06:00:47', - '2023-08-04 23:38:09', - 6 - ), - ( - 257, - 'Centre for Structural Systems Biology', - 'CSSB', - 'info@cssb-hamburg.de', - 'cssb-hamburg', - '', - 'https://www.cssb-hamburg.de/', - 'CSSB is a joint initiative of nine research partners from Northern Germany, including three universities and six research institutes that devotes itself to infection biology research. ', - '2023-08-04 22:00:31', - '2023-08-04 22:05:08', - 1 - ), - ( - 258, - 'UMC Groningen', - 'UMCG', - '', - 'umcg', - '', - 'https://www.umcg.nl/', - 'The University Medical Center Groningen (UMCG) is one of the largest hospitals in the Netherlands and is the largest employer in the Northern Netherlands. The more than 12,000 employees work together on care, research, training and education with the common goal: building the future of health.', - '2023-08-04 22:07:45', - '2023-08-04 22:09:44', - 1 - ), - ( - 259, - 'Eindhoven University of Technology', - 'TU/e', - '', - 'tue', - '', - 'https://www.tue.nl/en/', - 'We educate students and advance knowledge in science & technology for the benefit of humanity. We integrate education and research to enable our students and scientists to become thought leaders and to design and achieve the unimaginable. In close collaboration with our public and private partners, we translate our basic research into meaningful solutions.', - '2023-08-04 22:12:40', - '2023-08-04 22:14:15', - 1 - ), - ( - 260, - 'Wageningen University & Research', - 'WUR', - '', - 'wur', - '', - 'https://www.wur.nl/en.htm', - '', - '2023-08-04 22:15:19', - '2023-08-04 22:15:58', - 1 - ), - ( - 261, - 'UMC Utrecht', - '', - 'researchoffice@umcutrecht.nl', - 'umc-utrecht', - '', - 'https://www.umcutrecht.nl/en/research', - 'In the UMC Utrecht research is concentrated in six strategic programs with each a limited number of disease targets. Patient care is integrated in these programs. A relentless multidisciplinary approach guarantees patients benefit from the latest available expertise and innovative technological solutions.', - '2023-08-04 22:16:49', - '2023-08-04 22:19:36', - 3 - ), - ( - 262, - 'Amsterdam UMC', - '', - '', - 'amsterdam-university-medical-centers', - '', - 'https://www.amsterdamumc.org/en.htm', - 'Amsterdam UMC is a leading medical center that combines complex high-quality patient care, innovative scientific research, and education of the next generation health care professionals. We believe that health care practice, research and education belong together, with each shaping and informing the other.', - '2023-08-04 22:19:22', - '2023-08-04 22:20:09', - 1 - ), - ( - 263, - 'Maastricht University', - 'UM', - '', - 'um', - '', - 'https://www.maastrichtuniversity.nl/', - 'Maastricht University (UM) is the most international university in the Netherlands and, with nearly 22,000 students and 4,400 employees, is still growing. The university distinguishes itself with its innovative education model, international character and multidisciplinary approach to research and education.', - '2023-08-04 22:24:47', - '2023-08-04 23:14:35', - 1 - ), - ( - 264, - 'Delft University of Technology', - '', - '', - 'tu-delft', - '', - 'https://www.tudelft.nl/en/', - 'Top education and research are at the heart of the oldest and largest technical university in the Netherlands. Our 8 faculties offer 16 bachelor''s and more than 30 master''s programmes. Our more than 25,000 students and 6,000 employees share a fascination for science, design and technology. Our common mission: impact for a better society.', - '2023-08-04 23:14:17', - '2023-08-04 23:15:52', - 1 - ), - ( - 265, - 'alliance TU/e, WUR, UU, UMC Utrecht', - 'EWUU', - 'info@ewuu.nl', - 'ewuu', - '', - 'https://ewuu.nl/en/', - 'In 2019 Eindhoven University of Technology, Wageningen University & Research, Utrecht University and University Medical Centre Utrecht decided to form an alliance and to work together. The motto of this strategic collaboration is challenging future generations. Young researchers, lecturers and students are at the helm and work together right across disciplines. The challenges future generations will face are large but so are the possibilities for meeting those challenges. The institutions combine their expertise in order to contribute to social transitions in energy, sustainability, health and food.', - '2023-08-04 23:17:20', - '2023-08-04 23:34:13', - 1 - ), - ( - 266, - 'Utrecht University', - 'UU', - '', - 'uu', - '', - 'https://www.uu.nl/en', - 'We are Utrecht University. The place for new collaborations and cross-pollination. Students, academic and administrative staff, policymakers, members of the public, professionals and business owners; you are invited to contribute to a better world.', - '2023-08-04 23:19:33', - '2023-08-04 23:35:18', - 1 - ), - ( - 267, - 'Surgical Science', - '', - '', - 'surgical-science', - '', - 'https://surgicalscience.com/', - 'Training without putting patients at risk. This is why we exist – to give surgeons an excellent platform to train in the fundamental technical skills before entering the operation room. For over 20 years, we have been committed to providing state-of-the-art medical training simulators that focus on ease of use and validation. The simple idea is to learn the practical techniques of instrument handling in a realistic but safe environment so that you can pay full attention to the patient when you begin the operation.', - '2023-08-04 23:51:56', - '2023-08-04 23:52:44', - 1 - ), - ( - 268, - 'Wellcome/EPSRC Centre for Interventional and Surgical Sciences', - 'WEISS', - '', - 'weiss', - '', - 'https://www.ucl.ac.uk/interventional-surgical-sciences', - 'At the Wellcome/EPSRC Centre for Interventional and Surgical Sciences (WEISS), engineers, clinicians and scientists work together to develop technologies that enable safer and more effective treatments for patients across a wide range of conditions. The Centre is based at Charles Bell House, a building that brings together researchers from a wide range of departments at UCL, including Medical Physics and Biomedical Engineering, Computer Science and Mechanical Engineering. These academic researchers work in partnership with clinical researchers from areas such as the UCL Division of Surgery & Interventional Sciences and leading hospitals. At WEISS, research is being developed with a wide range of clinical applications in mind, including cardiovascular, paediatric, ophthalmic, neurological and urological surgical interventions. In particular, the Centre aims to advance engineering sciences in intraoperative imaging and sensing, data fusion and extraction, human-technology interfac...', - '2023-08-05 00:00:44', - '2023-08-05 00:01:47', - 1 - ), - ( - 269, - 'Medtronic', - '', - '', - 'medtronic', - '', - 'https://www.medtronic.com/us-en/index.html', - 'Health tech for a better future. From AI to connected care and beyond, our technology is building a bridge to better health for more people.', - '2023-08-05 00:02:47', - '2023-08-05 00:03:26', - 1 - ), - ( - 270, - 'King''s College Hospital', - 'KCH', - '', - 'kch', - '', - 'https://www.kch.nhs.uk/', - 'We are one of London’s largest and busiest teaching hospitals. We provide a strong profile of local hospital services for people living in the boroughs of Lambeth, Southwark, Lewisham, and Bromley. Our specialist services are also available to patients from a wider area. We providing nationally and internationally recognised treatment and care in liver disease and transplantation, neurosciences, haemato-oncology, and fetal medicine. Our vision is to be bold, and our new Trust values – Kind, Respectful Team – help ensure we bring a positive attitude to the way we interact with patients, relatives, and the many people who use our services.', - '2023-08-05 00:08:37', - '2023-08-05 00:09:46', - 2 - ), - ( - 271, - 'Western University', - '', - '', - 'western', - '', - 'https://www.uwo.ca/index.html', - '', - '2023-08-05 00:10:52', - '2023-08-05 00:11:11', - 1 - ), - ( - 272, - 'Robarts Research Institute', - '', - '', - 'robarts', - '', - 'https://www.robarts.ca/', - 'Opened in 1986, Robarts Research Institute at Western University is a medical research facility in London, Ontario, with more than 600 people working to investigate some of the most debilitating diseases of our time, from heart disease and stroke to diabetes, Alzheimer’s and many forms of cancer. We believe we’ve got a winning formula to accelerate medical discovery: attract the brightest and best people, give them the freedom to think big and set the bar high. From our roots under the scientific leadership of renowned neurologist Dr. Henry Barnett - whose work with Aspirin as a preventive therapy for heart attack and stroke remains one of the most important developments in 20th century medicine - the Institute has applied that formula to become a national leader in biological, clinical and imaging research.', - '2023-08-05 00:12:27', - '2023-08-05 00:13:00', - 1 - ), - ( - 273, - 'British Acoustic Neuroma Association', - 'BANA', - '', - 'bana-uk', - '', - 'https://www.bana-uk.com/', - 'BANA was formed in 1992 by a group of patients and their partners. They were introduced to each other by ENT and Neurosurgeon Consultants from the Queen’s Medical Centre Hospital in Nottingham and from the very beginning, mutual support was their primary aim. They also wanted to provide reliable information to those diagnosed and to promote research into Acoustic Neuromas and the effects associated with them. More than two decades on, these fledgling intentions remain the charitable objectives that drive the charity forward on behalf of all those affected.', - '2023-08-05 00:15:03', - '2023-08-05 00:16:46', - 1 - ), - ( - 274, - 'Ninewells Hospital', - '', - '', - 'ninewells-hospital', - '', - 'https://www.nhstayside.scot.nhs.uk/GoingToHospital/OurPremisesA-Z/NinewellsHospital/index.htm', - '', - '2023-08-05 00:20:05', - '2023-08-05 00:20:45', - 1 - ), - ( - 275, - 'UniProt', - '', - '', - 'uniprot', - '', - 'https://www.uniprot.org/', - 'The Universal Protein Resource (UniProt) is a comprehensive resource for protein sequence and annotation data. The UniProt databases are the UniProt Knowledgebase (UniProtKB), the UniProt Reference Clusters (UniRef), and the UniProt Archive (UniParc). The UniProt consortium and host institutions EMBL-EBI, SIB and PIR are committed to the long-term preservation of the UniProt databases. ', - '2023-08-05 05:21:46', - '2023-08-05 05:23:45', - 1 - ), - ( - 276, - 'Charing Cross Hospital', - '', - '', - 'charing-cross-hospital', - '', - 'https://www.imperial.nhs.uk/our-locations/charing-cross-hospital', - 'Charing Cross Hospital provides a range of acute and specialist services, a 24/7 accident and emergency department and hosts the hyper acute stroke unit for the region. It is also a growing hub for integrated care in partnership with local GPs and community providers.', - '2023-08-05 05:27:03', - '2023-08-05 05:27:34', - 1 - ), - ( - 277, - 'Elisabeth-TweeSteden Hospital', - 'ETZ', - '', - 'etz', - '', - 'https://www.etz.nl/', - 'The ETZ (Elisabeth-TweeSteden Hospital) is a top clinical teaching hospital and trauma center. With three locations in Tilburg and Waalwijk, ETZ is the hospital for all residents of the Central Brabant region, but also (far) beyond.', - '2023-08-05 05:28:21', - '2023-08-05 05:30:27', - 1 - ), - ( - 278, - 'InVitro Cell Research', - 'ICR', - '', - 'icr', - '', - 'https://invitrocellresearch.com/', - 'Founded in 2015, InVitro Cell Research, LLC (ICR) is a privately funded company focused on regenerative and preventive personalized medicine. We are dedicated to discovering and developing interventions to slow and reverse biological aging and prevent major age-related diseases. While our offices and labs in the greater New York City area offer over 15,000 square feet of state-of-the-art research space, our scientists set us apart and make us special. They help guide and define our mission. What is our mission? Researching how to repair aging people, fast. ', - '2023-08-05 05:33:19', - '2023-08-05 05:34:04', - 1 - ), - ( - 279, - 'AMP-PD', - 'AMP-PD', - '', - 'amp-pd', - '', - 'https://www.amp-pd.org/', - 'The Accelerating Medicines Partnership(R) (AMP(R)) program is a public-private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and non-profit organizations. Managed through the Foundation for the NIH (FNIH), AMP aims to identify and validate the most promising biological targets for therapeutics. Disease areas covered by AMP at the launch of this site include Alzheimer’s disease, type 2 diabetes, the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus) and Parkinson’s disease. Additional disease areas are being evaluated for addition to AMP.', - '2023-08-05 05:39:55', - '2023-08-05 05:42:53', - 1 - ), - ( - 280, - 'Vanderbilt University', - '', - '', - 'vanderbilt', - '', - 'https://www.vanderbilt.edu/', - 'From its founding in 1873 as an institution devoted to “strengthening the ties which should exist between all sections of our common country,” Vanderbilt University has forged a tradition of academic excellence infused with a unique spirit of collaboration and collegiality. Our mission lies in the quest to bring out the best in humanity—pushing new ideas into the frontiers of discovery, challenging the limits of what’s possible and working diligently in the service of others. Vanderbilt’s closely connected park-like campus, set in the heart of the rapidly growing city of Nashville, Tennessee, is representative of the enduring bonds that unite us as One Vanderbilt community.', - '2023-08-07 20:28:32', - '2023-08-07 20:29:06', - 1 - ), - ( - 281, - 'Basque Center On Cognition, Brain and Language', - 'BCBL', - '', - 'bcbl', - '', - 'https://www.bcbl.eu/en', - 'Our research aims to unravel the neurocognitive mechanisms involved in the acquisition, comprehension and production of language, with special emphasis on bilingualism and multilingualism. We study processes involved in normal child language acquisition and second language learning in adults, as well as learning disorders, language disorders, language-related effects of aging and neurodegeneration and language use in different social contexts.', - '2023-08-07 20:29:41', - '2023-08-07 20:30:41', - 1 - ), - ( - 282, - 'Erasmus MC', - 'EMC', - '', - 'emc', - '', - 'https://www.erasmusmc.nl/en/', - 'We are Erasmus MC. Every day our staff, volunteers, and students work with dedication and commitment and are passionate about everything that we stand for.', - '2023-08-07 20:31:10', - '2023-08-07 20:31:47', - 1 - ), - ( - 283, - 'Indiana University', - 'IU', - '', - 'iu', - '', - 'https://www.iu.edu/index.html', - 'IU is home to top-ranked business and music schools. We’re home to the world’s first school of philanthropy, the nation’s first school of informatics, and the country’s largest medical school. Our hundreds of academic programs are among the world’s best, and we’re always looking toward the horizon, thinking about what’s next. To better prepare our students for the careers of tomorrow, we’ve launched or reconfigured 10 schools in the last decade, and we’re constantly adding new academic programs, like IU Bloomington’s Intelligent Systems Engineering program and IU Online’s 100% virtual Master of Science in Educational Technology for Learning.', - '2023-08-08 17:26:11', - '2023-08-08 17:28:12', - 2 - ), - ( - 284, - 'SciLifeLab', - '', - '', - 'scilifelab', - '', - 'https://www.scilifelab.se/', - 'SciLifeLab, Science for Life Laboratory, is an institution for the advancement of molecular biosciences in Sweden. We are funded as a national research infrastructure by the Swedish government. -Our organization leverages the unique strengths of individual researchers across Sweden into a focused resource for the life science community. We provide access for thousands of researchers to the cutting-edge instrumentation and deep scientific expertise necessary to be internationally competitive in bioscience research. This infrastructure is supported and developed by our research community, including internationally recognized experts in life science and technology. Our units and expertise create a unique environment for carrying out health and environmental research at the highest level. SciLifeLab started out in 2010 as a joint effort between four universities: Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University and Uppsala University. Today, we support rese...', - '2023-08-08 17:26:35', - '2023-08-08 17:27:34', - 1 - ), - ( - 285, - 'Uppsala University', - 'UU', - '', - 'uppsala', - '', - 'https://www.uu.se/en', - 'Uppsala University was founded in 1477. Today it is a strong, comprehensive research university ranked among the best in the world, with 50,000 students and close to 5,000 researchers.', - '2023-08-08 17:28:30', - '2023-08-08 17:29:20', - 1 - ), - ( - 286, - 'Google', - '', - '', - 'google', - '', - 'https://about.google/', - 'Our mission is to organize the world’s information and make it universally accessible and useful.', - '2023-08-08 17:29:33', - '2023-08-08 17:30:47', - 3 - ), - ( - 287, - 'Precision Value & Health', - '', - '', - 'precision-value-health', - '', - 'https://www.precisionvaluehealth.com/', - 'Across the commercialization continuum, Precision Value & Health teams are focused on transforming data for health and leveraging evidence and insights to tailor communications for every stakeholder. From payers to health systems, scientists to healthcare providers, and consumers to advocates, our results are designed to shift the trajectory and accelerate your success. Precision Value & Health’s teams include PRECISIONadvisors (global pricing and market access strategy), PRECISIONeffect (branding and launch experts), PRECISIONheor (evidence generation and strategy), PRECISIONscientia (medical communications), PRECISIONvalue (managed markets marketing), and PRECISIONxtract (data-driven solutions and engagement).', - '2023-08-08 17:37:16', - '2023-08-08 17:40:34', - 1 - ), - ( - 288, - 'STLogics', - '', - '', - 'stlogics', - '', - 'https://www.stlogics.com/index.html', - 'The STLogics Team has over 60 years of combined business experience to share. This broad business savvy enables our team to provide mentorship to those seeking to enhance the velocity of their trajectory to success. We can assist from small start-up initiatives to large corporations with our keen management skills and futuristic thinking capabilities. If your organization desires growth optimization or is entertaining the thought of acquisition consultation or a merger, STLogics can propel your revolutionary vision to reality. STLogics Holding Company provides operational and strategic advice to our affiliates in an effort to enhance their effectiveness and growth. We simply support and nurture our family of companies to enable them to maximize service to their clients. Our goal is to expand and diversify over various verticals, thus allowing us to foster innovation and create optimal results for client needs.', - '2023-08-08 17:41:14', - '2023-08-08 17:41:34', - 1 - ), - ( - 289, - 'Conference Ventures', - '', - '', - 'conference-ventures', - '', - 'http://conferenceventures.com/', - 'This organization may no longer exist or has been merged under another organization.', - '2023-08-08 17:44:00', - '2023-08-08 17:59:39', - 1 - ), - ( - 290, - 'Google Brain', - '', - '', - 'google-brain', - '', - 'https://research.google/teams/brain/', - 'This organization may no longer exist or has been merged under another organization.', - '2023-08-08 17:56:04', - '2023-08-08 18:00:27', - 1 - ), - ( - 291, - 'Princeton University', - '', - '', - 'princeton', - '', - 'https://www.princeton.edu/', - 'Princeton is about people. Our University is enriched by the wide range of experiences and perspectives of our students, faculty, staff and alumni.', - '2023-08-08 18:02:09', - '2023-08-08 18:02:58', - 1 - ), - ( - 292, - 'Prairie View A&M University', - 'PVAMU', - '', - 'pvamu', - '', - 'https://www.pvamu.edu/', - 'Welcome to Prairie View A&M University, home of the Panthers. Our HBCU, affectionately known as “The Hill,” is deeply rooted in culture & tradition and provides an undeniable educational experience to more than 9,000 diverse students on one of the most beautiful campuses in the state of Texas. Our award-winning faculty work diligently to create challenging and rewarding experiences that inspire you to dream big and soar to new heights. Are YOU ready to EXPERIENCE PVAMU?', - '2023-08-08 18:17:53', - '2023-08-08 18:26:36', - 1 - ), - ( - 293, - 'University of California, Berkeley', - '', - '', - 'berkeley', - '', - 'https://www.berkeley.edu/', - 'From a group of academic pioneers in 1868 to the Free Speech Movement in 1964, Berkeley is a place where the brightest minds from across the globe come together to explore, ask questions and improve the world.', - '2023-08-08 18:48:17', - '2023-08-08 18:51:02', - 1 - ), - ( - 294, - 'NSF Center for Genetically Encoded Materials', - 'C-GEM', - '', - 'c-gem', - '', - 'https://gem-net.net/', - 'C-GEM is establishing a fundamentally new way to program chemical matter and transform the way scientists design and produce materials and medicines. Using computation and experiment, C-GEM is repurposing nature’s protein synthesizing machine–the ribosome and its associated translation factors–to biosynthesize genetically encoded, sequence-defined chemical polymers with unprecedented functions and activities. Our combined activities span the fields of chemical biology, synthetic biology, synthetic chemistry, structural biology, computational biology, and molecular biology, and are highly collaborative. To catalyze these efforts, C-GEM implemented GEM-NET, a sophisticated data management system to promote data sharing within and outside the team, and with industry, the NSF, and the public. By fostering innovation at the chemical-biology-materials frontier, C-GEM is establishing a diverse chemical workforce, perfecting the integration of research with training, and captivating scient...', - '2023-08-08 19:14:43', - '2023-08-08 19:38:06', - 1 - ), - ( - 295, - 'Oregon State University', - 'OSU', - '', - 'oregon-state', - '', - 'https://oregonstate.edu/', - 'Oregon State University is a dynamic community of dreamers, doers, problem-solvers and change-makers. We don’t wait for challenges to present themselves — we seek them out and take them on. We welcome students, faculty and staff from every background and perspective into a community where everyone feels seen and heard. We have deep-rooted mindfulness for the natural world and all who depend on it, and together, we apply knowledge, tools and skills to build a better future for all.', - '2023-08-08 19:23:28', - '2023-08-08 19:37:53', - 1 - ), - ( - 296, - 'Laboratory for Innovation Science at Harvard', - 'LISH', - '', - 'lish', - '', - 'https://lish.harvard.edu/', - 'The Laboratory for Innovation Science at Harvard (LISH) is spurring the development of a science of innovation through a systematic program of solving real-world innovation challenges while simultaneously conducting rigorous scientific research and analysis. LISH is a Harvard-wide research program led by faculty co-directors Karim Lakhani, Harvard Business School; Eva Guinan, Harvard Medical School; David Parkes, Harvard School of Engineering and Applied Sciences; and Kyle Myers, Harvard Business School; with support from the Institute for Quantitative Social Science. With our partners in both academia and industry, LISH conducts research on innovation within three areas of application: Crowdsourcing & Open Innovation; Data Science & AI Development; and Science of Science; addressing questions under three main research tracks: Incentives & Governance; Creativity & Problem-Solving; and Organization & Processes.', - '2023-08-08 19:24:59', - '2023-08-08 19:30:57', - 1 - ), - ( - 297, - 'NIH LINCS Program', - 'LINCS', - '', - 'nih-lincs-program', - '', - 'https://lincsproject.org/LINCS/', - 'The LINCS project is based on the premise that disrupting any one of the many steps of a given biological process will cause related changes in the molecular and cellular characteristics, behavior, and/or function of the cell – the observable composite of which is known as the cellular phenotype. Observing how and when a cell’s phenotype is altered by specific stressors can provide clues about the underlying mechanisms involved in perturbation and, ultimately, disease.', - '2023-08-08 19:25:32', - '2023-08-08 19:37:57', - 1 - ), - ( - 298, - 'Recursion', - '', - '', - 'recursion', - '', - 'https://www.recursion.com/', - 'From our earliest days, our story was unlikely. We are a company started by two graduate students and a professor, headquartered in Salt Lake City, Utah. Our humble and unlikely beginnings are foundational to what we’ve built today. We were underdogs, and felt that way. Now we are leaders in this space, and we vow to stay hungry and focused on our mission. We are a biotechnology company scaling more like a technology company, and we are just getting started.', - '2023-08-08 19:41:20', - '2023-08-08 19:42:43', - 1 - ), - ( - 299, - 'Google Cloud', - '', - '', - 'google-cloud', - '', - 'https://cloud.google.com/?hl=en', - 'Google Cloud is widely recognized as a global leader in delivering a secure, open and intelligent enterprise cloud platform. Our technology is built on Google’s private network and is the product of nearly 20 years of innovation in security, network architecture, collaboration, artificial intelligence and open source software. We offer a simply engineered set of tools and unparalleled technology across Google Cloud Platform and G Suite that help bring people, insights and ideas together. Customers across more than 150 countries trust Google Cloud to modernize their computing environment for today’s digital world.', - '2023-08-08 19:43:02', - '2023-08-08 19:44:33', - 1 - ), - ( - 300, - 'DoiT', - '', - '', - 'doit', - '', - 'https://www.doit.com/', - 'You have the cloud and we have your back. For nearly a decade, we’ve been helping businesses build and scale cloud solutions with our world-class cloud engineering support. We help our customers with technical support and consulting on building and operating complex large-scale distributed systems, developing better machine learning models and setting up big data solutions using Google Cloud, Amazon AWS and Microsoft Azure.', - '2023-08-08 19:43:17', - '2023-08-08 19:44:51', - 1 - ), - ( - 301, - 'Lambda', - '', - '', - 'lambda', - '', - 'https://lambdalabs.com/', - 'Our workstations, servers, laptops, and cloud services power engineers and researchers at the forefront of human knowledge. Our customers include Intel, Microsoft, Amazon Research, Kaiser Permanente, MIT, Stanford, Harvard, Caltech, and the Department of Defense. With Lambda, you simply plug the system into the wall and get started making business and scientific breakthroughs. That''s why the greatest companies and research labs in the world work with Lambda.', - '2023-08-08 19:43:31', - '2023-08-08 19:44:16', - 1 - ), - ( - 302, - 'Center for the Study of Movement, Cognition, and Mobility', - 'CMCM', - '', - 'cmcm', - '', - 'https://rnd.tasmc.org.il/laboratories/center-for-the-study-of-movement-cognition-and-mobility-prof-jeff-hausdorff/', - 'As the baby boomers age, the number of adults who suffer from frequent falls, gait disorders, cognitive impairment, dementia, and other neurological diseases continues to increase dramatically. New understandings and therapeutic approaches are needed. Our research aims to improve the personalized treatment of age-related movement, cognition, and mobility disorders and to alleviate the burden associated with them.`', - '2023-08-08 19:54:16', - '2023-08-08 19:54:33', - 1 - ), - ( - 303, - 'Research Group for Neurorehabilitation', - 'eNRGy', - '', - 'enrgy', - '', - 'https://gbiomed.kuleuven.be/english/research/50000743/research/research-units/enrgy', - 'The mission of the Neurorehabilitation Research Group (eNRGy) is to advance the evidence-base of neurorehabilitation of child and adult populations with acute and chronic neurological conditions. In doing so, our research activities tackle both fundamental and translational research questions aimed at increasing our understanding of neurobehavioral and neuromuscular mechanisms, relevant for innovation and refinement of rehabilitation interventions. The clinical challenge of eNRGy lies in addressing the complexity of the brain and its role in neuromotor function, including deficits in the motor, sensory, social and cognitive domain.', - '2023-08-08 19:55:53', - '2023-08-08 19:57:47', - 1 - ), - ( - 304, - 'Hinda and Arthur Marcus Institute for Aging', - '', - '', - 'marcus-institute', - '', - 'https://www.marcusinstituteforaging.org/', - 'Since 1966, the Hinda and Arthur Marcus Institute for Aging Research has challenged conventional wisdom to better understand how we age. The questions we ask - and the answers we uncover - directly impact standards of care and help seniors live more vital, meaningful lives. The Marcus Institute is one of the largest gerontological research facilities in a clinical setting in the U.S. Our decades-long relationship with Harvard Medical School attracts expert teaching staff and outstanding research fellows. Our research portfolio increased 90% from 2010 to 2022 and ranks us in the top 10% of institutions funded by the National Institutes of Health.', - '2023-08-08 19:59:31', - '2023-08-08 20:00:08', - 1 - ), - ( - 305, - 'University Hospital Zurich', - 'USZ', - '', - 'usz', - '', - 'https://www.usz.ch/en/', - 'The University Hospital Zurich (USZ) is open to all patients every day and provides fundamental medical care and cutting-edge medicine in a central location in Zurich. We use our superior academic knowledge to treat a wide range of health issues, taking a personal touch and utilizing highly specialized and up-to-date research.', - '2023-08-09 22:21:15', - '2023-08-09 22:21:34', - 1 - ), - ( - 306, - 'Zurich University of Applied Sciences', - 'ZHAW', - '', - 'zhaw', - '', - 'https://www.zhaw.ch/en/university/', - 'The ZHAW is one of the leading universities of applied sciences in Switzerland. It offers teaching, research, continuing education and other services that are both practice-oriented and science-based. Research & development at the ZHAW focuses on key societal challenges, with a particular emphasis on energy and societal integration. With its expertise in sustainable development and digital transformation, the ZHAW imparts forward-looking knowledge and takes an active part in shaping the digital and ecological transformation. With locations in Winterthur, Zurich and Wädenswil, the ZHAW is firmly anchored in its region whilst collaborating with international partners.', - '2023-08-09 22:22:32', - '2023-08-09 22:22:57', - 1 - ), - ( - 307, - 'Helmholtz Munich', - '', - '', - 'helmholtz-munich', - '', - 'https://www.helmholtz-munich.de/en', - 'We are Helmholtz Munich. We discover breakthrough solutions for better health in a rapidly changing world. Our world is constantly changing. This impacts our health. Many widespread diseases such as diabetes, allergies and lung diseases are on the rise. Climate change is causing new diseases to emerge. We develop solutions for a healthier future. Our cutting-edge research is the springboard for medical innovations. Together with our partners, we accelerate the transfer from ideas to applications, from labs to startups, from science to society.', - '2023-08-09 22:23:10', - '2023-08-09 22:24:12', - 1 - ), - ( - 308, - 'Imperial College London', - '', - '', - 'imperial', - '', - 'https://www.imperial.ac.uk/', - 'Imperial is a global top ten university with a world-class reputation in science, engineering, business and medicine. Together, we are Imperial.', - '2023-08-09 22:24:26', - '2023-08-09 22:25:15', - 1 - ), - ( - 309, - 'Geneva University Hospitals', - 'HUG', - '', - 'hug', - '', - 'https://www.hug.ch/', - 'The result of a centuries-old tradition of excellence in medicine and science, the HUG was created in 1995. Bringing together the eight Geneva public hospitals and, since July 1, 2016, two clinics (Joli-Mont and Crans-Montana), they represent the leading university hospital in Switzerland. They also have 30 outpatient consultations, spread throughout the canton of Geneva.', - '2023-08-09 22:26:11', - '2023-08-09 22:26:46', - 1 - ), - ( - 310, - 'National University Hospital', - 'NUH', - '', - 'nuh', - '', - 'https://www.nuh.com.sg/Pages/Home.aspx', - 'The National University Hospital (NUH) is Singapore’s leading university hospital. While the hospital at Kent Ridge first received its patients on 24 June 1985, our legacy started from 1905, the date of the founding of what is today the NUS Yong Loo Lin School of Medicine. NUH is the principal teaching hospital of the medical school. Our unique identity as a university hospital is a key attraction for healthcare professionals who aspire to do more than practise tertiary medical care. We offer an environment where research and teaching are an integral part of medicine, and continue to shape medicine and transform care for the community we care for. We are an academic medical centre with over 1,200 beds, serving more than one million patients a year with over 50 medical, surgical and dental specialties. NUH is the only public and not-for-profit hospital in Singapore to provide trusted care for adults, women and children under one roof, including the only paediatric kidney and liver...', - '2023-08-09 22:27:16', - '2023-09-13 00:06:26', - 1 - ), - ( - 311, - 'Princess Maxima Center for Pediatric Oncology', - '', - '', - 'princess-maxima-center', - '', - 'https://www.prinsesmaximacentrum.nl/en', - 'When a child is seriously ill with cancer, only one thing comes first: cure. That is why at the Princess Máxima Center for pediatric oncology we work together every day in a groundbreaking and passionate way to improve the survival rate and quality of life of children with cancer. Now, and in the longer term. Because children still have a whole life ahead of them. The Princess Máxima Center is not an ordinary hospital, but a research hospital. All children with cancer in the Netherlands are treated here. This makes the Princess Máxima Center the largest pediatric cancer center in Europe. Over 450 researchers and 900 healthcare professionals work closely with Dutch and international hospitals on better treatments and new perspectives on cures. In this way, we give the child of today the very best care and take important steps to improve the chances of survival for the children who are not yet cured.', - '2023-08-09 22:29:04', - '2023-08-09 22:30:33', - 1 - ), - ( - 312, - 'CHAIMELEON Consortium', - '', - '', - 'chaimeleon', - '', - 'https://chaimeleon.eu/#partners', - 'The interdisciplinary CHAIMELEON consortium is made up of 18 partners from 9 countries: Fundación para la Investigación del Hospital Universitario la Fe de la Comunidad Valenciana (ES), Universita di Pisa (IT), Universita Degli Studi di Roma la Sapienza (IT), Centro Hospitalar Universitário de Santo António (PT), ICCS Policlinico San Donato (IT), College des Enseignants de Radiologie (FR), Universiteit Masstricht (NL), Charité Universitätsmedizin Berlin (DE), Imperial College London (UK), Ben-Gurion University of the Negev (IL), Universitat Politècnica de Valencia (ES), GE Healthcare (DE), Quibim (ES), Medexprim (FR), Bahia (ES), Matical Innovation (ES), European Institute of Biomedical Imaging Research (AT), Universitat de Valencia (ES). It constitutes a pan-European ecosystem of knowledge, infrastructures, biobanks and technologies on oncology, AI/in-silico and cloud computing addressed to health. The CHAIMELON project also collaborates with other European projects and initiatives.', - '2023-08-09 22:48:43', - '2023-08-09 22:51:15', - 1 - ), - ( - 313, - 'FDA Office of Digital Transformation', - 'ODT', - '', - 'odt', - 'logo/fda.svg', - 'https://www.fda.gov/about-fda/office-commissioner/office-digital-transformation', - 'The Office of Digital Transformation (ODT) provides the vision and leadership in information technology (IT), data, and cybersecurity needed to advance FDA’s mission and strategic priorities. ODT is led by the Chief Information Officer and reports to the FDA Commissioner. ODT directs and coordinates enterprise strategic planning, policy, and resource management to ensure that Agency IT, data, and cybersecurity investments and activities provide maximum value to FDA. ODT is comprised of the Office of Information Management and Technology (OIMT), Office of Data, Analytics, and Research (ODAR), and the Office of Information Security (OIS), under the direction of the Chief Technology Officer (CTO), Chief Data Officer (CDO), and Chief Information Security Officer (CISO). ODT is committed to delivering trusted technology and data solutions that enable FDA to reimagine the possible. Watch this video to learn more about our organization and how we are striving to make an impact at FDA. ', - '2023-08-10 21:37:33', - '2023-08-10 21:39:34', - 2 - ), - ( - 314, - 'FDA Office of Minority Health and Health Equity', - 'OMHHE', - '', - 'omhhe', - 'logo/fda.svg', - 'https://www.fda.gov/about-fda/office-commissioner/office-minority-health-and-health-equity', - 'The FDA Office of Minority Health and Health Equity (OMHHE) serves to promote and protect the health of diverse populations through research and communication of science that addresses health disparities.', - '2023-08-10 21:37:42', - '2023-08-10 21:40:30', - 1 - ), - ( - 315, - 'FDA Office of Data, Analytics, and Research', - 'ODAR', - '', - 'odar', - 'logo/fda.svg', - 'https://www.fda.gov/about-fda/office-digital-transformation/office-data-analytics-and-research-odar', - 'The Office of Data, Analytics, and Research (ODAR) manages and improves FDA’s ability to leverage data as a strategic asset by establishing enterprise data strategy and priorities. ', - '2023-08-10 21:37:44', - '2023-08-10 21:38:28', - 2 - ), - ( - 316, - 'Medicines and Healthcare products Regulatory Agency', - 'MHRA', - '', - 'mhra', - '', - 'https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency', - 'We are the regulator of medicines, medical devices and blood components for transfusion in the UK. We put patients first in everything we do, right across the lifecycle of the products we regulate. We rigorously use science and data to inform our decisions, enable medical innovation and to make sure that medicines and healthcare products available in the UK are safe and effective.', - '2023-08-10 22:10:11', - '2023-08-10 22:11:14', - 1 - ), - ( - 317, - 'MDClone', - '', - '', - 'mdclone', - '', - 'https://www.mdclone.com/', - 'MDClone is a technology firm focused on unlocking healthcare data and empowering exploration, discovery, and collaboration to improve patients'' health. At MDClone, we are a growing startup with big aspirations. We are determined to make an impact on healthcare worldwide with tools, processes, and services focused on turning data into better outcomes. MDClone is focused on empowering healthcare institutions, enabling stronger and more secure relationships between healthcare providers and life science companies, and developing regional and global collaboration with privacy-enabled shared data sets. ', - '2023-08-10 22:11:58', - '2023-08-10 22:12:33', - 1 - ), - ( - 318, - 'Washington Business Dynamics', - 'WBD', - '', - 'wbd', - '', - 'https://www.wbdynamics.com/', - 'Since our founding, WBD has sought to be a management consulting provider of choice for the federal government and the private sector. We are privileged to count many of the world’s foremost institutions and organizations among our client list. We partnered with these organizations’ senior leaders and immediately began uncovering value. Our staff brings a superior analytic capability, time-tested best practices, and a logical approach to solve problems and position organizations for future success.', - '2023-08-10 22:12:50', - '2023-08-10 22:13:23', - 1 - ), - ( - 319, - 'Medical College of Wisconsin', - 'MCW', - '', - 'mcw', - 'logo/medical-college-wisconsin-logo.svg', - 'https://www.mcw.edu/', - 'The Medical College of Wisconsin is a private medical school, pharmacy school, and graduate school of sciences headquartered in Milwaukee, Wisconsin. The school was established in 1893 and is the largest research center in eastern Wisconsin.', - '2023-09-09 01:40:31', - '2023-09-09 03:10:17', - 5 - ), - ( - 320, - 'Boston University', - 'BU', - '', - 'bu', - '', - 'https://www.bu.edu/', - 'Boston University is no small operation. With over 36,000 students from more than 130 countries, over 10,000 faculty and staff, 17 schools and colleges and the Faculty of Computing & Data Sciences, and more than 300 programs of study, our three campuses are always humming, always in high gear. Get to know the people and teams that keep the University running smoothly.', - '2023-09-12 23:58:11', - '2023-09-12 23:58:49', - 1 - ), - ( - 321, - 'Telethon Institute of Genetics and Medicine', - 'TIGEM', - '', - 'tigem', - '', - 'https://www.tigem.it/', - 'The Telethon Institute of Genetics and Medicine (TIGEM), a Telethon Foundation organization, was founded in 1994 as a leading European research center. TIGEM is a Telethon Foundation research centre in Pozzuoli, Italy. TIGEM comprises several research groups and over 200 staff members, all dedicated to understanding the molecular mechanisms behind rare genetic diseases and developing novel treatments. These diseases, often overlooked by pharmaceutical industries, are most common in children and adolescents. TIGEM’s research falls into three main themes: Cell Biology and Disease Mechanisms, Genomic Medicine, and Molecular Therapy. Our research is supported by a number of in-house highly specialised facilities, as well as significant international support in the form of funding and collaborative opportunities.', - '2023-09-13 00:01:07', - '2023-09-13 00:01:39', - 1 - ), - ( - 322, - 'Genome Institute of Singapore', - 'GIS', - '', - 'gis', - '', - 'https://www.a-star.edu.sg/gis', - 'When the Genome Institute of Singapore (GIS) was established in 2000, the science of genomics was still in its infancy. Since then, genomics has proved its relevance to all aspects of biology and medicine. It is now possible to sequence entire populations and communities, resolve organs at the single-cell level, and develop treatments guided by genomic data. We are now able to edit genomes at will, synthesise chromosomes, and perform complex experiments in silico by harnessing the ever-growing reservoir of public-access data. Importantly, while much has been done, much remains to be discovered as our knowledge of genomes, both human and non-human, remains incomplete. Through it all, GIS has maintained its leadership and relevance in genomic science by focusing on its three core strengths – asking the right biological questions, applying and developing cutting-edge technology platforms, and embracing multi-disciplinary team science. These core strengths have served us well, and wil...', - '2023-09-13 00:05:51', - '2023-09-13 00:06:34', - 1 - ), - ( - 323, - 'University of Rostock', - '', - '', - 'university-of-rostock', - '', - 'https://www.uni-rostock.de/en/', - 'Founded in 1419, the University of Rostock is the oldest in the Baltic Sea Region. True to the motto “Traditio et Innovatio”, the University of Rostock has constantly further developed. The multitude of new buildings represents the university’s modernity.', - '2023-09-13 00:22:55', - '2023-09-13 00:24:16', - 1 - ), - ( - 324, - 'FlowCAP', - '', - '', - 'flowcap', - '', - '', - 'This organization may no longer exist or has been merged under another organization.', - '2023-09-13 00:36:41', - '2023-09-13 00:37:01', - 1 - ), - ( - 325, - 'University of California, Santa Barbara', - 'UCSB', - '', - 'uc-santa-barbara', - '', - 'https://www.ucsb.edu/', - 'At UC Santa Barbara, we offer a dynamic environment that prizes academic inquiry and interpersonal connection to inspire scholarly ambition, creativity, and discoveries with wide-ranging impact. We’re inquisitive and curious, community-driven and globally-focused. Across our campus, you’ll find independent thinkers and consensus builders, Nobel Laureates and leaders chasing noble causes. But no matter how you define us, we are above all Gauchos — diverse in our pursuits, yet connected in our collective drive toward excellence. ', - '2023-09-13 16:57:59', - '2023-09-13 16:59:12', - 2 - ), - ( - 326, - 'GSK', - '', - '', - 'gsk', - '', - 'https://www.gsk.com/en-gb/', - 'We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.', - '2023-09-13 17:17:03', - '2023-09-15 16:02:05', - 2 - ), - ( - 327, - 'Carnegie Mellon University', - 'CMU', - '', - 'cmu', - '', - 'https://www.cmu.edu/', - 'Carnegie Mellon University challenges the curious and passionate to imagine and deliver work that matters. A private, global research university, Carnegie Mellon stands among the world''s most renowned educational institutions, and sets its own course. Start the journey here. Over the past 10 years, more than 400 startups linked to CMU have raised more than $7 billion in follow-on funding. Those investment numbers are especially high because of the sheer size of Pittsburgh’s growing autonomous vehicles cluster – including Uber, Aurora, Waymo and Motional – all of which are here because of their strong ties to CMU. With cutting-edge brain science, path-breaking performances, innovative startups, driverless cars, big data, big ambitions, Nobel and Turing prizes, hands-on learning, and a whole lot of robots, CMU doesn''t imagine the future, we create it. ', - '2023-09-13 23:36:25', - '2023-09-13 23:37:36', - 1 - ), - ( - 328, - 'ContextVision', - '', - '', - 'contextvision', - '', - 'https://www.contextvision.com/', - 'Our cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. Healthcare providers worldwide face the same key challenge – a challenge that ContextVision is helping to solve: how to increase patient care while coping with limited resources. ContextVision provides intelligent technology that improves healthcare service and outcomes for more people. The company specializes in image analysis and artificial intelligence.', - '2023-09-15 17:21:50', - '2023-09-15 17:22:34', - 1 - ), - ( - 329, - 'Karolinska Institute', - 'KI', - '', - 'ki', - '', - 'https://ki.se/en', - 'Karolinska Institutet is one of the world’s leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.', - '2023-09-15 17:24:17', - '2023-09-15 17:53:16', - 1 - ); -- organization_category data - INSERT INTO organization_category (id, organization_id, category) VALUES (1, 1, 'featured'), (2, 12, 'featured'), (3, 13, 'featured'); --- contributor_roles data -INSERT INTO challenge_contribution (id, challenge_id, organization_id, role) -VALUES (1, 1, 75, 'sponsor'), - (2, 2, 28, 'data_contributor'), - (3, 2, 45, 'data_contributor'), - (4, 2, 151, 'data_contributor'), - (5, 2, 52, 'sponsor'), - (6, 3, 154, 'data_contributor'), - (7, 3, 118, 'data_contributor'), - (8, 3, 17, 'data_contributor'), - (9, 3, 142, 'data_contributor'), - (10, 4, 150, 'data_contributor'), - (11, 4, 52, 'data_contributor'), - (12, 4, 131, 'sponsor'), - (13, 5, 134, 'challenge_organizer'), - (14, 5, 132, 'challenge_organizer'), - (15, 5, 211, 'challenge_organizer'), - (16, 5, 101, 'data_contributor'), - (17, 6, 54, 'challenge_organizer'), - (18, 6, 146, 'challenge_organizer'), - (19, 6, 171, 'challenge_organizer'), - (20, 6, 227, 'challenge_organizer'), - (21, 6, 27, 'challenge_organizer'), - (22, 6, 128, 'challenge_organizer'), - (23, 6, 93, 'challenge_organizer'), - (24, 6, 179, 'challenge_organizer'), - (25, 6, 89, 'challenge_organizer'), - (26, 6, 73, 'challenge_organizer'), - (27, 6, 170, 'challenge_organizer'), - (28, 6, 119, 'challenge_organizer'), - (29, 6, 171, 'sponsor'), - (30, 6, 93, 'sponsor'), - (31, 6, 57, 'sponsor'), - (32, 6, 146, 'sponsor'), - (33, 6, 120, 'sponsor'), - (34, 7, 171, 'challenge_organizer'), - (35, 7, 128, 'challenge_organizer'), - (36, 7, 93, 'challenge_organizer'), - (37, 7, 71, 'challenge_organizer'), - (38, 7, 89, 'challenge_organizer'), - (39, 7, 73, 'challenge_organizer'), - (40, 7, 170, 'challenge_organizer'), - (41, 7, 150, 'challenge_organizer'), - (42, 7, 130, 'challenge_organizer'), - (43, 8, 171, 'challenge_organizer'), - (44, 8, 206, 'challenge_organizer'), - (45, 8, 128, 'challenge_organizer'), - (46, 8, 93, 'challenge_organizer'), - (47, 8, 56, 'challenge_organizer'), - (48, 8, 37, 'challenge_organizer'), - (49, 8, 25, 'challenge_organizer'), - (50, 8, 78, 'challenge_organizer'), - (51, 8, 125, 'challenge_organizer'), - (52, 8, 23, 'challenge_organizer'), - (53, 8, 55, 'data_contributor'), - (54, 8, 24, 'sponsor'), - (55, 8, 125, 'sponsor'), - (56, 8, 145, 'sponsor'), - (57, 8, 181, 'sponsor'), - (58, 8, 93, 'sponsor'), - (59, 9, 171, 'challenge_organizer'), - (60, 9, 150, 'challenge_organizer'), - (61, 9, 128, 'challenge_organizer'), - (62, 9, 93, 'challenge_organizer'), - (63, 9, 197, 'challenge_organizer'), - (64, 9, 149, 'challenge_organizer'), - (65, 9, 23, 'challenge_organizer'), - (66, 9, 99, 'data_contributor'), - (67, 10, 165, 'challenge_organizer'), - (68, 10, 171, 'challenge_organizer'), - (69, 10, 128, 'challenge_organizer'), - (70, 10, 93, 'challenge_organizer'), - (71, 10, 23, 'challenge_organizer'), - (72, 10, 122, 'challenge_organizer'), - (73, 10, 122, 'data_contributor'), - (74, 10, 122, 'sponsor'), - (75, 10, 93, 'sponsor'), - (76, 10, 171, 'sponsor'), - (77, 10, 165, 'sponsor'), - (78, 11, 171, 'challenge_organizer'), - (79, 11, 150, 'challenge_organizer'), - (80, 11, 128, 'challenge_organizer'), - (81, 11, 41, 'challenge_organizer'), - (82, 11, 58, 'challenge_organizer'), - (83, 11, 205, 'challenge_organizer'), - (84, 11, 93, 'challenge_organizer'), - (85, 11, 23, 'challenge_organizer'), - (86, 11, 41, 'data_contributor'), - (87, 11, 58, 'data_contributor'), - (88, 11, 46, 'sponsor'), - (89, 11, 109, 'sponsor'), - (90, 12, 107, 'challenge_organizer'), - (91, 12, 171, 'challenge_organizer'), - (92, 12, 204, 'challenge_organizer'), - (93, 12, 128, 'challenge_organizer'), - (94, 12, 93, 'challenge_organizer'), - (95, 12, 38, 'challenge_organizer'), - (96, 12, 223, 'challenge_organizer'), - (97, 12, 119, 'challenge_organizer'), - (98, 12, 23, 'challenge_organizer'), - (99, 12, 82, 'challenge_organizer'), - (100, 12, 169, 'data_contributor'), - (101, 12, 18, 'data_contributor'), - (102, 12, 94, 'data_contributor'), - (103, 12, 19, 'sponsor'), - (104, 12, 39, 'sponsor'), - (105, 12, 74, 'sponsor'), - (106, 12, 153, 'sponsor'), - (107, 12, 164, 'sponsor'), - (108, 12, 168, 'sponsor'), - (109, 12, 172, 'sponsor'), - (110, 12, 181, 'sponsor'), - (111, 13, 206, 'challenge_organizer'), - (112, 13, 167, 'challenge_organizer'), - (113, 13, 171, 'challenge_organizer'), - (114, 13, 93, 'challenge_organizer'), - (115, 13, 128, 'challenge_organizer'), - (116, 13, 23, 'challenge_organizer'), - (117, 13, 167, 'data_contributor'), - (118, 13, 100, 'sponsor'), - (119, 13, 93, 'sponsor'), - (120, 13, 171, 'sponsor'), - (121, 13, 1, 'sponsor'), - (122, 14, 58, 'challenge_organizer'), - (123, 14, 93, 'challenge_organizer'), - (124, 14, 124, 'challenge_organizer'), - (125, 14, 155, 'challenge_organizer'), - (126, 14, 157, 'challenge_organizer'), - (127, 14, 171, 'challenge_organizer'), - (128, 14, 188, 'challenge_organizer'), - (129, 14, 196, 'challenge_organizer'), - (130, 14, 199, 'challenge_organizer'), - (131, 14, 219, 'challenge_organizer'), - (132, 14, 26, 'data_contributor'), - (133, 14, 47, 'data_contributor'), - (134, 14, 172, 'data_contributor'), - (135, 14, 124, 'data_contributor'), - (136, 14, 157, 'sponsor'), - (137, 14, 131, 'sponsor'), - (138, 14, 21, 'sponsor'), - (139, 15, 128, 'challenge_organizer'), - (140, 15, 93, 'challenge_organizer'), - (141, 15, 171, 'challenge_organizer'), - (142, 15, 118, 'challenge_organizer'), - (143, 15, 154, 'challenge_organizer'), - (144, 15, 187, 'challenge_organizer'), - (145, 15, 115, 'challenge_organizer'), - (146, 15, 23, 'challenge_organizer'), - (147, 15, 154, 'data_contributor'), - (148, 15, 140, 'data_contributor'), - (149, 15, 142, 'data_contributor'), - (150, 15, 154, 'sponsor'), - (151, 15, 93, 'sponsor'), - (152, 15, 171, 'sponsor'), - (153, 15, 1, 'sponsor'), - (154, 15, 32, 'sponsor'), - (155, 15, 67, 'sponsor'), - (156, 16, 128, 'challenge_organizer'), - (157, 16, 93, 'challenge_organizer'), - (158, 16, 26, 'challenge_organizer'), - (159, 16, 89, 'challenge_organizer'), - (160, 16, 73, 'challenge_organizer'), - (161, 16, 170, 'challenge_organizer'), - (162, 16, 171, 'challenge_organizer'), - (163, 16, 23, 'challenge_organizer'), - (164, 16, 26, 'data_contributor'), - (165, 16, 235, 'data_contributor'), - (166, 16, 29, 'data_contributor'), - (167, 16, 26, 'sponsor'), - (168, 17, 128, 'challenge_organizer'), - (169, 17, 93, 'challenge_organizer'), - (170, 17, 197, 'challenge_organizer'), - (171, 17, 149, 'challenge_organizer'), - (172, 17, 171, 'challenge_organizer'), - (173, 17, 23, 'challenge_organizer'), - (174, 17, 99, 'data_contributor'), - (175, 17, 149, 'sponsor'), - (176, 17, 81, 'sponsor'), - (177, 17, 138, 'sponsor'), - (178, 17, 171, 'sponsor'), - (179, 17, 197, 'sponsor'), - (180, 17, 150, 'sponsor'), - (181, 18, 235, 'challenge_organizer'), - (182, 18, 128, 'challenge_organizer'), - (183, 18, 93, 'challenge_organizer'), - (184, 18, 197, 'challenge_organizer'), - (185, 18, 150, 'challenge_organizer'), - (186, 18, 149, 'challenge_organizer'), - (187, 18, 79, 'challenge_organizer'), - (188, 18, 220, 'challenge_organizer'), - (189, 18, 171, 'challenge_organizer'), - (190, 18, 23, 'challenge_organizer'), - (191, 18, 149, 'data_contributor'), - (192, 18, 99, 'data_contributor'), - (193, 18, 149, 'data_contributor'), - (194, 18, 156, 'sponsor'), - (195, 18, 81, 'sponsor'), - (196, 18, 138, 'sponsor'), - (197, 19, 171, 'challenge_organizer'), - (198, 19, 64, 'challenge_organizer'), - (199, 19, 229, 'challenge_organizer'), - (200, 19, 59, 'challenge_organizer'), - (201, 19, 59, 'sponsor'), - (202, 20, 171, 'challenge_organizer'), - (203, 20, 205, 'challenge_organizer'), - (204, 20, 128, 'challenge_organizer'), - (205, 20, 93, 'challenge_organizer'), - (206, 20, 89, 'challenge_organizer'), - (207, 20, 73, 'challenge_organizer'), - (208, 20, 170, 'challenge_organizer'), - (209, 20, 118, 'challenge_organizer'), - (210, 20, 23, 'challenge_organizer'), - (211, 20, 111, 'challenge_organizer'), - (212, 20, 205, 'data_contributor'), - (213, 20, 180, 'sponsor'), - (214, 21, 179, 'challenge_organizer'), - (215, 21, 171, 'challenge_organizer'), - (216, 21, 128, 'challenge_organizer'), - (217, 21, 93, 'challenge_organizer'), - (218, 21, 199, 'challenge_organizer'), - (219, 21, 150, 'challenge_organizer'), - (220, 21, 115, 'challenge_organizer'), - (221, 21, 23, 'challenge_organizer'), - (222, 21, 69, 'data_contributor'), - (223, 22, 220, 'challenge_organizer'), - (224, 22, 91, 'challenge_organizer'), - (225, 22, 127, 'challenge_organizer'), - (226, 22, 95, 'challenge_organizer'), - (227, 22, 128, 'challenge_organizer'), - (228, 22, 93, 'challenge_organizer'), - (229, 22, 171, 'challenge_organizer'), - (230, 22, 23, 'challenge_organizer'), - (231, 22, 64, 'data_contributor'), - (232, 22, 229, 'data_contributor'), - (233, 23, 232, 'challenge_organizer'), - (234, 23, 128, 'challenge_organizer'), - (235, 23, 93, 'challenge_organizer'), - (236, 23, 197, 'challenge_organizer'), - (237, 23, 150, 'challenge_organizer'), - (238, 23, 149, 'challenge_organizer'), - (239, 23, 171, 'challenge_organizer'), - (240, 23, 23, 'challenge_organizer'), - (241, 23, 99, 'data_contributor'), - (242, 23, 131, 'data_contributor'), - (243, 23, 149, 'data_contributor'), - (244, 23, 138, 'sponsor'), - (245, 23, 81, 'sponsor'), - (246, 23, 156, 'sponsor'), - (247, 23, 131, 'sponsor'), - (248, 24, 171, 'challenge_organizer'), - (249, 24, 93, 'challenge_organizer'), - (250, 24, 106, 'challenge_organizer'), - (251, 24, 128, 'challenge_organizer'), - (252, 24, 175, 'challenge_organizer'), - (253, 24, 189, 'challenge_organizer'), - (254, 24, 36, 'data_contributor'), - (255, 24, 128, 'data_contributor'), - (256, 24, 110, 'sponsor'), - (257, 24, 80, 'sponsor'), - (258, 24, 236, 'sponsor'), - (259, 24, 93, 'sponsor'), - (260, 24, 20, 'sponsor'), - (261, 25, 47, 'challenge_organizer'), - (262, 25, 129, 'challenge_organizer'), - (263, 25, 171, 'challenge_organizer'), - (264, 25, 193, 'data_contributor'), - (265, 25, 58, 'data_contributor'), - (266, 25, 86, 'data_contributor'), - (267, 25, 89, 'data_contributor'), - (268, 25, 129, 'data_contributor'), - (269, 25, 47, 'sponsor'), - (270, 26, 85, 'challenge_organizer'), - (271, 26, 197, 'challenge_organizer'), - (272, 26, 63, 'challenge_organizer'), - (273, 26, 149, 'challenge_organizer'), - (274, 26, 171, 'challenge_organizer'), - (275, 26, 131, 'data_contributor'), - (276, 26, 88, 'data_contributor'), - (277, 26, 179, 'data_contributor'), - (278, 26, 49, 'data_contributor'), - (279, 26, 108, 'data_contributor'), - (280, 26, 202, 'data_contributor'), - (281, 26, 197, 'data_contributor'), - (282, 26, 149, 'data_contributor'), - (283, 26, 99, 'data_contributor'), - (284, 26, 41, 'data_contributor'), - (285, 27, 126, 'challenge_organizer'), - (286, 27, 65, 'challenge_organizer'), - (287, 27, 230, 'challenge_organizer'), - (288, 27, 88, 'challenge_organizer'), - (289, 27, 171, 'challenge_organizer'), - (290, 27, 224, 'challenge_organizer'), - (291, 27, 208, 'challenge_organizer'), - (292, 27, 216, 'challenge_organizer'), - (293, 27, 126, 'data_contributor'), - (294, 27, 171, 'data_contributor'), - (295, 27, 126, 'sponsor'), - (296, 27, 166, 'sponsor'), - (297, 28, 141, 'challenge_organizer'), - (298, 28, 128, 'challenge_organizer'), - (299, 28, 93, 'challenge_organizer'), - (300, 28, 131, 'challenge_organizer'), - (301, 28, 89, 'challenge_organizer'), - (302, 28, 73, 'challenge_organizer'), - (303, 28, 170, 'challenge_organizer'), - (304, 28, 149, 'challenge_organizer'), - (305, 28, 59, 'challenge_organizer'), - (306, 28, 152, 'challenge_organizer'), - (307, 28, 171, 'challenge_organizer'), - (308, 28, 51, 'data_contributor'), - (309, 28, 51, 'sponsor'), - (310, 28, 59, 'sponsor'), - (311, 28, 147, 'sponsor'), - (312, 29, 211, 'challenge_organizer'), - (313, 29, 128, 'challenge_organizer'), - (314, 29, 210, 'challenge_organizer'), - (315, 29, 171, 'challenge_organizer'), - (316, 29, 195, 'challenge_organizer'), - (317, 29, 128, 'data_contributor'), - (318, 29, 128, 'sponsor'), - (319, 30, 89, 'challenge_organizer'), - (320, 30, 128, 'challenge_organizer'), - (321, 30, 93, 'challenge_organizer'), - (322, 30, 73, 'challenge_organizer'), - (323, 30, 170, 'challenge_organizer'), - (324, 30, 121, 'challenge_organizer'), - (325, 30, 171, 'challenge_organizer'), - (326, 30, 121, 'data_contributor'), - (327, 31, 171, 'challenge_organizer'), - (328, 31, 96, 'challenge_organizer'), - (329, 31, 128, 'challenge_organizer'), - (330, 31, 93, 'challenge_organizer'), - (331, 31, 190, 'data_contributor'), - (332, 31, 15, 'sponsor'), - (333, 32, 87, 'challenge_organizer'), - (334, 32, 48, 'challenge_organizer'), - (335, 32, 66, 'challenge_organizer'), - (336, 32, 128, 'challenge_organizer'), - (337, 32, 93, 'challenge_organizer'), - (338, 32, 171, 'challenge_organizer'), - (339, 32, 182, 'data_contributor'), - (340, 32, 116, 'data_contributor'), - (341, 32, 15, 'data_contributor'), - (342, 32, 31, 'sponsor'), - (343, 33, 233, 'challenge_organizer'), - (344, 33, 196, 'challenge_organizer'), - (345, 33, 128, 'challenge_organizer'), - (346, 33, 93, 'challenge_organizer'), - (347, 33, 199, 'challenge_organizer'), - (348, 33, 179, 'challenge_organizer'), - (349, 33, 72, 'challenge_organizer'), - (350, 33, 72, 'data_contributor'), - (351, 33, 233, 'data_contributor'), - (352, 33, 117, 'data_contributor'), - (353, 34, 89, 'challenge_organizer'), - (354, 34, 226, 'challenge_organizer'), - (355, 34, 171, 'challenge_organizer'), - (356, 34, 73, 'challenge_organizer'), - (357, 34, 170, 'challenge_organizer'), - (358, 34, 71, 'challenge_organizer'), - (359, 34, 226, 'data_contributor'), - (360, 34, 71, 'data_contributor'), - (361, 35, 171, 'challenge_organizer'), - (362, 35, 224, 'challenge_organizer'), - (363, 35, 224, 'data_contributor'), - (364, 35, 133, 'sponsor'), - (365, 35, 97, 'sponsor'), - (366, 35, 224, 'sponsor'), - (367, 36, 43, 'challenge_organizer'), - (368, 36, 171, 'challenge_organizer'), - (369, 36, 234, 'challenge_organizer'), - (370, 36, 114, 'challenge_organizer'), - (371, 36, 224, 'challenge_organizer'), - (372, 36, 16, 'challenge_organizer'), - (373, 36, 93, 'challenge_organizer'), - (374, 36, 43, 'data_contributor'), - (375, 36, 114, 'data_contributor'), - (376, 36, 234, 'data_contributor'), - (377, 37, 95, 'challenge_organizer'), - (378, 37, 113, 'challenge_organizer'), - (379, 37, 150, 'challenge_organizer'), - (380, 37, 171, 'challenge_organizer'), - (381, 37, 179, 'challenge_organizer'), - (382, 37, 16, 'data_contributor'), - (383, 37, 234, 'data_contributor'), - (384, 37, 114, 'data_contributor'), - (385, 37, 43, 'data_contributor'), - (386, 37, 171, 'data_contributor'), - (387, 37, 131, 'sponsor'), - (388, 38, 171, 'challenge_organizer'), - (389, 38, 52, 'challenge_organizer'), - (390, 38, 176, 'challenge_organizer'), - (391, 38, 15, 'challenge_organizer'), - (392, 38, 131, 'challenge_organizer'), - (393, 38, 46, 'challenge_organizer'), - (394, 38, 128, 'challenge_organizer'), - (395, 38, 93, 'challenge_organizer'), - (396, 38, 89, 'challenge_organizer'), - (397, 38, 73, 'challenge_organizer'), - (398, 38, 170, 'challenge_organizer'), - (399, 38, 52, 'data_contributor'), - (400, 39, 171, 'challenge_organizer'), - (401, 39, 150, 'challenge_organizer'), - (402, 39, 128, 'challenge_organizer'), - (403, 39, 15, 'challenge_organizer'), - (404, 39, 131, 'challenge_organizer'), - (405, 39, 46, 'challenge_organizer'), - (406, 39, 112, 'data_contributor'), - (407, 39, 150, 'data_contributor'), - (408, 40, 131, 'challenge_organizer'), - (409, 40, 171, 'challenge_organizer'), - (410, 40, 150, 'challenge_organizer'), - (411, 40, 22, 'data_contributor'), - (412, 40, 44, 'data_contributor'), - (413, 40, 131, 'sponsor'), - (414, 41, 192, 'challenge_organizer'), - (415, 41, 128, 'challenge_organizer'), - (416, 41, 93, 'challenge_organizer'), - (417, 41, 199, 'challenge_organizer'), - (418, 41, 171, 'challenge_organizer'), - (419, 41, 192, 'data_contributor'), - (420, 41, 133, 'sponsor'), - (421, 41, 40, 'sponsor'), - (422, 42, 171, 'challenge_organizer'), - (423, 42, 144, 'challenge_organizer'), - (424, 42, 126, 'challenge_organizer'), - (425, 42, 76, 'challenge_organizer'), - (426, 42, 126, 'data_contributor'), - (427, 42, 144, 'data_contributor'), - (428, 42, 216, 'data_contributor'), - (429, 42, 191, 'data_contributor'), - (430, 42, 198, 'data_contributor'), - (431, 42, 161, 'data_contributor'), - (432, 43, 171, 'challenge_organizer'), - (433, 43, 52, 'challenge_organizer'), - (434, 43, 176, 'challenge_organizer'), - (435, 43, 15, 'challenge_organizer'), - (436, 43, 46, 'challenge_organizer'), - (437, 43, 128, 'challenge_organizer'), - (438, 43, 89, 'challenge_organizer'), - (439, 43, 52, 'data_contributor'), - (440, 43, 46, 'sponsor'), - (441, 44, 171, 'challenge_organizer'), - (442, 44, 224, 'challenge_organizer'), - (443, 44, 224, 'data_contributor'), - (444, 45, 211, 'challenge_organizer'), - (445, 45, 40, 'challenge_organizer'), - (446, 45, 148, 'challenge_organizer'), - (447, 45, 171, 'challenge_organizer'), - (448, 45, 40, 'data_contributor'), - (449, 46, 215, 'challenge_organizer'), - (450, 46, 131, 'challenge_organizer'), - (451, 46, 196, 'data_contributor'), - (452, 46, 220, 'data_contributor'), - (453, 46, 171, 'challenge_organizer'), - (454, 46, 185, 'data_contributor'), - (455, 46, 61, 'data_contributor'), - (456, 46, 226, 'challenge_organizer'), - (457, 46, 148, 'data_contributor'), - (458, 47, 47, 'challenge_organizer'), - (459, 47, 171, 'challenge_organizer'), - (460, 47, 158, 'challenge_organizer'), - (461, 47, 124, 'challenge_organizer'), - (462, 47, 58, 'challenge_organizer'), - (463, 47, 160, 'challenge_organizer'), - (464, 47, 47, 'sponsor'), - (465, 59, 30, 'data_contributor'), - (466, 59, 224, 'data_contributor'), - (467, 59, 196, 'data_contributor'), - (468, 61, 64, 'data_contributor'), - (469, 62, 173, 'data_contributor'), - (470, 63, 224, 'data_contributor'), - (471, 64, 184, 'data_contributor'), - (472, 65, 33, 'data_contributor'), - (473, 66, 196, 'data_contributor'), - (474, 67, 159, 'data_contributor'), - (475, 67, 70, 'data_contributor'), - (476, 68, 42, 'data_contributor'), - (477, 69, 200, 'data_contributor'), - (478, 70, 91, 'data_contributor'), - (479, 71, 214, 'data_contributor'), - (480, 72, 179, 'data_contributor'), - (481, 73, 41, 'data_contributor'), - (482, 74, 213, 'data_contributor'), - (483, 75, 91, 'data_contributor'), - (484, 76, 88, 'data_contributor'), - (485, 77, 220, 'data_contributor'), - (486, 78, 222, 'data_contributor'), - (487, 79, 217, 'data_contributor'), - (488, 80, 221, 'data_contributor'), - (489, 81, 173, 'data_contributor'), - (490, 82, 173, 'data_contributor'), - (491, 83, 220, 'data_contributor'), - (492, 84, 218, 'data_contributor'), - (493, 85, 41, 'data_contributor'), - (494, 90, 104, 'challenge_organizer'), - (495, 90, 3, 'challenge_organizer'), - (496, 90, 102, 'challenge_organizer'), - (497, 90, 215, 'challenge_organizer'), - (498, 90, 143, 'challenge_organizer'), - (499, 90, 224, 'challenge_organizer'), - (500, 90, 203, 'challenge_organizer'), - (501, 90, 219, 'challenge_organizer'), - (502, 90, 137, 'sponsor'), - (503, 90, 15, 'sponsor'), - (504, 90, 60, 'sponsor'), - (505, 90, 68, 'sponsor'), - (506, 91, 209, 'challenge_organizer'), - (507, 91, 183, 'challenge_organizer'), - (508, 91, 194, 'challenge_organizer'), - (509, 91, 207, 'challenge_organizer'), - (510, 91, 135, 'sponsor'), - (511, 92, 209, 'challenge_organizer'), - (512, 92, 183, 'challenge_organizer'), - (513, 92, 194, 'challenge_organizer'), - (514, 92, 207, 'challenge_organizer'), - (515, 92, 135, 'sponsor'), - (516, 93, 189, 'sponsor'), - (517, 94, 13, 'challenge_organizer'), - (518, 94, 189, 'challenge_organizer'), - (519, 94, 34, 'challenge_organizer'), - (520, 94, 62, 'challenge_organizer'), - (521, 94, 228, 'challenge_organizer'), - (522, 94, 136, 'challenge_organizer'), - (523, 94, 189, 'sponsor'), - (524, 95, 13, 'challenge_organizer'), - (525, 95, 189, 'challenge_organizer'), - (526, 95, 152, 'challenge_organizer'), - (527, 95, 201, 'challenge_organizer'), - (528, 95, 128, 'challenge_organizer'), - (529, 95, 93, 'challenge_organizer'), - (530, 95, 62, 'challenge_organizer'), - (531, 95, 34, 'challenge_organizer'), - (532, 95, 189, 'sponsor'), - (533, 96, 13, 'challenge_organizer'), - (534, 96, 189, 'challenge_organizer'), - (535, 96, 82, 'challenge_organizer'), - (536, 96, 62, 'challenge_organizer'), - (537, 96, 34, 'challenge_organizer'), - (538, 96, 189, 'sponsor'), - (539, 97, 13, 'challenge_organizer'), - (540, 97, 189, 'challenge_organizer'), - (541, 97, 83, 'challenge_organizer'), - (542, 97, 34, 'challenge_organizer'), - (543, 97, 189, 'sponsor'), - (544, 98, 13, 'challenge_organizer'), - (545, 98, 189, 'challenge_organizer'), - (546, 98, 62, 'challenge_organizer'), - (547, 98, 53, 'challenge_organizer'), - (548, 98, 34, 'challenge_organizer'), - (549, 98, 189, 'sponsor'), - (550, 99, 136, 'challenge_organizer'), - (551, 99, 13, 'challenge_organizer'), - (552, 99, 189, 'challenge_organizer'), - (553, 99, 62, 'challenge_organizer'), - (554, 99, 34, 'challenge_organizer'), - (555, 99, 189, 'sponsor'), - (556, 100, 13, 'challenge_organizer'), - (557, 100, 189, 'challenge_organizer'), - (558, 100, 231, 'challenge_organizer'), - (559, 100, 34, 'challenge_organizer'), - (560, 100, 62, 'challenge_organizer'), - (561, 100, 189, 'sponsor'), - (562, 101, 13, 'challenge_organizer'), - (563, 101, 189, 'challenge_organizer'), - (564, 101, 34, 'challenge_organizer'), - (565, 101, 62, 'challenge_organizer'), - (566, 101, 189, 'sponsor'), - (567, 102, 13, 'challenge_organizer'), - (568, 102, 189, 'challenge_organizer'), - (569, 102, 34, 'challenge_organizer'), - (570, 102, 62, 'challenge_organizer'), - (571, 102, 189, 'sponsor'), - (572, 103, 13, 'challenge_organizer'), - (573, 103, 189, 'challenge_organizer'), - (574, 103, 34, 'challenge_organizer'), - (575, 103, 62, 'challenge_organizer'), - (576, 103, 131, 'challenge_organizer'), - (577, 103, 177, 'challenge_organizer'), - (578, 103, 189, 'sponsor'), - (579, 104, 12, 'challenge_organizer'), - (580, 104, 215, 'challenge_organizer'), - (581, 104, 84, 'challenge_organizer'), - (582, 104, 7, 'challenge_organizer'), - (583, 104, 15, 'sponsor'), - (584, 104, 90, 'sponsor'), - (585, 104, 103, 'sponsor'), - (586, 104, 50, 'sponsor'), - (587, 105, 12, 'challenge_organizer'), - (588, 105, 147, 'sponsor'), - (589, 105, 35, 'sponsor'), - (590, 106, 12, 'challenge_organizer'), - (591, 106, 186, 'sponsor'), - (592, 106, 178, 'sponsor'), - (593, 107, 12, 'challenge_organizer'), - (594, 107, 77, 'sponsor'), - (595, 124, 12, 'sponsor'), - (596, 124, 215, 'challenge_organizer'), - (597, 124, 84, 'challenge_organizer'), - (598, 124, 7, 'challenge_organizer'), - (599, 124, 98, 'sponsor'), - (600, 124, 139, 'sponsor'), - (601, 124, 162, 'sponsor'), - (602, 161, 13, 'challenge_organizer'), - (603, 161, 237, 'challenge_organizer'), - (604, 162, 13, 'challenge_organizer'), - (605, 162, 238, 'challenge_organizer'), - (606, 163, 13, 'challenge_organizer'), - (607, 163, 238, 'challenge_organizer'), - (608, 164, 13, 'challenge_organizer'), - (609, 164, 231, 'challenge_organizer'), - (610, 165, 13, 'challenge_organizer'), - (611, 55, 1, 'sponsor'), - (612, 53, 1, 'sponsor'), - (613, 52, 1, 'sponsor'), - (614, 54, 1, 'sponsor'), - (615, 166, 1, 'sponsor'), - (616, 45, 1, 'sponsor'), - (617, 44, 1, 'sponsor'), - (618, 43, 1, 'sponsor'), - (619, 40, 1, 'sponsor'), - (620, 42, 1, 'sponsor'), - (621, 39, 1, 'sponsor'), - (622, 41, 1, 'sponsor'), - (623, 35, 1, 'sponsor'), - (624, 36, 1, 'sponsor'), - (625, 34, 1, 'sponsor'), - (626, 37, 1, 'sponsor'), - (627, 33, 1, 'sponsor'), - (628, 32, 1, 'sponsor'), - (629, 31, 1, 'sponsor'), - (630, 30, 1, 'sponsor'), - (631, 29, 1, 'sponsor'), - (632, 21, 1, 'sponsor'), - (633, 27, 1, 'sponsor'), - (634, 26, 1, 'sponsor'), - (635, 28, 1, 'sponsor'), - (636, 24, 1, 'sponsor'), - (637, 25, 1, 'sponsor'), - (638, 23, 1, 'sponsor'), - (639, 20, 1, 'sponsor'), - (640, 19, 1, 'sponsor'), - (641, 18, 1, 'sponsor'), - (642, 17, 1, 'sponsor'), - (643, 16, 1, 'sponsor'), - (644, 14, 1, 'sponsor'), - (645, 8, 1, 'sponsor'), - (646, 7, 1, 'sponsor'), - (647, 11, 1, 'sponsor'), - (648, 12, 1, 'sponsor'), - (649, 10, 1, 'sponsor'), - (650, 9, 1, 'sponsor'), - (651, 6, 1, 'sponsor'), - (652, 5, 1, 'sponsor'), - (653, 4, 1, 'sponsor'), - (654, 1, 1, 'sponsor'), - (655, 3, 1, 'sponsor'), - (656, 167, 215, 'challenge_organizer'), - (657, 167, 171, 'challenge_organizer'), - (658, 167, 239, 'challenge_organizer'), - (659, 167, 240, 'challenge_organizer'), - (660, 167, 195, 'challenge_organizer'), - (661, 167, 226, 'challenge_organizer'), - (662, 167, 241, 'challenge_organizer'), - (663, 167, 242, 'challenge_organizer'), - (664, 167, 185, 'challenge_organizer'), - (665, 167, 196, 'challenge_organizer'), - (666, 167, 243, 'challenge_organizer'), - (667, 167, 244, 'challenge_organizer'), - (668, 167, 245, 'challenge_organizer'), - (669, 167, 246, 'challenge_organizer'), - (670, 167, 247, 'challenge_organizer'), - (671, 167, 248, 'challenge_organizer'), - (672, 167, 13, 'challenge_organizer'), - (673, 167, 249, 'challenge_organizer'), - (674, 167, 34, 'challenge_organizer'), - (675, 167, 62, 'challenge_organizer'), - (676, 167, 215, 'data_contributor'), - (677, 167, 240, 'data_contributor'), - (678, 167, 250, 'data_contributor'), - (679, 167, 251, 'data_contributor'), - (680, 167, 241, 'data_contributor'), - (681, 167, 185, 'data_contributor'), - (682, 167, 243, 'data_contributor'), - (683, 167, 245, 'data_contributor'), - (684, 167, 49, 'data_contributor'), - (685, 167, 252, 'data_contributor'), - (686, 167, 253, 'data_contributor'), - (687, 167, 98, 'sponsor'), - (688, 167, 139, 'sponsor'), - (689, 167, 254, 'sponsor'), - (690, 167, 255, 'sponsor'), - (691, 169, 209, 'challenge_organizer'), - (692, 169, 195, 'challenge_organizer'), - (693, 169, 194, 'challenge_organizer'), - (694, 169, 257, 'challenge_organizer'), - (695, 169, 135, 'sponsor'), - (696, 170, 258, 'challenge_organizer'), - (697, 170, 258, 'data_contributor'), - (698, 170, 161, 'challenge_organizer'), - (699, 170, 161, 'data_contributor'), - (700, 170, 259, 'challenge_organizer'), - (701, 170, 260, 'challenge_organizer'), - (702, 170, 261, 'challenge_organizer'), - (703, 170, 261, 'data_contributor'), - (704, 170, 262, 'challenge_organizer'), - (705, 170, 263, 'challenge_organizer'), - (706, 170, 264, 'challenge_organizer'), - (707, 170, 265, 'sponsor'), - (708, 170, 260, 'sponsor'), - (709, 170, 266, 'sponsor'), - (710, 170, 261, 'sponsor'), - (711, 171, 267, 'challenge_organizer'), - (712, 171, 267, 'sponsor'), - (713, 171, 267, 'data_contributor'), - (714, 172, 269, 'sponsor'), - (715, 172, 268, 'challenge_organizer'), - (716, 173, 272, 'challenge_organizer'), - (717, 173, 271, 'challenge_organizer'), - (718, 173, 270, 'challenge_organizer'), - (719, 174, 273, 'sponsor'), - (720, 174, 107, 'challenge_organizer'), - (721, 174, 256, 'challenge_organizer'), - (722, 174, 270, 'challenge_organizer'), - (723, 174, 147, 'challenge_organizer'), - (724, 174, 215, 'challenge_organizer'), - (725, 174, 270, 'data_contributor'), - (726, 176, 104, 'challenge_organizer'), - (727, 176, 143, 'challenge_organizer'), - (728, 176, 213, 'challenge_organizer'), - (729, 176, 275, 'challenge_organizer'), - (730, 176, 102, 'challenge_organizer'), - (731, 174, 274, 'data_contributor'), - (732, 174, 276, 'data_contributor'), - (733, 174, 277, 'data_contributor'), - (734, 177, 162, 'challenge_organizer'), - (735, 176, 3, 'challenge_organizer'), - (736, 175, 278, 'challenge_organizer'), - (737, 179, 279, 'challenge_organizer'), - (738, 174, 12, 'sponsor'), - (739, 172, 12, 'sponsor'), - (740, 173, 12, 'sponsor'), - (741, 171, 12, 'sponsor'), - (742, 167, 12, 'sponsor'), - (743, 181, 12, 'sponsor'), - (744, 181, 280, 'challenge_organizer'), - (745, 181, 281, 'challenge_organizer'), - (746, 181, 211, 'challenge_organizer'), - (747, 181, 282, 'challenge_organizer'), - (748, 181, 171, 'challenge_organizer'), - (749, 182, 283, 'challenge_organizer'), - (750, 182, 284, 'challenge_organizer'), - (751, 182, 285, 'challenge_organizer'), - (752, 182, 67, 'challenge_organizer'), - (753, 182, 286, 'challenge_organizer'), - (754, 182, 12, 'sponsor'), - (755, 182, 15, 'sponsor'), - (756, 183, 283, 'challenge_organizer'), - (757, 183, 67, 'challenge_organizer'), - (758, 183, 287, 'challenge_organizer'), - (759, 183, 286, 'challenge_organizer'), - (760, 183, 288, 'challenge_organizer'), - (761, 183, 289, 'challenge_organizer'), - (762, 183, 12, 'sponsor'), - (763, 183, 15, 'sponsor'), - (764, 184, 290, 'challenge_organizer'), - (765, 184, 291, 'challenge_organizer'), - (766, 185, 179, 'challenge_organizer'), - (767, 186, 179, 'challenge_organizer'), - (768, 186, 292, 'challenge_organizer'), - (769, 187, 179, 'challenge_organizer'), - (770, 187, 119, 'challenge_organizer'), - (771, 188, 179, 'challenge_organizer'), - (772, 188, 293, 'challenge_organizer'), - (773, 189, 179, 'challenge_organizer'), - (774, 190, 197, 'challenge_organizer'), - (775, 191, 179, 'challenge_organizer'), - (776, 191, 294, 'challenge_organizer'), - (777, 191, 144, 'challenge_organizer'), - (778, 191, 295, 'challenge_organizer'), - (779, 192, 41, 'challenge_organizer'), - (780, 192, 296, 'challenge_organizer'), - (781, 192, 297, 'challenge_organizer'), - (782, 193, 298, 'challenge_organizer'), - (783, 193, 299, 'sponsor'), - (784, 193, 300, 'sponsor'), - (785, 193, 147, 'sponsor'), - (786, 193, 301, 'sponsor'), - (787, 194, 302, 'challenge_organizer'), - (788, 194, 302, 'data_contributor'), - (789, 194, 303, 'data_contributor'), - (790, 194, 304, 'data_contributor'), - (791, 194, 126, 'sponsor'), - (792, 195, 75, 'sponsor'), - (793, 195, 312, 'challenge_organizer'), - (794, 196, 12, 'sponsor'), - (795, 196, 226, 'challenge_organizer'), - (796, 196, 306, 'challenge_organizer'), - (797, 196, 307, 'challenge_organizer'), - (798, 196, 308, 'challenge_organizer'), - (799, 196, 248, 'challenge_organizer'), - (800, 196, 305, 'challenge_organizer'), - (801, 196, 309, 'challenge_organizer'), - (802, 196, 310, 'challenge_organizer'), - (803, 196, 220, 'challenge_organizer'), - (804, 196, 261, 'data_contributor'), - (805, 196, 311, 'data_contributor'), - (806, 197, 261, 'challenge_organizer'), - (807, 197, 261, 'data_contributor'), - (808, 197, 12, 'sponsor'), - (809, 196, 305, 'data_contributor'), - (810, 198, 13, 'challenge_organizer'), - (811, 198, 313, 'challenge_organizer'), - (812, 198, 314, 'challenge_organizer'), - (813, 198, 315, 'challenge_organizer'), - (814, 199, 231, 'challenge_organizer'), - (815, 199, 249, 'challenge_organizer'), - (816, 199, 313, 'challenge_organizer'), - (817, 199, 315, 'challenge_organizer'), - (818, 199, 136, 'challenge_organizer'), - (819, 199, 316, 'challenge_organizer'), - (820, 199, 34, 'challenge_organizer'), - (821, 199, 317, 'challenge_organizer'), - (822, 199, 318, 'challenge_organizer'), - (823, 206, 171, 'challenge_organizer'), - (824, 207, 171, 'challenge_organizer'), - (825, 208, 171, 'challenge_organizer'), - (826, 209, 171, 'challenge_organizer'), - (827, 210, 171, 'challenge_organizer'), - (828, 206, 319, 'data_contributor'), - (829, 207, 319, 'data_contributor'), - (830, 208, 319, 'data_contributor'), - (831, 209, 319, 'data_contributor'), - (832, 210, 319, 'data_contributor'), - (833, 206, 247, 'data_contributor'), - (834, 207, 247, 'data_contributor'), - (835, 208, 247, 'data_contributor'), - (836, 209, 247, 'data_contributor'), - (837, 210, 247, 'data_contributor'), - (838, 211, 1, 'sponsor'), - (839, 212, 1, 'sponsor'), - (840, 213, 1, 'sponsor'), - (841, 214, 1, 'sponsor'), - (842, 215, 1, 'sponsor'), - (843, 216, 1, 'sponsor'), - (844, 217, 1, 'sponsor'), - (845, 218, 1, 'sponsor'), - (846, 219, 1, 'sponsor'), - (847, 220, 1, 'sponsor'), - (848, 221, 1, 'sponsor'), - (849, 222, 1, 'sponsor'), - (850, 223, 1, 'sponsor'), - (851, 224, 1, 'sponsor'), - (852, 225, 1, 'sponsor'), - (853, 226, 1, 'sponsor'), - (854, 202, 1, 'sponsor'), - (855, 203, 1, 'sponsor'), - (856, 204, 1, 'sponsor'), - (857, 205, 1, 'sponsor'), - (858, 211, 52, 'data_contributor'), - (859, 212, 58, 'data_contributor'), - (860, 213, 320, 'data_contributor'), - (861, 214, 321, 'data_contributor'), - (862, 215, 124, 'data_contributor'), - (863, 216, 322, 'data_contributor'), - (864, 217, 256, 'data_contributor'), - (865, 217, 119, 'data_contributor'), - (866, 217, 93, 'challenge_organizer'), - (867, 218, 256, 'data_contributor'), - (868, 218, 119, 'data_contributor'), - (869, 218, 93, 'challenge_organizer'), - (870, 218, 256, 'challenge_organizer'), - (871, 218, 119, 'challenge_organizer'), - (872, 219, 220, 'data_contributor'), - (873, 219, 242, 'data_contributor'), - (874, 219, 93, 'challenge_organizer'), - (875, 220, 220, 'data_contributor'), - (876, 220, 93, 'challenge_organizer'), - (877, 220, 256, 'challenge_organizer'), - (878, 220, 119, 'challenge_organizer'), - (879, 221, 93, 'challenge_organizer'), - (880, 221, 256, 'challenge_organizer'), - (881, 221, 119, 'challenge_organizer'), - (882, 221, 323, 'challenge_organizer'), - (883, 221, 323, 'data_contributor'), - (884, 222, 234, 'data_contributor'), - (885, 222, 93, 'challenge_organizer'), - (886, 223, 93, 'challenge_organizer'), - (887, 223, 256, 'challenge_organizer'), - (888, 223, 119, 'challenge_organizer'), - (889, 224, 93, 'challenge_organizer'), - (890, 225, 324, 'challenge_organizer'), - (891, 225, 93, 'challenge_organizer'), - (892, 226, 93, 'challenge_organizer'), - (893, 226, 242, 'challenge_organizer'), - (894, 226, 93, 'data_contributor'), - (895, 226, 242, 'data_contributor'), - (896, 228, 325, 'challenge_organizer'), - (897, 229, 325, 'challenge_organizer'), - (898, 227, 326, 'challenge_organizer'), - (899, 230, 326, 'challenge_organizer'), - (900, 2, 1, 'sponsor'), - (901, 38, 1, 'sponsor'), - (902, 49, 1, 'sponsor'), - (903, 58, 1, 'sponsor'), - (904, 231, 13, 'challenge_organizer'), - (905, 232, 327, 'challenge_organizer'), - (906, 232, 62, 'challenge_organizer'), - (907, 111, 34, 'challenge_organizer'), - (908, 113, 98, 'challenge_organizer'), - (909, 114, 105, 'challenge_organizer'), - (910, 116, 105, 'challenge_organizer'), - (911, 118, 12, 'sponsor'), - (912, 118, 328, 'sponsor'), - (913, 118, 286, 'sponsor'), - (914, 118, 161, 'challenge_organizer'), - (915, 118, 329, 'challenge_organizer'), - (916, 123, 225, 'challenge_organizer'), - (917, 124, 162, 'challenge_organizer'), - (918, 129, 92, 'challenge_organizer'), - (919, 131, 174, 'challenge_organizer'), - (920, 156, 162, 'challenge_organizer'), - (921, 178, 15, 'sponsor'); \ No newline at end of file +-- contributor_roles data +LOAD DATA LOCAL INFILE '/workspace/BOOT-INF/classes/db/contribution_roles.csv' INTO TABLE challenge_contribution + FIELDS TERMINATED BY ',' OPTIONALLY ENCLOSED BY '"' + LINES TERMINATED BY '\n' + IGNORE 1 LINES; diff --git a/apps/openchallenges/organization-service/src/main/resources/db/organizations.csv b/apps/openchallenges/organization-service/src/main/resources/db/organizations.csv new file mode 100644 index 0000000000..f8c4a21cad --- /dev/null +++ b/apps/openchallenges/organization-service/src/main/resources/db/organizations.csv @@ -0,0 +1,322 @@ +"id","name","email","login","avatar_url","website_url","description","challenge_count","createdAt","updatedAt","acronym" +"1","Dialogue on Reverse Engineering Assessment and Methods","dream@sagebionetworks.org","dream","logo/dream.png","https://dreamchallenges.org","Together, we share a vision to enable individuals and groups to collaborate openly so that the “wisdom of the crowd” provides the greatest impact on science and human health.","71","2023-08-04 07:33:09","2023-08-05 06:10:02","DREAM" +"3","Critical Assessment of protein Function Annotation","","cafa","logo/cafa.png","https://www.biofunctionprediction.org/cafa/","The Critical Assessment of protein Function Annotation algorithms (CAFA) is an experiment designed to assess the performance of computational methods dedicated to predicting protein function, often using a time challenge. Briefly, CAFA organizers provide a large number of unannotated or incompletely annotated protein sequences. The predictors then predict the function of these proteins by associating them with Gene Ontology terms or Human Phenoytpe Ontology terms. Following the prediction deadline, there is a wait period of several months during which some proteins whose functions were unknown will receive experimental verification. Those proteins constitute the benchmark set, against which the methods are tested. Other data sources include experiments by wet lab collaborators and biocuration dedicated to CAFA.","2","2023-06-23 00:00:00","2023-07-26 20:13:18","CAFA" +"4","Critical Assessment of Genome Interpretation","cagi@genomeinterpretation.org","cagi","logo/cagi.png","https://genomeinterpretation.org/challenges.html","The Critical Assessment of Genome Interpretation (CAGI) is a community experiment to objectively assess computational methods for predicting the phenotypic impacts of genomic variation. CAGI participants are provided genetic variants and make predictions of resulting phenotypes. These predictions are evaluated against experimental data by independent assessors.","26","2023-06-23 00:00:00","2023-07-26 20:13:19","CAGI" +"7","Critical Assessment of Metagenome Interpretation","","cami","logo/cami.png","https://data.cami-challenge.org/","CAMI, the initiative for the “Critical Assessment of Metagenome Interpretation” aims to evaluate methods in metagenomics independently, comprehensively and without bias. The initiative supplies users with exhaustive quantitative data about the performance of methods in all relevant scenarios. It therefore guides users in the selection and application of methods and in their proper interpretation. Furthermore it provides valuable information to developers, allowing them to identify promising directions for their future work. CAMI organized in 2015 the first community driven benchmarking challenge in metagenomics. For the second CAMI challenge (starting on January 16th, 2019) visit https://data.cami-challenge.org","2","2023-06-23 00:00:00","2023-07-26 20:13:21","CAMI" +"12","Medical Image Computing and Computer Assisted Intervention Society","","miccai","logo/miccai.png","http://www.miccai.org/special-interest-groups/challenges/miccai-registered-challenges/","The Medical Image Computing and Computer Assisted Intervention Society (the MICCAI Society) is dedicated to the promotion, preservation and facilitation of research, education and practice in the field of medical image computing and computer assisted medical interventions including biomedical imaging and medical robotics. The Society achieves this aim through the organization and operation of annual high quality international conferences, workshops, tutorials and publications that promote and foster the exchange and dissemination of advanced knowledge, expertise and experience in the field produced by leading institutions and outstanding scientists, physicians and educators around the world. The MICCAI Society is committed to maintaining high academic standards and independence from any personal, political or commercial interests.","16","2023-06-23 00:00:00","2023-07-26 20:13:24","MICCAI" +"13","precisionFDA","PrecisionFDA@fda.hhs.gov","pfda","logo/precisionfda.png","https://precision.fda.gov/challenges","A secure, collaborative, high-performance computing platform that builds a community of experts around the analysis of biological datasets in order to advance precision medicine.","18","2023-06-23 00:00:00","2023-07-26 20:13:25","pFDA" +"15","National Institutes of Health","","nih","logo/nih.png","https://www.nih.gov/","The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation's medical research agency — making important discoveries that improve health and save lives.","10","2023-06-23 00:00:00","2023-07-26 20:13:26","NIH" +"16","Allen Institute","","allen-institute","logo/allen-institute.svg","https://alleninstitute.org/","The Allen Institute is an independent nonprofit bioscience research institute aimed at unlocking the mysteries of human biology through foundational science that fuels the discovery of new treatments and cures.","2","2023-06-23 00:00:00","2023-07-26 20:13:27","" +"17","ALS Therapy Alliance","Staff@lstherapyalliance.org","ata","logo/als-therapy-alliance.png","https://alstherapyalliance.org/","For over a decade, researchers and scientists have been relying on the ALS Therapy Alliance's expertise and funding to advance their studies of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. 2015 marks the 14th year of our annual Breakthrough ALS fundraising campaign (formerly known as Researching a Cure). The ALS Therapy Alliance's ongoing grant award process is overseen by the organization's board of award-winning researchers and scientists, as well as corporate executives and individuals who strive to learn more about the neurodegenerative disease, its cause and possible cure.","1","2023-06-23 00:00:00","2023-07-26 20:13:28","ATA" +"18","Alzheimer's Disease Neuroimaging Initiative","","adni","logo/adni.jpg","http://adni.loni.usc.edu/","The Alzheimer's Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer's disease (AD). ADNI researchers collect, validate and utilize data, including MRI and PET images, genetics, cognitive tests, CSF and blood biomarkers as predictors of the disease. Study resources and data from the North American ADNI study are available through this website, including Alzheimer's disease patients, mild cognitive impairment subjects, and elderly controls.","1","2023-06-23 00:00:00","2023-07-26 20:13:29","ADNI" +"19","Alzheimer's Research UK","","alzheimers-research-uk","logo/alzheimers-research-uk.jpg","https://www.alzheimersresearchuk.org/","Without effective treatments, one in three children born today will die with dementia. Today, there are no dementia survivors but research can change this. Alzheimer's Research UK is the UK's leading dementia research charity, dedicated to causes, diagnosis, prevention, treatment and cure. Backed by our passionate scientists and supporters, we're challenging the way people think about dementia, uniting the big thinkers in the field and funding the innovative science that will deliver a cure.","1","2023-06-23 00:00:00","2023-07-26 20:13:31","" +"20","Amazon Web Services","","aws","logo/aws.svg","https://aws.amazon.com/","Whether you're looking for compute power, database storage, content delivery, or other functionality, AWS has the services to help you build sophisticated applications with increased flexibility, scalability and reliability","1","2023-06-23 00:00:00","2023-07-26 20:13:31","AWS" +"21","American Joint Committee on Cancer","","ajcc","","https://www.facs.org/quality-programs/cancer/ajcc","Validating science, improving patient care.","1","2023-06-23 00:00:00","2023-07-26 20:13:32","AJCC" +"22","APOLLO network","cancer.proteomics@mail.nih.gov","apollo","logo/apollo.png","https://proteomics.cancer.gov/programs/apollo-network","The Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) network is a collaboration between NCI, the Department of Defense (DoD), and the Department of Veterans Affairs (VA) to incorporate proteogenomics into patient care as a way of looking beyond the genome, to the activity and expression of the proteins that the genome encodes. The emerging field of proteogenomics aims to better predict how patients will respond to therapy by screening their tumors for both genetic abnormalities and protein information, an approach that has been made possible in recent years due to advances in proteomic technology.","1","2023-06-23 00:00:00","2023-07-26 20:13:33","" +"23","Apple Health","","apple-health","logo/wa-healthcare-authority.jpg","https://www.hca.wa.gov/","HCA is the largest purchaser of health care in the state. We lead the effort on transforming health care through programs and initiatives that range from the administration of Apple Health (Medicaid) and behavioral health activities to developing models for value-based purchasing and health technology assessments. We use data to inform our decisions and work in collaboration with local communities to ensure that Washington residents have access to better health care at a lower cost.","14","2023-06-23 00:00:00","2023-07-26 20:13:33","" +"24","Arthritis Foundation","","arthritis-foundation","logo/arthritis-foundation.png","https://www.arthritis.org/","Live your best life with the help of a compassionate and caring community. Get empowering information and make meaningful connections. Online and in person, we are all working together to promote life-changing resources and research, push for change and create community connections that welcome, inform and uplift. This is what makes our community of millions thrive — and why we are all Champions of Yes.","1","2023-06-23 00:00:00","2023-07-26 20:13:35","" +"25","Arthritis Internet Registry","","arthritis-internet-registry","","","This organization may no longer exist or has been merged under another organization.","1","2023-06-23 00:00:00","2023-08-08 17:59:48","" +"26","AstraZeneca","","astrazeneca","logo/astrazeneca.png","https://www.astrazeneca.com/","We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.","2","2023-06-23 00:00:00","2023-07-26 20:13:36","" +"27","Autodesk Research","autodesk.research@autodesk.com","autodesk","logo/autodesk-research.png","https://www.research.autodesk.com/","Autodesk is changing how the world is designed and made. At Autodesk Research, we advance this mission by exploring new possibilities where others see roadblocks. With a diverse team of scientists and industry experts, we conduct industrial research that helps customers design and make a better world for all.","1","2023-06-23 00:00:00","2023-07-26 20:13:36","" +"28","BC Cancer Research Centre","","bccrc","logo/bccrc.jpg","https://www.bccrc.ca/","BC Cancer Research strives to improve the lives of patients through the integration of basic biomedical research, genomics, clinical trials, health services research, cancer surveillance, population health, and the development of innovative new technology, programs, and interventions. Organized through departments and programs with various themes, BC Cancer supports groundbreaking cancer research and personalized care approaches through world-class facilities and platforms including genomics, bioinformatics, imaging, drug development and tissue banking.","1","2023-06-23 00:00:00","2023-07-26 20:13:36","BCCRC" +"29","Bellvitge Institute for Biomedical Research","info@idibell.cat","idibell","logo/idibell.jpg","https://idibell.cat/en/the-institute/","The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and the Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L'Hospitalet de Llobregat city council. In 2017, the Center for Regenerative Medicine of Barcelona (CMR[B]), now part of IDIBELL, launched the Program for Advancing the Clinical Translation of Regenerative Medicine of Catalonia (P-CMR[C]) together with IDIBELL.","1","2023-06-23 00:00:00","2023-07-26 20:13:37","IDIBELL" +"30","Berlin Institute of Health","info@bih-charite.de","bih","logo/bih.jpg","https://www.bihealth.org/en/","The mission of the BIH is medical translation: The BIH aims to translate findings from biomedical research into new approaches for personalised prediction, prevention and therapy and, conversely, to develop new research approaches from clinical observations.","1","2023-06-23 00:00:00","2023-07-26 20:13:38","BIH" +"31","Bill and Melinda Gates Foundation","","gates-foundation","logo/gates-foundation.jpg","https://www.gatesfoundation.org/","Our mission is to create a world where every person has the opportunity to live a healthy, productive life.","1","2023-06-23 00:00:00","2023-07-26 20:13:40","" +"32","Biogen","","biogen","logo/biogen.png","https://www.biogen.com/en_us/home.html","Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world. Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer's disease.","1","2023-06-23 00:00:00","2023-07-26 20:13:42","" +"33","BioMarin Pharmaceutical Inc.","","biomarin","logo/biomarin.jpg","https://www.biomarin.com/","Over two decades ago when we first opened our doors, we focused on giving much-needed attention to the underserved communities of those with rare diseases. These rare disease communities mostly affected children and were often ignored. At the time, BioMarin developed the only treatments for these life-altering conditions, giving hope to patients and families. Throughout our history, we've worked tirelessly to make a difference by pursuing bold science while respecting, educating, and connecting with patients. Through our expertise in genetics and molecular biology, we have been able to develop targeted therapies that address the root cause of the exact conditions we seek to treat. Our discoveries have led us to countless breakthroughs, best-in-class treatments and many ‘firsts' in the category. We are grateful to able to better the lives of those struggling with genetic diseases.","1","2023-06-23 00:00:00","2023-07-26 20:13:44","" +"34","Booz Allen Hamilton","","booz-allen","logo/booz-allen.jpg","https://www.boozallen.com/","Booz Allen Hamilton has been at the forefront of strategy and technology for more than 100 years. Today, the firm provides management and technology consulting and engineering services to leading Fortune 500 corporations, governments, and not-for-profits across the globe. Booz Allen partners with public and private sector clients to solve their most difficult challenges through a combination of consulting, analytics, mission operations, technology, systems delivery, cybersecurity, engineering, and innovation expertise. \n\nWith international headquarters in McLean, Virginia, the firm employs more than 22,600 people globally and had revenue of $5.41 billion for the 12 months ended March 31, 2016.\n\nBooz Allen brings its pioneering work in advanced analytics—and the industry-leading expertise of its more than 600-member data science team—to transform our clients' data into actions that keep them competitive in today's data-driven economy. To learn about Booz Allen's data science ca...","13","2023-06-23 00:00:00","2023-07-26 20:13:45","" +"35","Braille Authority of North America","chair@brailleauthority.org","bana","logo/bana.jpeg","http://www.brailleauthority.org/","The purpose of BANA is to promote and to facilitate the uses, teaching, and production of braille. Pursuant to this purpose, BANA will promulgate rules, make interpretations, and render opinions pertaining to braille codes and guidelines for the provisions of literary and technical materials and related forms and formats of embossed materials now in existence or to be developed in the future for the use of blind persons in North America. When appropriate, BANA shall accomplish these activities in international collaboration with countries using English braille. In exercising its function and authority, BANA shall consider the effects of its decisions on other existing braille codes and guidelines, forms and formats; ease of production by various methods; and acceptability to readers.","1","2023-06-23 00:00:00","2023-07-26 20:13:46","BANA" +"36","Breast Cancer Surveillance Consortium","KPWA.scc@kp.org","bcsc","logo/bcsc.jpeg","https://www.bcsc-research.org/","The Breast Cancer Surveillance Consortium (BCSC) is a collaborative network of six active breast imaging registries and two historic registries focused on research to assess and improve the delivery and quality of breast cancer screening and related outcomes in the United States. The registries perform annual linkages to tumor and pathology registries in their geographic region and are supported by a central Statistical Coordinating Center.","1","2023-06-23 00:00:00","2023-07-26 20:13:47","BCSC" +"37","Brigham and Women's Hospital","","bwh","logo/bwh.png","https://www.brighamandwomens.org/","Brigham and Women's Hospital is a world-class academic medical center based in Boston, Massachusetts. The Brigham serves patients from New England, across the United States and from 120 countries around the world. A major teaching hospital of Harvard Medical School, Brigham and Women's Hospital has a legacy of clinical excellence that continues to grow year after year.","1","2023-06-23 00:00:00","2023-07-26 20:13:47","BWH" +"38","Brigham Young University","byu-info@byu.edu","byu","logo/byu.jpg","https://www.byu.edu/","At BYU, helping students to develop their full divine potential is central to both our teaching and our scholarship. As the flagship higher education institution of The Church of Jesus Christ of Latter-day Saints, BYU strives to emit a unique light for the benefit of the world—a light that will enable BYU to be counted among the exceptional universities in the world and an essential example for the world.","1","2023-06-23 00:00:00","2023-07-26 20:13:48","BYU" +"39","BrightFocus Foundation","info@brightfocus.org","brightfocus-foundation","logo/bright-focus.jpg","https://www.brightfocus.org/","BrightFocus funds exceptional scientific research worldwide to defeat Alzheimer's disease, macular degeneration, and glaucoma and provides expert information on these heartbreaking diseases.","1","2023-06-23 00:00:00","2023-07-26 20:13:49","" +"40","Bristol Myers Squibb","","bms","logo/bms.jpg","https://www.bms.com/","At Bristol Myers Squibb, we work every day to transform patients' lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. We have the brightest people in the industry and believe that their diverse experiences and perspectives help to bring out our best ideas, drive innovation and achieve transformative business results.","2","2023-06-23 00:00:00","2023-07-26 20:13:50","BMS" +"41","Broad Institute","","broad","logo/broad.jpg","https://www.broadinstitute.org/","We seek to better understand the roots of disease and narrow the gap between new biological insights and impact for patients.","5","2023-06-23 00:00:00","2023-07-26 20:13:51","" +"42","Brown University","","brown","logo/brown.jpg","https://www.brown.edu/","Founded in 1764, Brown is a nonprofit leading research university, home to world-renowned faculty, and also an innovative educational institution where the curiosity, creativity and intellectual joy of students drives academic excellence. The spirit of the undergraduate Open Curriculum infuses every aspect of the University. Brown is a place where rigorous scholarship, complex problem-solving and service to the public good are defined by intense collaboration, intellectual discovery and working in ways that transcend traditional boundaries. As a private, nonprofit institution, the University advances its mission through support from a community invested in Brown's commitment to advance knowledge and make a positive difference locally and globally.","1","2023-06-23 00:00:00","2023-07-26 20:13:52","" +"43","California Institute of Technology","","caltech","logo/caltech.jpg","https://www.caltech.edu/","Caltech is a world-renowned science and engineering institute that marshals some of the world's brightest minds and most innovative tools to address fundamental scientific questions and pressing societal challenges.","2","2023-06-23 00:00:00","2023-07-26 20:13:52","" +"44","Cancer Imaging Archive","","tcia","logo/tcia.jpeg","https://www.cancerimagingarchive.net/","The Cancer Imaging Archive (TCIA) is a service which de-identifies and hosts a large publicly available archive of medical images of cancer. TCIA is funded by the Cancer Imaging Program (CIP), a part of the United States National Cancer Institute (NCI), and is managed by the Frederick National Laboratory for Cancer Research (FNLCR).","1","2023-06-23 00:00:00","2023-07-26 20:13:53","TCIA" +"45","Cancer Research UK","","cancer-research-uk","logo/cancer-research-uk.jpg","https://www.cancerresearchuk.org/","Cancer Research UK was formed 20 years ago, in 2002. However, our history goes back much further, to 1902, with the founding of the Imperial Cancer Research Fund. Thanks to supporters like you, our pioneering work into how to prevent, diagnose and treat cancer has benefitted millions of lives over the past 120 years. Find out more about how our research has already made a difference to patients and what we are funding right now.","1","2023-06-23 00:00:00","2023-07-26 20:13:54","" +"46","Cancer Target Discovery and Development","","ctd2","logo/ctd2.png","https://ocg.cancer.gov/programs/ctd2","The Cancer Target Discovery and Development (CTD2) Network, also known as C-T-D-Squared, is a functional genomics initiative that bridges the gap between genomics and development of effective therapeutics. The Network aims to understand tumor development, heterogeneity, drug resistance, and metastasis to develop optimal combinations of chemotherapy with immunotherapy.","4","2023-06-23 00:00:00","2023-07-26 20:13:55","CTD2" +"47","Celgene","","celgene","logo/celgene.jpg","https://www.celgene.com","This organization may no longer exist or has been merged under another organization.","3","2023-06-23 00:00:00","2023-08-08 17:58:26","" +"48","Center for Research Computing","CRCSupport@nd.edu","crc","logo/crc.jpeg","https://crc.nd.edu/","The Center for Research Computing (CRC) at University of Notre Dame is an innovative and multidisciplinary research environment that supports collaboration to facilitate multidisciplinary discoveries through advanced computation, software engineering, artificial intelligence, and other digital research tools. The Center enhances the University's innovative applications of cyberinfrastructure, provides support for interdisciplinary research and education, and conducts computational research.","1","2023-06-23 00:00:00","2023-07-26 20:13:57","CRC" +"49","Cincinnati Children's Hospital Medical Center","","cchmc","logo/cchmc.jpg","https://www.cincinnatichildrens.org/","Cincinnati Children's, a nonprofit academic medical center established in 1883, is one of the oldest and most distinguished pediatric hospitals in the United States.","2","2023-06-23 00:00:00","2023-07-26 20:13:57","CCHMC" +"50","Climb 4 Kidney Cancer","","c4kc","logo/c4kc.jpg","https://climb4kc.org/","Climb 4 Kidney Cancer is a nonprofit organization that aims to raise money for kidney cancer research while bringing people together through climbing. We are physicians, scientists, survivors, and loved ones who share a passion for climbing and a passion for improving the lives of those affected by kidney cancer.","1","2023-06-23 00:00:00","2023-07-26 20:13:58","C4KC" +"51","Clinical Proteomic Tumor Analysis Consortium","","cptac","logo/cptac.png","https://proteomics.cancer.gov/programs/cptac","The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","1","2023-06-23 00:00:00","2023-07-26 20:13:58","CPTAC" +"52","Columbia University","askcuit@columbia.edu","columbia","logo/columbia.jpg","https://www.columbia.edu/","Columbia University is one of the world's most important centers of research and at the same time a distinctive and distinguished learning environment for undergraduates and graduate students in many scholarly and professional fields. The University recognizes the importance of its location in New York City and seeks to link its research and teaching to the vast resources of a great metropolis. It seeks to attract a diverse and international faculty, staff, and student body, to support research and teaching on global issues, and to create academic relationships with many countries and regions. It expects all areas of the University to advance knowledge and learning at the highest level and to convey the products of its efforts to the world.","5","2023-06-23 00:00:00","2023-07-26 20:13:59","" +"53","Conceptant","connect@conceptant.com","conceptant","logo/conceptant.webp","https://www.conceptant.com/","We want to improve humanity and the world through technology, plain and simple. Tech has so much promise to improve lives, but we felt it was constantly overshadowed by stuffy boardrooms and corporate red tape. Which is why Conceptant takes a different path, one we created. We go against the grain using creative techniques to develop cutting edge solutions while avoiding the pot holes of slow stuffy suits.","1","2023-06-23 00:00:00","2023-07-26 20:14:00","" +"54","Consejo Superior de Investigaciones Cientificas","","csic","logo/csic.jpg","https://www.csic.es/","The Higher Council for Scientific Research (CSIC) is a State Agency for scientific research and technological development, with differentiated legal personality, its own assets and treasury, functional and management autonomy, full legal capacity to act and of indefinite duration (art. 1 Statute).","1","2023-06-23 00:00:00","2023-07-26 20:14:00","CSIC" +"55","CorEvitas","info@corevitas.com","corevitas","logo/corevitas.jpeg","https://www.corevitas.com/","CorEvitas is a science-led, data intelligence company that provides the life sciences industry with the objective data and clinical insights needed to demonstrate the real-world safety, effectiveness, and patient experience of therapeutics in the post-approval setting","1","2023-06-23 00:00:00","2023-07-26 20:14:02","" +"56","Corrona","","corrona","logo/corrona.jpeg","https://www.corrona.org","This organization may no longer exist or has been merged under another organization.","1","2023-06-23 00:00:00","2023-08-08 17:58:48","" +"57","Covert Lab","covert.lab@gmail.com","covert-lab","","https://www.covert.stanford.edu/","We're a scrappy bunch of scientists who like to do cutting-edge research with the latest technology (often home-made)! Our primary biological focus is in host-pathogen interactions, most particularly in terms of the innate immune system, and our technological foci are whole-cell modeling and live-cell imaging, as shown above. We're always looking for top talent - if you're a budding, intellectually ambidextrous scientist with a creative streak and an aptitude for team play, this could be the place for you!","1","2023-06-23 00:00:00","2023-07-26 20:14:04","" +"58","Dana-Farber Cancer Institute","","dfci","logo/dfci.png","https://www.dana-farber.org/","Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.","5","2023-06-23 00:00:00","2023-07-26 20:14:04","DFCI" +"59","Defense Advanced Research Projects Agency","","darpa","logo/darpa.jpg","https://www.darpa.mil/","For sixty years, DARPA has held to a singular and enduring mission: to make pivotal investments in breakthrough technologies for national security. The genesis of that mission and of DARPA itself dates to the launch of Sputnik in 1957, and a commitment by the United States that, from that time forward, it would be the initiator and not the victim of strategic technological surprises. Working with innovators inside and outside of government, DARPA has repeatedly delivered on that mission, transforming revolutionary concepts and even seeming impossibilities into practical capabilities. The ultimate results have included not only game-changing military capabilities such as precision weapons and stealth technology, but also such icons of modern civilian society such as the Internet, automated voice recognition and language translation, and Global Positioning System receivers small enough to embed in myriad consumer devices.","2","2023-06-23 00:00:00","2023-07-26 20:14:05","DARPA" +"60","Department of Energy","","doe","logo/doe.jpg","https://www.energy.gov/","The mission of the Energy Department is to ensure America's security and prosperity by addressing its energy, environmental and nuclear challenges through transformative science and technology solutions.","1","2023-06-23 00:00:00","2023-07-26 20:14:06","DOE" +"61","Diagnosticos da America SA","","dasa","logo/dasa.jpeg","https://dasa.com.br/","We are Dasa. A new model that expands and integrates health care throughout life. We have brought together the largest diagnostic medicine network, a robust hospital group and the best care management company, so that nothing is missing and full care is provided. We connect spaces, technologies, knowledge, multiply specialties and become a complete company, alive and moving, always evolving. We develop the most innovative technology and health with new digital solutions that we seek in the market, via open innovation and in Dasa startups. Today we are more than 40,000 professionals ready to meet‌ ‌all‌ ‌‌‌your‌ health needs. We are for you. A comprehensive health network with a ‌grand purpose, which is to make sure you experience the best of your health every day.","1","2023-06-23 00:00:00","2023-07-26 20:14:06","DASA" +"62","DNAnexus","","dnanexus","logo/dnanexus.png","https://www.dnanexus.com/","DNAnexus(R) has built the world's most secure cloud platform and global network for scientific collaboration and accelerated discovery. We embrace challenges and partnership to tackle the world's most exciting opportunities in human health.","11","2023-06-23 00:00:00","2023-07-26 20:14:08","" +"63","Dockstore","","dockstore","logo/dockstore.jpg","https://dockstore.org/","Dockstore is a free and open source platform for sharing reusable and scalable analytical tools and workflows. It's developed by the Cancer Genome Collaboratory and used by the GA4GH.","1","2023-06-23 00:00:00","2023-07-26 20:14:08","" +"64","Duke University","","duke","logo/duke.jpg","https://duke.edu/","The mission of Duke University is to provide a superior liberal education to undergraduate students, attending not only to their intellectual growth but also to their development as adults committed to high ethical standards and full participation as leaders in their communities; to prepare future members of the learned professions for lives of skilled and ethical service by providing excellent graduate and professional education; to advance the frontiers of knowledge and contribute boldly to the international community of scholarship; to promote an intellectual environment built on a commitment to free and open inquiry; to help those who suffer, cure disease, and promote health, through sophisticated medical research and thoughtful patient care; to provide wide ranging educational opportunities, on and beyond our campuses, for traditional students, active professionals and life-long learners using the power of information technologies; and to promote a deep appreciation for the r...","3","2023-06-23 00:00:00","2023-07-26 20:14:09","" +"65","Early Signal Foundation","","early-signal","","http://www.earlysignal.org","This organization may no longer exist or has been merged under another organization.","1","2023-06-23 00:00:00","2023-08-08 17:58:54","" +"66","Eck Institute for Global Health","","eigh","logo/eigh.jpg","https://globalhealth.nd.edu/","The University of Notre Dame's Eck Institute for Global Health (EIGH) serves as a university-wide enterprise that recognizes health as a fundamental human right and works to promote research, training, and service to advance health standards and reduce health disparities for all. The EIGH brings together multidisciplinary teams to understand and address health challenges that disproportionately affect the poor and to train the next generation of global health leaders.","1","2023-06-23 00:00:00","2023-07-26 20:14:10","EIGH" +"67","Eli Lilly and Company","","lilly","logo/lilly.png","https://www.lilly.com/","Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: ""Take what you find here and make it better and better."" More than 145 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live.","3","2023-06-23 00:00:00","2023-07-26 20:14:11","" +"68","Elixir","","elixir","logo/elixir.jpg","https://www.elixirsolutions.com/","Elixir is a pharmacy benefits and services company with the scale, flexibility and expertise to help our clients achieve their unique business goals. We have been purposely built and own all the assets needed to optimize the full pharmacy care experience, including: a) An industry leading adjudication platform, offering flexibility, efficiency and data privacy protection; b) Accredited mail and specialty pharmacies, creating an exceptional member experience, waste reduction and cost savings; c) Population health services through our sister company, Health Dialog; and d) Prescription discount programs for uninsured and under-insured and Medicare Part D plans for individuals, associations and groups.","1","2023-06-23 00:00:00","2023-07-26 20:14:12","" +"69","Encyclopedia of DNA Elements Data Coordinating Center","encode-help@lists.stanford.edu","encode","logo/encode.png","https://www.encodeproject.org/","The ENCODE Data Coordination Center (DCC)'s primary task is to curate, uniformly process and validate the data generated and submitted by ENCODE Consortium members in preparation for release to the scientific community.","1","2023-06-23 00:00:00","2023-07-26 20:14:13","ENCODE" +"70","ENIGMA Consortium","enigma@ini.usc.edu","enigma","logo/enigma.jpg","http://enigma.ini.usc.edu/","The ENIGMA Consortium brings together researchers in imaging genomics to understand brain structure, function, and disease, based on brain imaging and genetic data. We welcome brain researchers, imagers, geneticists, methods developers, and others interested in cracking the neuro-genetic code!","1","2023-06-23 00:00:00","2023-07-26 20:14:13","ENIGMA" +"71","ETH Zurich","","eth","logo/eth.jpg","https://ethz.ch/en.html","Freedom and individual responsibility, entrepreneurial spirit and open-​​mindedness: ETH Zurich stands on a bedrock of true Swiss values.","2","2023-06-23 00:00:00","2023-07-26 20:14:14","ETH" +"72","Eunice Kennedy Shriver National Institute","NICHDInformationResourceCenter@mail.nih.gov","nichd","logo/nichd.jpg","https://www.nichd.nih.gov/","NICHD was founded in 1962 to investigate human development throughout the entire life process, with a focus on understanding disabilities and important events that occur during pregnancy. Since then, research conducted and funded by NICHD has helped save lives, improve wellbeing, and reduce societal costs associated with illness and disability. NICHD's mission is to lead research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all.","1","2023-06-23 00:00:00","2023-07-26 20:14:15","NICHD" +"73","European Bioinformatics Institute","","embl-ebi","logo/embl-ebi.jpg","https://www.ebi.ac.uk/","At EMBL's European Bioinformatics Institute (EMBL-EBI), we help scientists realise the potential of big data in biology, exploiting complex information to make discoveries that benefit humankind.","8","2023-06-23 00:00:00","2023-07-26 20:14:15","EMBL-EBI" +"74","European Medicines Agency","","ema","logo/ema.jpg","https://www.ema.europa.eu/en","The mission of the European Medicines Agency (EMA) is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health in the European Union (EU).","1","2023-06-23 00:00:00","2023-07-26 20:14:16","EMA" +"75","European Union","","eu","logo/eu.png","https://europa.eu/european-union/index_en","The common principles and values that underlie life in the EU: freedom, democracy, equality and the rule of law, promoting peace and stability.","2","2023-06-23 00:00:00","2023-07-26 20:14:16","EU" +"76","Evidation Health","","evidation","logo/evidation.png","https://evidation.com/","We believe everyday health data is the most compelling force in medicine—because under rigorous study, it's proving to be a new and exceptionally powerful lens on health. These novel discoveries—emanating from data generated and controlled by individuals—can be turned into tools they use to take control of their health. By connecting our member community to research and innovation partners across the health ecosystem, we're creating a new platform for medical advancements and innovation.","1","2023-06-23 00:00:00","2023-07-26 20:14:17","" +"77","Fehling Instruments","","fehling-instruments","logo/fehling-instruments.jpeg","https://www.fehling-instruments.de/en/","Fehling Instruments is a traditional family owned and family run company with more than thirty years of experience in the medical business. Fehling Instruments is constantly striving for excellence in function and economy of products. This objective is achieved by continuous innovation in materials, mechanics and design. Customer satisfaction is the prevailing goal of our business. Therefore, Fehling Instruments provides outstanding service in addition to quality products. Fehling Instruments develops, manufactures, and distributes surgical instruments, implants and single use products for use mainly in the OR. FI also provides all corresponding repair service. The most important target markets for Fehling Instruments are neuro surgery (spine and brain) and thoracic, cardiac and vascular surgery.","1","2023-06-23 00:00:00","2023-07-26 20:14:18","" +"78","Feinstein Institutes for Medical Research","","feinstein-institute","logo/feinstein-institute.png","https://feinstein.northwell.edu/","The Feinstein Institutes for Medical Research is the home of research at Northwell Health. In conjunction with our partners in government, academia, industry and philanthropy, we strive to advance knowledge and make innovative therapies a reality. Our researchers work to transform the treatment of conditions like lupus, arthritis, sepsis, cancer, psychiatric illness and Alzheimer's disease. As the global headquarters of bioelectronic medicine, we're exploring ways to raise the standard of medical innovation and are using electronic medical devices to signal the body to heal itself.","1","2023-06-23 00:00:00","2023-07-26 20:14:19","" +"79","Francis Crick Institute","info@crick.ac.uk","francis-crick-institute","logo/francis-crick-institute.jpeg","https://www.crick.ac.uk/","The Francis Crick Institute is a biomedical research institute working with organisations across academia, medicine and industry to make discoveries about how life works.","1","2023-06-23 00:00:00","2023-07-26 20:14:20","" +"80","Fred Hutchinson Cancer Research Center","","fred-hutch","logo/fred-hutch.jpg","https://www.fredhutch.org/","Fred Hutchinson Cancer Center unites innovative research and compassionate care to prevent and eliminate cancer and infectious disease. We're driven by the urgency of our patients, the hope of our community and our passion for discovery to pursue scientific breakthroughs and healthier lives for every person in every community.","1","2023-06-23 00:00:00","2023-07-26 20:14:21","" +"81","Genome Canada","info@genomecanada.ca","genome-canada","logo/genome-canada.png","https://www.genomecanada.ca/","Genome Canada is an independent, federally funded not-for-profit organization and a national leader for Canada's genomics ecosystem. Working in partnership, and across sectors, we invest in, and coordinate, genomics research, innovation, data and talent to generate solutions to today's biggest challenges.","3","2023-06-23 00:00:00","2023-07-26 20:14:21","" +"82","George Washington University","","gwu","logo/gwu.jpg","https://www.gwu.edu/","Since our capital city's first days, people have traveled here for many reasons. They come to explore the past and to chart new futures. They come to ask questions and to seek expert answers. They come to start discourse and to remember in silence. They come to demand change and to be that change. They come to grow. They come to learn. They come to make history and join the ranks alongside many monumental GW alumni.","2","2023-06-23 00:00:00","2023-07-26 20:14:23","GWU" +"83","Georgetown University","","georgetown","logo/georgetown.png","https://www.georgetown.edu/","We're a leading research university with a heart. Founded in the decade that the U.S. Constitution was signed, we're the nation's oldest Catholic and Jesuit university. Today we're a forward-looking, diverse community devoted to social justice, restless inquiry and respect for each person's individual needs and talents.","1","2023-06-23 00:00:00","2023-07-26 20:14:23","" +"84","German Cancer Research Center","","dkfz","logo/dkfz.jpg","https://www.dkfz.de/en/index.html","More than 450,000 people are diagnosed with cancer each year in Germany. Cancer is a disease that poses enormous challenges to research, because every cancer is different and its course can vary immensely even from one patient to the next. To perform research into cancer is the task of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) according to its statutes. DKFZ is the largest biomedical research institute in Germany and a member of the Helmholtz Association of National Research Centers. In more than 100 divisions and research groups, our more than 3,000 employees, of which more than 1,200 are scientists, are investigating the mechanisms of cancer, are identifying cancer risk factors and are trying to find strategies to prevent people from getting cancer.They are developing novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.","2","2023-06-23 00:00:00","2023-07-26 20:14:24","DKFZ" +"85","Global Alliance for Genomics and Health","info@ga4gh.org","ga4gh","logo/ga4gh.png","https://www.ga4gh.org/","The Global Alliance for Genomics and Health (GA4GH) is an international, nonprofit alliance formed in 2013 to accelerate the potential of research and medicine to advance human health. Bringing together 600+ leading organizations working in healthcare, research, patient advocacy, life science, and information technology, the GA4GH community is working together to create frameworks and standards to enable the responsible, voluntary, and secure sharing of genomic and health-related data. All of our work builds upon the Framework for Responsible Sharing of Genomic and Health-Related Data.","1","2023-06-23 00:00:00","2023-07-26 20:14:24","GA4GH" +"86","H. Lee Moffitt Cancer Center and Research Institute","","moffitt","logo/moffitt.png","https://moffitt.org/","At Moffitt Cancer Center, we are working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease. We are committed to the health and safety of our patients and dedicated to providing expert cancer care.","1","2023-06-23 00:00:00","2023-07-26 20:14:25","" +"87","H3ABioNet","info@h3abionet.org","h3abionet","logo/h3abionet.png","https://h3abionet.org/","H3ABioNet is a Pan African Bioinformatics network comprising 28 Nodes distributed amongst 17 countries, 16 of which are African. H3ABioNet was developed to support H3Africa research projects through the development of bioinformatics capacity on the continent. Specifically H3ABioNet aims to: a) Implement a Pan African informatics infrastructure; b) Develop an H3Africa data coordinating center; c) Provide high quality informatics support to H3Africa; d) Enable and enhance innovative translational research; and e) Address outreach, development and sustainability.","1","2023-06-23 00:00:00","2023-07-26 20:14:26","" +"88","Harvard University","","harvard","logo/harvard.jpg","https://www.harvard.edu/","As a research university and nonprofit institution, Harvard is focused on creating educational opportunities for people from many lived experiences.","3","2023-06-23 00:00:00","2023-07-26 20:14:26","" +"89","Heidelberg University","","heidelberg-university","logo/heidelberg-university.jpg","https://www.heidelberg.edu/","A day at Heidelberg University is filled with connection. Whether it's walking to class, receiving one-on-one instruction from excellent faculty, or perfecting new skills at practice, students are uplifted every moment. Each time a Student Prince makes their own success, they know they have a dedicated community standing behind them.","10","2023-06-23 00:00:00","2023-07-26 20:14:27","" +"90","HistoSonics Inc.","","histosonics","logo/histosonics.jpg","https://histosonics.com/","Minimally invasive isn't minimal enough. HistoSonics(R) is developing a non-invasive, sonic beam therapy platform capable of destroying tissue at a sub-cellular level.","1","2023-06-23 00:00:00","2023-07-26 20:14:28","" +"91","Hospital for Sick Children","","sickkids","logo/sickkids.jpg","https://www.sickkids.ca/Research/","SickKids Research Institute (RI) is where over 2,000 researchers, trainees, and staff are working together to take on the toughest challenges in child health. As Canada's largest, hospital-based child health research institute, we conduct and translate groundbreaking research to improve child health outcomes, policy, and clinical care, train the next generation of researchers, and support global scientific communities with knowledge and state-of-the-art facilities. Innovation and collaboration across our seven distinct research programs have led to a number of incredible discoveries at SickKids, uncovering the mechanisms and outcomes of childhood disease. And with every research question in the lab, we are driving clinical changes.","3","2023-06-23 00:00:00","2023-07-26 20:14:28","" +"92","Human Protein Atlas","","hpa","logo/hpa.png","www.proteinatlas.org","The Human Protein Atlas is a Swedish-based program initiated in 2003 with the aim to map the expression and spatial distribution of all human proteins in cells and tissues using an integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics and systems biology. The data is freely available in the Protein Atlas database (www.proteinatlas.org) to allow scientists both in academia and industry to freely access the data for exploration of the human proteome with the mission to accelerate life science research and drug discovery.The database is used by over 200,000 users per month and nearly 10 publications per day use data from the Protein Atlas.\n\nThe image data in the challenge comes from the HPA Cell Atlas, led by Dr. Emma Lundberg.","1","2023-06-23 00:00:00","2023-07-26 20:14:29","HPA" +"93","International Business Machines Corporation","","ibm","logo/ibm.svg","https://www.research.ibm.com/","At IBM Research we live by the scientific method. It's at the core of everything we do. We choose impact over market cycles, vision over vanity. We deeply believe that creative freedom, excellence, and integrity are essential to any breakthrough. We operate with a backbone. We don't cut corners. We take responsibility for technology and its role in society. We make decisions with a conscience — for a future that we believe is worth living in. We recognize the immense power and potential of computing — not as a commodity, but as an agent of progress and connection. This is the future, built right.","37","2023-06-23 00:00:00","2023-07-26 20:14:30","IBM" +"94","Innovative Medicines Initiative","","imi","logo/imi.png","http://www.imi.europa.eu/","At the Innovative Medicines Initiative (IMI), we are working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. We do this by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through the IMI2 programme, we have a €3.3 billion budget for the period 2014-2020.","1","2023-06-23 00:00:00","2023-07-26 20:14:30","IMI" +"95","Institut Curie","","institut-curie","logo/institut-curie.jpg","https://institut-curie.org/","Institut Curie is the leading cancer research and treatment centre in France and has been a recognised public utility foundation since 1921. Since its creation by Marie Curie, Institut Curie has worked on three missions: Care, Reserach, Transmission.","2","2023-06-23 00:00:00","2023-07-26 20:14:31","" +"96","Institute for Molecular Medicine Finland","","fimm","logo/fimm.png","https://www.helsinki.fi/en/hilife-helsinki-institute-life-science/units/fimm","FIMM – Institute for Molecular Medicine Finland is a translational research institute focusing on human genomics and precision medicine as part of the Helsinki Institute of Life Science HiLIFE at the University of Helsinki. FIMM has a driving mission to perform innovative research on patients and populations targeted towards understanding drivers of health and disease. We aim at delivering improvements to the safety, efficacy, and efficiency of healthcare in Finland and beyond.","1","2023-06-23 00:00:00","2023-07-26 20:14:33","FIMM" +"97","Institute of Translational Health Sciences","","iths","logo/iths.jpg","https://www.iths.org/","The Institute of Translational Health Sciences is dedicated to speeding science to the clinic for the benefit of patients and communities throughout Washington, Wyoming, Alaska, Montana, and Idaho.","1","2023-06-23 00:00:00","2023-07-26 20:14:34","ITHS" +"98","Intel","","intel","logo/intel.svg","https://www.intel.com/content/www/us/en/homepage.html","Intel(R) Software sits at the intersection of hardware, interoperability, and amazing customer experiences. We partner with the global technology ecosystem to make development EASY, OPEN, and SCALABLE so developers can do what they do best: deliver groundbreaking applications and end-to-end solutions on Intel technologies. Visit the Intel(r) Nervana(TM) AI Academy to gain access to tools, Intel optimized frameworks, libraries, technical experts and training, getting started guides, and more.","3","2023-06-23 00:00:00","2023-07-26 20:14:37","" +"99","International Cancer Genome Consortium","","icgc","logo/icgc.jpg","https://dcc.icgc.org/","The ICGC Data Portal provides many tools for visualizing, querying, and downloading cancer data, which is released on a quarterly schedule.","5","2023-06-23 00:00:00","2023-07-26 20:14:38","ICGC" +"100","International Flavors and Fragrances Inc.","","iff","logo/iff.png","https://www.iff.com/","We apply science and creativity for a better world. With the beauty of art and the precision of science, we are an international collective of thinkers who partner with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. As a global leader in food, beverage, health, biosciences and sensorial experiences, we do a lot and continually innovate to do it better. For more than 130 years we've been focused on finding the most innovative solutions to help bring “better for you” products to market. While we have grown over the years, we remain agile in our approach and put our customers' needs at the forefront of our thinking. We offer end-to-end service that few can deliver on. Our unparalleled product portfolio is the most robust in the industry and we have leadership positions across key taste, texture, scent, nutrition, enzymes, cultures, soy proteins and probiotics categories.","1","2023-06-23 00:00:00","2023-07-26 20:14:38","IFF" +"101","International Genome Sample Resource","","igsr","logo/igsr.jpg","https://www.internationalgenome.org/home","The 1000 Genomes Project created a catalogue of common human genetic variation, using openly consented samples from people who declared themselves to be healthy. The reference data resources generated by the project remain heavily used by the biomedical science community. The International Genome Sample Resource (IGSR) maintains and shares the human genetic variation resources built by the 1000 Genomes Project. We also update the resources to the current reference assembly, add new data sets generated from the 1000 Genomes Project samples and add data from projects working with other openly consented samples.","1","2023-06-23 00:00:00","2023-07-26 20:14:39","IGSR" +"102","International Society for Computational Biology","","iscb","logo/iscb.png","https://www.iscb.org/cms_addon/conferences/ismbeccb2021/tracks/function","Society membership reflects commitment toward the advancement of computational biology. The ISCB is an international non-profit organization whose members come from the global bioinformatics and computational biology communities. The ISCB serves its global membership by providing high-quality meetings, publications, and reports on methods and tools; by disseminating key information about bioinformatics resources and relevant news from related fields; and by actively facilitating training, education, employment, career development, and networking. We advocate and provide leadership for resources and policies in support of scientific endeavors and to benefit society at large.","2","2023-06-23 00:00:00","2023-07-26 20:14:40","ISCB" +"103","Intuitive Surgical Inc.","","intuitive","logo/intuitive.jpg","https://www.intuitive.com/en-us","Intuitive advances minimally invasive care by innovating at the point of possibility. For nearly three decades we've created products and services born of inspiration and intelligence—from robotic-assisted surgical systems to data generation that unlocks the potential to benefit care systems worldwide. We work closely and collaboratively with our customers to help achieve better outcomes, better care team experiences, better patient experiences, and lower cost of care. Together, we envision a future of care that's less invasive, profoundly better, and where diseases are identified early and treated quickly so patients can get back to what matters most.","1","2023-06-23 00:00:00","2023-07-26 20:14:41","" +"104","Iowa State University","contact@iastate.edu","iowa-state-university","logo/iowa-state-university.png","https://www.iastate.edu/","Iowa State is a large university with a small feel. Forge lifelong friendships and earn a degree that will take you anywhere.","2","2023-06-23 00:00:00","2023-07-26 20:14:42","" +"105","Kaggle","","kaggle","logo/kaggle.png","https://www.kaggle.com/","Kaggle is a community of data scientists and data enthusiasts. Our platform enables you to learn from and mentor each other on your personal, academic, and professional data science journeys. \n\nTo get involved, you can [enter a machine learning competition](https://www.kaggle.com/competitions), [publish an open dataset](https://www.kaggle.com/datasets), or [share code in our reproducible data science environment](https://www.kaggle.com/kernels). \n\nKaggle's headquarters is located in San Francisco, but we have team members working from across the US and Australia. [Join our team](https://www.kaggle.com/careers) from wherever you call home.","2","2023-06-23 00:00:00","2023-09-15 16:54:08","" +"106","Kaiser Permanente Washington Health Research Institute","","kpwhri","logo/kpwhri.jpg","https://www.kpwashingtonresearch.org/","Kaiser Permanente Washington Health Research Institute (KPWHRI) is the non-proprietary, public-interest research center within Kaiser Permanente Washington, a nonprofit health system based in Seattle. Kaiser Permanente Washington provides coverage and care for more than 710,170 people in Washington. Our research produces timely, relevant findings that help people everywhere stay healthy and get the care they need. From testing new vaccines to helping people quit smoking to finding ways to delay or prevent Alzheimer's disease, our discoveries have helped millions of people worldwide lead healthier, happier lives.","1","2023-06-23 00:00:00","2023-07-26 20:14:44","KPWHRI" +"107","King's College London","","kcl","logo/kcl.jpg","https://www.kcl.ac.uk/","King's College London is an internationally renowned university delivering exceptional education and world-leading research. We are dedicated to driving positive and sustainable change in society and realising our vision of making the world a better place.","2","2023-06-23 00:00:00","2023-07-26 20:14:44","KCL" +"108","Knowledge Engine for Genomics","knoweng@illinois.edu","knoweng","logo/knoweng.png","https://knoweng.org/","KnowEnG, The Knowledge Engine for Genomics, will transform the way biomedical researchers analyze their genome-wide data by integrating multiple analytical methods derived from the most advanced data mining and machine learning research. Embedded with the breadth of existing knowledge of genes, and an intuitive and professionally designed user interface, the Knowledge Engine platform provides advanced capabilities in data analytics. The KnowEnG environment is deployed in a cloud infrastructure and will be fully available to the research community, as will be the software developed by the Center.","1","2023-06-23 00:00:00","2023-07-26 20:14:45","" +"109","Koch Institute","cancer@mit.edu","koch-institute","logo/koch-institute.jpg","https://ki.mit.edu/","At the Koch Institute for Integrative Cancer Research, we take a uniquely MIT approach to solving some of the most difficult problems in cancer. Our research combines MIT's rich traditions of interdisciplinary inquiry and technological innovation with the most advanced investigation into the fundamental biology of cancer. With an unprecedented commitment to cross-disciplinary collaboration, we are accelerating the discovery and application of new ways to detect, monitor, treat, and prevent the disease.","1","2023-06-23 00:00:00","2023-07-26 20:14:46","" +"110","Laura and John Arnold Foundation","","arnold-ventures","logo/arnold-ventures.jpg","https://www.arnoldventures.org/people/laura-arnold-john-arnold/","Arnold Ventures is a philanthropy working to improve the lives of all Americans by pursuing evidence-based solutions to our nation's most pressing problems. We fund research to better understand the root causes of broken systems that limit opportunity and create injustice. Our focus areas include Criminal Justice, Higher Education, Health, and Public Finance. In each area, we advocate for policy reforms that will lead to lasting, scalable change.","1","2023-06-23 00:00:00","2023-07-26 20:14:46","" +"111","Lausanne University Hospital","","chuv","logo/chuv.jpg","https://www.lausanneuniversityhospital.com/home","Lausanne University Hospital is one of the five university hospitals in Switzerland, with Geneva, Bern, Basel and Zurich. With its 16 clinical and medico-technical departments and their numerous services, the CHUV is renowned for its academic achievements in health care, research, and teaching. The CHUV is also a well-known center of medical education and research thanks to its collaboration with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). Together, these institutions form a vast campus in the Lake Geneva region.","1","2023-06-23 00:00:00","2023-07-26 20:14:47","CHUV" +"112","Leukemia and Lymphoma Society","","lls","logo/lls.jpg","https://www.lls.org/","The Leukemia & Lymphoma Society (LLS) is at the forefront of the fight to cure blood cancer. We are the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, we've invested more than $1.6 billion in groundbreaking research, pioneering many of today's most innovative approaches. LLS is a global leader in the fight against blood cancer.","1","2023-06-23 00:00:00","2023-07-26 20:14:48","LLS" +"113","Ligue Nationale Contre le Cancer","","ligue-cancer","logo/ligue-cancer.jpg","https://www.ligue-cancer.net/","Since 1918, the League has been fighting against cancer by being the first independent funder of research","1","2023-06-23 00:00:00","2023-07-26 20:14:48","" +"114","London's Global University","","ucl","logo/ucl.jpg","https://www.ucl.ac.uk/","Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 16,000 staff and 50,000 students from over 150 different countries. We are a diverse community with the freedom and courage to challenge, to question and to think differently.","2","2023-06-23 00:00:00","2023-07-26 20:14:49","UCL" +"115","Ludwig Maximilian University of Munich","","lmu","logo/lmu.jpg","https://www.lmu.de/en/index.html","Ludwig-Maximilians-Universitat Munchen is a leading research university in Europe. Since its founding in 1472 it has been committed to the highest international standards of excellence in research and teaching.","2","2023-06-23 00:00:00","2023-07-26 20:14:51","LMU" +"116","Mahidol Oxford Tropical Medicine Research Unit","","moru","logo/moru.jpeg","https://www.tropmedres.ac/","The MORU Tropical Health Network, which hosts the ‘Thailand Wellcome Africa and Asia Programme', conducts targeted clinical and public health research that aims to discover and develop appropriate, practical, affordable interventions that measurably improve the health of people living in resource-limited parts of the world.","1","2023-06-23 00:00:00","2023-07-26 20:14:51","MORU" +"117","March of Dimes","","march-of-dimes","logo/march-of-dimes.jpg","https://www.marchofdimes.org/","March of Dimes is a nonprofit organization committed to ending preventable maternal health risks and death, ending preventable preterm birth and infant death and closing the health equity gap for all families.","1","2023-06-23 00:00:00","2023-07-26 20:14:51","" +"118","Massachusetts General Hospital","","mass-general","logo/mass-general.png","https://www.massgeneral.org/","In the delivery of our care, through our research and within our communities, Mass General is committed to the well-being of our patients locally and globally.","3","2023-06-23 00:00:00","2023-07-26 20:14:54","" +"119","Massachusetts Institute of Technology","","mit","logo/mit.jpg","https://www.mit.edu/","The MIT community is driven by a shared purpose: to make a better world through education, research, and innovation. We are fun and quirky, elite but not elitist, inventive and artistic, obsessed with numbers, and welcoming to talented people regardless of where they come from.","8","2023-06-23 00:00:00","2023-08-08 18:47:20","MIT" +"120","MathWorks","","mathworks","logo/mathworks.jpg","https://www.mathworks.com/","We at MathWorks believe in the importance of engineers and scientists. They increase human knowledge and profoundly improve our standard of living. We created MATLAB and Simulink to help them do their best work.","1","2023-06-23 00:00:00","2023-07-26 20:14:56","" +"121","Max Delbruck Center for Molecular Medicine","","mdc","logo/mdc.jpg","https://www.mdc-berlin.de/","The Max Delbruck Center is an internationally renowned biomedical research center in Berlin. It is named after Max Delbrück, one of the founders of modern genetics and molecular biology.","1","2023-06-23 00:00:00","2023-07-26 20:14:56","MDC" +"122","MD Anderson Cancer Center","","md-anderson","logo/md-anderson.jpg","https://www.mdanderson.org/","At MD Anderson, we understand how hard it can be to choose a hospital for cancer treatment. You've just received life-changing news, and now you have to decide how to handle it. Here are some of the reasons why MD Anderson is your best hope for cancer care.","1","2023-06-23 00:00:00","2023-07-26 20:14:57","" +"123","Medical Research Council","","mrc","","https://www.ukri.org/councils/mrc/","The Medical Research Council (MRC) improves the health of people in the UK – and around the world – by supporting excellent science, and training the very best scientists.","0","2023-06-23 00:00:00","2023-07-26 20:14:58","MRC" +"124","Memorial Sloan Kettering Cancer Center","","msk","logo/msk.jpg","https://www.mskcc.org/","The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world's most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.","3","2023-06-23 00:00:00","2023-07-26 20:14:58","MSK" +"125","Merck Co.","","merck","logo/merck.jpg","https://www.merck.com/","Our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.","1","2023-06-23 00:00:00","2023-07-26 20:14:59","" +"126","Michael J. Fox Foundation","info@michaeljfox.org","mjff","logo/mjff.jpg","https://www.michaeljfox.org/","The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.","3","2023-06-23 00:00:00","2023-07-26 20:15:00","MJFF" +"127","MINES ParisTech","contact@mines-paristech.fr","mines-paristech","","http://www.mines-paristech.eu/","250 years of history for the Graduate School. 1 500 students. 17 research centres, 230 talented research professors, 1st school for collaborative research, a unique link with companies. Values built over the years, which we are proud to display, to maintain, to share.","1","2023-06-23 00:00:00","2023-07-26 20:15:00","" +"128","Mount Sinai","","mt-sinai","logo/mt-sinai.jpg","https://www.mountsinai.org/","The Mount Sinai Health System is an integrated health care system providing exceptional medical care to our local and global communities. Encompassing the Icahn School of Medicine at Mount Sinai and eight hospital campuses in the New York metropolitan area, as well as a large, regional ambulatory footprint, Mount Sinai is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties. The Mount Sinai Health System was created from the combination of the Mount Sinai Medical Center and Continuum Health Partners, which both agreed unanimously to combine the two entities in July 2013.","28","2023-06-23 00:00:00","2023-07-26 20:15:01","" +"129","Multiple Myeloma Research Foundation","","mmrf","logo/mmrf.jpg","https://themmrf.org/","The MMRF is the largest nonprofit in the world focused on accelerating the cure for multiple myeloma. Our work is not done until each and every multiple myeloma patient has the answers they need. With our exceptional leadership, strategic collaboration and uniquely innovative approach, we are on the path to finding a cure for multiple myeloma.","1","2023-06-23 00:00:00","2023-07-26 20:15:03","MMRF" +"130","Nathan S. Kline Institute for Psychiatric Research","Webmaster@nki.rfmh.org","nki","logo/nki.png","https://www.nki.rfmh.org/","As one of the nation's most respected research centers focused on mental health, investigators at the Nathan S. Kline Institute for Psychiatric Research (NKI) study the causes, treatment, prevention, and rehabilitation of severe and persistent mental illnesses. As a facility of the New York State Office of Mental Health, founded in 1952, NKI has earned a reputation for its landmark contributions in psychiatric research, especially in the areas of psychopharmacological treatments for schizophrenia and major mood disorders, dementia research, clinical trials methodology, neuroimaging, therapeutic drug monitoring, and the application of computer technology to mental health services.","1","2023-06-23 00:00:00","2023-07-26 20:15:03","NKI" +"131","National Cancer Institute","NCIinfo@nih.gov","nci","logo/nci.jpg","https://www.cancer.gov/","The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. NCI leads, conducts, and supports cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives.","11","2023-06-23 00:00:00","2023-07-26 20:15:04","NCI" +"132","National Center for Advancing Translational Sciences","info@ncats.nih.gov","ncats","logo/ncats.jpg","https://ncats.nih.gov/","The National Center for Advancing Translational Sciences (NCATS) — one of 27 Institutes and Centers at the National Institutes of Health (NIH) — was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.","1","2023-06-23 00:00:00","2023-07-26 20:15:05","NCATS" +"133","National Center for Data to Health","","cd2h","","https://cd2h.org/","The National Center for Data to Health (CD2H) accelerates advancements in informatics by using findable, accessible, interoperable, and reusable (FAIR) principles to promote collaboration across the Clinical and Translational Science Awards (CTSA) Program community. CD2H tools and resources make it simple and valuable for CTSA Program members to get engaged, connect with peers, and contribute. By promoting collaboration, CD2H fosters a robust translational science informatics ecosystem that collectively develops solutions to solve clinical problems faster, more efficiently, and more effectively. CTSA Program members are poised to lead this charge by harnessing collective expertise and strengths to solve key informatics challenges. With this team science approach, advancements in translational research can ultimately improve patient care.","2","2023-06-23 00:00:00","2023-07-26 20:15:05","CD2H" +"134","National Institute of Environmental Health Sciences","","niehs","logo/niehs.png","https://www.niehs.nih.gov/","The National Institute of Environmental Health Sciences (NIEHS) is expanding and accelerating its contributions to scientific knowledge of human health and the environment, and to the health and well-being of people everywhere.","1","2023-06-23 00:00:00","2023-07-26 20:15:06","NIEHS" +"135","National Institute of General Medical Sciences","","nigms","logo/nigms.jpg","https://www.nigms.nih.gov/","The National Institute of General Medical Sciences (NIGMS) supports basic research that increases our understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS-funded scientists investigate how living systems work at a range of levels—from molecules and cells to tissues and organs—in research organisms, humans, and populations. Additionally, to ensure the vitality and continued productivity of the research enterprise, NIGMS provides leadership in training the next generation of scientists, enhancing the diversity of the scientific workforce, and developing research capacity throughout the country.","3","2023-06-23 00:00:00","2023-07-26 20:15:07","NIGMS" +"136","National Institute of Standards and Technology","do-webmaster@nist.gov","nist","logo/nist.png","https://www.nist.gov/","The National Institute of Standards and Technology (NIST) was founded in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation's oldest physical science laboratories. Congress established the agency to remove a major challenge to U.S. industrial competitiveness at the time — a second-rate measurement infrastructure that lagged behind the capabilities of the United Kingdom, Germany and other economic rivals. From the smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials and computer chips, innumerable products and services rely in some way on technology, measurement and standards provided by the National Institute of Standards and Technology.","3","2023-06-23 00:00:00","2023-07-26 20:15:08","NIST" +"137","National Science Foundation","","nsf","logo/nsf.jpg","https://www.nsf.gov/","The U.S. National Science Foundation is an independent federal agency that supports science and engineering in all 50 states and U.S. territories. NSF was established in 1950 by Congress to: a) Promote the progress of science. b) Advance the national health, prosperity and welfare. c) Secure the national defense.","1","2023-06-23 00:00:00","2023-07-26 20:15:09","NSF" +"138","Natural Sciences and Engineering Research Council","","nserc","logo/nserc.jpg","https://www.nserc-crsng.gc.ca/index_eng.asp","The Natural Sciences and Engineering Research Council of Canada funds visionaries, explorers and innovators who are searching for the scientific and technical breakthroughs that will benefit our country. We are Canada's largest supporter of discovery and innovation. We work with universities, colleges, businesses and not-for-profits to remove barriers, develop opportunities and attract new expertise to make Canada's research community thrive. We give Canadian scientists and engineers the means to go further because we believe in research without borders and beyond frontiers.","3","2023-06-23 00:00:00","2023-07-26 20:15:09","NSERC" +"139","Neosoma Inc.","","neosoma","logo/neosoma.jpg","https://www.neosomainc.com/","Every brain cancer patient is unique, and so is every brain tumor. Neuro-oncology teams need new tools and insights to advance the state of care. At Neosoma, our mission is to help clinicians improve outcomes by providing novel disease insights to physicians and clinical trials through innovative AI technology.","2","2023-06-23 00:00:00","2023-07-26 20:15:10","" +"140","Neurological Clinical Research Institute","NCRI-info@mgh.harvard.edu","ncri","","https://www.massgeneral.org/ncri","The Neurological Clinical Research Institute (NCRI) at Mass General is an academic research organization composed of innovative researchers experienced and passionate about designing, developing, facilitating, and conducting multicenter clinical trials in neurological diseases. Our goal is to develop new treatments for the patients we care for and for patients around the globe. We have particular expertise in ALS, Parkinson's disease and other neurodegenerative diseases.","1","2023-06-23 00:00:00","2023-07-26 20:15:11","NCRI" +"141","New York University","","nyc","logo/nyu.png","https://www.nyu.edu/","Since its founding in 1831, NYU has been an innovator in higher education, reaching out to an emerging middle class, embracing an urban identity and professional focus, and promoting a global vision that informs its 20 schools and colleges. Today, that trailblazing spirit makes NYU one of the most prominent and respected research universities in the world, featuring top-ranked academic programs and accepting fewer than one in eight undergraduates. Anchored in New York City and with degree-granting campuses in Abu Dhabi and Shanghai as well as 12 study away sites throughout the world, NYU is a leader in global education, with more international students and more students studying abroad than any other US university.","1","2023-06-23 00:00:00","2023-07-26 20:15:12","NYC" +"142","Northeast ALS Consortium","alstrials@neals.org","neals","logo/neals.jpg","https://www.neals.org/","The mission of the Northeast Amyotrophic Lateral Sclerosis Consortium(R) (NEALS) is to rapidly translate scientific advances into clinical research and new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and motor neuron disease.","2","2023-06-23 00:00:00","2023-07-26 20:15:12","NEALS" +"143","Northeastern University","","neu","logo/neu.jpg","https://www.northeastern.edu/","At Northeastern, experience is our essence and ethos. It's what you gain when you make the world your classroom, your laboratory, and your platform to create change or grow your enterprise. Throughout our university network, experience draws you into society and compels you to solve its complex challenges. It makes you agile and able to reinvent yourself. To find ways of doing things differently, and better. And to seize opportunities as they unfold—anytime, anywhere.","2","2023-06-23 00:00:00","2023-07-26 20:15:13","NEU" +"144","Northwestern University","","nu","logo/nu.jpg","https://www.northwestern.edu/","Northwestern is committed to excellent teaching, innovative research and the personal and intellectual growth of its students in a diverse academic community.","2","2023-06-23 00:00:00","2023-07-26 20:15:14","NU" +"145","Novo Nordisk","","novo-nordisk","logo/novo-nordisk.jpg","https://www.novonordisk-us.com/","For more than 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems. Our treatments today are helping millions of people living with diabetes, obesity, rare bleeding disorders and growth hormone-related disorders. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.","1","2023-06-23 00:00:00","2023-07-26 20:15:15","" +"146","Numerate","","numerate","","","This organization may no longer exist or has been merged under another organization.","1","2023-06-23 00:00:00","2023-08-08 17:59:10","" +"147","NVIDIA","","nvidia","logo/nvidia.png","https://www.nvidia.com/en-us/","NVIDIA pioneered accelerated computing to tackle challenges no one else can solve. Our work in AI and the metaverse is transforming the world's largest industries and profoundly impacting society.","4","2023-06-23 00:00:00","2023-07-26 20:15:16","" +"148","Ohio State University","webmaster@osu.edu","osu","logo/osu.png","https://www.osu.edu/","Discover the Ohio State difference. We create unrivaled experiences that bring together expertise, ideas and resources that improve communities locally and globally.","2","2023-06-23 00:00:00","2023-07-26 20:15:17","OSU" +"149","Ontario Institute for Cancer Research","info@oicr.on.ca","oicr","logo/oicr.svg","https://oicr.on.ca/","The Ontario Institute for Cancer Research helps close the gap between groundbreaking cancer discoveries and life-changing patient outcomes. OICR is a research institute that collaborates with partners across Ontario and around the world to accelerate the development of new cancer research discoveries and propel them from the lab to the clinic, bringing health and economic benefits to the people of Ontario.","6","2023-06-23 00:00:00","2023-07-26 20:15:18","OICR" +"150","Oregon Health and Science University","","ohsu","logo/ohsu.jpg","https://www.ohsu.edu/","OHSU is Oregon's only public academic health center. We are a system of hospitals and clinics across Oregon and southwest Washington. We are an institution of higher learning, with schools of medicine, nursing, pharmacy, dentistry and public health – and with a network of campuses and partners throughout Oregon. We are a national research hub, with thousands of scientists developing lifesaving therapies and deeper understanding. We are a statewide economic engine and Portland's largest employer. And as a public organization, we provide services for the most vulnerable Oregonians, and outreach to improve health in communities across the state.","11","2023-06-23 00:00:00","2023-07-26 20:15:19","OHSU" +"151","Oslo University Hospital","","ous","logo/ous.png","https://oslo-universitetssykehus.no/oslo-university-hospital","​Oslo University Hospital (OUS) ​is a highly specialised hospital in charge of extensive regional and local hospital assignments and the provision of high quality services for the citizens of Oslo. The hospital also has a nationwide responsibility for a number of national and multi-regional assignments and has several national centres of competence.","1","2023-06-23 00:00:00","2023-07-26 20:15:21","OUS" +"152","Pacific Northwest National Laboratory","","pnnl","logo/pnnl.png","https://www.pnnl.gov/","Pacific Northwest National Laboratory is a different kind of national lab. PNNL advances the frontiers of knowledge, taking on some of the world's greatest science and technology challenges. Distinctive strengths in chemistry, Earth sciences, biology, and data science are central to our scientific discovery mission. Our research lays a foundation for innovations that advance sustainable energy through decarbonization and energy storage and enhance national security through nuclear materials and threat analyses. PNNL collaborates with academia in fundamental research and with industry to transition technologies to market.","2","2023-06-23 00:00:00","2023-07-26 20:15:22","PNNL" +"153","Pfizer Inc.","","pfizer","logo/pfizer.jpg","https://www.pfizer.com/","We're in relentless pursuit of breakthroughs that change patients' lives. We innovate every day to make the world a healthier place. It was Charles Pfizer's vision at the beginning and it holds true today.","1","2023-06-23 00:00:00","2023-07-26 20:15:22","" +"154","Prize4Life","","prize4life","logo/prize4life.jpeg","http://www.prize4life.org","This organization may no longer exist or has been merged under another organization. ======== Prize4Life seeks to create breakthroughs in effective treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease) using the leverage of large inducement prizes. Instead of recognizing historical accomplishments, Prize4Life has a simple formula for transformational change. We design and launch prizes that we believe are achievable in a 2-3 year timeframe and then recruit teams to compete for the prize purse. The first team to find and demonstrate the required breakthrough wins the prize.","2","2023-06-23 00:00:00","2023-08-08 17:45:38","" +"155","Project Data Sphere","","project-data-sphere","logo/project-data-sphere.jpg","https://www.projectdatasphere.org/","At Project Data Sphere®, we believe in breaking down barriers to cancer clinical trial data sharing — barriers that historically have kept valuable trial data from ultimately benefitting the patients who so selflessly participate in them. By aggregating trial data from biopharmaceutical companies, academic medical centers, and government organizations and making it freely available on our open-access platform, we have established ourselves as a premier resource for the global oncology research community. Our deep relationships with renowned oncology experts allow us to convene research collaborations that leverage the power of pooled clinical trial data and which ultimately position PDS to be a catalyst for the discovery of urgently needed new treatments while helping to make cancer trials faster, more effective, and less expensive.","1","2023-06-23 00:00:00","2023-07-26 20:15:26","" +"156","Prostate Cancer Canada","","prostate-cancer-canada","logo/prostate-cancer-canada.png","https://cancer.ca/en/","At the Canadian Cancer Society, we are committed to improving and saving lives. That's why we are always looking for new ways to prevent cancer, find it early and treat it more successfully. It's why we're always ready to give people with cancer the help and support they need to lead more fulfilling lives.","2","2023-06-23 00:00:00","2023-07-26 20:15:27","" +"157","Prostate Cancer Foundation","","pcf","logo/pcf.jpg","https://www.pcf.org/","The Prostate Cancer Foundation (PCF) funds the world's most promising research to improve the prevention, detection, and treatment of prostate cancer and ultimately cure it for good.","1","2023-06-23 00:00:00","2023-07-26 20:15:28","PCF" +"158","Providence Health and Services","","providence","logo/providence.jpg","https://www.providence.org/en","At Providence we see more than patients, we see the life that pulses through us all. That's why we're dedicated to a holistic approach to medicine that employs not only the most advanced treatments to improve outcomes, but also puts compassion and humanity at the heart of every interaction.","1","2023-06-23 00:00:00","2023-07-26 20:15:29","" +"159","QIMR Berghofer Medical Research Institute","","qimr-berghofer","logo/qimr-berghofer.jpg","https://www.qimrberghofer.edu.au/","From humble beginnings in 1945, the Queensland Institute of Medical Research, now known as QIMR Berghofer, is one of Australia's most successful medical research institutes, translating discoveries from bench to bedside for a better future of health.","1","2023-06-23 00:00:00","2023-07-26 20:15:30","" +"160","Queen's University","","queensu","logo/queensu.jpg","https://www.queensu.ca/","We stand on a strong history of scholarship, discovery, and innovation. nOur education transforms Queen's students. Our diversity enriches the community. Our research changes the world. Together, we are tackling humanity's greatest challenges.","1","2023-06-23 00:00:00","2023-07-26 20:15:31","" +"161","Radboud University Medical Center","","radboud-umc","logo/radboud-umc.jpeg","https://www.radboudumc.nl/en/research","Radboud university medical center specializes in patient care, scientific research, teaching and training. Our mission is to have a significant impact on health care. We aim to be pioneers in shaping the health care of the future. We do this in a person-centered and innovative way.","3","2023-06-23 00:00:00","2023-07-26 20:15:31","" +"162","Radiological Society of North America","","rsna","logo/rsna.png","https://www.rsna.org/","The Radiological Society of North America (RSNA(R)) is an international society of radiologists, medical physicists and other medical professionals with more than 53,400 members from 136 countries across the globe. RSNA hosts the world's premier radiology forum, drawing approximately 55,000 attendees annually to McCormick Place in Chicago, and publishes two top peer-reviewed journals: *Radiology*, the highest-impact scientific journal in the field, and *RadioGraphics*, the only journal dedicated to continuing education in radiology. The Society is based in Oak Brook, Ill.","3","2023-06-23 00:00:00","2023-07-26 20:15:33","RSNA" +"164","Ray and Dagmar Dolby Family Fund","info@dolbyventures.com","dolby-family-ventures","logo/dolby-family-ventures.jpg","http://www.dolbyventures.com/","Dolby Family Ventures is an early stage venture firm focused on building great technology companies. We partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company's development. The fund honors the legacy of Ray Dolby and his commitment to engineers and their vision to solve the world's toughest problems. Dolby Family Ventures formalizes the Dolby family's ongoing multi-generational commitment to supporting talented entrepreneurs. We work actively with entrepreneurs to implement best practices in operational finance, strategy, and board development processes.","1","2023-06-23 00:00:00","2023-07-26 20:15:34","" +"165","Rice University","","rice","logo/rice.jpg","https://www.rice.edu/","Located in an urban environment on a 300-acre tree-lined campus, Rice University seizes its advantageous position to pursue pathbreaking research and create innovative collaboration opportunities that contribute to the betterment of our world.","1","2023-06-23 00:00:00","2023-07-26 20:15:35","" +"166","Robert Wood Johnson Foundation","","rwjf","logo/rwjf.jpg","https://www.rwjf.org/","RWJF works in collaboration with policymakers, business leaders, community groups and many others. Together, we share a common interest in addressing the many harmful obstacles to wellbeing, including poverty, powerlessness, and discrimination, and advancing health equity for all. We focus on identifying, illuminating, and addressing barriers to health, particularly those caused by structural racism and its intersection with other forms of discrimination, including sexism, ableism, and prejudice based on sexual orientation. We lean on evidence to advance health equity. We cultivate leaders who work individually and collectively across sectors to address health equity. We promote policies, practices, and systems change to dismantle the structural barriers to wellbeing created by racism. And we work to amplify voices to shift national conversations and attitudes about health and health equity.","1","2023-06-23 00:00:00","2023-07-26 20:15:35","RWJF" +"167","Rockefeller University","","rockefeller","logo/rockefeller.jpg","https://www.rockefeller.edu/","The world's leading biomedical research university, Rockefeller draws top scientists and graduate students from around the world in pursuit of one mission: to conduct science for the benefit of humanity.","1","2023-06-23 00:00:00","2023-07-26 20:15:36","" +"168","Rosenberg Alzheimer's Project","","rosenberg-alzheimers-project","","","This organization may no longer exist or has been merged under another organization.","1","2023-06-23 00:00:00","2023-08-08 17:59:30","" +"169","Rush University Medical Center","","rush","logo/rush.jpg","https://www.rush.edu/","Rush University System for Health is consistently recognized for our outstanding patient care, education, research and community partnerships. Learn more about our mission, history, policies and leadership.","1","2023-06-23 00:00:00","2023-07-26 20:15:38","RUSH" +"170","RWTH Aachen University","","rwth-aachen","logo/rwth-aachen.png","https://www.rwth-aachen.de/go/id/a/?lidx=1","RWTH Aachen University is a place where the future of our industrialised world is thought out. The University is proving to be a hotspot with increasing international recognition where innovative answers to global challenges are developed.","8","2023-06-23 00:00:00","2023-07-26 20:15:39","" +"171","Sage Bionetworks","info@sagebase.org","sage","logo/sage-bionetworks.png","https://sagebionetworks.org/","Sage Bionetworks is a nonprofit health research organization that is speeding the translation of science into medicine. We believe that high-quality, well-annotated data acts as the foundation of modern biomedical innovation. We dream of a world where people work together across institutional boundaries to meaningfully address major medical research problems. We incubate new ways for diverse groups of people to practice research together. We advance our practices using an integrated and iterative design cycle that plays out between our scientific teams and our core service teams. As our innovations become norms, we develop them into robust core capabilities that can be put into practice across our portfolio of research programs. This portfolio includes publicly funded programs that create data resources and knowledge bases, pre-competitive collaborations across industry partners, and federated networks of healthcare data providers. In turn, these projects provide an active p...","48","2023-06-23 00:00:00","2023-07-26 20:15:40","" +"172","Sanofi","","sanofi","logo/sanofi.jpg","https://www.sanofi.com/","We are Sanofi. We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world's poorest countries.","2","2023-06-23 00:00:00","2023-07-26 20:15:41","" +"173","Sapienza University of Rome","","sapienza","logo/sapienza.png","https://www.uniroma1.it/en/pagina-strutturale/home","Founded in 1303, Sapienza is the oldest university in Rome and the largest in Europe. Its mission is to contribute to the development of a knowledge society through research, excellence, quality education and international cooperation.","3","2023-06-23 00:00:00","2023-07-26 20:15:43","" +"174","Sartorius AG","","sartorius","logo/sartorius.jpg","https://www.sartorius.com/en","Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services.","1","2023-06-23 00:00:00","2023-07-26 20:15:42","" +"175","Seattle Cancer Care Alliance","","scca","logo/fred-hutch.jpg","https://www.seattlecca.org/","SCCA is now Fred Hutchinson Cancer Center, an independent, nonprofit cancer care and research center that also serves as the cancer program for UW Medicine. The superior care you have come to expect will continue uninterrupted.","1","2023-06-23 00:00:00","2023-07-26 20:15:43","SCCA" +"176","Semmelweis University","","semmelweis-university","logo/semmelweis-university.png","https://semmelweis.hu/english/","Semmelweis University is a leading institution of higher education in Hungary and the Central European region within the area of medicine and health sciences. Its main commitment is based on the integrity of education, research and healing, which make Semmelweis University an internationally renowned centre of knowledge.","2","2023-06-23 00:00:00","2023-07-26 20:15:43","" +"177","Sentieon","​info@sentieon.com","sentieon","logo/sentieon.jpg","https://www.sentieon.com/","Sentieon(R), incorporated in July 2014, develops highly-optimized algorithms for bioinformatics applications, using the team's expertise in algorithm, software, and system optimization. Sentieon(R) is a team of professionals experienced in image processing, telecom, computational lithography, large-scale data mining, and bioinformatics. Using our accumulated expertise in modeling, optimization, machine learning, and high-performance computing, we strive to enable precision data for precision medicine.","1","2023-06-23 00:00:00","2023-07-26 20:15:44","" +"178","Siemens Healthineers","","siemens-healthineers","logo/siemens-healthineers.jpg","https://www.siemens-healthineers.com/","We pioneer breakthroughs in healthcare. For everyone. Everywhere.","1","2023-06-23 00:00:00","2023-07-26 20:15:45","" +"179","Stanford University","","stanford","logo/stanford.jpg","https://www.stanford.edu/","Stanford was founded almost 150 years ago on a bedrock of societal purpose. Our mission is to contribute to the world by educating students for lives of leadership and purposeful contribution; advancing fundamental knowledge and cultivating creativity; and accelerating solutions and amplifying their impact.","13","2023-06-23 00:00:00","2023-07-26 20:15:46","" +"180","Swiss Initiative in Systems Biology","admin@systemsx.ch","systemsx","logo/systemsx.jpg","http://www.systemsx.ch/","SystemsX.ch is the largest ever public research initiative in Switzerland and focuses specifically on a broad topical area of basic research. The initiative advances systems biology in our country with the claim of belonging to the best in the world in this area of research.","1","2023-06-23 00:00:00","2023-07-26 20:15:47","" +"181","Takeda","","takeda","logo/takeda.jpg","https://www.takeda.com/en-us/","Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan.","2","2023-06-23 00:00:00","2023-07-26 20:15:48","" +"182","Texas Biomedical Research Institute","","texas-biomedical-research-institute","logo/texas_biomed.png","https://www.txbiomed.org/","Texas Biomedical Research Institute is pioneering and sharing scientific breakthroughs to protect you, your families and our global community from the threat of infectious diseases. The Institute has an 80-year history of success that includes work on the first COVID-19 vaccine and therapies, the first Ebola treatment, the first Hepatitis-C therapy, and thousands of developmental discoveries. Texas Biomed helps create healthier communities with science that inspires new generations through STEM education programs, delivers jobs and economic impact in our community and heals through innovative research. Learn more about how you can #Stand4Science.","1","2023-06-23 00:00:00","2023-07-26 20:15:50","" +"183","The University of California-Davis","","uc-davis","logo/uc_davis.png","https://www.ucdavis.edu/","We grow California. UC Davis was founded in 1908 to serve the state of California. We do and we always will. And today, the seed that was planted those years ago has grown into one of the world's top universities.","2","2023-06-23 00:00:00","2023-07-26 20:15:51","" +"184","The University of Texas at Austin","","ut","logo/ut-austin.svg","https://www.utexas.edu/","Like the state it calls home, The University of Texas at Austin is a bold, ambitious leader supporting some 52,000 diverse students, 3,000 teaching faculty, and top national programs across 18 colleges and schools. As Texas' leading research university, UT attracts more than $650 million annually for discovery. Amid the backdrop of Austin, Texas, a city recognized for its creative and entrepreneurial spirit, the university provides a place to explore countless opportunities for tomorrow's artists, scientists, athletes, doctors, entrepreneurs and engineers.","1","2023-06-23 00:00:00","2023-07-26 20:15:52","UT" +"185","Thomas Jefferson University Hospital","","jefferson-health","logo/jefferson.jpeg","https://hospitals.jefferson.edu/","We are Jefferson. At Jefferson Health, we are reimagining health care through our service-minded and diverse community of providers and specialists. Our mission is to improve lives. We strive to be bold and innovative, while putting your health and safety first. Each day, we are focused on you.","2","2023-06-23 00:00:00","2023-07-26 20:15:52","" +"186","TracInnovations","info@tracinno.dk","tracinnovations","logo/tracinnovations.webp","https://tracinnovations.com/","TracInnovations is a Danish company established in 2015 focusing on innovative solutions for image based diagnosis and treatment. TracInnovations has developed the Tracoline system, which is a MRI Markerless Motion Tracker and Monitor System that unnoticed records patient's head movements during brain scans.","1","2023-06-23 00:00:00","2023-07-26 20:15:53","" +"187","Trinity College Institute of Neuroscience","neuroscience@tcd.ie","tcd---neuroscience","logo/tcd.png","https://www.tcd.ie/Neuroscience/","The Trinity College Institute of Neuroscience (TCIN) is a Trinity Research Institute (TRI) with 50 Principal Investigators and 250 researchers from a wide range of disciplines including Psychology, Psychiatry, Physiology, Pharmacology, Medicine, Biochemistry, Engineering, and Genetics, among others. These diverse disciplinary origins contribute to its core activities: promoting and supporting interdisciplinary basic and translational research, as well as teaching, public engagement, and national leadership in Neuroscience.","1","2023-06-23 00:00:00","2023-07-26 20:15:53","" +"188","Tulane University","","tulane","logo/tu_new_shield.svg","https://tulane.edu/","Tulane's motto — non sibi, sed suis — embodies who we are and what we stand for. We are entrepreneurs on the front lines of life-changing technologies, as well as hometown heroes. Tulanians see challenges as opportunities, and strive to improve the lives of others in our own community and around the globe.","1","2023-06-23 00:00:00","2023-07-26 20:15:54","" +"189","U.S. Food and Drug Administration","","fda","logo/fda.svg","https://www.fda.gov/home","The Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. FDA also plays a significant role in the Nation's counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to r...","12","2023-06-23 00:00:00","2023-07-26 20:15:55","FDA" +"190","UNC Eshelman School of Pharmacy","","unc-eshelman-school-of-pharmacy","logo/unc.png","https://pharmacy.unc.edu/","Everything we do begins and ends with a patient in mind. Developing leaders in pharmacy education, pharmacy practice and pharmaceutical sciences who make a difference in human health worldwide.","1","2023-06-23 00:00:00","2023-07-26 20:15:56","" +"191","University of Alabama","","ua","logo/ua.png","https://www.ua.edu/","We are dedicated to excellence in teaching, research and service. We provide a robust campus environment where our students can reach their greatest potential while learning from the best and brightest faculty and making a positive difference in the community, the state and the world.","1","2023-06-23 00:00:00","2023-07-26 20:15:57","UA" +"192","University of Alabama at Birmingham","","uab","logo/uab.jpg","https://www.uab.edu/home/","At UAB, we have never settled on merely finding what's next—we have helped build the future through new ideas and initiatives in the classroom, the laboratory, the studio and the clinic.","1","2023-06-23 00:00:00","2023-07-26 20:15:58","UAB" +"193","University of Arkansas for Medical Sciences","","uams","logo/uams.jpg","https://www.uams.edu/","By 2029, the University of Arkansas for Medical Sciences (UAMS) will lead Arkansas to be the healthiest state in the region through its synergies of education, clinical care, research and purposeful leadership. With this bold statement, UAMS resolved that in the coming decade its status as Arkansas' only academic health system will allow it to deliver dramatic and lasting health and health care improvements to its home state. Aiding in this vision will be its statewide network of campuses for public education and clinical outreach, along with cores of expertise in medical specialties, population health, digital health, health informatics and translational research.","1","2023-06-23 00:00:00","2023-07-26 20:15:59","UAMS" +"194","University of Basel","","university-of-basel","logo/uni_basel.svg","https://www.unibas.ch/en.html","As a comprehensive university offering a wide range of high-quality educational opportunities, the University of Basel attracts students from Switzerland and the entire world, offering them outstanding studying conditions as they work towards their bachelor's, master's or PhD degrees. Today, the University of Basel has around 13,000 students from over a hundred nations, including 2,900 PhD students. The University of Basel has seven faculties covering a wide spectrum of academic disciplines. At the same time, the university has positioned itself amidst the international competition in the form of five strategic focal areas: Life Sciences, Visual Studies, Nanosciences, Sustainability and Energy Research and European and Global Studies. In international rankings, the University of Basel is regularly placed among the 100 top universities in the world thanks to its research achievements. The University of Basel has deep roots in the economically powerful and culturally rich Basel re...","3","2023-06-23 00:00:00","2023-07-26 20:15:59","" +"195","University of California, San Diego","","ucsd","logo/ucsd.png","https://ucsd.edu/","We make changemakers. Recognized as one of the top 15 research universities worldwide, our culture of collaboration sparks discoveries that advance society and drive economic impact. Everything we do is dedicated to ensuring our students have the opportunity to become changemakers, equipped with the multidisciplinary tools needed to accelerate answers to our world's most pressing issues.","3","2023-06-23 00:00:00","2023-08-08 18:48:47","UCSD" +"196","University of California, San Francisco","","ucsf","logo/ucsf.svg","https://www.ucsf.edu/","At UC San Francisco, we are driven by the idea that when the best research, the best teaching and the best patient care converge, we can deliver breakthroughs that help heal the world. Excellence is in our DNA. From genomics and immunology to specialty care for women and children, UCSF brings together the world's leading experts in nearly every area of health. We are home to five Nobel laureates who have advanced the understanding of cancer, neurodegenerative diseases, aging and stem cells. Our hospitals and educational programs consistently rank among the best in the country, according to the latest surveys by U.S. News & World Report. We are the leading university dedicated exclusively to the health sciences.","6","2023-06-23 00:00:00","2023-08-08 18:48:39","UCSF" +"197","University of California, Santa Cruz","","ucsc","logo/uc-santa-cruz-2021.svg","https://www.ucsc.edu/","An inspired, global, public research university leading at the intersection of innovation and justice.","6","2023-06-23 00:00:00","2023-08-08 18:48:44","UCSC" +"198","University of Cincinnati","","uc","logo/uc.png","https://www.uc.edu/","The University of Cincinnati offers students a balance of educational excellence and real-world experience. UC is a public research university with an enrollment of nearly 48,000 students and is ranked No. 4 in the nation for co-ops and internships by U.S. News & World Report (No. 1 among public institutions). Today, more than 315,000 living alumni count themselves as Bearcats — united not just by their loyalty to our nationally known sports teams, but by their common love of the place, the people and the ideas that make up the University of Cincinnati.","1","2023-06-23 00:00:00","2023-07-26 20:16:03","UC" +"199","University of Colorado Anschutz Medical Campus","","cu-anschutz","logo/cu_anschutz.svg","https://www.cuanschutz.edu/","The ​University of Colorado Anschutz Medical Campus is the largest academic health center in the Rocky Mountain region at the forefront of transformative education, science, medicine and healthcare. The campus includes the University of Colorado health professional schools, multiple centers and institutes and two nationally ranked hospitals, UCHealth University of Colorado Hospital and Children's Hospital Colorado, which treat nearly 2 million patients each year. All interconnected, these organizations collaboratively improve the quality of patient care they deliver, research they conduct and health professionals they train.","4","2023-06-23 00:00:00","2023-07-26 20:16:03","" +"200","University of Connecticut","","uconn","logo/uconn.png","https://uconn.edu/","Learning and academics are about exploring the things that interest you, growing with that knowledge, and finding the path on which you'll be most successful. With 14 schools and colleges and more than 115+ undergraduate majors, you'll find what you're looking for at UConn. And what if you come up with something unique to study? You can create your own major. Whether you want to learn from the past by studying history or you want to set the course for the future with groundbreaking scientific research, learning opportunities here abound. Challenge yourself to reach new academic heights in rigorous courses taught by our expert faculty. Take advantage of undergraduate research awards including the Summer Undergraduate Research Fund or UConn IDEA Grants; study in a lab; or pursue a creative endeavor. Push yourself further, supplementing traditional coursework with enrichment such as Education Abroad or our acclaimed Honors Program. Whatever you choose, we're here to help you find y...","1","2023-06-23 00:00:00","2023-07-26 20:16:05","UCONN" +"201","University of Houston","","uh","logo/uh-primary.svg","https://www.uh.edu/","At the University of Houston, we spur innovation by encouraging the very spark of an idea to the transfer of knowledge and technology. The UH innovation ecosystem has a rich history of advancing Houston's innovation economy.","1","2023-06-23 00:00:00","2023-07-26 20:16:06","UH" +"202","University of Illinois Urbana-Champaign","","uiuc","logo/wordmark_horizontal.png","https://illinois.edu/","Illinois students, scholars, and alumni are a community with the power to change the world. With our land-grant heritage as a foundation, we pioneer innovative research that tackles global problems and expands the human experience. Our transformative learning experiences, in and out of the classroom, are designed to produce alumni who desire to make a significant, societal impact.","1","2023-06-23 00:00:00","2023-07-26 20:16:07","UIUC" +"203","University of Kent","","kent","logo/ukent.jpeg","https://www.kent.ac.uk/","Welcome to the university of ambition where desire meets determination. We stand for ambition, with our diverse community of staff and students committed to making a difference at regional, national and global level. It's something we're very proud of.","1","2023-06-23 00:00:00","2023-07-26 20:16:07","" +"204","University of Kentucky","","uk","logo/uky.png","http://www.uky.edu/","The University of Kentucky has a broad range of resources centered on a single campus in the heart of the Bluegrass. Our wide array of programs allows us to excel in multidisciplinary studies and fosters an environment of cooperative engagement across all colleges, programs, and research endeavors. Because of the lives we touch and teach, we remain anchored in our mission to Kentucky– to educate, innovate, heal, and serve. To be sure, our complex, multi-faceted mission looks different today in many ways than it did in 1865. However, our sense of responsibility to our communities on campus and across the region is resolute. The mission has evolved and grown. The vision of service to our Commonwealth and the world beyond remains the same. They remain our compass – the soul of the University of Kentucky.","1","2023-06-23 00:00:00","2023-07-26 20:16:19","UK" +"205","University of Lausanne","","unil","logo/unil-logo.svg","https://www.unil.ch/central/en/home.html","The University of Lausanne is a higher teaching and research institution composed of seven faculties with approximately 17,100 students and about 4,400 research, teaching and technical staff. Its research activities focus on three main themes: human and social sciences, life sciences and medicine, and environmental sciences. UNIL lays great store by the quality and innovation of its teaching. This is characterised by a highly interdisciplinary approach which is even reflected in the organisation of its faculties.","2","2023-06-23 00:00:00","2023-07-26 20:16:09","UNIL" +"206","University of Lisbon","","ulisboa","logo/ulisboa.png","https://www.ulisboa.pt/en","Universidade de Lisboa (ULisboa) is the largest and most prestigious university in Portugal and is one of Europe's leading universities. Heir to a university tradition that spans over seven centuries, ULisboa acquired its current status in July 2013, following the merger of the former Universidade Técnica de Lisboa and Universidade de Lisboa. ULisboa brings together various areas of knowledge and has a privileged position for facilitating the contemporary evolution of science, technology, arts and humanities. The quality of teaching, research, innovation and culture of ULisboa is attracting an ever increasing amount of talent from around the world.","2","2023-06-23 00:00:00","2023-07-26 20:16:10","" +"207","University of London","","uol","logo/uol.jpg","https://london.ac.uk/","The University of London is the UK's leading provider of digital and blended distance education internationally, offering programmes to 45,000 students in 190 countries around the world. Although proudly rooted in London, our community and impact are global. We are a national leader in the humanities, and we promote their value to society and the economy through knowledge creation and exchange. We are also a federation of 17 esteemed higher education institutions, with collaboration at the heart of our ethos. The University of London federation is a collective community of more than 240,000 learners and 50,000 staff, delivering world-leading research across all disciplines. Our passion for increasing access to education and mobilising the collective power and expertise of the federation is central to our ability to transform lives around the world and address the global challenges of the future.","2","2023-06-23 00:00:00","2023-07-26 20:16:10","UoL" +"208","University of Luxembourg","","university-of-luxembourg","logo/university-of-luxembourg.png","https://wwwen.uni.lu/","Founded in 2003, the University of Luxembourg is the only public university of the Grand Duchy of Luxembourg. Multilingual, international and research-oriented, it is also a modern institution with a personal atmosphere.","1","2023-06-23 00:00:00","2023-07-26 20:16:11","" +"209","University of Maryland","","umd","logo/umd.png","https://www.umd.edu/","The University of Maryland, College Park is the state's flagship university and one of the nation's preeminent public research universities. A global leader in research, entrepreneurship and innovation, the university is home to more than 40,700 students, 14,000 faculty and staff, and nearly 400,000 alumni all dedicated to the pursuit of Fearless Ideas. Located just outside Washington, D.C., we discover and share new knowledge every day through our renowned research enterprise and programs in academics, the arts and athletics. And we are committed to social entrepreneurship as the nation's first “Do Good” campus.","3","2023-06-23 00:00:00","2023-07-26 20:16:12","UMD" +"210","University of Michigan","","umich","logo/block-m-maize.png","https://umich.edu/","Welcome to the University of Michigan, a place with deep traditions focused on creating brighter futures. We invite you to explore the diverse and vibrant community that makes us the home of Leaders & Best. More than any other university, we have the potential to be so much more than the sum of our many excellent parts. It's this potential to have a positive impact on the society we serve that represents our greatest value as a university.","1","2023-06-23 00:00:00","2023-07-26 20:16:14","" +"211","University of North Carolina at Chapel Hill","","unc","logo/univ-unc.png","https://www.unc.edu/","The nation's first public university is at the heart of what's next, preparing a diverse student body to become creators, explorers, innovators and leaders in North Carolina and throughout the world. Carolina's nationally recognized, innovative teaching, campus-wide spirit of inquiry and dedication to public service continue the legacy that began in 1795 when the University first opened its doors to students. In Chapel Hill, students develop a voice for critical thought and the courage to guide change. They connect to the future they're already shaping. Carolina is committed to access for all, providing life-changing opportunities such as the Carolina Covenant, which promises a debt-free education to low-income students. In its third century – an era of groundbreaking study and research – UNC-Chapel Hill is harnessing the very best of our fast-changing world. We're proud to advance knowledge for this and each generation to come.","4","2023-06-23 00:00:00","2023-07-26 20:16:15","UNC" +"212","University of Notre Dame","","notre-dame","logo/notre_dame.png","https://www.nd.edu/","The University of Notre Dame was founded in November 1842 by Rev. Edward F. Sorin, C.S.C., a priest of the Congregation of Holy Cross, a French missionary order. It is located adjacent to South Bend, Indiana, the center of a metropolitan area with a population of more than 315,000. Chartered by the state of Indiana in 1844, the University was governed by the Holy Cross priests until 1967, when governance was transferred to a two-tiered, mixed board of lay and religious trustees and fellows. Notre Dame has grown from the vision of Father Sorin, who sought to establish a great Catholic university in America, and has remained faithful to both its religious and intellectual traditions. Today, we seek to be an enlightening force for a world deeply in need. Our departments of theology and philosophy are regarded as among the finest in the world while faculty in all departments participate in our mission to ensure that Notre Dame's Catholic character informs all of our endeavors. From l...","0","2023-06-23 00:00:00","2023-07-26 20:16:15","" +"213","University of Padova","","university-of-padova","logo/university-of-padua.jpg","https://www.unipd.it/en/","The University of Padua is one of Europe's oldest and most prestigious seats of learning. As a multi-disciplinary institute of higher education, the University aims to provide its students with professional training and a solid cultural background. The qualification received from the University of Padua act as a symbol of the ambitious objectives respected and coveted by both students and employers alike. Founded in 1222, Padua's Studium Patavinum was a place of study that readily welcomed Italian students and scholars, as well as those from various European countries searching for cultural freedom and expression. This freedom continues to define and express the essence of the University through its motto as Universa universis patavina libertas.","2","2023-06-23 00:00:00","2023-07-26 20:16:16","" +"214","University of Padua","","university-of-padua","logo/university-of-padua.jpg","https://www.unipd.it/en/","The University of Padua is one of Europe's oldest and most prestigious seats of learning. As a multi-disciplinary institute of higher education, the University aims to provide its students with professional training and a solid cultural background. The qualification received from the University of Padua act as a symbol of the ambitious objectives respected and coveted by both students and employers alike. Founded in 1222, Padua's Studium Patavinum was a place of study that readily welcomed Italian students and scholars, as well as those from various European countries searching for cultural freedom and expression. This freedom continues to define and express the essence of the University through its motto as Universa universis patavina libertas.","1","2023-06-23 00:00:00","2023-07-26 20:16:17","" +"215","University of Pennsylvania","","upenn","logo/upenn.png","https://www.upenn.edu/","Penn's academics are boosted by its inherent culture and ecosystem of innovation. You name it, if it's cutting-edge, the University's faculty—and students—have their hands in it. Grounded in the liberal arts and sciences and enriched by the integrated resources of four undergraduate and 12 graduate schools, Penn offers students an unparalleled education informed by inclusivity, intellectual rigor, research, and the impetus to create new knowledge to the benefit of individuals and communities around the world.","6","2023-06-23 00:00:00","2023-07-26 20:16:17","" +"216","University of Rochester","","rochester","logo/rochester.jpeg","https://www.rochester.edu/","One of the world's leading research universities, Rochester has a long tradition of breaking boundaries—always pushing and questioning, learning and unlearning. We transform ideas into enterprises that create value and make the world ever better.","2","2023-06-23 00:00:00","2023-07-26 20:16:18","" +"217","University of South Florida","","usf","logo/usf.png","https://www.usf.edu/","Welcome to the University of South Florida. Though a relatively young university, founded in 1956, we have rich traditions – traditions of access and opportunity for students, of academic excellence, of groundbreaking research, of serving our communities.","1","2023-06-23 00:00:00","2023-07-26 20:16:19","USF" +"218","University of Southampton","","university-of-southampton","logo/university-of-southampton.png","https://www.southampton.ac.uk/","As a global top 100 university, our expert academics and wide range of study options will help you achieve your goals.","1","2023-06-23 00:00:00","2023-07-26 20:16:21","" +"219","University of Texas Southwestern Medical Center","","ut-southwestern","logo/ut-swestern.gif","https://www.utsouthwestern.edu/","UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution's faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. The faculty of more than 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.","2","2023-06-23 00:00:00","2023-07-26 20:16:21","" +"220","University of Toronto","","utoronto","logo/utoronto.png","https://www.utoronto.ca/","We are proud to be one of the world's top research-intensive universities, bringing together top minds from every conceivable background and discipline to collaborate on the world's most pressing challenges. Our community is a catalyst for discovery, innovation and progress, creating knowledge and solutions that make a tangible difference around the globe. And we prepare our students for success through an outstanding global education rooted in excellence, inclusion and close-knit learning communities. The ideas, innovations and contributions of more than 660,000 graduates advance U of T's impact on communities across the globe. Together, we continue to defy gravity by taking on what might seem unattainable today and generating the ideas and talent needed to build a more equitable, sustainable and prosperous future.","8","2023-06-23 00:00:00","2023-07-26 20:16:21","U of T" +"221","University of Vermont","","uvm","logo/the-university-of-vermont.png","https://www.uvm.edu/","UVM is a top research university of ideal size, large enough to offer a breadth of ideas, resources, and opportunities, yet scaled to enable close faculty-student mentorship across all levels of study, from bachelor's to doctoral programs.","1","2023-06-23 00:00:00","2023-07-26 20:16:22","UVM" +"222","University of Verona","relazioni.internazionali@ateneo.univr.it","university-of-verona","logo/university-of-verona.png","https://www.univr.it/en/international","","1","2023-06-23 00:00:00","2023-07-26 20:16:22","" +"223","University of Virginia","","uva","logo/uva_primary_logo.jpg","https://www.virginia.edu/","The University is an iconic public institution of higher education, boasting nationally ranked schools and programs, diverse and distinguished faculty, a major academic medical center and proud history as a renowned research university. The community and culture of the University are enriched by active student self-governance, sustained commitment to the arts and a robust NCAA Division I Athletics program.","1","2023-06-23 00:00:00","2023-07-26 20:16:24","UVA" +"224","University of Washington","","uw","logo/uw.svg","https://www.washington.edu/","Since our founding in 1861, the University of Washington has been a hub for learning, innovation, problem solving and community building. Driven by a mission to serve the greater good, our students, faculty and staff tackle today's most pressing challenges with courage and creativity, making a difference across Washington state — and around the world.","7","2023-06-23 00:00:00","2023-07-26 20:16:25","UW" +"225","University of Wisconsin-Madison","","uw-madison","logo/uw-logo.png","https://www.wisc.edu/","Since its founding in 1848, this campus has been a catalyst for the extraordinary. As a public land-grant university and major research institution, our students, staff, and faculty engage in a world-class education while solving real-world problems. With public service — or as we call it, the Wisconsin Idea — as our guiding principle, Badgers are creating a better future for everyone.","1","2023-06-23 00:00:00","2023-07-26 20:16:26","" +"226","University of Zurich","","uzh","logo/uzh.png","https://www.uzh.ch/en.html","With its 28,000 enrolled students, the University of Zurich is Switzerland's largest university. Founded in the year 1833, UZH was Europe's first university to be established by a democratic political system. Made up of seven faculties covering some 100 different subject areas, the University offers a wide variety of Bachelor's, Master's and PhD programs.","4","2023-06-23 00:00:00","2023-07-26 20:16:26","UZH" +"227","Urban Green Energy","","uge","logo/ugei-logo.svg","https://www.ugei.com/","Since 2008 when our journey began, we've been focused on expanding utilization of renewable energy. In our early days, we worked on finding use cases for clean energy technologies before they were widely adopted, building projects ranging from wind and solar microgrids in remote locations, to lighting the Eiffel Tower with 100% renewable energy in 2014. Over time we turned our focus entirely to solar and battery storage in the U.S. where we're building a growing portfolio of distributed energy assets, Leaning on more than a decade of experience across 700 projects totaling more than 500 megawatts, we're proud to be making a significant impact on the world's transition to clean energy, and we're just getting started.","1","2023-06-23 00:00:00","2023-07-26 20:16:28","UGE" +"228","US Army Medical Research Institute of Infectious Diseases","","usamriid","logo/usarmy.png","https://www.usamriid.army.mil/","","1","2023-06-23 00:00:00","2023-07-26 20:16:28","USAMRIID" +"229","VA Durham Health Care","","va-durham-health-care","logo/va-logo-white.png","https://www.durham.va.gov/","Since 1953, Durham Veterans Affairs Medical Center has been improving the health of the men and women who have so proudly served our nation. We consider it our privilege to serve your healthcare needs in any way we can. Services are available to more than 200,000 Veterans living in a 27-county area of central and eastern North Carolina. The VA Durham Healthcare System provides you with outstanding health care, trains America's future health care providers, and conducts important medical research.","2","2023-06-23 00:00:00","2023-07-26 20:16:29","" +"230","Verily","info@verily.com","verily","logo/verily.jpeg","https://verily.com/","True, comprehensive health is expanding exponentially. Massive increases in health information & computing power are coinciding with health challenges of a scale & magnitude we've never seen—creating urgency for value-based care and improved outcomes for all. Precision health represents a fundamental shift to health and to care that is more individualized, accessible, and affordable.","1","2023-06-23 00:00:00","2023-07-26 20:16:29","" +"231","VHA Innovation Ecosystem","","vha-ie","logo/vaInnovation.jpeg","https://www.innovation.va.gov/ecosystem/views/home.html","VHA Innovation Ecosystem (VHA IE) is the catalyst for enabling the discovery and spread of mission-driven health care innovation that exceeds expectations, restores hope, and builds trust within the Veteran community. VHA IE leverages the collective power of innovation champions from across VA, academia, non-profit and industry to operationalize innovation in the Nation's largest integrated health care system.","3","2023-06-23 00:00:00","2023-07-26 20:16:31","VHA IE" +"232","Washington University in St. Louis","","wustl","logo/wustl.png","https://wustl.edu/","At WashU, we generate, disseminate, and apply knowledge. We foster freedom of inquiry and expression of ideas in our research, teaching and learning. We aim to create an environment that encourages and supports wide-ranging exploration at the frontier of discovery by embracing diverse perspectives from individuals of all identities and backgrounds. We promote higher education and rigorous research as a fundamental component of an open, vibrant society. We strive to enhance the lives and livelihoods not only of our students, patients, and employees but also of the people of the greater St. Louis community and beyond. We do so by addressing scientific, social, economic, medical, and other challenges in the local, national, and international realms.","1","2023-06-23 00:00:00","2023-07-26 20:16:32","WUStL" +"233","Wayne State University","","wayne-state-university","logo/wayne-state-university.png","https://wayne.edu/","Our mission is to create and advance knowledge, prepare a diverse student body to thrive, and positively impact local and global communities. Our guiding values cut across organizational boundaries, bind us culturally, and permeate our strategic and tactical initiatives. They are the defining traits of the WSU community.","1","2023-06-23 00:00:00","2023-07-26 20:16:32","" +"234","Weizmann Institute of Science","contact-us@weizmann.ac.il","weizmann-institute-of-science","logo/wiz.jpeg","https://www.weizmann.ac.il/pages/","The Weizmann Institute of Science is one of the world's leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.","3","2023-06-23 00:00:00","2023-07-26 20:16:33","" +"235","Wellcome Sanger Institute","","sanger","logo/sanger.jpeg","https://www.sanger.ac.uk/","We tackle some of the most difficult challenges in genomic research. This demands science at scale; a visionary and creative approach to research that pushes the boundaries of our understanding in ever new and exciting ways.","2","2023-06-23 00:00:00","2023-07-26 20:16:34","" +"236","White House Office of Science and Technology Policy","","ostp","logo/ostp.png","https://www.whitehouse.gov/ostp/","President Biden often says, 'America is the only nation that can be defined by a single word: possibilities.' The White House Office of Science and Technology (OSTP) works to bring that idea to life by harnessing the power of science, technology, and innovation to achieve America's greatest aspirations. OSTP's mission includes: a) Providing advice to the President and the Executive Office of the President on matters related to science and technology; b) Strengthening and advancing American science and technology; c) Working with federal departments and agencies and with Congress to create bold visions, unified strategies, clear plans, wise policies, and effective, equitable programs for science and technology; d) Engaging with external partners, including industry, academia, philanthropic organizations, and civil society; state, local, Tribal and territorial governments; and other nations; and, e) Ensuring equity, inclusion, and integrity in all aspects of science and technology.","1","2023-06-23 00:00:00","2023-07-26 20:16:34","OSTP" +"237","InChI Trust","","inchi","logo/inchi.png","https://www.inchi-trust.org/","InChI: open-source chemical structure representation algorithm. InChI is a structure-based chemical identifier, originally developed by IUPAC. As a standard identifier for chemical databases, InChI is essential for enabling effective information management across chemistry. InChI with InChIKey are non-proprietary open standards. InChI turns chemical structures into unique machine readable strings, used for describing, storing and searching chemical structures. All associated algorithms and software are open source.","1","2023-06-23 00:00:00","2023-07-26 20:16:35","" +"238","National Center for Toxicological Research","","nctr","","https://www.fda.gov/about-fda/office-chief-scientist/national-center-toxicological-research","The National Center for Toxicological Research (NCTR), is the only FDA Center located outside the Washington D.C. metropolitan area. The one-million square foot research campus in Jefferson, Arkansas plays a critical role in the missions of FDA and the Department of Health and Human Services to promote and protect public health. Regulatory science researchers, academia, and other regulatory science research organizations and groups from around the world investigate, learn, and train at the Federal facility. NCTR, FDA's internationally recognized research center, plays a critical role in FDA's mission. The unique scientific expertise of NCTR is critical in supporting FDA product centers and their regulatory roles.","2","2023-06-23 00:00:00","2023-07-26 20:16:36","NCTR" +"239","McGill University","","mcgill","logo/mcgill.jpg","https://www.mcgill.ca/","McGill University is one of Canada's best-known institutions of higher learning and one of the leading universities in the world. International students from more than 150 countries make up nearly 30% of McGill's student body ‒ the highest proportion of any Canadian research university.","1","2023-06-23 00:00:00","2023-07-26 20:16:36","" +"240","Medical Artificial Intelligence Lab","spark@mailab.io","mai-lab","logo/mai-lab.jpg","https://mailab.io/","We are a leading ecosystem for data science and artificial intelligence (AI) innovations in medical diagnostic imaging. Our lab is dedicated to creating AI solutions and data science applications to transform the healthcare landscape of countries in Africa. We are a team of scientists from around the world working locally to disrupt healthcare challenges in resourced limited settings by implementing AI innovations in Africa where it has the most potential.","1","2023-06-23 00:00:00","2023-07-26 20:16:37","" +"241","Duke University Medical Center","","duke-health","logo/duke-health.jpg","https://www.dukehealth.org/locations/duke-university-medical-center","Duke University Medical Center is the name given to the group of patient care, education and medical research facilities on the medical campus of Duke University in Durham, North Carolina.","1","2023-06-23 00:00:00","2023-07-26 20:16:37","" +"242","Yale University","","yale","logo/yale.jpg","https://www.yale.edu/","Since its founding in 1701, Yale has been dedicated to expanding and sharing knowledge, inspiring innovation, and preserving cultural and scientific information for future generations. Yale’s reach is both local and international. It partners with its hometown of New Haven, Connecticut to strengthen the city’s community and economy. And it engages with people and institutions across the globe in the quest to promote cultural understanding, improve the human condition, delve more deeply into the secrets of the universe, and train the next generation of world leaders.","3","2023-06-23 00:00:00","2023-07-26 20:16:40","" +"243","Missouri University","","mizzou","logo/mizzou.jpg","https://missouri.edu/","","1","2023-06-23 00:00:00","2023-07-26 20:16:40","" +"244","Yale School of Medicine","","ysm","logo/ysm.png","https://medicine.yale.edu/","Yale School of Medicine educates and nurtures creative leaders in medicine and science, promoting curiosity and critical inquiry in an inclusive environment enriched by diversity. We advance discovery and innovation fostered by partnerships across the university, our local community, and the world. We care for patients with compassion, and commit to improving the health of all people.","1","2023-06-23 00:00:00","2023-07-26 20:16:42","YSM" +"245","Children's National Hospital","","childrens-national","logo/childrens-national.jpg","https://childrensnational.org/","Children's National Hospital is ranked #5 in the nation by U.S. News & World Report. We're ranked #1 for newborns and we're the best pediatric hospital for neurology and neurosurgery in the Mid-Atlantic. What's more, we ranked in all 10 specialties, with top 10 honors in neurology and neurosurgery, cancer, nephrology, orthopedics, pulmonology and lung surgery, and diabetes and endocrinology. This recognition of our commitment to bringing health and well-being to all children continues to inspire our teams.","1","2023-06-23 00:00:00","2023-07-26 20:16:42","" +"246","Helmholtz AI","","helmholtz-ai","logo/helmholtz-ai.jpg","https://www.helmholtz.ai/","We are a research-driven hub for applied artificial intelligence (AI) that: a) fosters cross-field creativity by stimulating collaborative research projects; b) identifies and leverages similarities between applications to advance generalised AI / machine learning (ML) methods; c) integrates field-specific excellence and AI/ML prowess; d) improves the quality, scalability and timely availability of emerging methods and tools; and e) empowers and trains the current and next generation of scientists, to enable the efficient and agile development and implementation of AI/ML assets across the whole Helmholtz Association.","1","2023-06-23 00:00:00","2023-07-26 20:16:43","" +"247","Mayo Clinic","","mayo-clinic","logo/mayo-clinic.png","https://www.mayoclinic.org/","Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing.","6","2023-06-23 00:00:00","2023-07-26 20:16:43","" +"248","Technical University of Munich","","tum","logo/tum.jpg","https://www.tum.de/en/","TUM has once again been named a University of Excellence and is thus the only technical university to continuously retain this status since 2006. The title is awarded as a part of the Excellence Strategy of the German federal and state governments, in strategic international support of German cutting-edge research. We are using this funding to realize the future concept TUM Agenda 2030. We are expanding technically-oriented humanities and social sciences and are reorganizing previous internal structures to be more innovation-oriented: The constraining, discipline-based Faculty structure is being replaced by seven Schools which are linked to one another by integrative research institutes. In the sense of an ""open marketplace of knowledge"", we support talented individuals in all their diversity, at all levels and across substantive subject boundaries. We work in alliances with international partners to re-orient towards Europe as well as to the southern global hemisphere in order t...","2","2023-06-23 00:00:00","2023-07-26 20:16:44","TUM" +"249","Center for Devices and Radiological Health","","cdrh","logo/fda.svg","https://www.fda.gov/about-fda/fda-organization/center-devices-and-radiological-health","In keeping with our mission, the Center for Devices and Radiological Health (CDRH) is responsible for protecting and promoting the public health. We assure that patients and providers have timely and continued access to safe, effective, and high-quality medical devices and safe radiation-emitting products. We provide consumers, patients, their caregivers, and providers with understandable and accessible science-based information about the products we oversee. We facilitate medical device innovation by advancing regulatory science, providing industry with predictable, consistent, transparent, and efficient regulatory pathways, and assuring consumer confidence in devices marketed in the U.S. We seek to continually improve our effectiveness in fulfilling our mission by planning strategically and regularly monitoring our progress.","2","2023-06-23 00:00:00","2023-08-10 21:36:27","CDRH" +"250","Lagos State University Teaching Hospital","","lasuth","logo/lasuth.jpg","https://www.lasuth.org.ng/","To provide high quality Healthcare Services in a friendly Environment where patients' satisfaction is the ultimate. Guided by the needs of our patients and their families, we aim to deliver the very best health care in a safe and compassionate environment; to advance care through innovative research and education; and to improve the health and well-being of the diverse communities we serve.","1","2023-06-23 00:00:00","2023-07-26 20:16:45","LASUTH" +"251","NSIA-Kano Diagnostic Center","enquiries@nkdc.ng","nkdc","logo/nkdc.jpeg","https://www.nhdic.ng/facility/nkdc/","The NKDC medical diagnostics facility opened its doors to the public on the 16th of March, 2020, in Kano - Northern Nigeria’s commercial centre. This state-of-the-art facility is home to a group of enthusiastic, passionate and patient-centric medical professionals who continuously aim to improve patient experiences. We offer 24/7 radiology and medical laboratory services all year round.","1","2023-06-23 00:00:00","2023-07-26 20:16:45","NKDC" +"252","Nationwide Children's Hospital","","nationwide-childrens","logo/nationwide-childrens.jpg","https://www.nationwidechildrens.org/","At Nationwide Children’s Hospital, our vision remains unchanged. We aspire to create the best outcomes for children everywhere. This means families come to Nationwide Children’s from around the globe knowing they will get the highest quality care. It means we will reach to cure rare diseases. It means we will sequence a child’s tumor to select the best care pathway. It means we will strive to make an entire population healthier, not just through their physical health, but also in their mental health. It means we will redefine the role of the children’s hospital in the achievement of optimal health.","1","2023-06-23 00:00:00","2023-07-26 20:16:46","" +"253","Dana-Farber Brigham Cancer Center","","dana-farber-brigham-cancer-center","logo/bwh.png","https://www.brighamandwomens.org/cancer","At Dana-Farber Brigham Cancer Center, all we do is cancer. Because no two people are the same, our approach to treatment and care is personalized – with a deep understanding of your cancer and how to get you well. Through our 12 specialized disease treatment centers, experts from our two organizations, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, work together as one team to offer the most advanced treatments with compassion and care that makes all the difference.","1","2023-06-23 00:00:00","2023-07-26 20:16:46","" +"254","Lacunda Fund","secretariat@lacunafund.org","lacunda-fund","logo/lacuna-fund.jpg","https://lacunafund.org/","Lacuna Fund is the world’s first collaborative effort to provide data scientists, researchers, and social entrepreneurs in low- and middle-income contexts globally with the resources they need to produce labeled datasets that address urgent problems in their communities.","1","2023-06-23 00:00:00","2023-08-04 22:03:25","" +"255","MLCommons","","mlcommons","logo/mlc.jpg","https://mlcommons.org/en/","The mission of MLCommons(R) is to accelerate machine learning innovation and increase its positive impact on society. Together with its 50+ founding Members and Affiliates, including startups, leading companies, academics, and non-profits from around the globe, MLCommons will help grow machine learning from a research field into a mature industry through benchmarks, public datasets and best practices. Every major technological advance follows a similar trajectory towards universal adoption and impact. The arc from research to broad accessibility generally takes from 30-40 years: from early automobiles to the family car, from development of ARPANET to the mainstream World Wide Web, from the first cellular phones to an smartphone in every pocket. Each of these examples started with technological breakthroughs, but for decades was limited by expertise, access, and expense. Machine learning is no different. ML and artificial intelligence have been around for decades, but even today ...","1","2023-06-23 00:00:00","2023-08-04 23:38:22","" +"256","Harvard Medical School","","hms","logo/hms.jpg","https://hms.harvard.edu/","Since the School was established in 1782, faculty members have improved human health by innovating in their roles as physicians, mentors and scholars. They’ve piloted educational models, developed new curricula to address emerging needs in health care, and produced thousands of leaders and compassionate caregivers who are shaping the fields of science and medicine throughout the world with their expertise and passion.","6","2023-08-04 06:00:47","2023-08-04 23:38:09","HMS" +"257","Centre for Structural Systems Biology","info@cssb-hamburg.de","cssb-hamburg","","https://www.cssb-hamburg.de/","CSSB is a joint initiative of nine research partners from Northern Germany, including three universities and six research institutes that devotes itself to infection biology research.","1","2023-08-04 22:00:31","2023-08-04 22:05:08","CSSB" +"258","University Medical Center Groningen","","umcg","","https://www.umcg.nl/","The University Medical Center Groningen (UMCG) is one of the largest hospitals in the Netherlands and is the largest employer in the Northern Netherlands. The more than 12,000 employees work together on care, research, training and education with the common goal: building the future of health.","1","2023-08-04 22:07:45","2023-08-04 22:09:44","UMCG" +"259","Eindhoven University of Technology","","tue","","https://www.tue.nl/en/","We educate students and advance knowledge in science & technology for the benefit of humanity. We integrate education and research to enable our students and scientists to become thought leaders and to design and achieve the unimaginable. In close collaboration with our public and private partners, we translate our basic research into meaningful solutions.","1","2023-08-04 22:12:40","2023-08-04 22:14:15","TU/e" +"260","Wageningen University & Research","","wur","","https://www.wur.nl/en.htm","","1","2023-08-04 22:15:19","2023-08-04 22:15:58","WUR" +"261","University Medical Center Utrecht","researchoffice@umcutrecht.nl","umc-utrecht","","https://www.umcutrecht.nl/en/research","In the UMC Utrecht research is concentrated in six strategic programs with each a limited number of disease targets. Patient care is integrated in these programs. A relentless multidisciplinary approach guarantees patients benefit from the latest available expertise and innovative technological solutions.","3","2023-08-04 22:16:49","2023-08-04 22:19:36","" +"262","Amsterdam University Medical Centers","","amsterdam-university-medical-centers","","https://www.amsterdamumc.org/en.htm","Amsterdam UMC is a leading medical center that combines complex high-quality patient care, innovative scientific research, and education of the next generation health care professionals. We believe that health care practice, research and education belong together, with each shaping and informing the other.","1","2023-08-04 22:19:22","2023-08-04 22:20:09","" +"263","Maastricht University","","um","","https://www.maastrichtuniversity.nl/","Maastricht University (UM) is the most international university in the Netherlands and, with nearly 22,000 students and 4,400 employees, is still growing. The university distinguishes itself with its innovative education model, international character and multidisciplinary approach to research and education.","1","2023-08-04 22:24:47","2023-08-04 23:14:35","UM" +"264","Delft University of Technology","","tu-delft","","https://www.tudelft.nl/en/","Top education and research are at the heart of the oldest and largest technical university in the Netherlands. Our 8 faculties offer 16 bachelor's and more than 30 master's programmes. Our more than 25,000 students and 6,000 employees share a fascination for science, design and technology. Our common mission: impact for a better society.","1","2023-08-04 23:14:17","2023-08-04 23:15:52","" +"265","Alliance of TU/e, WUR, UU and UMC Utrecht","info@ewuu.nl","ewuu","","https://ewuu.nl/en/","In 2019 Eindhoven University of Technology, Wageningen University & Research, Utrecht University and University Medical Centre Utrecht decided to form an alliance and to work together. The motto of this strategic collaboration is challenging future generations. Young researchers, lecturers and students are at the helm and work together right across disciplines. The challenges future generations will face are large but so are the possibilities for meeting those challenges. The institutions combine their expertise in order to contribute to social transitions in energy, sustainability, health and food.","1","2023-08-04 23:17:20","2023-08-04 23:34:13","EWUU" +"266","Utrecht University","","uu","","https://www.uu.nl/en","We are Utrecht University. The place for new collaborations and cross-pollination. Students, academic and administrative staff, policymakers, members of the public, professionals and business owners; you are invited to contribute to a better world.","1","2023-08-04 23:19:33","2023-08-04 23:35:18","UU" +"267","Surgical Science","","surgical-science","","https://surgicalscience.com/","Training without putting patients at risk. This is why we exist – to give surgeons an excellent platform to train in the fundamental technical skills before entering the operation room. For over 20 years, we have been committed to providing state-of-the-art medical training simulators that focus on ease of use and validation. The simple idea is to learn the practical techniques of instrument handling in a realistic but safe environment so that you can pay full attention to the patient when you begin the operation.","1","2023-08-04 23:51:56","2023-08-04 23:52:44","" +"268","Wellcome/EPSRC Centre for Interventional and Surgical Sciences","","weiss","","https://www.ucl.ac.uk/interventional-surgical-sciences","At the Wellcome/EPSRC Centre for Interventional and Surgical Sciences (WEISS), engineers, clinicians and scientists work together to develop technologies that enable safer and more effective treatments for patients across a wide range of conditions. The Centre is based at Charles Bell House, a building that brings together researchers from a wide range of departments at UCL, including Medical Physics and Biomedical Engineering, Computer Science and Mechanical Engineering. These academic researchers work in partnership with clinical researchers from areas such as the UCL Division of Surgery & Interventional Sciences and leading hospitals. At WEISS, research is being developed with a wide range of clinical applications in mind, including cardiovascular, paediatric, ophthalmic, neurological and urological surgical interventions. In particular, the Centre aims to advance engineering sciences in intraoperative imaging and sensing, data fusion and extraction, human-technology interfa...","1","2023-08-05 00:00:44","2023-08-05 00:01:47","WEISS" +"269","Medtronic","","medtronic","","https://www.medtronic.com/us-en/index.html","Health tech for a better future. From AI to connected care and beyond, our technology is building a bridge to better health for more people.","1","2023-08-05 00:02:47","2023-08-05 00:03:26","" +"270","King's College Hopistal","","kch","","https://www.kch.nhs.uk/","We are one of London’s largest and busiest teaching hospitals. We provide a strong profile of local hospital services for people living in the boroughs of Lambeth, Southwark, Lewisham, and Bromley. Our specialist services are also available to patients from a wider area. We providing nationally and internationally recognised treatment and care in liver disease and transplantation, neurosciences, haemato-oncology, and fetal medicine. Our vision is to be bold, and our new Trust values – Kind, Respectful Team – help ensure we bring a positive attitude to the way we interact with patients, relatives, and the many people who use our services.","2","2023-08-05 00:08:37","2023-08-05 00:09:46","KCH" +"271","Western University","","western","","https://www.uwo.ca/index.html","","1","2023-08-05 00:10:52","2023-08-05 00:11:11","" +"272","Robarts Research Institute","","robarts","","https://www.robarts.ca/","Opened in 1986, Robarts Research Institute at Western University is a medical research facility in London, Ontario, with more than 600 people working to investigate some of the most debilitating diseases of our time, from heart disease and stroke to diabetes, Alzheimer’s and many forms of cancer. We believe we’ve got a winning formula to accelerate medical discovery: attract the brightest and best people, give them the freedom to think big and set the bar high. From our roots under the scientific leadership of renowned neurologist Dr. Henry Barnett - whose work with Aspirin as a preventive therapy for heart attack and stroke remains one of the most important developments in 20th century medicine - the Institute has applied that formula to become a national leader in biological, clinical and imaging research.","1","2023-08-05 00:12:27","2023-08-05 00:13:00","" +"273","British Acoustic Neuroma Association","","bana-uk","","https://www.bana-uk.com/","BANA was formed in 1992 by a group of patients and their partners. They were introduced to each other by ENT and Neurosurgeon Consultants from the Queen’s Medical Centre Hospital in Nottingham and from the very beginning, mutual support was their primary aim. They also wanted to provide reliable information to those diagnosed and to promote research into Acoustic Neuromas and the effects associated with them. More than two decades on, these fledgling intentions remain the charitable objectives that drive the charity forward on behalf of all those affected.","1","2023-08-05 00:15:03","2023-08-05 00:16:46","BANA" +"274","Ninewells Hospital","","ninewells-hospital","","https://www.nhstayside.scot.nhs.uk/GoingToHospital/OurPremisesA-Z/NinewellsHospital/index.htm","","1","2023-08-05 00:20:05","2023-08-05 00:20:45","" +"275","Universal Protein Resource","","uniprot","","https://www.uniprot.org/","The Universal Protein Resource (UniProt) is a comprehensive resource for protein sequence and annotation data. The UniProt databases are the UniProt Knowledgebase (UniProtKB), the UniProt Reference Clusters (UniRef), and the UniProt Archive (UniParc). The UniProt consortium and host institutions EMBL-EBI, SIB and PIR are committed to the long-term preservation of the UniProt databases.","1","2023-08-05 05:21:46","2023-08-05 05:23:45","" +"276","Charing Cross Hospital","","charing-cross-hospital","","https://www.imperial.nhs.uk/our-locations/charing-cross-hospital","Charing Cross Hospital provides a range of acute and specialist services, a 24/7 accident and emergency department and hosts the hyper acute stroke unit for the region. It is also a growing hub for integrated care in partnership with local GPs and community providers.","1","2023-08-05 05:27:03","2023-08-05 05:27:34","" +"277","Elisabeth-TweeSteden Hospital","","etz","","https://www.etz.nl/","The ETZ (Elisabeth-TweeSteden Hospital) is a top clinical teaching hospital and trauma center. With three locations in Tilburg and Waalwijk, ETZ is the hospital for all residents of the Central Brabant region, but also (far) beyond.","1","2023-08-05 05:28:21","2023-08-05 05:30:27","ETZ" +"278","InVitro Cell Research","","icr","","https://invitrocellresearch.com/","Founded in 2015, InVitro Cell Research, LLC (ICR) is a privately funded company focused on regenerative and preventive personalized medicine. We are dedicated to discovering and developing interventions to slow and reverse biological aging and prevent major age-related diseases. While our offices and labs in the greater New York City area offer over 15,000 square feet of state-of-the-art research space, our scientists set us apart and make us special. They help guide and define our mission. What is our mission? Researching how to repair aging people, fast.","1","2023-08-05 05:33:19","2023-08-05 05:34:04","ICR" +"279","Accelerating Medicines Partnership(R) Parkinson's Disease","","amp-pd","","https://www.amp-pd.org/","The Accelerating Medicines Partnership(R) (AMP(R)) program is a public-private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and non-profit organizations. Managed through the Foundation for the NIH (FNIH), AMP aims to identify and validate the most promising biological targets for therapeutics. Disease areas covered by AMP at the launch of this site include Alzheimer’s disease, type 2 diabetes, the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus) and Parkinson’s disease. Additional disease areas are being evaluated for addition to AMP.","1","2023-08-05 05:39:55","2023-08-05 05:42:53","AMP-PD" +"280","Vanderbilt University","","vanderbilt","","https://www.vanderbilt.edu/","From its founding in 1873 as an institution devoted to “strengthening the ties which should exist between all sections of our common country,” Vanderbilt University has forged a tradition of academic excellence infused with a unique spirit of collaboration and collegiality. Our mission lies in the quest to bring out the best in humanity—pushing new ideas into the frontiers of discovery, challenging the limits of what’s possible and working diligently in the service of others. Vanderbilt’s closely connected park-like campus, set in the heart of the rapidly growing city of Nashville, Tennessee, is representative of the enduring bonds that unite us as One Vanderbilt community.","1","2023-08-07 20:28:32","2023-08-07 20:29:06","" +"281","Basque Center On Cognition, Brain and Language","","bcbl","","https://www.bcbl.eu/en","Our research aims to unravel the neurocognitive mechanisms involved in the acquisition, comprehension and production of language, with special emphasis on bilingualism and multilingualism. We study processes involved in normal child language acquisition and second language learning in adults, as well as learning disorders, language disorders, language-related effects of aging and neurodegeneration and language use in different social contexts.","1","2023-08-07 20:29:41","2023-08-07 20:30:41","BCBL" +"282","Erasmus Medical Center","","emc","","https://www.erasmusmc.nl/en/","We are Erasmus MC. Every day our staff, volunteers, and students work with dedication and commitment and are passionate about everything that we stand for.","1","2023-08-07 20:31:10","2023-08-07 20:31:47","EMC" +"283","Indiana University","","iu","","https://www.iu.edu/index.html","IU is home to top-ranked business and music schools. We’re home to the world’s first school of philanthropy, the nation’s first school of informatics, and the country’s largest medical school. Our hundreds of academic programs are among the world’s best, and we’re always looking toward the horizon, thinking about what’s next. To better prepare our students for the careers of tomorrow, we’ve launched or reconfigured 10 schools in the last decade, and we’re constantly adding new academic programs, like IU Bloomington’s Intelligent Systems Engineering program and IU Online’s 100% virtual Master of Science in Educational Technology for Learning.","2","2023-08-08 17:26:11","2023-08-08 17:28:12","IU" +"284","Science for Life Laboratory","","scilifelab","","https://www.scilifelab.se/","SciLifeLab, Science for Life Laboratory, is an institution for the advancement of molecular biosciences in Sweden. We are funded as a national research infrastructure by the Swedish government. Our organization leverages the unique strengths of individual researchers across Sweden into a focused resource for the life science community. We provide access for thousands of researchers to the cutting-edge instrumentation and deep scientific expertise necessary to be internationally competitive in bioscience research. This infrastructure is supported and developed by our research community, including internationally recognized experts in life science and technology. Our units and expertise create a unique environment for carrying out health and environmental research at the highest level. SciLifeLab started out in 2010 as a joint effort between four universities: Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University and Uppsala University. Today, we support re...","1","2023-08-08 17:26:35","2023-08-08 17:27:34","" +"285","Uppsala University","","uppsala","","https://www.uu.se/en","Uppsala University was founded in 1477. Today it is a strong, comprehensive research university ranked among the best in the world, with 50,000 students and close to 5,000 researchers.","1","2023-08-08 17:28:30","2023-08-08 17:29:20","UU" +"286","Google LLC","","google","","https://about.google/","Our mission is to organize the world’s information and make it universally accessible and useful.","3","2023-08-08 17:29:33","2023-08-08 17:30:47","" +"287","Precision Value & Health","","precision-value-health","","https://www.precisionvaluehealth.com/","Across the commercialization continuum, Precision Value & Health teams are focused on transforming data for health and leveraging evidence and insights to tailor communications for every stakeholder. From payers to health systems, scientists to healthcare providers, and consumers to advocates, our results are designed to shift the trajectory and accelerate your success. Precision Value & Health’s teams include PRECISIONadvisors (global pricing and market access strategy), PRECISIONeffect (branding and launch experts), PRECISIONheor (evidence generation and strategy), PRECISIONscientia (medical communications), PRECISIONvalue (managed markets marketing), and PRECISIONxtract (data-driven solutions and engagement).","1","2023-08-08 17:37:16","2023-08-08 17:40:34","" +"288","STLogics","","stlogics","","https://www.stlogics.com/index.html","The STLogics Team has over 60 years of combined business experience to share. This broad business savvy enables our team to provide mentorship to those seeking to enhance the velocity of their trajectory to success. We can assist from small start-up initiatives to large corporations with our keen management skills and futuristic thinking capabilities. If your organization desires growth optimization or is entertaining the thought of acquisition consultation or a merger, STLogics can propel your revolutionary vision to reality. STLogics Holding Company provides operational and strategic advice to our affiliates in an effort to enhance their effectiveness and growth. We simply support and nurture our family of companies to enable them to maximize service to their clients. Our goal is to expand and diversify over various verticals, thus allowing us to foster innovation and create optimal results for client needs.","1","2023-08-08 17:41:14","2023-08-08 17:41:34","" +"289","Conference Ventures","","conference-ventures","","http://conferenceventures.com/","This organization may no longer exist or has been merged under another organization.","1","2023-08-08 17:44:00","2023-08-08 17:59:39","" +"290","Google Brain","","google-brain","","https://research.google/teams/brain/","This organization may no longer exist or has been merged under another organization.","1","2023-08-08 17:56:04","2023-08-08 18:00:27","" +"291","Princeton University","","princeton","","https://www.princeton.edu/","Princeton is about people. Our University is enriched by the wide range of experiences and perspectives of our students, faculty, staff and alumni.","1","2023-08-08 18:02:09","2023-08-08 18:02:58","" +"292","Prairie View A&M University","","pvamu","","https://www.pvamu.edu/","Welcome to Prairie View A&M University, home of the Panthers. Our HBCU, affectionately known as “The Hill,” is deeply rooted in culture & tradition and provides an undeniable educational experience to more than 9,000 diverse students on one of the most beautiful campuses in the state of Texas. Our award-winning faculty work diligently to create challenging and rewarding experiences that inspire you to dream big and soar to new heights. Are YOU ready to EXPERIENCE PVAMU?","1","2023-08-08 18:17:53","2023-08-08 18:26:36","PVAMU" +"293","University of California, Berkeley","","berkeley","","https://www.berkeley.edu/","From a group of academic pioneers in 1868 to the Free Speech Movement in 1964, Berkeley is a place where the brightest minds from across the globe come together to explore, ask questions and improve the world.","1","2023-08-08 18:48:17","2023-08-08 18:51:02","" +"294","Center for Genetically Engineered Materials","","c-gem","","https://gem-net.net/","C-GEM is establishing a fundamentally new way to program chemical matter and transform the way scientists design and produce materials and medicines. Using computation and experiment, C-GEM is repurposing nature’s protein synthesizing machine–the ribosome and its associated translation factors–to biosynthesize genetically encoded, sequence-defined chemical polymers with unprecedented functions and activities. Our combined activities span the fields of chemical biology, synthetic biology, synthetic chemistry, structural biology, computational biology, and molecular biology, and are highly collaborative. To catalyze these efforts, C-GEM implemented GEM-NET, a sophisticated data management system to promote data sharing within and outside the team, and with industry, the NSF, and the public. By fostering innovation at the chemical-biology-materials frontier, C-GEM is establishing a diverse chemical workforce, perfecting the integration of research with training, and captivating scien...","1","2023-08-08 19:14:43","2023-08-08 19:38:06","C-GEM" +"295","Oregon State University","","oregon-state","","https://oregonstate.edu/","Oregon State University is a dynamic community of dreamers, doers, problem-solvers and change-makers. We don’t wait for challenges to present themselves — we seek them out and take them on. We welcome students, faculty and staff from every background and perspective into a community where everyone feels seen and heard. We have deep-rooted mindfulness for the natural world and all who depend on it, and together, we apply knowledge, tools and skills to build a better future for all.","1","2023-08-08 19:23:28","2023-08-08 19:37:53","OSU" +"296","Laboratory for Innovation Science at Harvard","","lish","","https://lish.harvard.edu/","The Laboratory for Innovation Science at Harvard (LISH) is spurring the development of a science of innovation through a systematic program of solving real-world innovation challenges while simultaneously conducting rigorous scientific research and analysis. LISH is a Harvard-wide research program led by faculty co-directors Karim Lakhani, Harvard Business School; Eva Guinan, Harvard Medical School; David Parkes, Harvard School of Engineering and Applied Sciences; and Kyle Myers, Harvard Business School; with support from the Institute for Quantitative Social Science. With our partners in both academia and industry, LISH conducts research on innovation within three areas of application: Crowdsourcing & Open Innovation; Data Science & AI Development; and Science of Science; addressing questions under three main research tracks: Incentives & Governance; Creativity & Problem-Solving; and Organization & Processes.","1","2023-08-08 19:24:59","2023-08-08 19:30:57","LISH" +"297","NIH Common Funds Library of Integrated Network-Based Cellular Signatures","","nih-lincs-program","","https://lincsproject.org/LINCS/","The LINCS project is based on the premise that disrupting any one of the many steps of a given biological process will cause related changes in the molecular and cellular characteristics, behavior, and/or function of the cell – the observable composite of which is known as the cellular phenotype. Observing how and when a cell’s phenotype is altered by specific stressors can provide clues about the underlying mechanisms involved in perturbation and, ultimately, disease.","1","2023-08-08 19:25:32","2023-08-08 19:37:57","LINCS" +"298","Recursion Pharmaceuticals","","recursion","","https://www.recursion.com/","From our earliest days, our story was unlikely. We are a company started by two graduate students and a professor, headquartered in Salt Lake City, Utah. Our humble and unlikely beginnings are foundational to what we’ve built today. We were underdogs, and felt that way. Now we are leaders in this space, and we vow to stay hungry and focused on our mission. We are a biotechnology company scaling more like a technology company, and we are just getting started.","1","2023-08-08 19:41:20","2023-08-08 19:42:43","" +"299","Google Cloud","","google-cloud","","https://cloud.google.com/?hl=en","Google Cloud is widely recognized as a global leader in delivering a secure, open and intelligent enterprise cloud platform. Our technology is built on Google’s private network and is the product of nearly 20 years of innovation in security, network architecture, collaboration, artificial intelligence and open source software. We offer a simply engineered set of tools and unparalleled technology across Google Cloud Platform and G Suite that help bring people, insights and ideas together. Customers across more than 150 countries trust Google Cloud to modernize their computing environment for today’s digital world.","1","2023-08-08 19:43:02","2023-08-08 19:44:33","" +"300","DoiT","","doit","","https://www.doit.com/","You have the cloud and we have your back. For nearly a decade, we’ve been helping businesses build and scale cloud solutions with our world-class cloud engineering support. We help our customers with technical support and consulting on building and operating complex large-scale distributed systems, developing better machine learning models and setting up big data solutions using Google Cloud, Amazon AWS and Microsoft Azure.","1","2023-08-08 19:43:17","2023-08-08 19:44:51","" +"301","Lambda","","lambda","","https://lambdalabs.com/","Our workstations, servers, laptops, and cloud services power engineers and researchers at the forefront of human knowledge. Our customers include Intel, Microsoft, Amazon Research, Kaiser Permanente, MIT, Stanford, Harvard, Caltech, and the Department of Defense. With Lambda, you simply plug the system into the wall and get started making business and scientific breakthroughs. That's why the greatest companies and research labs in the world work with Lambda.","1","2023-08-08 19:43:31","2023-08-08 19:44:16","" +"302","Center for the Study of Movement, Cognition, and Mobility","","cmcm","","https://rnd.tasmc.org.il/laboratories/center-for-the-study-of-movement-cognition-and-mobility-prof-jeff-hausdorff/","As the baby boomers age, the number of adults who suffer from frequent falls, gait disorders, cognitive impairment, dementia, and other neurological diseases continues to increase dramatically. New understandings and therapeutic approaches are needed. Our research aims to improve the personalized treatment of age-related movement, cognition, and mobility disorders and to alleviate the burden associated with them.`","1","2023-08-08 19:54:16","2023-08-08 19:54:33","CMCM" +"303","Research Group for Neurorehabilitation","","enrgy","","https://gbiomed.kuleuven.be/english/research/50000743/research/research-units/enrgy","The mission of the Neurorehabilitation Research Group (eNRGy) is to advance the evidence-base of neurorehabilitation of child and adult populations with acute and chronic neurological conditions. In doing so, our research activities tackle both fundamental and translational research questions aimed at increasing our understanding of neurobehavioral and neuromuscular mechanisms, relevant for innovation and refinement of rehabilitation interventions. The clinical challenge of eNRGy lies in addressing the complexity of the brain and its role in neuromotor function, including deficits in the motor, sensory, social and cognitive domain.","1","2023-08-08 19:55:53","2023-08-08 19:57:47","eNRGy" +"304","Hinda and Arthur Marcus Institute for Aging","","marcus-institute","","https://www.marcusinstituteforaging.org/","Since 1966, the Hinda and Arthur Marcus Institute for Aging Research has challenged conventional wisdom to better understand how we age. The questions we ask - and the answers we uncover - directly impact standards of care and help seniors live more vital, meaningful lives. The Marcus Institute is one of the largest gerontological research facilities in a clinical setting in the U.S. Our decades-long relationship with Harvard Medical School attracts expert teaching staff and outstanding research fellows. Our research portfolio increased 90% from 2010 to 2022 and ranks us in the top 10% of institutions funded by the National Institutes of Health.","1","2023-08-08 19:59:31","2023-08-08 20:00:08","" +"305","University Hospital Zurich","","usz","","https://www.usz.ch/en/","The University Hospital Zurich (USZ) is open to all patients every day and provides fundamental medical care and cutting-edge medicine in a central location in Zurich. We use our superior academic knowledge to treat a wide range of health issues, taking a personal touch and utilizing highly specialized and up-to-date research.","1","2023-08-09 22:21:15","2023-08-09 22:21:34","USZ" +"306","Zurich University of Applied Sciences","","zhaw","","https://www.zhaw.ch/en/university/","The ZHAW is one of the leading universities of applied sciences in Switzerland. It offers teaching, research, continuing education and other services that are both practice-oriented and science-based. Research & development at the ZHAW focuses on key societal challenges, with a particular emphasis on energy and societal integration. With its expertise in sustainable development and digital transformation, the ZHAW imparts forward-looking knowledge and takes an active part in shaping the digital and ecological transformation. With locations in Winterthur, Zurich and Wädenswil, the ZHAW is firmly anchored in its region whilst collaborating with international partners.","1","2023-08-09 22:22:32","2023-08-09 22:22:57","ZHAW" +"307","Helmholtz Munich","","helmholtz-munich","","https://www.helmholtz-munich.de/en","We are Helmholtz Munich. We discover breakthrough solutions for better health in a rapidly changing world. Our world is constantly changing. This impacts our health. Many widespread diseases such as diabetes, allergies and lung diseases are on the rise. Climate change is causing new diseases to emerge. We develop solutions for a healthier future. Our cutting-edge research is the springboard for medical innovations. Together with our partners, we accelerate the transfer from ideas to applications, from labs to startups, from science to society.","1","2023-08-09 22:23:10","2023-08-09 22:24:12","" +"308","Imperial College London","","imperial","","https://www.imperial.ac.uk/","Imperial is a global top ten university with a world-class reputation in science, engineering, business and medicine. Together, we are Imperial.","1","2023-08-09 22:24:26","2023-08-09 22:25:15","" +"309","Geneva University Hospitals","","hug","","https://www.hug.ch/","The result of a centuries-old tradition of excellence in medicine and science, the HUG was created in 1995. Bringing together the eight Geneva public hospitals and, since July 1, 2016, two clinics (Joli-Mont and Crans-Montana), they represent the leading university hospital in Switzerland. They also have 30 outpatient consultations, spread throughout the canton of Geneva.","1","2023-08-09 22:26:11","2023-08-09 22:26:46","HUG" +"310","National University Hospital","","nuh","","https://www.nuh.com.sg/Pages/Home.aspx","The National University Hospital (NUH) is Singapore’s leading university hospital. While the hospital at Kent Ridge first received its patients on 24 June 1985, our legacy started from 1905, the date of the founding of what is today the NUS Yong Loo Lin School of Medicine. NUH is the principal teaching hospital of the medical school. Our unique identity as a university hospital is a key attraction for healthcare professionals who aspire to do more than practise tertiary medical care. We offer an environment where research and teaching are an integral part of medicine, and continue to shape medicine and transform care for the community we care for. We are an academic medical centre with over 1,200 beds, serving more than one million patients a year with over 50 medical, surgical and dental specialties. NUH is the only public and not-for-profit hospital in Singapore to provide trusted care for adults, women and children under one roof, including the only paediatric kidney and live...","1","2023-08-09 22:27:16","2023-09-13 00:06:26","NUH" +"311","Princess Maxima Center for Pediatric Oncology","","princess-maxima-center","","https://www.prinsesmaximacentrum.nl/en","When a child is seriously ill with cancer, only one thing comes first: cure. That is why at the Princess Máxima Center for pediatric oncology we work together every day in a groundbreaking and passionate way to improve the survival rate and quality of life of children with cancer. Now, and in the longer term. Because children still have a whole life ahead of them. The Princess Máxima Center is not an ordinary hospital, but a research hospital. All children with cancer in the Netherlands are treated here. This makes the Princess Máxima Center the largest pediatric cancer center in Europe. Over 450 researchers and 900 healthcare professionals work closely with Dutch and international hospitals on better treatments and new perspectives on cures. In this way, we give the child of today the very best care and take important steps to improve the chances of survival for the children who are not yet cured.","1","2023-08-09 22:29:04","2023-08-09 22:30:33","" +"312","CHAIMELEON Consortium","","chaimeleon","","https://chaimeleon.eu/#partners","The interdisciplinary CHAIMELEON consortium is made up of 18 partners from 9 countries: Fundación para la Investigación del Hospital Universitario la Fe de la Comunidad Valenciana (ES), Universita di Pisa (IT), Universita Degli Studi di Roma la Sapienza (IT), Centro Hospitalar Universitário de Santo António (PT), ICCS Policlinico San Donato (IT), College des Enseignants de Radiologie (FR), Universiteit Masstricht (NL), Charité Universitätsmedizin Berlin (DE), Imperial College London (UK), Ben-Gurion University of the Negev (IL), Universitat Politècnica de Valencia (ES), GE Healthcare (DE), Quibim (ES), Medexprim (FR), Bahia (ES), Matical Innovation (ES), European Institute of Biomedical Imaging Research (AT), Universitat de Valencia (ES). It constitutes a pan-European ecosystem of knowledge, infrastructures, biobanks and technologies on oncology, AI/in-silico and cloud computing addressed to health. The CHAIMELON project also collaborates with other European projects and initiatives.","1","2023-08-09 22:48:43","2023-08-09 22:51:15","" +"313","Office of Digital Transformation","","odt","logo/fda.svg","https://www.fda.gov/about-fda/office-commissioner/office-digital-transformation","The Office of Digital Transformation (ODT) provides the vision and leadership in information technology (IT), data, and cybersecurity needed to advance FDA’s mission and strategic priorities. ODT is led by the Chief Information Officer and reports to the FDA Commissioner. ODT directs and coordinates enterprise strategic planning, policy, and resource management to ensure that Agency IT, data, and cybersecurity investments and activities provide maximum value to FDA. ODT is comprised of the Office of Information Management and Technology (OIMT), Office of Data, Analytics, and Research (ODAR), and the Office of Information Security (OIS), under the direction of the Chief Technology Officer (CTO), Chief Data Officer (CDO), and Chief Information Security Officer (CISO). ODT is committed to delivering trusted technology and data solutions that enable FDA to reimagine the possible. Watch this video to learn more about our organization and how we are striving to make an impact at FDA.","2","2023-08-10 21:37:33","2023-08-10 21:39:34","ODT" +"314","Office of Minority Health and Health Equity","","omhhe","logo/fda.svg","https://www.fda.gov/about-fda/office-commissioner/office-minority-health-and-health-equity","The FDA Office of Minority Health and Health Equity (OMHHE) serves to promote and protect the health of diverse populations through research and communication of science that addresses health disparities.","1","2023-08-10 21:37:42","2023-08-10 21:40:30","OMHHE" +"315","Office of Data, Analytics, and Research","","odar","logo/fda.svg","https://www.fda.gov/about-fda/office-digital-transformation/office-data-analytics-and-research-odar","The Office of Data, Analytics, and Research (ODAR) manages and improves FDA’s ability to leverage data as a strategic asset by establishing enterprise data strategy and priorities.","2","2023-08-10 21:37:44","2023-08-10 21:38:28","ODAR" +"316","Medicines and Healthcare products Regulatory Agency","","mhra","","https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency","We are the regulator of medicines, medical devices and blood components for transfusion in the UK. We put patients first in everything we do, right across the lifecycle of the products we regulate. We rigorously use science and data to inform our decisions, enable medical innovation and to make sure that medicines and healthcare products available in the UK are safe and effective.","1","2023-08-10 22:10:11","2023-08-10 22:11:14","MHRA" +"317","MDClone","","mdclone","","https://www.mdclone.com/","MDClone is a technology firm focused on unlocking healthcare data and empowering exploration, discovery, and collaboration to improve patients' health. At MDClone, we are a growing startup with big aspirations. We are determined to make an impact on healthcare worldwide with tools, processes, and services focused on turning data into better outcomes. MDClone is focused on empowering healthcare institutions, enabling stronger and more secure relationships between healthcare providers and life science companies, and developing regional and global collaboration with privacy-enabled shared data sets.","1","2023-08-10 22:11:58","2023-08-10 22:12:33","" +"318","Washington Business Dynamics, LLC","","wbd","","https://www.wbdynamics.com/","Since our founding, WBD has sought to be a management consulting provider of choice for the federal government and the private sector. We are privileged to count many of the world’s foremost institutions and organizations among our client list. We partnered with these organizations’ senior leaders and immediately began uncovering value. Our staff brings a superior analytic capability, time-tested best practices, and a logical approach to solve problems and position organizations for future success.","1","2023-08-10 22:12:50","2023-08-10 22:13:23","WBD" +"319","Medical College of Wisconsin","","mcw","logo/medical-college-wisconsin-logo.svg","https://www.mcw.edu/","The Medical College of Wisconsin is a private medical school, pharmacy school, and graduate school of sciences headquartered in Milwaukee, Wisconsin. The school was established in 1893 and is the largest research center in eastern Wisconsin.","5","2023-09-09 01:40:31","2023-09-09 03:10:17","MCW" +"320","Boston University","","bu","","https://www.bu.edu/","Boston University is no small operation. With over 36,000 students from more than 130 countries, over 10,000 faculty and staff, 17 schools and colleges and the Faculty of Computing & Data Sciences, and more than 300 programs of study, our three campuses are always humming, always in high gear. Get to know the people and teams that keep the University running smoothly.","1","2023-09-12 23:58:11","2023-09-12 23:58:49","BU" +"321","Telethon Institute of Genetics and Medicine","","tigem","","https://www.tigem.it/","The Telethon Institute of Genetics and Medicine (TIGEM), a Telethon Foundation organization, was founded in 1994 as a leading European research center. TIGEM is a Telethon Foundation research centre in Pozzuoli, Italy. TIGEM comprises several research groups and over 200 staff members, all dedicated to understanding the molecular mechanisms behind rare genetic diseases and developing novel treatments. These diseases, often overlooked by pharmaceutical industries, are most common in children and adolescents. TIGEM’s research falls into three main themes: Cell Biology and Disease Mechanisms, Genomic Medicine, and Molecular Therapy. Our research is supported by a number of in-house highly specialised facilities, as well as significant international support in the form of funding and collaborative opportunities.","1","2023-09-13 00:01:07","2023-09-13 00:01:39","TIGEM" +"322","Genome Institute of Singapore","","gis","","https://www.a-star.edu.sg/gis","When the Genome Institute of Singapore (GIS) was established in 2000, the science of genomics was still in its infancy. Since then, genomics has proved its relevance to all aspects of biology and medicine. It is now possible to sequence entire populations and communities, resolve organs at the single-cell level, and develop treatments guided by genomic data. We are now able to edit genomes at will, synthesise chromosomes, and perform complex experiments in silico by harnessing the ever-growing reservoir of public-access data. Importantly, while much has been done, much remains to be discovered as our knowledge of genomes, both human and non-human, remains incomplete. Through it all, GIS has maintained its leadership and relevance in genomic science by focusing on its three core strengths – asking the right biological questions, applying and developing cutting-edge technology platforms, and embracing multi-disciplinary team science. These core strengths have served us well, and wi...","1","2023-09-13 00:05:51","2023-09-13 00:06:34","GIS" +"323","University of Rostock","","university-of-rostock","","https://www.uni-rostock.de/en/","Founded in 1419, the University of Rostock is the oldest in the Baltic Sea Region. True to the motto “Traditio et Innovatio”, the University of Rostock has constantly further developed. The multitude of new buildings represents the university’s modernity.","1","2023-09-13 00:22:55","2023-09-13 00:24:16","" +"324","FlowCAP","","flowcap","","","This organization may no longer exist or has been merged under another organization.","1","2023-09-13 00:36:41","2023-09-13 00:37:01","" +"325","University of California, Santa Barbara","","uc-santa-barbara","","https://www.ucsb.edu/","At UC Santa Barbara, we offer a dynamic environment that prizes academic inquiry and interpersonal connection to inspire scholarly ambition, creativity, and discoveries with wide-ranging impact. We’re inquisitive and curious, community-driven and globally-focused. Across our campus, you’ll find independent thinkers and consensus builders, Nobel Laureates and leaders chasing noble causes. But no matter how you define us, we are above all Gauchos — diverse in our pursuits, yet connected in our collective drive toward excellence.","2","2023-09-13 16:57:59","2023-09-13 16:59:12","UCSB" +"326","GlaxoSmithKline","","gsk","","https://www.gsk.com/en-gb/","We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.","2","2023-09-13 17:17:03","2023-09-15 16:02:05","" +"327","Carnegie Mellon University","","cmu","","https://www.cmu.edu/","Carnegie Mellon University challenges the curious and passionate to imagine and deliver work that matters. A private, global research university, Carnegie Mellon stands among the world's most renowned educational institutions, and sets its own course. Start the journey here. Over the past 10 years, more than 400 startups linked to CMU have raised more than $7 billion in follow-on funding. Those investment numbers are especially high because of the sheer size of Pittsburgh’s growing autonomous vehicles cluster – including Uber, Aurora, Waymo and Motional – all of which are here because of their strong ties to CMU. With cutting-edge brain science, path-breaking performances, innovative startups, driverless cars, big data, big ambitions, Nobel and Turing prizes, hands-on learning, and a whole lot of robots, CMU doesn't imagine the future, we create it.","1","2023-09-13 23:36:25","2023-09-13 23:37:36","CMU" +"328","ContextVision","","contextvision","","https://www.contextvision.com/","Our cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. Healthcare providers worldwide face the same key challenge – a challenge that ContextVision is helping to solve: how to increase patient care while coping with limited resources. ContextVision provides intelligent technology that improves healthcare service and outcomes for more people. The company specializes in image analysis and artificial intelligence.","1","2023-09-15 17:21:50","2023-09-15 17:22:34","" +"329","Karolinska Institute","","ki","","https://ki.se/en","Karolinska Institutet is one of the world’s leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.","1","2023-09-15 17:24:17","2023-09-15 17:53:16","KI" +"330","Research to the People","hello@researchtothepeople.org","research-to-the-people","logo/research-to-the-people.png","https://www.researchtothepeople.org/","Research to the People is a patient- partnered research program for open Oncology and Rare Disease Cases.","1","2023-09-28 21:15:01","2023-09-28 23:23:01",""